WO2013173635A1

WO2013173635A1 - Compositions and methods for modulating gene expression

Info

Publication number: WO2013173635A1
Application number: PCT/US2013/041434
Authority: WO
Inventors: Arthur M. Krieg; Romesh Subramanian; James Mcswiggen; Jeannie T. Lee
Original assignee: Rana Therapeutics, Inc.; The General Hospital Corporation D/B/A Massachusetts General Hospital
Priority date: 2012-05-16
Filing date: 2013-05-16
Publication date: 2013-11-21
Also published as: EP2850183A4; EP2850183A1; US20150232836A1; JP2016528873A

Abstract

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.

Description

COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/647,915, entitled "COMPOSITIONS AND METHODS FOR

MODULATING CFTR EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/647,938, entitled "COMPOSITIONS AND METHODS FOR MODULATING PAH EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/648,030, entitled "COMPOSITIONS AND METHODS FOR MODULATING CEP290 EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/648,045, entitled "COMPOSITIONS AND METHODS FOR MODULATING ADIPOQ EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/648,052, entitled "COMPOSITIONS AND METHODS FOR MODULATING CD274 EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/648,069, entitled "COMPOSITIONS AND METHODS FOR

MODULATING GENE EXPRESSION", filed May 16, 2012; U.S. Provisional Application No. 61/786,095, entitled "COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION", filed March 14, 2013, the contents of each of which are incorporated herein by reference in their entireties. FIELD OF THE INVENTION

The invention relates to oligonucleotide based compositions, as well as methods of using oligonucleotide based compositions for treating disease.

BACKGROUND OF THE INVENTION

Transcriptome analyses have suggested that, although only 1-2% of the mammalian genome is protein coding, 70-90% is transcriptionally active. Recent discoveries argue that a subset of these non-protein coding transcripts play crucial roles in epigenetic regulation. In spite of their ubiquity, the structure and function of many of such transcripts remains uncharacterized. Recent studies indicate that some long non-coding RNAs function as an epigenetic regulator/RNA cofactor in chromatin remodeling through interactions with Polycomb repressor complex 2 (PRC2) and thus function to regulate gene expression. SUMMARY OF THE INVENTION

Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating expression of a target gene in cells. In some embodiments, single stranded oligonucleotides are provided that target a PRC2-associated region of a target gene encoding a protein of interest. In some embodiments, single stranded oligonucleotides are provided that target a PRC2-associated region of a target gene (e.g., a human gene) and thereby cause upregulation of the gene. In some embodiments, the target gene is a gene listed in Table 4. In some embodiments, these single stranded oligonucleotides activate or enhance expression of a target gene by relieving or preventing PRC2 mediated repression of the target gene. In some embodiments, the target gene is listed in Table 4. In some embodiments, these single stranded oligonucleotides activate or enhance expression of a target gene to treat a disease associated with reduced expression of the target gene. In some embodiments, the disease associated with reduced expression of the target gene is listed is Table 4. In some embodiments, a phenotype associated with the disease is referred to in Table 4 by an OMIM identification number.

Further aspects of the invention provide methods for selecting oligonucleotides for activating or enhancing expression of a target. In some embodiments, the target gene may be a target gene listed in Table 4, such as BCL2L11, BRCA1, F8, FLU, FMR1, FNDC5, GCK, GLP1R, GRN, HAMP, HPRT1, IDOl, IGF1, IL10, LDLR, NANOG, PTGS2, RB I,

SERPINF1, SIRT1, SIRT6, SMAD7, ST7, CFTR, PAH, CEP290, CD274, ADIPOQ or

STAT3. In some embodiments, methods are provided for selecting a set of oligonucleotides that is enriched in candidates (e.g. , compared with a random selection of oligonucleotides) for activating or enhancing expression of a target. Accordingly, the methods may be used to establish sets of clinical candidates that are enriched in oligonucleotides that activate or enhance expression of a target. Such libraries may be utilized, for example, to identify lead oligonucleotides for developing therapeutics to treat a disease associated with reduced expression of the target gene. In some embodiments, the disease associated with reduced expression of the target gene is listed is Table 4 or otherwise disclosed herein. Furthermore, in some embodiments, oligonucleotide chemistries are provided that are useful for controlling the pharmacokinetics, biodistribution, bioavailability and/or efficacy of the single stranded oligonucleotides for activating expression of a target gene. According to some aspects of the invention single stranded oligonucleotides are provided that have a region of complementarity that is complementarty with (e.g. , at least 8 consecutive nucleotides of ) a PRC2-associated region of the nucleotide sequence set forth as any one of SEQ ID NOS: 1 to 96.

According to some aspects of the invention single stranded oligonucleotides are provided that have a region of complementarity that is complementarty with (e.g. , at least 8 consecutive nucleotides of ) a PRC2-associated region of a target gene listed in Table 4, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, 43, 44, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 815175, 815176, 868590, 868591, 899865, 899866, 962801, 962802, 981187, or 981188. In some embodiments, the oligonucleotide has at least one of the following features: a) a sequence that is 5'X-Y-Z, in which X is any nucleotide and in which X is at the 5' end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length; b) a sequence that does not comprise three or more consecutive guanosine nucleotides; c) a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length to the second nucleotide sequence, that are between 50 kilobases upstream of a 5 '-end of an off-target gene and 50 kilobases downstream of a 3 '-end of the off-target gene; d) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and e) a sequence that has greater than 60% G-C content. In some embodiments, the single stranded oligonucleotide has at least two of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least three of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has at least four of features a), b), c), d), and e), each independently selected. In some embodiments, the single stranded oligonucleotide has each of features a), b), c), d), and e). In certain embodiments, the oligonucleotide has the sequence 5'X-Y-Z, in which the oligonucleotide is 8-50 nucleotides in length.

According to some aspects of the invention, single stranded oligonucleotides are provided that have a sequence X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with a PRC2- associated region of a target gene listed in Table 4, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, 43, 44, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 815175, 815176, 868590, 868591, 899865, 899866, 962801, 962802, 981187, or 981188. In some aspects of the invention, single stranded oligonucleotides are provided that have a sequence 5' -X-Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length, in which the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a target gene listed in Table 4, e.g., a PRC2-associated region of the nucleotide sequence set forth as SEQ ID NO: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, 43, 44, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 815175, 815176, 868590, 868591, 899865, 899866, 962801, 962802, 981187, or 981188. In some

embodiments, Y is a sequence selected from Table 1. In some embodiments, the PRC2- associated region is a sequence listed in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, 962805 to 962816 or 981191 to 981196.

In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676, or a fragment thereof that is at least 8 nucleotides. In some

embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676, in which the 5' end of the nucleotide sequence provided is the 5' end of the oligonucleotide. In some embodiments, the region of complementarity (e.g. , the at least 8 consecutive nucleotides) is also present within the nucleotide sequence set forth as SEQ ID NO: 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39, 40, 41, 42, 47, 48, 51, 52, 55, 56, 59, 60, 63, 64, 67, 68, 71, 72, 75, 76, 79, 80, 83, 84, 87, 88, 91, 92, 95, 96, 815177, 815178, 868592, 868593, 899867, 899868, 962803, 962804, 981189, or 981190.

In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676. In some embodiments, the single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676.

In some embodiments, the PRC2-associated region is a sequence listed in any one of

SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, 962805 to 962816 or 981191 to 981196. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 497442, 815209 to 842011, 868618 to 887872, 899933 to 949635, 962817 to 976788, 981197 to 987384, 989617 to 989640, 989650 to 989675, or 989676 to 1412676 or a fragment thereof that is at least 8 nucleotides. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 497442, 815209 to 842011, 868618 to 887872, 899933 to 949635, 962817 to 976788, 981197 to 987384, 989617 to 989640, 989650 to 989675, or 989676 to 1412676, wherein the 5' end of the nucleotide sequence provided in any one of SEQ ID NOS: 1211 to 497442, 815209 to

842011, 868618 to 887872, 899933 to 949635, 962817 to 976788, 981197 to 987384, 989617 to 989640, 989650 to 989675, or 989676 to 1412676 is the 5' end of the oligonucleotide. In some embodiments, the at least 8 consecutive nucleotides are also present within the nucleotide sequence set forth as SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 41, 47, 51, 55, 59, 63, 67, 71, 75, 79, 83, 87 , 91, 95, 815177 , 868592, 899867 , 962803, or 981189.

In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 497443 to 815174, 842012 to 868589, 887873 to 899864, 949636 to 962800, 976789 to 980845, 987385 to 989598, or 989641 to 989649, 1412677-1914950 or a fragment thereof that is at least 8 nucleotides. In some embodiments, the single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 497443 to 815174, 842012 to 868589, 887873 to 899864, 949636 to 962800, 976789 to 980845, 987385 to 989598, or 989641 to 989649, 1412677- 1914950, wherein the 5' end of the nucleotide sequence provided in any one of SEQ ID NOS: 497443 to 815174, 842012 to 868589, 887873 to 899864, 949636 to 962800, 976789 to 980845, 987385 to 989598, or 989641 to 989649, 1412677-1914950 is the 5' end of the oligonucleotide. In some embodiments, the at least 8 consecutive nucleotides are present within the nucleotide sequence set forth as SEQ ID NO: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 42, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 815178, 868593, 899868, 962804, or 981190.

In some embodiments, a single stranded oligonucleotide comprises a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676. In some embodiments, the oligonucleotide is up to 50 nucleotides in length. In some embodiments, a single stranded oligonucleotide comprises a fragment of at least 8 nucleotides of a nucleotide sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676.

In some embodiments, a single stranded oligonucleotide comprises a nucleotide sequence as set forth in Table 2 or Table 6. In some embodiments, the oligonucleotide is up to 50 nucleotides in length. In some embodiments, a single stranded oligonucleotide consists of a nucleotide sequence as set forth in Table 2 or Table 6.

In some embodiments, the single stranded oligonucleotide does not comprise three or more consecutive guanosine nucleotides. In some embodiments, the single stranded oligonucleotide does not comprise four or more consecutive guanosine nucleotides.

In some embodiments, the single stranded oligonucleotide is 8 to 30 nucleotides in length. In some embodiments, the single stranded oligonucleotide is up to 50 nucleotides in length. In some embodiments, the single stranded oligonucleotide is 8 to 10 nucleotides in length and all but 1, 2, or 3 of the nucleotides of the complementary sequence of the PRC2- associated region are cytosine or guanosine nucleotides.

In some embodiments, the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a target gene listed in Table 4, e.g., a PRC2-associated region of a nucleotide sequence set forth as SEQ ID NO: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, 43, 44, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 815175, 815176, 868590, 868591, 899865, 899866, 962801, 962802, 981187, or 981188, in which the nucleotide sequence of the single stranded oligonucleotide comprises one or more of a nucleotide sequence selected from the group consisting of

(a) (X)Xxxxxx, (X)xXxxxx, (X)xxXxxx, (X)xxxXxx, (X)xxxxXx and (X)xxxxxX,

(b) (X)XXxxxx, (X)XxXxxx, (X)XxxXxx, (X)XxxxXx, (X)XxxxxX, (X)xXXxxx, (X)xXxXxx, (X)xXxxXx, (X)xXxxxX, (X)xxXXxx, (X)xxXxXx, (X)xxXxxX, (X)xxxXXx, (X)xxxXxX and (X)xxxxXX,

(c) (X)XXXxxx, (X)xXXXxx, (X)xxXXXx, (X)xxxXXX, (X)XXxXxx, (X)XXxxXx,

(X)XXxxxX, (X)xXXxXx, (X)xXXxxX, (X)xxXXxX, (X)XxXXxx, (X)XxxXXx

(X)XxxxXX, (X)xXxXXx, (X)xXxxXX, (X)xxXxXX, (X)xXxXxX and (X)XxXxXx,

(d) (X)xxXXX, (X)xXxXXX, (X)xXXxXX, (X)xXXXxX, (X)xXXXXx,

(X)XxxXXXX, (X)XxXxXX, (X)XxXXxX, (X)XxXXx, (X)XXxxXX, (X)XXxXxX, (X)XXxXXx, (X)XXXxxX, (X)XXXxXx, and (X)XXXXxx,

(e) (X)xXXXXX, (X)XxXXXX, (X)XXxXXX, (X)XXXxXX, (X)XXXXxX and (X)XXXXXx, and

(f) XXXXXX, XxXXXXX, XXxXXXX, XXXxXXX, XXXXxXX, XXXXXxX and XXXXXXx, wherein "X" denotes a nucleotide analogue, (X) denotes an optional nucleotide analogue, and "x" denotes a DNA or RNA nucleotide unit.

In some embodiments, at least one nucleotide of the oligonucleotide is a nucleotide analogue. In some embodiments, the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5 °C compared with an oligonucleotide that does not have the at least one nucleotide analogue.

In some embodiments, at least one nucleotide of the oligonucleotide comprises a 2'

O-methyl. In some embodiments, each nucleotide of the oligonucleotide comprises a 2' O- methyl. In some embodiments, the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide. In some embodiments, the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide. In some embodiments, each nucleotide of the oligonucleotide is a LNA nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2'-fluoro-deoxyribonucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2'-0- methyl nucleotides. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues. In some embodiments, the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides. In some embodiments, the 5' nucleotide of the oligonucleotide is a

deoxyribonucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2'-0-methyl nucleotides. In some embodiments, the 5' nucleotide of the oligonucleotide is a LNA nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5' and 3' ends of the deoxyribonucleotides.

In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g. , phosphorothioate internucleotide linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleotides. In some embodiments, the single stranded oligonucleotide comprises modified internucleotide linkages (e.g. , phosphorothioate internucleotide linkages or other linkages) between between all nucleotides.

In some embodiments, the nucleotide at the 3' position of the oligonucleotide has a 3' hydroxyl group. In some embodiments, the nucleotide at the 3' position of the

oligonucleotide has a 3' thiophosphate. In some embodiments, the single stranded oligonucleotide has a biotin moiety or other moiety conjugated to its 5' or 3' nucleotide. In some embodiments, the single stranded oligonucleotide has cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5' or 3' end.

According to some aspects of the invention compositions are provided that comprise any of the oligonucleotides disclosed herein, and a carrier. In some embodiments, compositions are provided that comprise any of the oligonucleotides in a buffered solution. In some embodiments, the oligonucleotide is conjugated to the carrier. In some embodiments, the carrier is a peptide. In some embodiments, the carrier is a steroid. According to some aspects of the invention pharmaceutical compositions are provided that comprise any of the oligonucleotides disclosed herein, and a pharmaceutically acceptable carrier.

According to other aspects of the invention, kits are provided that comprise a container housing any of the compositions disclosed herein.

According to some aspects of the invention, methods of increasing expression of a target gene in a cell are provided. In some embodiments, the methods involve delivering any one or more of the single stranded oligonucleotides disclosed herein into the cell. In some embodiments, delivery of the single stranded oligonucleotide into the cell results in a level of expression of a target gene that is greater (e.g. , at least 50% greater) than a level of expression of the target gene in a control cell that does not comprise the single stranded oligonucleotide.

According to some aspects of the invention, methods of increasing levels of a target gene in a subject are provided. According to some aspects of the invention, methods of treating a condition (e.g. , a disease listed in Table 4 or otherwise disclosed herein) associated with decreased levels of the target gene in a subject are provided. In some embodiments, the methods involve administering any one or more of the single stranded oligonucleotides disclosed herein to the subject. In some embodiments, the target gene is BCL2L11, BRCA1, F8, FLU, FMR1, FNDC5, GCK, GLP1R, GRN, HAMP, HPRT1, IDOl, IGF1, IL10, LDLR, NANOG, PTGS2, RB I, SERPINF1, SIRT1, SIRT6, SMAD7, ST7, CFTR, PAH, CEP290, CD274, ADIPOQ or STAT3.

BRIEF DESCRIPTION OF TABLES

Table 1: Hexamers that are not seed sequences of human miRNAs

Table 2: Oligonucleotide sequences made for testing in the lab. RQ (column 2) and

RQ SE (column 3) shows the activity of the oligo relative to a control well (usually carrier alone) and the standard error or the triplicate replicates of the experiment, [oligo] is shown in nanomolar for in vitro experiments and in milligrams per kilogram of body weight for in vivo experiments. The Formatted Sequence column shows the sequence of the modified nucleotides, where InaX represents an LNA nucleotide with 3' phosphorothioate linkage, omeX is a 2'-0-methyl nucleotide, dX is a deoxy nucleotide. An s at the end of a nucleotide code indicates that the nucleotide had a 3' phosphorothioate linkage. The "-Sup" at the end of the sequence marks the fact that the 3' end lacks either a phosphate or thiophosphate on the 3' linkage.

Table 3: A listing of oligonucleotide modifications

Table 4: Target Genes and Related Diseases

Table 5: Oligonucleotides made for testing in the lab. RQ (column 4) and RQ SE (column 5) shows the activity of the oligo relative to a control well (usually carrier alone) and the standard error for the triplicate replicates of the experiment, [oligo] is shown in nanomolar for in vitro experiments and in milligrams per kilogram of body weight for in vivo experiments. The sequence of each oligonucleotide including any modified nucleotides in is shown in Table 6.

Table 6: Formatted oligonucleotide sequences made for testing in the lab showing nucleotide modifications. The Formatted Sequence column shows the sequence of the modified nucleotides, where InaX represents an LNA nucleotide with 3' phosphorothioate linkage, omeX is a 2'-0-methyl nucleotide, dX is a deoxy nucleotide. An s at the end of a nucleotide code indicates that the nucleotide had a 3' phosphorothioate linkage. The "-Sup" at the end of the sequence marks the fact that the 3' end lacks either a phosphate or thiophosphate on the 3' linkage. The Formatted Sequence column shows the sequence of the oligonucleotide, including modified nucleotides, for the oligonucleotides tested in Table 5.

Table 7: Cell lines

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

Aspects of the invention provided herein relate to the discovery of polycomb repressive complex 2 (PRC2)-interacting RNAs. Polycomb repressive complex 2 (PRC2) is a histone methyltransferase and a known epigenetic regulator involved in silencing of genomic regions through methylation of histone H3. Among other functions, PRC2 interacts with long noncoding RNAs (IncRNAs), such as Rep A, Xist, and Tsix, to catalyze

trimethylation of histone H3-lysine27. PRC2 contains four subunits, Eed, Suzl2, RbAp48, and Ezh2. Aspects of the invention relate to the recognition that single stranded

oligonucleotides that bind to PRC2-associated regions of RNAs (e.g. , IncRNAs) that are expressed from within a genomic region that encompasses or that is in functional proximity to the target gene can induce or enhance expression of the target gene. In some

embodiments, this upregulation is believed to result from inhibition of PRC2 mediated repression of the target gene.

As used herein, the term "PRC2-associated region" refers to a region of a nucleic acid that comprises or encodes a sequence of nucleotides that interact directly or indirectly with a component of PRC2. A PRC2-associated region may be present in a RNA (e.g. , a long non- coding RNA (IncRNA)) that that interacts with a PRC2. A PRC2-associated region may be present in a DNA that encodes an RNA that interacts with PRC2. In some cases, the PRC2- associated region is equivalently referred to as a PRC2-interacting region.

In some embodiments, a PRC2-associated region is a region of an RNA that crosslinks to a component of PRC2 in response to in situ ultraviolet irradiation of a cell that expresses the RNA, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that immunoprecipitates with an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4 (which as noted above are components of PRC2), or a region of genomic DNA that encodes that RNA region.

In some embodiments, a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g. , RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that protected RNA region. In some embodiments, a PRC2-associated region is a region of an RNA that is protected from nucleases (e.g. , RNases) in an RNA-immunoprecipitation assay that employs an antibody that targets SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region.

In some embodiments, a PRC2-associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets a component of PRC2, or a region of genomic DNA that encodes that RNA region. In some embodiments, a PRC2- associated region is a region of an RNA within which occur a relatively high frequency of sequence reads in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that binds specifically to SUZ12, EED, EZH2 or RBBP4, or a region of genomic DNA that encodes that protected RNA region. In such embodiments, the PRC2-associated region may be referred to as a "peak."

In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that interact with PRC2 complex. In some embodiments, a PRC2-associated region comprises a sequence of 40 to 60 nucleotides that encode an RNA that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5kb in length that comprises a sequence (e.g. , of 40 to 60 nucleotides) that interacts with

PRC2. In some embodiments, a PRC2-associated region comprises a sequence of up to 5kb in length within which an RNA is encoded that has a sequence (e.g. , of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4kb in length that comprise a sequence (e.g. , of 40 to 60 nucleotides) that interacts with PRC2. In some embodiments, a PRC2-associated region comprises a sequence of about 4kb in length within which an RNA is encoded that includes a sequence (e.g. , of 40 to 60 nucleotides) that is known to interact with PRC2. In some embodiments, a PRC2-associated region has a sequence as set forth in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, or 962805 to 962816, or 981191 to 981196.

In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region in a genomic region that encompasses or that is in proximity to the target gene. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2- associated region that has a sequence as set forth in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, or 962805 to 962816, or 981191 to 981196. In some embodiments, single stranded oligonucleotides are provided that specifically bind to, or are complementary to, a PRC2-associated region that has a sequence as set forth in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, 962805 to 962816, or 981191 to 981196 combined with up to 2kb, up to 5kb, or up to lOkb of flanking sequences from a corresponding genomic region to which these SEQ IDs map (e.g., in a human genome). In some embodiments, single stranded oligonucleotides have a sequence as set forth in any one of SEQ ID NOS: 1211 to 815174, 815209 to 868589, 868618 to 899864, 899933 to 962800, 962817 to 980845, 981197 to 989598, 989617 to 989649, or 989650 to 1412676. In some embodiments, single stranded oligonucleotides have a sequence as set forth in Table 2 or Table 6.

Without being bound by a theory of invention, these oligonucleotides are able to interfere with the binding of and function of PRC2, by preventing recruitment of PRC2 to a specific chromosomal locus. For example, a single administration of single stranded oligonucleotides designed to specifically bind a PRC2-associated region IncRNA can stably displace not only the IncRNA, but also the PRC2 that binds to the IncRNA, from binding chromatin. After displacement, the full complement of PRC2 is not recovered for up to 24 hours. Further, IncRNA can recruit PRC2 in a cis fashion, repressing gene expression at or near the specific chromosomal locus from which the IncRNA was transcribed.

Methods of modulating gene expression are provided, in some embodiments, that may be carried out in vitro, ex vivo, or in vivo. It is understood that any reference to uses of compounds throughout the description contemplates use of the compound in preparation of a pharmaceutical composition or medicament for use in the treatment of condition (e.g., a disease listed in Table 4 or otherwise disclosed herein) associated with decreased levels or activity of the target gene. Thus, as one nonlimiting example, this aspect of the invention includes use of such single stranded oligonucleotides in the preparation of a medicament for use in the treatment of disease, wherein the treatment involves upregulating expression of a target gene.

In further aspects of the invention, methods are provided for selecting a candidate oligonucleotide for activating expression of a target gene. The methods generally involve selecting as a candidate oligonucleotide, a single stranded oligonucleotide comprising a nucleotide sequence that is complementary to a PRC2-associated region (e.g., a nucleotide sequence as set forth in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, 962805 to 962816, or 981191 to 981196). In some embodiments, sets of oligonucleotides may be selected that are enriched (e.g., compared with a random selection of oligonucleotides) in oligonucleotides that activate expression of a target gene.

Table 4: Target Genes and Related Diseases

Gene Protein name Related Diseases Related *OMIM

Symbol Phenotype

numbers

IL10 interleukin 10 Autoimmune and 614395, 180300 inflammatory

diseases, e.g. graft vs.

host disease and

rheumatoid arthritis

LDLR low density lipoprotein dyslipidemias, 143890

receptor atherosclerosis , and

hypercholesterolemia

NANOG Nanog homeobox tissue regeneration

PTGS2 prostaglandin- inflammation, cancer,

endoperoxide synthase 2 infectious disease

(prostaglandin G/H

synthase and

cyclooxygenase)

RBI retinoblastoma 1 cancer, e.g. bladder 109800, 259500, cancer, osteosarcoma, 180200, 182280 retinoblastoma, small

cell lung cancer

SERPINF1 serpin peptidase inhibitor, cancer, choroidal 613982

clade F (alpha-2 neovascularization,

antiplasmin, pigment cardiovascular

epithelium derived disease, diabetes, and

factor), member 1 osteogenesis

imperfecta

SIRT1 sirtuin 1 Metabolic disease,

aging

SIRT6 sirtuin 6 antioxidative

pathway, anti-NFkB

SMAD7 SMAD family member 7 Acute kidney injury 612229

(anti-TGFb),

colorectal cancer

ST7 suppression of cancer, e.g. myeloid

tumorigenicity 7 cancer, head and neck

squamous cell

carcinomas, breast

cancer, colon

carcinoma, and

prostate cancer

STAT3 signal transducer and tissue regeneration 147060

activator of transcription and Hyper- IgE

3 (acute-phase response recurrent infection

factor) syndrome Gene Protein name Related Diseases Related *OMIM Symbol Phenotype

numbers

CFTR Cystic fibrosis Cystic fibrosis (CF) 602421

transmembrane and congenital

conductance regulator bilateral absence of

vas deferens

(CBAVD)

PAH Phenylalanine Phenylketonuria 612349

hydroxylase (PKU)

CEP290 Centrosomal protein of Leber's congenital 610142

290 kDa amaurosis (LCA),

Bardet-Biedl

syndrome (BBS),

Joubert syndrome,

Meckel syndrome,

Sior-Loken syndrome

CD274 cluster of differentiation Autoimmune disease, 605402

(also 274 (also known as transplant rejection,

known as Programmed cell death 1 allergies or asthma

PD-L1) ligand 1)

ADIPOQ adiponectin, C1Q and Obesity and obesity- 605441, 612556

collagen domain linked diseases (e.g.,

containing (also known as hypertension,

adiponectin) metabolic

dysfunction, type 2

diabetes,

atherosclerosis, and

ischemic heart

disease)

*Online Mendelian Inheritance in Man® An Online Catalog of Human Genes and Genetic Disorders (omim.org)

Target Genes and Related Disease and Biological Pathways

Cancer - SERPINFl, BCL2L11, BRCAl, RBI, and ST7

Cancer is a broad group of various diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade nearby parts of the body. Several genes, many classified as tumor suppressors, are down-regulated during cancer progression, e.g., SERPINFl, BCL2L11, BRCAl, RBI, and ST7, and have roles in inhibiting genomic instability, metabolic processes, immune response, cell growth/cell cycle progression, migration, and/or survival. These cellular processes are important for blocking tumor progression. SERPINF1 encodes an anti-angiogenic factor. BCL2L11 encodes an apoptosis facilitator. BRCAl encodes a RING finger protein involved in DNA damage repair. RBI prevents excessive cell growth by inhibiting cell cycle progression until a cell is ready to divide. ST7 suppresses tumor growth in mouse models and is involved in regulation of genes involved in differentiation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating

SERPINF1, BCL2L11, BRCAl, RBI, and ST7 for the treatment and/or prevention of diseases associated with reduced SERPINF1, BCL2L11, BRCAl, RBI, and ST7 expression or function such as cancer. For example, aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating BCL2L11 for the treatment or prevention of human T-cell acute lymphoblastic leukemia and lymphoma. In another example, aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating BRCAl for the treatment or prevention of breast cancer or pancreatic cancer. In another example, aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating RB 1 for the treatment or prevention of bladder cancer, osteosarcoma, retinoblastoma, or small cell lung cancer. In another example, aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating ST7 for the treatment or prevention of myeloid cancer, head and neck squamous cell carcinomas, breast cancer, colon carcinoma, or prostate cancer.

Examples of cancer include but are not limited to leukemias, lymphomas, myelomas, carcinomas, metastatic carcinomas, sarcomas, adenomas, nervous system cancers and genitourinary cancers. In some embodiments, the cancer is adult and pediatric acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, anal cancer, cancer of the appendix, astrocytoma, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma, fibrous histiocytoma, brain cancer, brain stem glioma, cerebellar astrocytoma, malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, hypothalamic glioma, breast cancer, male breast cancer, bronchial adenomas, Burkitt lymphoma, carcinoid tumor, carcinoma of unknown origin, central nervous system lymphoma, cerebellar astrocytoma, malignant glioma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colorectal cancer, cutaneous T-cell lymphoma, endometrial cancer, ependymoma, esophageal cancer, Ewing family tumors, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, extracranial germ cell tumor, extragonadal germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, hypopharyngeal cancer, hypothalamic and visual pathway glioma, intraocular melanoma, islet cell tumors, Kaposi sarcoma, kidney cancer, renal cell cancer, laryngeal cancer, lip and oral cavity cancer, small cell lung cancer, non-small cell lung cancer, primary central nervous system lymphoma, Waldenstrom macro globulinema, malignant fibrous histiocytoma, medulloblastoma, melanoma, Merkel cell carcinoma, malignant mesothelioma, squamous neck cancer, multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides, myelodysplasia syndromes, myeloproliferative disorders, chronic myeloproliferative disorders, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oropharyngeal cancer, ovarian cancer, pancreatic cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary cancer, plasma cell neoplasms, pleuropulmonary blastoma, prostate cancer, rectal cancer,

rhabdomyosarcoma, salivary gland cancer, soft tissue sarcoma, uterine sarcoma, Sezary syndrome, non-melanoma skin cancer, small intestine cancer, squamous cell carcinoma, squamous neck cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer, trophoblastic tumors, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, or Wilms tumor. Hemophilia-F8

Hemophilia is a group of hereditary genetic disorders that impair the body's ability to control blood clotting or coagulation, which is used to stop bleeding when a blood vessel is broken. Like most recessive sex-linked, X chromosome disorders, haemophilia is more likely to occur in males than females. For example, Haemophilia A (clotting factor VIII deficiency), the most common form of the disorder, is present in about 1 in 5,000-10,000 male births. Haemophilia B (factor IX deficiency) occurs in around 1 in about 20,000-34,000 male births. Hemophilia lowers blood plasma clotting factor levels of the coagulation factors, e.g. F8, needed for a normal clotting process. Thus when a blood vessel is injured, a temporary scab does form, but the missing coagulation factors prevent fibrin formation, which is necessary to maintain the blood clot. F8, for example, encodes Factor VIII (FVIII), an essential blood clotting protein. Factor VIII participates in blood coagulation; it is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids forms a complex that converts factor X to the activated form Xa. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating F8 for the treatment and/or prevention of diseases associated with reduced F8 expression or function such as hemophilia.

Fragile X syndrome-FMRl

Fragile X syndrome (FXS) (also known as Martin-Bell syndrome, or Escalante's syndrome) is a genetic syndrome that is the most common known single-gene cause of autism and the most common inherited cause of intellectual disability. It results in a spectrum of intellectual disability ranging from mild to severe as well as physical characteristics such as an elongated face, large or protruding ears, and larger testes (macroorchidism), behavioral characteristics such as stereotypical movements (e.g. hand-flapping), and social anxiety. Fragile X syndrome is associated with the expansion of the CGG trinucleotide repeat affecting the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting reduced expression of the X mental retardation protein (FMRP), which is required for normal neural development. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating FMR1 for the treatment and/or prevention of diseases associated with reduced FMR1 expression or function such as Fragile X syndrome.

Premature Ovarian Failure-FMRl

Premature Ovarian Failure (POF), also known as premature ovarian insufficiency, primary ovarian insufficiency, premature menopause, or hypergonadotropic hypogonadism, is the loss of function of the ovaries before age 40. POF can be associated mutations in the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting reduced expression of the X mental retardation protein (FMRP). Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating FMRl for the treatment and/or prevention of diseases associated with reduced FMRl expression or function such as Premature Ovarian Failure. Obesity FNDC5, GCK, ADIPOQ

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems. A person is considered obese when his or her weight is 20% or more above normal weight. The most common measure of obesity is the body mass index or BMI. A person is considered overweight if his or her BMI is between 25 and 29.9; a person is considered obese if his or her BMI is over 30. Obesity increases the likelihood of various diseases, particularly heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis. Obesity is most commonly caused by a combination of excessive food energy intake, lack of physical activity, and genetic susceptibility. Overexpression of FNDC5, fibronectin type II containing 5, has been shown in animal models to reduce body weight in obese mice. GCK, glucokinase (hexokinase 4), phosphorylates glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Mutations in the GCK gene have been found to be associated with obesity in humans. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating FNDC5 for the treatment and/or prevention of diseases associated with reduced

FNDC5expression or function such as obesity. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GCK for the treatment and/or prevention of diseases associated with reduced GCK expression or function such as obesity.

Adiponectin, encoded by the ADIPOQ gene, is a hormone that regulates metabolism of lipids and glucose. Adipocytes found in adipose tissue secrete adiponectin into the bloodstream where it self-associates into larger structures by binding of multiple adiponectin trimers to form hexamers and dodecamers. Adiponectin levels are inversely related to the amount of body fat in an individual and positively associated with insulin sensitivity both in healthy subjects and in diabetic patients. Adiponectin has a variety of protective properties against obesity-linked complications, such as hypertension, metabolic dysfunction, type 2 diabetes, atherosclerosis, and ischemic heart disease through its anti-inflammatory and antiatherogenic properties. Specifically with regard to type 2 diabetes, administration of adiponectin has been accompanied by a reduction in plasma glucose and an increase in insulin sensitivity. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating ADIPOQ for the treatment and/or prevention of diseases associated with reduced ADIPOQ expression or function such as obesity or an obesity-linked disease or disorders such as hypertension, metabolic dysfunction, type 2 diabetes, atherosclerosis, and ischemic heart disease. Type 2 Diabetes- FNDC5, GCK, GLP1R, SIRT1, ADIPOQ

Type 2 diabetes (also called Diabetes mellitus type 2 and formally known as adult- onset diabetes) a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. Type 2 diabetes makes up about 90% of cases of diabetes with the other 10% due primarily to diabetes mellitus type 1 and gestational diabetes. Obesity is thought to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease. The prevalence of diabetes has increased dramatically in the last 50 years. As of 2010 there were approximately 285 million people with the disease compared to around 30 million in 1985. Overexpression of FNDC5, fibronectin type II containing 5, has been shown in animal models to improve their insulin sensitivity. GCK, glucokinase (hexokinase 4), phosphorylates glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Mutations in the GCK gene are known to be associated with Type 2 Diabetes. Glucagon-like peptide 1 receptor (GLP1R) is known to be expressed in pancreatic beta cells. Activated GLP1R stimulates the adenylyl cyclase pathway which results in increased insulin synthesis and release of insulin. SIRT1 (Sirtuin 1, also known as NAD-dependent deacetylase sirtuin- 1) is an enzyme that deacetylates proteins that contribute to cellular regulation. Sirtuin 1 is downregulated in cells that have high insulin resistance and inducing its expression increases insulin sensitivity, suggesting the molecule is associated with improving insulin sensitivity. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating FNDC5 for the treatment and/or prevention of diseases associated with reduced FNDC5 expression or function such as Type 2 Diabetes. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GCK for the treatment and/or prevention of diseases associated with reduced GCK expression or function such as Type 2 Diabetes.

Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GLP1R for the treatment and/or prevention of diseases associated with reduced GLP1R expression or function such as Type 2 Diabetes. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SIRT1 for the treatment and/or prevention of diseases associated with reduced SIRT1 expression or function such as Type 2 Diabetes. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating ADIPOQ for the treatment and/or prevention of diseases associated with reduced ADIPOQ expression or function such as Type 2 Diabetes.

Metabolic Disease- IGF1, SIRT1

Inborn errors of metabolism comprise a large class of genetic diseases involving disorders of metabolism. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are now often referred to as congenital metabolic diseases or inherited metabolic diseases. IGF-1, Insulin growth factor- 1, is a hormone similar in molecular structure to insulin. IGF-1 plays an important role in childhood growth and continues to have anabolic effects in adults. Reduced IGF-1 and mutations in the IGF-1 gene are associated with metabolic disease. SIRT1 (Sirtuin 1, also known as NAD-dependent deacetylase sirtuin- 1) is an enzyme that deacetylates proteins that contribute to cellular regulation. SIRT1 has been shown to de-acetylate and affect the activity of both members of the PGCl-alpha/ERR-alpha complex, which are essential metabolic regulatory transcription factors. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IGF-1 for the treatment and/or prevention of diseases associated with reduced IGF-1 expression or function such as metabolic disease. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SIRT1 for the treatment and/or prevention of diseases associated with reduced SIRTl expression or function such as metabolic disease.

Aging/Senescence- SIRTl

Senescence is the state or process of aging. Cellular senescence is a phenomenon where isolated cells demonstrate a limited ability to divide in culture, while organismal senescence is the aging of organisms. After a period of near perfect renewal (in humans, between 20 and 35 years of age), organismal senescence/aging is characterised by the declining ability to respond to stress, increasing homeostatic imbalance and increased risk of disease. This currently irreversible series of changes inevitably ends in death. SIRTl (Sirtuin 1, also known as NAD-dependent deacetylase sirtuin-1) is an enzyme that deacetylates proteins that contribute to cellular regulation. Mice overexpressing SIRTl present lower levels of DNA damage, decreased expression of the ageing-associated gene pl6Ink4a, a better general health and fewer spontaneous carcinomas and sarcomas. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SIRTl for the treatment and/or prevention of biological processes associated with reduced SIRTl expression or function such as aging.

Autoimmune- GRN, IDOl, CD274

Autoimmune diseases arise from an inappropriate immune response of the body against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. Autoimmune diseases are classified by corresponding types of hypersensitivity: type II, type III, or type IV. Examples of autoimmune disease include, but are not limited to, Ankylosing Spondylitis, Autoimmune cardiomyopathy, Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, immune lymphoproliferative syndrome, Autoimmune peripheral neuropathy, Autoimmune pancreatitis, Autoimmune polyendocrine syndrome, Autoimmune thrombocytopenic purpura, Celiac disease, Cold agglutinin disease, Contact dermatitis, Crohn's disease, Dermatomyositis, Diabetes mellitus type 1, Eosinophilic fasciitis, Gastrointestinal pemphigoid, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalopathy, Hashimoto's thyroiditis, Idiopathic thrombocytopenic purpura, Lupus erythematosus, Miller-Fisher syndrome, Myasthenia gravis, Pemphigus vulgaris, Pernicious anaemia, Polymyositis, Primary biliary cirrhosis, Psoriasis, Psoriatic arthritis, Relapsing polychondritis, Rheumatoid arthritis, Sjogren's syndrome, Temporal arteritis, Transverse myelitis, Ulcerative colitis, Undifferentiated connective tissue disease, Vasculitis, Vitiligo, and Wegener's granulomatosis. IDOl encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of

pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Increased catabolism of tryptophan by IDOl suppresses T cell responses in a variety of diseases or states, including autoimmune disorders. GRN encodes a precursor protein called Progranulin, which is then cleaved to form the secreted protein granulin. Granulin regulates cell division, survival, motility and migration. Granulin has roles in cancer, inflammation, host defense, cartilage development and degeneration, and neurological functions. Downregulation of GRN has been shown to increase the onset of autoimmune diseases like rheumatoid arthritis. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IDOl for the treatment and/or prevention of diseases associated with reduced IDOl expression or function such as autoimmune diseases. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GRN for the treatment and/or prevention of diseases associated with reduced GRN expression or function such as autoimmune diseases.

CD274 (also known as PDL1) is a transmembrane protein containing IgV-like and IgC-like extracellular domains expressed on immune cells and non-hematopoietic cells, and is a ligand for the programmed death receptor (PD-1) expressed on lymphocytes and macrophages. PD-1 and CD274 interactions are essential in maintaining the balance of T- cell activation, tolerance, and immune-mediated tissue damage. CD274 is involved in inhibiting the initial phase of activation and expansion of self -reactive T cells, and restricting self -reactive T-cell effector function and target organ injury. More specifically, activation of PD-1 by CD274 inhibits T-cell proliferation, cytokine production, and cytolytic function by blocking the induction of phosphatidylinositol-3-kinase (PI3K) activity and downstream activation of Akt.

Decreased expression of CD274 results in autoimmunity in animal models. For example, mice deficient for the CD274 receptor, PD-1, developed features of late onset lupus. In another instance, blockade of CD274 activity in a mouse model of Type 1 diabetes resulted in accelerated progression of diabetes. In yet another example, CD274 blockade in an animal model of multiple sclerosis resulted in accelerated disease onset and progression.

Increasing expression of CD274 offers a novel approach for treating diseases related to inappropriate or undesireable activation of the immune system, including in the context of translation rejection, allergies, asthma and autoimmune disorders. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating CD274 for the treatment and/or prevention of diseases associated with reduced CD274 expression or function such as autoimmune disease, transplant rejection, allergies or asthma. Inflammation (Chronic inflammation) - GRN, IDOl, IL10

Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli and to initiate the healing process. However, chronic inflammation can also lead to a host of diseases, such as hay fever, periodontitis, atherosclerosis, and rheumatoid arthritis. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of

inflammation and is characterized by simultaneous destruction and healing of the tissue from the inflammatory process. Inflammatory disorder include, but are not limited to, acne vulgaris,asthma, autoimmune diseases, celiac disease, chronic prostatitis, glomerulonephritis, inflammatory bowel diseases, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection (graft vs host disease), vasculitis and interstitial cystitis.

GRN encodes a precursor protein called Progranulin, which is then cleaved to form the secreted protein granulin. Granulin regulates cell division, survival, motility and migration. Granulin has roles in cancer, inflammation, host defense, cartilage development and degeneration, and neurological functions. GRN has been shown to alleviate inflammatory arthritis symptoms in mouse models. Indoleamine 2,3-dioxygenase 1 (IDOl; previously referred as IDO or INDO) is the main inducible and rate-limiting enzyme for the catabolism of the amino acid tryptophan through the kynurenine pathway. Increased catabolism of tryptophan by IDOl suppresses T cell responses in a variety of diseases, such as allograft rejection.

IL-10 is capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNFa and GM-CSF made by cells such as macrophages and regulatory T-cells. It also displays a potent ability to suppress the antigen-presentation capacity of antigen presenting cells. Treatment with IL-10 (e.g. as a recombinant protein given to patients) is currently in clinical trials for Crohn's disease. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease. Mouse models of arthritis have been shown to have decreased levels of IL-10. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GRN for the treatment and/or prevention of diseases associated with reduced GRN expression or function such as chronic inflammation.

Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GRN for the treatment and/or prevention of diseases associated with reduced GRN expression or function such as chronic inflammation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GRN for the treatment and/or prevention of diseases associated with reduced GRN expression or function such as rheumatoid arthritis. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IDOl for the treatment and/or prevention of diseases associated with reduced IDOl expression or function such as chronic inflammation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IDOl for the treatment and/or prevention of diseases associated with reduced IDOl expression or function such as graft vs. host disease.

Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IL10 for the treatment and/or prevention of diseases associated with reduced IL10 expression or function such as chronic inflammation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IL10 for the treatment and/or prevention of diseases associated with reduced IL10 expression or function such as rheumatoid arthritis. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IL10 for the treatment and/or prevention of diseases associated with reduced IL10 expression or function such as graft vs host disease. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IL10 for the treatment and/or prevention of diseases associated with reduced IL10 expression or function such as Crohn's disease.

Infectious disease - PTGS2

Infectious diseases, also known as transmissible diseases or communicable diseases comprise clinically evident illness (i.e., characteristic medical signs and/or symptoms of disease) resulting from the infection, presence and growth of pathogenic biological agents in an individual host organism. Infectious pathogens include some viruses, bacteria, fungi, protozoa, multicellular parasites, and aberrant proteins known as prions. A contageous disease is a subset of infectious disease that is especially infective or easily transmitted. Prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2 or simply COX-2, is an enzyme that in humans is encoded by the PTGS2 gene. Prostaglandin endoperoxide H synthase, COX 2, converts arachidonic acid (AA) to prostaglandin endoperoxide H2. COX-2 is elevated during inflammation and infection. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating PTGS2 for the treatment and/or prevention of diseases associated with reduced PTGS2 expression or function such as infectious disease.

CNS disease - IGF1, GRN

Central nervous system (CNS) disease can affect either the spinal cord (myelopathy) or brain (encephalopathy), both of which are part of the central nervous system. CNS diseases include Encephalitis, Meningitis, Tropical spastic paraparesis, Arachnoid cysts, Amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Dementia, Locked- in syndrome, Parkinson's disease, Tourette', and Multiple sclerosis. CNS diseases have a variety of causes including Trauma, Infections, Degeneration, Structural defects, Tumors, Autoimmune Disorders, and Stroke. Symptoms range from persistent headache, loss of feeling, memory loss, loss of muscle strength, tremors, seizures, slurred speech, and in some cases, death. IGF-1, Insulin growth factor- 1, is a hormone similar in molecular structure to insulin. IGF-I deficiency is associated with neurodegenerative disease and has been shown to improve survival of neurons both in vitro and in vivo. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IGFl for the treatment and/or prevention of diseases associated with reduced IGFl expression or function such as CNS disease.

GRN encodes a precursor protein called Progranulin, which is then cleaved to form the secreted protein granulin. Granulin regulates cell division, survival, motility and migration. Granulin has roles in cancer, inflammation, host defense, cartilage development and degeneration, and neurological functions. Mutations in granulin are associated with dementia. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating GRN for the treatment and/or prevention of diseases associated with reduced GRN expression or function such as CNS disease. Hemochromatosis - HAMP

Hemochromatosis is the abnormal accumulation of iron in parenchymal organs, leading to organ toxicity. This is the most common inherited liver disease in Caucasians and the most common autosomal recessive genetic disorder. HAMP (hepcidin antimicrobial peptide) encodes the protein hepcidin, which plays a major role in maintaining iron balance in the body. Hepcidin circulates in the blood and inhibits iron absorption by the small intestine when the body's supply of iron is too high. Hepcidin interacts primarily with other proteins in the intestines, liver, and certain white blood cells to adjust iron absorption and storage. At least eight mutations in the HAMP gene have been identified that result in reduced levels of hepcidin and hemochromatosis. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating HAMP for the treatment and/or prevention of diseases associated with reduced HAMP expression or function such as hemochromato sis .

Acute kidney injury - SMAD7

Acute kidney injury (AKI), previously called acute renal failure (ARF), is a rapid loss of kidney function. Its causes are numerous and include low blood volume from any cause, exposure to substances harmful to the kidney, and obstruction of the urinary tract. AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects to other organ systems. SMAD7 (Mothers against decapentaplegic homolog 7) is a protein that, as its name describes, is a homolog of the Drosophila gene: "Mothers against decapentaplegic". It belongs to the SMAD family of proteins, which belong to the TGFP superfamily of ligands. Like many other TGFP family members, SMAD7 is involved in cell signalling. It is a TGFP type 1 receptor antagonist. It blocks TGFpi and activin associating with the receptor, blocking access to SMAD2. It is an inhibitory SMAD (I-SMAD) and is enhanced by SMURF2. Upon TGF- β treatment, Smad7 binds to discrete regions of Pellino-1 via distinct regions of the Smad MH2 domains. The interaction block formation of the IRAKI -mediated IL-1R/TLR signaling complex therefore abrogates NF-κΒ activity, which subsequently causes reduced expression of proinflammatory genes. Overexpression of SMAD7 in the kidney using gene therapy inhibited renal fibrosis and inflammatory pathways. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SMAD7 for the treatment and/or prevention of diseases associated with reduced SMAD7 expression or function such as acute kidney injury.

Thalassemia- HAMP

Thalassemia is a group of inherited autosomal recessive blood disorders, resulting in a reduced rate of synthesis or no synthesis of one of the globin chains that make up

hemoglobin. This can cause the formation of abnormal hemoglobin molecules or reduced numbers of hemoglobin, thus causing anemia, the characteristic presenting symptom of the thalassemias. HAMP (hepcidin antimicrobial peptide) encodes the protein hepcidin, which plays a major role in maintaining iron balance in the body. Hepcidin circulates in the blood and inhibits iron absorption by the small intestine when the body's supply of iron is too high. HAMP expression has been shown to be lower in patients with thalassemia and is associated with iron-overload (sometimes called hemochromatosis) in these patients. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating HAMP for the treatment and/or prevention of diseases associated with reduced HAMP expression or function such as thalassemia. Lesch-Nyhan disease- HPRT1

Lesch-Nyhan syndrome (LNS), also known as Nyhan's syndrome, Kelley-Seegmiller syndrome and Juvenile gout, is a rare inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT), produced by mutations in the HPRT gene located on the X chromosome. LNS affects about one in 380,000 live births. The HGPRT deficiency causes a build-up of uric acid in all body fluids. This results in both hyperuricemia and hyperuricosuria, associated with severe gout and kidney problems.

Neurological signs include poor muscle control and moderate mental retardation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating HPRT for the treatment and/or prevention of diseases associated with reduced HPRT expression or function such as Lesch-Nyhan syndrome.

Delayed Growth - IGF- 1

Delayed growth is poor or abnormally slow height or weight gains in a child typically younger than age 5. IGF-1, Insulin growth factor- 1, is a hormone similar in molecular structure to insulin. IGF-1 plays an important role in childhood growth and continues to have anabolic effects in adults. IGF1 deficiency has been shown to be associated with delayed growth and short stature in humans. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating IGF1 for the treatment and/or prevention of diseases associated with reduced IGF1 expression or function such as delayed growth.

Dyslipidemias and Atherosclerosis- LDLR

Accumulation of lipids in the blood can cause a variety of conditions and diseases, e.g. dyslipidemia and atherosclerosis. Atherosclerosis in particular is the leading cause of death in industrialized societies, making prevention and treatment a high public health concern. Low-density lipoprotein (LDL) is a major transporter of fat molecules, e.g., cholesterol, in the blood stream that delivers fat molecules to cells. High-density lipoprotein (HDL) is another transporter of fat molecules that moves lipids, e.g. cholesterol, from cells to the liver. High levels of LDL are associated with health problems such as dyslipidemia and atherosclerosis, while HDL is protective against atherosclerosis and is involved in maintenance of cholesterol homeostasis.

Dyslipidemia generally describes a condition when an abnormal amount of lipids is present in the blood. Hyperlipidemia, which accounts for the majority of dyslipidemias, refers to an abnormally high amount of lipids in the blood. Hyperlipidemia is often associated with hormonal diseases such as diabetes, hypothyroidism, metabolic syndrome, and Cushing syndrome. Examples of common lipids in dyslipidemias include triglycerides like cholesterol and fat. Abnormal amounts lipids or lipoproteins in the blood can lead to atherosclerosis, heart disease, and stroke.

Athero sclera sic diseases, e.g. coronary artery disease (CAD) and myocardial infarction (MI), involve a thickening of artery walls caused by accumulation of fat in the blood, most commonly cholesterol. This thickening is thought to be the result of chronic inflammation of arteriole walls due to accumulation of LDLs in the vessel walls. LDL molecules can become oxidized once inside vessel walls, resulting in cell damage and recruitment of immune cells like macrophages to absorb the oxidized LDL. Once macrophages internalize oxidized LDL, they become saturated with cholesterol and are referred to as foam cells. Smooth muscle cells are then recruited and form a fibrous region. These processes eventually lead to formation of plaques block arteries and can cause heart attack and stroke. HDL is capable of transporting cholesterol from foam cells to the liver, which aids in inhibition of inflammation and plaque formation.

The LDLR gene encodes the Low-Density Lipoprotein (LDL) Receptor, which is a mosaic protein of -840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes -70% of LDL from the circulation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating LDLR for the treatment and/or prevention of diseases associated with reduced LDLR expression or function such as dyslipidemia or atherosclerosis.

Tissue regeneration - NANOG

Regeneration is the process of renewal, restoration, and growth of cells and organs in response to disturbance or damage. Strategies for regeneration of tissue include the rearrangement of pre-existing tissue, the use of adult somatic stem cells and the

dedifferentiation and/or transdifferentiation of cells, and more than one mode can operate in different tissues of the same animal. During the developmental process genes are activated that serve to modify the properties of cells as they differentiate into different tissues.

Development and regeneration involves the coordination and organization of populations cells into a blastema, which is a mound of stem cells from which regeneration begins.

Dedifferentiation of cells means that they lose their tissue-specific characteristics as tissues remodel during the regeneration process. Transdifferentiation of cells occurs when they lose their tissue-specific characteristics during the regeneration process, and then re-differentiate to a different kind of cell . These strategies result in the re-establishment of appropriate tissue polarity, structure and form. NANOG is a transcription factor critically involved with self- renewal of undifferentiated embryonic stem cells through maintanence of pluripotency. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating NANOG for tissue regeneration.

Oxidative stress/Antioxidative pathway- SIRT6

Cells are protected against oxidative stress by an interacting network of antioxidant enzymes. Oxidation reactions can produce superoxides or free radicals. In turn, these radicals can start chain reactions. When the chain reaction occurs in a cell, it can cause damage or death to the cell. Antioxidants terminate these chain reactions by removing free radical intermediates, and inhibit other oxidation reactions. The superoxide released by processes such as oxidative phosphorylation is first converted to hydrogen peroxide and then further reduced to give water. This detoxification pathway is the result of multiple enzymes, with superoxide dismutases catalysing the first step and then catalases and various peroxidases removing hydrogen peroxide. As oxidative stress appears to be an important part of many human diseases, the use of antioxidants in pharmacology is highly attractive. Mono-ADP- ribosyltransferase sirtuin-6 is an enzyme that in humans is encoded by the SIRT6 gene. Sirtuin-6 has been shown to have a protective role against metabolic damage caused by a high fat diet. SIRT6 deficiency is associated with metabolic defects that lead to oxidative stress. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SIRT6 for tissue regeneration. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SIRT6 for the treatment and/or prevention of diseases associated with reduced SIRT6 expression or function such as oxidative stress.

Choroidal neovascularization - SERPINFl

Choroidal neovascularization (CNV) is the creation of new blood vessels in the choroid layer of the eye. This is a common symptom of the degenerative maculopathy wet AMD (age-related macular degeneration). Serpin Fl (SERPINFl), also known as Pigment epithelium-derived factor (PEDF), is a multifunctional secreted protein that has anti- angiogenic, anti-tumorigenic, and neurotrophic functions. The anti-angiogenic properties of SERPINFl allow it to block new blood vessel formation. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SERPINFlfor the treatment and/or prevention of diseases associated with reduced SERPINFl expression or function such as Choroidal neovascularization.

Cardiovascular Disease - SERPINFl

Cardiovascular disease is a class of diseases that involve the heart or blood vessels

(arteries and veins). Cardiovascular diseases remain the biggest cause of deaths worldwide. Types of cardiovascular disease include, Coronary heart disease, Cardiomyopathy,

Hypertensive heart disease, Heart failure, Cor pulmonale, Cardiac dysrhythmias,

Inflammatory heart disease, Valvular heart disease, Stroke and Peripheral arterial disease.

Serpin Fl (SERPINFl), also known as Pigment epithelium-derived factor (PEDF), is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. SERPINFl has been shown to have a protective role in atherosclerosis, the main cause of coronary heart disease, myocardial infarction and heart failure due to its anti- inflammatory, antioxidant and antithrombotic effects in the vessel wall and platelets.

Additionally SERPINF1 has strong antiangiogenic effects by inducing apoptosis in endothelial cells and by regulating the expression of other angiogenic factors. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating SERPINF1 for the treatment and/or prevention of diseases associated with reduced

SERPINF1 expression or function such as cardiovascular disease.

Hyperimmunoglobulin E syndrome - STAT3

Loss-of-function mutations in the STAT3 gene result in Hyperimmunoglobulin E syndrome, associated with recurrent infections as well as disordered bone and tooth development.

Leber's congenital amaurosis (LCA), Bardet-Biedl syndrome (BBS), Joubert syndrome, Meckel syndrome, Sior-Loken syndrome - CEP290

Leber's congenital amaurosis (LCA) is a rare autosomal recessive eye disease resulting in a severe form of retinal dystrophy that is present from birth. LCA results in slow or non-existent pupillary responses, involuntary eye movement, and severe loss of vision. LCA is thought to be caused by abnormal photoreceptor cell development or degeneration. Bardet-Biedl syndrome (BBS) is characterized by retinal dystrophy and retinitis pigmentosa. Other manifestations include Polydactyly and renal abnormalities. Both LCA and BBS are associated with mutations in Centrosomal protein 290 kDA (CEP290).

CEP290 is a large coiled-coil protein found in the centrosome and cilia of cells.

CEP290 modulates ciliary formation and is involved in trafficking ciliary proteins between the cell body and the cilium of a cell. Reduction or abolishment of CEP290 activity, results in retinal and photoreceptor degeneration. This generation is thought to be the result of defects in ciliogenesis. CEP290 is also associated with Joubert syndrome, Meckel syndrome, and Sior-Loken syndrome. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating CEP290 for the treatment and/or prevention of diseases associated with reduced CEP290 expression or function such as Leber' s congenital amaurosis (LCA), Bardet-Biedl syndrome (BBS), Joubert syndrome, Meckel syndrome, Sior- Loken syndrome. Phenylketonuria- PAH Phenylketonuria (PKU) is an autosomal recessive metabolic disease caused by elevated levels of Phenyalanine (Phe) in the blood. Phe is a large neutral amino acid (LNAA) that interacts with the LNAA transporter in order to cross the blood- brain barrier. When Phe is in excess in the blood, it saturates the LNAA transporter, prevent other essential LNAAs from crossing the blood-brain barrier. This results in depletion of these amino acids in the brain, leading to slowing of the development of the brain and mental retardation. PKU can be managed by strictly controlling and monitoring Phe levels in the diet in infants and children. However, if left untreated, severe mental retardation, irregular motor functions, and behavioral disorders result from Phe accumulation in the blood.

Phe accumulation in the blood is the result of mutations in the Phenylalanine hydroxylase (PAH) gene, which encodes phenylalanine hydroxylase protein. Phenylalanine hydroxylase is an enzyme that generates tyrosine through hydroxylation of the aromatic side- chain of Phe. Phenylalanine hydroxylase is the rate-limiting enzyme in the degradation of excess Phe. When phenylalanine hydroxylase levels are decreased or enzyme functionality is compromised, Phe begins to accumulate in the blood, resulting in PKU. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating PAH for the treatment and/or prevention of diseases associated with reduced PAH expression or function such PKU.

Congenital Bilateral Absence Of Vas Deferens (CBAVD) And Cystic Fibrosis (CF) - CFTR

CFTR is a cyclic- AMP activated ATP-gated anion channel that transports ions across cell membranes. CFTR is predominantly found in epithelial cells in the lung, liver, pancreas, digestive tract, reproductive tract, and skin. A main function of CFTR is to move chloride and thiocyanate ions out of epithelial cells. In order to maintain electrical balance, sodium ions move with the chloride and thiocyanate ions, resulting in an increase of electrolytes outside of the cell. This increase results in movement of water out of the cell by osmosis, creating bodily fluids such as mucus, sweat, and digestive juices, depending on the organ. When CFTR activity is reduced or abolished, ion transport is affected, resulting in reduced water movement out of cells and abnormally viscous bodily fluids (e.g. sticky and viscous mucus, sweat, or digestives juices).

Mutations in CFTR are associated with congenital bilateral absence of vas deferens (CBAVD) and cystic fibrosis. Males with congenital bilateral absence of the vas deferens often have mutations that result in reduced CFTR activity. As a result of these mutations, the movement of water and salt into and out of cells is disrupted. This disturbance leads to the production of a large amount of thick mucus that blocks the developing vas deferens (a tube that carries sperm from the testes) and causes it to degenerate, resulting in infertility.

Cystic fibrosis (CF) is an autosomal recessive disease characterized by overly viscous secretions in the lungs, pancreas, liver, and intestine. In the lungs, difficulty breathing and frequent infection are common results of mucus build-up. Viscous secretions in the pancreas lead to scarring, fibrosis, and cyst formation which can subsequently lead to diabetes.

Additionally, absorption of nutrients in the intestine is decreased due to a lack of digestive enzymes provided by the pancreas. Blockage of the intestine is also common due to thickening of the feces. Aspects of the invention disclosed herein provide methods and compositions that are useful for upregulating CFTR for the treatment and/or prevention of diseases associated with reduced CFTR expression or function such CBAVD or CF.

Single Stranded Oligonucleotides for Modulating Expression of Target Genes

In one aspect of the invention, single stranded oligonucleotides complementary to the

PRC2-associated regions are provided for modulating expression of a target gene in a cell. In some embodiments, expression of the target gene is upregulated or increased. In some embodiments, single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts such that gene expression is upregulated or increased. In some embodiments, single stranded oligonucleotides complementary to these PRC2-associated regions inhibit the interaction of PRC2 with long RNA transcripts, resulting in reduced methylation of histone H3 and reduced gene inactivation, such that gene expression is upregulated or increased. In some embodiments, this interaction may be disrupted or inhibited due to a change in the structure of the long RNA that prevents or reduces binding to PRC2. The oligonucleotide may be selected using any of the methods disclosed herein for selecting a candidate oligonucleotide for activating expression of a target gene.

The single stranded oligonucleotide may comprise a region of complementarity that is complementary with a PRC2-associated region of a nucleotide sequence set forth in any one of SEQ ID NOS: 1 to 96. The region of complementarity of the single stranded

oligonucleotide may be complementary with at least 6, e.g. , at least 7, at least 8, at least 9, at least 10, at least 15 or more consecutive nucleotides of the PRC2-associated region.

The PRC2-associated region may map to a position in a chromosome between 50 kilobases upstream of a 5 '-end of the target gene and 50 kilobases downstream of a 3 '-end of the target gene. The PRC2-associated region may map to a position in a chromosome between 25 kilobases upstream of a 5 '-end of the target gene and 25 kilobases downstream of a 3 '-end of the target gene. The PRC2-associated region may map to a position in a chromosome between 12 kilobases upstream of a 5'-end of the target gene and 12 kilobases downstream of a 3 '-end of the target gene. The PRC2-associated region may map to a position in a chromosome between 5 kilobases upstream of a 5'-end of the target gene and 5 kilobases downstream of a 3 '-end of the target gene.

The genomic position of the selected PRC2-associated region relative to the target gene may vary. For example, the PRC2-associated region may be upstream of the 5' end of the target gene. The PRC2-associated region may be downstream of the 3' end of the target gene. The PRC2-associated region may be within an intron of the target gene. The PRC2- associated region may be within an exon of the target gene. The PRC2-associated region may traverse an intron-exon junction, a 5 '-UTR-exon junction or a 3 '-UTR-exon junction of the target gene.

The single stranded oligonucleotide may comprise a sequence having the formula X- Y-Z, in which X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of varying length. In some embodiments X is the 5' nucleotide of the oligonucleotide. In some embodiments, when X is anchored at the 5' end of the oligonucleotide, the oligonucleotide does not have any nucleotides or nucleotide analogs linked 5' to X. In some embodiments, other compounds such as peptides or sterols may be linked at the 5' end in this embodiment as long as they are not nucleotides or nucleotide analogs. In some embodiments, the single stranded oligonucleotide has a sequence 5'X-Y-Z and is 8-50 nucleotides in length.

Oligonucleotides that have these sequence characteristics are predicted to avoid the miRNA pathway. Therefore, in some embodiments, oligonucleotides having these sequence characteristics are unlikely to have an unintended consequence of functioning in a cell as a miRNA molecule. The Y sequence may be a nucleotide sequence of 6 nucleotides in length set forth in Table 1.

The single stranded oligonucleotide may have a sequence that does not contain guanosine nucleotide stretches (e.g. , 3 or more, 4 or more, 5 or more, 6 or more consecutive guanosine nucleotides). In some embodiments, oligonucleotides having guanosine nucleotide stretches have increased non-specific binding and/or off-target effects, compared with oligonucleotides that do not have guanosine nucleotide stretches.

The single stranded oligonucleotide may have a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length, that map to a genomic position encompassing or in proximity to an off-target gene. For example, an oligonucleotide may be designed to ensure that it does not have a sequence that maps to genomic positions encompassing or in proximity with all known genes (e.g. , all known protein coding genes) other than the target gene. In a similar embodiment, an oligonucleotide may be designed to ensure that it does not have a sequence that maps to any other known PRC2-associated region, particularly PRC2-associated regions that are functionally related to any other known gene (e.g. , any other known protein coding gene). In either case, the oligonucleotide is expected to have a reduced likelihood of having off-target effects. The threshold level of sequence identity may be 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99% or 100% sequence identity.

The single stranded oligonucleotide may have a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops. In has been discovered that, in some embodiments, oligonucleotides that are complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising one or more single stranded loops (e.g. , at least two single stranded loops) have a greater likelihood of being active (e.g. , of being capable of activating or enhancing expression of a target gene) than a randomly selected

oligonucleotide. In some cases, the secondary structure may comprise a double stranded stem between the at least two single stranded loops. Accordingly, the region of

complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2-associated region that encodes at least a portion of at least one of the loops. In some cases, the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2-associated region that encodes at least a portion of at least two of the loops. In some cases, the region of complementarity between the oligonucleotide and the PRC2-associated region may be at a location of the PRC2 associated region that encodes at least a portion of the double stranded stem. In some embodiments, a PRC2-associated region (e.g. , of an IncRNA) is identified (e.g. , using RIP- Seq methodology or information derived therefrom). In some embodiments, the predicted secondary structure RNA (e.g. , IncRNA) containing the PRC2-associated region is determined using RNA secondary structure prediction algorithms, e.g. , RNAfold, mfold. In some embodiments, oligonucleotides are designed to target a region of the RNA that forms a secondary structure comprising one or more single stranded loop (e.g. , at least two single stranded loops) structures which may comprise a double stranded stem between the at least two single stranded loops.

The single stranded oligonucleotide may have a sequence that is has greater than 30% G-C content, greater than 40% G-C content, greater than 50% G-C content, greater than 60% G-C content, greater than 70% G-C content, or greater than 80% G-C content. The single stranded oligonucleotide may have a sequence that has up to 100% G-C content, up to 95% G-C content, up to 90% G-C content, or up to 80% G-C content. In some embodiments in which the oligonucleotide is 8 to 10 nucleotides in length, all but 1, 2, 3, 4, or 5 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides. In some embodiments, the sequence of the PRC2- associated region to which the single stranded oligonucleotide is complementary comprises no more than 3 nucleotides selected from adenine and uracil.

The single stranded oligonucleotide may be complementary to a chromosome of a different species (e.g. , a mouse, rat, rabbit, goat, monkey, etc.) at a position that encompasses or that is in proximity to that species' homolog of the target gene. The single stranded oligonucleotide may be complementary to a human genomic region encompassing or in proximity to the target gene and also be complementary to a mouse genomic region encompassing or in proximity to the mouse homolog of the target gene. For example, the single stranded oligonucleotide may be complementary to a sequence as set forth in SEQ ID NO: 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21, 22, 25, 26, 29, 30, 33, 34, 37, 38, 43, 44, 45, 46, 49, 50, 53, 54, 57, 58, 61, 62, 65, 66, 69, 70, 73, 74, 77, 78, 81, 82, 85, 86, 89, 90, 93, 94, 815175, 815176, 868590, 868591, 899865, 899866, 962801, 962802, 981187, or 981188, which is a human genomic region encompassing or in proximity to the target gene, and also be complementary to a sequence as set forth in SEQ ID NO: 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, 24, 27, 28, 31, 32, 35, 36, 39, 40, 41, 42, 47, 48, 51, 52, 55, 56, 59, 60, 63, 64, 67, 68, 71, 72, 75, 76, 79, 80, 83, 84, 87, 88, 91, 92, 95, 96, 815177, 815178, 868592, 868593, 899867, 899868, 962803, 962804, 981189, or 981190, which is a mouse genomic region

encompassing or in proximity to the mouse homolog of the target gene. Oligonucleotides having these characteristics may be tested in vivo or in vitro for efficacy in multiple species (e.g., human and mouse). This approach also facilitates development of clinical candidates for treating human disease by selecting a species in which an appropriate animal exists for the disease.

In some embodiments, the region of complementarity of the single stranded oligonucleotide is complementary with at least 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, or 5 to 40 bases, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides of a PRC2-associated region. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a PRC2-associated region. In some embodiments the sequence of the single stranded oligonucleotide is based on an RNA sequence that binds to PRC2, or a portion thereof, said portion having a length of from 5 to 40 contiguous base pairs, or about 8 to 40 bases, or about 5 to 15, or about 5 to 30, or about 5 to 40 bases, or about 5 to 50 bases.

Complementary, as the term is used in the art, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an

oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of PRC2-associated region, then the single stranded nucleotide and PRC2-associated region are considered to be complementary to each other at that position. The single stranded nucleotide and PRC2-associated region are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other through their bases. Thus, "complementary" is a term which is used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the single stranded nucleotide and PRC2-associated region. For example, if a base at one position of a single stranded nucleotide is capable of hydrogen bonding with a base at the corresponding position of a PRC2-associated region, then the bases are considered to be complementary to each other at that position. 100% complementarity is not required.

The single stranded oligonucleotide may be at least 80% complementary to

(optionally one of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary to) the consecutive nucleotides of a PRC2-associated region. In some embodiments the single stranded oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of a PRC2-associated region. In some embodiments the single stranded oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

It is understood in the art that a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable. In some

embodiments, a complementary nucleic acid sequence for purposes of the present disclosure is specifically hybridizable when binding of the sequence to the target molecule (e.g., IncRNA) interferes with the normal function of the target (e.g., IncRNA) to cause a loss of activity (e.g., inhibiting PRC2-associated repression with consequent up-regulation of gene expression) and there is a sufficient degree of complementarity to avoid non-specific binding of the sequence to non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed under suitable conditions of stringency.

In some embodiments, the single stranded oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or more nucleotides in length. In a preferred embodiment, the oligonucleotide is 8 to 30 nucleotides in length. In some embodiments, the PRC2-associated region occurs on the same DNA strand as a gene sequence (sense). In some embodiments, the PRC2-associated region occurs on the opposite DNA strand as a gene sequence (anti-sense). Oligonucleotides complementary to a PRC2-associated region can bind either sense or anti-sense sequences. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g. , Wobble base pairing and Hoogsteen base pairing). It is understood that for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be replaced with any other nucleotide suitable for base pairing (e.g., via a Watson-Crick base pair) with an adenosine nucleotide. In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) or uridine (U) nucleotides (or a modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a different pyrimidine nucleotide or vice versa. In some embodiments, any one or more thymidine (T) nucleotides (or modified nucleotide thereof) in a sequence provided herein, including a sequence provided in the sequence listing, may be suitably replaced with a uridine (U) nucleotide (or a modified nucleotide thereof) or vice versa.

In some embodiments, GC content of the single stranded oligonucleotide is preferably between about 30-60 %. Contiguous runs of three or more Gs or Cs may not be preferable in some embodiments. Accordingly, in some embodiments, the oligonucleotide does not comprise a stretch of three or more guanosine nucleotides.

In some embodiments, the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome) as a single contiguous transcript (e.g., a non-spliced RNA). In some embodiments, the single stranded oligonucleotide specifically binds to, or is complementary to an RNA that is encoded in a genome (e.g., a human genome), in which the distance in the genome between the 5 'end of the coding region of the RNA and the 3' end of the coding region of the RNA is less than 1 kb, less than 2 kb, less than 3 kb, less than 4 kb, less than 5 kb, less than 7 kb, less than 8 kb, less than 9 kb, less than 10 kb, or less than 20 kb.

It is to be understood that any oligonucleotide provided herein can be excluded. In some embodiments, a single stranded oligonucleotide is not complementary to any one or more of SEQ ID NOs: 989599 to 989617.

In some embodiments, it has been found that single stranded oligonucleotides disclosed herein may increase expression of mRNA corresponding to the gene by at least about 50% (i.e. 150% of normal or 1.5 fold), or by about 2 fold to about 5 fold. In some embodiments it is contemplated that expression may be increased by at least about 15 fold, 20 fold, 30 fold, 40 fold, 50 fold or 100 fold, or any range between any of the foregoing numbers. It has also been found that increased mRNA expression has been shown to correlate to increased protein expression.

In some or any of the embodiments of the oligonucleotides described herein, or processes for designing or synthesizing them, the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to the PRC2 binding RNA that is transcribed from the same strand as a protein coding reference gene. The oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5' UTR, 3' UTR, a translation initiation region, or a translation termination region of a protein coding sense strand of a reference gene (refGene).

In some or any of the embodiments of oligonucleotides described herein, or processes for designing or synthesizing them, the oligonucleotides will upregulate gene expression and may specifically bind or specifically hybridize or be complementary to a PRC2 binding RNA that transcribed from the opposite strand (the antisense strand) of a protein coding reference gene. The oligonucleotide may bind to a region of the PRC2 binding RNA that originates within or overlaps an intron, exon, intron exon junction, 5' UTR, 3' UTR, a translation initiation region, or a translation termination region of a protein coding antisense strand of a reference gene The oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide and/or combinations thereof. In addition, the oligonucleotides can exhibit one or more of the following properties: do not induce substantial cleavage or degradation of the target RNA; do not cause

substantially complete cleavage or degradation of the target RNA; do not activate the RNAse H pathway; do not activate RISC; do not recruit any Argonaute family protein; are not cleaved by Dicer; do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; may have improved endosomal exit; do interfere with interaction of IncRNA with PRC2, preferably the Ezh2 subunit but optionally the Suzl2, Eed, RbAp46/48 subunits or accessory factors such as Jarid2; do decrease histone H3 lysine27 methylation and/or do upregulate gene expression.

Oligonucleotides that are designed to interact with RNA to modulate gene expression are a distinct subset of base sequences from those that are designed to bind a DNA target (e.g., are complementary to the underlying genomic DNA sequence from which the RNA is transcribed).

Any of the oligonucleotides disclosed herein may be linked to one or more other oligonucleotides disclosed herein by a linker, e.g., a cleavable linker. Method for Selecting Candidate Oligonucleotides for Activating Expression of a

Target Gene

Methods are provided herein for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene. The target selection methods may generally involve steps for selecting single stranded oligonucleotides having any of the structural and functional characteristics disclosed herein. Typically, the methods involve one or more steps aimed at identifying oligonucleotides that target a PRC2-associated region that is functionally related to the target gene, for example a PRC2-associated region of a IncRNA that regulates expression of the target gene by facilitating (e.g., in a -regulatory manner) the recruitment of PRC2 to the target gene. Such oligonucleotides are expected to be candidates for activating expression of the target gene because of their ability to hybridize with the PRC2- associated region of a nucleic acid (e.g., a IncRNA). In some embodiments, this hybridization event is understood to disrupt interaction of PRC2 with the nucleic acid (e.g. , a IncRNA) and as a result disrupt recruitment of PRC2 and its associated co-repressors (e.g. , chromatin remodeling factors) to the target gene locus.

Methods of selecting a candidate oligonucleotide may involve selecting a PRC2- associated region (e.g. , a nucleotide sequence as set forth in any one of SEQ ID NOS: 97 to 1210, 815179 to 815208, 868594 to 868617, 899869 to 899932, 962805 to 962816, or 981191 to 981196) that maps to a chromosomal position encompassing or in proximity to the target gene (e.g. , a chromosomal position having a sequence as set forth in any one of SEQ ID NOS: 1 to 96, 815175 to 815178, 868590 to 868593, 899865 to 899868, 962801 to 962804, or 981187 to 981190). The PRC2-associated region may map to the strand of the chromosome comprising the sense strand of the target gene, in which case the candidate oligonucleotide is complementary to the sense strand of the target gene (i.e. , is antisense to the target gene). Alternatively, the PRC2-associated region may map to the strand of the first chromosome comprising the antisense strand of the target gene, in which case the

oligonucleotide is complementary to the antisense strand (the template strand) of the target gene (i.e. , is sense to the target gene).

Methods for selecting a set of candidate oligonucleotides that is enriched in oligonucleotides that activate expression of the target gene may involve selecting one or more PRC2-associated regions that map to a chromosomal position that encompasses or that is in proximity to the target gene and selecting a set of oligonucleotides, in which each

oligonucleotide in the set comprises a nucleotide sequence that is complementary with the one or more PRC2-associated regions. As used herein, the phrase, "a set of oligonucleotides that is enriched in oligonucleotides that activate expression of refers to a set of

oligonucleotides that has a greater number of oligonucleotides that activate expression of a target gene (e.g. , a gene listed in Table 4) compared with a random selection of

oligonucleotides of the same physicochemical properties (e.g. , the same GC content, T_m, length etc.) as the enriched set.

Where the design and/or synthesis of a single stranded oligonucleotide involves design and/or synthesis of a sequence that is complementary to a nucleic acid or PRC2- associated region described by such sequence information, the skilled person is readily able to determine the complementary sequence, e.g., through understanding of Watson Crick base pairing rules which form part of the common general knowledge in the field.

In some embodiments design and/or synthesis of a single stranded oligonucleotide involves manufacture of an oligonucleotide from starting materials by techniques known to those of skill in the art, where the synthesis may be based on a sequence of a PRC2- associated region, or portion thereof.

Methods of design and/or synthesis of a single stranded oligonucleotide may involve one or more of the steps of:

Identifying and/or selecting PRC2-associated region;

Designing a nucleic acid sequence having a desired degree of sequence identity or complementarity to a PRC2-associated region or a portion thereof;

Synthesizing a single stranded oligonucleotide to the designed sequence;

Purifying the synthesized single stranded oligonucleotide; and

Optionally mixing the synthesized single stranded oligonucleotide with at least one pharmaceutically acceptable diluent, carrier or excipient to form a pharmaceutical composition or medicament.

Single stranded oligonucleotides so designed and/or synthesized may be useful in method of modulating gene expression as described herein.

Preferably, single stranded oligonucleotides of the invention are synthesized chemically. Oligonucleotides used to practice this invention can be synthesized in vitro by well-known chemical synthesis techniques.

Oligonucleotides of the invention can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide modification. For example, nucleic acid sequences of the invention include a phosphorothioate at least the first, second, or third internucleotide linkage at the 5' or 3' end of the nucleotide sequence. As another example, the nucleic acid sequence can include a 2'-modified nucleotide, e.g., a 2'-deoxy, 2'- deoxy-2'-fluoro, 2'-0-methyl, 2'-0-methoxyethyl (2'-0-MOE), 2'-0-aminopropyl (2'-0-AP), 2'-0-dimethylaminoethyl (2'-0-DMAOE), 2'-0-dimethylaminopropyl (2'-0-DMAP), 2'-0- dimethylaminoethyloxyethyl (2'-0-DMAEOE), or 2'-0-N-methylacetamido (2'-0-NMA). As another example, the nucleic acid sequence can include at least one 2'-0-methyl-modified nucleotide, and in some embodiments, all of the nucleotides include a 2'-0-methyl modification. In some embodiments, the nucleic acids are "locked," i.e., comprise nucleic acid analogues in which the ribose ring is "locked" by a methylene bridge connecting the 2'- O atom and the 4'-C atom.

It is understood that any of the modified chemistries or formats of single stranded oligonucleotides described herein can be combined with each other, and that one, two, three, four, five, or more different types of modifications can be included within the same molecule.

In some embodiments, the method may further comprise the steps of amplifying the synthesized single stranded oligonucleotide, and/or purifying the single stranded

oligonucleotide (or amplified single stranded oligonucleotide), and/or sequencing the single stranded oligonucleotide so obtained.

As such, the process of preparing a single stranded oligonucleotide may be a process that is for use in the manufacture of a pharmaceutical composition or medicament for use in the treatment of disease, optionally wherein the treatment involves modulating expression of a gene associated with a PRC2-associated region.

In the methods described above a PRC2-associated region may be, or have been, identified, or obtained, by a method that involves identifying RNA that binds to PRC2.

Such methods may involve the following steps: providing a sample containing nuclear ribonucleic acids, contacting the sample with an agent that binds specifically to PRC2 or a subunit thereof, allowing complexes to form between the agent and protein in the sample, partitioning the complexes, synthesizing nucleic acid that is complementary to nucleic acid present in the complexes.

Where the single stranded oligonucleotide is based on a PRC2-associated region, or a portion of such a sequence, it may be based on information about that sequence, e.g., sequence information available in written or electronic form, which may include sequence information contained in publicly available scientific publications or sequence databases.

Nucleotide Analogues

In some embodiments, the oligonucleotide may comprise at least one ribonucleotide, at least one deoxyribonucleotide, and/or at least one bridged nucleotide. In some

embodiments, the oligonucleotide may comprise a bridged nucleotide, such as a locked nucleic acid (LNA) nucleotide, a constrained ethyl (cEt) nucleotide, or an ethylene bridged nucleic acid (ENA) nucleotide. Examples of such nucleotides are disclosed herein and known in the art. In some embodiments, the oligonucleotide comprises a nucleotide analog disclosed in one of the following United States Patent or Patent Application Publications: US 7,399,845, US 7,741,457, US 8,022, 193, US 7,569,686, US 7,335,765, US 7,314,923, US 7,335,765, and US 7,816,333, US 20110009471, the entire contents of each of which are incorporated herein by reference for all purposes. The oligonucleotide may have one or more 2' O-methyl nucleotides. The oligonucleotide may consist entirely of 2' O-methyl nucleotides.

Often the single stranded oligonucleotide has one or more nucleotide analogues. For example, the single stranded oligonucleotide may have at least one nucleotide analogue that results in an increase in T_m of the oligonucleotide in a range of 1°C, 2 °C, 3°C, 4 °C, or 5°C compared with an oligonucleotide that does not have the at least one nucleotide analogue. The single stranded oligonucleotide may have a plurality of nucleotide analogues that results in a total increase in T_m of the oligonucleotide in a range of 2 °C, 3 °C, 4 °C, 5 °C, 6 °C, 7 °C, 8 °C, 9 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or more compared with an oligonucleotide that does not have the nucleotide analogue.

The oligonucleotide may be of up to 50 nucleotides in length in which 2 to 10, 2 to 15₅ 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides of the oligonucleotide are nucleotide analogues. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15₅ 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides of the oligonucleotide are nucleotide analogues.

The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides of the oligonucleotide are nucleotide analogues. Optionally, the oligonucleotides may have every nucleotide except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides modified.

The oligonucleotide may consist entirely of bridged nucleotides (e.g. , LNA nucleotides, cEt nucleotides, ENA nucleotides). The oligonucleotide may comprise alternating deoxyribonucleotides and 2'-fluoro-deoxyribonucleotides. The oligonucleotide may comprise alternating deoxyribonucleotides and 2' -O-methyl nucleotides. The oligonucleotide may comprise alternating deoxyribonucleotides and ENA nucleotide analogues. The oligonucleotide may comprise alternating deoxyribonucleotides and LNA nucleotides. The oligonucleotide may comprise alternating LNA nucleotides and 2'-0- methyl nucleotides. The oligonucleotide may have a 5' nucleotide that is a bridged nucleotide (e.g. , a LNA nucleotide, cEt nucleotide, ENA nucleotide). The oligonucleotide may have a 5' nucleotide that is a deoxyribonucleotide.

The oligonucleotide may comprise deoxyribonucleotides flanked by at least one bridged nucleotide (e.g. , a LNA nucleotide, cEt nucleotide, ENA nucleotide) on each of the 5' and 3' ends of the deoxyribonucleotides. The oligonucleotide may comprise

deoxyribonucleotides flanked by 1, 2, 3, 4, 5, 6, 7, 8 or more bridged nucleotides (e.g. , LNA nucleotides, cEt nucleotides, ENA nucleotides) on each of the 5' and 3' ends of the deoxyribonucleotides. The 3' position of the oligonucleotide may have a 3' hydroxyl group. The 3' position of the oligonucleotide may have a 3' thiophosphate.

The oligonucleotide may be conjugated with a label. For example, the

oligonucleotide may be conjugated with a biotin moiety, cholesterol, Vitamin A, folate, sigma receptor ligands, aptamers, peptides, such as CPP, hydrophobic molecules, such as lipids, ASGPR or dynamic polyconjugates and variants thereof at its 5' or 3' end.

Preferably the single stranded oligonucleotide comprises one or more modifications comprising: a modified sugar moiety, and/or a modified internucleoside linkage, and/or a modified nucleotide and/or combinations thereof. It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the

modifications described herein may be incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, the single stranded oligonucleotides are chimeric

oligonucleotides that contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. Chimeric single stranded oligonucleotides of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but are not limited to, US patent nos. 5,013,830; 5,149,797; 5, 220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133;

5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, each of which is herein incorporated by reference.

In some embodiments, the single stranded oligonucleotide comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-0-alkyl, 2'-0-alkyl-0- alkyl or 2'-fluoro-modified nucleotide. In other preferred embodiments, RNA modifications include 2'-fluoro, 2'-amino and 2' O-methyl modifications on the ribose of pyrimidines, abasic residues or an inverted base at the 3' end of the RNA. Such modifications are routinely incorporated into oligonucleotides and these oligonucleotides have been shown to have a higher Tm (i.e., higher target binding affinity) than 2'-deoxyoligonucleotides against a given target.

A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide; these modified oligos survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are oligonucleotides with

phosphorothioate backbones and those with heteroatom backbones, particularly CH₂ -NH-O- CH₂, CH,~N(CH₃)~0~CH₂ (known as a methylene(methylimino) or MMI backbone, CH₂ - O-N (CH₃)-CH₂, CH₂ -N (CH₃)-N (CH₃)-CH₂ and O-N (CH₃)- CH₂ -CH₂ backbones, wherein the native phosphodiester backbone is represented as O- P— O- CH,); amide backbones (see De Mesmaeker et al. Ace. Chem. Res. 1995, 28:366-374); morpholino backbone structures (see Summerton and Weller, U.S. Pat. No. 5,034,506); peptide nucleic acid (PNA) backbone (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., Science 1991, 254, 1497). Phosphorus-containing linkages include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3 -5' to 5'-3' or 2 -5' to 5'-2'; see US patent nos. 3,687,808; 4,469,863;

4,476,301 ; 5,023,243; 5, 177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321, 131 ; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519, 126; 5,536,821 ; 5,541,306; 5,550, 111 ; 5,563, 253; 5,571,799; 5,587,361 ; and 5,625,050.

Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, Biochemistry, 2002, 41(14), 4503-4510); Genesis, volume 30, issue 3, 2001 ; Heasman, J., Dev. Biol., 2002, 243, 209-214; Nasevicius et al., Nat. Genet., 2000, 26, 216- 220; Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g. , as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001 ; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

Cyclohexenyl nucleic acid oligonucleotide mimetics are described in Wang et al., J. Am. Chem. Soc, 2000, 122, 8595-8602.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones;

sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts; see US patent nos. 5,034,506; 5, 166,315; 5,185,444; 5,214,134; 5,216, 141 ; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596, 086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

Modified oligonucleotides are also known that include oligonucleotides that are based on or constructed from arabinonucleotide or modified arabinonucleotide residues.

Arabinonucleosides are stereoisomers of ribonucleosides, differing only in the configuration at the 2'-position of the sugar ring. In some embodiments, a 2'-arabino modification is 2'-F arabino. In some embodiments, the modified oligonucleotide is 2' -fluoro-D-arabinonucleic acid (FANA) (as described in, for example, Lon et al., Biochem., 41 :3457-3467, 2002 and Min et al., Bioorg. Med. Chem. Lett., 12:2651-2654, 2002; the disclosures of which are incorporated herein by reference in their entireties). Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on a 3' terminal nucleoside or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.

PCT Publication No. WO 99/67378 discloses arabinonucleic acids (ANA) oligomers and their analogues for improved sequence specific inhibition of gene expression via association to complementary messenger RNA.

Other preferred modifications include ethylene-bridged nucleic acids (ENAs) (e.g. , International Patent Publication No. WO 2005/042777, Morita et al., Nucleic Acid Res., Suppl 1 :241-242, 2001 ; Surono et al., Hum. Gene Ther., 15:749-757, 2004; Koizumi, Curr. Opin. Mol. Ther., 8: 144- 149, 2006 and Horie et al., Nucleic Acids Symp. Ser (Oxf), 49: 171- 172, 2005; the disclosures of which are incorporated herein by reference in their entireties). Preferred ENAs include, but are not limited to, 2'-0,4'-C-ethylene -bridged nucleic acids.

Examples of LNAs are described in WO/2008/043753 and include compounds of the following general formula.

where X and Y are independently selected among the groups -S-, -N(H)-, N(R)-, -CH₂- or -CH- (if part of a double bond),

-CH₂-0-, -CH₂-S-, -CH₂-N(H)-, -CH₂-N(R)-, -CH₂-CH₂- or -CH₂-CH- (if part of a double bond),

-CH=CH-, where R is selected from hydrogen and Ci-4-alkyl; Z and Z* are independently selected among an intemucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety; and the asymmetric groups may be found in either orientation.

Preferably, the LNA used in the oligonucleotides described herein comprises at least one LNA unit according any of the formulas

wherein Y is -0-, -S-, -NH-, or N(R ); Z and Z* are independently selected among an intemucleoside linkage, a terminal group or a protecting group; B constitutes a natural or non-natural nucleotide base moiety, and RH is selected from hydrogen and Ci-4-alkyl.

In some embodiments, the Locked Nucleic Acid (LNA) used in the oligonucleotides described herein comprises a Locked Nucleic Acid (LNA) unit according any of the formulas shown in Scheme 2 of PCT/DK2006/000512.

In some embodiments, the LNA used in the oligomer of the invention comprises intemucleoside linkages selected from -0-P(O)₂-O-, -0-P(0,S)-0-, -0-P(S)₂-O-, -S-P(0)₂-0-, -S-P(0,S)-0-, -S-P(S)₂-0-, -0-P(O)₂-S-, -0-P(0,S)-S-, -S-P(0)₂-S-, -0-PO(R^H)-0-, o- PO(OCH₃)-0-, -0-PO(NR^H)-0-, -0-PO(OCH₂CH₂S-R)-O-, -0-PO(BH₃)-0-, -0-PO(NHR^H)- 0-, -0-P(0)₂-NR^H-, -NR^H-P(0)₂-0-, -NR^H-CO-0-, where R^H is selected from hydrogen and Ci-4-alkyl.

Specifically preferred LNA units are shown in scheme 2:

p-D-oxy-LNA

Scheme 2

The term "thio-LNA" comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from S or -CH₂-S-. Thio-LNA can be in both beta-D and alpha-L-configuration.

The term "amino-LNA" comprises a locked nucleotide in which at least one of X or Y in the general formula above is selected from -N(H)-, N(R)-, CH₂-N(H)-, and -CH₂-N(R)- where R is selected from hydrogen and Ci-4-alkyl. Amino-LNA can be in both beta-D and alpha-L-configuration.

The term "oxy-LNA" comprises a locked nucleotide in which at least one of X or Y in the general formula above represents -O- or -CH₂-0-. Oxy-LNA can be in both beta-D and alpha-L-configuration.

The term "ena-LNA" comprises a locked nucleotide in which Y in the general formula above is -CH₂-0- (where the oxygen atom of -CH₂-0- is attached to the 2'-position relative to the base B).

LNAs are described in additional detail herein. One or more substituted sugar moieties can also be included, e.g. , one of the following at the 2' position: OH, SH, SCH₃, F, OCN, OCH₃ OCH₃, OCH₃ 0(CH₂)n CH₃, 0(CH₂)n NH₂ or 0(CH₂)n CH₃ where n is from 1 to about 10; Ci to CIO lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; CI; Br; CN; CF ; OCF ; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; SOCH₃; S0₂ CH₃; ON0₂; N0₂; N₃; NH2; heterocycloalkyl; heterocyclo alkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy [2'-0-CH₂CH₂OCH₃, also known as 2'-0-(2-methoxyethyl)] (Martin et al, Helv. Chim. Acta, 1995, 78, 486). Other preferred modifications include 2'- methoxy (2'-0-CH₃), 2'-propoxy (2'-OCH₂ CH₂CH₃) and 2'-fluoro (2'-F). Similar

modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group.

Single stranded oligonucleotides can also include, additionally or alternatively, nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U). Modified nucleobases include nucleobases found only infrequently or transiently in natural nucleic acids, e.g. , hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2'

deoxycytosine and often referred to in the art as 5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, isocytosine, pseudoisocytosine, as well as synthetic nucleobases, e.g. , 2-aminoadenine, 2- (methylamino)adenine, 2-(imidazolylalkyl)adenine, 2- (aminoalklyamino)adenine or other hetero substituted alkyladenines, 2-thiouracil, 2- thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 5-propynyluracil, 8-azaguanine, 7- deazaguanine, N6 (6-aminohexyl)adenine, 6-aminopurine, 2-aminopurine, 2-chloro-6- aminopurine and 2,6-diaminopurine or other diaminopurines. See, e.g. , Kornberg, "DNA Replication," W. H. Freeman & Co., San Francisco, 1980, pp75-77; and Gebeyehu, G., et al. Nucl. Acids Res., 15:4513 (1987)). A "universal" base known in the art, e.g. , inosine, can also be included. 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, in Crooke, and Lebleu, eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and may be used as base substitutions.

It is not necessary for all positions in a given oligonucleotide to be uniformly modified, and in fact more than one of the modifications described herein may be

incorporated in a single oligonucleotide or even at within a single nucleoside within an oligonucleotide.

In some embodiments, both a sugar and an internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar- backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, Science, 1991, 254, 1497-1500.

Single stranded oligonucleotides can also include one or more nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases comprise the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified

nucleobases comprise other synthetic and natural nucleobases such as 5-methylcytosine (5- me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8- thioalkyl, 8-hydroxyl and other 8- substituted adenines and guanines, 5-halo particularly 5- bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3- deazaguanine and 3-deazaadenine.

Further, nucleobases comprise those disclosed in United States Patent No. 3,687,808, those disclosed in "The Concise Encyclopedia of Polymer Science And Engineering", pages 858-859, Kroschwitz, ed. John Wiley & Sons, 1990;, those disclosed by Englisch et al., Angewandle Chemie, International Edition, 1991, 30, page 613, and those disclosed by Sanghvi, Chapter 15, Antisense Research and Applications," pages 289- 302, Crooke, and Lebleu, eds., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladenine, 5-propynyluracil and 5- propynylcytosine. 5- methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6- 1.2<0>C (Sanghvi, et al., eds, "Antisense Research and Applications," CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications. Modified nucleobases are described in US patent nos. 3,687,808, as well as 4,845,205; 5,130,302; 5,134,066; 5, 175, 273; 5, 367,066; 5,432,272; 5,457, 187; 5,459,255; 5,484,908; 5,502,177; 5,525,711 ; 5,552,540; 5,587,469; 5,596,091 ; 5,614,617; 5,750,692, and 5,681,941, each of which is herein incorporated by reference.

In some embodiments, the single stranded oligonucleotides are chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide. For example, one or more single stranded oligonucleotides, of the same or different types, can be conjugated to each other; or single stranded

oligonucleotides can be conjugated to targeting moieties with enhanced specificity for a cell type or tissue type. Such moieties include, but are not limited to, lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g. , hexyl-S- tritylthiol (Manoharan et al, Ann. N. Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g. , dodecandiol or undecyl residues (Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49- 54), a phospholipid, e.g. , di-hexadecyl-rac-glycerol or triethylammonium 1,2- di-O-hexadecyl- rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-t oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937). See also US patent nos. 4,828,979; 4,948,882; 5,218, 105; 5,525,465; 5,541,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731 ; 5,580,731 ; 5,591,584; 5,109, 124; 5, 118,802; 5,138,045; 5,414,077; 5,486, 603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762, 779; 4,789,737; 4,824,941 ; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082, 830; 5,112,963; 5,214,136; 5,082,830; 5, 112,963; 5,214, 136; 5, 245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391, 723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5, 565,552; 5,567,810; 5,574, 142; 5,585,481 ; 5,587,371 ; 5,595,726; 5,597,696; 5,599,923; 5,599, 928 and 5,688,941, each of which is herein incorporated by reference.

These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence- specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application No. PCT/US92/09196, filed Oct. 23, 1992, and U.S. Pat. No. 6,287,860, which are incorporated herein by reference. Conjugate moieties include, but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g. , hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g. , dodecandiol or undecyl residues, a phospholipid, e.g. , di-hexadecyl-rac- glycerol or triethylammonium 1,2- di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxy cholesterol moiety. See, e.g. , U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218, 105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731 ; 5,580,731 ; 5,591,584; 5,109, 124; 5,118,802; 5, 138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941 ; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5, 112,963; 5,214, 136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574, 142; 5,585,481 ; 5,587,371 ; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941.

In some embodiments, single stranded oligonucleotide modification include modification of the 5' or 3' end of the oligonucleotide. In some embodiments, the 3' end of the oligonucleotide comprises a hydroxyl group or a thiophosphate. It should be appreciated that additional molecules (e.g. a biotin moiety or a fluorophor) can be conjugated to the 5' or 3' end of the single stranded oligonucleotide. In some embodiments, the single stranded oligonucleotide comprises a biotin moiety conjugated to the 5' nucleotide.

In some embodiments, the single stranded oligonucleotide comprises locked nucleic acids (LNA), ENA modified nucleotides, 2'-0-methyl nucleotides, or 2'-fluoro- deoxyribonucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2'-fluoro-deoxyribonucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and 2'-0- methyl nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and ENA modified nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating deoxyribonucleotides and locked nucleic acid nucleotides. In some embodiments, the single stranded oligonucleotide comprises alternating locked nucleic acid nucleotides and 2'-0-methyl nucleotides.

In some embodiments, the 5' nucleotide of the oligonucleotide is a

deoxyribonucleotide. In some embodiments, the 5' nucleotide of the oligonucleotide is a locked nucleic acid nucleotide. In some embodiments, the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one locked nucleic acid nucleotide on each of the 5' and 3' ends of the deoxyribonucleotides. In some embodiments, the nucleotide at the 3' position of the oligonucleotide has a 3' hydroxyl group or a 3' thiophosphate.

In some embodiments, the single stranded oligonucleotide comprises

phosphorothioate internucleotide linkages. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between at least two nucleotides. In some embodiments, the single stranded oligonucleotide comprises phosphorothioate internucleotide linkages between all nucleotides.

It should be appreciated that the single stranded oligonucleotide can have any combination of modifications as described herein.

The oligonucleotide may comprise a nucleotide sequence having one or more of the following modification patterns.

(a) (X)Xxxxxx, (X)xXxxxx, (X)xxXxxx, (X)xxxXxx, (X)xxxxXx and (X)xxxxxX,

(b) (X)XXxxxx, (X)XxXxxx, (X)XxxXxx, (X)XxxxXx, (X)XxxxxX, (X)xXXxxx, (X)xXxXxx, (X)xXxxXx, (X)xXxxxX, (X)xxXXxx, (X)xxXxXx, (X)xxXxxX, (X)xxxXXx,

(X)xxxXxX and (X)xxxxXX,

(c) (X)XXXxxx, (X)xXXXxx, (X)xxXXXx, (X)xxxXXX, (X)XXxXxx, (X)XXxxXx, (X)XXxxxX, (X)xXXxXx, (X)xXXxxX, (X)xxXXxX, (X)XxXXxx, (X)XxxXXx

(X)XxxxXX, (X)xXxXXx, (X)xXxxXX, (X)xxXxXX, (X)xXxXxX and (X)XxXxXx,

(d) (X)xxXXX, (X)xXxXXX, (X)xXXxXX, (X)xXXXxX, (X)xXXXXx,

(e) (X)xXXXXX, (X)XxXXXX, (X)XXxXXX, (X)XXXxXX, (X)XXXXxX and (X)XXXXXx, and

(f) XXXXXX, XxXXXXX, XXxXXXX, XXXxXXX, XXXXxXX, XXXXXxX and

XXXXXXx, in which "X" denotes a nucleotide analogue, (X) denotes an optional nucleotide analogue, and "x" denotes a DNA or RNA nucleotide unit. Each of the above listed patterns may appear one or more times within an oligonucleotide, alone or in combination with any of the other disclosed modification patterns.

Methods for Modulating Gene Expression In one aspect, the invention relates to methods for modulating gene expression in a cell (e.g. , a cell for which levels of a target gene are reduced) for research purposes (e.g. , to study the function of the gene in the cell). In another aspect, the invention relates to methods for modulating gene expression in a cell (e.g. , a cell for which levels of a target gene are reduced) for gene or epigenetic therapy. The cells can be in vitro, ex vivo, or in vivo (e.g. , in a subject who has a disease resulting from reduced expression or activity of the target gene. In some embodiments, methods for modulating gene expression in a cell comprise delivering a single stranded oligonucleotide as described herein. In some embodiments, delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200% or more greater than a level of expression of gene in a control cell to which the single stranded

oligonucleotide has not been delivered. In certain embodiments, delivery of the single stranded oligonucleotide to the cell results in a level of expression of gene that is at least 50% greater than a level of expression of gene in a control cell to which the single stranded oligonucleotide has not been delivered.

In another aspect of the invention, methods comprise administering to a subject (e.g. a human) a composition comprising a single stranded oligonucleotide as described herein to increase protein levels in the subject. In some embodiments, the increase in protein levels is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or more, higher than the amount of a protein in the subject before administering.

As another example, to increase expression of the target gene in a cell, the methods include introducing into the cell a single stranded oligonucleotide that is sufficiently complementary to a PRC2-associated region (e.g. , of a long non-coding RNA) that maps to a genomic position encompassing or in proximity to the target gene.

In another aspect of the invention provides methods of treating a condition (e.g. , a disease listed in Table 4) associated with decreased levels of expression of a target gene in a subject, the method comprising administering a single stranded oligonucleotide as described herein.

A subject can include a non-human mammal, e.g. mouse, rat, guinea pig, rabbit, cat, dog, goat, cow, or horse. In preferred embodiments, a subject is a human. Single stranded oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Single stranded oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.

For therapeutics, an animal, preferably a human, suspected of having a disease associated with reduced expression levels of the target gene is treated by administering single stranded oligonucleotide in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of a single stranded oligonucleotide as described herein.

Formulation, Delivery, And Dosing

The oligonucleotides described herein can be formulated for administration to a subject for treating a condition (e.g., a disease of Table 4 or otherwise disclosed herein) associated with decreased levels of a target gene. It should be understood that the

formulations, compositions and methods can be practiced with any of the oligonucleotides disclosed herein.

The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient (e.g., an oligonucleotide or compound of the invention) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration, e.g., intradermal or inhalation. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect, e.g. tumor regression.

Pharmaceutical formulations of this invention can be prepared according to any method known to the art for the manufacture of pharmaceuticals. Such formulations can contain sweetening agents, flavoring agents, coloring agents and preserving agents. A formulation can be admixtured with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture. Formulations may comprise one or more diluents, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, lyophilized powders, sprays, creams, lotions, controlled release formulations, tablets, pills, gels, on patches, in implants, etc.

A formulated single stranded oligonucleotide composition can assume a variety of states. In some examples, the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g. , less than 80, 50, 30, 20, or 10% water). In another example, the single stranded oligonucleotide is in an aqueous phase, e.g. , in a solution that includes water. The aqueous phase or the crystalline compositions can, e.g. , be incorporated into a delivery vehicle, e.g. , a liposome (particularly for the aqueous phase) or a particle (e.g. , a microparticle as can be appropriate for a crystalline composition). Generally, the single stranded oligonucleotide composition is formulated in a manner that is compatible with the intended method of administration.

In some embodiments, the composition is prepared by at least one of the following methods: spray drying, lyophilization, vacuum drying, evaporation, fluid bed drying, or a combination of these techniques; or sonication with a lipid, freeze-drying, condensation and other self-assembly.

A single stranded oligonucleotide preparation can be formulated or administered (together or separately) in combination with another agent, e.g. , another therapeutic agent or an agent that stabilizes a single stranded oligonucleotide, e.g. , a protein that complexes with single stranded oligonucleotide. Still other agents include chelators, e.g. , EDTA (e.g. , to remove divalent cations such as Mg²⁺), salts, RNAse inhibitors (e.g. , a broad specificity RNAse inhibitor such as RNAsin) and so forth.

In one embodiment, the single stranded oligonucleotide preparation includes another single stranded oligonucleotide, e.g. , a second single stranded oligonucleotide that modulates expression of a second gene or a second single stranded oligonucleotide that modulates expression of the first gene. Still other preparation can include at least 3, 5, ten, twenty, fifty, or a hundred or more different single stranded oligonucleotide species. Such single stranded oligonucleotides can mediated gene expression with respect to a similar number of different genes. In one embodiment, the single stranded oligonucleotide preparation includes at least a second therapeutic agent (e.g. , an agent other than an oligonucleotide).

Route of Delivery A composition that includes a single stranded oligonucleotide can be delivered to a subject by a variety of routes. Exemplary routes include: intravenous, intradermal, topical, rectal, parenteral, anal, intravaginal, intranasal, pulmonary, ocular. The term "therapeutically effective amount" is the amount of oligonucleotide present in the composition that is needed to provide the desired level of target gene expression in the subject to be treated to give the anticipated physiological response. The term "physiologically effective amount" is that amount delivered to a subject to give the desired palliative or curative effect. The term "pharmaceutically acceptable carrier" means that the carrier can be administered to a subject with no significant adverse toxicological effects to the subject.

The single stranded oligonucleotide molecules of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically include one or more species of single stranded oligonucleotide and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or

intraventricular administration.

The route and site of administration may be chosen to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscles of interest would be a logical choice. Lung cells might be targeted by administering the single stranded oligonucleotide in aerosol form. The vascular endothelial cells could be targeted by coating a balloon catheter with the single stranded oligonucleotide and mechanically introducing the oligonucleotide. Topical administration refers to the delivery to a subject by contacting the formulation directly to a surface of the subject. The most common form of topical delivery is to the skin, but a composition disclosed herein can also be directly applied to other surfaces of the body, e.g. , to the eye, a mucous membrane, to surfaces of a body cavity or to an internal surface. As mentioned above, the most common topical delivery is to the skin. The term encompasses several routes of administration including, but not limited to, topical and transdermal. These modes of administration typically include penetration of the skin's permeability barrier and efficient delivery to the target tissue or stratum. Topical administration can be used as a means to penetrate the epidermis and dermis and ultimately achieve systemic delivery of the composition. Topical administration can also be used as a means to selectively deliver oligonucleotides to the epidermis or dermis of a subject, or to specific strata thereof, or to an underlying tissue.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Transdermal delivery is a valuable route for the administration of lipid soluble therapeutics. The dermis is more permeable than the epidermis and therefore absorption is much more rapid through abraded, burned or denuded skin. Inflammation and other physiologic conditions that increase blood flow to the skin also enhance transdermal adsorption. Absorption via this route may be enhanced by the use of an oily vehicle

(inunction) or through the use of one or more penetration enhancers. Other effective ways to deliver a composition disclosed herein via the transdermal route include hydration of the skin and the use of controlled release topical patches. The transdermal route provides a potentially effective means to deliver a composition disclosed herein for systemic and/or local therapy. In addition, iontophoresis (transfer of ionic solutes through biological membranes under the influence of an electric field), phonophoresis or sonophoresis (use of ultrasound to enhance the absorption of various therapeutic agents across biological membranes, notably the skin and the cornea), and optimization of vehicle characteristics relative to dose position and retention at the site of administration may be useful methods for enhancing the transport of topically applied compositions across skin and mucosal sites. Both the oral and nasal membranes offer advantages over other routes of administration. For example, oligonucleotides administered through these membranes may have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the oligonucleotides to the hostile gastrointestinal (GI) environment. Additional advantages include easy access to the membrane sites so that the oligonucleotide can be applied, localized and removed easily.

In oral delivery, compositions can be targeted to a surface of the oral cavity, e.g. , to sublingual mucosa which includes the membrane of ventral surface of the tongue and the floor of the mouth or the buccal mucosa which constitutes the lining of the cheek. The sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many agents. Further, the sublingual mucosa is convenient, acceptable and easily accessible.

A pharmaceutical composition of single stranded oligonucleotide may also be administered to the buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical

formulation as described above and a propellant. In one embodiment, the dispenser is first shaken prior to spraying the pharmaceutical formulation and propellant into the buccal cavity.

Compositions for oral administration include powders or granules, suspensions or solutions in water, syrups, slurries, emulsions, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches. In the case of tablets, carriers that can be used include lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.

Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, intrathecal or intraventricular administration. In some embodiments, parental administration involves administration directly to the site of disease (e.g. injection into a tumor). Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.

Any of the single stranded oligonucleotides described herein can be administered to ocular tissue. For example, the compositions can be applied to the surface of the eye or nearby tissue, e.g. , the inside of the eyelid. For ocular administration, ointments or droppable liquids may be delivered by ocular delivery systems known to the art such as applicators or eye droppers. Such compositions can include mucomimetics such as hyaluronic acid, chondroitin sulfate, hydroxypropyl methylcellulose or poly(vinyl alcohol), preservatives such as sorbic acid, EDTA or benzylchronium chloride, and the usual quantities of diluents and/or carriers. The single stranded oligonucleotide can also be administered to the interior of the eye, and can be introduced by a needle or other delivery device which can introduce it to a selected area or structure.

Pulmonary delivery compositions can be delivered by inhalation by the patient of a dispersion so that the composition, preferably single stranded oligonucleotides, within the dispersion can reach the lung where it can be readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.

Pulmonary delivery can be achieved by different approaches, including the use of nebulized, aerosolized, micellular and dry powder-based formulations. Delivery can be achieved with liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices are preferred. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self-contained. Dry powder dispersion devices, for example, deliver agents that may be readily formulated as dry powders. A single stranded oligonucleotide composition may be stably stored as lyophilized or spray-dried powders by itself or in combination with suitable powder carriers. The delivery of a composition for inhalation can be mediated by a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.

The term "powder" means a composition that consists of finely dispersed solid particles that are free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a subject so that the particles reach the lungs to permit penetration into the alveoli. Thus, the powder is said to be "respirable." Preferably the average particle size is less than about 10 μιη in diameter preferably with a relatively uniform spheroidal shape distribution. More preferably the diameter is less than about 7.5 μ m and most preferably less than about 5.0 μ m. Usually the particle size distribution is between about 0.1 μ m and about 5 μ m in diameter, particularly about 0.3 μ m to about 5 μ m.

The term "dry" means that the composition has a moisture content below about 10% by weight (% w) water, usually below about 5% w and preferably less it than about 3% w. A dry composition can be such that the particles are readily dispersible in an inhalation device to form an aerosol.

The types of pharmaceutical excipients that are useful as carrier include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.

Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred. Pulmonary administration of a micellar single stranded oligonucleotide formulation may be achieved through metered dose spray devices with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants.

Exemplary devices include devices which are introduced into the vasculature, e.g. , devices inserted into the lumen of a vascular tissue, or which devices themselves form a part of the vasculature, including stents, catheters, heart valves, and other vascular devices. These devices, e.g. , catheters or stents, can be placed in the vasculature of the lung, heart, or leg.

Other devices include non- vascular devices, e.g. , devices implanted in the peritoneum, or in organ or glandular tissue, e.g. , artificial organs. The device can release a therapeutic substance in addition to a single stranded oligonucleotide, e.g. , a device can release insulin.

In one embodiment, unit doses or measured doses of a composition that includes single stranded oligonucleotide are dispensed by an implanted device. The device can include a sensor that monitors a parameter within a subject. For example, the device can include pump, e.g. , and, optionally, associated electronics.

Tissue, e.g. , cells or organs can be treated with a single stranded oligonucleotide, ex vivo and then administered or implanted in a subject. The tissue can be autologous, allogeneic, or xenogeneic tissue. E.g. , tissue can be treated to reduce graft v. host disease . In other embodiments, the tissue is allogeneic and the tissue is treated to treat a disorder characterized by unwanted gene expression in that tissue. E.g. , tissue, e.g. , hematopoietic cells, e.g. , bone marrow hematopoietic cells, can be treated to inhibit unwanted cell proliferation. Introduction of treated tissue, whether autologous or transplant, can be combined with other therapies. In some implementations, the single stranded oligonucleotide treated cells are insulated from other cells, e.g. , by a semi-permeable porous barrier that prevents the cells from leaving the implant, but enables molecules from the body to reach the cells and molecules produced by the cells to enter the body. In one embodiment, the porous barrier is formed from alginate.

In one embodiment, a contraceptive device is coated with or contains a single stranded oligonucleotide. Exemplary devices include condoms, diaphragms, IUD

(implantable uterine devices, sponges, vaginal sheaths, and birth control devices.

Dosage

In one aspect, the invention features a method of administering a single stranded oligonucleotide (e.g., as a compound or as a component of a composition) to a subject (e.g. , a human subject). In one embodiment, the unit dose is between about 10 mg and 25 mg per kg of bodyweight. In one embodiment, the unit dose is between about 1 mg and 100 mg per kg of bodyweight. In one embodiment, the unit dose is between about 0.1 mg and 500 mg per kg of bodyweight. In some embodiments, the unit dose is more than 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 5, 10, 25, 50 or 100 mg per kg of bodyweight. The defined amount can be an amount effective to treat or prevent a disease or disorder, e.g. , a disease or disorder associated with the target gene. The unit dose, for example, can be administered by injection (e.g. , intravenous or intramuscular), an inhaled dose, or a topical application.

In some embodiments, the unit dose is administered daily. In some embodiments, less frequently than once a day, e.g. , less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered with a frequency (e.g. , not a regular frequency). For example, the unit dose may be administered a single time. In some embodiments, the unit dose is administered more than once a day, e.g. , once an hour, two hours, four hours, eight hours, twelve hours, etc.

In one embodiment, a subject is administered an initial dose and one or more maintenance doses of a single stranded oligonucleotide. The maintenance dose or doses are generally lower than the initial dose, e.g. , one-half less of the initial dose. A maintenance regimen can include treating the subject with a dose or doses ranging from 0.0001 to 100 mg/kg of body weight per day, e.g. , 100, 10, 1, 0.1, 0.01, 0.001, or 0.0001 mg per kg of bodyweight per day. The maintenance doses may be administered no more than once every 1, 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient. In some embodiments the dosage may be delivered no more than once per day, e.g. , no more than once per 24, 36, 48, or more hours, e.g. , no more than once for every 5 or 8 days. Following treatment, the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state. The dosage of the oligonucleotide may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.

The effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g. , a pump, semi- permanent stent (e.g. , intravenous, intraperitoneal, intracisternal or intracapsular), or reservoir may be advisable. In some embodiments, the oligonucleotide pharmaceutical composition includes a plurality of single stranded oligonucleotide species. In another embodiment, the single stranded oligonucleotide species has sequences that are non- overlapping and non-adjacent to another species with respect to a naturally occurring target sequence (e.g. , a PRC2-associated region). In another embodiment, the plurality of single stranded oligonucleotide species is specific for different PRC2-associated regions. In another embodiment, the single stranded oligonucleotide is allele specific. In some cases, a patient is treated with a single stranded oligonucleotide in conjunction with other therapeutic modalities.

Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the compound of the invention is administered in maintenance doses, ranging from 0.0001 mg to 100 mg per kg of body weight.

The concentration of the single stranded oligonucleotide composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans. The concentration or amount of single stranded oligonucleotide administered will depend on the parameters determined for the agent and the method of administration, e.g. nasal, buccal, pulmonary. For example, nasal formulations may tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is sometimes desirable to dilute an oral formulation up to 10- 100 times in order to provide a suitable nasal formulation.

Certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a single stranded oligonucleotide can include a single treatment or, preferably, can include a series of treatments. It will also be appreciated that the effective dosage of a single stranded oligonucleotide used for treatment may increase or decrease over the course of a particular treatment. For example, the subject can be monitored after administering a single stranded oligonucleotide composition. Based on information from the monitoring, an additional amount of the single stranded

oligonucleotide composition can be administered. Dosing is dependent on severity and responsiveness of the disease condition to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of disease state is achieved. Optimal dosing schedules can be calculated from measurements of target gene expression levels in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models. In some embodiments, the animal models include transgenic animals that express a human target gene. In another embodiment, the composition for testing includes a single stranded oligonucleotide that is complementary, at least in an internal region, to a sequence that is conserved between a target gene in the animal model and the target gene in a human.

In one embodiment, the administration of the single stranded oligonucleotide composition is parenteral, e.g. intravenous (e.g. , as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral or ocular. Administration can be provided by the subject or by another person, e.g. , a health care provider. The composition can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.

Kits

In certain aspects of the invention, kits are provided, comprising a container housing a composition comprising a single stranded oligonucleotide. In some embodiments, the composition is a pharmaceutical composition comprising a single stranded oligonucleotide and a pharmaceutically acceptable carrier. In some embodiments, the individual components of the pharmaceutical composition may be provided in one container. Alternatively, it may be desirable to provide the components of the pharmaceutical composition separately in two or more containers, e.g. , one container for single stranded oligonucleotides, and at least another for a carrier compound. The kit may be packaged in a number of different configurations such as one or more containers in a single box. The different components can be combined, e.g. , according to instructions provided with the kit. The components can be combined according to a method described herein, e.g. , to prepare and administer a pharmaceutical composition. The kit can also include a delivery device. The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

EXAMPLES

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

MATERIALS AND METHODS:

Real Time PCR

RNA was harvested from the cells using Promega SV 96 Total RNA Isolation system or Trizol omitting the DNAse step. In separate pilot experiments, 50 ng of RNA was determined to be sufficient template for the reverse transcriptase reaction. RNA harvested from cells was normalized so that 50ng of RNA was input to each reverse transcription reaction. For the few samples that were too dilute to reach this limit, the maximum input volume was added. Reverse transcriptase reaction was performed using the Superscript II kit and real time PCR performed on cDNA samples using icycler SYBR green chemistry (Biorad). A baseline level of mRNA expression for each target gene was determined through quantitative PCR as outlined above. Baseline levels were also determined for mRNA of various housekeeping genes which are constitutively expressed. A "control" housekeeping gene with approximately the same level of baseline expression as the target gene was chosen for comparison purposes. ELISA

An ELISA assay using a commercially available kit [DEPOO, RnD Systems] was used according to the manufacturer's instructions to determine secreted protein present in cellular supernatant. Fold induction of protein was determined by normalizing protein levels induced by oligonucleotides to the protein levels induced by control (Lipofectamine alone).

Cell Culture

Human hepatocyte Hep3B, human hepatocyte HepG2 cells, mouse hepatoma Hepal-6 cells, and human renal proximal tubule epithelial cells (RPTEC) were cultured using conditions known in the art (see, e.g. Current Protocols in Cell Biology). Details of the cell lines used in the experiments described herein are provided in Table 7.

Table 7. Cell lines

Oligonucleotide design

Oligonucleotides were designed within PRC2-interacting regions in order to upregulate target genes listed in Table 4. The sequence and structure of each oligonucleotide is shown in Table 2 or Table 6. The following table provides a description of the nucleotide analogs, modifications and intranucleotide linkages used for certain oligonucleotides tested and described in Table 2 or Table 6.

Table 3: Oligonucleotide Modifications

Symbol Feature Description

bio 5' biotin

dAs DNA w/3' thiophosphate Symbol Feature Description

dCs DNA w/3' thiophosphate dGs DNA w/3' thiophosphate dTs DNA w/3' thiophosphate dG DNA

enaAs EN A w/3' thiophosphate enaCs ENA w/3' thiophosphate enaGs EN A w/3' thiophosphate enaTs ENA w/3' thiophosphate fluAs 2'-fluoro w/3' thiophosphate fluCs 2'-fluoro w/3' thiophosphate fluGs 2'-fluoro w/3' thiophosphate fluUs 2'-fluoro w/3' thiophosphate

InaAs LNA w/3' thiophosphate

InaCs LNA w/3' thiophosphate

InaGs LNA w/3' thiophosphate

InaTs LNA w/3' thiophosphate omeAs 2'-OMe w/3' thiophosphate omeCs 2'-OMe w/3' thiophosphate omeGs 2'-OMe w/3' thiophosphate omeTs 2'-OMe w/3' thiophosphate

InaAs-Sup LNA w/3' thiophosphate at 3' terminus

InaCs-Sup LNA w/3' thiophosphate at 3' terminus

InaGs-Sup LNA w/3' thiophosphate at 3' terminus

InaTs-Sup LNA w/3' thiophosphate at 3' terminus

InaA-Sup LNA w/3' OH at 3' terminus

InaC-Sup LNA w/3' OH at 3' terminus

InaG-Sup LNA w/3' OH at 3' terminus

InaT-Sup LNA w/3' OH at 3' terminus omeA-Sup 2'-OMe w/3' OH at 3' terminus omeC-Sup 2'-OMe w/3' OH at 3' terminus omeG-Sup 2'-OMe w/3' OH at 3' terminus omeU-Sup 2'-OMe w/3' OH at 3' terminus dAs-Sup DNA w/3' thiophosphate at 3' terminus dCs-Sup DNA w/3' thiophosphate at 3' terminus dGs-Sup DNA w/3' thiophosphate at 3' terminus dTs-Sup DNA w/3' thiophosphate at 3' terminus dA-Sup DNA w/3' OH at 3' terminus dC-Sup DNA w/3' OH at 3' terminus dG-Sup DNA w/3' OH at 3' terminus Symbol Feature Description

dT-Sup DNA w/3' OH at 3' terminus

In vitro transfection of cells with oligonucleotides

Cells were seeded into each well of 24- well plates at a density of 25,000 cells per 500uL and transfections were performed with Lipofectamine and the single stranded oligonucleotides. Control wells contained Lipofectamine alone. At 48 hours post- transfection, approximately 200 uL of cell culture supernatants were stored at -80 C for ELISA. At 48 hours post-transfection, RNA was harvested from the cells and quantitative PCR was carried out as outlined above. The percent induction of target mRNA expression by each oligonucleotide was determined by normalizing mRNA levels in the presence of the oligonucleotide to the mRNA levels in the presence of control (Lipofectamine alone). This was compared side-by-side with the increase in mRNA expression of the "control" housekeeping gene.

RESULTS:

In vitro delivery of single stranded oligonucleotides upregulated gene expression

Oligonucleotides were designed as candidates for upregulating gene expression of target genes listed in Table 4. Single stranded oligonucleotides were designed to be complementary to a PRC2-interacting region. The oligonucleotides were tested in at least duplicate. The sequence and structural features of the oligonucleotides are set forth in Table 2 or Table 6. Briefly, cells were transfected in vitro with the oligonucleotides as described above. Gene or expression in cells or protein levels following treatment was evaluated by qRT-PCR or ELISA. Oligonucleotides that upregulated expression of target genes listed in Table 4 were identified. Further details are outlined in Table 2 and Table 6.

Tables

Table 1: Hexamers that are not seed sequences of human miRNAs

AAA AAA, AAAAAG, AAAACA, AAAAGA, AAAAGC, AAAAGG, AAAAUA, AAACAA, AAACAC, AAACAG, AAACAU, AAACCC, AAACCU, AAACGA, AAACGC, AAACGU, AAACUA, AAACUC, AAACUU, AAAGAU, AAAGCC, AAAGGA, AAAGGG, AAAGUC, AAAUAC, AAAUAU, AAAUCG, AAAUCU, AAAUGC, AAAUGU, AAAUUA, AAAUUG, AACAAC, AACAAG, AACAAU, AACACA, AACACG, AACAGA, AACAGC, AACAGG, AACAUC, AACAUG, AACCAA, AACCAC, AACCAG, AACCAU, AACCCC, AACCCG, AACCGA, AACCGC, AACCGG, AACCUA, AACCUU, AACGAA, AACGAC, AACGAG, AACGAU, AACGCU, AACGGG, AACGGU, AACGUA, AACGUC, AACGUG, AACGUU, AACUAU, AACUCA, AACUCC, AACUCG, AACUGA, AACUGC, AACUGU, AACU UA, AACUUC, AACU UG, AACUUU, AAGAAA, AAGAAG, AAGAAU, AAGACG, AAGAGA, AAGAGC, AAGAGG, AAGAGU, AAGAUU, AAGCAA, AAGCAC, AAGCAG, AAGCAU, AAGCCA, AAGCCC, AAGCCG, AAGCCU, AAGCGA, AAGCGG, AAGCGU, AAGCUA, AAGGAA, AAGGAC, AAGGCU, AAGGGC, AAGGGU, AAGGUU, AAGUAA, AAGUAC, AAGUAU, AAGUCC, AAGUCG, AAGUGA, AAGUGG, AAGUUA, AAGU UU, AAUAAA, AAUAAC, AAUAAG, AAUAAU, AAUACA, AAUACC, AAUACG, AAUAGA, AAUAGC, AAUAGG, AAUAGU, AAUAUC, AAUAU U, AAUCAA, AAUCAU, AAUCCA, AAUCCC, AAUCCG, AAUCGA, AAUCGC, AAUCGU, AAUCUA, AAUCUG, AAUCUU, AAUGAA, AAUGAC, AAUGAG, AAUGAU, AAUGCG, AAUGCU, AAUGGA, AAUGGU, AAUGUA, AAUGUC, AAUGUG, AAUUAA, AAUUAC, AAUUAG, AAU UCC, AAU UCG, AAUUGA, AAUUGG, AAU UGU, AAUUUC, AAU UUG, ACAAAA, ACAAAC, ACAAAG, ACAAAU, ACAACC, ACAACG, ACAACU, ACAAGA, ACAAGC, ACAAGU, ACAAUC, ACAAUG, ACAAUU, ACACAG, ACACCA, ACACCC, ACACCG, ACACCU, ACACGA, ACACGC, ACACGU, ACACUC, ACACUG, ACACUU, ACAGAA, ACAGAC, ACAGCC, ACAGCG, ACAGCU, ACAGGG, ACAGUC, ACAGUG, ACAGU U, ACAUAA, ACAUAC, ACAUCC, ACAUCG, ACAUCU, ACAUGA, ACAUGC, ACAUGU, ACAU UG, ACAU UU, ACCAAA, ACCAAC, ACCAAG, ACCAAU, ACCACC, ACCACG, ACCAGA, ACCAGU, ACCAUA, ACCAUG, ACCAU U, ACCCAA, ACCCAC, ACCCCA, ACCCCG, ACCCGA, ACCCGC, ACCCUA, ACCCUC, ACCCUU, ACCGAA, ACCGAC, ACCGAU, ACCGCA, ACCGCC, ACCGCG, ACCGCU, ACCGGA, ACCGGC, ACCGGU, ACCGUA, ACCGUC, ACCGUG, ACCGUU, ACCUAA, ACCUAC, ACCUAG, ACCUAU, ACCUCA, ACCUCC, ACCUCG, ACCUCU, ACCUGA, ACCUGC, ACCUGU, ACCUUA, ACCUUC, ACCUU U, ACGAAA, ACGAAC, ACGAAG, ACGAAU, ACGACA, ACGACC, ACGACG, ACGACU, ACGAGA, ACGAGC, ACGAGG, ACGAGU, ACGAUA, ACGAUC, ACGAUG, ACGAUU, ACGCAA, ACGCAG, ACGCAU, ACGCCC, ACGCCG, ACGCCU, ACGCGA, ACGCGG, ACGCGU, ACGCUA, ACGCUG, ACGCUU, ACGGAA, ACGGAC, ACGGAG, ACGGAU, ACGGCC, ACGGCG, ACGGCU, ACGGGC, ACGGGG, ACGGGU, ACGGUA, ACGGUC, ACGGUG, ACGGUU, ACGUAA, ACGUAC, ACGUAU, ACGUCC, ACGUCG, ACGUCU, ACGUGA, ACGUGC, ACGUGG, ACGUGU, ACGUUA, ACGU UC, ACGUUG, ACGUU U, AC U AAA, ACUAAG, ACUAAU, ACUACA, ACUACC, ACUACG, ACUACU, ACUAGG, ACUAUC, ACUAUG, ACUAUU, ACUCAU, ACUCCC, ACUCCG, ACUCCU, ACUCGA, ACUCGC, ACUCGG, ACUCUC, ACUCUU, ACUGAG, ACUGAU, ACUGCC, ACUGCG, ACUGCU, ACUGGG, ACUGGU, ACUGUC, ACUUAA, ACU UAC, ACUUAU, ACU UCA, ACUUCC, ACUUCG, ACUUCU, ACUUGA, ACU UGC, ACU UGU, ACUUUA, ACU UUC, ACUU UG, AGAAAA, AGAAAC, AGAAAG, AGAACC, AGAACG, AGAACU, AGAAGC, AGAAGU, AGAAUA, AGAAUC, AGAAUG, AGAAUU, AGACAA, AGACAC, AGACAU, AGACCA, AGACCC, AGACCG, AGACCU, AGACGA, AGACGC, AGACGU, AGACUA, AGACUC, AGACUU, AGAGAC, AGAGAG, AGAGAU, AGAGCC, AGAGCG, AGAGCU, AGAGGC, AGAGGG, AGAGGU, AGAGUA, AGAGUU, AGAUAC, AGAUAG, AGAUAU, AGAUCC, AGAUCG, AGAUCU, AGAUGA, AGAUGC, AGAUGG, AGAU UA, AGAU UC, AGAUUG, AGAUU U, AGCAAC, AGCACA, AGCACG, AGCACU, AGCAGA, AGCAUA, AGCAUC, AGCAUG, AGCCAA, AGCCAU, AGCCCA, AGCCGA, AGCCGC, AGCCGG, AGCCGU, AGCCUA, AGCCUC, AGCGAA, AGCGAG, AGCGAU, AGCGCA, AGCGCC, AGCGCG, AGCGCU, AGCGGA, AGCGGC, AGCGGU, AGCGUA, AGCGUC, AGCGUG, AGCGUU, AGCUAA, AGCUAC, AGCUAG, AGCUAU, AGCUCA, AGCUCC, AGCUCG, AGCUCU, AGCUGA, AGCUGG, AGCUGU, AGCU UC, AGCUU U, AGGAAU, AGGACC, AGGACG, AGGAGA, AGGAGU, AGGAUA, AGGCAA, AGGCAU, AGGCCG, AGGCGA, AGGCGC, AGGCGG, AGGCUA, AGGCUC, AGGCUU, AGGGAC, AGGGAU, AGGGGA, AGGGGU, AGGGUA, AGGGUG, AGGUAA, AGGUAC, AGGUCA, AGGUCC, AGGUCU, AGGUGA, AGGUGC, AGGUGG, AGGUGU, AGGU UC,

AGGUUG, AGUAAA, AGUAAG, AGUAAU, AGUACA, AGUACG, AGUAGC, AGUAGG, AGUAUA, AGUAUC, AGUAUG, AGUAUU, AGUCAA, AGUCAC, AGUCAG, AGUCAU, AGUCCA, AGUCCG, AGUCCU, AGUCGA, AGUCGC, AGUCGG, AGUCGU, AGUCUA, AGUCUC, AGUCUG, AGUCU U, AGUGAA, AGUGAC, AGUGCG, AGUGGG, AGUGUC, AGU UAA, AGU UAC, AGUUAG, AGUUCC, AGU UCG, AGUUGA, AGUUGC,

AGUUGU, AGUUUA, AGUUUC, AGUU UG, AGU UU U, AUAAAC, AUAAAU, AUAACA, AUAACC, AUAACG, AUAACU, AUAAGA, AUAAGC, AUAAGG, AUAAGU, AUAAUC, AUAAUG, AUAAUU, AUACAC, AUACAG, AUACAU, AUACCA, AUACCC, AUACCG, AUACGA, AUACGC, AUACGG, AUACGU, AUACUA, AUACUC, AUACUG, AUACUU, AUAGAA, AUAGAC, AUAGAU, AUAGCA, AUAGCG, AUAGCU, AUAGGA, AUAGGU, AUAGUA, AUAGUC, AUAGUG, AUAGUU, AUAUAC, AUAUAG, AUAUCC, AUAUCG, AUAUCU, AUAUGA, AUAUGC, AUAUGG, AUAUGU, AUAUUC, AUAU UG, AUAUU U, AUCAAA, AUCAAC, AUCAAG, AUCAAU, AUCACA, AUCACC, AUCACG, AUCAGC, AUCAGG, AUCCAA, AUCCAU, AUCCCC, AUCCCG, AUCCGA, AUCCGC, AUCCGG, AUCCUA, AUCCUC, AUCCUG, AUCGAA, AUCGAC, AUCGAG, AUCGAU, AUCGCA, AUCGCC, AUCGCG, AUCGCU, AUCGGC, AUCGGG, AUCGGU, AUCGUC, AUCGUG, AUCGU U, AUCUAA, AUCUAC, AUCUAG, AUCUAU, AUCUCC, AUCUCG, AUCUGU, AUCUUG, AUCUU U, AUGAAA, AUGAAC, AUGAAG, AUGAAU, AUGACC, AUGACU, AUGAGG, AUGAGU, AUGAUA, AUGAUC, AUGAU U, AUGCAA, AUGCAG, AUGCCA, AUGCCC, AUGCCG, AUGCGA, AUGCGG, AUGCGU, AUGCUC, AUGCUU, AUGGAC, AUGGCC, AUGGGA, AUGGGC, AUGGGU, AUGGUC, AUGGUG, AUGUAC, AUGUAU, AUGUCA, AUGUCC, AUGUCG, AUGUGU, AUGUUA, AUGUUC, AU UAAA, AUUAAC, AU UAAG, AU UAAU, AU UACA, AUUACC, AUUACG, AUUACU, AU UAGA, AUUAGC, AUUAGG, AUUAGU, AU UAUA, AUUAUC, AUUAUG, AUUCAC, AUUCCA, AU UCCG, AU UCCU, AUUCGA, AUUCGC, AUUCGG, AU UCGU, AUUCUA, AUUCUC, AUUCU U, AUUGAA, AUUGAC, AUUGAU, AU UGCC, AUUGCG, AU UGCU, AUUGGA, AUUGGC,

AUUGGG, AU UGGU, AUUGUA, AUUGUC, AUUGUG, AU UGU U, AU UUAA, AU UUAG, AU UUAU, AUU UCC, AUU UCG, AUU UCU, AU UUGA, AU UUGC, AU UUGU, AU UUUA, AU UU UC, AUU UUG,

AUU UU U, CAAAAG, CAAACA, CAAACC, CAAACG, CAAACU, CAAAGA, CAAAGG, CAAAUA, CAAAUU, CAACAC, CAACAU, CAACCA, CAACCC, CAACCG, CAACGA, CAACGC, CAACGG, CAACGU, CAACUA, CAACUC, CAACUG, CAACUU, CAAGAA, CAAGAC, CAAGAU, CAAGCA, CAAGCC, CAAGCG, CAAGCU, CAAGGA, CAAGGG, CAAGUC, CAAGUG, CAAGU U, CAAUAA, CAAUAC, CAAUAG, CAAUCC, CAAUCG, CAAUCU, CAAUGA, CAAUGC, CAAUGG, CAAUGU, CAAU UC, CAAU UG, CAAU UU, CACAAU, CACACA, CACACG, CACACU, CACAGA, CACAGC, CACAGG, CACAUA, CACAUC, CACAUU, CACCAA, CACCAC, CACCAU, CACCCA, CACCCC, CACCCG, CACCGA, CACCGC, CACCGG, CACCGU, CACCUA, CACCU U, CACGAA, CACGAC, CACGAG, CACGAU, CACGCA, CACGCC, CACGCU, CACGGA, CACGGC, CACGGG, CACGG U, CACGUA, CACGUC, CACGUG, CACGU U, CACUAA, CACUAG, CACUAU, CACUCA, CACUCG, CACUGA, CACUGC, CACUGG, CACUUA, CACU UC, CACU UU, CAGAAA, CAGAAG, CAGAAU, CAGACC, CAGACG, CAGAGC, CAGAUA, CAGAUC, CAGCCG, CAGCCU, CAGCGA, CAGCGC, CAGCGG, CAGCGU, CAGCUC, CAGCUU, CAGGAU, CAGGGG, CAGGGU, CAGGUA, CAGGUC, CAGGUU, CAGUAC, CAGUCG, CAGU UG, CAUAAA, CAUAAC, CAUAAG, CAUAAU, CAUACA, CAUACC, CAUACG, CAUACU, CAUAGA, CAUAGG, CAUAGU, CAUAUA, CAUAUC, CAUAUG, CAUCAA, CAUCAC, CAUCAG, CAUCAU, CAUCCA, CAUCCC, CAUCCG, CAUCGA, CAUCGC, CAUCGG, CAUCGU, CAUCUA, CAUCUC, CAUCUG, CAUCUU, CAUGAA, CAUGAC, CAUGAG, CAUGAU, CAUGCA, CAUGCC, CAUGCG, CAUGCU, CAUGGC, CAUGGG, CAUGGU, CAUGUA, CAUGUC, CAUGUU, CAU UAA, CAUUAC, CAUUAG, CAUUCA, CAU UCC, CAU UCG, CAU UCU, CAU UGA, CAU UGG, CAUU UC, CAU UUG, CAUU UU, CCAAAA, CCAAAC, CCAAAG, CCAAAU, CCAACA, CCAACC, CCAACG, CCAACU, CCAAGA, CCAAGC, CCAAGG, CCAAUC, CCAAUG, CCAAU U, CCACAA, CCACAC, CCACAG, CCACAU, CCACCA, CCACCC, CCACCG, CCACCU, CCACGA, CCACGC, CCACGG, CCACGU, CCACUA, CCACUC, CCACUU, CCAGAA, CCAGAC, CCAGAG, CCAGCC, CCAGGU, CCAGUC, CCAGUU, CCAUAA, CCAUAC, CCAUAG, CCAUAU, CCAUCA, CCAUCC, CCAUCU, CCAUGA, CCAUGC, CCAUGG, CCAUUC, CCAUUG, CCAUU U, CCCAAC, CCCAAG, CCCAAU, CCCACA, CCCAGA, CCCAGC, CCCAGU, CCCAUA, CCCAUC, CCCAUG, CCCAUU, CCCCAA, CCCCAG, CCCCAU, CCCCCC, CCCCCG, CCCCCU, CCCCGA, CCCCGC, CCCCGU, CCCCUA, CCCCUC, CCCGAA, CCCGAC, CCCGAU, CCCGCA, CCCGCU, CCCGGA, CCCGGC, CCCGUA, CCCGUG, CCCGU U, CCCUAA, CCCUAG, CCCUCA, CCCUCU, CCCUGC, CCCUUA, CCCU UC, CCCU UU, CCGAAA, CCGAAC, CCGAAU, CCGACA, CCGACC, CCGACG, CCGACU, CCGAGA, CCGAGG, CCGAGU, CCGAUA, CCGAUC, CCGAUG, CCGAU U, CCGCAA, CCGCAC, CCGCAG, CCGCAU, CCGCCA, CCGCCC, CCGCCG, CCGCCU, CCGCGA, CCGCGC, CCGCGG, CCGCGU, CCGCUA, CCGCUC, CCGCUG, CCGCU U, CCGGAA, CCGGAU, CCGGCA, CCGGCC, CCGGCG, CCGGCU, CCGGGA, CCGGGC, CCGGGG, CCGGGU, CCGGUA, CCGGUC, CCGGUG, CCGUAA, CCGUAG, CCGUAU, CCGUCA, CCGUCC, CCGUCG, CCGUGA, CCGUGU, CCGUUA, CCGUUC, CCGU UG, CCGUU U, CCUAAC, CCUAAG, CCUAAU, CCUACA, CCUACC, CCUACG, CCUACU, CCUAGA, CCUAGC, CCUAGG, CCUAGU, CCUAUA, CCUAUC, CCUAUG, CCUAUU, CCUCAA, CCUCAC, CCUCAG, CCUCAU, CCUCCA, CCUCCC, CCUCCG, CCUCGA, CCUCGC, CCUCGG, CCUCGU, CCUCUA, CCUCUG, CCUGAC, CCUGAU, CCUGCA, CCUGGG, CCUGGU, CCUGU U, CCUUAA, CCUUAC, CCUUAG, CCUUAU, CCUUCG, CCUUGA, CCUUGU, CCU UUA, CCUU UC, CCU UU U, CGAAAA, CGAAAC, CGAAAG, CGAAAU, CGAACA, CGAACC, CGAACG, CGAACU, CGAAGA, CGAAGC, CGAAGG, CGAAGU, CGAAUA, CGAAUC, CGAAUG, CGAAUU, CGACAA, CGACAC, CGACAU, CGACCA, CGACCU, CGACGA, CGACGC, CGACGG, CGACGU, CGACUA, CGACUG, CGACU U, CGAGAA, CGAGAC, CGAGAG, CGAGAU, CGAGCA, CGAGCC, CGAGCG, CGAGCU, CGAGGC, CGAGGG, CGAGGU, CGAGUA, CGAGUC, CGAGUG, CGAGUU, CGAUAA, CGAUAC, CGAUAG, CGAUAU, CGAUCA, CGAUCC, CGAUCG, CGAUCU, CGAUGA, CGAUGC, CGAUGG, CGAUGU, CGAUUA, CGAU UC, CGAUUG, CGAUU U, CGCAAA, CGCAAC, CGCAAG, CGCAAU, CGCACA, CGCACC, CGCACG, CGCAGA, CGCAGC, CGCAGG, CGCAGU, CGCAUA, CGCAUC, CGCAUG, CGCAU U, CGCCAA, CGCCAC, CGCCAG, CGCCAU, CGCCCA, CGCCCC, CGCCCG, CGCCGA, CGCCGC, CGCCGG, CGCCGU, CGCCUA, CGCCUG, CGCCUU, CGCGAA, CGCGAC, CGCGAG, CGCGAU, CGCGCA, CGCGCC, CGCGCG, CGCGCU, CGCGGA, CGCGGC, CGCGGG, CGCGGU, CGCGUA, CGCGUC, CGCGUG, CGCGU U, CGCUAA, CGCUAC, CGCUAG, CGCUAU, CGCUCA, CGCUCC, CGCUCG, CGCUCU, CGCUGA, CGCUGC, CGCUGG, CGCUGU, CGCUUA, CGCU UC, CGCU UG, CGGAAA, CGGAAC, CGGAAG, CGGACA, CGGACC, CGGACG, CGGACU, CGGAGC, CGGAGG, CGGAGU, CGGAUA, CGGAU U, CGGCAA, CGGCAC, CGGCAG, CGGCCA, CGGCCC, CGGCCG, CGGCGC, CGGCGG, CGGCGU, CGGCUA, CGGCUC, CGGCUG, CGGCU U, CGGGAA, CGGGAC, CGGGAG, CGGGAU, CGGGCA, CGGGCC, CGGGCG, CGGGCU, CGGGGU, CGGGUA, CGGGUC, CGGGUG, CGGUAA, CGGUAC, CGGUAG, CGGUAU, CGGUCA, CGGUCG, CGGUCU, CGGUGA, CGGUGG, CGGUGU, CGGU UA, CGGU UC, CGGUUG, CGGUUU, CGUAAA, CGUAAC, CGUAAG, CGUAAU, CGUACA, CGUACG, CGUACU, CGUAGA, CGUAGC, CGUAGG, CGUAGU, CGUAUA, CGUAUC, CGUAUG, CGUAUU, CGUCAA, CGUCAC, CGUCAG, CGUCAU, CGUCCA, CGUCCC, CGUCCG, CGUCCU, CG UCGA, CGUCGG, CGUCGU, CGUCUA, CGUCUC, CGUCUG, CGUCU U, CGUGAA, CGUGAC, CGUGAG, CGUGAU, CGUGCC, CGUGCG, CGUGCU, CGUGGA, CGUGGG, CGUGGU, CGUGUA, CGUGUG, CGUUAA, CGUUAC, CGU UAG,

CGU UAU, CGUUCA, CGUUCC, CGUUCG, CGU UCU, CGUUGA, CGUUGC, CGU UGU, CGU UUA, CGUUUC, CGU U UU, CUAAAA, CUAAAC, CUAAAU, CUAACA, CUAACC, CUAACG, CUAACU, CUAAGA, CUAAGC, CUAAGU, CUAAUA, CUAAUC, CUAAUG, CUACAC, CUACAU, CUACCA, CUACCC, CUACCG, CUACCU, CUACGA, CUACGC, CUACGG, CUACGU, CUACUA, CUACUC, CUACUG, CUAGAA, CUAGAG, CUAGAU, CUAGCA, CUAGCC, CUAGCG, CUAGCU, CUAGGA, CUAGGG, CUAGGU, CUAGUG, CUAGUU, CUAUAA, CUAUAG, CUAUAU, CUAUCA, CUAUCC, CUAUCG, CUAUCU, CUAUGA, CUAUGC, CUAUGG, CUAUGU, CUAUUA, CUAUUG, CUCAAC, CUCAAG, CUCAAU, CUCACC, CUCACG, CUCAGC, CUCAUA, CUCAUC, CUCAUG, CUCAU U, CUCCAC, CUCCCC, CUCCCG, CUCCGA, CUCCGC, CUCCGG, CUCCUA, CUCCUC, CUCCU U, CUCGAA, CUCGAC, CUCGAG, CUCGAU, CUCGCA, CUCGCC, CUCGCG, CUCGGG, CUCGGU, CUCGUA, CUCGUC, CUCGUG, CUCGU U, CUCUAA, CUCUAC, CUCUAU, CUCUCA, CUCUCC, CUCUCU, CUCUGC, CUCUGU, CUCUUA, CUCU UG, CUGAAG, CUGACC, CUGACG, CUGAGC, CUGAUA, CUGAUC, CUGCCG, CUGCCU, CUGCGA, CUGCUA, CUGCUU, CUGGAG, CUGGAU, CUGGCG, CUGGGU, CUGUAC, CUGUCA, CUGUCC, CUGUCG, CUGUGG, CUGUGU, CUGUUA, CUGU UU, CUUAAC, CUUAAG, CU UAAU, CU UACC, CUUACG, CUUAGA, CU UAGC, CU UAGG, CUUAGU, CUUAUA, CU UAUC, CU UAUG, CUUAUU, CU UCAG, CU UCAU, CUUCCA, CUUCCC, CU UCCG, CU UCCU, CUUCGA, CUUCGC, CU UCGG, CUUCGU, CU UCUA, CUUGAC, CUUGAG, CUUGAU, CUUGCA, CUUGCC, CUUGCG, CU UGCU, CUUGGC, CUUGGU, CU UGUU, CUU UAC, CU UUAG, CU UUAU, CUU UCA, CUU UCG, CU UUCU, CUUUGA, CU UUGC, CU UUGU, CU U UUA, CUUU UC, CUU UUG, CUU UUU, GAAAAA, GAAAAG, GAAAAU, GAAACC, GAAACG, GAAAGA, GAAAGC, GAAAGU, GAAAUA, GAAAUC, GAAAUG, GAAAUU, GAACAA, GAACAC, GAACAG, GAACAU, GAACCA, GAACCC, GAACCG, GAACCU, GAACGA, GAACGC, GAACGG, GAACGU, GAACUA, GAACUG, GAACUU, GAAGAC, GAAGAG, GAAGCA, GAAGCG, GAAGCU, GAAGUC, GAAUAA, GAAUAC, GAAUAG, GAAUAU, GAAUCC, GAAUCG, GAAUCU, GAAUGA, GAAUGC, GAAUGU, GAAU UA, GAAU UC, GAAUU U, GACAAA, GACAAG, GACAAU, GACACC, GACAGA, GACAGG, GACAUA, GACAUG, GACAUU, GACCAA, GACCAC, GACCAG, GACCCA, GACCCC, GACCCG, GACCGC, GACCGG, GACCGU, GACCUA, GACCUC, GACCU U, GACGAA, GACGAC, GACGAG, GACGAU, GACGCA, GACGCC, GACGCG, GACGCU, GACGGA, GACGGC, GACGGG, GACGGU, GACGUA, GACGUC, GACGUG, GACGUU, GACUAA, GACUAC, GACUAG, GACUAU, GACUCA, GACUCC, GACUCG, GACUGG, GACUGU, GACUUA, GACUUG, GACUU U, GAGAAU, GAGAGA, GAGAGC, GAGAGG, GAGAUA, GAGAUC, GAGCAA, GAGCAU, GAGCCA, GAGCGA, GAGCGG, GAGCGU, GAGGGU, GAGGUC, GAGGUG, GAGUAA, GAGUAG, GAGUCC, GAGUUC, GAGU UU,

GAUAAA, GAUAAC, GAUAAG, GAUAAU, GAUACA, GAUACC, GAUACG, GAUACU, GAUAGA, GAUAGC, GAUAGG, GAUAGU, GAUAUA, GAUCAA, GAUCAC, GAUCAU, GAUCCA, GAUCCC, GAUCCU, GAUCGC, GAUCGG, GAUCGU, GAUCUA, GAUCUG, GAUCU U, GAUGAA, GAUGAC, GAUGAG, GAUGCA, GAUGCC, GAUGCG, GAUGCU, GAUGGC, GAUGGG, GAUGGU, GAUGUG, GAUGUU, GAUUAA, GAUUAC, GAUUAG, GAUUAU, GAUUCA, GAUUCG, GAU UCU, GAUUGA, GAUUGC, GAU UUA, GAU UUC,

GAUU UG, GAUUU U, GCAAAC, GCAAAG, GCAAAU, GCAACA, GCAACC, GCAAGC, GCAAGU, GCAAUA, GCAAUC, GCAAUG, GCAAUU, GCACAA, GCACAC, GCACAG, GCACCC, GCACCG, GCACCU, GCACGA, GCACGC, GCACGU, GCACUA, GCACUC, GCACUG, GCACUU, GCAGAU, GCAGCC, GCAGCG, GCAGGC, GCAGUA, GCAGUC, GCAGUG, GCAGUU, GCAUAA, GCAUAG, GCAUAU, GCAUCG, GCAUCU, GCAUGA, GCAUGC, GCAUGG, GCAUGU, GCAU UA, GCAU UC, GCAUUG, GCAUU U, GCCAAA, GCCAAC, GCCAAU, GCCACA, GCCACC, GCCACG, GCCAGA, GCCAGU, GCCAUA, GCCAUC, GCCAUG, GCCAUU, GCCCAA, GCCCAC, GCCCAG, GCCCCG, GCCCGA, GCCCGG, GCCCGU, GCCGAA, GCCGAC, GCCGAG, GCCGAU, GCCGCA, GCCGCU, GCCGGA, GCCGGC, GCCGGG, GCCGGU, GCCGUA, GCCGUC, GCCGUG, GCCGU U, GCCUAA, GCCUAU, GCCUCA, GCCUCC, GCCUCG, GCCUGA, GCCU UA, GCCU UU, GCGAAA, GCGAAC, GCGAAG, GCGAAU, GCGACC, GCGACG, GCGACU, GCGAGA, GCGAGC, GCGAGG, GCGAGU, GCGAUA, GCGAUC, GCGAUG, GCGAUU, GCGCAA, GCGCAC, GCGCAG, GCGCAU, GCGCCA, GCGCCC, GCGCCU, GCGCGA, GCGCGU, GCGCUA, GCGCUC, GCGCUG, GCGCUU, GCGGAA, GCGGAC, GCGGAU, GCGGCA, GCGGCC, GCGGCU, GCGGGA, GCGGUA, GCGGUC, GCGGUU, GCGUAA, GCGUAC, GCGUAG, GCGUAU, GCGUCA, GCGUCC, GCGUCG, GCGUCU, GCGUGA, GCGUGC, GCGUGG, GCGUGU, GCGU UA, GCGUUC, GCGU UG, GCGUU U, GCUAAA, GCUAAC, GCUAAG, GCUAAU, GCUACC, GCUACG, GCUACU, GCUAGA, GCUAGG, GCUAGU, GCUAUA, GCUAUC, GCUAUU, GCUCAA, GCUCAC, GCUCAG, GCUCAU, GCUCCA, GCUCCC, GCUCCG, GCUCGA, GCUCGC, GCUCGU, GCUCUA, GCUCUC, GCUCU U, GCUGAA, GCUGAC, GCUGAU, GCUGCA, GCUGCC, GCUGCG, GCUGCU, GCUGUG, GCUGUU, GCUUAC, GCUUAG, GCUUAU, GCU UCA, GCUUCG, GCU UGA, GCUUGG, GCUUGU, GCUU UA, GCU UUG, GGAAAG, GGAACA, GGAACC, GGAACG, GGAACU, GGAAGU, GGAAUA, GGAAUC, GGAAU U, GGACAA, GGACAC, GGACAG, GGACAU, GGACCG, GGACGA, GGACGC, GGACGU, GGACUA, GGACUC, GGACU U, GGAGAC, GGAGCA, GGAGCG, GGAGGG, GGAGUA, GGAUAA, GGAUAC, GGAUCA, GGAUCC, GGAUCG, GGAUCU, GGAUGC, GGAUUA, GGAUUG, GGCAAU, GGCACA, GGCACU, GGCAGA, GGCAUA, GGCAUC, GGCCAC, GGCCAG, GGCCCC, GGCCGA, GGCCGC, GGCCGU, GGCCUA, GGCCUG, GGCCU U, GGCGAA, GGCGAG, GGCGAU, GGCGCA, GGCGCU, GGCGGU, GGCGUA, GGCGUC, GGCGUG, GGCGU U, GGCUAA, GGCUAC, GGCUAG, GGCUAU, GGCUCC, GGCUCG, GGCUGA, GGCU UA, GGCUUC, GGCUUG, GGGAAU, GGGACA, GGGAGA, GGGAGU, GGGAUA, GGGAU U, GGGCAA, GGGCAC, GGGCAG, GGGCCG, GGGCGG, GGGGCC, GGGGGG,

GGGGGU, GGGGUA, GGGUAC, GGGUAU, GGGUCA, GGGUCC, GGGUCG, GGGUGA, GGGUGC, GGGU UA, GGGU UG, GGUAAA, GGUAAC, GGUAAG, GGUAAU, GGUACA, GGUACC, GGUACG,

GGUACU, GGUAGC, GGUAGG, GGUAGU, GGUAUA, GGUAUC, GGUAUG, GGUCAA, GGUCAC, GGUCAG, GGUCAU, GGUCCA, GGUCCG, GGUCCU, GGUCGA, GGUCGC, GG UCGG, GGUCGU, GGUCUC, GGUCU U, GGUGAA, GGUGAC, GGUGAU, GGUGCA, GGUGCC, GGUGGC, GGUGUA, GGUGUC, GGU UAA, GGU UAG, GGU UAU, GGUUCA, GGU UCC, GGU UCG, GGU UGC, GGU UUC, GGUU UU, GUAAAA, GUAAAG, GUAAAU, GUAACC, GUAACG, GUAACU, GUAAGA, GUAAGC, GUAAGG, GUAAGU, GUAAUA, GUAAUC, GUAAUG, GUAAUU, GUACAA, GUACAC, GUACAG, GUACAU, GUACCA, GUACCC, GUACCG, GUACCU, GUACGA, GUACGC, GUACGG, GUACGU, GUACUA, GUACUC, GUACUG, GUACUU, GUAGAA, GUAGAC, GUAGCA, GUAGCC, GUAGCG, GUAGCU, GUAGGA, GUAGGC, GUAGGG,

GUAGGU, GUAGUA, GUAGUC, GUAUAA, GUAUAC, GUAUAG, GUAUAU, GUAUCA, GUAUCG, GUAUCU, GUAUGA, GUAUGC, GUAUGG, GUAUUA, GUAU UG, G UAU UU, GUCAAA, GUCAAG, GUCAAU, GUCACA, GUCACC, GUCACG, GUCAGA, GUCAGC, GUCAGG, GUCAUA, GUCAUC, GUCAUG, GUCCAA, GUCCAC, GUCCAU, GUCCCC, GUCCCU, GUCCGA, GUCCGC, GUCCGG, GUCCGU, GUCCUA, GUCCUG, GUCCU U, GUCGAA, GUCGAC, GUCGAG, GUCGAU, GUCGCA, GUCGCC, GUCGCG, GUCGCU, GUCGGA, GUCGGC, GUCGGG, GUCGGU, GUCGUA, GUCGUC, GUCGU U, GUCUAA, GUCUAG, GUCUCA, GUCUCC, GUCUCG, GUCUGA, GUCUGG, GUCUGU, GUCU UC, GUCU UU, GUGAAA, GUGAAC, GUGAAG, GUGACC, GUGACG, GUGAGA, GUGAGC, GUGAGU, GUGAUC, GUGAUG, GUGAUU, GUGCAC,

GUGCAU, GUGCCC, GUGCCG, GUGCGA, GUGCGG, GUGCGU, GUGCUA, GUGCUC, GUGCUG,

GUGGAG, GUGGCG, GUGGCU, GUGGGU, GUGGUC, GUGGUG, GUGUAA, GUGUAG, GUGUCG, GUGUGA, GUGUGC, GUGUGU, GUGUUG, GUGU UU, GU UAAA, GUUAAC, GUUAAG, GU UACA, GU UACC, GUUACG, GU UACU, GU UAGA, GUUAGC, GUUAGU, GUUAUA, GUUAUC, GUUAUG, GU UAUU, GUUCAA, GUUCAC, GUUCAG, GU UCCA, GUUCCG, GUUCGA, GU UCGC, GU UCGG, GU UCGU, GU UCUA, GUUCUG, GUUGAA, GU UGAC, GUUGAG, GUUGAU, GUUGCG, GUUGCU, GUUGGA, GU UGGC, GU UGGU, GU UGUC, GUUGUG, GUUGU U, GUU UAA, GU UUAC, GU UUAG, GUU UAU, GU UUCA, GUUUCC, GU UUCU, GU UUGA, GUU UGC, GUU UGG, GUU UGU, GU UUUA, GU UU UC, GU UU UU, UAAAAA, UAAAAC, UAAAAG, UAAAAU, UAAACA, UAAACC, UAAACG, UAAACU, UAAAGA, UAAAGG, UAAAGU, UAAAUA, UAAAUC, UAAAUG, UAAAU U, U A AC A A, UAACAC, UAACAG, UAACCA, UAACCC, UAACCG, UAACCU, UAACGA, UAACGC, UAACGG, UAACGU, UAACUA, UAACUG, UAACUU, UAAGAG, UAAGAU, UAAGCA, UAAGCC, UAAGCG, UAAGCU, UAAGGA, UAAGGC, UAAGGG, UAAGGU, UAAGUA, UAAGUC, UAAGUG, UAAGUU, UAAUAA, UAAUCA, UAAUCC, UAAUCG, UAAUCU, UAAUGA, UAAUGG, UAAUGU, UAAUUA, UAAU UC, UAAUUG, UACAAC, UACAAG, UACAAU, UACACC, UACACG, UACACU, UACAGA, UACAGC, UACAUA, UACAUC, UACAU U, UACCAA, UACCAC, UACCAG, UACCAU, UACCCC, UACCCG, UACCCU, UACCGA, UACCGC, UACCGG, UACCGU, UACCUA, UACCUG, UACGAA, UACGAC, UACGAG, UACGAU, UACGCA, UACGCC, UACGCG, UACGCU, UACGGC, UACGGG, UACGGU, UACGUA, UACGUC, UACGUG, UACGUU, UACUAA, UACUAC, UACUAG, UACUAU, UACUCA, UACUCC, UACUCG, UACUCU, UACUGA, UACUGC, UACUGG, UACU UA, UACU UG, UACU UU, UAGAAA, UAGAAG, UAGAAU, UAGACA, UAGACG, UAGAGA, UAGAGC, UAGAGU, UAGAUA, UAGAUC, UAGAUG, UAGCAU, UAGCCC, UAGCCG, UAGCCU, UAGCGA, UAGCGC, UAGCGU, UAGCUA, UAGCUC, UAGCUG, UAGGAA, UAGGAU, UAGGCG, UAGGCU, UAGGGU, UAGGUC, UAGGUG, UAGGUU, UAGUAA, UAGUAC, UAGUAG, UAGUAU, UAGUCA, UAGUCG, UAGUGU, UAGUUA, UAGU UC, UAGU UG, UAGUU U, UAUAAC, UAUAAG, UAUACU, UAUAGA, UAUAGC, UAUAGG, UAUAGU, UAUAUA, UAUAUC, UAUAUG, UAUAU U, UAUCAA, UAUCAC, UAUCAU, UAUCCA, UAUCCC, UAUCCG, UAUCCU, UAUCGA, UAUCGC, UAUCGG, UAUCGU, UAUCUA, UAUCUC, UAUCUG, UAUCUU, UAUGAA, UAUGAC, UAUGAG,

UAUGAU, UAUGCA, UAUGCG, UAUGCU, UAUGGA, UAUGGC, UAUGUC, UAUGUG, UAUGU U, UAU UAG, UAUUCA, UAU UCC, UAUUCG, UAUUCU, UAUUGA, UAUUGG, UAUU UA, UAU UUC, UAU UUG, UAUUU U, UCAAAA, UCAAAC, UCAAAG, UCAACC, UCAACU, UCAAGA, UCAAGC, UCAAUA, UCAAUC, UCAAUG, UCAAUU, UCACCC, UCACCG, UCACCU, UCACGA, UCACGC, UCACGG, UCACGU, UCACUA, UCACUC, UCACUU, UCAGAA, UCAGAC, UCAGAG, UCAGCG, UCAGCU, UCAGGA, UCAGGC, UCAGGU, UCAGUC, UCAGU U, UCAUAA, UCAUCA, UCAUCC, UCAUCG, UCAUGC, UCAUGG, UCAUGU, UCAUUA, UCAUUG, UCCAAA, UCCAAC, UCCAAG, UCCAAU, UCCACA, UCCACC, UCCACG, UCCAGC, UCCAGG, UCCAUA, UCCAUC, UCCAU U, UCCCAA, UCCCAG, UCCCAU, UCCCCC, UCCCCG, UCCCCU, UCCCGA, UCCCGC, UCCCGG, UCCCGU, UCCCUA, UCCCUC, UCCGAA, UCCGAC, UCCGAG, UCCGAU, UCCGCA, UCCGCC, UCCGGA, UCCGGC, UCCGGU, UCCGUA, UCCGUC, UCCGUG, UCCUAA, UCCUCA, UCCUCG, UCCUCU, UCCUGC, UCCUGU, UCCU UA, UCCU UC, UCCUU U, UCGAAA, UCGAAC, UCGAAG, UCGAAU, UCGACA, UCGACC, UCGACG, UCGACU, UCGAGA, UCGAGC, UCGAGG, UCGAUA, UCGAUC, UCGAUG, UCGAU U, UCGCAA, UCGCAC, UCGCAG, UCGCAU, UCGCCA, UCGCCC, UCGCCG, UCGCCU, UCGCGA, UCGCGC, UCGCGU, UCGCUA, UCGCUC, UCGGAA, UCGGAC, UCGGAG, UCGGAU, UCGGCA, UCGGCU, UCGGGG, UCGGGU, UCGGUC, UCGGUG, UCGGU U, UCGUAA, UCGUAC, UCGUAG,

UCGUAU, UCGUCA, UCGUCC, UCGUCG, UCGUCU, UCGUGA, UCGUGU, UCGUUA, UCGU UC, UCGU UG, UCGU UU, UCUAAC, UCUAAG, UCUAAU, UCUACA, UCUACC, UCUACG, UCUACU, UCUAGC, UCUAGG, UCUAGU, UCUAUA, UCUAUC, UCUAUG, UCUAUU, UCUCAG, UCUCAU, UCUCCG, UCUCGC, UCUCGG, UCUCGU, UCUCUC, UCUGAA, UCUGAU, UCUGCA, UCUGCG, UCUGCU, UCUGGC, UCUGGU, UCUGUC, UCUGUG, UCUGUU, UCUUAA, UCUUAC, UCUUAG, UCUUAU, UCUUCA, UCUUCC, UCUUCG, UCUUCU, UCUUGC, UCUUGG, UCUUGU, UCUUUA, UCUUUC, UCUUUG, UCUUUU, UGAAAA, UGAAAC, UGAACA, UGAACC, UGAAGG, UGAAUC, UGAAUG, UGACAA, UGACAC, UGACAG, UGACCA, UGACCC, UGACCG, UGACGA, UGACGC, UGACGG, UGACGU, UGACUA, UGACUC, UGACUU, UGAGAG, UGAGAU, UGAGCA, UGAGCC, UGAGCU, UGAGGC, UGAGGU, UGAGUA, UGAGUU, UGAUAC, UGAUAG, UGAUAU, UGAUCA, UGAUCG, UGAUCU, UGAUGA, UGAUGC, UGAUGG, UGAUGU, UGAUUA, UGAUUC, UGAUUG, UGAUUU, UGCAAC, UGCAAG, UGCACA, UGCACG, UGCAGG, UGCAGU, UGCAUC, UGCCCA, UGCCCC, UGCCCG, UGCCGA, UGCCGC, UGCCGG, UGCCGU, UGCCUA, UGCCUC, UGCCUG, UGCCUU, UGCGAA, UGCGAC, UGCGAU, UGCGCC, UGCGCG, UGCGCU, UGCGGC, UGCGGG, UGCGGU, UGCGUA, UGCGUC, UGCGUG, UGCGUU, UGCUAC, UGCUAU, UGCUCC, UGCUCG, UGCUGC, UGCUGG, UGCUGU, UGCUUA, UGCUUU, UGGAAC, UGGAAG, UGGAGC, UGGAUC, UGGAUU, UGGCAA, UGGCAC, UGGCAG, UGGCCG, UGGCCU, UGGCGA, UGGCGC, UGGCGU, UGGCUA, UGGCUC, UGGCUU, UGGGAA, UGGGCA, UGGGCC, UGGGGC, UGGGUC, UGGUAA, UGGUAG, UGGUAU, UGGUCC, UGGUCG, UGGUCU, UGGUGA, UGGUGC, UGGUGG, UGGUGU, UGGUUA, UGGUUG, UGUAAA, UGUAAC, UGUAAG, UGUACC, UGUACG, UGUACU, UGUAGA, UGUAGC, UGUAGU, UGUAUC, UGUAUU, UGUCAA, UGUCAC, UGUCAG, UGUCAU, UGUCCA, UGUCCC, UGUCCG, UGUCGA, UGUCGC, UGUCGG, UGUCGU, UGUCUA, UGUCUC, UGUGAC, UGUGAG, UGUGAU, UGUGCA, UGUGGU, UGUGUA, UGUGUU, UGUUAC, UGUUAG, UGUUAU, UGUUCA, UGUUCC, UGUUCG, UGUUGG, UGUUGU, UGUUUA, UGUUUC, UGUUUG, UGUUUU, UUAAAA, UUAAAC, UUAAAG, UUAAAU, UUAACC, UUAACG, UUAACU, UUAAGU, UUAAUA, UUAAUC, UUAAUG, UUAAUU, UUACAA, UUACAC, UUACAG, UUACAU, UUACCA, UUACCC, UUACCG, UUACCU, UUACGA, UUACGC, UUACGG, UUACGU, UUACUA, UUACUC, UUACUG, UUACUU, UUAGAA, UUAGAC, UUAGCC, UUAGCG, UUAGCU, UUAGGC, UUAGGU, UUAGUA, UUAGUC, UUAGUU, UUAUAA, UUAUAC, UUAUAG, UUAUAU, UUAUCC, UUAUCG, UUAUCU, UUAUGA, UUAUGG, UUAUGU, UUAUUA, UUAUUC, UUAUUG, UUAUUU, UUCAAC, UUCAAU, UUCACA, UUCACC, UUCACG, UUCACU, UUCAGC, UUCAGG, UUCAGU, UUCAUA, UUCAUC, UUCAUG, UUCAUU, UUCCAA, UUCCCA, UUCCCG, UUCCGA, UUCCGU, UUCCUU, UUCGAA, UUCGAC, UUCGAG, UUCGAU, UUCGCA, UUCGCC, UUCGCG, UUCGCU, UUCGGA, UUCGGC, UUCGGG, UUCGGU, UUCGUA, UUCGUC, UUCGUG, UUCGUU, UUCUAC, UUCUAG, UUCUCA, UUCUCG,

UUCUGG, UUCUUA, UUCUUU, UUGAAA, UUGAAC, UUGAAG, UUGAAU, UUGACC, UUGACG, UUGACU, UUGAGA, UUGAGC, UUGAGU, UUGAUA, UUGAUC, UUGAUG, UUGAUU, UUGCAA, UUGCAC, UUGCAG, UUGCAU, UUGCCC, UUGCCG, UUGCGA, UUGCGC, UUGCGG, UUGCGU, UUGCUA, UUGCUC, UUGCUG, UUGCUU, UUGGAA, UUGGAG, UUGGCC, UUGGCG, UUGGCU, UUGGGC, UUGGGU, UUGGUA, UUGGUG, UUGUAA, UUGUAC, UUGUCA, UUGUCG, UUGUCU, UUGUGC, UUGUGG, UUGUUA, UUGUUG, UUGUUU, UUUAAA, UUUAAC, UUUAAG, UUUAAU, UUUACA, UUUACC, UUUACG, UUUACU, UUUAGA, UUUAGC, UUUAGG, UUUAGU, UUUAUA, UUUAUC, UUUAUG, UUUAUU, UUUCAU, UUUCCA, UUUCCG, UUUCCU, UUUCGA, UUUCGC, UUUCGG, UUUCGU, UUUCUA, UUUCUC, UUUCUG, UUUCUU, UUUGAA, UUUGAC, UUUGAG, UUUGAU, UUUGCC, UUUGCU, UUUGGA, UUUGGC, UUUGGG, UUUGGU, UUUGUA, UUUGUC, UUUGUU, UUUUAA, UUUUAG, UUUUAU, UUUUCC, UUUUCG, UUUUCU, UUUUGA, UUUUGC, UUUUGG, UUUUGU, UUUUUA, UUUUUC, UUUUUU

Table 2: Oligonucleotide sequences made for testing in the lab.

Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

BRCAl-01 1.994 0.016 BRCA in Hep3B 30 qRTPCR ACUACUG dAs;lnaCs;dTs;ln BRCA1

51200 08509 1 vitro ACUGCAG aAs;dCs;lnaTs;dG :79639 8 6 C s;lnaAs;dCs;lnaTs U 15

;dGs;lnaCs;dAs;l naGs;dC-Sup

BRCAl-01 1.397 0.083 BRCA in Hep3B 10 qRTPCR ACUACUG dAs;lnaCs;dTs;ln BRCA1

04636 70883 1 vitro ACUGCAG aAs;dCs;lnaTs;dG :79639 9 4 C s;lnaAs;dCs;lnaTs U 15

;dGs;lnaCs;dAs;l naGs;dC-Sup

BRCAl-02 1.140 0.022 BRCA in Hep3B 30 qRTPCR ACAGAGC dAs;lnaCs;dAs;ln BRCA1

88361 00688 1 vitro CACAGGA aGs;dAs;lnaGs;d :79665 3 2 C Cs;lnaCs;dAs;lna U 15

Cs;dAs;lnaGs;dG s;lnaAs;dC-Sup

BRCAl-02 1.252 0.072 BRCA in Hep3B 10 qRTPCR ACAGAGC dAs;lnaCs;dAs;ln BRCA1

40798 87098 1 vitro CACAGGA aGs;dAs;lnaGs;d :79665 3 6 C Cs;lnaCs;dAs;lna U 15

Cs;dAs;lnaGs;dG s;lnaAs;dC-Sup

BRCAl-03 0.826 0.046 BRCA in Hep3B 30 qRTPCR UGGUGGU dTs;lnaGs;dGs;ln BRCA1

11158 74458 1 vitro G UCUGGC aTs;dGs;lnaGs;dT :54365 5 5 C s;lnaGs;dTs;lnaCs U 15

;dTs;lnaGs;dGs;l naCs;dC-Sup

BRCAl-03 0.884 0.026 BRCA in Hep3B 10 qRTPCR UGGUGGU dTs;lnaGs;dGs;ln BRCA1

15819 00173 1 vitro G UCUGGC aTs;dGs;lnaGs;dT :54365

5 C s;lnaGs;dTs;lnaCs U 15

;dTs;lnaGs;dGs;l naCs;dC-Sup

BRCAl-04 1.408 0.028 BRCA in Hep3B 30 qRTPCR ACU U U UC dAs;lnaCs;dTs;ln BRCA1

54126 75936 1 vitro UGUGAAG aTs;dTs;lnaTs;dC :48718

6 U s;lnaTs;dGs;lnaTs L15

;dGs;lnaAs;dAs;l naGs;dT-Sup

BRCAl-04 1.389 0.038 BRCA in Hep3B 10 qRTPCR ACU U U UC dAs;lnaCs;dTs;ln BRCA1

86887 58610 1 vitro UGUGAAG aTs;dTs;lnaTs;dC :48718 4 8 U s;lnaTs;dGs;lnaTs L15

;dGs;lnaAs;dAs;l naGs;dT-Sup

BRCAl-05 1.714 0.039 BRCA in Hep3B 30 qRTPCR AACAAGA dAs;lnaAs;dCs;ln BRCA1

03697 79217 1 vitro CAUGAGU aAs;dAs;lnaGs;d :48211 1 1 G As;lnaCs;dAs;lna L15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Ts;dGs;lnaAs;dGs ;lnaTs;dG-Sup

BRCAl-05 1.117 0.082 BRCA in Hep3B 10 qRTPCR AACAAGA dAs;lnaAs;dCs;ln BRCA1

57792 42459 1 vitro CAUGAGU aAs;dAs;lnaGs;d :48211 8 9 G As;lnaCs;dAs;lna L15

Ts;dGs;lnaAs;dGs

;lnaTs;dG-Sup

BRCAl-06 1.473 0.023 BRCA in Hep3B 30 qRTPCR UGAAAGA dTs;lnaGs;dAs;ln BRCA1

20475 02077 1 vitro AAAAACA aAs;dAs;lnaGs;d : 48189 5 2 G As;lnaAs;dAs;lna L15

As;dAs;lnaAs;dCs

;lnaAs;dG-Sup

BRCAl-06 1.311 0.023 BRCA in Hep3B 10 qRTPCR UGAAAGA dTs;lnaGs;dAs;ln BRCA1

25172 56337 1 vitro AAAAACA aAs;dAs;lnaGs;d : 48189 7 4 G As;lnaAs;dAs;lna L15

As;dAs;lnaAs;dCs

;lnaAs;dG-Sup

BRCAl-07 1.817 0.413 BRCA in Hep3B 30 qRTPCR UGAUG UU dTs;lnaGs;dAs;ln BRCA1

31164 01491 1 vitro AUUGUGA aTs;dGs;lnaTs;dT :42499 9 1 U s;lnaAs;dTs;lnaTs L15

;dGs;lnaTs;dGs;l naAs;dT-Sup

BRCAl-07 1.401 0.197 BRCA in Hep3B 10 qRTPCR UGAUG UU dTs;lnaGs;dAs;ln BRCA1

31162 64605 1 vitro AUUGUGA aTs;dGs;lnaTs;dT :42499 5 6 U s;lnaAs;dTs;lnaTs L15

;dGs;lnaTs;dGs;l naAs;dT-Sup

BRCAl-08 1.098 0.228 BRCA in Hep3B 30 qRTPCR UCU U U UA dTs;lnaCs;dTs;lna BRCA1

98684 10810 1 vitro AAGCUAG Ts;dTs;lnaTs;dAs; :42462 9 9 G lnaAs;dAs;lnaGs; L15 dCs;lnaTs;dAs;ln aGs;dG-Sup

BRCAl-08 1.056 0.207 BRCA in Hep3B 10 qRTPCR UCU U U UA dTs;lnaCs;dTs;lna BRCA1

05776 81195 1 vitro AAGCUAG Ts;dTs;lnaTs;dAs; :42462 1 G lnaAs;dAs;lnaGs; L15 dCs;lnaTs;dAs;ln aGs;dG-Sup

BRCAl-09 1.149 0.301 BRCA in Hep3B 30 qRTPCR AUGAUGA dAs;lnaTs;dGs;ln BRCA1

70998 79689 1 vitro AGAAAGA aAs;dTs;lnaGs;dA :33821 9 1 G s;lnaAs;dGs;lnaA U 15 s;dAs;lnaAs;dGs;l naAs;dG-Sup

BRCAl-09 0.996 0.224 BRCA in Hep3B 10 qRTPCR AUGAUGA dAs;lnaTs;dGs;ln BRCA1

07442 81569 1 vitro AGAAAGA aAs;dTs;lnaGs;dA :33821 7 6 G s;lnaAs;dGs;lnaA U 15 s;dAs;lnaAs;dGs;l naAs;dG-Sup

BRCAl-10 1.048 0.115 BRCA in Hep3B 30 qRTPCR U UUGGCU dTs;lnaTs;dTs;lna BRCA1

73885 69880 1 vitro CAGGGU U Gs;dGs;lnaCs;dTs :33384 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

6 4 A ;lnaCs;dAs;lnaGs; U 15 dGs;lnaGs;dTs;ln aTs;dA-Sup

BRCAl-10 0.981 0.083 BRCA in Hep3B 10 qRTPCR U UUGGCU dTs;lnaTs;dTs;lna BRCA1

15221 37130 1 vitro CAGGGU U Gs;dGs;lnaCs;dTs :33384 9 5 A ;lnaCs;dAs;lnaGs; U 15 dGs;lnaGs;dTs;ln aTs;dA-Sup

BRCAl-11 2.015 0.578 BRCA in Hep3B 30 qRTPCR AAU UGAA dAs;lnaAs;dTs;ln BRCA1

27795 84256 1 vitro UGCUAUG aTs;dGs;lnaAs;dA :33029 2 C s;lnaTs;dGs;lnaCs U 15

;dTs;lnaAs;dTs;ln aGs;dC-Sup

BRCAl-11 1.490 0.316 BRCA in Hep3B 10 qRTPCR AAU UGAA dAs;lnaAs;dTs;ln BRCA1

76894 10897 1 vitro UGCUAUG aTs;dGs;lnaAs;dA :33029

9 C s;lnaTs;dGs;lnaCs U 15

;dTs;lnaAs;dTs;ln aGs;dC-Sup

BRCAl-12 1.670 0.505 BRCA in Hep3B 30 qRTPCR U UGAAUG dTs;lnaTs;dGs;ln BRCA1

43722 97090 1 vitro U UCCUCA aAs;dAs;lnaTs;dG :32801 7 5 A s;lnaTs;dTs;lnaCs L15

;dCs;lnaTs;dCs;ln aAs;dA-Sup

BRCAl-12 1.306 0.329 BRCA in Hep3B 10 qRTPCR U UGAAUG dTs;lnaTs;dGs;ln BRCA1

45311 94997 1 vitro U UCCUCA aAs;dAs;lnaTs;dG :32801 7 4 A s;lnaTs;dTs;lnaCs L15

;dCs;lnaTs;dCs;ln aAs;dA-Sup

BRCAl-13 1.554 0.034 BRCA in Hep3B 30 qRTPCR AU U UCUC dAs;lnaTs;dTs;ln BRCA1

70177 23328 1 vitro U U UCAGG aTs;dCs;lnaTs;dC :32820 9 7 U s;lnaTs;dTs;lnaTs L15

;dCs;lnaAs;dGs;l naGs;dT-Sup

BRCAl-13 1.249 0.146 BRCA in Hep3B 10 qRTPCR AU U UCUC dAs;lnaTs;dTs;ln BRCA1

32363 44839 1 vitro U U UCAGG aTs;dCs;lnaTs;dC :32820 8 6 U s;lnaTs;dTs;lnaTs L15

;dCs;lnaAs;dGs;l naGs;dT-Sup

BRCAl-14 1.438 0.023 BRCA in Hep3B 30 qRTPCR UUGAU UU dTs;lnaTs;dGs;ln BRCA1

58141 12550 1 vitro UCU UCCU aAs;dTs;lnaTs;dT :32509 6 7 U s;lnaTs;dCs;lnaTs L15

;dTs;lnaCs;dCs;ln aTs;dT-Sup

BRCAl-14 1.409 0.112 BRCA in Hep3B 10 qRTPCR UUGAU UU dTs;lnaTs;dGs;ln BRCA1

56908 51354 1 vitro UCU UCCU aAs;dTs;lnaTs;dT :32509 2 4 U s;lnaTs;dCs;lnaTs L15

;dTs;lnaCs;dCs;ln aTs;dT-Sup

BRCAl-15 1.361 0.048 BRCA in Hep3B 30 qRTPCR UGACU U U dTs;lnaGs;dAs;ln BRCA1 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

41593 40053 1 vitro UGGUCUU aCs;dTs;lnaTs;dT :32637 7 5 U s;lnaTs;dGs;lnaG L15 s;dTs;lnaCs;dTs;l naTs;dT-Sup

BRCAl-15 1.132 0.081 BRCA in Hep3B 10 qRTPCR UGACU U U dTs;lnaGs;dAs;ln BRCA1

67864 22881 1 vitro UGGUCUU aCs;dTs;lnaTs;dT :32637 1 3 U s;lnaTs;dGs;lnaG L15 s;dTs;lnaCs;dTs;l naTs;dT-Sup

BRCAl-16 1.836 0.058 BRCA in Hep3B 30 qRTPCR AGUCGGG dAs;lnaGs;dTs;ln BRCA1

66214 26162 1 vitro AAACAAG aCs;dGs;lnaGs;d :32311 9 7 C Gs;lnaAs;dAs;lna U 15

As;dCs;lnaAs;dAs

;lnaGs;dC-Sup

BRCAl-16 1.837 0.069 BRCA in Hep3B 10 qRTPCR AGUCGGG dAs;lnaGs;dTs;ln BRCA1

66378 08524 1 vitro AAACAAG aCs;dGs;lnaGs;d :32311 1 5 C Gs;lnaAs;dAs;lna U 15

As;dCs;lnaAs;dAs

;lnaGs;dC-Sup

BRCAl-17 0.693 0.019 BRCA in Hep3B 30 qRTPCR AGUCAG U dAs;lnaGs;dTs;ln BRCA1

55541 66852 1 vitro GUGCAGC aCs;dAs;lnaGs;dT :32200 1 9 A s;lnaGs;dTs;lnaG U 15 s;dCs;lnaAs;dGs;l naCs;dA-Sup

BRCAl-17 0.876 0.024 BRCA in Hep3B 10 qRTPCR AGUCAG U dAs;lnaGs;dTs;ln BRCA1

76375 21672 1 vitro GUGCAGC aCs;dAs;lnaGs;dT :32200 3 6 A s;lnaGs;dTs;lnaG U 15 s;dCs;lnaAs;dGs;l naCs;dA-Sup

BRCAl-18 1.587 0.068 BRCA in Hep3B 30 qRTPCR GAAU UUG dGs;lnaAs;dAs;ln BRCA1

83227 89659 1 vitro UCAAUCC aTs;dTs;lnaTs;dG :31951 5 4 U s;lnaTs;dCs;lnaAs U 15

;dAs;lnaTs;dCs;ln aCs;dT-Sup

BRCAl-18 1.229 0.009 BRCA in Hep3B 10 qRTPCR GAAU UUG dGs;lnaAs;dAs;ln BRCA1

07279 59259 1 vitro UCAAUCC aTs;dTs;lnaTs;dG :31951 9 7 U s;lnaTs;dCs;lnaAs U 15

;dAs;lnaTs;dCs;ln aCs;dT-Sup

BRCAl-19 1.096 0.045 BRCA in Hep3B 30 qRTPCR AAUCCUA dAs;lnaAs;dTs;ln BRCA1

69636 76832 1 vitro GCCU UCC aCs;dCs;lnaTs;dA : 31960 5 3 A s;lnaGs;dCs;lnaC U 15 s;dTs;lnaTs;dCs;l naCs;dA-Sup

BRCAl-19 0.982 0.014 BRCA in Hep3B 10 qRTPCR AAUCCUA dAs;lnaAs;dTs;ln BRCA1

46841 95650 1 vitro GCCU UCC aCs;dCs;lnaTs;dA : 31960 3 5 A s;lnaGs;dCs;lnaC U 15 s;dTs;lnaTs;dCs;l naCs;dA-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

BRCAl-20 2.783 0.113 BRCA in Hep3B 30 qRTPCR AAGAACC dAs;lnaAs;dGs;ln BRCA1

19272 59947 1 vitro UGCAACU aAs;dAs;lnaCs;dC : 31808 1 7 G s;lnaTs;dGs;lnaCs U 15

;dAs;lnaAs;dCs;ln aTs;dG-Sup

BRCAl-20 1.756 0.093 BRCA in Hep3B 10 qRTPCR AAGAACC dAs;lnaAs;dGs;ln BRCA1

82317 80640 1 vitro UGCAACU aAs;dAs;lnaCs;dC : 31808 7 6 G s;lnaTs;dGs;lnaCs U 15

;dAs;lnaAs;dCs;ln aTs;dG-Sup

BRCAl-21 2.222 0.153 BRCA in Hep3B 30 qRTPCR ACUGAAU dAs;lnaCs;dTs;ln BRCA1

03365 44086 1 vitro UGCAAAU aGs;dAs;lnaAs;dT :31702 1 2 U s;lnaTs;dGs;lnaCs U 15

;dAs;lnaAs;dAs;ln aTs;dT-Sup

BRCAl-21 1.487 0.102 BRCA in Hep3B 10 qRTPCR ACUGAAU dAs;lnaCs;dTs;ln BRCA1

69906 48282 1 vitro UGCAAAU aGs;dAs;lnaAs;dT :31702 4 5 U s;lnaTs;dGs;lnaCs U 15

;dAs;lnaAs;dAs;ln aTs;dT-Sup

BRCAl-22 2.910 0.117 BRCA in Hep3B 30 qRTPCR AAUAUCC dAs;lnaAs;dTs;ln BRCA1

70295 77800 1 vitro ACAAUUC aAs;dTs;lnaCs;dC : 31588 6 6 A s;lnaAs;dCs;lnaA U 15 s;dAs;lnaTs;dTs;l naCs;dA-Sup

BRCAl-22 1.896 0.066 BRCA in Hep3B 10 qRTPCR AAUAUCC dAs;lnaAs;dTs;ln BRCA1

40218 00260 1 vitro ACAAUUC aAs;dTs;lnaCs;dC : 31588 9 2 A s;lnaAs;dCs;lnaA U 15 s;dAs;lnaTs;dTs;l naCs;dA-Sup

BRCAl-23 2.583 0.089 BRCA in Hep3B 30 qRTPCR AU UCUCA dAs;lnaTs;dTs;ln BRCA1

59937 68384 1 vitro UGACCAC aCs;dTs;lnaCs;dA : 31444 7 9 U s;lnaTs;dGs;lnaA L15 s;dCs;lnaCs;dAs;l naCs;dT-Sup

BRCAl-23 1.503 0.017 BRCA in Hep3B 10 qRTPCR AU UCUCA dAs;lnaTs;dTs;ln BRCA1

17171 44413 1 vitro UGACCAC aCs;dTs;lnaCs;dA : 31444 4 7 U s;lnaTs;dGs;lnaA L15 s;dCs;lnaCs;dAs;l naCs;dT-Sup

BRCAl-24 2.164 0.024 BRCA in Hep3B 30 qRTPCR AU UAGUA dAs;lnaTs;dTs;ln BRCA1

12746 01863 1 vitro AUAU UCA aAs;dGs;lnaTs;dA : 31429 5 U s;lnaAs;dTs;lnaAs L15

;dTs;lnaTs;dCs;ln aAs;dT-Sup

BRCAl-24 1.458 0.040 BRCA in Hep3B 10 qRTPCR AU UAGUA dAs;lnaTs;dTs;ln BRCA1

64589 74015 1 vitro AUAU UCA aAs;dGs;lnaTs;dA : 31429 5 U s;lnaAs;dTs;lnaAs L15

;dTs;lnaTs;dCs;ln Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

aAs;dT-Sup

BRCAl-25 2.153 0.048 BRCA in Hep3B 30 qRTPCR CUGAAAA dCs;lnaTs;dGs;ln BRCA1

50382 62076 1 vitro UCUAAU U aAs;dAs;lnaAs;d :31226 4 A As;lnaTs;dCs;lna U 15

Ts;dAs;lnaAs;dTs

;lnaTs;dA-Sup

BRCAl-25 1.626 0.086 BRCA in Hep3B 10 qRTPCR CUGAAAA dCs;lnaTs;dGs;ln BRCA1

09354 12513 1 vitro UCUAAU U aAs;dAs;lnaAs;d :31226 2 6 A As;lnaTs;dCs;lna U 15

Ts;dAs;lnaAs;dTs

;lnaTs;dA-Sup

BRCAl-26 1.679 0.102 BRCA in Hep3B 30 qRTPCR UU UGU UA dTs;lnaTs;dTs;lna BRCA1

37256 26940 1 vitro CUGAGCC Gs;dTs;lnaTs;dAs : 31249 2 3 A ;lnaCs;dTs;lnaGs; U 15 dAs;lnaGs;dCs;ln aCs;dA-Sup

BRCAl-26 1.457 0.017 BRCA in Hep3B 10 qRTPCR UU UGU UA dTs;lnaTs;dTs;lna BRCA1

02419 60725 1 vitro CUGAGCC Gs;dTs;lnaTs;dAs : 31249 8 9 A ;lnaCs;dTs;lnaGs; U 15 dAs;lnaGs;dCs;ln aCs;dA-Sup

BRCAl-27 1.015 0.028 BRCA in Hep3B 30 qRTPCR GUCCAAC dGs;lnaTs;dCs;ln BRCA1

20168 93728 1 vitro UCUCUAA aCs;dAs;lnaAs;dC :25462 3 3 C s;lnaTs;dCs;lnaTs U 15

;dCs;lnaTs;dAs;ln aAs;dC-Sup

BRCAl-27 1.150 0.042 BRCA in Hep3B 10 qRTPCR GUCCAAC dGs;lnaTs;dCs;ln BRCA1

13659 53655 1 vitro UCUCUAA aCs;dAs;lnaAs;dC :25462 1 4 C s;lnaTs;dCs;lnaTs U 15

;dCs;lnaTs;dAs;ln aAs;dC-Sup

BRCAl-28 3.024 0.121 BRCA in Hep3B 30 qRTPCR AACU UGG dAs;lnaAs;dCs;ln BRCA1

45350 59844 1 vitro AACUGUG aTs;dTs;lnaGs;dG :25635 6 6 A s;lnaAs;dAs;lnaC U 15 s;dTs;lnaGs;dTs;l naGs;dA-Sup

BRCAl-28 2.009 0.086 BRCA in Hep3B 10 qRTPCR AACU UGG dAs;lnaAs;dCs;ln BRCA1

83961 22422 1 vitro AACUGUG aTs;dTs;lnaGs;dG :25635 8 2 A s;lnaAs;dAs;lnaC U 15 s;dTs;lnaGs;dTs;l naGs;dA-Sup

BRCAl-29 0.901 0.033 BRCA in Hep3B 30 qRTPCR AGU UAU U dAs;lnaGs;dTs;ln BRCA1

46766 77541 1 vitro U UCCU UU aTs;dAs;lnaTs;dT : 21087 9 4 U s;lnaTs;dTs;lnaCs L15

;dCs;lnaTs;dTs;ln aTs;dT-Sup

BRCAl-29 0.813 0.025 BRCA in Hep3B 10 qRTPCR AGU UAU U dAs;lnaGs;dTs;ln BRCA1

51361 65305 1 vitro U UCCU UU aTs;dAs;lnaTs;dT : 21087 6 1 U s;lnaTs;dTs;lnaCs L15 Oligo I RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

;dCs;lnaTs;dTs;ln aTs;dT-Sup

BRCAl-30 1.628 0.041 BRCA in Hep3B 30 qRTPCR U UU UGCA dTs;lnaTs;dTs;lna BRCA1

87159 36518 1 vitro AAAU UAU Ts;dGs;lnaCs;dAs : 21074 5 2 A ;lnaAs;dAs;lnaAs; L15 dTs;lnaTs;dAs;ln aTs;dA-Sup

BRCAl-30 1.370 0.038 BRCA in Hep3B 10 qRTPCR U UU UGCA dTs;lnaTs;dTs;lna BRCA1

38626 18180 1 vitro AAAU UAU Ts;dGs;lnaCs;dAs : 21074 6 4 A ;lnaAs;dAs;lnaAs; L15 dTs;lnaTs;dAs;ln aTs;dA-Sup

F8-01 NA NA F8 NA NA 0 NA ACAGGUC lnaAs;omeCs;lna F8:531

UGAUUGG As;omeGs;lnaGs; 68U 15 A omeUs;lnaCs;om

eUs;lnaGs;omeA s;lnaTs;omeUs;ln aGs;omeGs;lnaA-

Sup

F8-02 NA NA F8 NA NA 0 NA AUCAGUC lnaAs;omeUs;lna F8:531

UAU UGGC Cs;omeAs;lnaGs; 94U 15 A omeUs;lnaCs;om

eUs;lnaAs;omeU s;lnaTs;omeGs;ln aGs;omeCs;lnaA- Sup

F8-03 NA NA F8 NA NA 0 NA CUCAAUA lnaCs;omeUs;lna F8:532

U UCCUCG Cs;omeAs;lnaAs; 42U 15 A omeUs;lnaAs;om

eUs;lnaTs;omeCs

;lnaCs;omeUs;ln aCs;omeGs;lnaA-

Sup

F8-04 NA NA F8 NA NA 0 NA CAAUAU U lnaCs;omeAs;lna F8:532

CCUCGAA As;omeUs;lnaAs; 44U 15 G omeUs;lnaTs;om

eCs;lnaCs;omeUs

;lnaCs;omeGs;ln aAs;omeAs;lnaG-

Sup

F8-05 NA NA F8 NA NA 0 NA AAUAUUC lnaAs;omeAs;lna F8-.532

CUCGAAG Ts;omeAs;lnaTs; 45U 15 G omeUs;lnaCs;om

eCs;lnaTs;omeCs

;lnaGs;omeAs;ln aAs;omeGs;lnaG-

Sup

F8-06 NA NA F8 NA NA 0 NA AUAU UCC lnaAs;omeUs;lna F8:532

UCGAAGG As;omeUs;lnaTs; 46U 15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

U omeCs;lnaCs;om

eUs;lnaCs;omeG s;lnaAs;omeAs;ln aGs;omeGs;lnaT-

Sup

F8-07 NA NA F8 NA NA 0 NA UAU UCCU lnaTs;omeAs;lna F8:532

CGAAGGU Ts;omeUs;lnaCs; 47U 15 C omeCs;lnaTs;om

eCs;lnaGs;omeAs

;lnaAs;omeGs;ln aGs;omeUs;lnaC-

Sup

F8-08 NA NA F8 NA NA 0 NA UCCUCGA lnaTs;omeCs;lna F8:532

AGG UCAC Cs;omeUs;lnaCs; 50U 15 A omeGs;lnaAs;om

eAs;lnaGs;omeG s;lnaTs;omeCs;ln aAs;omeCs;lnaA-

Sup

F8-09 NA NA F8 NA NA 0 NA CCUCGAA lnaCs;omeCs;lna F8:532

GG UCACA Ts;omeCs;lnaGs; 51U 15 C omeAs;lnaAs;om

eGs;lnaGs;omeU s;lnaCs;omeAs;ln aCs;omeAs;lnaC- Sup

F8-10 NA NA F8 NA NA 0 NA CUCGAAG lnaCs;omeUs;lna F8:532

GUCACAC Cs;omeGs;lnaAs; 52U 15 A omeAs;lnaGs;om

eGs;lnaTs;omeCs

;lnaAs;omeCs;lna

As;omeCs;lnaA-

Sup

F8-11 NA NA F8 NA NA 0 NA UCGCCAA lnaTs;omeCs;lna F8:533

UAACUU U Gs;omeCs;lnaCs; 06U 15 C omeAs;lnaAs;om

eUs;lnaAs;omeA s;lnaCs;omeUs;ln aTs;omeUs;lnaC-

Sup

F8-12 NA NA F8 NA NA 0 NA CGCCAAU lnaCs;omeGs;lna F8:533

AACU UUC Cs;omeCs;lnaAs; 07U 15 C omeAs;lnaTs;om

eAs;lnaAs;omeCs

;lnaTs;omeUs;lna

Ts;omeCs;lnaC-

Sup

F8-13 NA NA F8 NA NA 0 NA CUCCGAA lnaCs;omeUs;lna F8:546

ACUCAUA Cs;omeCs;lnaGs; 02L15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

U omeAs;lnaAs;om

eAs;lnaCs;omeUs

;lnaCs;omeAs;lna

Ts;omeAs;lnaT-

Sup

F8-14 NA NA F8 NA NA 0 NA CGUCCCU lnaCs;omeGs;lna F8:117

AUUCCUU Ts;omeCs;lnaCs; 725U 1 c omeCs;lnaTs;om 5 eAs;lnaTs;omeUs

;lnaCs;omeCs;lna

Ts;omeUs;lnaC-

Sup

F8-15 NA NA F8 NA NA 0 NA ACU UUGU lnaAs;omeCs;lna F8:117

CAAGCCU Ts;omeUs;lnaTs; 798U 1 A omeGs;lnaTs;om 5 eCs;lnaAs;omeAs

;lnaGs;omeCs;ln aCs;omeUs;lnaA-

Sup

F8-16 NA NA F8 NA NA 0 NA UU UGUCA lnaTs;omeUs;lna F8:117

AGCCUAA Ts;omeGs;lnaTs; 800 U l U omeCs;lnaAs;om 5 eAs;lnaGs;omeCs

;lnaCs;omeUs;ln aAs;omeAs;lnaT-

Sup

F8-17 NA NA F8 NA NA 0 NA AAGCCUA lnaAs;omeAs;lna F8:117

AUGAAAC Gs;omeCs;lnaCs; 806 U l C omeUs;lnaAs;om 5 eAs;lnaTs;omeGs

;lnaAs;omeAs;ln aAs;omeCs;lnaC-

Sup

F8-18 NA NA F8 NA NA 0 NA CAUAUGG lnaCs;omeAs;lna F8:117

CACCCACU Ts;omeAs;lnaTs; 848 U l omeGs;lnaGs;om 5 eCs;lnaAs;omeCs

;lnaCs;omeCs;lna

As;omeCs;lnaT-

Sup

F8-19 NA NA F8 NA NA 0 NA CAGAUGG lnaCs;omeAs;lna F8:118

AAGAUCC Gs;omeAs;lnaTs; 386U 1 C omeGs;lnaGs;om 5 eAs;lnaAs;omeG s;lnaAs;omeUs;ln aCs;omeCs;lnaC-

Sup

F8-20 NA NA F8 NA NA 0 NA AAAGAGA lnaAs;omeAs;lna F8:118

AUUAUCG As;omeGs;lnaAs; 407 U l Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeGs;lnaAs;om 5 eAs;lnaTs;omeUs

;lnaAs;omeUs;ln aCs;omeGs;lnaC-

Sup

F8-21 NA NA F8 NA NA 0 NA AGAGAAU lnaAs;omeGs;lna F8:118

UAUCGCU As;omeGs;lnaAs; 409 U l U omeAs;lnaTs;om 5 eUs;lnaAs;omeU s;lnaCs;omeGs;ln aCs;omeUs;lnaT- Sup

F8-22 NA NA F8 NA NA 0 NA GAGAAUU lnaGs;omeAs;lna F8:118

AUCGCU U Gs;omeAs;lnaAs; 410U 1 C omeUs;lnaTs;om 5 eAs;lnaTs;omeCs

;lnaGs;omeCs;ln aTs;omeUs;lnaC-

Sup

F8-23 NA NA F8 NA NA 0 NA AGAAUUA lnaAs;omeGs;lna F8:118

UCGCU UC As;omeAs;lnaTs; 411U 1 C omeUs;lnaAs;om 5 eUs;lnaCs;omeG s;lnaCs;omeUs;ln aTs;omeCs;lnaC-

Sup

F8-24 NA NA F8 NA NA 0 NA AAUUAUC lnaAs;omeAs;lna F8:118

GCU UCCA Ts;omeUs;lnaAs; 413U 1 U omeUs;lnaCs;om 5 eGs;lnaCs;omeU s;lnaTs;omeCs;ln aCs;omeAs;lnaT- Sup

F8-25 NA NA F8 NA NA 0 NA UUAUCGC lnaTs;omeUs;lna F8:118

U UCCAUG As;omeUs;lnaCs; 415U 1 G omeGs;lnaCs;om 5 eUs;lnaTs;omeCs

;lnaCs;omeAs;lna

Ts;omeGs;lnaG-

Sup

F8-26 NA NA F8 NA NA 0 NA UAUCGCU lnaTs;omeAs;lna F8:118

UCCAUGG Ts;omeCs;lnaGs; 416U 1 U omeCs;lnaTs;om 5 eUs;lnaCs;omeCs

;lnaAs;omeUs;ln aGs;omeGs;lnaT-

Sup

F8-27 NA NA F8 NA NA 0 NA UCGCU UC lnaTs;omeCs;lna F8:118

CAUGG UA Gs;omeCs;lnaTs; 418U 1 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

A omeUs;lnaCs;om 5 eCs;lnaAs;omeUs

;lnaGs;omeGs;ln aTs;omeAs;lnaA-

Sup

F8-28 NA NA F8 NA NA 0 NA CUCCAGC lnaCs;omeUs;lna F8:118

AAUCAAU Cs;omeCs;lnaAs; 630U1 G omeGs;lnaCs;om 5 eAs;lnaAs;omeU s;lnaCs;omeAs;ln aAs;omeUs;lnaG-

Sup

F8-29 NA NA F8 NA NA 0 NA GGAUCAA lnaGs;omeGs;lna F8:118

AGGAU UC As;omeUs;lnaCs; 685 U l G omeAs;lnaAs;om 5 eAs;lnaGs;omeG s;lnaAs;omeUs;ln aTs;omeCs;lnaG-

Sup

F8-30 NA NA F8 NA NA 0 NA GAUCAAA lnaGs;omeAs;lna F8:118

GGAUUCG Ts;omeCs;lnaAs; 686 U l A omeAs;lnaAs;om 5 eGs;lnaGs;omeA s;lnaTs;omeUs;ln aCs;omeGs;lnaA-

Sup

F8-31 NA NA F8 NA NA 0 NA AUCAAAG lnaAs;omeUs;lna F8:118

GAU UCGA Cs;omeAs;lnaAs; 687 U l U omeAs;lnaGs;om 5 eGs;lnaAs;omeU s;lnaTs;omeCs;ln aGs;omeAs;lnaT- Sup

F8-32 NA NA F8 NA NA 0 NA UCAAAGG lnaTs;omeCs;lna F8:118

AUUCGAU As;omeAs;lnaAs; 688 U l G omeGs;lnaGs;om 5 eAs;lnaTs;omeUs

;lnaCs;omeGs;ln aAs;omeUs;lnaG-

Sup

F8-33 NA NA F8 NA NA 0 NA CAAAGGA lnaCs;omeAs;lna F8:118

U UCGAUG As;omeAs;lnaGs; 689 U l G omeGs;lnaAs;om 5 eUs;lnaTs;omeCs

;lnaGs;omeAs;ln aTs;omeGs;lnaG-

Sup

F8-34 NA NA F8 NA NA 0 NA GGAUUCG lnaGs;omeGs;lna F8:118

AUGGUAU As;omeUs;lnaTs; 693 U l Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeCs;lnaGs;om 5 eAs;lnaTs;omeGs

;lnaGs;omeUs;ln aAs;omeUs;lnaC-

Sup

F8-35 NA NA F8 NA NA 0 NA GAUUCGA lnaGs;omeAs;lna F8:118

UGGUAUC Ts;omeUs;lnaCs; 694 U l U omeGs;lnaAs;om 5 eUs;lnaGs;omeG s;lnaTs;omeAs;ln aTs;omeCs;lnaT- Sup

F8-36 NA NA F8 NA NA 0 NA AUUCGAU lnaAs;omeUs;lna F8:118

GGUAUCU Ts;omeCs;lnaGs; 695 U l G omeAs;lnaTs;om 5 eGs;lnaGs;omeU s;lnaAs;omeUs;ln aCs;omeUs;lnaG-

Sup

F8-37 NA NA F8 NA NA 0 NA CUGUACG lnaCs;omeUs;lna F8:118

AAAAAAA Gs;omeUs;lnaAs; 768U 1 G omeCs;lnaGs;om 5 eAs;lnaAs;omeAs

;lnaAs;omeAs;ln aAs;omeAs;lnaG-

Sup

F8-38 NA NA F8 NA NA 0 NA UGUACGA lnaTs;omeGs;lna F8:118

AAAAAAG Ts;omeAs;lnaCs; 769 U l A omeGs;lnaAs;om 5 eAs;lnaAs;omeAs

;lnaAs;omeAs;ln aAs;omeGs;lnaA-

Sup

F8-39 NA NA F8 NA NA 0 NA GUACGAA lnaGs;omeUs;lna F8:118

AAAAAGA As;omeCs;lnaGs; 770U 1 G omeAs;lnaAs;om 5 eAs;lnaAs;omeAs

;lnaAs;omeAs;ln aGs;omeAs;lnaG-

Sup

F8-40 NA NA F8 NA NA 0 NA GGAAUGC lnaGs;omeGs;lna F8:120

CU UAU UG As;omeAs;lnaTs; 609 U l G omeGs;lnaCs;om 5 eCs;lnaTs;omeUs

;lnaAs;omeUs;ln aTs;omeGs;lnaG-

Sup

F8-41 NA NA F8 NA NA 0 NA AUGCCU U lnaAs;omeUs;lna F8:120

AU UGGCG Gs;omeCs;lnaCs; 612U 1 Oligo ID Q RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

A omeUs;lnaTs;om 5 eAs;lnaTs;omeUs

;lnaGs;omeGs;ln aCs;omeGs;lnaA-

Sup

F8-42 NA NA F8 NA NA 0 NA UGCCU UA lnaTs;omeGs;lna F8:120

U UGGCGA Cs;omeCs;lnaTs; 613U 1 G omeUs;lnaAs;om 5 eUs;lnaTs;omeG s;lnaGs;omeCs;ln aGs;omeAs;lnaG-

Sup

F8-43 NA NA F8 NA NA 0 NA GCCU UAU lnaGs;omeCs;lna F8:120

UGGCGAG Cs;omeUs;lnaTs; 614U 1 C omeAs;lnaTs;om 5 eUs;lnaGs;omeG s;lnaCs;omeGs;ln aAs;omeGs;lnaC- Sup

F8-44 NA NA F8 NA NA 0 NA CCU UAUU lnaCs;omeCs;lna F8:120

GGCGAGC Ts;omeUs;lnaAs; 615U 1 A omeUs;lnaTs;om 5 eGs;lnaGs;omeC s;lnaGs;omeAs;ln aGs;omeCs;lnaA-

Sup

F8-45 NA NA F8 NA NA 0 NA CUUAU UG lnaCs;omeUs;lna F8:120

GCGAGCA Ts;omeAs;lnaTs; 616U 1 U omeUs;lnaGs;om 5 eGs;lnaCs;omeG s;lnaAs;omeGs;ln aCs;omeAs;lnaT-

Sup

F8-46 NA NA F8 NA NA 0 NA CAACAGA lnaCs;omeAs;lna F8:- UCCACCU As;omeCs;lnaAs; 9932L1 A omeGs;lnaAs;om 5 eUs;lnaCs;omeCs

;lnaAs;omeCs;lna

Cs;omeUs;lnaA-

Sup

F8-47 NA NA F8 NA NA 0 NA UCU UGAU lnaTs;omeCs;lna F8:- GCCGUGA Ts;omeUs;lnaGs; 9904L1 A omeAs;lnaTs;om 5 eGs;lnaCs;omeCs

;lnaGs;omeUs;ln aGs;omeAs;lnaA-

Sup

F8-48 NA NA F8 NA NA 0 NA CUGACGG lnaCs;omeUs;lna F8:- GCACCCU Gs;omeAs;lnaCs; 9887L1 Oligo I RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

G omeGs;lnaGs;om 5 eGs;lnaCs;omeAs

;lnaCs;omeCs;lna

Cs;omeUs;lnaG-

Sup

F8-49 NA NA F8 NA NA 0 NA UCUGACG lnaTs;omeCs;lna F8:- GGCACCC Ts;omeGs;lnaAs; 9886L1 U omeCs;lnaGs;om 5 eGs;lnaGs;omeC s;lnaAs;omeCs;ln aCs;omeCs;lnaT- Sup

F8-50 NA NA F8 NA NA 0 NA GAAU UUC lnaGs;omeAs;lna F8:- CUCGAUA As;omeUs;lnaTs; 9804 LI A omeUs;lnaCs;om 5 eCs;lnaTs;omeCs ;lnaGs;omeAs;ln aTs;omeAs;lnaA- Sup

F8-51 NA NA F8 NA NA 0 NA GGAAU U U lnaGs;omeGs;lna F8:- CCUCGAU As;omeAs;lnaTs; 9803L1 A omeUs;lnaTs;om 5 eCs;lnaCs;omeUs

;lnaCs;omeGs;ln aAs;omeUs;lnaA-

Sup

F8-52 NA NA F8 NA NA 0 NA UGGAAU U lnaTs;omeGs;lna F8:- UCCUCGA Gs;omeAs;lnaAs; 9802L1 U omeUs;lnaTs;om 5 eUs;lnaCs;omeCs

;lnaTs;omeCs;lna

Gs;omeAs;lnaT-

Sup

F8-53 NA NA F8 NA NA 0 NA CCAUUAA lnaCs;omeCs;lna F8:- GG UUCCA As;omeUs;lnaTs; 9787L1 G omeAs;lnaAs;om 5 eGs;lnaGs;omeU s;lnaTs;omeCs;ln aCs;omeAs;lnaG- Sup

F8-54 NA NA F8 NA NA 0 NA UACCAUU lnaTs;omeAs;lna F8:- AAGGU UC Cs;omeCs;lnaAs; 9785L1 C omeUs;lnaTs;om 5 eAs;lnaAs;omeG s;lnaGs;omeUs;l naTs;omeCs;lnaC

-Sup

F8-55 NA NA F8 NA NA 0 NA AUACCAU lnaAs;omeUs;lna F8:- UAAGGU U As;omeCs;lnaCs; 9784L1 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeAs;lnaTs;om 5 eUs;lnaAs;omeA s;lnaGs;omeGs;l naTs;omeUs;lna

C-Sup

F8-56 NA NA F8 NA NA 0 NA CAUACCA lnaCs;omeAs;lna F8:- UUAAGGU Ts;omeAs;lnaCs; 9783L1 U omeCs;lnaAs;om 5 eUs;lnaTs;omeAs

;lnaAs;omeGs;ln aGs;omeUs;lnaT-

Sup

F MR 1-01 NA NA FM R1 NA NA 0 NA GACGGCG lnaGs;omeAs;lna FMR1:

AGCGCGG Cs;omeGs;lnaGs; 40U 15 G omeCs;lnaGs;om

eAs;lnaGs;omeCs

;lnaGs;omeCs;ln aGs;omeGs;lnaG

-Sup

FMR1-02 NA NA FM R1 NA NA 0 NA GGUGGUG lnaGs;omeGs;lna FMR1:

GAAGUGC Ts;omeGs;lnaGs; 241U 1 G omeUs;lnaGs;om 5 eGs;lnaAs;omeA s;lnaGs;omeUs;l naGs;omeCs;lna

G-Sup

FMR1-03 NA NA FM R1 NA NA 0 NA UGGCGCU lnaTs;omeGs;lna FMR1:

U UCUACA Gs;omeCs;lnaGs; 265U 1 A omeCs;lnaTs;om 5 eUs;lnaTs;omeCs

;lnaTs;omeAs;lna

Cs;omeAs;lnaA-

Sup

FMR1-04 NA NA FM R1 NA NA 0 NA GCAUUAG lnaGs;omeCs;lna FMR1:

CGAUGCU As;omeUs;lnaTs; 28662 L G omeAs;lnaGs;om 15 eCs;lnaGs;omeAs

;lnaTs;omeGs;lna

Cs;omeUs;lnaG-

Sup

FMR1-05 NA NA FM R1 NA NA 0 NA GGCAU UA lnaGs;omeGs;lna FMR1:

GCGAUGC Cs;omeAs;lnaTs; 28663 L U omeUs;lnaAs;om 15 eGs;lnaCs;omeG s;lnaAs;omeUs;ln aGs;omeCs;lnaT-

Sup

FMR1-06 NA NA FM R1 NA NA 0 NA CAAACGC lnaCs;omeAs;lna FMR1:

AACUGGU As;omeAs;lnaCs; 31189L Oligo ID Q RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeGs;lnaCs;om 15 eAs;lnaAs;omeCs

;lnaTs;omeGs;lna

Gs;omeUs;lnaC-

Sup

FMR1-07 NA NA FM R1 NA NA 0 NA CCAAACG lnaCs;omeCs;lna FMR1:

CAACUGG As;omeAs;lnaAs; 31190L U omeCs;lnaGs;om 15 eCs;lnaAs;omeAs

;lnaCs;omeUs;ln aGs;omeGs;lnaT-

Sup

F MR 1-08 NA NA FM R1 NA NA 0 NA UAUCUGU lnaTs;omeAs;lna FMR1:

ACGAU U U Ts;omeCs;lnaTs; 31262L G omeGs;lnaTs;om 15 eAs;lnaCs;omeGs

;lnaAs;omeUs;ln aTs;omeUs;lnaG-

Sup

F MR 1-09 NA NA FM R1 NA NA 0 NA CUCGACC lnaCs;omeUs;lna FMR1:

CAU UCCU Cs;omeGs;lnaAs; 31307L U omeCs;lnaCs;om 15 eCs;lnaAs;omeUs

;lnaTs;omeCs;lna

Cs;omeUs;lnaT-

Sup

FMRl-10 NA NA FM R1 NA NA 0 NA UACCUCG lnaTs;omeAs;lna FMR1:

ACCCAU U Cs;omeCs;lnaTs; 31310L c omeCs;lnaGs;om 15 eAs;lnaCs;omeCs

;lnaCs;omeAs;lna

Ts;omeUs;lnaC-

Sup

FMRl-11 NA NA FM R1 NA NA 0 NA ACUACCU lnaAs;omeCs;lna FMR1:

CGACCCA Ts;omeAs;lnaCs; 31312L u omeCs;lnaTs;om 15 eCs;lnaGs;omeAs

;lnaCs;omeCs;lna

Cs;omeAs;lnaT-

Sup

FMR1-12 NA NA FM R1 NA NA 0 NA UCUACUA lnaTs;omeCs;lna FMR1:

CCUCGAC Ts;omeAs;lnaCs; 31315L C omeUs;lnaAs;om 15 eCs;lnaCs;omeUs

;lnaCs;omeGs;ln aAs;omeCs;lnaC-

Sup

FMR1-13 NA NA FM R1 NA NA 0 NA GUCUACU lnaGs;omeUs;lna FMR1:

ACCUCGA Cs;omeUs;lnaAs; 31316L Oligo I RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

C omeCs;lnaTs;om 15 eAs;lnaCs;omeCs

;lnaTs;omeCs;lna

Gs;omeAs;lnaC-

Sup

FMR1-14 NA NA FMR1 NA NA 0 NA CGUGCCC lnaCs;omeGs;lna FMR1:

CCUAU UU Ts;omeGs;lnaCs; 31337L c omeCs;lnaCs;om 15 eCs;lnaCs;omeUs

;lnaAs;omeUs;ln aTs;omeUs;lnaC-

Sup

FM 1-15 NA NA FM R1 NA NA 0 NA GACCGCG lnaGs;omeAs;lna FMR1:

UCUGCCG Cs;omeCs;lnaGs; 31349 L U omeCs;lnaGs;om 15 eUs;lnaCs;omeU s;lnaGs;omeCs;ln aCs;omeGs;lnaT-

Sup

FMR1-16 NA NA FM R1 NA NA 0 NA AUCCAGG lnaAs;omeUs;lna FMR1:

ACCGCGU Cs;omeCs;lnaAs; 31355L C omeGs;lnaGs;om 15 eAs;lnaCs;omeCs

;lnaGs;omeCs;ln aGs;omeUs;lnaC-

Sup

FMR1-17 NA NA FM R1 NA NA 0 NA AUAUCCA lnaAs;omeUs;lna FMR1:

GGACCGC As;omeUs;lnaCs; 31357L G omeCs;lnaAs;om 15 eGs;lnaGs;omeA s;lnaCs;omeCs;ln aGs;omeCs;lnaG- Sup

FMR1-18 NA NA FM R1 NA NA 0 NA GUAUAUC lnaGs;omeUs;lna FMR1:

CAGGACC As;omeUs;lnaAs; 31359L G omeUs;lnaCs;om 15 eCs;lnaAs;omeGs

;lnaGs;omeAs;ln aCs;omeCs;lnaG-

Sup

FMR1-19 NA NA FMR1 NA NA 0 NA CCUAUCG lnaCs;omeCs;lna FMR1:

AGAGU UA Ts;omeAs;lnaTs; 32907L A omeCs;lnaGs;om 15 eAs;lnaGs;omeA s;lnaGs;omeUs;l naTs;omeAs;lna

A-Sup

FMR1-20 NA NA FM R1 NA NA 0 NA AUUAGU U lnaAs;omeUs;lna FMR1:

CCUAUCG Ts;omeAs;lnaGs; 32914L Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

A omeUs;lnaTs;om 15 eCs;lnaCs;omeUs

;lnaAs;omeUs;ln aCs;omeGs;lnaA-

Sup

FMR1-21 NA NA FM R1 NA NA 0 NA CGCCGUC lnaCs;omeGs;lna FMR1:

CGUCUCC Cs;omeCs;lnaGs; 33033L U omeUs;lnaCs;om 15 eCs;lnaGs;omeU s;lnaCs;omeUs;ln aCs;omeCs;lnaT-

Sup

FMR1-22 NA NA FM R1 NA NA 0 NA ACGCCGC lnaAs;omeCs;lna FMR1:

CGUCCGU Gs;omeCs;lnaCs; 33037L C omeGs;lnaCs;om 15 eCs;lnaGs;omeU s;lnaCs;omeCs;ln aGs;omeUs;lnaC-

Sup

FMR1-23 NA NA FM R1 NA NA 0 NA CGAU UAU lnaCs;omeGs;lna FMR1:

CUG UUCG As;omeUs;lnaTs; 33602L G omeAs;lnaTs;om 15 eCs;lnaTs;omeGs

;lnaTs;omeUs;lna

Cs;omeGs;lnaG-

Sup

FMR1-24 NA NA FM R1 NA NA 0 NA ACGAUUA lnaAs;omeCs;lna FMR1:

UCUGU UC Gs;omeAs;lnaTs; 33603L G omeUs;lnaAs;om 15 eUs;lnaCs;omeU s;lnaGs;omeUs;l naTs;omeCs;lna

G-Sup

FMR1-25 NA NA FM R1 NA NA 0 NA GGACGAU lnaGs;omeGs;lna FMR1:

UAUCUGU As;omeCs;lnaGs; 33605L U omeAs;lnaTs;om 15 eUs;lnaAs;omeU s;lnaCs;omeUs;ln aGs;omeUs;lnaT- Sup

FMR1-26 NA NA FM R1 NA NA 0 NA UGGACGA lnaTs;omeGs;lna FMR1:

U UAUCUG Gs;omeAs;lnaCs; 33606L U omeGs;lnaAs;om 15 eUs;lnaTs;omeAs

;lnaTs;omeCs;lna

Ts;omeGs;lnaT-

Sup

FMR1-27 NA NA FM R1 NA NA 0 NA ACG UGGA lnaAs;omeCs;lna FMR1:

CGAU UAU Gs;omeUs;lnaGs; 33609 L Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeGs;lnaAs;om 15 eCs;lnaGs;omeAs

;lnaTs;omeUs;lna

As;omeUs;lnaC-

Sup

FMR1-28 NA NA FM R1 NA NA 0 NA UACGUGG lnaTs;omeAs;lna FMR1:

ACGAUUA Cs;omeGs;lnaTs; 33610L U omeGs;lnaGs;om 15 eAs;lnaCs;omeGs

;lnaAs;omeUs;ln aTs;omeAs;lnaT-

Sup

FMR1-29 NA NA FM R1 NA NA 0 NA UUACG UG lnaTs;omeUs;lna FMR1:

GACGAU U As;omeCs;lnaGs; 33611L A omeUs;lnaGs;om 15 eGs;lnaAs;omeCs

;lnaGs;omeAs;ln aTs;omeUs;lnaA-

Sup

FMR1-30 NA NA FM R1 NA NA 0 NA AUUACG U lnaAs;omeUs;lna FMR1:

GGACGAU Ts;omeAs;lnaCs; 33612L U omeGs;lnaTs;om 15 eGs;lnaGs;omeA s;lnaCs;omeGs;ln aAs;omeUs;lnaT-

Sup

FMR1-31 NA NA FM R1 NA NA 0 NA GAU UACG lnaGs;omeAs;lna FMR1:

UGGACGA Ts;omeUs;lnaAs; 33613L U omeCs;lnaGs;om 15 eUs;lnaGs;omeG s;lnaAs;omeCs;ln aGs;omeAs;lnaT- Sup

FMR1-32 NA NA FM R1 NA NA 0 NA UGGAU UA lnaTs;omeGs;lna FMR1:

CGUGGAC Gs;omeAs;lnaTs; 33615L G omeUs;lnaAs;om 15 eCs;lnaGs;omeU s;lnaGs;omeGs;l naAs;omeCs;lna

G-Sup

FMR1-33 NA NA FM R1 NA NA 0 NA U UACCCG lnaTs;omeUs;lna FMR1:

UGCGCAG As;omeCs;lnaCs; 36809 L C omeCs;lnaGs;om 15 eUs;lnaGs;omeC s;lnaGs;omeCs;ln aAs;omeGs;lnaC-

Sup

FMR1-34 NA NA FM R1 NA NA 0 NA CUU UACC lnaCs;omeUs;lna FMR1:

CGUGCGC Ts;omeUs;lnaAs; 36811L Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

A omeCs;lnaCs;om 15 eCs;lnaGs;omeU s;lnaGs;omeCs;ln aGs;omeCs;lnaA-

Sup

FMR1-35 NA NA FM R1 NA NA 0 NA UCU U UAC lnaTs;omeCs;lna FMR1:

CCGUGCG Ts;omeUs;lnaTs; 36812L C omeAs;lnaCs;om 15 eCs;lnaCs;omeGs

;lnaTs;omeGs;lna

Cs;omeGs;lnaC-

Sup

FMR1-36 NA NA FM R1 NA NA 0 NA GAUCU UU lnaGs;omeAs;lna FMR1:

ACCCG UG Ts;omeCs;lnaTs; 36814L C omeUs;lnaTs;om 15 eAs;lnaCs;omeCs

;lnaCs;omeGs;ln aTs;omeGs;lnaC-

Sup

FMR1-37 NA NA FM R1 NA NA 0 NA CGAUCU U lnaCs;omeGs;lna FMR1:

UACCCGU As;omeUs;lnaCs; 36815L G omeUs;lnaTs;om 15 eUs;lnaAs;omeCs

;lnaCs;omeCs;lna

Gs;omeUs;lnaG-

Sup

FMR1-38 NA NA FM R1 NA NA 0 NA ACGAUCU lnaAs;omeCs;lna FMR1:

U UACCCG Gs;omeAs;lnaTs; 36816L U omeCs;lnaTs;om 15 eUs;lnaTs;omeAs

;lnaCs;omeCs;lna

Cs;omeGs;lnaT-

Sup

FMR1-39 NA NA FM R1 NA NA 0 NA UACGAUC lnaTs;omeAs;lna FMR1:

U U UACCC Cs;omeGs;lnaAs; 36817L G omeUs;lnaCs;om 15 eUs;lnaTs;omeU s;lnaAs;omeCs;ln aCs;omeCs;lnaG- Sup

F MR 1-40 NA NA FM R1 NA NA 0 NA GG UUACG lnaGs;omeGs;lna FMR1:

AUCUU UA Ts;omeUs;lnaAs; 36820L C omeCs;lnaGs;om 15 eAs;lnaTs;omeCs

;lnaTs;omeUs;lna

Ts;omeAs;lnaC-

Sup

FMR1-41 NA NA FM R1 NA NA 0 NA CUGGU UA lnaCs;omeUs;lna FMR1:

CGAUCU U Gs;omeGs;lnaTs; 36822L Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

U omeUs;lnaAs;om 15 eCs;lnaGs;omeAs

;lnaTs;omeCs;lna

Ts;omeUs;lnaT-

Sup

F MR 1-42 NA NA FM R1 NA NA 0 NA ACU UUCG lnaAs;omeCs;lna FMR1:

ACCAGGA Ts;omeUs;lnaTs; 37773L A omeCs;lnaGs;om 15 eAs;lnaCs;omeCs

;lnaAs;omeGs;ln aGs;omeAs;lnaA-

Sup

F MR 1-43 NA NA FM R1 NA NA 0 NA AACU UUC lnaAs;omeAs;lna FMR1:

GACCAGG Cs;omeUs;lnaTs; 37774L A omeUs;lnaCs;om 15 eGs;lnaAs;omeCs

;lnaCs;omeAs;lna

Gs;omeGs;lnaA-

Sup

FMR1-44 NA NA FM R1 NA NA 0 NA UAACUU U lnaTs;omeAs;lna FMR1:

CGACCAG As;omeCs;lnaTs; 37775L G omeUs;lnaTs;om 15 eCs;lnaGs;omeAs

;lnaCs;omeCs;lna

As;omeGs;lnaG-

Sup

FMR1-45 NA NA FM R1 NA NA 0 NA CUAACU U lnaCs;omeUs;lna FMR1:

UCGACCA As;omeAs;lnaCs; 37776L G omeUs;lnaTs;om 15 eUs;lnaCs;omeG s;lnaAs;omeCs;ln aCs;omeAs;lnaG- Sup

FMR1-46 NA NA FM R1 NA NA 0 NA ACUAACU lnaAs;omeCs;lna FMR1:

U UCGACC Ts;omeAs;lnaAs; 37777L A omeCs;lnaTs;om 15 eUs;lnaTs;omeCs

;lnaGs;omeAs;ln aCs;omeCs;lnaA-

Sup

FMR1-47 NA NA FM R1 NA NA 0 NA CCUACUA lnaCs;omeCs;lna FMR1:

ACU UUCG Ts;omeAs;lnaCs; 37780L A omeUs;lnaAs;om 15 eAs;lnaCs;omeUs

;lnaTs;omeUs;lna

Cs;omeGs;lnaA-

Sup

FMR1-48 NA NA FM R1 NA NA 0 NA UCCUACU lnaTs;omeCs;lna FMR1:

AACU UUC Cs;omeUs;lnaAs; 37781L Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

G omeCs;lnaTs;om 15 eAs;lnaAs;omeCs

;lnaTs;omeUs;lna

Ts;omeCs;lnaG-

Sup

F MR 1-49 NA NA FM R1 NA NA 0 NA UG UCGCU lnaTs;omeGs;lna FMR1:

AAUAUG U Ts;omeCs;lnaGs; 38582 L A omeCs;lnaTs;om 15 eAs;lnaAs;omeU s;lnaAs;omeUs;ln aGs;omeUs;lnaA-

Sup

FMR1-50 NA NA FM R1 NA NA 0 NA AAUCUG U lnaAs;omeAs;lna FMR1:

UG UCGCU Ts;omeCs;lnaTs; 38589 L A omeGs;lnaTs;om 15 eUs;lnaGs;omeU s;lnaCs;omeGs;ln aCs;omeUs;lnaA-

Sup

FMR1-51 NA NA FM R1 NA NA 0 NA CAAUCUG lnaCs;omeAs;lna FMR1:

U UGUCGC As;omeUs;lnaCs; 38590L U omeUs;lnaGs;om 15 eUs;lnaTs;omeG s;lnaTs;omeCs;ln aGs;omeCs;lnaT-

Sup

FMR1-52 NA NA FM R1 NA NA 0 NA AGCGCCU lnaAs;omeGs;lna FMR1:

UGCUGAA Cs;omeGs;lnaCs; 38935L U omeCs;lnaTs;om 15 eUs;lnaGs;omeC s;lnaTs;omeGs;ln aAs;omeAs;lnaT- Sup

FMR1-53 NA NA FM R1 NA NA 0 NA UAGCGCC lnaTs;omeAs;lna FMR1:

U UGCUGA Gs;omeCs;lnaGs; 38936L A omeCs;lnaCs;om 15 eUs;lnaTs;omeG s;lnaCs;omeUs;ln aGs;omeAs;lnaA-

Sup

FMR1-54 NA NA FM R1 NA NA 0 NA U UAGCGC lnaTs;omeUs;lna FMR1:

CU UGCUG As;omeGs;lnaCs; 38937L A omeGs;lnaCs;om 15 eCs;lnaTs;omeUs

;lnaGs;omeCs;ln aTs;omeGs;lnaA-

Sup

FMR1-55 NA NA FM R1 NA NA 0 NA AAGU UAG lnaAs;omeAs;lna FMR1:

CGCCU UG Gs;omeUs;lnaTs; 38940L Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

C omeAs;lnaGs;om 15 eCs;lnaGs;omeCs

;lnaCs;omeUs;ln aTs;omeGs;lnaC-

Sup

FMR1-56 NA NA FMR1 NA NA 0 NA GCAAGUU lnaGs;omeCs;lna FMR1:

AGCGCCU As;omeAs;lnaGs; 38942 L U omeUs;lnaTs;om 15 eAs;lnaGs;omeCs

;lnaGs;omeCs;ln aCs;omeUs;lnaT-

Sup

FMR1-57 NA NA FMR1 NA NA 0 NA UAAGCAA lnaTs;omeAs;lna FMR1:

GUUAGCG As;omeGs;lnaCs; 38945 L C omeAs;lnaAs;om 15 eGs;lnaTs;omeU s;lnaAs;omeGs;ln aCs;omeGs;lnaC-

Sup

GRN-01 0.922 NA GRN in Hep3B 30 qRTPCR GACACUG dGs;lnaAs;dCs;ln GRN:5

70683 vitro UGUGUGA aAs;dCs;lnaTs;dG 954U1 8 C s;lnaTs;dGs;lnaTs 5

;dGs;lnaTs;dGs;l naAs;dC-Sup

GRN-01 0.729 0.033 GRN in Hep3B 10 qRTPCR GACACUG dGs;lnaAs;dCs;ln GRN:5

96960 79581 vitro UGUGUGA aAs;dCs;lnaTs;dG 954U1 8 1 C s;lnaTs;dGs;lnaTs 5

;dGs;lnaTs;dGs;l naAs;dC-Sup

GRN-02 0.816 0.119 GRN in Hep3B 30 qRTPCR ACCUGAU dAs;lnaCs;dCs;ln GRN:5

23757 69853 vitro CCAGAGU aTs;dGs;lnaAs;dT 967U1 2 1 A s;lnaCs;dCs;lnaAs 5

;dGs;lnaAs;dGs;l naTs;dA-Sup

GRN-02 0.568 0.062 GRN in Hep3B 10 qRTPCR ACCUGAU dAs;lnaCs;dCs;ln GRN:5

43876 80735 vitro CCAGAGU aTs;dGs;lnaAs;dT 967U1 5 5 A s;lnaCs;dCs;lnaAs 5

;dGs;lnaAs;dGs;l naTs;dA-Sup

GRN-03 1.492 0.236 GRN in Hep3B 30 qRTPCR UUUACGU dTs;lnaTs;dTs;lna GRN:6

60442 53382 vitro GUGACAC As;dCs;lnaGs;dTs 470U1 8 9 G ;lnaGs;dTs;lnaGs; 5 dAs;lnaCs;dAs;ln aCs;dG-Sup

GRN-03 0.810 0.018 GRN in Hep3B 10 qRTPCR UUUACGU dTs;lnaTs;dTs;lna GRN:6

13299 07077 vitro GUGACAC As;dCs;lnaGs;dTs 470U1 1 6 G ;lnaGs;dTs;lnaGs; 5 dAs;lnaCs;dAs;ln aCs;dG-Sup Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

GRN-04 0.749 0.057 GRN in Hep3B 30 qRTPCR GGAUGGA dGs;lnaGs;dAs;ln GRN:6

12482 45329 vitro GAAGGCC aTs;dGs;lnaGs;d 525U1 4 7 C As;lnaGs;dAs;lna 5

As;dGs;lnaGs;dC s;lnaCs;dC-Sup

GRN-04 0.604 0.055 GRN in Hep3B 10 qRTPCR GGAUGGA dGs;lnaGs;dAs;ln GRN:6

49341 67359 vitro GAAGGCC aTs;dGs;lnaGs;d 525U1 3 5 C As;lnaGs;dAs;lna 5

As;dGs;lnaGs;dC s;lnaCs;dC-Sup

GRN-05 0.849 0.160 GRN in Hep3B 30 qRTPCR AGCUCAC dAs;lnaGs;dCs;ln GRN:6

60189 31287 vitro CUCAGCC aTs;dCs;lnaAs;dC 541U1 3 7 U s;lnaCs;dTs;lnaCs 5

;dAs;lnaGs;dCs;l naCs;dT-Sup

GRN-05 0.699 0.017 GRN in Hep3B 10 qRTPCR AGCUCAC dAs;lnaGs;dCs;ln GRN:6

17838 20577 vitro CUCAGCC aTs;dCs;lnaAs;dC 541U1 7 U s;lnaCs;dTs;lnaCs 5

;dAs;lnaGs;dCs;l naCs;dT-Sup

GRN-06 0.572 0.036 GRN in Hep3B 30 qRTPCR CGUGUGU dCs;lnaGs;dTs;ln GRN:6

55544 00644 vitro AGCUGAG aGs;dTs;lnaGs;dT 939U1 6 7 G s;lnaAs;dGs;lnaC 5 s;dTs;lnaGs;dAs;l naGs;dG-Sup

GRN-06 0.685 0.032 GRN in Hep3B 10 qRTPCR CGUGUGU dCs;lnaGs;dTs;ln GRN:6

44491 04943 vitro AGCUGAG aGs;dTs;lnaGs;dT 939U1 1 4 G s;lnaAs;dGs;lnaC 5 s;dTs;lnaGs;dAs;l naGs;dG-Sup

GRN-07 0.867 0.074 GRN in Hep3B 30 qRTPCR ACCCAGCC dAs;lnaCs;dCs;ln GRN:7

39777 89728 vitro UUGAGAC aCs;dAs;lnaGs;dC 651U1 8 7 s;lnaCs;dTs;lnaTs 5

;dGs;lnaAs;dGs;l naAs;dC-Sup

GRN-07 0.768 0.014 GRN in Hep3B 10 qRTPCR ACCCAGCC dAs;lnaCs;dCs;ln GRN:7

29638 94737 vitro UUGAGAC aCs;dAs;lnaGs;dC 651U1 7 1 s;lnaCs;dTs;lnaTs 5

;dGs;lnaAs;dGs;l naAs;dC-Sup

GRN-08 0.632 0.032 GRN in Hep3B 30 qRTPCR CUAACCA dCs;lnaTs;dAs;ln GRN:7

23418 65255 vitro AAUUCUC aAs;dCs;lnaCs;dA 757U1 4 4 C s;lnaAs;dAs;lnaTs 5

;dTs;lnaCs;dTs;ln aCs;dC-Sup

GRN-08 0.835 0.051 GRN in Hep3B 10 qRTPCR CUAACCA dCs;lnaTs;dAs;ln GRN:7

24072 88468 vitro AAUUCUC aAs;dCs;lnaCs;dA 757U1 8 4 C s;lnaAs;dAs;lnaTs 5

;dTs;lnaCs;dTs;ln Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

aCs;dC-Sup

G RN-09 0.890 0.173 GRN in Hep3B 30 qRTPCR AAU UCUC dAs;lnaAs;dTs;ln G RN :7

51649 44215 vitro CCUGGAC aTs;dCs;lnaTs;dC 764U 1 9 4 C s;lnaCs;dCs;lnaTs 5

;dGs;lnaGs;dAs;l naCs;dC-Sup

G RN-09 0.966 0.021 GRN in Hep3B 10 qRTPCR AAU UCUC dAs;lnaAs;dTs;ln G RN :7

52427 28436 vitro CCUGGAC aTs;dCs;lnaTs;dC 764U 1 2 3 C s;lnaCs;dCs;lnaTs 5

;dGs;lnaGs;dAs;l naCs;dC-Sup

G RN-10 0.868 0.031 GRN in Hep3B 30 qRTPCR U UACCUA dTs;lnaTs;dAs;ln GRN :- 45281 94925 vitro CCAGAUG aCs;dCs;lnaTs;dA 1932U 8 9 C s;lnaCs;dCs;lnaAs 15

;dGs;lnaAs;dTs;ln aGs;dC-Sup

G RN-10 0.897 0.063 GRN in Hep3B 10 qRTPCR U UACCUA dTs;lnaTs;dAs;ln GRN :- 09016 21228 vitro CCAGAUG aCs;dCs;lnaTs;dA 1932U 3 C s;lnaCs;dCs;lnaAs 15

;dGs;lnaAs;dTs;ln aGs;dC-Sup

G RN-11 1.013 0.086 GRN in Hep3B 30 qRTPCR UCCACCC dTs;lnaCs;dCs;ln GRN :- 51556 44694 vitro UGAGU UG aAs;dCs;lnaCs;dC 1908U 4 1 U s;lnaTs;dGs;lnaA 15 s;dGs;lnaTs;dTs;l naGs;dT-Sup

G RN-11 0.929 0.033 GRN in Hep3B 10 qRTPCR UCCACCC dTs;lnaCs;dCs;ln GRN :- 86494 61724 vitro UGAGU UG aAs;dCs;lnaCs;dC 1908U 9 U s;lnaTs;dGs;lnaA 15 s;dGs;lnaTs;dTs;l naGs;dT-Sup

G RN-12 1.199 0.272 GRN in Hep3B 30 qRTPCR AUCUGG U dAs;lnaTs;dCs;ln GRN :- 62633 78419 vitro AGG UAAG aTs;dGs;lnaGs;dT 1934L1 8 1 G s;lnaAs;dGs;lnaG 5 s;dTs;lnaAs;dAs;l naGs;dG-Sup

G RN-12 0.946 0.054 GRN in Hep3B 10 qRTPCR AUCUGG U dAs;lnaTs;dCs;ln GRN :- 27770 59138 vitro AGG UAAG aTs;dGs;lnaGs;dT 1934L1 2 1 G s;lnaAs;dGs;lnaG 5 s;dTs;lnaAs;dAs;l naGs;dG-Sup

G RN-13 0.967 0.052 GRN in Hep3B 30 qRTPCR AAACAUC dAs;lnaAs;dAs;ln GRN :- 51605 51231 vitro ACACGAC aCs;dAs;lnaTs;dC 1964L1 8 7 A s;lnaAs;dCs;lnaA 5 s;dCs;lnaGs;dAs;l naCs;dA-Sup

G RN-13 0.782 0.028 GRN in Hep3B 10 qRTPCR AAACAUC dAs;lnaAs;dAs;ln GRN :- 10725 79468 vitro ACACGAC aCs;dAs;lnaTs;dC 1964L1 8 A s;lnaAs;dCs;lnaA 5 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;dCs;lnaGs;dAs;l naCs;dA-Sup

G RN-14 1.133 0.043 GRN in Hep3B 30 qRTPCR UCCCAUC dTs;lnaCs;dCs;ln GRN :- 80441 94317 vitro UGGU UUC aCs;dAs;lnaTs;dC 1041U

4 C s;lnaTs;dGs;lnaG 15 s;dTs;lnaTs;dTs;l naCs;dC-Sup

G RN-14 0.977 0.071 GRN in Hep3B 10 qRTPCR UCCCAUC dTs;lnaCs;dCs;ln GRN :- 32033 53566 vitro UGGU UUC aCs;dAs;lnaTs;dC 1041U 9 2 C s;lnaTs;dGs;lnaG 15 s;dTs;lnaTs;dTs;l naCs;dC-Sup

G RN-15 0.782 0.033 GRN in Hep3B 30 qRTPCR ACCUGCC dAs;lnaCs;dCs;ln GRN :- 32264 37578 vitro AGU UAAA aTs;dGs;lnaCs;dC 998U 1 3 1 A s;lnaAs;dGs;lnaT 5 s;dTs;lnaAs;dAs;l naAs;dA-Sup

G RN-15 0.679 0.055 GRN in Hep3B 10 qRTPCR ACCUGCC dAs;lnaCs;dCs;ln GRN :- 19660 17363 vitro AGU UAAA aTs;dGs;lnaCs;dC 998U 1 6 1 A s;lnaAs;dGs;lnaT 5 s;dTs;lnaAs;dAs;l naAs;dA-Sup

G RN-16 1.127 0.017 GRN in Hep3B 30 qRTPCR UUCCCAG dTs;lnaTs;dCs;lna GRN :- 89386 68031 vitro ACUCAGC Cs;dCs;lnaAs;dGs 981U 1 9 1 U ;lnaAs;dCs;lnaTs; 5 dCs;lnaAs;dGs;ln aCs;dT-Sup

G RN-16 0.911 0.050 GRN in Hep3B 10 qRTPCR UUCCCAG dTs;lnaTs;dCs;lna GRN :- 11577 88438 vitro ACUCAGC Cs;dCs;lnaAs;dGs 981U 1 4 3 U ;lnaAs;dCs;lnaTs; 5 dCs;lnaAs;dGs;ln aCs;dT-Sup

G RN-17 1.628 0.072 GRN in Hep3B 30 qRTPCR AAGAU U U dAs;lnaAs;dGs;ln GRN :- 29641 18619 vitro UAACUGG aAs;dTs;lnaTs;dT 994L15 7 4 C s;lnaTs;dAs;lnaAs

;dCs;lnaTs;dGs;ln aGs;dC-Sup

G RN-17 1.531 0.063 GRN in Hep3B 10 qRTPCR AAGAU U U dAs;lnaAs;dGs;ln GRN :- 86082 43018 vitro UAACUGG aAs;dTs;lnaTs;dT 994L15 3 1 C s;lnaTs;dAs;lnaAs

;dCs;lnaTs;dGs;ln aGs;dC-Sup

G RN-18 0.895 0.016 GRN in Hep3B 30 qRTPCR UCAUCUC dTs;lnaCs;dAs;ln GRN :- 45176 44616 vitro UAGCAAA aTs;dCs;lnaTs;dC 130U 1 2 7 C s;lnaTs;dAs;lnaG 5 s;dCs;lnaAs;dAs;l naAs;dC-Sup

G RN-18 0.738 0.042 GRN in Hep3B 10 qRTPCR UCAUCUC dTs;lnaCs;dAs;ln GRN :- 17862 05647 vitro UAGCAAA aTs;dCs;lnaTs;dC 130U 1 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

1 8 C s;lnaTs;dAs;lnaG 5 s;dCs;lnaAs;dAs;l naAs;dC-Sup

G RN-19 0.792 0.113 GRN in Hep3B 30 qRTPCR AGGCGCC dAs;lnaGs;dGs;ln GRN :- 64572 05720 vitro UGCAGGA aCs;dGs;lnaCs;dC 109 U l 6 9 U s;lnaTs;dGs;lnaCs 5

;dAs;lnaGs;dGs;l naAs;dT-Sup

G RN-19 0.739 0.118 GRN in Hep3B 10 qRTPCR AGGCGCC dAs;lnaGs;dGs;ln GRN :- 97438 24269 vitro UGCAGGA aCs;dGs;lnaCs;dC 109 U l 6 3 U s;lnaTs;dGs;lnaCs 5

;dAs;lnaGs;dGs;l naAs;dT-Sup

G RN-20 0.909 0.082 GRN in Hep3B 30 qRTPCR UUAAGGA dTs;lnaTs;dAs;ln GRN :- 76407 34974 vitro AGGCGAC aAs;dGs;lnaGs;d 91U 15 7 3 G As;lnaAs;dGs;lna

Gs;dCs;lnaGs;dA s;lnaCs;dG-Sup

G RN-20 0.854 0.042 GRN in Hep3B 10 qRTPCR UUAAGGA dTs;lnaTs;dAs;ln GRN :- 65169 63957 vitro AGGCGAC aAs;dGs;lnaGs;d 91U 15 1 7 G As;lnaAs;dGs;lna

Gs;dCs;lnaGs;dA s;lnaCs;dG-Sup

G RN-21 1.174 0.062 GRN in Hep3B 30 qRTPCR UCCU UAA dTs;lnaCs;dCs;ln GRN :- 88608 64802 vitro CCCAUCC aTs;dTs;lnaAs;dA 99L15

1 u s;lnaCs;dCs;lnaCs

;dAs;lnaTs;dCs;ln aCs;dT-Sup

G RN-21 0.964 0.006 GRN in Hep3B 10 qRTPCR UCCU UAA dTs;lnaCs;dCs;ln GRN :- 98430 18487 vitro CCCAUCC aTs;dTs;lnaAs;dA 99L15 8 8 u s;lnaCs;dCs;lnaCs

;dAs;lnaTs;dCs;ln aCs;dT-Sup

G RN-22 0.708 0.127 GRN in Hep3B 30 qRTPCR GAG UU UG dGs;lnaAs;dGs;ln GRN :- 30563 19471 vitro CUAGUGA aTs;dTs;lnaTs;dG 128L15 6 4 U s;lnaCs;dTs;lnaAs

;dGs;lnaTs;dGs;l naAs;dT-Sup

G RN-22 0.700 0.152 GRN in Hep3B 10 qRTPCR GAG UU UG dGs;lnaAs;dGs;ln GRN :- 26494 58976 vitro CUAGUGA aTs;dTs;lnaTs;dG 128L15 3 7 U s;lnaCs;dTs;lnaAs

;dGs;lnaTs;dGs;l naAs;dT-Sup

G RN-23 0.875 0.139 GRN in Hep3B 30 qRTPCR AUG UGAG dAs;lnaTs;dGs;ln G RN :2

55345 72513 vitro CU UGAGG aTs;dGs;lnaAs;d 71U 15 4 5 U Gs;lnaCs;dTs;lna

Ts;dGs;lnaAs;dGs

;lnaGs;dT-Sup

G RN-23 0.703 0.071 GRN in Hep3B 10 qRTPCR AUG UGAG dAs;lnaTs;dGs;ln GRN :2 - Ill -

Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

77911 36665 vitro CUUGAGG aTs;dGs;lnaAs;d 71U15

U Gs;lnaCs;dTs;lna

Ts;dGs;lnaAs;dGs ;lnaGs;dT-Sup

GRN-24 0.810 0.001 GRN in Hep3B 30 qRTPCR AGCCGGA dAs;lnaGs;dCs;ln GRN:3

53555 68545 vitro GACAACA aCs;dGs;lnaGs;d 00U15 2 9 G As;lnaGs;dAs;lna

Cs;dAs;lnaAs;dCs

;lnaAs;dG-Sup

GRN-24 0.730 0.059 GRN in Hep3B 10 qRTPCR AGCCGGA dAs;lnaGs;dCs;ln GRN:3

99510 95018 vitro GACAACA aCs;dGs;lnaGs;d 00U15 2 G As;lnaGs;dAs;lna

Cs;dAs;lnaAs;dCs

;lnaAs;dG-Sup

GRN-25 1.273 0.011 GRN in Hep3B 30 qRTPCR UUACUGA dTs;lnaTs;dAs;ln GRN:3

72460 10902 vitro AACUCCU aCs;dTs;lnaGs;dA 24U15 6 9 U s;lnaAs;dAs;lnaC

s;dTs;lnaCs;dCs;l naTs;dT-Sup

GRN-25 1.215 0.046 GRN in Hep3B 10 qRTPCR UUACUGA dTs;lnaTs;dAs;ln GRN:3

83534 57757 vitro AACUCCU aCs;dTs;lnaGs;dA 24U15 7 2 U s;lnaAs;dAs;lnaC

s;dTs;lnaCs;dCs;l naTs;dT-Sup

GRN-26 0.951 0.007 GRN in Hep3B 30 qRTPCR AAGGAGU dAs;lnaAs;dGs;ln GRN:3

97405 91811 vitro UUCAGUA aGs;dAs;lnaGs;d 24L15 5 5 A Ts;lnaTs;dTs;lnaC

s;dAs;lnaGs;dTs;l naAs;dA-Sup

GRN-26 1.010 0.003 GRN in Hep3B 10 qRTPCR AAGGAGU dAs;lnaAs;dGs;ln GRN:3

59663 98246 vitro UUCAGUA aGs;dAs;lnaGs;d 24L15 2 1 A Ts;lnaTs;dTs;lnaC

s;dAs;lnaGs;dTs;l naAs;dA-Sup

GRN-27 1.019 0.142 GRN in Hep3B 30 qRTPCR AACCUCA dAs;lnaAs;dCs;ln GRN:2

98668 38456 vitro AGCUCAC aCs;dTs;lnaCs;dA 72L15 6 2 A s;lnaAs;dGs;lnaC

s;dTs;lnaCs;dAs;l naCs;dA-Sup

GRN-27 0.754 0.010 GRN in Hep3B 10 qRTPCR AACCUCA dAs;lnaAs;dCs;ln GRN:2

96753 92944 vitro AGCUCAC aCs;dTs;lnaCs;dA 72L15 4 5 A s;lnaAs;dGs;lnaC

s;dTs;lnaCs;dAs;l naCs;dA-Sup

GRN-28 0.835 0.035 GRN in Hep3B 30 qRTPCR AAUGCCC dAs;lnaAs;dTs;ln GRN:5

21406 34979 vitro GGACUUC aGs;dCs;lnaCs;dC 151U1

6 U s;lnaGs;dGs;lnaA 5 s;dCs;lnaTs;dTs;l naCs;dT-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

G RN-28 0.697 0.046 GRN in Hep3B 10 qRTPCR AAUGCCC dAs;lnaAs;dTs;ln G RN :5

42497 82103 vitro GGACU UC aGs;dCs;lnaCs;dC 151U 1 8 U s;lnaGs;dGs;lnaA 5 s;dCs;lnaTs;dTs;l naCs;dT-Sup

G RN-29 0.694 0.034 GRN in Hep3B 30 qRTPCR AUAACAC dAs;lnaTs;dAs;ln G RN :5

06110 82007 vitro AGCACGU aAs;dCs;lnaAs;dC 167L15 3 1 G s;lnaAs;dGs;lnaC

s;dAs;lnaCs;dGs;l naTs;dG-Sup

G RN-29 0.667 0.019 GRN in Hep3B 10 qRTPCR AUAACAC dAs;lnaTs;dAs;ln G RN :5

15125 69641 vitro AGCACGU aAs;dCs;lnaAs;dC 167L15 7 3 G s;lnaAs;dGs;lnaC

s;dAs;lnaCs;dGs;l naTs;dG-Sup

G RN-30 0.573 0.000 GRN in Hep3B 30 qRTPCR AUUCGAA dAs;lnaTs;dTs;ln G RN :5

53144 22952 vitro CUGACUA aCs;dGs;lnaAs;d 139L15 2 1 U As;lnaCs;dTs;lna

Gs;dAs;lnaCs;dTs

;lnaAs;dT-Sup

G RN-30 0.638 0.016 GRN in Hep3B 10 qRTPCR AUUCGAA dAs;lnaTs;dTs;ln G RN :5

94818 00772 vitro CUGACUA aCs;dGs;lnaAs;d 139L15 1 6 U As;lnaCs;dTs;lna

Gs;dAs;lnaCs;dTs

;lnaAs;dT-Sup

I LlO-01 41.45 8.665 I L10 in RPTEC 100 qRTPCR AACCCUCC omeAs;omeAs;o IL10:29

33365 05177 vitro UCCUGCG meCs;omeCs;om 9U20 6 2 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I LlO-01 15.45 2.463 I L10 in RPTEC 50 qRTPCR AACCCUCC omeAs;omeAs;o IL10:29

57425 20159 vitro UCCUGCG meCs;omeCs;om 9U20 2 7 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I LlO-01 1.528 0.144 I L10 in RPTEC 100 qRTPCR AACCCUCC omeAs;omeAs;o IL10:29

66080 92159 vitro UCCUGCG meCs;omeCs;om 9U20 8 9 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I LlO-01 1.064 0.259 I L10 in RPTEC 50 qRTPCR AACCCUCC omeAs;omeAs;o IL10:29

78408 82235 vitro UCCUGCG meCs;omeCs;om 9U20 4 3 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I LlO-01 1.807 0.133 I L10 in RPTEC 100 ELISA AACCCUCC omeAs;omeAs;o IL10:29

69230 23467 vitro UCCUGCG meCs;omeCs;om 9U20 8 8 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I LlO-01 1.131 0.066 I L10 in RPTEC 50 ELISA AACCCUCC omeAs;omeAs;o IL10:29

14754 25331 vitro UCCUGCG meCs;omeCs;om 9U20 1 CCUCC eCs;omeUs;ome

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeGs;o meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

I L10-02 91.05 12.42 I L10 in RPTEC 100 qRTPCR CCCUCCU omeCs;omeCs;o IL10:30

44326 09522 vitro CCUGCGC meCs;omeUs;om 1U20 5 2 CUCCAC eCs;omeCs;ome

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

I L10-02 33.95 3.140 I L10 in RPTEC 50 qRTPCR CCCUCCU omeCs;omeCs;o IL10:30

80591 88020 vitro CCUGCGC meCs;omeUs;om 1U20 2 8 CUCCAC eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

I L10-02 2.208 0.097 I L10 in RPTEC 100 qRTPCR CCCUCCU omeCs;omeCs;o IL10:30

58496 60851 vitro CCUGCGC meCs;omeUs;om 1U20 4 1 CUCCAC eCs;omeCs;ome

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

I L10-02 1.199 0.256 I L10 in RPTEC 50 qRTPCR CCCUCCU omeCs;omeCs;o IL10:30

04108 29619 vitro CCUGCGC meCs;omeUs;om 1U20 1 8 CUCCAC eCs;omeCs;ome

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

IL10-02 2.076 0.133 IL10 in RPTEC 100 ELISA CCCUCCU omeCs;omeCs;o IL10:30

92307 23467 vitro CCUGCGC meCs;omeUs;om 1U20 7 8 CUCCAC eCs;omeCs;ome

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

I L10-02 0.950 0.075 I L10 in RPTEC 50 ELISA CCCUCCU omeCs;omeCs;o IL10:30

81967 71806 vitro CCUGCGC meCs;omeUs;om 1U20 2 8 CUCCAC eCs;omeCs;ome

Us;omeCs;omeC s;omeUs;omeGs;

omeCs;omeGs;o meCs;omeCs;om eUs;omeCs;ome

Cs;omeAs;omeC-

Sup

I L10-03 5.655 1.333 I L10 in RPTEC 100 qRTPCR CCUGCGC omeCs;omeCs;o IL10:30

74761 53968 vitro CUCCACC meUs;omeGs;o 8U20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesjg ue

1 2 UCCAUC meCs;omeGs;om

eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

I L10-03 2.289 1.197 I L10 in RPTEC 50 qRTPCR CCUGCGC omeCs;omeCs;o IL10:30

90028 81323 vitro CUCCACC meUs;omeGs;o 8U20 7 UCCAUC meCs;omeGs;om

eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

IL10-03 0.972 0.148 IL10 in RPTEC 100 qRTPCR CCUGCGC omeCs;omeCs;o IL10:30

51778 62423 vitro CUCCACC meUs;omeGs;o 8U20 3 5 UCCAUC meCs;omeGs;om

eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

I L10-03 1.081 0.147 I L10 in RPTEC 50 qRTPCR CCUGCGC omeCs;omeCs;o IL10:30

71930 68726 vitro CUCCACC meUs;omeGs;o 8U20 3 6 UCCAUC meCs;omeGs;om

eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

I L10-03 1.384 0.111 I L10 in RPTEC 100 ELISA CCUGCGC omeCs;omeCs;o IL10:30

61538 02889 vitro CUCCACC meUs;omeGs;o 8U20 5 8 UCCAUC meCs;omeGs;om

eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

I L10-03 0.786 0.047 IL10 in RPTEC 50 ELISA CCUGCGC omeCs;omeCs;o IL10:30 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

88524 32379 vitro CUCCACC meUs;omeGs;o 8U20

6 3 UCCAUC meCs;omeGs;om eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

C-Sup

I L10-04 5.983 2.743 I L10 in RPTEC 100 qRTPCR UGCGCCU omeUs;omeGs;o IL10:31

31382 24318 vitro CCACCUCC meCs;omeGs;om 0U20

1 8 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-04 8.929 3.055 I L10 in RPTEC 50 qRTPCR UGCGCCU omeUs;omeGs;o IL10:31

48818 66133 vitro CCACCUCC meCs;omeGs;om 0U20

9 4 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-04 1.397 0.153 I L10 in RPTEC 100 qRTPCR UGCGCCU omeUs;omeGs;o IL10:31

14884 97469 vitro CCACCUCC meCs;omeGs;om 0U20

6 5 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-04 0.847 0.264 I L10 in RPTEC 50 qRTPCR UGCGCCU omeUs;omeGs;o IL10:31

29246 72904 vitro CCACCUCC meCs;omeGs;om 0U20

9 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

I L10-04 1.269 0.022 I L10 in RPTEC 100 ELISA UGCGCCU omeUs;omeGs;o IL10:31

23076 20578 vitro CCACCUCC meCs;omeGs;om 0U20

9 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-04 0.934 0.056 I L10 in RPTEC 50 ELISA UGCGCCU omeUs;omeGs;o IL10:31

42623 78855 vitro CCACCUCC meCs;omeGs;om 0U20

1 AUCCC eCs;omeCs;ome

Us;omeCs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-05 3.811 1.012 I L10 in RPTEC 100 qRTPCR GCGCCUC omeGs;omeCs;o IL10:31

20938 01873 vitro CACCUCCA meGs;omeCs;om 1U20

9 8 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC-

Sup

I L10-05 3.891 0.657 I L10 in RPTEC 50 qRTPCR GCGCCUC omeGs;omeCs;o IL10:31

70402 61931 vitro CACCUCCA meGs;omeCs;om 1U20

4 4 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC-

Sup

I L10-05 0.601 0.085 I L10 in RPTEC 100 qRTPCR GCGCCUC omeGs;omeCs;o IL10:31

82828 85304 vitro CACCUCCA meGs;omeCs;om 1U20

2 7 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC- Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Sup

I L10-05 1.513 0.409 I L10 in RPTEC 50 qRTPCR GCGCCUC omeGs;omeCs;o IL10:31

91236 37141 vitro CACCUCCA meGs;omeCs;om 1U20 3 5 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC-

Sup

I L10-05 1.384 0.111 I L10 in RPTEC 100 ELISA GCGCCUC omeGs;omeCs;o IL10:31

61538 02889 vitro CACCUCCA meGs;omeCs;om 1U20 5 8 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC-

Sup

I L10-05 0.967 0.066 I L10 in RPTEC 50 ELISA GCGCCUC omeGs;omeCs;o IL10:31

21311 25331 vitro CACCUCCA meGs;omeCs;om 1U20 5 UCCCC eCs;omeUs;ome

Cs;omeCs;omeAs

;omeCs;omeCs;o meUs;omeCs;om eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeC-

Sup

I L10-06 6.421 0.743 I L10 in RPTEC 100 qRTPCR GCCUCCA omeGs;omeCs;o IL10:31

92799 13538 vitro CCUCCAU meCs;omeUs;om 3U20 4 4 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeA-

Sup

I L10-06 2.779 0.436 I L10 in RPTEC 50 qRTPCR GCCUCCA omeGs;omeCs;o IL10:31

06571 37900 vitro CCUCCAU meCs;omeUs;om 3U20 5 9 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;omeAs;omeA- Sup

I L10-06 1.038 0.191 I L10 in RPTEC 100 qRTPCR GCCUCCA omeGs;omeCs;o IL10:31

67795 97518 vitro CCUCCAU meCs;omeUs;om 3U20 5 5 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeA-

Sup

I L10-06 1.115 0.243 I L10 in RPTEC 50 qRTPCR GCCUCCA omeGs;omeCs;o IL10:31

91344 38185 vitro CCUCCAU meCs;omeUs;om 3U20 1 7 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeA-

Sup

I L10-06 1.5 0.177 I L10 in RPTEC 100 ELISA GCCUCCA omeGs;omeCs;o IL10:31

64623 vitro CCUCCAU meCs;omeUs;om 3U20 7 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeA-

Sup

I L10-06 0.803 0.104 I L10 in RPTEC 50 ELISA GCCUCCA omeGs;omeCs;o IL10:31

27868 11234 vitro CCUCCAU meCs;omeUs;om 3U20 9 4 CCCCAA eCs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meCs;omeAs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeA-

Sup

I L10-07 9.066 3.552 I L10 in RPTEC 100 qRTPCR CAACACC omeCs;omeAs;o IL10:33

61675 36490 vitro UAU UCCC meAs;omeCs;om 0U20 6 3 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-07 2.021 0.196 I L10 in RPTEC 50 qRTPCR CAACACC omeCs;omeAs;o IL10:33

46682 39828 vitro UAU UCCC meAs;omeCs;om 0U20 5 2 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-07 0.963 0.173 I L10 in RPTEC 100 qRTPCR CAACACC omeCs;omeAs;o IL10:33

46561 19645 vitro UAU UCCC meAs;omeCs;om 0U20

5 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-07 0.923 0.348 I L10 in RPTEC 50 qRTPCR CAACACC omeCs;omeAs;o IL10:33

34474 31925 vitro UAU UCCC meAs;omeCs;om 0U20 1 9 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-07 1.346 0.133 I L10 in RPTEC 100 ELISA CAACACC omeCs;omeAs;o IL10:33

15384 23467 vitro UAU UCCC meAs;omeCs;om 0U20 6 8 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-07 1.065 0.132 I L10 in RPTEC 50 ELISA CAACACC omeCs;omeAs;o IL10:33

57377 50661 vitro UAU UCCC meAs;omeCs;om 0U20

9 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC- Sup

I L10-08 3.313 1.789 I L10 in RPTEC 100 qRTPCR CCAACACC omeCs;omeCs;o IL10:32

01455 20689 vitro UAU UCCC meAs;omeAs;om 9U20 3 3 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-08 2.530 0.727 I L10 in RPTEC 50 qRTPCR CCAACACC omeCs;omeCs;o IL10:32

03278 98747 vitro UAU UCCC meAs;omeAs;om 9U20 3 1 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-08 0.749 0.266 I L10 in RPTEC 100 qRTPCR CCAACACC omeCs;omeCs;o IL10:32

73101 90338 vitro UAU UCCC meAs;omeAs;om 9U20 8 4 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-08 1.005 0.134 I L10 in RPTEC 50 qRTPCR CCAACACC omeCs;omeCs;o IL10:32

07256 43925 vitro UAU UCCC meAs;omeAs;om 9U20 6 4 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-08 1.576 0.111 I L10 in RPTEC 100 ELISA CCAACACC omeCs;omeCs;o IL10:32

92307 02889 vitro UAU UCCC meAs;omeAs;om 9U20 7 8 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs; Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-08 0.885 0.066 I L10 in RPTEC 50 ELISA CCAACACC omeCs;omeCs;o IL10:32

24590 25331 vitro UAU UCCC meAs;omeAs;om 9U20 2 CCAAA eCs;omeAs;ome

Cs;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meCs;omeCs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

I L10-09 2.563 1.632 I L10 in RPTEC 100 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

94223 37731 vitro CUAUUCC meCs;omeAs;om 8U20 8 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-09 1.331 0.828 I L10 in RPTEC 50 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

91583 43107 vitro CUAUUCC meCs;omeAs;om 8U20 1 6 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

IL10-09 0.894 0.273 IL10 in RPTEC 100 qRTPCR CCCAACAC omeCs;omeCs;o IL10-.32

36606 37054 vitro CUAUUCC meCs;omeAs;om 8U20 9 6 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-09 0.970 0.207 I L10 in RPTEC 50 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

91748 32520 vitro CUAUUCC meCs;omeAs;om 8U20 2 8 CCCAA eAs;omeCs;ome

As;omeCs;omeCs Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-09 1.423 0.155 I L10 in RPTEC 100 ELISA CCCAACAC omeCs;omeCs;o IL10:32

07692 44045 vitro CUAUUCC meCs;omeAs;om 8U20 3 7 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-09 0.819 0.123 I L10 in RPTEC 50 ELISA CCCAACAC omeCs;omeCs;o IL10:32

67213 04186 vitro CUAUUCC meCs;omeAs;om 8U20 1 1 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I LlO-10 2.976 2.263 I L10 in RPTEC 100 qRTPCR CCCCAACA omeCs;omeCs;o IL10:32

08507 27937 vitro CCUAUUC meCs;omeCs;om 7U20 4 5 CCCCA eAs;omeAs;ome

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

I LlO-10 1.709 0.871 I L10 in RPTEC 50 qRTPCR CCCCAACA omeCs;omeCs;o IL10:32

30435 94738 vitro CCUAU UC meCs;omeCs;om 7U20 8 7 CCCCA eAs;omeAs;ome

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

I LlO-10 1.392 0.178 I L10 in RPTEC 100 qRTPCR CCCCAACA omeCs;omeCs;o IL10:32

24247 40879 vitro CCUAU UC meCs;omeCs;om 7U20 7 CCCCA eAs;omeAs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesjg ue

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

I LlO-10 0.867 0.052 I L10 in RPTEC 50 qRTPCR CCCCAACA omeCs;omeCs;o IL10:32

54819 82841 vitro CCUAU UC meCs;omeCs;om 7U20 4 7 CCCCA eAs;omeAs;ome

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

I LlO-10 1.769 0.177 I L10 in RPTEC 100 ELISA CCCCAACA omeCs;omeCs;o IL10:32

23076 64623 vitro CCUAU UC meCs;omeCs;om 7U20 9 7 CCCCA eAs;omeAs;ome

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

ILlO-10 0.868 0.123 IL10 in RPTEC 50 ELISA CCCCAACA omeCs;omeCs;o IL10:32

85245 04186 vitro CCUAU UC meCs;omeCs;om 7U20 9 1 CCCCA eAs;omeAs;ome

Cs;omeAs;omeCs

;omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeA-

Sup

I LlO-11 4.023 1.597 I L10 in RPTEC 100 qRTPCR UCCCCAAC omeUs;omeCs;o IL10:32

52700 59502 vitro ACCUAU U meCs;omeCs;om 6U20 1 1 ccccc eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

I LlO-11 0.851 0.376 I L10 in RPTEC 50 qRTPCR UCCCCAAC omeUs;omeCs;o IL10:32

73023 28183 vitro ACCUAU U meCs;omeCs;om 6U20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

9 8 CCCCC eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

I LlO-11 0.764 0.196 I L10 in RPTEC 100 qRTPCR UCCCCAAC omeUs;omeCs;o IL10:32

35984 08580 vitro ACCUAU U meCs;omeCs;om 6U20 1 5 CCCCC eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

ILlO-11 1.307 0.158 IL10 in RPTEC 50 qRTPCR UCCCCAAC omeUs;omeCs;o IL10:32

72045 68704 vitro ACCUAU U meCs;omeCs;om 6U20

3 CCCCC eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

I LlO-11 1.807 0.377 I L10 in RPTEC 100 ELISA UCCCCAAC omeUs;omeCs;o IL10:32

69230 49825 vitro ACCUAU U meCs;omeCs;om 6U20 8 3 CCCCC eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

I LlO-11 0.819 0.113 I L10 in RPTEC 50 ELISA UCCCCAAC omeUs;omeCs;o IL10:32

67213 57710 vitro ACCUAU U meCs;omeCs;om 6U20 1 2 CCCCC eCs;omeAs;ome

As;omeCs;omeA s;omeCs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

C-Sup

I L10-12 10.91 0.516 IL10 in RPTEC 100 qRTPCR AUCCCCA omeAs;omeUs;o I L10:32 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

81201 89698 vitro ACACCUA meCs;omeCs;om 5U20

9 8 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Sup

I L10-12 3.032 0.858 I L10 in RPTEC 50 qRTPCR AUCCCCA omeAs;omeUs;o IL10:32

06540 49299 vitro ACACCUA meCs;omeCs;om 5U20

7 2 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Sup

I L10-12 0.581 0.064 I L10 in RPTEC 100 qRTPCR AUCCCCA omeAs;omeUs;o IL10:32

76205 54667 vitro ACACCUA meCs;omeCs;om 5U20

6 6 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Sup

I L10-12 1.269 0.365 I L10 in RPTEC 50 qRTPCR AUCCCCA omeAs;omeUs;o IL10:32

07204 38836 vitro ACACCUA meCs;omeCs;om 5U20

8 8 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Sup

I L10-12 2.230 0.843 I L10 in RPTEC 100 ELISA AUCCCCA omeAs;omeUs;o IL10:32

76923 81962 vitro ACACCUA meCs;omeCs;om 5U20

1 4 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Name Type Line/Tiss ] Type Sequence ates_g ue

I L10-12 0.918 0.094 I L10 in RPTEC 50 ELISA AUCCCCA omeAs;omeUs;o IL10:32

03278 64758 vitro ACACCUA meCs;omeCs;om 5U20

7 5 U UCCCC eCs;omeCs;ome

As;omeAs;omeC s;omeAs;omeCs;

omeCs;omeUs;o meAs;omeUs;om eUs;omeCs;ome

Cs;omeCs;omeC-

Sup

I L10-13 4.659 2.409 I L10 in RPTEC 100 qRTPCR CAUCCCCA omeCs;omeAs;o IL10:32

41119 18077 vitro ACACCUA meUs;omeCs;om 4U20

4 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-13 1.441 0.531 I L10 in RPTEC 50 qRTPCR CAUCCCCA omeCs;omeAs;o IL10:32

35994 91482 vitro ACACCUA meUs;omeCs;om 4U20

5 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-13 0.910 0.083 I L10 in RPTEC 100 qRTPCR CAUCCCCA omeCs;omeAs;o IL10:32

39001 51157 vitro ACACCUA meUs;omeCs;om 4U20

7 2 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-13 0.923 0.117 I L10 in RPTEC 50 qRTPCR CAUCCCCA omeCs;omeAs;o IL10:32

31097 31168 vitro ACACCUA meUs;omeCs;om 4U20

5 5 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC- Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

Sup

I L10-13 1.384 0.310 I L10 in RPTEC 100 ELISA CAUCCCCA omeCs;omeAs;o IL10:32

61538 88091 vitro ACACCUA meUs;omeCs;om 4U20 5 4 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-13 0.901 0.141 I L10 in RPTEC 50 ELISA CAUCCCCA omeCs;omeAs;o IL10:32

63934 97137 vitro ACACCUA meUs;omeCs;om 4U20 4 8 U UCCC eCs;omeCs;ome

Cs;omeAs;omeA s;omeCs;omeAs;

omeCs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

I L10-14 2.532 0.658 I L10 in RPTEC 100 qRTPCR CCAUCCCC omeCs;omeCs;o IL10:32

07889 95604 vitro AACACCU meAs;omeUs;om 3U20 5 1 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU s;omeCs;omeC-

Sup

I L10-14 0.615 0.190 I L10 in RPTEC 50 qRTPCR CCAUCCCC omeCs;omeCs;o IL10:32

38584 60202 vitro AACACCU meAs;omeUs;om 3U20 6 1 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU s;omeCs;omeC-

Sup

I L10-14 0.747 0.216 I L10 in RPTEC 100 qRTPCR CCAUCCCC omeCs;omeCs;o IL10:32

96517 24145 vitro AACACCU meAs;omeUs;om 3U20 2 2 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

s;omeCs;omeC- Sup

I L10-14 0.988 0.118 I L10 in RPTEC 50 qRTPCR CCAUCCCC omeCs;omeCs;o IL10:32

25506 24025 vitro AACACCU meAs;omeUs;om 3U20

6 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU s;omeCs;omeC-

Sup

I L10-14 1.576 0.222 I L10 in RPTEC 100 ELISA CCAUCCCC omeCs;omeCs;o IL10:32

92307 05779 vitro AACACCU meAs;omeUs;om 3U20 7 6 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU s;omeCs;omeC-

Sup

I L10-14 0.655 0.056 I L10 in RPTEC 50 ELISA CCAUCCCC omeCs;omeCs;o IL10:32

73770 78855 vitro AACACCU meAs;omeUs;om 3U20 5 1 AU UCC eCs;omeCs;ome

Cs;omeCs;omeAs

;omeAs;omeCs;o meAs;omeCs;om eCs;omeUs;ome

As;omeUs;omeU s;omeCs;omeC-

Sup

I L10-15 10.46 1.591 I L10 in RPTEC 100 qRTPCR UCCAUCC omeUs;omeCs;o IL10:32

29136 17230 vitro CCAACACC meCs;omeAs;om 2U20 4 7 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-15 2.250 0.448 I L10 in RPTEC 50 qRTPCR UCCAUCC omeUs;omeCs;o IL10:32

90851 85276 vitro CCAACACC meCs;omeAs;om 2U20 8 8 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-15 1.157 0.218 I L10 in RPTEC 100 qRTPCR UCCAUCC omeUs;omeCs;o IL10:32

08295 34250 vitro CCAACACC meCs;omeAs;om 2U20 9 7 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-15 0.825 0.192 I L10 in RPTEC 50 qRTPCR UCCAUCC omeUs;omeCs;o IL10:32

53829 66398 vitro CCAACACC meCs;omeAs;om 2U20 8 4 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-15 1.346 0.155 I L10 in RPTEC 100 ELISA UCCAUCC omeUs;omeCs;o IL10:32

15384 44045 vitro CCAACACC meCs;omeAs;om 2U20 6 7 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-15 0.606 0.009 I L10 in RPTEC 50 ELISA UCCAUCC omeUs;omeCs;o IL10:32

55737 46475 vitro CCAACACC meCs;omeAs;om 2U20 7 9 UAU UC eUs;omeCs;ome

Cs;omeCs;omeCs

;omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU s;omeUs;omeC-

Sup

I L10-16 7.216 1.691 I L10 in RPTEC 100 qRTPCR CUCCAUC omeCs;omeUs;o IL10:32

51995 97504 vitro CCCAACAC meCs;omeCs;om 1U20 2 3 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeCs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU- Sup

I L10-16 2.672 1.387 I L10 in RPTEC 50 qRTPCR CUCCAUC omeCs;omeUs;o IL10:32

73481 96262 vitro CCCAACAC meCs;omeCs;om 1U20 9 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU-

Sup

I L10-16 1.060 0.246 I L10 in RPTEC 100 qRTPCR CUCCAUC omeCs;omeUs;o IL10:32

66379 98489 vitro CCCAACAC meCs;omeCs;om 1U20 5 4 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU-

Sup

I L10-16 1.422 0.248 I L10 in RPTEC 50 qRTPCR CUCCAUC omeCs;omeUs;o IL10:32

25322 54536 vitro CCCAACAC meCs;omeCs;om 1U20 2 6 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU-

Sup

I L10-16 1.5 0.044 I L10 in RPTEC 100 ELISA CUCCAUC omeCs;omeUs;o IL10:32

41155 vitro CCCAACAC meCs;omeCs;om 1U20 9 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU-

Sup

I L10-16 4.786 4.003 I L10 in RPTEC 50 ELISA CUCCAUC omeCs;omeUs;o IL10:32

88524 59285 vitro CCCAACAC meCs;omeCs;om 1U20 6 CUAU U eAs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeU- Sup

I L10-17 10.21 1.632 I L10 in RPTEC 100 qRTPCR CCUCCAU omeCs;omeCs;o IL10:32

67889 14764 vitro CCCCAACA meUs;omeCs;om 0U20 8 2 CCUAU eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

I L10-17 2.608 1.055 I L10 in RPTEC 50 qRTPCR CCUCCAU omeCs;omeCs;o IL10:32

94643 79298 vitro CCCCAACA meUs;omeCs;om 0U20 6 9 CCUAU eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

I L10-17 0.854 0.310 I L10 in RPTEC 100 qRTPCR CCUCCAU omeCs;omeCs;o IL10:32

70378 37103 vitro CCCCAACA meUs;omeCs;om 0U20 2 6 CCUAU eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

IL10-17 1.153 0.082 IL10 in RPTEC 50 qRTPCR CCUCCAU omeCs;omeCs;o IL10-.32

44781 01348 vitro CCCCAACA meUs;omeCs;om 0U20 6 8 CCUAU eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

I L10-17 1.653 0.111 I L10 in RPTEC 100 ELISA CCUCCAU omeCs;omeCs;o IL10:32

84615 02889 vitro CCCCAACA meUs;omeCs;om 0U20 4 8 CCUAU eCs;omeAs;ome

Us;omeCs;omeC Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

I L10-17 0.852 0.236 I L10 in RPTEC 50 ELISA CCUCCAU omeCs;omeCs;o IL10:32

45901 61896 vitro CCCCAACA meUs;omeCs;om 0U20 6 3 CCUAU eCs;omeAs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeAs;omeAs;o meCs;omeAs;om eCs;omeCs;ome

Us;omeAs;omeU

-Sup

I L10-18 11.35 2.287 I L10 in RPTEC 100 qRTPCR ACCUCCA omeAs;omeCs;o IL10:31

76051 36658 vitro UCCCCAAC meCs;omeUs;om 9U20 3 ACCUA eCs;omeCs;ome

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

I L10-18 5.126 0.447 I L10 in RPTEC 50 qRTPCR ACCUCCA omeAs;omeCs;o IL10:31

92407 35192 vitro UCCCCAAC meCs;omeUs;om 9U20 3 3 ACCUA eCs;omeCs;ome

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

I L10-18 0.609 0.078 I L10 in RPTEC 100 qRTPCR ACCUCCA omeAs;omeCs;o IL10:31

98197 55830 vitro UCCCCAAC meCs;omeUs;om 9U20 4 2 ACCUA eCs;omeCs;ome

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

I L10-18 1.127 0.045 I L10 in RPTEC 50 qRTPCR ACCUCCA omeAs;omeCs;o IL10:31

69239 74287 vitro UCCCCAAC meCs;omeUs;om 9U20 1 8 ACCUA eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

I L10-18 1.192 0.066 I L10 in RPTEC 100 ELISA ACCUCCA omeAs;omeCs;o IL10:31

30769 61733 vitro UCCCCAAC meCs;omeUs;om 9U20 2 9 ACCUA eCs;omeCs;ome

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

I L10-18 1.065 0.255 I L10 in RPTEC 50 ELISA ACCUCCA omeAs;omeCs;o IL10:31

57377 54848 vitro UCCCCAAC meCs;omeUs;om 9U20

ACCUA eCs;omeCs;ome

As;omeUs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeCs;om eAs;omeCs;ome

Cs;omeUs;omeA

-Sup

IL10-19 9.945 1.279 IL10 in RPTEC 100 qRTPCR CACCUCCA omeCs;omeAs;o IL10-.31

14229 29749 vitro UCCCCAAC meCs;omeCs;om 8U20

ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

I L10-19 2.723 0.586 I L10 in RPTEC 50 qRTPCR CACCUCCA omeCs;omeAs;o IL10:31

90749 02651 vitro UCCCCAAC meCs;omeCs;om 8U20 7 4 ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

I L10-19 1.000 0.190 I L10 in RPTEC 100 qRTPCR CACCUCCA omeCs;omeAs;o IL10:31

00956 32843 vitro UCCCCAAC meCs;omeCs;om 8U20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesjg ue

ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

I L10-19 1.231 0.265 I L10 in RPTEC 50 qRTPCR CACCUCCA omeCs;omeAs;o IL10:31

81615 16312 vitro UCCCCAAC meCs;omeCs;om 8U20 8 9 ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

IL10-19 2.038 0.555 IL10 in RPTEC 100 ELISA CACCUCCA omeCs;omeAs;o IL10:31

46153 14449 vitro UCCCCAAC meCs;omeCs;om 8U20 8 ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

I L10-19 1.655 0.776 I L10 in RPTEC 50 ELISA CACCUCCA omeCs;omeAs;o IL10:31

73770 11019 vitro UCCCCAAC meCs;omeCs;om 8U20 5 8 ACCU eUs;omeCs;ome

Cs;omeAs;omeU s;omeCs;omeCs;

omeCs;omeCs;o meAs;omeAs;om eCs;omeAs;ome

Cs;omeCs;omeU-

Sup

I L10-20 2.728 1.208 I L10 in RPTEC 100 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

37026 15903 vitro CUAUUCC meCs;omeAs;om 8U20 7 4 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-20 1.021 0.713 IL10 in RPTEC 50 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32 Oligo ID Q RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

06892 09500 vitro CUAUUCC meCs;omeAs;om 8U20

7 9 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-20 0.820 0.043 I L10 in RPTEC 100 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

62271 20975 vitro CUAUUCC meCs;omeAs;om 8U20

9 9 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-20 0.944 0.283 I L10 in RPTEC 50 qRTPCR CCCAACAC omeCs;omeCs;o IL10:32

46690 74557 vitro CUAUUCC meCs;omeAs;om 8U20

9 6 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

I L10-20 3.384 1.132 I L10 in RPTEC 100 ELISA CCCAACAC omeCs;omeCs;o IL10:32

61538 49475 vitro CUAUUCC meCs;omeAs;om 8U20

5 9 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Sup

IL10-20 5.229 2.243 IL10 in RPTEC 50 ELISA CCCAACAC omeCs;omeCs;o IL10-.32

50819 14776 vitro CUAUUCC meCs;omeAs;om 8U20

7 7 CCCAA eAs;omeCs;ome

As;omeCs;omeCs

;omeUs;omeAs;o meUs;omeUs;o meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA-

Name Type Line/Tiss ] Type Sequence atesj> ue

I L10-21 15.28 1.552 I L10 in RPTEC 100 qRTPCR CAACACC omeCs;omeAs;o IL10:33

01232 04675 vitro UAU UCCC meAs;omeCs;om 0U20

4 6 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-21 3.528 0.217 I L10 in RPTEC 50 qRTPCR CAACACC omeCs;omeAs;o IL10:33

44459 22925 vitro UAU UCCC meAs;omeCs;om 0U20

5 8 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-21 0.913 0.148 I L10 in RPTEC 100 qRTPCR CAACACC omeCs;omeAs;o IL10:33

49896 15638 vitro UAU UCCC meAs;omeCs;om 0U20

4 9 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-21 1.160 0.133 I L10 in RPTEC 50 qRTPCR CAACACC omeCs;omeAs;o IL10:33

95413 47011 vitro UAU UCCC meAs;omeCs;om 0U20

7 4 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

IL10-21 3.461 1.154 IL10 in RPTEC 100 ELISA CAACACC omeCs;omeAs;o IL10:33

53846 70053 vitro UAU UCCC meAs;omeCs;om 0U20

2 8 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC- Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Sup

I L10-21 2.213 1.183 I L10 in RPTEC 50 ELISA CAACACC omeCs;omeAs;o IL10:33

11475 09481 vitro UAU UCCC meAs;omeCs;om 0U20 4 4 CCAAAC eAs;omeCs;ome

Cs;omeUs;omeA s;omeUs;omeUs;

omeCs;omeCs;o meCs;omeCs;om eCs;omeAs;ome

As;omeAs;omeC-

Sup

I L10-22 32.51 1.622 I L10 in RPTEC 100 qRTPCR ACCUAU U omeAs;omeCs;o IL10:33

06016 15298 vitro CCCCCAAA meCs;omeUs;om 4U20 1 6 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA

-Sup

I L10-22 9.918 0.389 I L10 in RPTEC 50 qRTPCR ACCUAU U omeAs;omeCs;o IL10:33

40534 27546 vitro CCCCCAAA meCs;omeUs;om 4U20 2 2 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA

-Sup

I L10-22 1.531 0.090 I L10 in RPTEC 100 qRTPCR ACCUAU U omeAs;omeCs;o IL10:33

72253 32944 vitro CCCCCAAA meCs;omeUs;om 4U20 1 2 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA

-Sup

I L10-22 0.963 0.220 I L10 in RPTEC 50 qRTPCR ACCUAU U omeAs;omeCs;o IL10:33

40392 89751 vitro CCCCCAAA meCs;omeUs;om 4U20 4 7 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeAs;omeA

-Sup

I L10-22 3.769 1.154 I L10 in RPTEC 100 ELISA ACCUAU U omeAs;omeCs;o IL10:33

23076 70053 vitro CCCCCAAA meCs;omeUs;om 4U20 9 8 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA

-Sup

I L10-22 1.114 0.085 I L10 in RPTEC 50 ELISA ACCUAU U omeAs;omeCs;o IL10:33

75409 18282 vitro CCCCCAAA meCs;omeUs;om 4U20 8 7 CU UAA eAs;omeUs;ome

Us;omeCs;omeC s;omeCs;omeCs;

omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA

-Sup

I L10-23 31.29 1.526 I L10 in RPTEC 100 qRTPCR CCUAU UC omeCs;omeCs;o IL10:33

16751 05112 vitro CCCCAAAC meUs;omeAs;om 5U20 1 3 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-23 8.234 1.158 I L10 in RPTEC 50 qRTPCR CCUAU UC omeCs;omeCs;o IL10:33

80427 14341 vitro CCCCAAAC meUs;omeAs;om 5U20 5 9 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-23 0.676 0.152 I L10 in RPTEC 100 qRTPCR CCUAU UC omeCs;omeCs;o IL10:33

38613 53399 vitro CCCCAAAC meUs;omeAs;om 5U20 1 9 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-23 1.327 0.232 I L10 in RPTEC 50 qRTPCR CCUAU UC omeCs;omeCs;o IL10:33

83106 10943 vitro CCCCAAAC meUs;omeAs;om 5U20 9 3 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-23 4 1.487 I L10 in RPTEC 100 ELISA CCUAU UC omeCs;omeCs;o IL10:33

78723 vitro CCCCAAAC meUs;omeAs;om 5U20 2 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-23 5.409 4.145 I L10 in RPTEC 50 ELISA CCUAU UC omeCs;omeCs;o IL10:33

83606 56422 vitro CCCCAAAC meUs;omeAs;om 5U20 6 8 U UAAA eUs;omeUs;ome

Cs;omeCs;omeCs

;omeCs;omeCs;o meAs;omeAs;om eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeA-

Sup

I L10-24 28.86 5.048 I L10 in RPTEC 100 qRTPCR CUAU UCC omeCs;omeUs;o IL10:33

39979 62366 vitro CCCAAAC meAs;omeUs;om 6U20 9 7 U UAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU-

Sup

I L10-24 11.12 1.882 I L10 in RPTEC 50 qRTPCR CUAU UCC omeCs;omeUs;o IL10:33

97592 90974 vitro CCCAAAC meAs;omeUs;om 6U20 8 6 U UAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU- Sup

I L10-24 0.929 0.271 I L10 in RPTEC 100 qRTPCR CUAU UCC omeCs;omeUs;o IL10:33

50653 56223 vitro CCCAAAC meAs;omeUs;om 6U20 9 8 UUAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU-

Sup

I L10-24 1.239 0.485 I L10 in RPTEC 50 qRTPCR CUAU UCC omeCs;omeUs;o IL10:33

33989 89788 vitro CCCAAAC meAs;omeUs;om 6U20 1 7 U UAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU-

Sup

I L10-24 3.076 0.754 I L10 in RPTEC 100 ELISA CUAU UCC omeCs;omeUs;o IL10:33

92307 99650 vitro CCCAAAC meAs;omeUs;om 6U20 7 6 U UAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU-

Sup

I L10-24 1.081 0.397 I L10 in RPTEC 50 ELISA CUAU UCC omeCs;omeUs;o IL10:33

96721 51985 vitro CCCAAAC meAs;omeUs;om 6U20 3 7 U UAAAU eUs;omeCs;ome

Cs;omeCs;omeCs

;omeCs;omeAs;o meAs;omeAs;om eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeU-

Sup

I L10-25 80.29 2.432 I L10 in RPTEC 100 qRTPCR UAU UCCC omeUs;omeAs;o IL10:33

25769 50218 vitro CCAAACU meUs;omeUs;o 7U20 4 1 UAAAU U meCs;omeCs;om

eCs;omeCs;ome

Cs;omeAs;omeA Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj;

ue

s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-25 19.02 1.101 I L10 in RPTEC 50 qRTPCR UAU UCCC omeUs;omeAs;o IL10:33

22274 82831 vitro CCAAACU meUs;omeUs;o 7U20 1 4 UAAAU U meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-25 1.602 0.251 I L10 in RPTEC 100 qRTPCR UAU UCCC omeUs;omeAs;o IL10:33

24281 26398 vitro CCAAACU meUs;omeUs;o 7U20

UAAAU U meCs;omeCs;om

eCs;omeCs;ome

Cs;omeAs;omeA s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-25 1.122 0.107 I L10 in RPTEC 50 qRTPCR UAU UCCC omeUs;omeAs;o IL10:33

26051 50304 vitro CCAAACU meUs;omeUs;o 7U20 2 1 UAAAU U meCs;omeCs;om eCs;omeCs;ome

Cs;omeAs;omeA s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-25 1.115 0.022 I L10 in RPTEC 100 ELISA UAU UCCC omeUs;omeAs;o IL10:33

38461 20578 vitro CCAAACU meUs;omeUs;o 7U20 5 UAAAU U meCs;omeCs;om

eCs;omeCs;ome

Cs;omeAs;omeA s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-25 0.918 0.141 I L10 in RPTEC 50 ELISA UAU UCCC omeUs;omeAs;o IL10:33

03278 97137 vitro CCAAACU meUs;omeUs;o 7U20 7 8 UAAAU U meCs;omeCs;om

eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesjg ue

Cs;omeAs;omeA s;omeAs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eAs;omeUs;ome

U-Sup

I L10-26 1.538 0.199 I L10 in RPTEC 100 ELISA UCCCCCAA omeUs;omeCs;o IL10:34

46153 85201 vitro ACU UAAA meCs;omeCs;om 0U20 8 6 U UCU U eCs;omeCs;ome

As;omeAs;omeA s;omeCs;omeUs;

omeUs;omeAs;o meAs;omeAs;om eUs;omeUs;ome

Cs;omeUs;omeU

-Sup

I L10-26 0.819 0.028 I L10 in RPTEC 50 ELISA UCCCCCAA omeUs;omeCs;o IL10:34

67213 39427 vitro ACU UAAA meCs;omeCs;om 0U20 1 6 U UCU U eCs;omeCs;ome

As;omeAs;omeA s;omeCs;omeUs;

omeUs;omeAs;o meAs;omeAs;om eUs;omeUs;ome

Cs;omeUs;omeU

-Sup

I L10-27 28.91 2.613 I L10 in RPTEC 100 qRTPCR CCCCAAAC omeCs;omeCs;o IL10:34

45614 73868 vitro UUAAAUU meCs;omeCs;om 2U20 2 8 CU UAA eAs;omeAs;ome

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

IL10-27 10.00 0.552 IL10 in RPTEC 50 qRTPCR CCCCAAAC omeCs;omeCs;o IL10-.34

87719 35503 vitro U UAAAU U meCs;omeCs;om 2U20 8 3 CU UAA eAs;omeAs;ome

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

I L10-27 0.770 0.111 I L10 in RPTEC 100 qRTPCR CCCCAAAC omeCs;omeCs;o IL10:34

42772 94211 vitro U UAAAU U meCs;omeCs;om 2U20 9 7 CU UAA eAs;omeAs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates _g ue

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

I L10-27 1.126 0.476 I L10 in RPTEC 50 qRTPCR CCCCAAAC omeCs;omeCs;o IL10:34

80812 34675 vitro U UAAAU U meCs;omeCs;om 2U20 2 7 CU UAA eAs;omeAs;ome

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

I L10-27 1.115 0.088 I L10 in RPTEC 100 ELISA CCCCAAAC omeCs;omeCs;o IL10:34

38461 82311 vitro U UAAAU U meCs;omeCs;om 2U20 5 8 CU UAA eAs;omeAs;ome

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

I L10-27 1 0.141 I L10 in RPTEC 50 ELISA CCCCAAAC omeCs;omeCs;o IL10:34

97137 vitro U UAAAU U meCs;omeCs;om 2U20 8 CU UAA eAs;omeAs;ome

As;omeCs;omeU s;omeUs;omeAs;

omeAs;omeAs;o meUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

A-Sup

I L10-28 10.77 8.216 I L10 in RPTEC 100 qRTPCR CCCAAAC omeCs;omeCs;o IL10:34

20140 88631 vitro U UAAAU U meCs;omeAs;om 3U20 8 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-28 4.004 0.730 I L10 in RPTEC 50 qRTPCR CCCAAAC omeCs;omeCs;o IL10:34

60586 64599 vitro U UAAAU U meCs;omeAs;om 3U20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

3 7 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-28 1.796 0.167 I L10 in RPTEC 100 qRTPCR CCCAAAC omeCs;omeCs;o IL10:34

26446 88856 vitro U UAAAU U meCs;omeAs;om 3U20 9 6 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-28 4.201 0.345 I L10 in RPTEC 50 qRTPCR CCCAAAC omeCs;omeCs;o IL10:34

92240 54030 vitro U UAAAU U meCs;omeAs;om 3U20 7 6 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-28 1.038 0.044 I L10 in RPTEC 100 ELISA CCCAAAC omeCs;omeCs;o IL10:34

46153 41155 vitro U UAAAU U meCs;omeAs;om 3U20 8 9 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-28 0.868 0.028 I L10 in RPTEC 50 ELISA CCCAAAC omeCs;omeCs;o IL10:34

85245 39427 vitro U UAAAU U meCs;omeAs;om 3U20 9 6 CU UAAG eAs;omeAs;ome

Cs;omeUs;omeU s;omeAs;omeAs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

As;omeAs;omeG

-Sup

I L10-29 22.31 6.135 IL10 in RPTEC 100 qRTPCR CCAAACU omeCs;omeCs;o IL10:34 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

38134 48013 vitro UAAAUUC meAs;omeAs;om 4U20

8 6 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup

I L10-29 4.951 2.442 I L10 in RPTEC 50 qRTPCR CCAAACU omeCs;omeCs;o IL10:34

99674 20339 vitro UAAAUUC meAs;omeAs;om 4U20

6 3 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup

I L10-29 2.477 0.476 I L10 in RPTEC 100 qRTPCR CCAAACU omeCs;omeCs;o IL10:34

99958 02210 vitro UAAAUUC meAs;omeAs;om 4U20

6 5 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup

I L10-29 4.142 0.247 I L10 in RPTEC 50 qRTPCR CCAAACU omeCs;omeCs;o IL10:34

29382 99353 vitro UAAAUUC meAs;omeAs;om 4U20

1 6 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup

I L10-29 2.038 0.954 I L10 in RPTEC 100 ELISA CCAAACU omeCs;omeCs;o IL10:34

46153 84852 vitro UAAAUUC meAs;omeAs;om 4U20

8 2 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

I L10-29 1.442 0.615 I L10 in RPTEC 50 ELISA CCAAACU omeCs;omeCs;o IL10:34

62295 20930 vitro UAAAUUC meAs;omeAs;om 4U20

1 3 U UAAGA eAs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eUs;omeAs;ome

As;omeGs;omeA

-Sup

I L10-30 15.12 2.884 I L10 in RPTEC 100 qRTPCR ACU UAAA omeAs;omeCs;o IL10:34

42090 69133 vitro U UCU UAA meUs;omeUs;o 8U20

2 7 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome

U-Sup

I L10-30 3.914 2.332 I L10 in RPTEC 50 qRTPCR ACU UAAA omeAs;omeCs;o IL10:34

25421 81551 vitro U UCU UAA meUs;omeUs;o 8U20

2 5 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome

U-Sup

I L10-30 2.392 0.210 I L10 in RPTEC 100 qRTPCR ACU UAAA omeAs;omeCs;o IL10:34

17413 8329 vitro U UCU UAA meUs;omeUs;o 8U20

8 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome

U-Sup

I L10-30 5.245 0.475 I L10 in RPTEC 50 qRTPCR ACU UAAA omeAs;omeCs;o IL10:34

01381 07339 vitro UUCUUAA meUs;omeUs;o 8U20

3 5 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

U-Sup

I L10-30 2.615 0.932 I L10 in RPTEC 100 ELISA ACU UAAA omeAs;omeCs;o IL10:34

38461 64274 vitro U UCU UAA meUs;omeUs;o 8U20 5 3 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome

U-Sup

I L10-30 1.770 0.965 I L10 in RPTEC 50 ELISA ACU UAAA omeAs;omeCs;o IL10:34

49180 40536 vitro U UCU UAA meUs;omeUs;o 8U20 3 8 GAGAAU meAs;omeAs;om

eAs;omeUs;ome

Us;omeCs;omeU s;omeUs;omeAs;

omeAs;omeGs;o meAs;omeGs;om eAs;omeAs;ome

U-Sup

NANOG- 1.755 0.274 NAN in Hep3B 30 qRTPCR U UCUCAU dTs;lnaTs;dCs;lna NANO 01 07302 54852 OG vitro G UCUU UC Ts;dCs;lnaAs;dTs; G :- 2 1 A lnaGs;dTs;lnaCs; 940L15 dTs;lnaTs;dTs;lna

Cs;dA-Sup

NANOG- 0.605 0.071 NAN in Hep3B 10 qRTPCR U UCUCAU dTs;lnaTs;dCs;lna NANO 01 49818 86500 OG vitro G UCUU UC Ts;dCs;lnaAs;dTs; G :- 2 3 A lnaGs;dTs;lnaCs; 940L15 dTs;lnaTs;dTs;lna

Cs;dA-Sup

NANOG- 1.351 0.124 NAN in Hep3B 30 qRTPCR AGCUUCU dAs;lnaGs;dCs;ln NANO 02 34384 39644 OG vitro UCCCAGG aTs;dTs;lnaCs;dT G :- 1 U s;lnaTs;dCs;lnaCs 917L15

;dCs;lnaAs;dGs;l naGs;dT-Sup

NANOG- 0.625 0.038 NAN in Hep3B 10 qRTPCR AGCUUCU dAs;lnaGs;dCs;ln NANO 02 08954 57250 OG vitro UCCCAGG aTs;dTs;lnaCs;dT G :- 1 4 u s;lnaTs;dCs;lnaCs 917L15

;dCs;lnaAs;dGs;l naGs;dT-Sup

NANOG- 1.605 0.162 NAN in Hep3B 30 qRTPCR UCGACUU dTs;lnaCs;dGs;ln NANO 03 28465 43377 OG vitro CUGGCU U aAs;dCs;lnaTs;dT G :- 7 9 U s;lnaCs;dTs;lnaGs 886L15

;dGs;lnaCs;dTs;ln aTs;dT-Sup

NANOG- 0.806 0.050 NAN in Hep3B 10 qRTPCR UCGACUU dTs;lnaCs;dGs;ln NANO 03 33272 51486 OG vitro CUGGCU U aAs;dCs;lnaTs;dT G :- 4 5 U s;lnaCs;dTs;lnaGs 886L15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;dGs;lnaCs;dTs;ln aTs;dT-Sup

NANOG- 1.865 0.289 NAN in Hep3B 30 qRTPCR GGCUCUU dGs;lnaGs;dCs;ln NANO 04 63923 28481 OG vitro UAGCU UC aTs;dCs;lnaTs;dT G :- 7 7 U s;lnaTs;dAs;lnaG 909L15 s;dCs;lnaTs;dTs;l naCs;dT-Sup

NANOG- 0.668 0.031 NAN in Hep3B 10 qRTPCR GGCUCUU dGs;lnaGs;dCs;ln NANO 04 63112 70296 OG vitro UAGCU UC aTs;dCs;lnaTs;dT G :- 3 2 U s;lnaTs;dAs;lnaG 909L15 s;dCs;lnaTs;dTs;l naCs;dT-Sup

NANOG- 1.627 0.073 NAN in Hep3B 30 qRTPCR CCAAAGC dCs;lnaCs;dAs;ln NANO 05 29386 81423 OG vitro U UGCCUU aAs;dAs;lnaGs;d G:240

3 3 G Cs;lnaTs;dTs;lna U 15

Gs;dCs;lnaCs;dTs

;lnaTs;dG-Sup

NANOG- 0.477 0.043 NAN in Hep3B 10 qRTPCR CCAAAGC dCs;lnaCs;dAs;ln NANO 05 61436 20903 OG vitro U UGCCUU aAs;dAs;lnaGs;d G:240

3 4 G Cs;lnaTs;dTs;lna U 15

Gs;dCs;lnaCs;dTs

;lnaTs;dG-Sup

NANOG- 1.372 0.298 NAN in Hep3B 30 qRTPCR AACAUGA dAs;lnaAs;dCs;ln NANO 06 56575 74313 OG vitro GUGUGGA aAs;dTs;lnaGs;dA G:214

2 4 U s;lnaGs;dTs;lnaG U 15 s;dTs;lnaGs;dGs;l naAs;dT-Sup

NANOG- 0.372 0.088 NAN in Hep3B 10 qRTPCR AACAUGA dAs;lnaAs;dCs;ln NANO 06 96340 23516 OG vitro GUGUGGA aAs;dTs;lnaGs;dA G:214

9 8 U s;lnaGs;dTs;lnaG U 15 s;dTs;lnaGs;dGs;l naAs;dT-Sup

NANOG- 1.365 0.206 NAN in Hep3B 30 qRTPCR AAAACUA dAs;lnaAs;dAs;ln NANO 07 62985 36560 OG vitro UCCAUCC aAs;dCs;lnaTs;dA G:314

4 U s;lnaTs;dCs;lnaCs U 15

;dAs;lnaTs;dCs;ln aCs;dT-Sup

NANOG- 0.813 0.137 NAN in Hep3B 10 qRTPCR AAAACUA dAs;lnaAs;dAs;ln NANO 07 38152 25400 OG vitro UCCAUCC aAs;dCs;lnaTs;dA G:314

5 6 U s;lnaTs;dCs;lnaCs U 15

;dAs;lnaTs;dCs;ln aCs;dT-Sup

NANOG- 1.130 0.262 NAN in Hep3B 30 qRTPCR GUGAU UU dGs;lnaTs;dGs;ln NANO 08 96549 91437 OG vitro GUGGGCC aAs;dTs;lnaTs;dT G:295

7 5 U s;lnaGs;dTs;lnaG U 15 s;dGs;lnaGs;dCs;l naCs;dT-Sup

NANOG- 0.537 0.056 NAN in Hep3B 10 qRTPCR GUGAU UU dGs;lnaTs;dGs;ln NANO 08 20646 63978 OG vitro GUGGGCC aAs;dTs;lnaTs;dT G:295 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

3 5 U s;lnaGs;dTs;lnaG U 15 s;dGs;lnaGs;dCs;l naCs;dT-Sup

NANOG- 1.136 0.311 NAN in Hep3B 30 qRTPCR UAUAAUG dTs;lnaAs;dTs;ln NANO 09 23807 72165 OG vitro GAAAAAG aAs;dAs;lnaTs;dG G :512L

8 6 G s;lnaGs;dAs;lnaA 15 s;dAs;lnaAs;dAs;l naGs;dG-Sup

NANOG- 0.625 0.076 NAN in Hep3B 10 qRTPCR UAUAAUG dTs;lnaAs;dTs;ln NANO 09 98366 90175 OG vitro GAAAAAG aAs;dAs;lnaTs;dG G :512L

8 5 G s;lnaGs;dAs;lnaA 15 s;dAs;lnaAs;dAs;l naGs;dG-Sup

NANOG- 1.370 0.291 NAN in Hep3B 30 qRTPCR AGGUGCC dAs;lnaGs;dGs;ln NANO 10 67156 18338 OG vitro ACCAAGU aTs;dGs;lnaCs;dC G :526L

1 5 U s;lnaAs;dCs;lnaCs 15

;dAs;lnaAs;dGs;l naTs;dT-Sup

NANOG- 0.767 0.069 NAN in Hep3B 10 qRTPCR AGGUGCC dAs;lnaGs;dGs;ln NANO 10 10750 49914 OG vitro ACCAAGU aTs;dGs;lnaCs;dC G :526L

8 2 U s;lnaAs;dCs;lnaCs 15

;dAs;lnaAs;dGs;l naTs;dT-Sup

NANOG- 1.089 0.143 NAN in Hep3B 30 qRTPCR ACACUCC dAs;lnaCs;dAs;ln NANO 11 90829 76068 OG vitro UGAGACC aCs;dTs;lnaCs;dC G :560L

9 8 U s;lnaTs;dGs;lnaA 15 s;dGs;lnaAs;dCs;l naCs;dT-Sup

NANOG- 0.852 0.071 NAN in Hep3B 10 qRTPCR ACACUCC dAs;lnaCs;dAs;ln NANO 11 49590 43916 OG vitro UGAGACC aCs;dTs;lnaCs;dC G :560L

3 3 U s;lnaTs;dGs;lnaA 15 s;dGs;lnaAs;dCs;l naCs;dT-Sup

NANOG- 1.035 0.285 NAN in Hep3B 30 qRTPCR UAAU UAG dTs;lnaAs;dAs;ln NANO 12 11840 81262 OG vitro CAAUAAA aTs;dTs;lnaAs;dG G :737L

4 9 U s;lnaCs;dAs;lnaA 15 s;dTs;lnaAs;dAs;l naAs;dT-Sup

NANOG- 0.680 0.021 NAN in Hep3B 10 qRTPCR UAAU UAG dTs;lnaAs;dAs;ln NANO 12 35506 92116 OG vitro CAAUAAA aTs;dTs;lnaAs;dG G :737L

4 8 U s;lnaCs;dAs;lnaA 15 s;dTs;lnaAs;dAs;l naAs;dT-Sup

NANOG- 1.397 0.211 NAN in Hep3B 30 qRTPCR U UAGG UC dTs;lnaTs;dAs;ln NANO 13 51126 29862 OG vitro U UCUGGC aGs;dGs;lnaTs;d G :751L

1 3 U Cs;lnaTs;dTs;lnaC 15 s;dTs;lnaGs;dGs;l naCs;dT-Sup

NANOG- 1.339 0.049 NAN in Hep3B 10 qRTPCR UUAGG UC dTs;lnaTs;dAs;ln NANO Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

13 54146 75637 OG vitro U UCUGGC aGs;dGs;lnaTs;d G :751L

9 9 U Cs;lnaTs;dTs;lnaC 15 s;dTs;lnaGs;dGs;l naCs;dT-Sup

NANOG- 0.854 0.072 NAN in Hep3B 30 qRTPCR AAAUCAU dAs;lnaAs;dAs;ln NANO 14 82687 78864 OG vitro GCUCAUC aTs;dCs;lnaAs;dT G :779L

7 8 C s;lnaGs;dCs;lnaTs 15

;dCs;lnaAs;dTs;ln aCs;dC-Sup

NANOG- 0.967 0.110 NAN in Hep3B 10 qRTPCR AAAUCAU dAs;lnaAs;dAs;ln NANO 14 52583 57679 OG vitro GCUCAUC aTs;dCs;lnaAs;dT G :779L

5 C s;lnaGs;dCs;lnaTs 15

;dCs;lnaAs;dTs;ln aCs;dC-Sup

NANOG- 1.291 0.143 NAN in Hep3B 30 qRTPCR U UUGCCA dTs;lnaTs;dTs;lna NANO 15 05541 30444 OG vitro UGCCAU U Gs;dCs;lnaCs;dAs G :805L

5 1 U ;lnaTs;dGs;lnaCs; 15 dCs;lnaAs;dTs;ln aTs;dT-Sup

NANOG- 1.144 0.126 NAN in Hep3B 10 qRTPCR U UUGCCA dTs;lnaTs;dTs;lna NANO 15 75491 39541 OG vitro UGCCAU U Gs;dCs;lnaCs;dAs G :805L

2 U ;lnaTs;dGs;lnaCs; 15 dCs;lnaAs;dTs;ln aTs;dT-Sup

NANOG- 1.164 0.105 NAN in Hep3B 30 qRTPCR UUGAAAA dTs;lnaTs;dGs;ln NANO 16 00137 24044 OG vitro CUACUGA aAs;dAs;lnaAs;d G :1163

8 A As;lnaCs;dTs;lna L15

As;dCs;lnaTs;dGs

;lnaAs;dA-Sup

NANOG- 0.783 0.020 NAN in Hep3B 10 qRTPCR UUGAAAA dTs;lnaTs;dGs;ln NANO 16 75493 75812 OG vitro CUACUGA aAs;dAs;lnaAs;d G :1163

9 9 A As;lnaCs;dTs;lna L15

As;dCs;lnaTs;dGs

;lnaAs;dA-Sup

NANOG- 0.822 0.092 NAN in Hep3B 30 qRTPCR AU UCU UG dAs;lnaTs;dTs;ln NANO 17 54246 78917 OG vitro GUAAAG U aCs;dTs;lnaTs;dG G :1195

1 1 U s;lnaGs;dTs;lnaA L15 s;dAs;lnaAs;dGs;l naTs;dT-Sup

NANOG- 1.140 0.209 NAN in Hep3B 10 qRTPCR AU UCU UG dAs;lnaTs;dTs;ln NANO 17 92572 64007 OG vitro GUAAAG U aCs;dTs;lnaTs;dG G :1195

5 8 U s;lnaGs;dTs;lnaA L15 s;dAs;lnaAs;dGs;l naTs;dT-Sup

NANOG- 0.944 0.171 NAN in Hep3B 30 qRTPCR U UU UAAG dTs;lnaTs;dTs;lna NANO 18 53193 09292 OG vitro CUAU U UU Ts;dAs;lnaAs;dGs G :1233

5 1 A ;lnaCs;dTs;lnaAs; L15 dTs;lnaTs;dTs;lna Ts;dA-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

NANOG- 1.247 0.085 NAN in Hep3B 10 qRTPCR U UU UAAG dTs;lnaTs;dTs;lna NANO 18 56869 63565 OG vitro CUAU U UU Ts;dAs;lnaAs;dGs G :1233

6 2 A ;lnaCs;dTs;lnaAs; L15 dTs;lnaTs;dTs;lna Ts;dA-Sup

NANOG- 1.452 0.303 NAN in Hep3B 30 qRTPCR ACU UGAU dAs;lnaCs;dTs;ln NANO 19 01023 17547 OG vitro CUCAGGG aTs;dGs;lnaAs;dT G :1434

3 8 U s;lnaCs;dTs;lnaCs L15

;dAs;lnaGs;dGs;l naGs;dT-Sup

NANOG- 1.420 0.072 NAN in Hep3B 10 qRTPCR ACU UGAU dAs;lnaCs;dTs;ln NANO 19 05687 65037 OG vitro CUCAGGG aTs;dGs;lnaAs;dT G :1434

1 9 U s;lnaCs;dTs;lnaCs L15

;dAs;lnaGs;dGs;l naGs;dT-Sup

NANOG- 1.477 0.087 NAN in Hep3B 30 qRTPCR AGUAGU U dAs;lnaGs;dTs;ln NANO 20 17139 94810 OG vitro GGGAGGC aAs;dGs;lnaTs;dT G :1463

3 6 U s;lnaGs;dGs;lnaG L15 s;dAs;lnaGs;dGs;l naCs;dT-Sup

NANOG- 1.254 0.141 NAN in Hep3B 10 qRTPCR AGUAGU U dAs;lnaGs;dTs;ln NANO 20 11445 10088 OG vitro GGGAGGC aAs;dGs;lnaTs;dT G :1463

4 U s;lnaGs;dGs;lnaG L15 s;dAs;lnaGs;dGs;l naCs;dT-Sup

NANOG- 0.995 0.071 NAN in Hep3B 30 qRTPCR GGGCAUA dGs;lnaGs;dGs;ln NANO 21 61980 34220 OG vitro GUGACAC aCs;dAs;lnaTs;dA G :1491

5 7 A s;lnaGs;dTs;lnaG L15 s;dAs;lnaCs;dAs;l naCs;dA-Sup

NANOG- 0.848 0.086 NAN in Hep3B 10 qRTPCR GGGCAUA dGs;lnaGs;dGs;ln NANO 21 45503 33704 OG vitro GUGACAC aCs;dAs;lnaTs;dA G :1491

7 8 A s;lnaGs;dTs;lnaG L15 s;dAs;lnaCs;dAs;l naCs;dA-Sup

NANOG- 1.036 0.024 NAN in Hep3B 30 qRTPCR UAAU UU U dTs;lnaAs;dAs;ln NANO 22 46996 35961 OG vitro U UAAU UA aTs;dTs;lnaTs;dT G :1508

1 G s;lnaTs;dTs;lnaAs L15

;dAs;lnaTs;dTs;ln aAs;dG-Sup

NANOG- 0.829 0.109 NAN in Hep3B 10 qRTPCR UAAU UU U dTs;lnaAs;dAs;ln NANO 22 17701 95535 OG vitro U UAAU UA aTs;dTs;lnaTs;dT G :1508

7 9 G s;lnaTs;dTs;lnaAs L15

;dAs;lnaTs;dTs;ln aAs;dG-Sup

NANOG- 1.146 0.052 NAN in Hep3B 30 qRTPCR AGCUGAG dAs;lnaGs;dCs;ln NANO 23 51885 17763 OG vitro GU UCAGG aTs;dGs;lnaAs;d G :3792

9 9 A Gs;lnaGs;dTs;lna L15

Ts;dCs;lnaAs;dGs Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;lnaGs;dA-Sup

NANOG- 1.238 0.100 NAN in Hep3B 10 qRTPCR AGCUGAG dAs;lnaGs;dCs;ln NANO 23 96604 18695 OG vitro GU UCAGG aTs;dGs;lnaAs;d G :3792

7 5 A Gs;lnaGs;dTs;lna L15

Ts;dCs;lnaAs;dGs

;lnaGs;dA-Sup

NANOG- 1.045 0.072 NAN in Hep3B 30 qRTPCR GACAAAA dGs;lnaAs;dCs;ln NANO 24 27848 60045 OG vitro CAAGCCU aAs;dAs;lnaAs;d G :3816

A As;lnaCs;dAs;lna L15

As;dGs;lnaCs;dCs

;lnaTs;dA-Sup

NANOG- 0.851 0.106 NAN in Hep3B 10 qRTPCR GACAAAA dGs;lnaAs;dCs;ln NANO 24 59344 46071 OG vitro CAAGCCU aAs;dAs;lnaAs;d G :3816

4 8 A As;lnaCs;dAs;lna L15

As;dGs;lnaCs;dCs

;lnaTs;dA-Sup

NANOG- 0.998 0.206 NAN in Hep3B 30 qRTPCR UU UGU UC dTs;lnaTs;dTs;lna NANO 25 84904 76945 OG vitro ACCU UAU Gs;dTs;lnaTs;dCs G :3836

1 5 U ;lnaAs;dCs;lnaCs; L15 dTs;lnaTs;dAs;ln aTs;dT-Sup

NANOG- 0.951 0.048 NAN in Hep3B 10 qRTPCR UU UGU UC dTs;lnaTs;dTs;lna NANO 25 92089 32710 OG vitro ACCU UAU Gs;dTs;lnaTs;dCs G :3836

1 4 U ;lnaAs;dCs;lnaCs; L15 dTs;lnaTs;dAs;ln aTs;dT-Sup

NANOG- 1.586 0.637 NAN in Hep3B 30 qRTPCR AGUCCAA dAs;lnaGs;dTs;ln NANO 26 26851 41397 OG vitro U UU U UG aCs;dCs;lnaAs;dA G :3845

9 9 U U s;lnaTs;dTs;lnaTs L15

;dTs;lnaTs;dGs;ln aTs;dT-Sup

NANOG- 0.972 0.126 NAN in Hep3B 10 qRTPCR AGUCCAA dAs;lnaGs;dTs;ln NANO 26 90589 52689 OG vitro U UU U UG aCs;dCs;lnaAs;dA G :3845

8 5 U U s;lnaTs;dTs;lnaTs L15

;dTs;lnaTs;dGs;ln aTs;dT-Sup

NANOG- 1.831 0.712 NAN in Hep3B 30 qRTPCR ACAGAGG dAs;lnaCs;dAs;ln NANO 27 81357 19342 OG vitro UCU UAGC aGs;dAs;lnaGs;d G :3869

4 2 C Gs;lnaTs;dCs;lna L15

Ts;dTs;lnaAs;dGs

;lnaCs;dC-Sup

NANOG- 1.291 0.224 NAN in Hep3B 10 qRTPCR ACAGAGG dAs;lnaCs;dAs;ln NANO 27 40979 17730 OG vitro UCU UAGC aGs;dAs;lnaGs;d G :3869

5 5 C Gs;lnaTs;dCs;lna L15

Ts;dTs;lnaAs;dGs

;lnaCs;dC-Sup

NANOG- 1.366 0.428 NAN in Hep3B 30 qRTPCR AAAUACA dAs;lnaAs;dAs;ln NANO 28 38332 87920 OG vitro AAAAAUU aTs;dAs;lnaCs;dA G :4840

9 4 A s;lnaAs;dAs;lnaA L15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;dAs;lnaAs;dTs;l naTs;dA-Sup

NANOG- 1.297 0.254 NAN in Hep3B 10 qRTPCR AAAUACA dAs;lnaAs;dAs;ln NANO 28 82474 82482 OG vitro AAAAAUU aTs;dAs;lnaCs;dA G :4840

5 4 A s;lnaAs;dAs;lnaA L15 s;dAs;lnaAs;dTs;l naTs;dA-Sup

NANOG- 1.170 0.541 NAN in Hep3B 30 qRTPCR AGGCUAG dAs;lnaGs;dGs;ln NANO 29 76145 13903 OG vitro CCAACAU aCs;dTs;lnaAs;dG G :4875

5 9 G s;lnaCs;dCs;lnaAs L15

;dAs;lnaCs;dAs;ln aTs;dG-Sup

NANOG- 0.986 0.187 NAN in Hep3B 10 qRTPCR AGGCUAG dAs;lnaGs;dGs;ln NANO 29 83239 02160 OG vitro CCAACAU aCs;dTs;lnaAs;dG G :4875

2 7 G s;lnaCs;dCs;lnaAs L15

;dAs;lnaCs;dAs;ln aTs;dG-Sup

NANOG- 0.899 0.250 NAN in Hep3B 30 qRTPCR AAU U UAC dAs;lnaAs;dTs;ln NANO 30 03751 44105 OG vitro U UACAUA aTs;dTs;lnaAs;dC G :7087

4 5 U s;lnaTs;dTs;lnaAs L15

;dCs;lnaAs;dTs;ln aAs;dT-Sup

NANOG- 0.776 0.021 NAN in Hep3B 10 qRTPCR AAU U UAC dAs;lnaAs;dTs;ln NANO 30 39182 37680 OG vitro U UACAUA aTs;dTs;lnaAs;dC G :7087

5 U s;lnaTs;dTs;lnaAs L15

;dCs;lnaAs;dTs;ln aAs;dT-Sup

RBl-01 1.014 0.018 RBI in Hep3B 100 qRTPCR GAAGCCG omeGs;omeAs;o RB1:24

15747 11346 vitro GAAAAGU meAs;omeGs;om 771L20 4 3 CGCAAU eCs;omeCs;ome

Gs;omeGs;omeA s;omeAs;omeAs;

omeAs;omeGs;o meUs;omeCs;om eGs;omeCs;ome

As;omeAs;omeU

-Sup

RBl-01 2.057 0.044 RBI in Hep3B 50 qRTPCR GAAGCCG omeGs;omeAs;o RB1:24

47534 98680 vitro GAAAAGU meAs;omeGs;om 771L20 8 6 CGCAAU eCs;omeCs;ome

Gs;omeGs;omeA s;omeAs;omeAs;

omeAs;omeGs;o meUs;omeCs;om eGs;omeCs;ome

As;omeAs;omeU

-Sup

RB1-02 1.217 0.053 RBI in Hep3B 100 qRTPCR AGAAGCC omeAs;omeGs;o RB1:24

41130 65028 vitro GGAAAAG meAs;omeAs;om 772L20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

7 8 UCGCAA eGs;omeCs;ome

Cs;omeGs;omeG s;omeAs;omeAs;

omeAs;omeAs;o meGs;omeUs;o meCs;omeGs;om eCs;omeAs;ome

A-Sup

RB1-02 3.040 0.058 RBI in Hep3B 50 qRTPCR AGAAGCC omeAs;omeGs;o RB1:24

69006 87884 vitro GGAAAAG meAs;omeAs;om 772L20 1 5 UCGCAA eGs;omeCs;ome

Cs;omeGs;omeG s;omeAs;omeAs;

omeAs;omeAs;o meGs;omeUs;o meCs;omeGs;om eCs;omeAs;ome

A-Sup

RB1-03 1.128 0.048 RBI in Hep3B 100 qRTPCR GAGAAGC omeGs;omeAs;o RB1:24

52579 33813 vitro CGGAAAA meGs;omeAs;om 773L20 6 4 GUCGCA eAs;omeGs;ome

Cs;omeCs;omeG s;omeGs;omeAs;

omeAs;omeAs;o meAs;omeGs;om eUs;omeCs;ome

Gs;omeCs;omeA-

Sup

RB1-03 3.264 0.083 RBI in Hep3B 50 qRTPCR GAGAAGC omeGs;omeAs;o RB1:24

29624 02377 vitro CGGAAAA meGs;omeAs;om 773L20 9 GUCGCA eAs;omeGs;ome

Cs;omeCs;omeG s;omeGs;omeAs;

omeAs;omeAs;o meAs;omeGs;om eUs;omeCs;ome

Gs;omeCs;omeA-

Sup

RB1-04 0.939 0.050 RBI in Hep3B 100 qRTPCR GGAGAAG omeGs;omeGs;o RB1:24

18583 18126 vitro CCGGAAA meAs;omeGs;om 774L20

2 AGUCGC eAs;omeAs;ome

Gs;omeCs;omeC s;omeGs;omeGs;

omeAs;omeAs;o meAs;omeAs;om eGs;omeUs;ome

Cs;omeGs;omeC-

Sup

RB1-04 1.383 0.005 RBI in Hep3B 50 qRTPCR GGAGAAG omeGs;omeGs;o RB1:24 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

39373 76832 vitro CCGGAAA meAs;omeGs;om 774L20

9 AGUCGC eAs;omeAs;ome

Gs;omeCs;omeC s;omeGs;omeGs;

omeAs;omeAs;o meAs;omeAs;om eGs;omeUs;ome

Cs;omeGs;omeC-

Sup

RB1-05 0.965 0.062 RBI in Hep3B 100 qRTPCR AGGAGAA omeAs;omeGs;o RB1:24

30271 93715 vitro GCCGGAA meGs;omeAs;om 775L20

8 5 AAGUCG eGs;omeAs;ome

As;omeGs;omeC s;omeCs;omeGs;

omeGs;omeAs;o meAs;omeAs;om eAs;omeGs;ome

Us;omeCs;omeG

-Sup

RB1-05 1.945 0.103 RBI in Hep3B 50 qRTPCR AGGAGAA omeAs;omeGs;o RB1:24

22207 20096 vitro GCCGGAA meGs;omeAs;om 775L20

7 9 AAGUCG eGs;omeAs;ome

As;omeGs;omeC s;omeCs;omeGs;

omeGs;omeAs;o meAs;omeAs;om eAs;omeGs;ome

Us;omeCs;omeG

-Sup

RB1-06 1.189 0.028 RBI in Hep3B 100 qRTPCR GAGGAGA omeGs;omeAs;o RB1:24

73500 47106 vitro AGCCGGA meGs;omeGs;o 776L20

5 2 AAAGUC meAs;omeGs;om

eAs;omeAs;ome

Gs;omeCs;omeC s;omeGs;omeGs;

omeAs;omeAs;o meAs;omeAs;om eGs;omeUs;ome

C-Sup

RB1-06 4.164 0.316 RBI in Hep3B 50 qRTPCR GAGGAGA omeGs;omeAs;o RB1:24

26902 37978 vitro AGCCGGA meGs;omeGs;o 776L20

6 9 AAAGUC meAs;omeGs;om

eAs;omeAs;ome

Gs;omeCs;omeC s;omeGs;omeGs;

omeAs;omeAs;o meAs;omeAs;om eGs;omeUs;ome

C-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

RB1-07 1.022 0.031 RBI in Hep3B 100 qRTPCR AGAGGAG omeAs;omeGs;o RB1:24

18569 91055 vitro AAGCCGG meAs;omeGs;om 777L20

5 1 AAAAGU eGs;omeAs;ome

Gs;omeAs;omeA s;omeGs;omeCs;

omeCs;omeGs;o meGs;omeAs;om eAs;omeAs;ome

As;omeGs;omeU

-Sup

RB1-07 1.572 0.055 RBI in Hep3B 50 qRTPCR AGAGGAG omeAs;omeGs;o RB1:24

79286 43016 vitro AAGCCGG meAs;omeGs;om 777L20

6 4 AAAAGU eGs;omeAs;ome

Gs;omeAs;omeA s;omeGs;omeCs;

omeCs;omeGs;o meGs;omeAs;om eAs;omeAs;ome

As;omeGs;omeU

-Sup

RB1-08 0.915 0.139 RBI in Hep3B 100 qRTPCR GAGAGGA omeGs;omeAs;o RB1:24

67427 66390 vitro GAAGCCG meGs;omeAs;om 778L20

5 6 GAAAAG eGs;omeGs;ome

As;omeGs;omeA s;omeAs;omeGs;

omeCs;omeCs;o meGs;omeGs;o meAs;omeAs;om eAs;omeAs;ome

G-Sup

RB1-08 1.480 0.049 RBI in Hep3B 50 qRTPCR GAGAGGA omeGs;omeAs;o RB1:24

16406 03435 vitro GAAGCCG meGs;omeAs;om 778L20

2 3 GAAAAG eGs;omeGs;ome

As;omeGs;omeA s;omeAs;omeGs;

omeCs;omeCs;o meGs;omeGs;o meAs;omeAs;om eAs;omeAs;ome

G-Sup

RB1-09 0.798 0.128 RBI in Hep3B 100 qRTPCR GGAGAGG omeGs;omeGs;o RB1:24

69935 61035 vitro AGAAGCC meAs;omeGs;om 779L20

8 7 GGAAAA eAs;omeGs;ome

Gs;omeAs;omeG s;omeAs;omeAs;

omeGs;omeCs;o meCs;omeGs;om eGs;omeAs;ome

As;omeAs;omeA- Oligo I RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

Sup

RB1-09 1.548 0.026 RBI in Hep3B 50 qRTPCR GGAGAGG omeGs;omeGs;o RB1:24

21070 11322 vitro AGAAGCC meAs;omeGs;om 779L20 2 5 GGAAAA eAs;omeGs;ome

Gs;omeAs;omeG s;omeAs;omeAs;

omeGs;omeCs;o meCs;omeGs;om eGs;omeAs;ome

As;omeAs;omeA-

Sup

RBI- 10 1.017 0.097 RBI in Hep3B 100 qRTPCR GGAAAUG omeGs;omeGs;o RB1:24

98348 76230 vitro GCUGAUG meAs;omeAs;om 801L20 3 3 GGAAGG eAs;omeUs;ome

Gs;omeGs;omeC s;omeUs;omeGs;

omeAs;omeUs;o meGs;omeGs;o meGs;omeAs;om eAs;omeGs;ome

G-Sup

RBl-10 1.034 0.030 RBI in Hep3B 50 qRTPCR GGAAAUG omeGs;omeGs;o RB1:24

86083 40321 vitro GCUGAUG meAs;omeAs;om 801L20 2 7 GGAAGG eAs;omeUs;ome

Gs;omeGs;omeC s;omeUs;omeGs;

omeAs;omeUs;o meGs;omeGs;o meGs;omeAs;om eAs;omeGs;ome

G-Sup

RBl-11 1.397 0.270 RBI in Hep3B 100 qRTPCR UUAAAAA omeUs;omeUs;o RB1:24

80367 76008 vitro AACAAUG meAs;omeAs;om 822L20 5 1 CGGCGG eAs;omeAs;ome

As;omeAs;omeA s;omeCs;omeAs;

omeAs;omeUs;o meGs;omeCs;om eGs;omeGs;ome

Cs;omeGs;omeG

-Sup

RBl-11 3.934 0.100 RBI in Hep3B 50 qRTPCR UUAAAAA omeUs;omeUs;o RB1:24

37133 28619 vitro AACAAUG meAs;omeAs;om 822L20 9 8 CGGCGG eAs;omeAs;ome

As;omeAs;omeA s;omeCs;omeAs;

omeAs;omeUs;o meGs;omeCs;om eGs;omeGs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

Cs;omeGs;omeG

-Sup

RB1-12 1.651 0.496 RBI in Hep3B 100 qRTPCR CUUAAAA omeCs;omeUs;o RB1:24

46050 27675 vitro AAACAAU meUs;omeAs;om 823L20 7 7 GCGGCG eAs;omeAs;ome

As;omeAs;omeA s;omeAs;omeCs;

omeAs;omeAs;o meUs;omeGs;o meCs;omeGs;om eGs;omeCs;ome

G-Sup

RB1-12 3.925 0.195 RBI in Hep3B 50 qRTPCR CUUAAAA omeCs;omeUs;o RB1:24

4789 14847 vitro AAACAAU meUs;omeAs;om 823L20

1 GCGGCG eAs;omeAs;ome

As;omeAs;omeA s;omeAs;omeCs;

omeAs;omeAs;o meUs;omeGs;o meCs;omeGs;om eGs;omeCs;ome

G-Sup

RB1-13 3.091 0.155 RBI in Hep3B 100 qRTPCR UCU UAAA omeUs;omeCs;o RB1:24

22625 43262 vitro AAAACAA meUs;omeUs;o 824L20

1 UGCGGC meAs;omeAs;om

eAs;omeAs;ome

As;omeAs;omeA s;omeCs;omeAs;

omeAs;omeUs;o meGs;omeCs;om eGs;omeGs;ome

C-Sup

RB1-13 4.139 0.168 RBI in Hep3B 50 qRTPCR UCU UAAA omeUs;omeCs;o RB1:24

82018 69847 vitro AAAACAA meUs;omeUs;o 824L20 2 1 UGCGGC meAs;omeAs;om

eAs;omeAs;ome

As;omeAs;omeA s;omeCs;omeAs;

omeAs;omeUs;o meGs;omeCs;om eGs;omeGs;ome

C-Sup

RB1-14 2.661 0.308 RBI in Hep3B 100 qRTPCR AUCU UAA omeAs;omeUs;o RB1:24

21579 58636 vitro AAAAACA meCs;omeUs;om 825L20 5 3 AUGCGG eUs;omeAs;ome

As;omeAs;omeA s;omeAs;omeAs;

omeAs;omeCs;o meAs;omeAs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eUs;omeGs;ome Cs;omeGs;omeG

-Sup

RB1-14 3.360 0.134 RBI in Hep3B 50 qRTPCR AUCU UAA omeAs;omeUs;o RB1:24

76065 12034 vitro AAAAACA meCs;omeUs;om 825L20 5 6 AUGCGG eUs;omeAs;ome

As;omeAs;omeA s;omeAs;omeAs;

omeAs;omeCs;o meAs;omeAs;om eUs;omeGs;ome

Cs;omeGs;omeG

-Sup

RB1-15 2.978 0.333 RBI in Hep3B 100 qRTPCR AAUCUUA omeAs;omeAs;o RB1:24

42120 09652 vitro AAAAAAC meUs;omeCs;om 826L20 7 9 AAUGCG eUs;omeUs;ome

As;omeAs;omeA s;omeAs;omeAs;

omeAs;omeAs;o meCs;omeAs;om eAs;omeUs;ome

Gs;omeCs;omeG

-Sup

RB1-15 3.751 0.352 RBI in Hep3B 50 qRTPCR AAUCU UA omeAs;omeAs;o RB1:24

74300 86687 vitro AAAAAAC meUs;omeCs;om 826L20 9 1 AAUGCG eUs;omeUs;ome

As;omeAs;omeA s;omeAs;omeAs;

omeAs;omeAs;o meCs;omeAs;om eAs;omeUs;ome

Gs;omeCs;omeG

-Sup

RB1-16 5.022 1.125 RBI in Hep3B 100 qRTPCR AAAUCU U omeAs;omeAs;o RB1:24

22646 45155 vitro AAAAAAA meAs;omeUs;om 827L20 2 5 CAAUGC eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeAs;

omeAs;omeAs;o meAs;omeCs;om eAs;omeAs;ome

Us;omeGs;omeC

-Sup

RB1-16 4.995 0.307 RBI in Hep3B 50 qRTPCR AAAUCU U omeAs;omeAs;o RB1:24

12098 24072 vitro AAAAAAA meAs;omeUs;om 827L20

8 CAAUGC eCs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeAs;

omeAs;omeAs;o Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

meAs;omeCs;om eAs;omeAs;ome

Us;omeGs;omeC -Sup

RB1-17 4.098 0.193 RBI in Hep3B 100 qRTPCR GAAAUCU omeGs;omeAs;o RB1:24

24434 24185 vitro UAAAAAA meAs;omeAs;om 828L20 2 5 ACAAUG eUs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeAs;omeAs;o meAs;omeAs;om eCs;omeAs;ome

As;omeUs;omeG

-Sup

RB1-17 4.916 0.124 RBI in Hep3B 50 qRTPCR GAAAUCU omeGs;omeAs;o RB1:24

98834 65828 vitro UAAAAAA meAs;omeAs;om 828L20

6 ACAAUG eUs;omeCs;ome

Us;omeUs;omeA s;omeAs;omeAs;

omeAs;omeAs;o meAs;omeAs;om eCs;omeAs;ome

As;omeUs;omeG

-Sup

SERPI N F1- 0.350 0.043 SERPI in RPTEC 30 qRTPCR GU UCUGG dGs;lnaTs;dTs;ln SERPI N 01 37919 15007 N F1 vitro CAGCUGC aCs;dTs;lnaGs;d Fl:499

1 8 U Gs;lnaCs;dAs;lna 5L15

Gs;dCs;lnaTs;dGs

;lnaCs;dT-Sup

SERPI N F1- 0.858 0.212 SERPI in RPTEC 10 qRTPCR GU UCUGG dGs;lnaTs;dTs;ln SERPI N 01 66303 00142 N F1 vitro CAGCUGC aCs;dTs;lnaGs;d Fl:499

4 5 U Gs;lnaCs;dAs;lna 5L15

Gs;dCs;lnaTs;dGs

;lnaCs;dT-Sup

SERPI N F1- NA NA SERPI NA NA 0 NA uccuuuc dTs;lnaCs;dCs;ln SERPI N 02 N F1 U UCAAAG aTs;dTs;lnaTs;dC Fl:793

U s;lnaTs;dTs;lnaCs 5U15

;dAs;lnaAs;dAs;ln aGs;dT-Sup

SERPI N F1- 0.358 0.030 SERPI in RPTEC 30 qRTPCR UGCGAUC dTs;lnaGs;dCs;ln SERPI N 03 59684 90502 N F1 vitro CAGCACG aGs;dAs;lnaTs;dC F 1:800

6 4 A s;lnaCs;dAs;lnaG 6U15 s;dCs;lnaAs;dCs;l naGs;dA-Sup

SERPI N F1- 0.541 0.103 SERPI in RPTEC 10 qRTPCR UGCGAUC dTs;lnaGs;dCs;ln SERPI N 03 85821 19841 N F1 vitro CAGCACG aGs;dAs;lnaTs;dC F 1:800

4 7 A s;lnaCs;dAs;lnaG 6U15 s;dCs;lnaAs;dCs;l naGs;dA-Sup Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

SERPINF1- 0.497 0.138 SERPI in RPTEC 30 qRTPCR ACGACCA dAs;lnaCs;dGs;ln SERPIN 04 08703 01137 NF1 vitro ACGUGCU aAs;dCs;lnaCs;dA Fl:802

9 3 C s;lnaAs;dCs;lnaG 6U15 s;dTs;lnaGs;dCs;l naTs;dC-Sup

SERPINF1- 0.654 0.104 SERPI in RPTEC 10 qRTPCR ACGACCA dAs;lnaCs;dGs;ln SERPIN 04 87941 09567 NF1 vitro ACGUGCU aAs;dCs;lnaCs;dA Fl:802

4 4 C s;lnaAs;dCs;lnaG 6U15 s;dTs;lnaGs;dCs;l naTs;dC-Sup

SERPINF1- NA NA SERPI NA NA 0 NA UCAAGUC dTs;lnaCs;dAs;ln SERPIN 05 NF1 AUAGUAG aAs;dGs;lnaTs;dC Fl:910

A s;lnaAs;dTs;lnaAs 4L15

;dGs;lnaTs;dAs;ln aGs;dA-Sup

SERPINF1- 0.387 0.059 SERPI in RPTEC 30 qRTPCR UAUAGGU dTs;lnaAs;dTs;ln SERPIN 06 84459 59732 NF1 vitro ACCAUGG aAs;dGs;lnaGs;d Fl:913

8 8 A Ts;lnaAs;dCs;lna 4L15

Cs;dAs;lnaTs;dGs

;lnaGs;dA-Sup

SERPINF1- 0.541 0.059 SERPI in RPTEC 10 qRTPCR UAUAGGU dTs;lnaAs;dTs;ln SERPIN 06 14896 37123 NF1 vitro ACCAUGG aAs;dGs;lnaGs;d Fl:913

4 7 A Ts;lnaAs;dCs;lna 4L15

Cs;dAs;lnaTs;dGs

;lnaGs;dA-Sup

SERPINF1- 0.411 0.070 SERPI in RPTEC 30 qRTPCR CCGUGUC dCs;lnaCs;dGs;ln SERPIN 07 44306 02294 NF1 vitro AAGGAGC aTs;dGs;lnaTs;dC Fl:915

6 3 U s;lnaAs;dAs;lnaG 2L15 s;dGs;lnaAs;dGs;l naCs;dT-Sup

SERPINF1- 2.115 0.945 SERPI in RPTEC 10 qRTPCR CCGUGUC dCs;lnaCs;dGs;ln SERPIN 07 55698 93377 NF1 vitro AAGGAGC aTs;dGs;lnaTs;dC Fl:915

1 2 U s;lnaAs;dAs;lnaG 2L15 s;dGs;lnaAs;dGs;l naCs;dT-Sup

SERPINF1- 0.565 0.023 SERPI in RPTEC 30 qRTPCR ACAUCCA dAs;lnaCs;dAs;ln SERPIN 08 86554 30322 NF1 vitro UGGUACC aTs;dCs;lnaCs;dA Fl:913

5 7 U s;lnaTs;dGs;lnaG 1U15 s;dTs;lnaAs;dCs;l naCs;dT-Sup

SERPINF1- 1.359 0.281 SERPI in RPTEC 10 qRTPCR ACAUCCA dAs;lnaCs;dAs;ln SERPIN 08 59162 48327 NF1 vitro UGGUACC aTs;dCs;lnaCs;dA Fl:913

2 U s;lnaTs;dGs;lnaG 1U15 s;dTs;lnaAs;dCs;l naCs;dT-Sup

SERPINF1- 0.644 0.185 SERPI in RPTEC 30 qRTPCR UACCUAU dTs;lnaAs;dCs;ln SERPIN 09 49533 22675 NF1 vitro AAGGAGC aCs;dTs;lnaAs;dT Fl:914

7 U s;lnaAs;dAs;lnaG 1U15 s;dGs;lnaAs;dGs;l Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

naCs;dT-Sup

SERPINF1- 0.953 0.007 SERPI in RPTEC 10 qRTPCR UACCUAU dTs;lnaAs;dCs;ln SERPIN 09 35429 179 NF1 vitro AAGGAGC aCs;dTs;lnaAs;dT Fl:914

7 U s;lnaAs;dAs;lnaG 1U15 s;dGs;lnaAs;dGs;l naCs;dT-Sup

SERPINF1- 0.824 0.146 SERPI in RPTEC 30 qRTPCR AGCUCCU dAs;lnaGs;dCs;ln SERPIN 10 99290 71163 NF1 vitro UGACACG aTs;dCs;lnaCs;dT Fl:915

6 2 G s;lnaTs;dGs;lnaA 2U15 s;dCs;lnaAs;dCs;l naGs;dG-Sup

SERPINF1- 0.614 NA SERPI in RPTEC 10 qRTPCR AGCUCCU dAs;lnaGs;dCs;ln SERPIN 10 24739 NF1 vitro UGACACG aTs;dCs;lnaCs;dT Fl:915

2 G s;lnaTs;dGs;lnaA 2U15 s;dCs;lnaAs;dCs;l naGs;dG-Sup

SERPINF1- 0.409 0.069 SERPI in RPTEC 30 qRTPCR UUUCCAG dTs;lnaTs;dTs;lna SERPIN 11 94661 07295 NF1 vitro AGGAGCC Cs;dCs;lnaAs;dGs Fl:993

9 9 A ;lnaAs;dGs;lnaGs 2L15

;dAs;lnaGs;dCs;l naCs;dA-Sup

SERPINF1- 1.047 0.658 SERPI in RPTEC 10 qRTPCR UUUCCAG dTs;lnaTs;dTs;lna SERPIN 11 72541 53261 NF1 vitro AGGAGCC Cs;dCs;lnaAs;dGs Fl:993

1 8 A ;lnaAs;dGs;lnaGs 2L15

;dAs;lnaGs;dCs;l naCs;dA-Sup

SERPINF1- 0.470 0.185 SERPI in RPTEC 30 qRTPCR UGGUCCC dTs;lnaGs;dGs;ln SERPIN 12 34132 34670 NF1 vitro AUAUGAC aTs;dCs;lnaCs;dC Fl:994

2 9 U s;lnaAs;dTs;lnaAs 7L15

;dTs;lnaGs;dAs;ln aCs;dT-Sup

SERPINF1- 1.134 0.320 SERPI in RPTEC 10 qRTPCR UGGUCCC dTs;lnaGs;dGs;ln SERPIN 12 54179 17110 NF1 vitro AUAUGAC aTs;dCs;lnaCs;dC Fl:994

2 1 U s;lnaAs;dTs;lnaAs 7L15

;dTs;lnaGs;dAs;ln aCs;dT-Sup

SERPINF1- 0.880 0.090 SERPI in RPTEC 30 qRTPCR GAGGGUU dGs;lnaAs;dGs;ln SERPIN 13 66316 97602 NF1 vitro GCCCGUC aGs;dGs;lnaTs;dT Fl:997

8 8 A s;lnaGs;dCs;lnaC 4L15 s;dCs;lnaGs;dTs;l naCs;dA-Sup

SERPINF1- 0.678 0.089 SERPI in RPTEC 10 qRTPCR GAGGGUU dGs;lnaAs;dGs;ln SERPIN 13 38809 75099 NF1 vitro GCCCGUC aGs;dGs;lnaTs;dT Fl:997

8 A s;lnaGs;dCs;lnaC 4L15 s;dCs;lnaGs;dTs;l naCs;dA-Sup

SERPINF1- 0.620 0.173 SERPI in RPTEC 30 qRTPCR AGAGAUC dAs;lnaGs;dAs;ln SERPIN 14 12298 57326 NF1 vitro AACAACU aGs;dAs;lnaTs;dC Fl:100

8 G s;lnaAs;dAs;lnaC 02U15 Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;dAs;lnaAs;dCs;l naTs;dG-Sup

SERPINF1- 0.568 0.044 SERPI in RPTEC 10 qRTPCR AGAGAUC dAs;lnaGs;dAs;ln SERPIN 14 60089 19262 NF1 vitro AACAACU aGs;dAs;lnaTs;dC Fl:100

1 9 G s;lnaAs;dAs;lnaC 02U15 s;dAs;lnaAs;dCs;l naTs;dG-Sup

SERPINF1- 0.600 0.014 SERPI in RPTEC 30 qRTPCR AGGCCCA dAs;lnaGs;dGs;ln SERPIN 15 64516 87194 NF1 vitro GAGUCCU aCs;dCs;lnaCs;dA Fl:996

7 7 G s;lnaGs;dAs;lnaG 1U15 s;dTs;lnaCs;dCs;l naTs;dG-Sup

SERPINF1- 0.866 0.141 SERPI in RPTEC 10 qRTPCR AGGCCCA dAs;lnaGs;dGs;ln SERPIN 15 54473 96625 NF1 vitro GAGUCCU aCs;dCs;lnaCs;dA Fl:996

4 8 G s;lnaGs;dAs;lnaG 1U15 s;dTs;lnaCs;dCs;l naTs;dG-Sup

SERPINF1- 0.334 0.047 SERPI in RPTEC 30 qRTPCR GAAGGAG dGs;lnaAs;dAs;ln SERPIN 16 8382 94109 NF1 vitro AAUGCUG aGs;dGs;lnaAs;d Fl:100

3 A Gs;lnaAs;dAs;lna 76L15

Ts;dGs;lnaCs;dTs ;lnaGs;dA-Sup

SERPINF1- 0.880 0.179 SERPI in RPTEC 10 qRTPCR GAAGGAG dGs;lnaAs;dAs;ln SERPIN 16 12864 23252 NF1 vitro AAUGCUG aGs;dGs;lnaAs;d Fl:100

9 4 A Gs;lnaAs;dAs;lna 76L15

Ts;dGs;lnaCs;dTs ;lnaGs;dA-Sup

SERPINF1- 0.802 0.226 SERPI in RPTEC 30 qRTPCR AUCCUCG dAs;lnaTs;dCs;ln SERPIN 17 26894 58796 NF1 vitro AGGGAAG aCs;dTs;lnaCs;dG Fl:131

1 1 U s;lnaAs;dGs;lnaG 26L15 s;dGs;lnaAs;dAs;l naGs;dT-Sup

SERPINF1- 1.117 0.148 SERPI in RPTEC 10 qRTPCR AUCCUCG dAs;lnaTs;dCs;ln SERPIN 17 38298 91209 NF1 vitro AGGGAAG aCs;dTs;lnaCs;dG Fl:131

9 9 U s;lnaAs;dGs;lnaG 26L15 s;dGs;lnaAs;dAs;l naGs;dT-Sup

SERPINF1- 0.288 0.011 SERPI in RPTEC 30 qRTPCR AUGAAGA dAs;lnaTs;dGs;ln SERPIN 18 65991 89068 NF1 vitro GAGGACC aAs;dAs;lnaGs;d Fl:131

5 2 G As;lnaGs;dAs;lna 51U15

Gs;dGs;lnaAs;dC s;lnaCs;dG-Sup

SERPINF1- 0.814 NA SERPI in RPTEC 10 qRTPCR AUGAAGA dAs;lnaTs;dGs;ln SERPIN 18 25828 NF1 vitro GAGGACC aAs;dAs;lnaGs;d Fl:131

4 G As;lnaGs;dAs;lna 51U15

Gs;dGs;lnaAs;dC s;lnaCs;dG-Sup

SERPINF1- 0.162 0.022 SERPI in RPTEC 30 qRTPCR UGAAUCC dTs;lnaGs;dAs;ln SERPIN 19 24040 00750 NF1 vitro AAGCCAU aAs;dTs;lnaCs;dC Fl:132 Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

9 3 A s;lnaAs;dAs;lnaG 07L15 s;dCs;lnaCs;dAs;l naTs;dA-Sup

SERPINF1- 0.575 0.094 SERPI in RPTEC 10 qRTPCR UGAAUCC dTs;lnaGs;dAs;ln SERPIN 19 95487 57945 NF1 vitro AAGCCAU aAs;dTs;lnaCs;dC Fl:132

7 4 A s;lnaAs;dAs;lnaG 07L15 s;dCs;lnaCs;dAs;l naTs;dA-Sup

SERPINF1- 0.364 0.018 SERPI in RPTEC 30 qRTPCR AGAGAGA dAs;lnaGs;dAs;ln SERPIN 20 76018 84390 NF1 vitro UCCGUGU aGs;dAs;lnaGs;d Fl:139

8 7 G As;lnaTs;dCs;lna 57L15

Cs;dGs;lnaTs;dGs

;lnaTs;dG-Sup

SERPINF1- 0.725 0.064 SERPI in RPTEC 10 qRTPCR AGAGAGA dAs;lnaGs;dAs;ln SERPIN 20 18134 49009 NF1 vitro UCCGUGU aGs;dAs;lnaGs;d Fl:139

4 3 G As;lnaTs;dCs;lna 57L15

Cs;dGs;lnaTs;dGs

;lnaTs;dG-Sup

SERPINF1- 0.218 0.020 SERPI in RPTEC 30 qRTPCR AUUCUGG dAs;lnaTs;dTs;ln SERPIN 21 82334 38758 NF1 vitro GUCACUU aCs;dTs;lnaGs;d Fl:146

2 1 U Gs;lnaGs;dTs;lna 22L15

Cs;dAs;lnaCs;dTs

;lnaTs;dT-Sup

SERPINF1- 0.896 0.175 SERPI in RPTEC 10 qRTPCR AUUCUGG dAs;lnaTs;dTs;ln SERPIN 21 12716 14593 NF1 vitro GUCACUU aCs;dTs;lnaGs;d Fl:146

3 8 U Gs;lnaGs;dTs;lna 22L15

Cs;dAs;lnaCs;dTs

;lnaTs;dT-Sup

SERPINF1- 0.472 0.045 SERPI in RPTEC 30 qRTPCR UGAGGCU dTs;lnaGs;dAs;ln SERPIN 22 8922 18040 NF1 vitro CUCCUCU aGs;dGs;lnaCs;d Fl:146

6 A Ts;lnaCs;dTs;lnaC 47L15 s;dCs;lnaTs;dCs;l naTs;dA-Sup

SERPINF1- 1.062 0.243 SERPI in RPTEC 10 qRTPCR UGAGGCU dTs;lnaGs;dAs;ln SERPIN 22 90928 85602 NF1 vitro CUCCUCU aGs;dGs;lnaCs;d Fl:146

7 5 A Ts;lnaCs;dTs;lnaC 47L15 s;dCs;lnaTs;dCs;l naTs;dA-Sup

SERPINF1- 0.707 0.099 SERPI in RPTEC 30 qRTPCR AAAGUGA dAs;lnaAs;dAs;ln SERPIN 23 25381 02883 NF1 vitro CCCAGAA aGs;dTs;lnaGs;d Fl:146

1 5 U As;lnaCs;dCs;lna 22U15

Cs;dAs;lnaGs;dAs

;lnaAs;dT-Sup

SERPINF1- 0.670 0.002 SERPI in RPTEC 10 qRTPCR AAAGUGA dAs;lnaAs;dAs;ln SERPIN 23 93739 79028 NF1 vitro CCCAGAA aGs;dTs;lnaGs;d Fl:146

9 5 U As;lnaCs;dCs;lna 22U15

Cs;dAs;lnaGs;dAs

;lnaAs;dT-Sup

SERPINF1- 0.476 0.100 SERPI in RPTEC 30 qRTPCR AAUUUGA dAs;lnaAs;dTs;ln SERPIN Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

24 83893 91885 NF1 vitro CCUUGAU aTs;dTs;lnaGs;dA Fl:146

1 5 A s;lnaCs;dCs;lnaTs 34U15

;dTs;lnaGs;dAs;ln aTs;dA-Sup

SERPINF1- 0.723 0.197 SERPI in RPTEC 10 qRTPCR AAUUUGA dAs;lnaAs;dTs;ln SERPIN 24 45536 23274 NF1 vitro CCUUGAU aTs;dTs;lnaGs;dA Fl:146

1 6 A s;lnaCs;dCs;lnaTs 34U15

;dTs;lnaGs;dAs;ln aTs;dA-Sup

SERPINF1- 0.506 0.061 SERPI in RPTEC 30 qRTPCR CCAAGGG dCs;lnaCs;dAs;ln SERPIN 25 78877 79406 NF1 vitro AUCCCUU aAs;dGs;lnaGs;d Fl:151

6 2 U Gs;lnaAs;dTs;lna 54L15

Cs;dCs;lnaCs;dTs;

lnaTs;dT-Sup

SERPINF1- 0.508 0.072 SERPI in RPTEC 10 qRTPCR CCAAGGG dCs;lnaCs;dAs;ln SERPIN 25 69427 06558 NF1 vitro AUCCCUU aAs;dGs;lnaGs;d Fl:151

3 U Gs;lnaAs;dTs;lna 54L15

Cs;dCs;lnaCs;dTs;

lnaTs;dT-Sup

SERPINF1- 0.635 0.205 SERPI in RPTEC 30 qRTPCR GAUCCCU dGs;lnaAs;dTs;ln SERPIN 26 94990 17963 NF1 vitro UGGUUGG aCs;dCs;lnaCs;dT Fl:151

2 9 G s;lnaTs;dGs;lnaG 59U15 s;dTs;lnaTs;dGs;l naGs;dG-Sup

SERPINF1- 0.981 0.174 SERPI in RPTEC 10 qRTPCR GAUCCCU dGs;lnaAs;dTs;ln SERPIN 26 04913 40640 NF1 vitro UGGUUGG aCs;dCs;lnaCs;dT Fl:151

2 G s;lnaTs;dGs;lnaG 59U15 s;dTs;lnaTs;dGs;l naGs;dG-Sup

SERPINF1- 0.258 0.037 SERPI in RPTEC 30 qRTPCR UUAAGGU dTs;lnaTs;dAs;ln SERPIN 27 29413 95145 NF1 vitro GAUAGUC aAs;dGs;lnaGs;d Fl:153

2 5 C Ts;lnaGs;dAs;lna 83L15

Ts;dAs;lnaGs;dTs

;lnaCs;dC-Sup

SERPINF1- 1.347 0.493 SERPI in RPTEC 10 qRTPCR UUAAGGU dTs;lnaTs;dAs;ln SERPIN 27 13086 26034 NF1 vitro GAUAGUC aAs;dGs;lnaGs;d Fl:153

5 8 C Ts;lnaGs;dAs;lna 83L15

Ts;dAs;lnaGs;dTs

;lnaCs;dC-Sup

SERPINF1- 0.326 0.045 SERPI in RPTEC 30 qRTPCR UCGUUCC dTs;lnaCs;dGs;ln SERPIN 28 05363 69391 NF1 vitro ACUCAAA aTs;dTs;lnaCs;dC Fl:153

8 3 G s;lnaAs;dCs;lnaTs 08L15

;dCs;lnaAs;dAs;ln aAs;dG-Sup

SERPINF1- 0.985 0.078 SERPI in RPTEC 10 qRTPCR UCGUUCC dTs;lnaCs;dGs;ln SERPIN 28 57465 06850 NF1 vitro ACUCAAA aTs;dTs;lnaCs;dC Fl:153

2 G s;lnaAs;dCs;lnaTs 08L15

;dCs;lnaAs;dAs;ln aAs;dG-Sup Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

SERPINF1- 0.513 0.037 SERPI in RPTEC 30 qRTPCR CCAGGGC dCs;lnaCs;dAs;ln SERPIN 29 98623 69389 NF1 vitro UGCAGCC aGs;dGs;lnaGs;d Fl:153

2 5 U Cs;lnaTs;dGs;lna 48U15

Cs;dAs;lnaGs;dCs

;lnaCs;dT-Sup

SERPINF1- 1.408 0.175 SERPI in RPTEC 10 qRTPCR CCAGGGC dCs;lnaCs;dAs;ln SERPIN 29 53415 76280 NF1 vitro UGCAGCC aGs;dGs;lnaGs;d Fl:153

8 1 U Cs;lnaTs;dGs;lna 48U15

Cs;dAs;lnaGs;dCs

;lnaCs;dT-Sup

SERPINF1- 0.488 0.258 SERPI in RPTEC 30 qRTPCR UUGCCAA dTs;lnaTs;dGs;ln SERPIN 30 96640 78185 NF1 vitro UGAAGAG aCs;dCs;lnaAs;dA Fl:154

7 A s;lnaTs;dGs;lnaA 43L15 s;dAs;lnaGs;dAs;l naGs;dA-Sup

SERPINF1- 1.120 0.277 SERPI in RPTEC 10 qRTPCR UUGCCAA dTs;lnaTs;dGs;ln SERPIN 30 50838 07919 NF1 vitro UGAAGAG aCs;dCs;lnaAs;dA Fl:154

8 5 A s;lnaTs;dGs;lnaA 43L15 s;dAs;lnaGs;dAs;l naGs;dA-Sup

SERPINF1- 1.014 0.195 SERPI in RPTEC 30 qRTPCR UGUGUCU dTs;lnaGs;dTs;ln SERPIN 31 24327 15746 NF1 vitro GUGUCCC aGs;dTs;lnaCs;dT Fl:154

5 1 U s;lnaGs;dTs;lnaG 20L15 s;dTs;lnaCs;dCs;l naCs;dT-Sup

SERPINF1- 0.894 0.233 SERPI in RPTEC 10 qRTPCR UGUGUCU dTs;lnaGs;dTs;ln SERPIN 31 2259 59994 NF1 vitro GUGUCCC aGs;dTs;lnaCs;dT Fl:154

9 U s;lnaGs;dTs;lnaG 20L15 s;dTs;lnaCs;dCs;l naCs;dT-Sup

SERPINF1- 0.878 0.296 SERPI in RPTEC 30 qRTPCR UUCGUGU dTs;lnaTs;dCs;lna SERPIN 32 56488 24845 NF1 vitro CCUGUGG Gs;dTs;lnaGs;dTs Fl:155

2 1 A ;lnaCs;dCs;lnaTs; 36L15 dGs;lnaTs;dGs;ln aGs;dA-Sup

SERPINF1- 0.745 0.125 SERPI in RPTEC 10 qRTPCR UUCGUGU dTs;lnaTs;dCs;lna SERPIN 32 90115 45839 NF1 vitro CCUGUGG Gs;dTs;lnaGs;dTs Fl:155

9 1 A ;lnaCs;dCs;lnaTs; 36L15 dGs;lnaTs;dGs;ln aGs;dA-Sup

SERPINF1- NA NA SERPI NA NA 0 NA UGUCCAC dTs;lnaGs;dTs;ln SERPIN 33 NF1 AGUGGUU aCs;dCs;lnaAs;dC Fl:157

G s;lnaAs;dGs;lnaT 3L15 s;dGs;lnaGs;dTs;l naTs;dG-Sup

SERPINF1- NA NA SERPI NA NA 0 NA UCACUCU dTs;lnaCs;dAs;ln SERPIN 34 NF1 CCCGUUA aCs;dTs;lnaCs;dT Fl:144

G s;lnaCs;dCs;lnaCs 77L15 ;dGs;lnaTs;dTs;ln Oligo ID RQ RQSE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

aAs;dG-Sup

SERPINF1- NA NA SERPI NA NA 0 NA AGACCCG dAs;lnaGs;dAs;ln SERPIN 35 NF1 ACCCAGC aCs;dCs;lnaCs;dG Fl:477

A s;lnaAs;dCs;lnaCs L15

;dCs;lnaAs;dGs;l naCs;dA-Sup

SERPINF1- NA NA SERPI NA NA 0 NA UGAAUGA dTs;lnaGs;dAs;ln SERPIN 36 NF1 AGUGAGU aAs;dTs;lnaGs;dA Fl:417

G s;lnaAs;dGs;lnaT U15 s;dGs;lnaAs;dGs;l naTs;dG-Sup

SERPINF1- NA NA SERPI NA NA 0 NA ACAGAGC dAs;lnaCs;dAs;ln SERPIN 37 NF1 uuuuuu aGs;dAs;lnaGs;d F1:63L

UG Cs;lnaTs;dTs;lnaT 15 s;dTs;lnaTs;dTs;l naTs;dG-Sup

SERPINF1- NA NA SERPI NA NA 0 NA uccuuuc dTs;lnaCs;dCs;ln SERPIN 38 NF1 UUAAAGC aTs;dTs;lnaTs;dC F1:4L1

G s;lnaTs;dTs;lnaAs 5

;dAs;lnaAs;dGs;l naCs;dG-Sup

SERPINF1- NA NA SERPI NA NA 0 NA AGAAUCC dAs;lnaGs;dAs;ln SERPIN 39 NF1 AAAUUUG aAs;dTs;lnaCs;dC Fl:- A s;lnaAs;dAs;lnaA 18U15 s;dTs;lnaTs;dTs;l naGs;dA-Sup

SERPINF1- NA NA SERPI NA NA 0 NA UCGCUUU dTs;lnaCs;dGs;ln SERPIN 40 NF1 AAGAAAG aCs;dTs;lnaTs;dT F1:3U1

G s;lnaAs;dAs;lnaG 5 s;dAs;lnaAs;dAs;l naGs;dG-Sup

SIRT6-01 NA NA SIRT6 NA NA 0 NA AUCUGCA dAs;lnaTs;dCs;ln SIRT6:

GCGAUGU aTs;dGs;lnaCs;dA 7476L1 A s;lnaGs;dCs;lnaG 5 s;dAs;lnaTs;dGs;l naTs;dA-Sup

SIRT6-02 1.542 0.285 SIRT6 in Hep3B 30 qRTPCR ACCCAGC dAs;lnaCs;dCs;ln SIRT6:

98794 07431 vitro GUGAUGG aCs;dAs;lnaGs;dC 7462L1 3 3 A s;lnaGs;dTs;lnaG 5 s;dAs;lnaTs;dGs;l naGs;dA-Sup

SIRT6-02 1.355 0.112 SIRT6 in Hep3B 10 qRTPCR ACCCAGC dAs;lnaCs;dCs;ln SIRT6:

53992 11910 vitro GUGAUGG aCs;dAs;lnaGs;dC 7462L1 1 1 A s;lnaGs;dTs;lnaG 5 s;dAs;lnaTs;dGs;l naGs;dA-Sup

SIRT6-03 0.899 0.004 SIRT6 in Hep3B 30 qRTPCR CAGGUCG dCs;lnaAs;dGs;ln SIRT6:

29024 48653 vitro GCGUUCC aGs;dTs;lnaCs;d 7447L1 9 4 U Gs;lnaGs;dCs;lna 5 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Gs;dTs;lnaTs;dCs ;lnaCs;dT-Sup

I RT6-03 0.967 0.111 SI RT6 in Hep3B 10 qRTPCR CAGGUCG dCs;lnaAs;dGs;ln SIRT6:

82487 33782 vitro GCGU UCC aGs;dTs;lnaCs;d 7447L1 2 6 U Gs;lnaGs;dCs;lna 5

Gs;dTs;lnaTs;dCs

;lnaCs;dT-Sup

I RT6-04 0.560 0.010 SI RT6 in Hep3B 30 qRTPCR AU UCU UC dAs;lnaTs;dTs;ln SIRT6:

85502 94383 vitro CACAAAC aCs;dTs;lnaTs;dC 5491L1 7 3 A s;lnaCs;dAs;lnaCs 5

;dAs;lnaAs;dAs;ln aCs;dA-Sup

I RT6-04 0.724 0.015 SI RT6 in Hep3B 10 qRTPCR AU UCU UC dAs;lnaTs;dTs;ln SIRT6:

93529 65503 vitro CACAAAC aCs;dTs;lnaTs;dC 5491L1 3 6 A s;lnaCs;dAs;lnaCs 5

;dAs;lnaAs;dAs;ln aCs;dA-Sup

I RT6-05 0.824 0.016 SI RT6 in Hep3B 30 qRTPCR ACAUGU U dAs;lnaCs;dAs;ln SIRT6:

20832 66284 vitro CCCGUGG aTs;dGs;lnaTs;dT 5479L1 5 8 A s;lnaCs;dCs;lnaCs 5

;dGs;lnaTs;dGs;l naGs;dA-Sup

I RT6-05 0.921 0.035 SI RT6 in Hep3B 10 qRTPCR ACAUGU U dAs;lnaCs;dAs;ln SIRT6:

49197 01968 vitro CCCGUGG aTs;dGs;lnaTs;dT 5479L1 9 9 A s;lnaCs;dCs;lnaCs 5

;dGs;lnaTs;dGs;l naGs;dA-Sup

I RT6-06 0.691 0.029 SI RT6 in Hep3B 30 qRTPCR UGGAGCU dTs;lnaGs;dGs;ln SIRT6:

59289 13495 vitro CUGCCAG aAs;dGs;lnaCs;dT 5468L1 6 5 U s;lnaCs;dTs;lnaGs 5

;dCs;lnaCs;dAs;ln aGs;dT-Sup

I RT6-06 0.985 0.030 SI RT6 in Hep3B 10 qRTPCR UGGAGCU dTs;lnaGs;dGs;ln SIRT6:

99535 58132 vitro CUGCCAG aAs;dGs;lnaCs;dT 5468L1 8 7 U s;lnaCs;dTs;lnaGs 5

;dCs;lnaCs;dAs;ln aGs;dT-Sup

I RT6-07 1.114 0.088 SI RT6 in Hep3B 30 qRTPCR UG UCAGA dTs;lnaGs;dTs;ln SIRT6:- 80619 35538 vitro AGGAAGC aCs;dAs;lnaGs;d 123L15 9 7 C As;lnaAs;dGs;lna

Gs;dAs;lnaAs;dG s;lnaCs;dC-Sup

I RT6-07 1.730 0.451 SI RT6 in Hep3B 10 qRTPCR UG UCAGA dTs;lnaGs;dTs;ln SIRT6:- 35258 369 vitro AGGAAGC aCs;dAs;lnaGs;d 123L15 5 C As;lnaAs;dGs;lna

Gs;dAs;lnaAs;dG s;lnaCs;dC-Sup

I RT6-08 1.018 0.048 SI RT6 in Hep3B 30 qRTPCR UCU UUGC dTs;lnaCs;dTs;lna SIRT6:- 46494 97424 vitro AUGCAGG Ts;dTs;lnaGs;dCs 142L15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

3 9 U ;lnaAs;dTs;lnaGs;

dCs;lnaAs;dGs;ln aGs;dT-Sup

I RT6-08 1.087 0.043 SI RT6 in Hep3B 10 qRTPCR UCU UUGC dTs;lnaCs;dTs;lna SIRT6:- 23908 86831 vitro AUGCAGG Ts;dTs;lnaGs;dCs 142L15 4 3 U ;lnaAs;dTs;lnaGs;

dCs;lnaAs;dGs;ln aGs;dT-Sup

I RT6-09 0.849 0.059 SI RT6 in Hep3B 30 qRTPCR AUGCAGG dAs;lnaTs;dGs;ln SIRT6:- 50471 83822 vitro UG UU UGC aCs;dAs;lnaGs;d 149L15

3 G Gs;lnaTs;dGs;lna

Ts;dTs;lnaTs;dGs;

lnaCs;dG-Sup

I RT6-09 0.989 0.066 SI RT6 in Hep3B 10 qRTPCR AUGCAGG dAs;lnaTs;dGs;ln SIRT6:- 44793 20343 vitro UG UU UGC aCs;dAs;lnaGs;d 149L15 6 3 G Gs;lnaTs;dGs;lna

Ts;dTs;lnaTs;dGs;

lnaCs;dG-Sup

I RT6-10 0.802 0.038 SI RT6 in Hep3B 30 qRTPCR GGCGGCC dGs;lnaGs;dCs;ln SIRT6:- 22963 52426 vitro GCCUACG aGs;dGs;lnaCs;d 207L15 5 2 U Cs;lnaGs;dCs;lna

Cs;dTs;lnaAs;dCs

;lnaGs;dT-Sup

I RT6-10 0.862 0.116 SI RT6 in Hep3B 10 qRTPCR GGCGGCC dGs;lnaGs;dCs;ln SIRT6:- 26210 55343 vitro GCCUACG aGs;dGs;lnaCs;d 207L15 1 9 U Cs;lnaGs;dCs;lna

Cs;dTs;lnaAs;dCs

;lnaGs;dT-Sup

I RT6-11 0.482 0.049 SI RT6 in Hep3B 30 qRTPCR AUGCUCG dAs;lnaTs;dGs;ln SIRT6:

45443 60376 vitro GGACCCU aCs;dTs;lnaCs;dG 139L15 5 8 C s;lnaGs;dGs;lnaA s;dCs;lnaCs;dCs;l naTs;dC-Sup

I RT6-11 0.817 0.070 SI RT6 in Hep3B 10 qRTPCR AUGCUCG dAs;lnaTs;dGs;ln SIRT6:

2485 01095 vitro GGACCCU aCs;dTs;lnaCs;dG 139L15

6 C s;lnaGs;dGs;lnaA

s;dCs;lnaCs;dCs;l naTs;dC-Sup

I RT6-12 NA NA SIRT6 NA NA 0 NA ACCCUCA dAs;lnaCs;dCs;ln SIRT6:

GACGCGC aCs;dTs;lnaCs;dA 130L15 U s;lnaGs;dAs;lnaC

s;dGs;lnaCs;dGs;l naCs;dT-Sup

I RT6-13 0.696 0.076 SI RT6 in Hep3B 30 qRTPCR UCACCUC dTs;lnaCs;dAs;ln SIRT6:

61176 39813 vitro CGGGAGG aCs;dCs;lnaTs;dC 116L15 2 6 C s;lnaCs;dGs;lnaG s;dGs;lnaAs;dGs;l naGs;dC-Sup

I RT6-13 0.660 0.056 SI RT6 in Hep3B 10 qRTPCR UCACCUC dTs;lnaCs;dAs;ln SIRT6: Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

75574 46250 vitro CGGGAGG aCs;dCs;lnaTs;dC 116L15 1 2 C s;lnaCs;dGs;lnaG s;dGs;lnaAs;dGs;l naGs;dC-Sup

I RT6-14 0.022 0.000 SI RT6 in Hep3B 30 qRTPCR ACU UGCC dAs;lnaCs;dTs;ln SIRT6:

72863 63006 vitro CU UGUCC aTs;dGs;lnaCs;dC 98L15 2 1 G s;lnaCs;dTs;lnaTs

;dGs;lnaTs;dCs;ln aCs;dG-Sup

I RT6-14 0.050 0.014 SI RT6 in Hep3B 10 qRTPCR ACU UGCC dAs;lnaCs;dTs;ln SIRT6:

51788 41489 vitro CU UGUCC aTs;dGs;lnaCs;dC 98L15 3 8 G s;lnaCs;dTs;lnaTs

;dGs;lnaTs;dCs;ln aCs;dG-Sup

I RT6-15 NA NA SIRT6 NA NA 0 NA CCGCGUA dCs;lnaCs;dGs;ln SIRT6:- CGGCGGA aCs;dGs;lnaTs;dA 47627L CA s;lnaCs;dGs;lnaG 16 s;dCs;lnaGs;dGs;

dAs;lnaCs;dA-

Sup

I RT6-16 0.939 0.052 SI RT6 in Hep3B 30 qRTPCR ACUCCCCA dAs;lnaCs;dTs;ln SIRT6:

36639 75475 vitro GCCUGGC aCs;dCs;lnaCs;dC 463L15 3 4 s;lnaAs;dGs;lnaC s;dCs;lnaTs;dGs;l naGs;dC-Sup

I RT6-16 1.093 0.114 SI RT6 in Hep3B 10 qRTPCR ACUCCCCA dAs;lnaCs;dTs;ln SIRT6:

0298 33255 vitro GCCUGGC aCs;dCs;lnaCs;dC 463L15

8 s;lnaAs;dGs;lnaC

s;dCs;lnaTs;dGs;l naGs;dC-Sup

I RT6-17 0.849 0.054 SI RT6 in Hep3B 30 qRTPCR UCCUGGC dTs;lnaCs;dCs;ln SIRT6:

46489 84246 vitro CCGGCUC aTs;dGs;lnaGs;d 436L15 3 4 u Cs;lnaCs;dCs;lna

Gs;dGs;lnaCs;dTs

;lnaCs;dT-Sup

I RT6-17 0.882 0.076 SI RT6 in Hep3B 10 qRTPCR UCCUGGC dTs;lnaCs;dCs;ln SIRT6:

24471 42257 vitro CCGGCUC aTs;dGs;lnaGs;d 436L15 6 1 u Cs;lnaCs;dCs;lna

Gs;dGs;lnaCs;dTs

;lnaCs;dT-Sup

I RT6-18 1.203 0.135 SI RT6 in Hep3B 30 qRTPCR AACCUCCC dAs;lnaAs;dCs;ln SIRT6:

75247 46342 vitro AGGCCUA aCs;dTs;lnaCs;dC 418L15 1 9 s;lnaCs;dAs;lnaG s;dGs;lnaCs;dCs;l naTs;dA-Sup

I RT6-18 0.953 0.089 SI RT6 in Hep3B 10 qRTPCR AACCUCCC dAs;lnaAs;dCs;ln SIRT6:

97587 76200 vitro AGGCCUA aCs;dTs;lnaCs;dC 418L15 3 1 s;lnaCs;dAs;lnaG s;dGs;lnaCs;dCs;l Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

naTs;dA-Sup

I RT6-19 1.048 0.044 SI RT6 in Hep3B 30 qRTPCR CUCCAGG dCs;lnaTs;dCs;ln SIRT6:

86777 53241 vitro UGUGU U U aCs;dAs;lnaGs;d 397L15 9 4 A Gs;lnaTs;dGs;lna

Ts;dGs;lnaTs;dTs;

lnaTs;dA-Sup

I RT6-19 1.064 0.206 SI RT6 in Hep3B 10 qRTPCR CUCCAGG dCs;lnaTs;dCs;ln SIRT6:

61555 49329 vitro UGUGU U U aCs;dAs;lnaGs;d 397L15

8 A Gs;lnaTs;dGs;lna

Ts;dGs;lnaTs;dTs;

lnaTs;dA-Sup

I RT6-20 0.754 0.047 SI RT6 in Hep3B 30 qRTPCR AGACCCA dAs;lnaGs;dAs;ln SIRT6:

05377 32879 vitro AAAGGGA aCs;dCs;lnaCs;dA 628L15 4 3 A s;lnaAs;dAs;lnaA s;dGs;lnaGs;dGs;

lnaAs;dA-Sup

I RT6-20 0.870 0.111 SI RT6 in Hep3B 10 qRTPCR AGACCCA dAs;lnaGs;dAs;ln SIRT6:

44637 24633 vitro AAAGGGA aCs;dCs;lnaCs;dA 628L15 1 6 A s;lnaAs;dAs;lnaA s;dGs;lnaGs;dGs;

lnaAs;dA-Sup

I RT6-21 1.234 0.049 SI RT6 in Hep3B 30 qRTPCR UGACU UC dTs;lnaGs;dAs;ln SIRT6:

96103 08001 vitro CCCAAAG aCs;dTs;lnaTs;dC 612L15 2 1 U s;lnaCs;dCs;lnaCs

;dAs;lnaAs;dAs;ln aGs;dT-Sup

I RT6-21 0.978 0.072 SI RT6 in Hep3B 10 qRTPCR UGACU UC dTs;lnaGs;dAs;ln SIRT6:

50408 27638 vitro CCCAAAG aCs;dTs;lnaTs;dC 612L15 9 7 U s;lnaCs;dCs;lnaCs

;dAs;lnaAs;dAs;ln aGs;dT-Sup

I RT6-22 0.990 0.033 SI RT6 in Hep3B 30 qRTPCR AGCCGAU dAs;lnaGs;dCs;ln SIRT6:

18677 35312 vitro CCCUCCAC aCs;dGs;lnaAs;dT 576L15 5 7 s;lnaCs;dCs;lnaCs

;dTs;lnaCs;dCs;ln aAs;dC-Sup

I RT6-22 1.100 0.029 SI RT6 in Hep3B 10 qRTPCR AGCCGAU dAs;lnaGs;dCs;ln SIRT6:

84834 12677 vitro CCCUCCAC aCs;dGs;lnaAs;dT 576L15 5 8 s;lnaCs;dCs;lnaCs

;dTs;lnaCs;dCs;ln aAs;dC-Sup

I RT6-23 1.183 0.119 SI RT6 in Hep3B 30 qRTPCR AAAAUGG dAs;lnaAs;dAs;ln SIRT6:

96951 04290 vitro AU UGGAA aAs;dTs;lnaGs;d 1573L1

5 A Gs;lnaAs;dTs;lna 5

Ts;dGs;lnaGs;dAs

;lnaAs;dA-Sup

I RT6-23 1.388 0.081 SI RT6 in Hep3B 10 qRTPCR AAAAUGG dAs;lnaAs;dAs;ln SIRT6:

26666 52657 vitro AU UGGAA aAs;dTs;lnaGs;d 1573L1 5 7 A Gs;lnaAs;dTs;lna 5 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Ts;dGs;lnaGs;dAs ;lnaAs;dA-Sup

I RT6-24 1.084 0.136 SI RT6 in Hep3B 30 qRTPCR U UGUCCU dTs;lnaTs;dGs;ln SIRT6:

46647 40670 vitro CAUGCCC aTs;dCs;lnaCs;dT 1551L1 5 2 C s;lnaCs;dAs;lnaTs 5

;dGs;lnaCs;dCs;ln aCs;dC-Sup

I RT6-24 0.931 0.083 SI RT6 in Hep3B 10 qRTPCR U UGUCCU dTs;lnaTs;dGs;ln SIRT6:

50722 70839 vitro CAUGCCC aTs;dCs;lnaCs;dT 1551L1 6 8 C s;lnaCs;dAs;lnaTs 5

;dGs;lnaCs;dCs;ln aCs;dC-Sup

I RT6-25 0.861 0.045 SI RT6 in Hep3B 30 qRTPCR cuccucu dCs;lnaTs;dCs;ln SIRT6:

32645 28919 vitro UCCUACA aCs;dTs;lnaCs;dT 1537L1 3 9 A s;lnaTs;dCs;lnaCs 5

;dTs;lnaAs;dCs;ln aAs;dA-Sup

I RT6-25 0.910 0.057 SI RT6 in Hep3B 10 qRTPCR CUCCUCU dCs;lnaTs;dCs;ln SIRT6:

68893 24130 vitro UCCUACA aCs;dTs;lnaCs;dT 1537L1 2 5 A s;lnaTs;dCs;lnaCs 5

;dTs;lnaAs;dCs;ln aAs;dA-Sup

I RT6-26 NA NA SIRT6 NA NA 0 NA ACCUGCC dAs;lnaCs;dCs;ln SIRT6:

U UGUCAA aTs;dGs;lnaCs;dC 1507L1 A s;lnaTs;dTs;lnaGs 5

;dTs;lnaCs;dAs;ln aAs;dA-Sup

I RT6-27 0.643 0.027 SI RT6 in Hep3B 30 qRTPCR AAGCCCU dAs;lnaAs;dGs;ln SIRT6:

81003 32295 vitro GCCCUCC aCs;dCs;lnaCs;dT 2926L1 3 3 A s;lnaGs;dCs;lnaC 5 s;dCs;lnaTs;dCs;l naCs;dA-Sup

I RT6-27 0.812 0.085 SI RT6 in Hep3B 10 qRTPCR AAGCCCU dAs;lnaAs;dGs;ln SIRT6:

59464 99162 vitro GCCCUCC aCs;dCs;lnaCs;dT 2926L1 1 2 A s;lnaGs;dCs;lnaC 5 s;dCs;lnaTs;dCs;l naCs;dA-Sup

I RT6-28 0.957 0.042 SI RT6 in Hep3B 30 qRTPCR AAGCCCU dAs;lnaAs;dGs;ln SIRT6:

57442 73872 vitro UGAUCUU aCs;dCs;lnaCs;dT 2910L1 6 1 G s;lnaTs;dGs;lnaA 5 s;dTs;lnaCs;dTs;l naTs;dG-Sup

I RT6-28 1.030 0.049 SI RT6 in Hep3B 10 qRTPCR AAGCCCU dAs;lnaAs;dGs;ln SIRT6:

69541 16863 vitro UGAUCUU aCs;dCs;lnaCs;dT 2910L1 6 2 G s;lnaTs;dGs;lnaA 5 s;dTs;lnaCs;dTs;l naTs;dG-Sup

I RT6-29 0.908 0.221 SI RT6 in Hep3B 30 qRTPCR AGGUGGA dAs;lnaGs;dGs;ln SIRT6:

88036 22078 vitro CACAGAU aTs;dGs;lnaGs;d 2887L1 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

8 7 C As;lnaCs;dAs;lna 5

Cs;dAs;lnaGs;dAs

;lnaTs;dC-Sup

I RT6-29 0.893 0.130 SI RT6 in Hep3B 10 qRTPCR AGGUGGA dAs;lnaGs;dGs;ln SIRT6:

70543 58479 vitro CACAGAU aTs;dGs;lnaGs;d 2887L1 6 4 C As;lnaCs;dAs;lna 5

Cs;dAs;lnaGs;dAs

;lnaTs;dC-Sup

I RT6-30 NA NA SIRT6 NA NA 0 NA ACAGAUC dAs;lnaCs;dAs;ln SIRT6:

CUCUGGC aGs;dAs;lnaTs;dC 2879L1 C s;lnaCs;dTs;lnaCs 5

;dTs;lnaGs;dGs;l naCs;dC-Sup

SMAD7- NA NA SMA NA NA 0 NA UCAGCUC dTs;lnaCs;dAs;ln SMAD 01 D7 CAAAACU aGs;dCs;lnaTs;dC 7:- C s;lnaCs;dAs;lnaA 1770U s;dAs;lnaAs;dCs;l 15 naTs;dC-Sup

SMAD7- NA NA SMA NA NA 0 NA CCCUGCU dCs;lnaCs;dCs;ln SMAD 02 D7 U U UCCAA aTs;dGs;lnaCs;dT 7:- U s;lnaTs;dTs;lnaTs 1733U

;dCs;lnaCs;dAs;ln 15 aAs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA CCUCCGCC dCs;lnaCs;dTs;ln SMAD 03 D7 GCCGCCG aCs;dCs;lnaGs;dC 7:- s;lnaCs;dGs;lnaC 864 U l s;dCs;lnaGs;dCs;l 5 naCs;dG-Sup

SMAD7- NA NA SMA NA NA 0 NA CGCCGCG dCs;lnaGs;dCs;ln SMAD 04 D7 CCACCCUC aCs;dGs;lnaCs;d 7:-

Gs;lnaCs;dCs;lna 854U 1

As;dCs;lnaCs;dCs 5

;lnaTs;dC-Sup

SMAD7- NA NA SMA NA NA 0 NA GAAAGAC dGs;lnaAs;dAs;ln SMAD 05 D7 CAGAGAC aAs;dGs;lnaAs;d 7:- U Cs;lnaCs;dAs;lna 723U 1 Gs;dAs;lnaGs;dA 5 s;lnaCs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA UGUGCAA dTs;lnaGs;dTs;ln SMAD 06 D7 AGUGU UC aGs;dCs;lnaAs;d 7:763U

A As;lnaAs;dGs;lna 15

Ts;dGs;lnaTs;dTs;

lnaCs;dA-Sup

SMAD7- NA NA SMA NA NA 0 NA CCGGAUC dCs;lnaCs;dGs;ln SMAD 07 D7 UCAGGCA aGs;dAs;lnaTs;dC 7:783U

U s;lnaTs;dCs;lnaAs 15

;dGs;lnaGs;dCs;l naAs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA UUGGGCU dTs;lnaTs;dGs;ln SMAD Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

08 D7 AAAAGAA aGs;dGs;lnaCs;d 7:2186

U Ts;lnaAs;dAs;lna U 15 As;dAs;lnaGs;dAs ;lnaAs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AACCAAC dAs;lnaAs;dCs;ln SMAD 09 D7 UGGUGAG aCs;dAs;lnaAs;dC 7:2320

U s;lnaTs;dGs;lnaG U 15 s;dTs;lnaGs;dAs;l naGs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA ACCCGAU dAs;lnaCs;dCs;ln SMAD 10 D7 CCAU U UU aCs;dGs;lnaAs;dT 7:2302

C s;lnaCs;dCs;lnaAs U 15

;dTs;lnaTs;dTs;ln aTs;dC-Sup

SMAD7- NA NA SMA NA NA 0 NA ACUCACCC dAs;lnaCs;dTs;ln SMAD 11 D7 AAAACGU aCs;dAs;lnaCs;dC 7:4121 s;lnaCs;dAs;lnaA U 15 s;dAs;lnaAs;dCs;l naGs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AAAAUAG dAs;lnaAs;dAs;ln SMAD 12 D7 AACAAAA aAs;dTs;lnaAs;dG 7:4143

A s;lnaAs;dAs;lnaC U 15 s;dAs;lnaAs;dAs;l naAs;dA-Sup

SMAD7- NA NA SMA NA NA 0 NA UCAGU UU dTs;lnaCs;dAs;ln SMAD 13 D7 CUAUG UC aGs;dTs;lnaTs;dT 7:4435

C s;lnaCs;dTs;lnaAs U 15

;dTs;lnaGs;dTs;ln aCs;dC-Sup

SMAD7- NA NA SMA NA NA 0 NA UUAGG UU dTs;lnaTs;dAs;ln SMAD 14 D7 GAAU UU U aGs;dGs;lnaTs;dT 7:4451

U s;lnaGs;dAs;lnaA U 15 s;dTs;lnaTs;dTs;l naTs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AUUGCUU dAs;lnaTs;dTs;ln SMAD 15 D7 UGGUGUG aGs;dCs;lnaTs;dT 7:8474

U s;lnaTs;dGs;lnaG U 15 s;dTs;lnaGs;dTs;l naGs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AGCU UCU dAs;lnaGs;dCs;ln SMAD 16 D7 AAUGAGA aTs;dTs;lnaCs;dT 7:9421

A s;lnaAs;dAs;lnaTs U 15

;dGs;lnaAs;dGs;l naAs;dA-Sup

SMAD7- NA NA SMA NA NA 0 NA UGCUUGA dTs;lnaGs;dCs;ln SMAD 17 D7 GAU UCAU aTs;dTs;lnaGs;dA 7:1239

A s;lnaGs;dAs;lnaT 1U15 s;dTs;lnaCs;dAs;l naTs;dA-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

SMAD7- NA NA SMA NA NA 0 NA UAUGUGG dTs;lnaAs;dTs;ln SMAD 18 D7 CUACUAG aGs;dTs;lnaGs;d 7:1240

U Gs;lnaCs;dTs;lna 4U15

As;dCs;lnaTs;dAs

;lnaGs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA UUCUAAU dTs;lnaTs;dCs;lna SMAD 19 D7 GACACAG Ts;dAs;lnaAs;dTs 7:1665

G ;lnaGs;dAs;lnaCs; 9U15 dAs;lnaCs;dAs;ln aGs;dG-Sup

SMAD7- NA NA SMA NA NA 0 NA AGGGUGA dAs;lnaGs;dGs;ln SMAD 20 D7 UGAAUAG aGs;dTs;lnaGs;d 7:2220

U As;lnaTs;dGs;lna 0U15

As;dAs;lnaTs;dAs

;lnaGs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AAUAGUA dAs;lnaAs;dTs;ln SMAD 21 D7 AGACAGA aAs;dGs;lnaTs;dA 7:2220

G s;lnaAs;dGs;lnaA 9U15 s;dCs;lnaAs;dGs;l naAs;dG-Sup

SMAD7- NA NA SMA NA NA 0 NA CCCACCCA dCs;lnaCs;dCs;ln SMAD 22 D7 GCU UCCU aAs;dCs;lnaCs;dC 7:2625 s;lnaAs;dGs;lnaC 5U15 s;dTs;lnaTs;dCs;l naCs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA U UUGU UG dTs;lnaTs;dTs;lna SMAD 23 D7 UCCCGAA Gs;dTs;lnaTs;dGs 7:2654

U ;lnaTs;dCs;lnaCs; 1U15 dCs;lnaGs;dAs;ln aAs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA AAAGCU U dAs;lnaAs;dAs;ln SMAD 24 D7 CU UGUGU aGs;dCs;lnaTs;dT 7:2657

U s;lnaCs;dTs;lnaTs 0U15

;dGs;lnaTs;dGs;l naTs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA UCAGAAC dTs;lnaCs;dAs;ln SMAD 25 D7 ACCCUCC aGs;dAs;lnaAs;d 7:2658

U Cs;lnaAs;dCs;lna 5U15

Cs;dCs;lnaTs;dCs;

lnaCs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA UCCUCCA dTs;lnaCs;dCs;ln SMAD 26 D7 CACCAAA aTs;dCs;lnaCs;dA 7:2659

A s;lnaCs;dAs;lnaCs 6U15

;dCs;lnaAs;dAs;ln aAs;dA-Sup

SMAD7- NA NA SMA NA NA 0 NA AAGAGGA dAs;lnaAs;dGs;ln SMAD 27 D7 GGAGCUG aAs;dGs;lnaGs;d 7:2748

G As;lnaGs;dGs;lna 9U15 As;dGs;lnaCs;dTs Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;lnaGs;dG-Sup

SMAD7- NA NA SMA NA NA 0 NA CGU UCCU dCs;lnaGs;dTs;ln SMAD 28 D7 GCAGUCU aTs;dCs;lnaCs;dT 7:2763

G s;lnaGs;dCs;lnaA 5U15 s;dGs;lnaTs;dCs;l naTs;dG-Sup

SMAD7- NA NA SMA NA NA 0 NA UGUAGCG dTs;lnaGs;dTs;ln SMAD 29 D7 ucuuucu aAs;dGs;lnaCs;d 7:3005 u Gs;lnaTs;dCs;lna 2U15

Ts;dTs;lnaTs;dCs;

lnaTs;dT-Sup

SMAD7- NA NA SMA NA NA 0 NA ucuuuuu dTs;lnaCs;dTs;lna SMAD 30 D7 UGGCCAU Ts;dTs;lnaTs;dTs; 7:3006

C lnaTs;dGs;lnaGs; 3U15 dCs;lnaCs;dAs;ln aTs;dC-Sup

ST7-01 1.158 0.037 ST7 in RPTEC 100 qRTPCR GAAAUGA omeGs;omeAs;o ST7:26

94106 38487 vitro GCAUGAA meAs;omeAs;om 20L20 9 3 ACCAAA eUs;omeGs;ome

As;omeGs;omeC s;omeAs;omeUs;

omeGs;omeAs;o meAs;omeAs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

ST7-01 1.301 0.031 ST7 in RPTEC 50 qRTPCR GAAAUGA omeGs;omeAs;o ST7:26

57202 00481 vitro GCAUGAA meAs;omeAs;om 20L20 7 4 ACCAAA eUs;omeGs;ome

As;omeGs;omeC s;omeAs;omeUs;

omeGs;omeAs;o meAs;omeAs;om eCs;omeCs;ome

As;omeAs;omeA-

Sup

ST7-02 1.234 0.046 ST7 in RPTEC 100 qRTPCR GUAUCCU omeGs;omeUs;o ST7:31

57541 64519 vitro AAGUCAU meAs;omeUs;om 267L20 5 5 ACAGAC eCs;omeCs;ome

Us;omeAs;omeA s;omeGs;omeUs;

omeCs;omeAs;o meUs;omeAs;om eCs;omeAs;ome

Gs;omeAs;omeC-

Sup

ST7-02 1.243 0.049 ST7 in RPTEC 50 qRTPCR GUAUCCU omeGs;omeUs;o ST7:31

48311 59724 vitro AAGUCAU meAs;omeUs;om 267L20 2 8 ACAGAC eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeAs;omeA s;omeGs;omeUs;

omeCs;omeAs;o meUs;omeAs;om eCs;omeAs;ome

Gs;omeAs;omeC-

Sup

ST7-03 1.378 0.076 ST7 in RPTEC 100 qRTPCR CUAAAAU omeCs;omeUs;o ST7:32

69128 54884 vitro AGU UGCA meAs;omeAs;om 384L20

3 UAACAC eAs;omeAs;ome

Us;omeAs;omeG s;omeUs;omeUs;

omeGs;omeCs;o meAs;omeUs;om eAs;omeAs;ome

Cs;omeAs;omeC-

Sup

ST7-03 1.239 0.014 ST7 in RPTEC 50 qRTPCR CUAAAAU omeCs;omeUs;o ST7.32

95595 08910 vitro AGU UGCA meAs;omeAs;om 384L20 1 4 UAACAC eAs;omeAs;ome

Us;omeAs;omeG s;omeUs;omeUs;

omeGs;omeCs;o meAs;omeUs;om eAs;omeAs;ome

Cs;omeAs;omeC-

Sup

ST7-04 1.231 0.025 ST7 in RPTEC 100 qRTPCR CCUCCAA omeCs;omeCs;o ST7:48

36772 01985 vitro UACCAUA meUs;omeCs;om 459 U 2

8 GUAAUG eCs;omeAs;ome 0

As;omeUs;omeA s;omeCs;omeCs;

omeAs;omeUs;o meAs;omeGs;om eUs;omeAs;ome

As;omeUs;omeG

-Sup

ST7-04 1.200 0.016 ST7 in RPTEC 50 qRTPCR CCUCCAA omeCs;omeCs;o ST7:48

28321 53243 vitro UACCAUA meUs;omeCs;om 459 U 2 1 8 GUAAUG eCs;omeAs;ome 0

As;omeUs;omeA s;omeCs;omeCs;

omeAs;omeUs;o meAs;omeGs;om eUs;omeAs;ome

As;omeUs;omeG

-Sup

ST7-05 1.228 0.048 ST7 in RPTEC 100 qRTPCR GU UAUGU omeGs;omeUs;o ST7:57

26111 53082 vitro CACAUCCC meUs;omeAs;om 258L20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

1 AAU U U eUs;omeGs;ome

Us;omeCs;omeA s;omeCs;omeAs;

omeUs;omeCs;o meCs;omeCs;om eAs;omeAs;ome

Us;omeUs;omeU -Sup

ST7-05 1.285 0.018 ST7 in RPTEC 50 qRTPCR GU UAUGU omeGs;omeUs;o ST7:57

26328 26801 vitro CACAUCCC meUs;omeAs;om 258L20 1 8 AAU U U eUs;omeGs;ome

Us;omeCs;omeA s;omeCs;omeAs;

omeUs;omeCs;o meCs;omeCs;om eAs;omeAs;ome

Us;omeUs;omeU

-Sup

ST7-06 1.148 0.040 ST7 in RPTEC 100 qRTPCR AAGUCAA omeAs;omeAs;o ST7:57

06147 98205 vitro AAUGCCU meGs;omeUs;o 276L20 7 2 UAAGG U meCs;omeAs;om

eAs;omeAs;ome

As;omeUs;omeG s;omeCs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eGs;omeGs;ome

U-Sup

ST7-06 1.160 0.023 ST7 in RPTEC 50 qRTPCR AAGUCAA omeAs;omeAs;o ST7:57

98959 23737 vitro AAUGCCU meGs;omeUs;o 276L20 2 9 UAAGG U meCs;omeAs;om

eAs;omeAs;ome

As;omeUs;omeG s;omeCs;omeCs;

omeUs;omeUs;o meAs;omeAs;om eGs;omeGs;ome

U-Sup

ST7-07 1.255 0.031 ST7 in RPTEC 100 qRTPCR AAUCAUA omeAs;omeAs;o ST7:69

47649 07033 vitro CCUCAAU meUs;omeCs;om 488L20 7 2 U UAAAA eAs;omeUs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meAs;omeAs;om eUs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeA-

Sup

ST7-07 1.295 0.014 ST7 in RPTEC 50 qRTPCR AAUCAUA omeAs;omeAs;o ST7:69 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

89245 35609 vitro CCUCAAU meUs;omeCs;om 488L20

7 3 U UAAAA eAs;omeUs;ome

As;omeCs;omeCs

;omeUs;omeCs;o meAs;omeAs;om eUs;omeUs;ome

Us;omeAs;omeA s;omeAs;omeA-

Sup

ST7-08 1.203 0.007 ST7 in RPTEC 100 qRTPCR CCAUUAU omeCs;omeCs;o ST7:93

351 42789 vitro UGCACAA meAs;omeUs;om 361L20 2 AUCACC eUs;omeAs;ome

Us;omeUs;omeG s;omeCs;omeAs;

omeCs;omeAs;o meAs;omeAs;om eUs;omeCs;ome

As;omeCs;omeC-

Sup

ST7-08 1.194 0.027 ST7 in RPTEC 50 qRTPCR CCAUUAU omeCs;omeCs;o ST7:93

06643 60778 vitro UGCACAA meAs;omeUs;om 361L20

5 1 AUCACC eUs;omeAs;ome

Us;omeUs;omeG s;omeCs;omeAs;

omeCs;omeAs;o meAs;omeAs;om eUs;omeCs;ome

As;omeCs;omeC-

Sup

ST7-09 1.137 0.063 ST7 in RPTEC 100 qRTPCR UCAUAUC omeUs;omeCs;o ST7: 13

87984 50138 vitro CCCCCAAC meAs;omeUs;om 0984L2

9 9 CUGUC eAs;omeUs;ome 0

Cs;omeCs;omeCs

;omeCs;omeCs;o meCs;omeAs;om eAs;omeCs;ome

Cs;omeUs;omeG s;omeUs;omeC-

Sup

ST7-09 NA NA ST7 in RPTEC 50 qRTPCR UCAUAUC omeUs;omeCs;o ST7: 13 vitro CCCCCAAC meAs;omeUs;om 0984L2

CUGUC eAs;omeUs;ome 0

Cs;omeCs;omeCs

;omeCs;omeCs;o meCs;omeAs;om eAs;omeCs;ome

Cs;omeUs;omeG s;omeUs;omeC-

Name Type Line/Tiss ] Type Sequence ates_g ue

ST7-10 1.280 0.043 ST7 in RPTEC 100 qRTPCR AACCUCU omeAs;omeAs;o ST7: 13

16943 02086 vitro AUAU UCA meCs;omeCs;om 2367L2

1 1 AUU UGC eUs;omeCs;ome 0

Us;omeAs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meAs;omeAs;om eUs;omeUs;ome Us;omeGs;omeC

-Sup

ST7-10 1.273 0.011 ST7 in RPTEC 50 qRTPCR AACCUCU omeAs;omeAs;o ST7: 13

28407 52467 vitro AUAU UCA meCs;omeCs;om 2367L2

7 5 AUU UGC eUs;omeCs;ome 0

Us;omeAs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meAs;omeAs;om eUs;omeUs;ome Us;omeGs;omeC

-Sup

ST7-11 1.227 0.062 ST7 in RPTEC 100 qRTPCR UG UGAAC omeUs;omeGs;o ST7: 13

39644 18494 vitro UCCGG U U meUs;omeGs;o 3443 L2

7 4 AAAUCA meAs;omeAs;om 0 eCs;omeUs;ome

Cs;omeCs;omeG s;omeGs;omeUs;

omeUs;omeAs;o meAs;omeAs;om eUs;omeCs;ome

A-Sup

ST7-11 1.284 0.040 ST7 in RPTEC 50 qRTPCR UG UGAAC omeUs;omeGs;o ST7: 13

22394 80025 vitro UCCGG U U meUs;omeGs;o 3443 L2

AAAUCA meAs;omeAs;om 0 eCs;omeUs;ome

Cs;omeCs;omeG s;omeGs;omeUs;

omeUs;omeAs;o meAs;omeAs;om eUs;omeCs;ome

A-Sup

ST7-12 1.244 0.035 ST7 in RPTEC 100 qRTPCR CAAAGCU omeCs;omeAs;o ST7: 13

47605 83797 vitro UAUCCUU meAs;omeAs;om 4811U

3 CU U UCC eGs;omeCs;ome 20

Us;omeUs;omeA s;omeUs;omeCs;

omeCs;omeUs;o meUs;omeCs;om eUs;omeUs;ome Us;omeCs;omeC- Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Sup

ST7-12 1.170 0.029 ST7 in RPTEC 50 qRTPCR CAAAGCU omeCs;omeAs;o ST7: 13

17040 95028 vitro UAUCCUU meAs;omeAs;om 4811U 6 7 CU U UCC eGs;omeCs;ome 20

Us;omeUs;omeA s;omeUs;omeCs;

omeCs;omeUs;o meUs;omeCs;om eUs;omeUs;ome

Us;omeCs;omeC-

Sup

ST7-13 1.268 0.004 ST7 in RPTEC 100 qRTPCR UCCU UCU omeUs;omeCs;o ST7: 13

70156 32441 vitro U UCCAAG meCs;omeUs;om 4820U 9 8 CCCAGA eUs;omeCs;ome 20

Us;omeUs;omeU s;omeCs;omeCs;

omeAs;omeAs;o meGs;omeCs;om eCs;omeCs;ome

As;omeGs;omeA

-Sup

ST7-13 1.315 0.045 ST7 in RPTEC 50 qRTPCR UCCU UCU omeUs;omeCs;o ST7: 13

97648 60308 vitro U UCCAAG meCs;omeUs;om 4820U 2 8 CCCAGA eUs;omeCs;ome 20

Us;omeUs;omeU s;omeCs;omeCs;

omeAs;omeAs;o meGs;omeCs;om eCs;omeCs;ome

As;omeGs;omeA

-Sup

ST7-14 1.180 0.035 ST7 in RPTEC 100 qRTPCR CAACCU U omeCs;omeAs;o ST7: 16

42605 65888 vitro CCAAAUA meAs;omeCs;om 2564U

2 UCCU UC eCs;omeUs;ome 20

Us;omeCs;omeC s;omeAs;omeAs;

omeAs;omeUs;o meAs;omeUs;om eCs;omeCs;ome

Us;omeUs;omeC

-Sup

ST7-14 1.208 0.053 ST7 in RPTEC 50 qRTPCR CAACCU U omeCs;omeAs;o ST7: 16

76403 57658 vitro CCAAAUA meAs;omeCs;om 2564U 1 2 UCCU UC eCs;omeUs;ome 20

Us;omeCs;omeC s;omeAs;omeAs;

omeAs;omeUs;o meAs;omeUs;om eCs;omeCs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeUs;omeC -Sup

ST7-15 1.297 0.046 ST7 in RPTEC 100 qRTPCR AAAUGAC omeAs;omeAs;o ST7: 17

56634 09076 vitro CAAUGAG meAs;omeUs;om 1955U 1 8 AAGUGC eGs;omeAs;ome 20

Cs;omeCs;omeAs

;omeAs;omeUs;o meGs;omeAs;om eGs;omeAs;ome

As;omeGs;omeU s;omeGs;omeC-

Sup

ST7-15 1.392 0.053 ST7 in RPTEC 50 qRTPCR AAAUGAC omeAs;omeAs;o ST7: 17

43687 47849 vitro CAAUGAG meAs;omeUs;om 1955U 8 9 AAGUGC eGs;omeAs;ome 20

Cs;omeCs;omeAs

;omeAs;omeUs;o meGs;omeAs;om eGs;omeAs;ome

As;omeGs;omeU s;omeGs;omeC-

Sup

ST7-16 1.241 0.027 ST7 in RPTEC 100 qRTPCR CCU U UAC omeCs;omeCs;o ST7: 17

16231 29417 vitro U UCUAAU meUs;omeUs;o 2161U 9 1 CAU UG U meUs;omeAs;om 20 eCs;omeUs;ome

Us;omeCs;omeU s;omeAs;omeAs;

omeUs;omeCs;o meAs;omeUs;om eUs;omeGs;ome

U-Sup

ST7-16 1.280 0.008 ST7 in RPTEC 50 qRTPCR CCU U UAC omeCs;omeCs;o ST7: 17

01561 11923 vitro U UCUAAU meUs;omeUs;o 2161U 8 CAU UG U meUs;omeAs;om 20 eCs;omeUs;ome

Us;omeCs;omeU s;omeAs;omeAs;

omeUs;omeCs;o meAs;omeUs;om eUs;omeGs;ome

U-Sup

ST7-17 1.170 0.033 ST7 in RPTEC 100 qRTPCR GUAUAAU omeGs;omeUs;o ST7: 17

00238 11421 vitro AUGCAAA meAs;omeUs;om 6030L2 7 6 CAGCCU eAs;omeAs;ome 0

Us;omeAs;omeU s;omeGs;omeCs;

omeAs;omeAs;o meAs;omeCs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eAs;omeGs;ome

Cs;omeCs;omeU-

Sup

ST7-17 1.322 0.052 ST7 in RPTEC 50 qRTPCR GUAUAAU omeGs;omeUs;o ST7: 17

07883 98475 vitro AUGCAAA meAs;omeUs;om 6030L2 3 6 CAGCCU eAs;omeAs;ome 0

Us;omeAs;omeU s;omeGs;omeCs;

omeAs;omeAs;o meAs;omeCs;om eAs;omeGs;ome

Cs;omeCs;omeU-

Sup

ST7-18 1.113 0.031 ST7 in RPTEC 100 qRTPCR CGAGUCA omeCs;omeGs;o ST7: 17

29516 68337 vitro CAAGUAA meAs;omeGs;om 7236L2 8 5 AGAAUG eUs;omeCs;ome 0

As;omeCs;omeA s;omeAs;omeGs;

omeUs;omeAs;o meAs;omeAs;om eGs;omeAs;ome

As;omeUs;omeG

-Sup

ST7-18 1.090 0.004 ST7 in RPTEC 50 qRTPCR CGAGUCA omeCs;omeGs;o ST7: 17

85494 30555 vitro CAAGUAA meAs;omeGs;om 7236L2 3 1 AGAAUG eUs;omeCs;ome 0

As;omeCs;omeA s;omeAs;omeGs;

omeUs;omeAs;o meAs;omeAs;om eGs;omeAs;ome

As;omeUs;omeG

-Sup

ST7-19 1.236 0.041 ST7 in RPTEC 100 qRTPCR CAU UCU U omeCs;omeAs;o ST7: 17

22438 32016 vitro UACUUGU meUs;omeUs;o 7236U 4 2 GACUCG meCs;omeUs;om 20 eUs;omeUs;ome

As;omeCs;omeU s;omeUs;omeGs;

omeUs;omeGs;o meAs;omeCs;om eUs;omeCs;ome

G-Sup

ST7-19 1.192 0.027 ST7 in RPTEC 50 qRTPCR CAU UCU U omeCs;omeAs;o ST7: 17

95471 72919 vitro UACUUGU meUs;omeUs;o 7236U 8 6 GACUCG meCs;omeUs;om 20 eUs;omeUs;ome

As;omeCs;omeU s;omeUs;omeGs; Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

omeUs;omeGs;o meAs;omeCs;om eUs;omeCs;ome

G-Sup

ST7-20 1.270 0.036 ST7 in RPTEC 100 qRTPCR UACCAAA omeUs;omeAs;o ST7: 18

87623 13337 vitro GUAAG UC meCs;omeCs;om 0860U 9 8 AAGAAC eAs;omeAs;ome 20

As;omeGs;omeU s;omeAs;omeAs;

omeGs;omeUs;o meCs;omeAs;om eAs;omeGs;ome

As;omeAs;omeC-

Sup

ST7-20 1.172 0.026 ST7 in RPTEC 50 qRTPCR UACCAAA omeUs;omeAs;o ST7: 18

99465 83841 vitro GUAAG UC meCs;omeCs;om 0860U 2 8 AAGAAC eAs;omeAs;ome 20

As;omeGs;omeU s;omeAs;omeAs;

omeGs;omeUs;o meCs;omeAs;om eAs;omeGs;ome

As;omeAs;omeC-

Sup

ST7-21 1.276 0.043 ST7 in RPTEC 100 qRTPCR CAAAGUA omeCs;omeAs;o ST7: 18

10826 88134 vitro AGUCAAG meAs;omeAs;om 0863 U 5 9 AACCUG eGs;omeUs;ome 20

As;omeAs;omeG s;omeUs;omeCs;

omeAs;omeAs;o meGs;omeAs;om eAs;omeCs;ome

Cs;omeUs;omeG

-Sup

ST7-21 1.235 0.032 ST7 in RPTEC 50 qRTPCR CAAAGUA omeCs;omeAs;o ST7: 18

79388 33615 vitro AGUCAAG meAs;omeAs;om 0863 U 3 2 AACCUG eGs;omeUs;ome 20

As;omeAs;omeG s;omeUs;omeCs;

omeAs;omeAs;o meGs;omeAs;om eAs;omeCs;ome

Cs;omeUs;omeG

-Sup

ST7-22 1.239 0.026 ST7 in RPTEC 100 qRTPCR UCAGCUC omeUs;omeCs;o ST7: 18

15480 85417 vitro GAUGGAA meAs;omeGs;om 1002 L2 4 GAUAUA eCs;omeUs;ome 0

Cs;omeGs;omeA s;omeUs;omeGs; Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj;

ue

omeGs;omeAs;o meAs;omeGs;om eAs;omeUs;ome

As;omeUs;omeA

-Sup

ST7-22 1.279 0.024 ST7 in RPTEC 50 qRTPCR UCAGCUC omeUs;omeCs;o ST7: 18

23425 05123 vitro GAUGGAA meAs;omeGs;om 1002 L2 1 8 GAUAUA eCs;omeUs;ome 0

Cs;omeGs;omeA s;omeUs;omeGs;

omeGs;omeAs;o meAs;omeGs;om eAs;omeUs;ome

As;omeUs;omeA

-Sup

ST7-23 0.911 0.028 ST7 in RPTEC 100 qRTPCR CUGAGAG omeCs;omeUs;o ST7: 18

52966 18807 vitro CGUCGG U meGs;omeAs;om 2850L2 3 4 AACAGC eGs;omeAs;ome 0

Gs;omeCs;omeG s;omeUs;omeCs;

omeGs;omeGs;o meUs;omeAs;om eAs;omeCs;ome

As;omeGs;omeC-

Sup

ST7-23 1.137 0.068 ST7 in RPTEC 50 qRTPCR CUGAGAG omeCs;omeUs;o ST7: 18

54746 16478 vitro CGUCGG U meGs;omeAs;om 2850L2 1 7 AACAGC eGs;omeAs;ome 0

Gs;omeCs;omeG s;omeUs;omeCs;

omeGs;omeGs;o meUs;omeAs;om eAs;omeCs;ome

As;omeGs;omeC-

Sup

ST7-24 0.963 0.029 ST7 in RPTEC 100 qRTPCR CAUCAU U omeCs;omeAs;o ST7: 18

46733 10488 vitro U UCACUG meUs;omeCs;om 5181L2 8 8 CU UCCC eAs;omeUs;ome 0

Us;omeUs;omeU s;omeCs;omeAs;

omeCs;omeUs;o meGs;omeCs;om eUs;omeUs;ome

Cs;omeCs;omeC-

Sup

ST7-24 0.930 0.079 ST7 in RPTEC 50 qRTPCR CAUCAU U omeCs;omeAs;o ST7: 18

45924 50742 vitro U UCACUG meUs;omeCs;om 5181L2 2 4 CU UCCC eAs;omeUs;ome 0

Us;omeUs;omeU Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;omeCs;omeAs;

omeCs;omeUs;o meGs;omeCs;om eUs;omeUs;ome

Cs;omeCs;omeC- Sup

ST7-25 1.219 0.012 ST7 in RPTEC 100 qRTPCR CCCUGCCC omeCs;omeCs;o ST7:22

66247 29158 vitro CAAAUUA meCs;omeUs;om 4308U 3 4 CUAAG eGs;omeCs;ome 20

Cs;omeCs;omeCs

;omeAs;omeAs;o meAs;omeUs;om eUs;omeAs;ome

Cs;omeUs;omeA s;omeAs;omeG-

Sup

ST7-25 1.225 0.017 ST7 in RPTEC 50 qRTPCR CCCUGCCC omeCs;omeCs;o ST7:22

53284 91248 vitro CAAAUUA meCs;omeUs;om 4308U 6 3 CUAAG eGs;omeCs;ome 20

Cs;omeCs;omeCs

;omeAs;omeAs;o meAs;omeUs;om eUs;omeAs;ome

Cs;omeUs;omeA s;omeAs;omeG-

Sup

ST7-26 1.221 0.025 ST7 in RPTEC 100 qRTPCR U UUGGAC omeUs;omeUs;o ST7:22

77128 71511 vitro AAUAGAG meUs;omeGs;o 7971L2 4 2 UCAUAC meGs;omeAs;om 0 eCs;omeAs;ome

As;omeUs;omeA s;omeGs;omeAs;

omeGs;omeUs;o meCs;omeAs;om eUs;omeAs;ome

C-Sup

ST7-26 1.326 0.050 ST7 in RPTEC 50 qRTPCR U UUGGAC omeUs;omeUs;o ST7:22

96644 33355 vitro AAUAGAG meUs;omeGs;o 7971L2 2 1 UCAUAC meGs;omeAs;om 0 eCs;omeAs;ome

As;omeUs;omeA s;omeGs;omeAs;

omeGs;omeUs;o meCs;omeAs;om eUs;omeAs;ome

C-Sup

ST7-27 1.247 0.011 ST7 in RPTEC 100 qRTPCR CAGAUGA omeCs;omeAs;o ST7:23

86654 73800 vitro AAGAGCA meGs;omeAs;om 6615U 3 8 UAGAUG eUs;omeGs;ome 20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

As;omeAs;omeA s;omeGs;omeAs;

omeGs;omeCs;o meAs;omeUs;om eAs;omeGs;ome

As;omeUs;omeG

-Sup

ST7-27 1.285 0.019 ST7 in RPTEC 50 qRTPCR CAGAUGA omeCs;omeAs;o ST7:23

58175 05901 vitro AAGAGCA meGs;omeAs;om 6615U

8 UAGAUG eUs;omeGs;ome 20

As;omeAs;omeA s;omeGs;omeAs;

omeGs;omeCs;o meAs;omeUs;om eAs;omeGs;ome

As;omeUs;omeG

-Sup

ST7-28 1.312 0.051 ST7 in RPTEC 100 qRTPCR CUU U UAU omeCs;omeUs;o ST7:26

15354 86443 vitro GCCCU UG meUs;omeUs;o 8778L2 4 1 GCU UUC meUs;omeAs;om 0 eUs;omeGs;ome

Cs;omeCs;omeCs

;omeUs;omeUs;

omeGs;omeGs;o meCs;omeUs;om eUs;omeUs;ome

C-Sup

ST7-28 1.247 0.043 ST7 in RPTEC 50 qRTPCR CUU U UAU omeCs;omeUs;o ST7:26

03972 42659 vitro GCCCU UG meUs;omeUs;o 8778L2 7 4 GCU UUC meUs;omeAs;om 0 eUs;omeGs;ome

Cs;omeCs;omeCs

;omeUs;omeUs;

omeGs;omeGs;o meCs;omeUs;om eUs;omeUs;ome

C-Sup

ST7-29 1.287 0.038 ST7 in RPTEC 100 qRTPCR GCU U UGA omeGs;omeCs;o ST7:26

56567 47246 vitro U UCCAUU meUs;omeUs;o 8877 L2 4 1 GACGAU meUs;omeGs;o 0 meAs;omeUs;om eUs;omeCs;ome

Cs;omeAs;omeU s;omeUs;omeGs;

omeAs;omeCs;o meGs;omeAs;om eU-Sup

ST7-29 1.395 0.020 ST7 in RPTEC 50 qRTPCR GCU U UGA omeGs;omeCs;o ST7:26

45518 03969 vitro U UCCAUU meUs;omeUs;o 8877 L2 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

5 7 GACGAU meUs;omeGs;o 0 meAs;omeUs;om eUs;omeCs;ome

Cs;omeAs;omeU s;omeUs;omeGs;

omeAs;omeCs;o meGs;omeAs;om eU-Sup

ST7-30 1.205 0.065 ST7 in RPTEC 100 qRTPCR CCCU UAA omeCs;omeCs;o ST7:26

36071 51695 vitro UGCUU UG meCs;omeUs;om 8885 L2 1 6 AU UCCA eUs;omeAs;ome 0

As;omeUs;omeG s;omeCs;omeUs;

omeUs;omeUs;o meGs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeA-

Sup

ST7-30 1.162 0.018 ST7 in RPTEC 50 qRTPCR CCCU UAA omeCs;omeCs;o ST7:26

69994 65037 vitro UGCUU UG meCs;omeUs;om 8885 L2

2 AU UCCA eUs;omeAs;ome 0

As;omeUs;omeG s;omeCs;omeUs;

omeUs;omeUs;o meGs;omeAs;om eUs;omeUs;ome

Cs;omeCs;omeA-

Sup

STAT3-01 0.680 0.097 STAT in Hep3B 10 qRTPCR UACCUGC dTs;lnaAs;dCs;ln STAT3:

81293 98430 3 vitro AUUCUGC aCs;dTs;lnaGs;dC 72687 7 2 C s;lnaAs;dTs;lnaTs U 15

;dCs;lnaTs;dGs;ln aCs;dC-Sup

STAT3-02 0.714 0.073 STAT in Hep3B 10 qRTPCR GU UGACC dGs;lnaTs;dTs;ln STAT3:

23946 91344 3 vitro UCGGAGU aGs;dAs;lnaCs;dC 72610 7 5 G s;lnaTs;dCs;lnaGs U 15

;dGs;lnaAs;dGs;l naTs;dG-Sup

STAT3-03 0.770 0.038 STAT in Hep3B 10 qRTPCR AUG UGAG dAs;lnaTs;dGs;ln STAT3:

81487 45434 3 vitro GAGCUGA aTs;dGs;lnaAs;d 72638 3 7 G Gs;lnaGs;dAs;lna U 15

Gs;dCs;lnaTs;dGs

;lnaAs;dG-Sup

STAT3-04 0.999 0.096 STAT in Hep3B 10 qRTPCR UAUCCCU dTs;lnaAs;dTs;ln STAT3:

31236 36287 3 vitro GGGAAUG aCs;dCs;lnaCs;dT 71256 4 7 G s;lnaGs;dGs;lnaG U 15 s;dAs;lnaAs;dTs;l naGs;dG-Sup

STAT3-05 1.213 0.020 STAT in Hep3B 10 qRTPCR uccuuuc dTs;lnaCs;dCs;ln STAT3: Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

04667 80021 3 vitro CUGCCCA aTs;dTs;lnaTs;dC 68410 2 6 G s;lnaCs;dTs;lnaGs U 15

;dCs;lnaCs;dCs;ln aAs;dG-Sup

STAT3-06 0.781 0.061 STAT in Hep3B 10 qRTPCR GUCAGCG dGs;lnaTs;dCs;ln STAT3:

95959 32841 3 vitro U U UCCUC aAs;dGs;lnaCs;d 68429 7 5 A Gs;lnaTs;dTs;lna U 15

Ts;dCs;lnaCs;dTs;

lnaCs;dA-Sup

STAT3-07 0.836 0.118 STAT in Hep3B 10 qRTPCR CCAGGCA dCs;lnaCs;dAs;ln STAT3:

41565 73294 3 vitro CUCAUCA aGs;dGs;lnaCs;d 68448 2 7 G As;lnaCs;dTs;lna U 15

Cs;dAs;lnaTs;dCs

;lnaAs;dG-Sup

STAT3-08 1.071 0.297 STAT in Hep3B 10 qRTPCR UGGGAGU dTs;lnaGs;dGs;ln STAT3:

50322 06325 3 vitro AUGGU UU aGs;dAs;lnaGs;d 66790 9 4 A Ts;lnaAs;dTs;lna U 15

Gs;dGs;lnaTs;dTs

;lnaTs;dA-Sup

STAT3-09 0.650 0.109 STAT in Hep3B 10 qRTPCR UACACUA dTs;lnaAs;dCs;ln STAT3:

05666 65405 3 vitro GAG UAGA aAs;dCs;lnaTs;dA 66803 2 4 A s;lnaGs;dAs;lnaG U 15 s;dTs;lnaAs;dGs;l naAs;dA-Sup

STAT3-10 0.700 0.116 STAT in Hep3B 10 qRTPCR AGGCAU U dAs;lnaGs;dGs;ln STAT3:

10030 51817 3 vitro CGGAAAG aCs;dAs;lnaTs;dT 66047 3 8 U s;lnaCs;dGs;lnaG U 15 s;dAs;lnaAs;dAs;l naGs;dT-Sup

STAT3-11 1.021 0.228 STAT in Hep3B 10 qRTPCR U UGGG UG dTs;lnaTs;dGs;ln STAT3:

18476 81409 3 vitro GAGAAGG aGs;dGs;lnaTs;d 65362 4 3 A Gs;lnaGs;dAs;lna U 15

Gs;dAs;lnaAs;dG s;lnaGs;dA-Sup

STAT3-12 0.953 0.159 STAT in Hep3B 10 qRTPCR AGAGG UA dAs;lnaGs;dAs;ln STAT3:

57477 33069 3 vitro AGU UCUG aGs;dGs;lnaTs;d 62269 5 C As;lnaAs;dGs;lna U 15

Ts;dTs;lnaCs;dTs;

lnaGs;dC-Sup

STAT3-13 0.647 0.011 STAT in Hep3B 10 qRTPCR UGCAGCA dTs;lnaGs;dCs;ln STAT3:

06358 96402 3 vitro GAAUCGG aAs;dGs;lnaCs;d 62389

A As;lnaGs;dAs;lna U 15

As;dTs;lnaCs;dGs

;lnaGs;dA-Sup

STAT3-14 0.637 0.139 STAT in Hep3B 10 qRTPCR UCUGCAG dTs;lnaCs;dTs;lna STAT3:

52956 37564 3 vitro AAU UCAA Gs;dCs;lnaAs;dG 58814 3 2 A s;lnaAs;dAs;lnaTs U 15

;dTs;lnaCs;dAs;ln aAs;dA-Sup Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

STAT3-15 0.628 0.078 STAT in Hep3B 10 qRTPCR ACACU UG dAs;lnaCs;dAs;ln STAT3:

04006 78735 3 vitro G UAUG UG aCs;dTs;lnaTs;dG 58828 8 9 G s;lnaGs;dTs;lnaA U 15 s;dTs;lnaGs;dTs;l naGs;dG-Sup

STAT3-16 0.690 0.135 STAT in Hep3B 10 qRTPCR CAU UGAC dCs;lnaAs;dTs;ln STAT3:

18219 96219 3 vitro AAGUCCG aTs;dGs;lnaAs;dC 57016 6 9 U s;lnaAs;dAs;lnaG U 15 s;dTs;lnaCs;dCs;l naGs;dT-Sup

STAT3-17 0.976 0.086 STAT in Hep3B 10 qRTPCR UG UACAG dTs;lnaGs;dTs;ln STAT3:

43023 65291 3 vitro CACCGGC aAs;dCs;lnaAs;d 54435 6 6 C Gs;lnaCs;dAs;lna U 15

Cs;dCs;lnaGs;dGs

;lnaCs;dC-Sup

STAT3-18 0.965 0.042 STAT in Hep3B 10 qRTPCR AGAGGCG dAs;lnaGs;dAs;ln STAT3:

29563 38028 3 vitro GCAACAG aGs;dGs;lnaCs;d 50887 4 6 A Gs;lnaGs;dCs;lna U 15

As;dAs;lnaCs;dAs

;lnaGs;dA-Sup

STAT3-19 NA NA STAT NA NA 0 NA AGGAUGA dAs;lnaGs;dGs;ln STAT3:

3 CU U UGAU aAs;dTs;lnaGs;dA 49613

U s;lnaCs;dTs;lnaTs U 15 ;dTs;lnaGs;dAs;ln aTs;dT-Sup

STAT3-20 0.610 0.147 STAT in Hep3B 10 qRTPCR CUAUAAA dCs;lnaTs;dAs;ln STAT3:

60816 14544 3 vitro ACCCUCA aTs;dAs;lnaAs;dA 49632 3 A s;lnaAs;dCs;lnaCs U 15

;dCs;lnaTs;dCs;ln aAs;dA-Sup

STAT3-21 0.697 0.148 STAT in Hep3B 10 qRTPCR GCAGCAG dGs;lnaCs;dAs;ln STAT3:

49850 77837 3 vitro AUGCUGG aGs;dCs;lnaAs;d 49026 4 9 A Gs;lnaAs;dTs;lna U 15

Gs;dCs;lnaTs;dGs

;lnaGs;dA-Sup

STAT3-22 0.778 0.163 STAT in Hep3B 10 qRTPCR UGGAGCU dTs;lnaGs;dGs;ln STAT3:

87246 86159 3 vitro GCGGCAG aAs;dGs;lnaCs;dT 39954 6 6 U s;lnaGs;dCs;lnaG U 15 s;dGs;lnaCs;dAs;l naGs;dT-Sup

STAT3-23 0.559 0.207 STAT in Hep3B 10 qRTPCR UGACAGC dTs;lnaGs;dAs;ln STAT3:

62496 80565 3 vitro U UCCCAA aCs;dAs;lnaGs;dC 39940 5 6 U s;lnaTs;dTs;lnaCs U 15

;dCs;lnaCs;dAs;ln aAs;dT-Sup

STAT3-24 0.693 0.201 STAT in Hep3B 10 qRTPCR U UCCU UC dTs;lnaTs;dCs;lna STAT3:

55571 8482 3 vitro UCUGU UG Cs;dTs;lnaTs;dCs; 38779 5 U lnaTs;dCs;lnaTs;d U 15

Gs;lnaTs;dTs;lna Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Gs;dT-Sup

STAT3-25 0.593 0.221 STAT in Hep3B 10 qRTPCR UG UAGAA dTs;lnaGs;dTs;ln STAT3:

03203 70907 3 vitro UAACUAU aAs;dGs;lnaAs;d 33480

7 U As;lnaTs;dAs;lna U 15

As;dCs;lnaTs;dAs

;lnaTs;dT-Sup

STAT3-26 NA NA STAT NA NA 0 NA UAAAGUA dTs;lnaAs;dAs;ln STAT3:

3 U UACCUA aAs;dGs;lnaTs;dA 33494

U s;lnaTs;dTs;lnaAs U 15

;dCs;lnaCs;dTs;ln aAs;dT-Sup

STAT3-27 NA NA STAT NA NA 0 NA AUG UG UG dAs;lnaTs;dGs;ln STAT3:

3 AGGGCCA aTs;dGs;lnaTs;dG 25470

G s;lnaAs;dGs;lnaG U 15 s;dGs;lnaCs;dCs;l naAs;dG-Sup

STAT3-28 1.068 0.238 STAT in Hep3B 10 qRTPCR AGGAGCC dAs;lnaGs;dGs;ln STAT3:

81392 57380 3 vitro UGGUGU U aAs;dGs;lnaCs;dC 25493 5 8 U s;lnaTs;dGs;lnaG U 15 s;dTs;lnaGs;dTs;l naTs;dT-Sup

STAT3-29 0.759 0.094 STAT in Hep3B 10 qRTPCR U UGUGUC dTs;lnaTs;dGs;ln STAT3:

59175 08379 3 vitro UCAGGAA aTs;dGs;lnaTs;dC 8764U 7 8 G s;lnaTs;dCs;lnaAs 15

;dGs;lnaGs;dAs;l naAs;dG-Sup

STAT3-30 0.457 0.067 STAT in Hep3B 10 qRTPCR AAGCCAA dAs;lnaAs;dGs;ln STAT3:

09971 94825 3 vitro CAGGAGG aCs;dCs;lnaAs;dA 8779U 5 4 A s;lnaCs;dAs;lnaG 15 s;dGs;lnaAs;dGs;l naGs;dA-Sup

STAT3-31 0.914 0.037 STAT in Hep3B 10 qRTPCR U UAAUAU dTs;lnaTs;dAs;ln STAT3:

39092 47513 3 vitro GGUGGU U aAs;dTs;lnaAs;dT 4736U

2 A s;lnaGs;dGs;lnaT 15 s;dGs;lnaGs;dTs;l naTs;dA-Sup

STAT3-31 1.248 0.051 STAT in Hep3B 30 qRTPCR U UAAUAU dTs;lnaTs;dAs;ln STAT3:

66221 93176 3 vitro GGUGGU U aAs;dTs;lnaAs;dT 4736U

6 A s;lnaGs;dGs;lnaT 15 s;dGs;lnaGs;dTs;l naTs;dA-Sup

STAT3-31 0.593 0.001 STAT in Hep3B 10 qRTPCR U UAAUAU dTs;lnaTs;dAs;ln STAT3:

41428 98565 3 vitro GGUGGU U aAs;dTs;lnaAs;dT 4736U 2 6 A s;lnaGs;dGs;lnaT 15 s;dGs;lnaGs;dTs;l naTs;dA-Sup

STAT3-32 1.044 0.042 STAT in Hep3B 10 qRTPCR AUAUACU dAs;lnaTs;dAs;ln STAT3:

80633 08867 3 vitro CU U UG UU aTs;dAs;lnaCs;dT 4750U 3 5 A s;lnaCs;dTs;lnaTs 15 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

;dTs;lnaGs;dTs;ln aTs;dA-Sup

STAT3-32 1.519 0.017 STAT in Hep3B 30 qRTPCR AUAUACU dAs;lnaTs;dAs;ln STAT3:

95050 85135 3 vitro CU U UG UU aTs;dAs;lnaCs;dT 4750U 8 A s;lnaCs;dTs;lnaTs 15

;dTs;lnaGs;dTs;ln aTs;dA-Sup

STAT3-32 0.594 0.014 STAT in Hep3B 10 qRTPCR AUAUACU dAs;lnaTs;dAs;ln STAT3:

71737 00816 3 vitro CU U UG UU aTs;dAs;lnaCs;dT 4750U 4 8 A s;lnaCs;dTs;lnaTs 15

;dTs;lnaGs;dTs;ln aTs;dA-Sup

STAT3-33 0.961 0.068 STAT in Hep3B 10 qRTPCR AAGACG U dAs;lnaAs;dGs;ln STAT3:

49676 36506 3 vitro AAGCGUA aAs;dCs;lnaGs;dT 4780U 9 8 A s;lnaAs;dAs;lnaG 15 s;dCs;lnaGs;dTs;l naAs;dA-Sup

STAT3-33 1.081 0.129 STAT in Hep3B 30 qRTPCR AAGACG U dAs;lnaAs;dGs;ln STAT3:

81472 50676 3 vitro AAGCGUA aAs;dCs;lnaGs;dT 4780U 9 2 A s;lnaAs;dAs;lnaG 15 s;dCs;lnaGs;dTs;l naAs;dA-Sup

STAT3-33 0.704 0.078 STAT in Hep3B 10 qRTPCR AAGACG U dAs;lnaAs;dGs;ln STAT3:

16357 88393 3 vitro AAGCGUA aAs;dCs;lnaGs;dT 4780U 9 8 A s;lnaAs;dAs;lnaG 15 s;dCs;lnaGs;dTs;l naAs;dA-Sup

STAT3-34 1.015 0.059 STAT in Hep3B 10 qRTPCR AACU UCU dAs;lnaAs;dCs;ln STAT3:

11885 37698 3 vitro GGUGU UC aTs;dTs;lnaCs;dT 4646U 6 6 U s;lnaGs;dGs;lnaT 15 s;dGs;lnaTs;dTs;l naCs;dT-Sup

STAT3-34 0.874 0.100 STAT in Hep3B 30 qRTPCR AACU UCU dAs;lnaAs;dCs;ln STAT3:

65826 05428 3 vitro GGUGU UC aTs;dTs;lnaCs;dT 4646U 2 U s;lnaGs;dGs;lnaT 15 s;dGs;lnaTs;dTs;l naCs;dT-Sup

STAT3-34 0.958 0.430 STAT in Hep3B 30 qRTPCR AACU UCU dAs;lnaAs;dCs;ln STAT3:

44683 93232 3 vitro GGUGU UC aTs;dTs;lnaCs;dT 4646U 6 3 U s;lnaGs;dGs;lnaT 15 s;dGs;lnaTs;dTs;l naCs;dT-Sup

STAT3-35 0.867 0.053 STAT in Hep3B 10 qRTPCR UCU UAGC dTs;lnaCs;dTs;lna STAT3:

44037 69329 3 vitro U UAUGGU Ts;dAs;lnaGs;dCs 2813U

3 U ;lnaTs;dTs;lnaAs; 15 dTs;lnaGs;dGs;ln aTs;dT-Sup

STAT3-35 1.444 0.133 STAT in Hep3B 30 qRTPCR UCU UAGC dTs;lnaCs;dTs;lna STAT3:

67655 64241 3 vitro U UAUGGU Ts;dAs;lnaGs;dCs 2813U Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

9 U ;lnaTs;dTs;lnaAs; 15 dTs;lnaGs;dGs;ln aTs;dT-Sup

STAT3-35 0.420 0.078 STAT in Hep3B 30 qRTPCR UCU UAGC dTs;lnaCs;dTs;lna STAT3:

98621 65985 3 vitro U UAUGGU Ts;dAs;lnaGs;dCs 2813U

6 U ;lnaTs;dTs;lnaAs; 15 dTs;lnaGs;dGs;ln aTs;dT-Sup

STAT3-36 1.207 0.140 STAT in Hep3B 10 qRTPCR U UAUGAC dTs;lnaTs;dAs;ln STAT3:

24920 49173 3 vitro U UGG UUC aTs;dGs;lnaAs;dC 1388U 4 3 A s;lnaTs;dTs;lnaGs 15

;dGs;lnaTs;dTs;ln aCs;dA-Sup

STAT3-36 1.939 0.128 STAT in Hep3B 30 qRTPCR U UAUGAC dTs;lnaTs;dAs;ln STAT3:

90312 94180 3 vitro U UGG UUC aTs;dGs;lnaAs;dC 1388U 5 1 A s;lnaTs;dTs;lnaGs 15

;dGs;lnaTs;dTs;ln aCs;dA-Sup

STAT3-36 0.588 0.182 STAT in Hep3B 30 qRTPCR U UAUGAC dTs;lnaTs;dAs;ln STAT3:

15623 69271 3 vitro U UGG UUC aTs;dGs;lnaAs;dC 1388U 3 4 A s;lnaTs;dTs;lnaGs 15

;dGs;lnaTs;dTs;ln aCs;dA-Sup

STAT3-37 0.814 0.050 STAT in Hep3B 10 qRTPCR GU UGUGA dGs;lnaTs;dTs;ln STAT3:

96523 09795 3 vitro UGGACGC aGs;dTs;lnaGs;d 197U 1 8 7 U As;lnaTs;dGs;lna 5

Gs;dAs;lnaCs;dG s;lnaCs;dT-Sup

STAT3-37 0.809 0.102 STAT in Hep3B 30 qRTPCR GU UGUGA dGs;lnaTs;dTs;ln STAT3:

14963 12302 3 vitro UGGACGC aGs;dTs;lnaGs;d 197U 1 3 5 U As;lnaTs;dGs;lna 5

Gs;dAs;lnaCs;dG s;lnaCs;dT-Sup

STAT3-37 0.337 0.031 STAT in Hep3B 30 qRTPCR GU UGUGA dGs;lnaTs;dTs;ln STAT3:

79008 70181 3 vitro UGGACGC aGs;dTs;lnaGs;d 197U 1

7 U As;lnaTs;dGs;lna 5

Gs;dAs;lnaCs;dG s;lnaCs;dT-Sup

Oligo I D RQ RQ SE Gene Expt Cell [Olig Assay Base Formatted Coordi

Name Type Line/Tis o] Type Sequence Sequence nates_ sue g

ADIPOQ- 0.515 0.050 ADIP in RPTEC 100 qRTPCR CUCCACU omeCs;omeUs;o ADIPO 01 14922 00792 OQ vitro AAUAGG U meCs;omeCs;om Q:6321

1 9 GCGAUC eAs;omeCs;ome L20

Us;omeAs;omeA s;omeUs;omeAs;

omeGs;omeGs;o meUs;omeGs;o meCs;omeGs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eAs;omeUs;ome

C-Sup

ADIPOQ- 0.304 0.074 ADIP in RPTEC 50 qRTPCR CUCCACU omeCs;omeUs;o ADIPO 01 93534 69020 OQ vitro AAUAGG U meCs;omeCs;om Q:6321

5 4 GCGAUC eAs;omeCs;ome L20

Us;omeAs;omeA s;omeUs;omeAs;

omeGs;omeGs;o meUs;omeGs;o meCs;omeGs;om eAs;omeUs;ome

C-Sup

ADIPOQ- 1.025 0.141 ADIP in RPTEC 100 qRTPCR U UUCUCC omeUs;omeUs;o ADIPO 02 18734 07192 OQ vitro ACUAAUA meUs;omeCs;om Q:6324

8 6 GG UGCG eUs;omeCs;ome L20

Cs;omeAs;omeCs

;omeUs;omeAs;o meAs;omeUs;om eAs;omeGs;ome

Gs;omeUs;omeG s;omeCs;omeG-

Sup

ADIPOQ- 1.381 0.050 ADIP in RPTEC 50 qRTPCR U UUCUCC omeUs;omeUs;o ADIPO 02 25517 2061 OQ vitro ACUAAUA meUs;omeCs;om Q:6324

2 GG UGCG eUs;omeCs;ome L20

Cs;omeAs;omeCs

;omeUs;omeAs;o meAs;omeUs;om eAs;omeGs;ome

Gs;omeUs;omeG s;omeCs;omeG-

Sup

ADIPOQ- 1.148 0.177 ADIP in RPTEC 100 qRTPCR AU U UCUC omeAs;omeUs;o ADIPO 03 87525 90749 OQ vitro CACUAAU meUs;omeUs;o Q:6325

2 6 AGG UGC meCs;omeUs;om L20 eCs;omeCs;ome

As;omeCs;omeU s;omeAs;omeAs;

omeUs;omeAs;o meGs;omeGs;o meUs;omeGs;o meC-Sup

ADIPOQ- 1.074 0.141 ADIP in RPTEC 50 qRTPCR AU U UCUC omeAs;omeUs;o ADIPO 03 24822 16473 OQ vitro CACUAAU meUs;omeUs;o Q:6325

4 2 AGG UGC meCs;omeUs;om L20 eCs;omeCs;ome

As;omeCs;omeU s;omeAs;omeAs;

omeUs;omeAs;o Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

meGs;omeGs;o meUs;omeGs;o meC-Sup

ADIPOQ- 1.236 0.278 ADIP in RPTEC 100 qRTPCR CAGAUU U omeCs;omeAs;o ADIPO 04 37847 19345 OQ vitro CUCCACU meGs;omeAs;om Q:6328

5 AAUAGG eUs;omeUs;ome L20

Us;omeCs;omeU s;omeCs;omeCs;

omeAs;omeCs;o meUs;omeAs;om eAs;omeUs;ome

As;omeGs;omeG

-Sup

ADIPOQ- 0.996 0.120 ADIP in RPTEC 50 qRTPCR CAGAUU U omeCs;omeAs;o ADIPO 04 15800 51522 OQ vitro CUCCACU meGs;omeAs;om Q:6328

6 5 AAUAGG eUs;omeUs;ome L20

Us;omeCs;omeU s;omeCs;omeCs;

omeAs;omeCs;o meUs;omeAs;om eAs;omeUs;ome

As;omeGs;omeG

-Sup

ADIPOQ- 1.124 0.305 ADIP in RPTEC 100 qRTPCR ACAGAU U omeAs;omeCs;o ADIPO 05 97994 62006 OQ vitro UCUCCAC meAs;omeGs;om Q:6329

5 4 UAAUAG eAs;omeUs;ome L20

Us;omeUs;omeC s;omeUs;omeCs;

omeCs;omeAs;o meCs;omeUs;om eAs;omeAs;ome

Us;omeAs;omeG

-Sup

ADIPOQ- 0.949 0.102 ADIP in RPTEC 50 qRTPCR ACAGAU U omeAs;omeCs;o ADIPO 05 37882 88237 OQ vitro UCUCCAC meAs;omeGs;om Q:6329

1 2 UAAUAG eAs;omeUs;ome L20

Us;omeUs;omeC s;omeUs;omeCs;

omeCs;omeAs;o meCs;omeUs;om eAs;omeAs;ome

Us;omeAs;omeG

-Sup

ADIPOQ- 1.019 0.071 ADIP in RPTEC 100 qRTPCR GACAGAU omeGs;omeAs;o ADIPO 06 39099 10966 OQ vitro U UCUCCA meCs;omeAs;om Q:6330

7 3 CUAAUA eGs;omeAs;ome L20

Us;omeUs;omeU s;omeCs;omeUs;

Name Type Line/Tiss ] Type Sequence ates_g ue

meAs;omeCs;om eUs;omeAs;ome

As;omeUs;omeA

-Sup

ADIPOQ- 0.956 0.119 ADIP in RPTEC 50 qRTPCR GACAGAU omeGs;omeAs;o ADIPO 06 28442 18326 OQ vitro U UCUCCA meCs;omeAs;om Q:6330

1 2 CUAAUA eGs;omeAs;ome L20

Us;omeUs;omeU s;omeCs;omeUs;

omeCs;omeCs;o meAs;omeCs;om eUs;omeAs;ome

As;omeUs;omeA

-Sup

ADIPOQ- 0.876 0.019 ADIP in RPTEC 100 qRTPCR UAUGGAC omeUs;omeAs;o ADIPO 07 26729 37335 OQ vitro AGAU UUC meUs;omeGs;o Q:6334

7 1 UCCACU meGs;omeAs;om L20 eCs;omeAs;ome

Gs;omeAs;omeU s;omeUs;omeUs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeCs;ome

U-Sup

ADIPOQ- 0.706 0.322 ADIP in RPTEC 50 qRTPCR UAUGGAC omeUs;omeAs;o ADIPO 07 47746 99302 OQ vitro AGAU UUC meUs;omeGs;o Q:6334

7 6 UCCACU meGs;omeAs;om L20 eCs;omeAs;ome

Gs;omeAs;omeU s;omeUs;omeUs;

omeCs;omeUs;o meCs;omeCs;om eAs;omeCs;ome

U-Sup

ADIPOQ- 0.722 0.319 ADIP in RPTEC 100 qRTPCR UAU UAUG omeUs;omeAs;o ADIPO 08 96530 46229 OQ vitro GACAGAU meUs;omeUs;o Q:6337

7 3 U UCUCC meAs;omeUs;om L20 eGs;omeGs;ome

As;omeCs;omeA s;omeGs;omeAs;

omeUs;omeUs;o meUs;omeCs;om eUs;omeCs;ome

C-Sup

ADIPOQ- 1.337 0.092 ADIP in RPTEC 50 qRTPCR UAU UAUG omeUs;omeAs;o ADIPO 08 80363 51062 OQ vitro GACAGAU meUs;omeUs;o Q:6337

5 8 U UCUCC meAs;omeUs;om L20 eGs;omeGs;ome

As;omeCs;omeA Oligo ID Q RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

s;omeGs;omeAs;

omeUs;omeUs;o meUs;omeCs;om eUs;omeCs;ome

C-Sup

ADIPOQ- 1.239 0.100 ADIP in RPTEC 100 qRTPCR UCAGUAU omeUs;omeCs;o ADIPO 09 22400 20399 OQ vitro UAUGGAC meAs;omeGs;om Q:6341

9 6 AGAU U U eUs;omeAs;ome L20

Us;omeUs;omeA s;omeUs;omeGs;

omeGs;omeAs;o meCs;omeAs;om eGs;omeAs;ome

Us;omeUs;omeU

-Sup

ADIPOQ- 1.252 0.096 ADIP in RPTEC 50 qRTPCR UCAGUAU omeUs;omeCs;o ADIPO 09 85827 80058 OQ vitro UAUGGAC meAs;omeGs;om Q:6341

1 2 AGAU U U eUs;omeAs;ome L20

Us;omeUs;omeA s;omeUs;omeGs;

omeGs;omeAs;o meCs;omeAs;om eGs;omeAs;ome

Us;omeUs;omeU

-Sup

ADIPOQ- 1.683 0.363 ADIP in RPTEC 100 qRTPCR U UCAGUA omeUs;omeUs;o ADIPO 10 82290 79778 OQ vitro U UAUGGA meCs;omeAs;om Q:6342

7 7 CAGAUU eGs;omeUs;ome L20

As;omeUs;omeU s;omeAs;omeUs;

omeGs;omeGs;o meAs;omeCs;om eAs;omeGs;ome

As;omeUs;omeU

-Sup

ADIPOQ- 1.793 0.240 ADIP in RPTEC 50 qRTPCR U UCAGUA omeUs;omeUs;o ADIPO 10 96163 39286 OQ vitro U UAUGGA meCs;omeAs;om Q:6342

4 CAGAUU eGs;omeUs;ome L20

As;omeUs;omeU s;omeAs;omeUs;

omeGs;omeGs;o meAs;omeCs;om eAs;omeGs;ome

As;omeUs;omeU -Sup

ADIPOQ- 1.574 0.332 ADIP in RPTEC 100 qRTPCR ACU UCAG omeAs;omeCs;o ADIPO 11 32842 84435 OQ vitro UAU UAUG meUs;omeUs;o Q:6344

4 6 GACAGA meCs;omeAs;om L20 eGs;omeUs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

As;omeUs;omeU s;omeAs;omeUs;

omeGs;omeGs;o meAs;omeCs;om eAs;omeGs;ome

A-Sup

ADIPOQ- 1.296 0.231 ADIP in RPTEC 50 qRTPCR ACU UCAG omeAs;omeCs;o ADIPO 11 81110 46412 OQ vitro UAU UAUG meUs;omeUs;o Q:6344

9 5 GACAGA meCs;omeAs;om L20 eGs;omeUs;ome

As;omeUs;omeU s;omeAs;omeUs;

omeGs;omeGs;o meAs;omeCs;om eAs;omeGs;ome

A-Sup

ADIPOQ- 1.224 0.010 ADIP in RPTEC 100 qRTPCR AACU UCA omeAs;omeAs;o ADIPO 12 49862 53095 OQ vitro G UAUUAU meCs;omeUs;om Q:6345

1 4 GGACAG eUs;omeCs;ome L20

As;omeGs;omeU s;omeAs;omeUs;

omeUs;omeAs;o meUs;omeGs;o meGs;omeAs;om eCs;omeAs;ome

G-Sup

ADIPOQ- 1.150 0.209 ADIP in RPTEC 50 qRTPCR AACU UCA omeAs;omeAs;o ADIPO 12 03175 61333 OQ vitro G UAUUAU meCs;omeUs;om Q:6345

2 7 GGACAG eUs;omeCs;ome L20

As;omeGs;omeU s;omeAs;omeUs;

omeUs;omeAs;o meUs;omeGs;o meGs;omeAs;om eCs;omeAs;ome

G-Sup

ADIPOQ- 0.647 0.300 ADIP in RPTEC 100 qRTPCR UCCUCCU omeUs;omeCs;o ADIPO 13 25684 15828 OQ vitro CUAUUCU meCs;omeUs;om Q:1117

2 1 GCCUAC eCs;omeCs;ome 2L20

Us;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meUs;omeGs;o meCs;omeCs;om eUs;omeAs;ome

C-Sup

ADIPOQ- 0.863 0.445 ADIP in RPTEC 50 qRTPCR UCCUCCU omeUs;omeCs;o ADIPO 13 62273 57552 OQ vitro CUAUUCU meCs;omeUs;om Q:1117

8 8 GCCUAC eCs;omeCs;ome 2L20 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Us;omeCs;omeU s;omeAs;omeUs;

omeUs;omeCs;o meUs;omeGs;o meCs;omeCs;om eUs;omeAs;ome

C-Sup

ADIPOQ- 0.413 0.270 ADIP in RPTEC 100 qRTPCR CUCCUCC omeCs;omeUs;o ADIPO 14 67193 1389 OQ vitro UCUAU UC meCs;omeCs;om Q:1117

2 UGCCUA eUs;omeCs;ome 3L20

Cs;omeUs;omeC s;omeUs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eGs;omeCs;ome

Cs;omeUs;omeA

-Sup

ADIPOQ- 0.166 NA ADIP in RPTEC 50 qRTPCR CUCCUCC omeCs;omeUs;o ADIPO 14 82335 OQ vitro UCUAU UC meCs;omeCs;om Q:1117

4 UGCCUA eUs;omeCs;ome 3L20

Cs;omeUs;omeC s;omeUs;omeAs;

omeUs;omeUs;o meCs;omeUs;om eGs;omeCs;ome

Cs;omeUs;omeA

-Sup

ADIPOQ- 1.123 0.036 ADIP in RPTEC 100 qRTPCR UCUCCUC omeUs;omeCs;o ADIPO 15 17662 26554 OQ vitro CUCUAUU meUs;omeCs;om Q:1117

2 7 CUGCCU eCs;omeUs;ome 4L20

Cs;omeCs;omeU s;omeCs;omeUs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeGs;ome

Cs;omeCs;omeU-

Sup

ADIPOQ- 0.770 0.356 ADIP in RPTEC 50 qRTPCR UCUCCUC omeUs;omeCs;o ADIPO 15 45229 13437 OQ vitro CUCUAUU meUs;omeCs;om Q:1117

6 8 CUGCCU eCs;omeUs;ome 4L20

Cs;omeCs;omeU s;omeCs;omeUs;

omeAs;omeUs;o meUs;omeCs;om eUs;omeGs;ome

Cs;omeCs;omeU-

Sup

ADIPOQ- 1.360 0.161 ADIP in RPTEC 100 qRTPCR cucuccu omeCs;omeUs;o ADIPO 16 62854 88525 OQ vitro CCUCUAU meCs;omeUs;om Q:1117 Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

8 7 UCUGCC eCs;omeCs;ome 5L20

Us;omeCs;omeC s;omeUs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeUs;om eGs;omeCs;ome

C-Sup

ADIPOQ- 1.231 0.099 ADIP in RPTEC 50 qRTPCR cucuccu omeCs;omeUs;o ADIPO 16 82067 65215 OQ vitro CCUCUAU meCs;omeUs;om Q:1117

8 5 UCUGCC eCs;omeCs;ome 5L20

Us;omeCs;omeC s;omeUs;omeCs;

omeUs;omeAs;o meUs;omeUs;o meCs;omeUs;om eGs;omeCs;ome

C-Sup

ADIPOQ- 0.971 0.077 ADIP in RPTEC 100 qRTPCR GUCUCUC omeGs;omeUs;o ADIPO 17 84944 07272 OQ vitro cuccucu meCs;omeUs;om Q:1117

5 5 AUUCUG eCs;omeUs;ome 7L20

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeUs;omeG

-Sup

ADIPOQ- 1.101 0.076 ADIP in RPTEC 50 qRTPCR GUCUCUC omeGs;omeUs;o ADIPO 17 14748 40098 OQ vitro CUCCUCU meCs;omeUs;om Q:1117

8 8 AUUCUG eCs;omeUs;ome 7L20

Cs;omeCs;omeU s;omeCs;omeCs;

omeUs;omeCs;o meUs;omeAs;om eUs;omeUs;ome

Cs;omeUs;omeG

-Sup

ADIPOQ- 1.145 0.219 ADIP in RPTEC 100 qRTPCR GGAUGUC omeGs;omeGs;o ADIPO 18 67488 48812 OQ vitro UCUCCUC meAs;omeUs;om Q:1118

3 7 CUCUAU eGs;omeUs;ome 1L20

Cs;omeUs;omeC s;omeUs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eUs;omeCs;ome

Us;omeAs;omeU

-Sup

ADIPOQ- 1.378 NA ADIP in RPTEC 50 qRTPCR GGAUGUC omeGs;omeGs;o ADI PO Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

18 78085 OQ vitro ucuccuc meAs;omeUs;om Q:1118

4 CUCUAU eGs;omeUs;ome 1L20

Cs;omeUs;omeC s;omeUs;omeCs;

omeCs;omeUs;o meCs;omeCs;om eUs;omeCs;ome

Us;omeAs;omeU

-Sup

ADIPOQ- 1.045 0.133 ADIP in RPTEC 100 qRTPCR AUCUAGG omeAs;omeUs;o ADIPO

19 22097 96060 OQ vitro AUG UCUC meCs;omeUs;om Q:1118

5 3 UCCUCC eAs;omeGs;ome 6L20

Gs;omeAs;omeU s;omeGs;omeUs;

omeCs;omeUs;o meCs;omeUs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

ADIPOQ- 0.925 0.152 ADIP in RPTEC 50 qRTPCR AUCUAGG omeAs;omeUs;o ADIPO

19 39615 99917 OQ vitro AUG UCUC meCs;omeUs;om Q:1118

3 1 UCCUCC eAs;omeGs;ome 6L20

Gs;omeAs;omeU s;omeGs;omeUs;

omeCs;omeUs;o meCs;omeUs;om eCs;omeCs;ome

Us;omeCs;omeC-

Sup

ADIPOQ- 1.217 0.169 ADIP in RPTEC 100 qRTPCR CAUCUAG omeCs;omeAs;o ADIPO

20 73063 30608 OQ vitro GAUGUCU meUs;omeCs;om Q:1118

5 CUCCUC eUs;omeAs;ome 7L20

Gs;omeGs;omeA s;omeUs;omeGs;

omeUs;omeCs;o meUs;omeCs;om eUs;omeCs;ome

Cs;omeUs;omeC-

Sup

ADIPOQ- 1.253 0.131 ADIP in RPTEC 50 qRTPCR CAUCUAG omeCs;omeAs;o ADIPO

20 72617 33298 OQ vitro GAUGUCU meUs;omeCs;om Q:1118

6 6 CUCCUC eUs;omeAs;ome 7L20

Gs;omeGs;omeA s;omeUs;omeGs;

omeUs;omeCs;o meUs;omeCs;om eUs;omeCs;ome

Cs;omeUs;omeC-

Sup Oligo I RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence atesj> ue

ADIPOQ- 0.929 0.235 ADIP in RPTEC 100 qRTPCR CUCCAUC omeCs;omeUs;o ADIPO

21 66678 21238 OQ vitro UAGGAUG meCs;omeCs;om Q:1119

7 2 UCUCUC eAs;omeUs;ome 0L20

Cs;omeUs;omeA s;omeGs;omeGs;

omeAs;omeUs;o meGs;omeUs;o meCs;omeUs;om eCs;omeUs;ome

C-Sup

ADIPOQ- 1.440 0.112 ADIP in RPTEC 50 qRTPCR CUCCAUC omeCs;omeUs;o ADIPO

21 50684 72446 OQ vitro UAGGAUG meCs;omeCs;om Q:1119

8 4 UCUCUC eAs;omeUs;ome 0L20

Cs;omeUs;omeA s;omeGs;omeGs;

omeAs;omeUs;o meGs;omeUs;o meCs;omeUs;om eCs;omeUs;ome

C-Sup

ADIPOQ- 1.421 0.142 ADIP in RPTEC 100 qRTPCR CCUCCAU omeCs;omeCs;o ADIPO

22 28841 88092 OQ vitro CUAGGAU meUs;omeCs;om Q:1119

8 7 G UCUCU eCs;omeAs;ome 1L20

Us;omeCs;omeU s;omeAs;omeGs;

omeGs;omeAs;o meUs;omeGs;o meUs;omeCs;om eUs;omeCs;ome

U-Sup

ADIPOQ- 1.006 0.058 ADIP in RPTEC 50 qRTPCR CCUCCAU omeCs;omeCs;o ADIPO

22 71183 11564 OQ vitro CUAGGAU meUs;omeCs;om Q:1119

9 3 G UCUCU eCs;omeAs;ome 1L20

Us;omeCs;omeU s;omeAs;omeGs;

omeGs;omeAs;o meUs;omeGs;o meUs;omeCs;om eUs;omeCs;ome

U-Sup

ADIPOQ- 1.550 0.160 ADIP in RPTEC 100 qRTPCR CCCUCCA omeCs;omeCs;o ADIPO

23 26205 22053 OQ vitro UCUAGGA meCs;omeUs;om Q:1119

7 5 UG UCUC eCs;omeCs;ome 2L20

As;omeUs;omeC s;omeUs;omeAs;

omeGs;omeGs;o meAs;omeUs;om eGs;omeUs;ome

Cs;omeUs;omeC- Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

Sup

ADIPOQ- 1.428 0.050 ADIP in RPTEC 50 qRTPCR CCCUCCA omeCs;omeCs;o ADIPO 23 85124 12771 OQ vitro UCUAGGA meCs;omeUs;om Q:1119

7 2 UG UCUC eCs;omeCs;ome 2L20

As;omeUs;omeC s;omeUs;omeAs;

omeGs;omeGs;o meAs;omeUs;om eGs;omeUs;ome

Cs;omeUs;omeC-

Sup

ADIPOQ- 1.009 0.118 ADIP in RPTEC 100 qRTPCR CCCCUCCA omeCs;omeCs;o ADIPO 24 91172 56009 OQ vitro UCUAGGA meCs;omeCs;om Q:1119

2 4 UGUCU eUs;omeCs;ome 3L20

Cs;omeAs;omeU s;omeCs;omeUs;

omeAs;omeGs;o meGs;omeAs;om eUs;omeGs;ome

Us;omeCs;omeU

-Sup

ADIPOQ- 1.014 0.060 ADIP in RPTEC 50 qRTPCR CCCCUCCA omeCs;omeCs;o ADIPO 24 58272 07473 OQ vitro UCUAGGA meCs;omeCs;om Q:1119

1 6 UGUCU eUs;omeCs;ome 3L20

Cs;omeAs;omeU s;omeCs;omeUs;

omeAs;omeGs;o meGs;omeAs;om eUs;omeGs;ome

Us;omeCs;omeU

-Sup

ADIPOQ- 0.594 0.184 ADIP in RPTEC 100 qRTPCR AUCU UCU omeAs;omeUs;o ADIPO 25 58886 76916 OQ vitro ACAAUCA meCs;omeUs;om Q:1169

8 4 GCAAAA eUs;omeCs;ome 9U20

Us;omeAs;omeC s;omeAs;omeAs;

omeUs;omeCs;o meAs;omeGs;om eCs;omeAs;ome

As;omeAs;omeA-

Sup

ADIPOQ- 1.016 0.053 ADIP in RPTEC 50 qRTPCR AUCU UCU omeAs;omeUs;o ADIPO 25 47738 39948 OQ vitro ACAAUCA meCs;omeUs;om Q:1169

3 6 GCAAAA eUs;omeCs;ome 9U20

Us;omeAs;omeC s;omeAs;omeAs;

omeUs;omeCs;o meAs;omeGs;om eCs;omeAs;ome Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

As;omeAs;omeA- Sup

ADIPOQ- 1.091 0.175 ADIP in RPTEC 100 qRTPCR CU UCUAC omeCs;omeUs;o ADIPO 26 72675 37426 OQ vitro AAUCAGC meUs;omeCs;om Q:1170

8 8 AAAACC eUs;omeAs;ome 1U20

Cs;omeAs;omeA s;omeUs;omeCs;

omeAs;omeGs;o meCs;omeAs;om eAs;omeAs;ome

As;omeCs;omeC-

Sup

ADIPOQ- 0.924 0.330 ADIP in RPTEC 50 qRTPCR CU UCUAC omeCs;omeUs;o ADIPO 26 67787 17401 OQ vitro AAUCAGC meUs;omeCs;om Q:1170

5 8 AAAACC eUs;omeAs;ome 1U20

Cs;omeAs;omeA s;omeUs;omeCs;

omeAs;omeGs;o meCs;omeAs;om eAs;omeAs;ome

As;omeCs;omeC-

Sup

ADIPOQ- 1.212 0.048 ADIP in RPTEC 100 qRTPCR UCUACAA omeUs;omeCs;o ADIPO 27 25523 19870 OQ vitro UCAGCAA meUs;omeAs;om Q:1170

4 AACCAC eCs;omeAs;ome 3U20

As;omeUs;omeC s;omeAs;omeGs;

omeCs;omeAs;o meAs;omeAs;om eAs;omeCs;ome

Cs;omeAs;omeC-

Sup

ADIPOQ- 1.169 0.154 ADIP in RPTEC 50 qRTPCR UCUACAA omeUs;omeCs;o ADIPO 27 66985 74619 OQ vitro UCAGCAA meUs;omeAs;om Q:1170

1 9 AACCAC eCs;omeAs;ome 3U20

As;omeUs;omeC s;omeAs;omeGs;

omeCs;omeAs;o meAs;omeAs;om eAs;omeCs;ome

Cs;omeAs;omeC-

Sup

ADIPOQ- 1.056 0.100 ADIP in RPTEC 100 qRTPCR CUACAAU omeCs;omeUs;o ADIPO 28 96366 09712 OQ vitro CAGCAAA meAs;omeCs;om Q:1170

9 ACCACU eAs;omeAs;ome 4U20

Us;omeCs;omeA s;omeGs;omeCs;

omeAs;omeAs;o meAs;omeAs;om Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

eCs;omeCs;ome

As;omeCs;omeU

-Sup

ADIPOQ- 0.927 0.058 ADIP in RPTEC 50 qRTPCR CUACAAU omeCs;omeUs;o ADIPO 28 77065 52773 OQ vitro CAGCAAA meAs;omeCs;om Q:1170

7 ACCACU eAs;omeAs;ome 4U20

Us;omeCs;omeA s;omeGs;omeCs;

omeAs;omeAs;o meAs;omeAs;om eCs;omeCs;ome

As;omeCs;omeU

-Sup

ADIPOQ- 1.128 0.112 ADIP in RPTEC 100 qRTPCR ACAAUCA omeAs;omeCs;o ADIPO 29 55195 33464 OQ vitro GCAAAAC meAs;omeAs;om Q:1170

2 CACUAU eUs;omeCs;ome 6U20

As;omeGs;omeC s;omeAs;omeAs;

omeAs;omeAs;o meCs;omeCs;om eAs;omeCs;ome

Us;omeAs;omeU

-Sup

ADIPOQ- 0.581 0.130 ADIP in RPTEC 50 qRTPCR ACAAUCA omeAs;omeCs;o ADIPO 29 43590 78237 OQ vitro GCAAAAC meAs;omeAs;om Q:1170

1 8 CACUAU eUs;omeCs;ome 6U20

As;omeGs;omeC s;omeAs;omeAs;

omeAs;omeAs;o meCs;omeCs;om eAs;omeCs;ome

Us;omeAs;omeU

-Sup

ADIPOQ- 0.639 0.106 ADIP in RPTEC 100 qRTPCR CAAUCAG omeCs;omeAs;o ADIPO 30 87927 81572 OQ vitro CAAAACC meAs;omeUs;om Q:1170

7 9 ACUAUG eCs;omeAs;ome 7U20

Gs;omeCs;omeA s;omeAs;omeAs;

omeAs;omeCs;o meCs;omeAs;om eCs;omeUs;ome

As;omeUs;omeG

-Sup

ADIPOQ- 0.736 0.085 ADIP in RPTEC 50 qRTPCR CAAUCAG omeCs;omeAs;o ADIPO 30 3361 19554 OQ vitro CAAAACC meAs;omeUs;om Q:1170

8 ACUAUG eCs;omeAs;ome 7U20

Gs;omeCs;omeA s;omeAs;omeAs;

omeAs;omeCs;o Oligo ID RQ RQ SE Gene Expt Cell [Oligo Assay Base Formatted Sequence Coordin

Name Type Line/Tiss ] Type Sequence ates_g ue

meCs;omeAs;om eCs;omeUs;ome

As;omeUs;omeG

-Sup

Table 5: Oligonucleotide sequences made for testing in the lab.

SeqID Oligo Oligos Avg RQ Avg RQ SE Target [oligo] cell line Assay

Name Type

954316 CEP290- 1 1.0416402 0.036096998 CEP290 30 A PE19 qRTPCR

01 mOl

902370 CEP290- 2 1.27450807 0.054221217 CEP290 30 ARPE19 qRTPCR

02 mOl

902371 CEP290- 3 0.9428591 0.027875026 CEP290 30 ARPE19 qRTPCR

03 mOl

902373 CEP290- 4 1.09271782 0.04108145 CEP290 30 ARPE19 qRTPCR

04m01

907318 CEP290- 5 0.09832549 0.013344853 CEP290 30 ARPE19 qRTPCR

05 mOl

907319 CEP290- 6 0.12442296 0.007198073 CEP290 30 ARPE19 qRTPCR

06m01

907320 CEP290- 7 0.16861203 0.010712861 CEP290 30 ARPE19 qRTPCR

07 mOl

907321 CEP290- 8 0.25142385 0.021758031 CEP290 30 ARPE19 qRTPCR

08 mOl

907712 CEP290- 9 0.83865195 0.023355566 CEP290 30 ARPE19 qRTPCR

09 mOl

910029 CEP290- 10 0.09903006 0.006184909 CEP290 30 ARPE19 qRTPCR lOmOl

910032 CEP290- 11 0.11772221 0.016956102 CEP290 30 ARPE19 qRTPCR

11 mOl

910036 CEP290- 12 0.23171022 0.007178508 CEP290 30 ARPE19 qRTPCR

12 mOl

910037 CEP290- 13 0.20367464 0.013015179 CEP290 30 ARPE19 qRTPCR

13 mOl

910038 CEP290- 14 0.06090379 0.012455375 CEP290 30 ARPE19 qRTPCR

14m01

910039 CEP290- 15 0.11417853 0.01229879 CEP290 30 ARPE19 qRTPCR

15 mOl

910041 CEP290- 16 0.05252015 0.007925117 CEP290 30 ARPE19 qRTPCR

16m01

910681 CEP290- 17 0.86631525 0.031980981 CEP290 30 ARPE19 qRTPCR

17 mOl 910684 CEP290- 18 1.0631187 0.006804705 CEP290 30 A PE19 qRTPCR 18 mOl

910913 CEP290- 19 0.79333172 0.0187856 CEP290 30 ARPE19 qRTPCR

19 mOl

910914 CEP290- 20 0.80226201 0.02600059 CEP290 30 ARPE19 qRTPCR

20 m01

910916 CEP290- 21 0.76461391 0.023626069 CEP290 30 ARPE19 qRTPCR

21 mOl

910917 CEP290- 22 0.70594073 0.042045901 CEP290 30 ARPE19 qRTPCR

22 mOl

910918 CEP290- 23 0.68037828 0.028671495 CEP290 30 ARPE19 qRTPCR

23 mOl

910919 CEP290- 24 0.75941031 0.014614815 CEP290 30 ARPE19 qRTPCR

24 m01

910920 CEP290- 25 1.00011088 0.029045969 CEP290 30 ARPE19 qRTPCR

25 mOl

910923 CEP290- 26 0.94641261 0.013086455 CEP290 30 ARPE19 qRTPCR

26 m01

910924 CEP290- 27 1.0228747 0.038722299 CEP290 30 ARPE19 qRTPCR

27 mOl

910925 CEP290- 28 1.13165663 0.015959587 CEP290 30 ARPE19 qRTPCR

28 mOl

917988 CEP290- 29 0.95116952 0.048890759 CEP290 30 ARPE19 qRTPCR

29 mOl

917989 CEP290- 30 1.01860563 0.056667541 CEP290 30 ARPE19 qRTPCR

30 m01

Ctrl Un Un 0.94206047 0.042626911 CEP290 30 ARPE19 qRTPCR

Ctrl Lipo Lipo 1 0.040054174 CEP290 30 ARPE19 qRTPCR

917991 CEP290- 31 0.88899689 0.028353039 CEP290 30 ARPE19 qRTPCR

31 mOl

917992 CEP290- 32 0.84010418 0.029349559 CEP290 30 ARPE19 qRTPCR

32 mOl

921640 CEP290- 33 0.98468041 0.044455323 CEP290 30 ARPE19 qRTPCR

33 mOl

921641 CEP290- 34 1.08670485 0.008700861 CEP290 30 ARPE19 qRTPCR

34 m01

921642 CEP290- 35 0.77512037 0.011206871 CEP290 30 ARPE19 qRTPCR

35 mOl

956697 CEP290- 36 0.78211427 0.036933702 CEP290 30 ARPE19 qRTPCR

36 m01

924441 CEP290- 37 0.61806369 0.007799104 CEP290 30 ARPE19 qRTPCR

37 mOl

924465 CEP290- 38 1.01870777 0.005060153 CEP290 30 ARPE19 qRTPCR

38 mOl

924466 CEP290- 39 1.15255336 0.038334812 CEP290 30 ARPE19 qRTPCR

39 mOl 925830 CEP290- 40 0.5845297 0.034388726 CEP290 30 A PE19 qRTPCR 40 m01

927453 CEP290- 41 0.78148855 0.015047826 CEP290 30 ARPE19 qRTPCR

41 mOl

927454 CEP290- 42 0.83191165 0.040862957 CEP290 30 ARPE19 qRTPCR

42 mOl

927455 CEP290- 43 0.73021674 0.022800123 CEP290 30 ARPE19 qRTPCR

43 mOl

927456 CEP290- 44 1.03370831 0.016043957 CEP290 30 ARPE19 qRTPCR

44 m01

927463 CEP290- 45 1.17744431 0.025929893 CEP290 30 ARPE19 qRTPCR

45 mOl

929045 CEP290- 46 1.07120327 0.024690562 CEP290 30 ARPE19 qRTPCR

46 m01

929046 CEP290- 47 1.16599382 0.049492339 CEP290 30 ARPE19 qRTPCR

47 mOl

929051 CEP290- 48 1.2510358 0.011018145 CEP290 30 ARPE19 qRTPCR

48 mOl

931917 CEP290- 49 1.20521885 0.065612711 CEP290 30 ARPE19 qRTPCR

49 mOl

932905 CEP290- 50 1.00325765 0.061689826 CEP290 30 ARPE19 qRTPCR

50 m01

932906 CEP290- 51 0.46125479 0.038835209 CEP290 30 ARPE19 qRTPCR

51 mOl

932907 CEP290- 52 0.5260114 0.014298517 CEP290 30 ARPE19 qRTPCR

52 mOl

932908 CEP290- 53 0.92554978 0.026115575 CEP290 30 ARPE19 qRTPCR

53 mOl

933029 CEP290- 54 0.6260272 0.03544901 CEP290 30 ARPE19 qRTPCR

54 m01

936226 CEP290- 55 0.74916693 0.023573081 CEP290 30 ARPE19 qRTPCR

55 mOl

936231 CEP290- 56 0.65440291 0.023862414 CEP290 30 ARPE19 qRTPCR

56 m01

959197 CEP290- 57 0.57401714 0.010390733 CEP290 30 ARPE19 qRTPCR

57 mOl

960537 CEP290- 58 1.10059433 0.022722133 CEP290 30 ARPE19 qRTPCR

58 mOl

981185 unc-232 232 1.03820143 0.024449043 CEP290 30 ARPE19 qRTPCR ml2 LD

981186 unc-293 293 1.09425013 0.052137282 CEP290 30 ARPE19 qRTPCR ml2 LD

Ctrl Un Un 0.97357703 0.035187982 CEP290 30 ARPE19 qRTPCR

Ctrl Lipo Lipo 1 0.027019188 CEP290 30 ARPE19 qRTPCR

954316 CEP290- 1 1.53799516 0.112794885 CEP290 50 ARPE19 qRTPCR

01 mOl 902370 CEP290- 2 1.61633105 0.088217503 CEP290 50 A PE19 qRTPCR 02 mOl

902371 CEP290- 3 1.04453122 0.05683902 CEP290 50 ARPE19 qRTPCR

03 mOl

902373 CEP290- 4 1.13260266 0.074904157 CEP290 50 ARPE19 qRTPCR

04m01

907318 CEP290- 5 0.06461218 0.004975055 CEP290 50 ARPE19 qRTPCR

05 mOl

907319 CEP290- 6 0.05459299 0.010126057 CEP290 50 ARPE19 qRTPCR

06m01

907320 CEP290- 7 0.1024441 0.006577877 CEP290 50 ARPE19 qRTPCR

07 mOl

907321 CEP290- 8 0.12762217 0.003705875 CEP290 50 ARPE19 qRTPCR

08 mOl

907712 CEP290- 9 0.56515925 0.038952676 CEP290 50 ARPE19 qRTPCR

09 mOl

910029 CEP290- 10 0.03238516 0.006755565 CEP290 50 ARPE19 qRTPCR lOmOl

910032 CEP290- 11 0.04200595 0.005557071 CEP290 50 ARPE19 qRTPCR

11 mOl

910036 CEP290- 12 0.06783573 0.003737101 CEP290 50 ARPE19 qRTPCR

12 mOl

910037 CEP290- 13 0.07950506 0.010205582 CEP290 50 ARPE19 qRTPCR

13 mOl

910038 CEP290- 14 0.01855027 0.007280657 CEP290 50 ARPE19 qRTPCR

14m01

910039 CEP290- 15 0.02163402 0.005738812 CEP290 50 ARPE19 qRTPCR

15 mOl

910041 CEP290- 16 0.00822603 0.001748359 CEP290 50 ARPE19 qRTPCR

16m01

910681 CEP290- 17 0.80811438 0.007857627 CEP290 50 ARPE19 qRTPCR

17 mOl

910684 CEP290- 18 1.30424216 0.049022665 CEP290 50 ARPE19 qRTPCR

18 mOl

910913 CEP290- 19 0.75222231 0.019876812 CEP290 50 ARPE19 qRTPCR

19 mOl

910914 CEP290- 20 0.86922711 0.04947023 CEP290 50 ARPE19 qRTPCR

20m01

910916 CEP290- 21 0.90230923 0.079568583 CEP290 50 ARPE19 qRTPCR

21 mOl

910917 CEP290- 22 1.13749991 0.03474645 CEP290 50 ARPE19 qRTPCR

22 mOl

910918 CEP290- 23 0.79886185 0.026398986 CEP290 50 ARPE19 qRTPCR

23 mOl

910919 CEP290- 24 1.11894656 0.046596078 CEP290 50 ARPE19 qRTPCR

24m01 910920 CEP290- 25 0.80818953 0.070715488 CEP290 50 A PE19 qRTPCR 25 mOl

910923 CEP290- 26 1.13070531 0.083803448 CEP290 50 ARPE19 qRTPCR

26 m01

910924 CEP290- 27 1.21642668 0.018149347 CEP290 50 ARPE19 qRTPCR

27 mOl

910925 CEP290- 28 1.25745057 0.042001163 CEP290 50 ARPE19 qRTPCR

28 mOl

917988 CEP290- 29 0.9185524 0.057616798 CEP290 50 ARPE19 qRTPCR

29 mOl

917989 CEP290- 30 1.0551978 0.072900225 CEP290 50 ARPE19 qRTPCR

30 m01

Ctrl Un Un 1.12115187 0.108593026 CEP290 50 ARPE19 qRTPCR

Ctrl Lipo Lipo 1 0.080781243 CEP290 50 ARPE19 qRTPCR

917991 CEP290- 31 0.88881612 0.289269793 CEP290 50 ARPE19 qRTPCR

31 mOl

917992 CEP290- 32 0.43469333 0.024749984 CEP290 50 ARPE19 qRTPCR

32 mOl

921640 CEP290- 33 0.61067512 0.023492131 CEP290 50 ARPE19 qRTPCR

33 mOl

921641 CEP290- 34 0.79595853 0.043359647 CEP290 50 ARPE19 qRTPCR

34 m01

921642 CEP290- 35 0.44941728 0.032516014 CEP290 50 ARPE19 qRTPCR

35 mOl

956697 CEP290- 36 0.53076448 0.01670564 CEP290 50 ARPE19 qRTPCR

36 m01

924441 CEP290- 37 0.44421861 0.012695206 CEP290 50 ARPE19 qRTPCR

37 mOl

924465 CEP290- 38 0.92072523 0.053797283 CEP290 50 ARPE19 qRTPCR

38 mOl

924466 CEP290- 39 0.94881642 0.029948758 CEP290 50 ARPE19 qRTPCR

39 mOl

925830 CEP290- 40 0.32938481 0.006556332 CEP290 50 ARPE19 qRTPCR

40 m01

927453 CEP290- 41 0.45387755 0.011569687 CEP290 50 ARPE19 qRTPCR

41 mOl

927454 CEP290- 42 0.62469083 0.031341492 CEP290 50 ARPE19 qRTPCR

42 mOl

927455 CEP290- 43 0.46026914 0.006936678 CEP290 50 ARPE19 qRTPCR

43 mOl

927456 CEP290- 44 0.82665615 0.034067383 CEP290 50 ARPE19 qRTPCR

44 m01

927463 CEP290- 45 1.04598447 0.057161086 CEP290 50 ARPE19 qRTPCR

45 mOl

929045 CEP290- 46 1.25423183 0.062041229 CEP290 50 ARPE19 qRTPCR

46 m01 929046 CEP290- 47 0.98439687 0.017692467 CEP290 50 ARPE19 qRTPCR 47 mOl

929051 CEP290- 48 0.90243527 0.008216266 CEP290 50 ARPE19 qRTPCR

48 mOl

931917 CEP290- 49 1.00740163 0.015979061 CEP290 50 ARPE19 qRTPCR

49 mOl

932905 CEP290- 50 0.70812241 0.037665493 CEP290 50 ARPE19 qRTPCR

50 m01

932906 CEP290- 51 0.14578569 0.010996925 CEP290 50 ARPE19 qRTPCR

51 mOl

932907 CEP290- 52 0.30372913 0.022398187 CEP290 50 ARPE19 qRTPCR

52 mOl

932908 CEP290- 53 0.58643511 0.025784531 CEP290 50 ARPE19 qRTPCR

53 mOl

933029 CEP290- 54 0.62730978 0.023210008 CEP290 50 ARPE19 qRTPCR

54 m01

936226 CEP290- 55 0.4938567 0.035176796 CEP290 50 ARPE19 qRTPCR

55 mOl

936231 CEP290- 56 0.43946129 0.002214719 CEP290 50 ARPE19 qRTPCR

56 m01

959197 CEP290- 57 0.42174255 0.020990305 CEP290 50 ARPE19 qRTPCR

57 mOl

960537 CEP290- 58 0.99565062 0.031303424 CEP290 50 ARPE19 qRTPCR

58 mOl

981185 unc-232 232 0.98744564 0.013203575 CEP290 50 ARPE19 qRTPCR ml2 LD

981186 unc-293 293 1.46773478 0.361360377 CEP290 50 ARPE19 qRTPCR ml2 LD

Ctrl Un Un 0.90002863 0.03003841 CEP290 50 ARPE19 qRTPCR

Ctrl Lipo Lipo 1 0.009510284 CEP290 50 ARPE19 qRTPCR

981096 CFT -01 1 0.79281285 0.184413463 CFTR 100 RPTEC qRTPCR m03

981097 CFTR-02 2 1.19726828 0.466073658 CFTR 100 RPTEC qRTPCR m03

981098 CFTR-03 3 1.68031042 0.221569397 CFTR 100 RPTEC qRTPCR m03

981099 CFTR-04 4 0.30256318 0.06030635 CFTR 100 RPTEC qRTPCR m03

981100 CFTR-05 5 0.78893457 0.258285973 CFTR 100 RPTEC qRTPCR m03

981101 CFTR-06 6 0.67486527 0.078492631 CFTR 100 RPTEC qRTPCR m03

981102 CFTR-07 7 1.15861342 0.0852313 CFTR 100 RPTEC qRTPCR m03

981103 CFTR-08 8 0.80641895 0.274712322 CFTR 100 RPTEC qRTPCR m03 981104 CFT -09 9 0.84180523 0.30810345 CFTR 100 RPTEC qRTPCR m03

981105 CFTR-10 10 0.98257627 0.252414601 CFTR 100 RPTEC qRTPCR m03

981106 CFT -11 11 0.76420251 0.268108937 CFTR 100 RPTEC qRTPCR m03

981107 CFTR-12 12 0.74645918 0.091852496 CFTR 100 RPTEC qRTPCR m03

981108 CFTR-13 13 1.02755274 0.19955176 CFTR 100 RPTEC qRTPCR m03

981109 CFTR-14 14 0.97624687 0.36826384 CFTR 100 RPTEC qRTPCR m03

981110 CFTR-15 15 0.51045359 0.230213509 CFTR 100 RPTEC qRTPCR m03

981111 CFTR-16 16 0.55372434 0.151068461 CFTR 100 RPTEC qRTPCR m03

981112 CFTR-17 17 2.52912155 1.225698133 CFTR 100 RPTEC qRTPCR m03

981113 CFTR-18 18 1.32319022 0.059735821 CFTR 100 RPTEC qRTPCR m03

981114 CFTR-19 19 1.02158789 0.242829879 CFTR 100 RPTEC qRTPCR m03

981115 CFTR-20 20 0.93631117 0.232849017 CFTR 100 RPTEC qRTPCR m03

981116 CFTR-21 21 0.55168062 0.421376798 CFTR 100 RPTEC qRTPCR m03

981117 CFTR-22 22 1.12224588 0.025142805 CFTR 100 RPTEC qRTPCR m03

981118 CFTR-23 23 0.59928327 0.077017402 CFTR 100 RPTEC qRTPCR m03

981119 CFTR-24 24 0.51858709 0.139923956 CFTR 100 RPTEC qRTPCR m03

981120 CFTR-25 25 0.8327123 0.177190013 CFTR 100 RPTEC qRTPCR m03

981121 CFTR-26 26 1.05576915 0.049746733 CFTR 100 RPTEC qRTPCR m03

981122 CFTR-27 27 0.75306615 0.124938866 CFTR 100 RPTEC qRTPCR m03

981123 CFTR-28 28 0.88610265 0.169682384 CFTR 100 RPTEC qRTPCR m03

981124 CFTR-29 29 0.91693169 0.16691104 CFTR 100 RPTEC qRTPCR m03

981125 CFTR-30 30 0.56928413 0.078330035 CFTR 100 RPTEC qRTPCR m03

Ctrl Un Un 0.84145238 0.044850029 CFTR 100 RPTEC qRTPCR

Ctrl Lipo Lipo 1 0.018435703 CFTR 100 RPTEC qRTPCR 981096 CFT -01 1 0.5758401 0.056001303 CFTR 50 RPTEC qRTPCR m03

981097 CFTR-02 2 0.57110537 0.234612166 CFTR 50 RPTEC qRTPCR m03

981098 CFTR-03 3 1.09356032 0.192228041 CFTR 50 RPTEC qRTPCR m03

981099 CFTR-04 4 0.45202197 0.230631447 CFTR 50 RPTEC qRTPCR m03

981100 CFTR-05 5 0.89687385 0.484520905 CFTR 50 RPTEC qRTPCR m03

981101 CFTR-06 6 0.9106006 0.083284148 CFTR 50 RPTEC qRTPCR m03

981102 CFTR-07 7 0.48889587 0.244635697 CFTR 50 RPTEC qRTPCR m03

981103 CFTR-08 8 0.57724641 0.186638729 CFTR 50 RPTEC qRTPCR m03

981104 CFTR-09 9 2.29274676 0.249245367 CFTR 50 RPTEC qRTPCR m03

981105 CFTR-10 10 0.79535469 0.312610938 CFTR 50 RPTEC qRTPCR m03

981106 CFTR-11 11 0.29614519 0.093888846 CFTR 50 RPTEC qRTPCR m03

981107 CFTR-12 12 0.60233476 0.210104005 CFTR 50 RPTEC qRTPCR m03

981108 CFTR-13 13 0.56395557 0.235434045 CFTR 50 RPTEC qRTPCR m03

981109 CFTR-14 14 0.41734906 0.045211303 CFTR 50 RPTEC qRTPCR m03

981110 CFTR-15 15 0.53390918 0.176295141 CFTR 50 RPTEC qRTPCR m03

981111 CFTR-16 16 0.4524799 0.104170584 CFTR 50 RPTEC qRTPCR m03

981112 CFTR-17 17 0.6160011 0.189615377 CFTR 50 RPTEC qRTPCR m03

981113 CFTR-18 18 1.35630703 0.308296212 CFTR 50 RPTEC qRTPCR m03

981114 CFTR-19 19 1.05232148 0.100649968 CFTR 50 RPTEC qRTPCR m03

981115 CFTR-20 20 1.12591661 0.078383985 CFTR 50 RPTEC qRTPCR m03

981116 CFTR-21 21 1.1514542 0.074529491 CFTR 50 RPTEC qRTPCR m03

981117 CFTR-22 22 0.88637711 0.058032965 CFTR 50 RPTEC qRTPCR m03

981118 CFTR-23 23 0.55996955 0.071853326 CFTR 50 RPTEC qRTPCR m03 981119 CFT -24 24 0.73286794 0.537382517 CFTR 50 RPTEC qRTPCR m03

981120 CFTR-25 25 0.34596108 0.134271928 CFTR 50 RPTEC qRTPCR m03

981121 CFTR-26 26 0.80966162 0.229310703 CFTR 50 RPTEC qRTPCR m03

981122 CFTR-27 27 0.68763309 0.122547388 CFTR 50 RPTEC qRTPCR m03

981123 CFTR-28 28 0.66075517 0.223035757 CFTR 50 RPTEC qRTPCR m03

981124 CFTR-29 29 0.61850434 0.042956135 CFTR 50 RPTEC qRTPCR m03

981125 CFTR-30 30 0.44192061 0.131245117 CFTR 50 RPTEC qRTPCR m03

Ctrl Un Un 0.71002409 0.024005767 CFTR 50 RPTEC qRTPCR

Ctrl Lipo Lipo 1 0.136806536 CFTR 50 RPTEC qRTPCR

980846 BRCAl-01 1.99451201 0.016085096 BRCA1 30 Hep3B qRTPCR m02

980846 BRCAl-01 1.39704637 0.083708834 BRCA1 10 Hep3B qRTPCR m02

980847 BRCAl-02 1.14088361 0.022006882 BRCA1 30 Hep3B qRTPCR m02

980847 BRCAl-02 1.25240798 0.072870986 BRCA1 10 Hep3B qRTPCR m02

980848 BRCAl-03 0.82611159 0.046744585 BRCA1 30 Hep3B qRTPCR m02

980848 BRCAl-03 0.88415819 0.026001735 BRCA1 10 Hep3B qRTPCR m02

40033 BRCAl-04 1.40854126 0.028759366 BRCA1 30 Hep3B qRTPCR m02

40033 BRCAl-04 1.38986887 0.038586108 BRCA1 10 Hep3B qRTPCR m02

39787 BRCAl-05 1.71403697 0.039792171 BRCA1 30 Hep3B qRTPCR m02

39787 BRCAl-05 1.11757793 0.082424599 BRCA1 10 Hep3B qRTPCR m02

39765 BRCAl-06 1.47320476 0.023020772 BRCA1 30 Hep3B qRTPCR m02

39765 BRCAl-06 1.31125173 0.023563374 BRCA1 10 Hep3B qRTPCR m02

36210 BRCAl-07 1.81731165 0.413014911 BRCA1 30 Hep3B qRTPCR m02

36210 BRCAl-07 1.40131163 0.197646056 BRCA1 10 Hep3B qRTPCR m02

36173 BRCAl-08 1.09898685 0.228108109 BRCA1 30 Hep3B qRTPCR m02 36173 B CAl-08 1.05605776 0.20781195 BRCA1 10 Hep3B qRTPCR m02

980849 BRCAl-09 1.14970999 0.301796891 BRCA1 30 Hep3B qRTPCR m02

980849 BRCAl-09 0.99607443 0.224815696 BRCA1 10 Hep3B qRTPCR m02

980850 BRCAl-10 1.04873886 0.115698804 BRCA1 30 Hep3B qRTPCR m02

980850 BRCAl-10 0.98115222 0.083371305 BRCA1 10 Hep3B qRTPCR m02

980851 BRCAl-11 2.01527795 0.57884256 BRCA1 30 Hep3B qRTPCR m02

980851 BRCAl-11 1.49076894 0.316108979 BRCA1 10 Hep3B qRTPCR m02

32373 BRCAl-12 1.67043723 0.505970905 BRCA1 30 Hep3B qRTPCR m02

32373 BRCAl-12 1.30645312 0.329949974 BRCA1 10 Hep3B qRTPCR m02

32392 BRCAl-13 1.55470178 0.034233287 BRCA1 30 Hep3B qRTPCR m02

32392 BRCAl-13 1.24932364 0.146448396 BRCA1 10 Hep3B qRTPCR m02

32081 BRCAl-14 1.43858142 0.023125507 BRCA1 30 Hep3B qRTPCR m02

32081 BRCAl-14 1.40956908 0.112513544 BRCA1 10 Hep3B qRTPCR m02

980852 BRCAl-15 1.36141594 0.048400535 BRCA1 30 Hep3B qRTPCR m02

980852 BRCAl-15 1.13267864 0.081228813 BRCA1 10 Hep3B qRTPCR m02

980853 BRCAl-16 1.83666215 0.058261627 BRCA1 30 Hep3B qRTPCR m02

980853 BRCAl-16 1.83766378 0.069085245 BRCA1 10 Hep3B qRTPCR m02

980854 BRCAl-17 0.69355541 0.019668529 BRCA1 30 Hep3B qRTPCR m02

980854 BRCAl-17 0.87676375 0.024216726 BRCA1 10 Hep3B qRTPCR m02

980855 BRCAl-18 1.58783228 0.068896594 BRCA1 30 Hep3B qRTPCR m02

980855 BRCAl-18 1.2290728 0.009592597 BRCA1 10 Hep3B qRTPCR m02

980856 BRCAl-19 1.09669637 0.045768323 BRCA1 30 Hep3B qRTPCR m02

980856 BRCAl-19 0.98246841 0.014956505 BRCA1 10 Hep3B qRTPCR m02 521928 B CAl-20 2.78319272 0.113599477 BRCA1 30 Hep3B qRTPCR m02

521928 BRCAl-20 1.75682318 0.093806406 BRCA1 10 Hep3B qRTPCR m02

521823 BRCAl-21 2.22203365 0.153440862 BRCA1 30 Hep3B qRTPCR m02

521823 BRCAl-21 1.48769906 0.102482825 BRCA1 10 Hep3B qRTPCR m02

980857 BRCAl-22 2.91070296 0.117778006 BRCA1 30 Hep3B qRTPCR m02

980857 BRCAl-22 1.89640219 0.066002602 BRCA1 10 Hep3B qRTPCR m02

31294 BRCAl-23 2.58359938 0.089683849 BRCA1 30 Hep3B qRTPCR m02

31294 BRCAl-23 1.50317171 0.017444137 BRCA1 10 Hep3B qRTPCR m02

31279 BRCAl-24 2.16412747 0.02401863 BRCA1 30 Hep3B qRTPCR m02

31279 BRCAl-24 1.4586459 0.04074015 BRCA1 10 Hep3B qRTPCR m02

980858 BRCAl-25 2.15350382 0.04862076 BRCA1 30 Hep3B qRTPCR m02

980858 BRCAl-25 1.62609354 0.086125136 BRCA1 10 Hep3B qRTPCR m02

980859 BRCAl-26 1.67937256 0.102269403 BRCA1 30 Hep3B qRTPCR m02

980859 BRCAl-26 1.4570242 0.017607259 BRCA1 10 Hep3B qRTPCR m02

980860 BRCAl-27 1.01520168 0.028937283 BRCA1 30 Hep3B qRTPCR m02

980860 BRCAl-27 1.15013659 0.042536554 BRCA1 10 Hep3B qRTPCR m02

980861 BRCAl-28 3.02445351 0.121598446 BRCA1 30 Hep3B qRTPCR m02

980861 BRCAl-28 2.00983962 0.086224222 BRCA1 10 Hep3B qRTPCR m02

25727 BRCAl-29 0.90146767 0.033775414 BRCA1 30 Hep3B qRTPCR m02

25727 BRCAl-29 0.81351362 0.025653051 BRCA1 10 Hep3B qRTPCR m02

25714 BRCAl-30 1.6288716 0.041365182 BRCA1 30 Hep3B qRTPCR m02

25714 BRCAl-30 1.37038627 0.038181804 BRCA1 10 Hep3B qRTPCR m02

980907 GRN-01 0.92270684 NA GRN 30 Hep3B qRTPCR m02 980907 G N-01 0.72996961 0.033795811 GRN 10 Hep3B qRTPCR m02

980908 GRN-02 0.81623757 0.119698531 GRN 30 Hep3B qRTPCR m02

980908 GRN-02 0.56843877 0.062807355 GRN 10 Hep3B qRTPCR m02

980909 GRN-03 1.49260443 0.236533829 GRN 30 Hep3B qRTPCR m02

980909 GRN-03 0.81013299 0.018070776 GRN 10 Hep3B qRTPCR m02

980910 GRN-04 0.74912482 0.057453297 GRN 30 Hep3B qRTPCR m02

980910 GRN-04 0.60449341 0.055673595 GRN 10 Hep3B qRTPCR m02

980911 GRN-05 0.84960189 0.160312877 GRN 30 Hep3B qRTPCR m02

980911 GRN-05 0.69917839 0.01720577 GRN 10 Hep3B qRTPCR m02

980912 GRN-06 0.57255545 0.036006447 GRN 30 Hep3B qRTPCR m02

980912 GRN-06 0.68544491 0.032049434 GRN 10 Hep3B qRTPCR m02

980913 GRN-07 0.86739778 0.074897287 GRN 30 Hep3B qRTPCR m02

980913 GRN-07 0.76829639 0.014947371 GRN 10 Hep3B qRTPCR m02

980914 GRN-08 0.63223418 0.032652554 GRN 30 Hep3B qRTPCR m02

980914 GRN-08 0.83524073 0.051884684 GRN 10 Hep3B qRTPCR m02

980915 GRN-09 0.8905165 0.173442154 GRN 30 Hep3B qRTPCR m02

980915 GRN-09 0.96652427 0.021284363 GRN 10 Hep3B qRTPCR m02

614647 GRN-10 0.86845282 0.031949259 GRN 30 Hep3B qRTPCR m02

614647 GRN-10 0.89709016 0.06321228 GRN 10 Hep3B qRTPCR m02

614671 GRN-11 1.01351556 0.086446941 GRN 30 Hep3B qRTPCR m02

614671 GRN-11 0.92986495 0.03361724 GRN 10 Hep3B qRTPCR m02

980916 GRN-12 1.19962634 0.272784191 GRN 30 Hep3B qRTPCR m02

980916 GRN-12 0.9462777 0.054591381 GRN 10 Hep3B qRTPCR m02 980917 G N-13 0.96751606 0.052512317 GRN 30 Hep3B qRTPCR m02

980917 GRN-13 0.78210726 0.02879468 GRN 10 Hep3B qRTPCR m02

615538 GRN-14 1.13380441 0.043943174 GRN 30 Hep3B qRTPCR m02

615538 GRN-14 0.97732034 0.071535662 GRN 10 Hep3B qRTPCR m02

615581 GRN-15 0.78232264 0.033375781 GRN 30 Hep3B qRTPCR m02

615581 GRN-15 0.67919661 0.055173631 GRN 10 Hep3B qRTPCR m02

615598 GRN-16 1.12789387 0.017680311 GRN 30 Hep3B qRTPCR m02

615598 GRN-16 0.91111577 0.050884383 GRN 10 Hep3B qRTPCR m02

980918 GRN-17 1.62829642 0.072186194 GRN 30 Hep3B qRTPCR m02

980918 GRN-17 1.53186082 0.063430181 GRN 10 Hep3B qRTPCR m02

616370 GRN-18 0.89545176 0.016446167 GRN 30 Hep3B qRTPCR m02

616370 GRN-18 0.73817862 0.042056478 GRN 10 Hep3B qRTPCR m02

616391 GRN-19 0.79264573 0.113057209 GRN 30 Hep3B qRTPCR m02

616391 GRN-19 0.73997439 0.118242693 GRN 10 Hep3B qRTPCR m02

616409 GRN-20 0.90976408 0.082349743 GRN 30 Hep3B qRTPCR m02

616409 GRN-20 0.85465169 0.042639577 GRN 10 Hep3B qRTPCR m02

980919 GRN-21 1.17488608 0.062648021 GRN 30 Hep3B qRTPCR m02

980919 GRN-21 0.96498431 0.006184878 GRN 10 Hep3B qRTPCR m02

980920 GRN-22 0.70830564 0.127194714 GRN 30 Hep3B qRTPCR m02

980920 GRN-22 0.70026494 0.152589767 GRN 10 Hep3B qRTPCR m02

616771 GRN-23 0.87555345 0.139725135 GRN 30 Hep3B qRTPCR m02

616771 GRN-23 0.70377911 0.07136665 GRN 10 Hep3B qRTPCR m02

616800 GRN-24 0.81053555 0.001685459 GRN 30 Hep3B qRTPCR m02 616800 G N-24 0.7309951 0.05995018 GRN 10 Hep3B qRTPCR m02

616824 GRN-25 1.27372461 0.011109029 GRN 30 Hep3B qRTPCR m02

616824 GRN-25 1.21583535 0.046577572 GRN 10 Hep3B qRTPCR m02

980921 GRN-26 0.95197406 0.007918115 GRN 30 Hep3B qRTPCR m02

980921 GRN-26 1.01059663 0.003982461 GRN 10 Hep3B qRTPCR m02

980922 GRN-27 1.01998669 0.142384562 GRN 30 Hep3B qRTPCR m02

980922 GRN-27 0.75496753 0.010929445 GRN 10 Hep3B qRTPCR m02

619515 GRN-28 0.83521406 0.035349796 GRN 30 Hep3B qRTPCR m02

619515 GRN-28 0.69742498 0.04682103 GRN 10 Hep3B qRTPCR m02

980923 GRN-29 0.6940611 0.034820071 GRN 30 Hep3B qRTPCR m02

980923 GRN-29 0.66715126 0.019696413 GRN 10 Hep3B qRTPCR m02

980924 GRN-30 0.57353144 0.000229521 GRN 30 Hep3B qRTPCR m02

980924 GRN-30 0.63894818 0.016007726 GRN 10 Hep3B qRTPCR m02

980925 ILlO-01 41.4533366 8.665051772 IL-10 100 RPTEC qRTPCR m03

980925 ILlO-01 15.4557425 2.463201597 IL-10 50 RPTEC qRTPCR m03

980925 ILlO-01 1.52866081 0.144921599 IL-10 100 RPTEC qRTPCR m03

980925 ILlO-01 1.06478408 0.259822353 IL-10 50 RPTEC qRTPCR m03

980925 ILlO-01 1.80769231 0.133234678 IL-10 100 RPTEC qRTPCR m03

980925 ILlO-01 1.13114754 0.06625331 IL-10 50 RPTEC qRTPCR m03

980926 IL10-02 91.0544327 12.42095222 IL-10 100 RPTEC qRTPCR m03

980926 IL10-02 33.9580591 3.140880208 IL-10 50 RPTEC qRTPCR m03

980926 IL10-02 2.20858496 0.097608511 IL-10 100 RPTEC qRTPCR m03

980926 IL10-02 1.19904108 0.256296198 IL-10 50 RPTEC qRTPCR m03 980926 IL10-02 2.07692308 0.133234678 IL-10 100 PTEC qRTPCR m03

980926 IL10-02 0.95081967 0.075718068 IL-10 50 RPTEC qRTPCR m03

980927 IL10-03 5.65574761 1.333539682 IL-10 100 RPTEC qRTPCR m03

980927 IL10-03 2.28990029 1.19781323 IL-10 50 RPTEC qRTPCR m03

980927 IL10-03 0.97251778 0.148624235 IL-10 100 RPTEC qRTPCR m03

980927 IL10-03 1.0817193 0.147687266 IL-10 50 RPTEC qRTPCR m03

980927 IL10-03 1.38461539 0.111028898 IL-10 100 RPTEC qRTPCR m03

980927 IL10-03 0.78688525 0.047323793 IL-10 50 RPTEC qRTPCR m03

980928 IL10-04 5.98331382 2.743243188 IL-10 100 RPTEC qRTPCR m03

980928 IL10-04 8.92948819 3.055661334 IL-10 50 RPTEC qRTPCR m03

980928 IL10-04 1.39714885 0.153974695 IL-10 100 RPTEC qRTPCR m03

980928 IL10-04 0.84729247 0.26472904 IL-10 50 RPTEC qRTPCR m03

980928 IL10-04 1.26923077 0.02220578 IL-10 100 RPTEC qRTPCR m03

980928 IL10-04 0.93442623 0.056788551 IL-10 50 RPTEC qRTPCR m03

980929 IL10-05 3.81120939 1.012018738 IL-10 100 RPTEC qRTPCR m03

980929 IL10-05 3.89170402 0.657619314 IL-10 50 RPTEC qRTPCR m03

980929 IL10-05 0.60182828 0.085853047 IL-10 100 RPTEC qRTPCR m03

980929 IL10-05 1.51391236 0.409371415 IL-10 50 RPTEC qRTPCR m03

980929 IL10-05 1.38461539 0.111028898 IL-10 100 RPTEC qRTPCR m03

980929 IL10-05 0.96721312 0.06625331 IL-10 50 RPTEC qRTPCR m03

980930 IL10-06 6.42192799 0.743135384 IL-10 100 RPTEC qRTPCR m03

980930 IL10-06 2.77906572 0.436379009 IL-10 50 RPTEC qRTPCR m03

980930 IL10-06 1.03867796 0.191975185 IL-10 100 RPTEC qRTPCR m03 980930 IL10-06 1.11591344 0.243381857 IL-10 50 PTEC qRTPCR m03

980930 IL10-06 1.5 0.177646237 IL-10 100 RPTEC qRTPCR m03

980930 IL10-06 0.80327869 0.104112344 IL-10 50 RPTEC qRTPCR m03

980931 IL10-07 9.06661676 3.552364903 IL-10 100 RPTEC qRTPCR m03

980931 IL10-07 2.02146683 0.196398282 IL-10 50 RPTEC qRTPCR m03

980931 IL10-07 0.96346561 0.173196455 IL-10 100 RPTEC qRTPCR m03

980931 IL10-07 0.92334474 0.348319259 IL-10 50 RPTEC qRTPCR m03

980931 IL10-07 1.34615385 0.133234678 IL-10 100 RPTEC qRTPCR m03

980931 IL10-07 1.06557377 0.132506619 IL-10 50 RPTEC qRTPCR m03

980932 IL10-08 3.31301455 1.789206893 IL-10 100 RPTEC qRTPCR m03

980932 IL10-08 2.53003278 0.727987471 IL-10 50 RPTEC qRTPCR m03

980932 IL10-08 0.74973102 0.266903384 IL-10 100 RPTEC qRTPCR m03

980932 IL10-08 1.00507257 0.134439254 IL-10 50 RPTEC qRTPCR m03

980932 IL10-08 1.57692308 0.111028898 IL-10 100 RPTEC qRTPCR m03

980932 IL10-08 0.8852459 0.06625331 IL-10 50 RPTEC qRTPCR m03

980933 IL10-09 2.56394224 1.63237731 IL-10 100 RPTEC qRTPCR m03

980933 IL10-09 1.33191583 0.828431076 IL-10 50 RPTEC qRTPCR m03

980933 IL10-09 0.89436607 0.273370546 IL-10 100 RPTEC qRTPCR m03

980933 IL10-09 0.97091748 0.207325208 IL-10 50 RPTEC qRTPCR m03

980933 IL10-09 1.42307692 0.155440457 IL-10 100 RPTEC qRTPCR m03

980933 IL10-09 0.81967213 0.123041861 IL-10 50 RPTEC qRTPCR m03

980934 ILlO-10 2.97608507 2.263279375 IL-10 100 RPTEC qRTPCR m03

980934 ILlO-10 1.70930436 0.871947387 IL-10 50 RPTEC qRTPCR m03 980934 ILlO-10 1.39224248 0.17840879 IL-10 100 PTEC qRTPCR m03

980934 ILlO-10 0.86754819 0.052828417 IL-10 50 RPTEC qRTPCR m03

980934 ILlO-10 1.76923077 0.177646237 IL-10 100 RPTEC qRTPCR m03

980934 ILlO-10 0.86885246 0.123041861 IL-10 50 RPTEC qRTPCR m03

980935 ILlO-11 4.023527 1.597595021 IL-10 100 RPTEC qRTPCR m03

980935 ILlO-11 0.85173024 0.376281838 IL-10 50 RPTEC qRTPCR m03

980935 ILlO-11 0.76435984 0.196085805 IL-10 100 RPTEC qRTPCR m03

980935 ILlO-11 1.30772045 0.158687043 IL-10 50 RPTEC qRTPCR m03

980935 ILlO-11 1.80769231 0.377498253 IL-10 100 RPTEC qRTPCR m03

980935 ILlO-11 0.81967213 0.113577102 IL-10 50 RPTEC qRTPCR m03

980936 IL10-12 10.9181202 0.516896988 IL-10 100 RPTEC qRTPCR m03

980936 IL10-12 3.03206541 0.858492992 IL-10 50 RPTEC qRTPCR m03

980936 IL10-12 0.58176206 0.064546676 IL-10 100 RPTEC qRTPCR m03

980936 IL10-12 1.26907205 0.365388368 IL-10 50 RPTEC qRTPCR m03

980936 IL10-12 2.23076923 0.843819624 IL-10 100 RPTEC qRTPCR m03

980936 IL10-12 0.91803279 0.094647585 IL-10 50 RPTEC qRTPCR m03

980937 IL10-13 4.65941119 2.409180774 IL-10 100 RPTEC qRTPCR m03

980937 IL10-13 1.44135994 0.531914825 IL-10 50 RPTEC qRTPCR m03

980937 IL10-13 0.91039002 0.083511572 IL-10 100 RPTEC qRTPCR m03

980937 IL10-13 0.92331098 0.117311685 IL-10 50 RPTEC qRTPCR m03

980937 IL10-13 1.38461539 0.310880914 IL-10 100 RPTEC qRTPCR m03

980937 IL10-13 0.90163934 0.141971378 IL-10 50 RPTEC qRTPCR m03

980938 IL10-14 2.5320789 0.658956041 IL-10 100 RPTEC qRTPCR m03 980938 IL10-14 0.61538585 0.190602021 IL-10 50 PTEC qRTPCR m03

980938 IL10-14 0.74796517 0.216241452 IL-10 100 RPTEC qRTPCR m03

980938 IL10-14 0.98825506 0.118240256 IL-10 50 RPTEC qRTPCR m03

980938 IL10-14 1.57692308 0.222057796 IL-10 100 RPTEC qRTPCR m03

980938 IL10-14 0.65573771 0.056788551 IL-10 50 RPTEC qRTPCR m03

980939 IL10-15 10.4629136 1.591172307 IL-10 100 RPTEC qRTPCR m03

980939 IL10-15 2.25090852 0.448852768 IL-10 50 RPTEC qRTPCR m03

980939 IL10-15 1.15708296 0.218342507 IL-10 100 RPTEC qRTPCR m03

980939 IL10-15 0.8255383 0.192663984 IL-10 50 RPTEC qRTPCR m03

980939 IL10-15 1.34615385 0.155440457 IL-10 100 RPTEC qRTPCR m03

980939 IL10-15 0.60655738 0.009464759 IL-10 50 RPTEC qRTPCR m03

980940 IL10-16 7.21651995 1.691975043 IL-10 100 RPTEC qRTPCR m03

980940 IL10-16 2.67273482 1.38796262 IL-10 50 RPTEC qRTPCR m03

980940 IL10-16 1.0606638 0.246984894 IL-10 100 RPTEC qRTPCR m03

980940 IL10-16 1.42225322 0.248545366 IL-10 50 RPTEC qRTPCR m03

980940 IL10-16 1.5 0.044411559 IL-10 100 RPTEC qRTPCR m03

980940 IL10-16 4.78688525 4.00359285 IL-10 50 RPTEC qRTPCR m03

980941 IL10-17 10.216789 1.632147642 IL-10 100 RPTEC qRTPCR m03

980941 IL10-17 2.60894644 1.055792989 IL-10 50 RPTEC qRTPCR m03

980941 IL10-17 0.85470378 0.310371036 IL-10 100 RPTEC qRTPCR m03

980941 IL10-17 1.15344782 0.082013488 IL-10 50 RPTEC qRTPCR m03

980941 IL10-17 1.65384615 0.111028898 IL-10 100 RPTEC qRTPCR m03

980941 IL10-17 0.85245902 0.236618963 IL-10 50 RPTEC qRTPCR m03 980942 IL10-18 11.3576051 2.28736658 IL-10 100 PTEC qRTPCR m03

980942 IL10-18 5.12692407 0.447351923 IL-10 50 RPTEC qRTPCR m03

980942 IL10-18 0.60998197 0.078558302 IL-10 100 RPTEC qRTPCR m03

980942 IL10-18 1.12769239 0.045742878 IL-10 50 RPTEC qRTPCR m03

980942 IL10-18 1.19230769 0.066617339 IL-10 100 RPTEC qRTPCR m03

980942 IL10-18 1.06557377 0.25554848 IL-10 50 RPTEC qRTPCR m03

980943 IL10-19 9.94514229 1.27929749 IL-10 100 RPTEC qRTPCR m03

980943 IL10-19 2.7239075 0.586026514 IL-10 50 RPTEC qRTPCR m03

980943 IL10-19 1.00000956 0.19032843 IL-10 100 RPTEC qRTPCR m03

980943 IL10-19 1.23181616 0.265163129 IL-10 50 RPTEC qRTPCR m03

980943 IL10-19 2.03846154 0.55514449 IL-10 100 RPTEC qRTPCR m03

980943 IL10-19 1.65573771 0.776110198 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-20 2.72837027 1.208159034 IL-10 100 RPTEC qRTPCR m03

#N/A IL10-20 1.02106893 0.713095009 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-20 0.82062272 0.043209759 IL-10 100 RPTEC qRTPCR m03

#N/A IL10-20 0.94446691 0.283745576 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-20 3.38461539 1.132494759 IL-10 100 RPTEC qRTPCR m03

#N/A IL10-20 5.2295082 2.243147767 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-21 15.2801232 1.552046756 IL-10 100 RPTEC qRTPCR m03

#N/A IL10-21 3.5284446 0.217229258 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-21 0.91349896 0.148156389 IL-10 100 RPTEC qRTPCR m03

#N/A IL10-21 1.16095414 0.133470114 IL-10 50 RPTEC qRTPCR m03

#N/A IL10-21 3.46153846 1.154700538 IL-10 100 RPTEC qRTPCR m03 #N/A IL10-21 2.21311475 1.183094814 IL-10 50 PTEC qRTPCR m03

980944 IL10-22 32.5106016 1.622152986 IL-10 100 RPTEC qRTPCR m03

980944 IL10-22 9.91840534 0.389275462 IL-10 50 RPTEC qRTPCR m03

980944 IL10-22 1.53172253 0.090329442 IL-10 100 RPTEC qRTPCR m03

980944 IL10-22 0.96340392 0.220897517 IL-10 50 RPTEC qRTPCR m03

980944 IL10-22 3.76923077 1.154700538 IL-10 100 RPTEC qRTPCR m03

980944 IL10-22 1.1147541 0.085182827 IL-10 50 RPTEC qRTPCR m03

980945 IL10-23 31.2916751 1.526051123 IL-10 100 RPTEC qRTPCR m03

980945 IL10-23 8.23480428 1.158143419 IL-10 50 RPTEC qRTPCR m03

980945 IL10-23 0.67638613 0.152533999 IL-10 100 RPTEC qRTPCR m03

980945 IL10-23 1.32783107 0.232109433 IL-10 50 RPTEC qRTPCR m03

980945 IL10-23 4 1.487787232 IL-10 100 RPTEC qRTPCR m03

980945 IL10-23 5.40983607 4.145564228 IL-10 50 RPTEC qRTPCR m03

980946 IL10-24 28.863998 5.048623667 IL-10 100 RPTEC qRTPCR m03

980946 IL10-24 11.1297593 1.882909746 IL-10 50 RPTEC qRTPCR m03

980946 IL10-24 0.92950654 0.271562238 IL-10 100 RPTEC qRTPCR m03

980946 IL10-24 1.23933989 0.485897887 IL-10 50 RPTEC qRTPCR m03

980946 IL10-24 3.07692308 0.754996506 IL-10 100 RPTEC qRTPCR m03

980946 IL10-24 1.08196721 0.397519857 IL-10 50 RPTEC qRTPCR m03

980947 IL10-25 80.2925769 2.432502181 IL-10 100 RPTEC qRTPCR m03

980947 IL10-25 19.0222274 1.101828314 IL-10 50 RPTEC qRTPCR m03

980947 IL10-25 1.60224281 0.25126398 IL-10 100 RPTEC qRTPCR m03

980947 IL10-25 1.12226051 0.107503041 IL-10 50 RPTEC qRTPCR m03 980947 IL10-25 1.11538462 0.02220578 IL-10 100 PTEC qRTPCR m03

980947 IL10-25 0.91803279 0.141971378 IL-10 50 RPTEC qRTPCR m03

980948 IL10-26 1.53846154 0.199852016 IL-10 100 RPTEC qRTPCR m03

980948 IL10-26 0.81967213 0.028394276 IL-10 50 RPTEC qRTPCR m03

980949 IL10-27 28.9145614 2.613738688 IL-10 100 RPTEC qRTPCR m03

980949 IL10-27 10.008772 0.552355033 IL-10 50 RPTEC qRTPCR m03

980949 IL10-27 0.77042773 0.111942117 IL-10 100 RPTEC qRTPCR m03

980949 IL10-27 1.12680812 0.476346757 IL-10 50 RPTEC qRTPCR m03

980949 IL10-27 1.11538462 0.088823118 IL-10 100 RPTEC qRTPCR m03

980949 IL10-27 1 0.141971378 IL-10 50 RPTEC qRTPCR m03

980950 IL10-28 10.7720141 8.21688631 IL-10 100 RPTEC qRTPCR m03

980950 IL10-28 4.00460586 0.730645997 IL-10 50 RPTEC qRTPCR m03

980950 IL10-28 1.79626447 0.167888566 IL-10 100 RPTEC qRTPCR m03

980950 IL10-28 4.20192241 0.345540306 IL-10 50 RPTEC qRTPCR m03

980950 IL10-28 1.03846154 0.044411559 IL-10 100 RPTEC qRTPCR m03

980950 IL10-28 0.86885246 0.028394276 IL-10 50 RPTEC qRTPCR m03

980951 IL10-29 22.3138135 6.135480136 IL-10 100 RPTEC qRTPCR m03

980951 IL10-29 4.95199675 2.442203393 IL-10 50 RPTEC qRTPCR m03

980951 IL10-29 2.47799959 0.476022105 IL-10 100 RPTEC qRTPCR m03

980951 IL10-29 4.14229382 0.247993536 IL-10 50 RPTEC qRTPCR m03

980951 IL10-29 2.03846154 0.954848522 IL-10 100 RPTEC qRTPCR m03

980951 IL10-29 1.44262295 0.615209303 IL-10 50 RPTEC qRTPCR m03

980952 IL10-30 15.124209 2.884691337 IL-10 100 RPTEC qRTPCR m03 980952 IL10-30 3.91425421 2.332815515 IL-10 50 PTEC qRTPCR m03

980952 IL10-30 2.39217414 0.2108329 IL-10 100 RPTEC qRTPCR m03

980952 IL10-30 5.24501381 0.475073395 IL-10 50 RPTEC qRTPCR m03

980952 IL10-30 2.61538462 0.932642743 IL-10 100 RPTEC qRTPCR m03

980952 IL10-30 1.7704918 0.965405368 IL-10 50 RPTEC qRTPCR m03

980953 NANOG- 1.75507302 0.274548521 NANOG 30 Hep3B qRTPCR

01 m02

980953 NANOG- 0.60549818 0.071865003 NANOG 10 Hep3B qRTPCR

01 m02

256221 NANOG- 1.35134384 0.12439644 NANOG 30 Hep3B qRTPCR

02 m02

256221 NANOG- 0.62508954 0.038572504 NANOG 10 Hep3B qRTPCR

02 m02

256252 NANOG- 1.60528466 0.162433779 NANOG 30 Hep3B qRTPCR

03 m02

256252 NANOG- 0.80633272 0.050514865 NANOG 10 Hep3B qRTPCR

03 m02

256229 NANOG- 1.86563924 0.289284817 NANOG 30 Hep3B qRTPCR

04 m02

256229 NANOG- 0.66863112 0.031702962 NANOG 10 Hep3B qRTPCR

04 m02

676139 NANOG- 1.62729386 0.073814233 NANOG 30 Hep3B qRTPCR

05 m02

676139 NANOG- 0.47761436 0.043209034 NANOG 10 Hep3B qRTPCR

05 m02

676113 NANOG- 1.37256575 0.298743134 NANOG 30 Hep3B qRTPCR

06 m02

676113 NANOG- 0.37296341 0.088235168 NANOG 10 Hep3B qRTPCR

06 m02

676172 NANOG- 1.36562985 0.206365604 NANOG 30 Hep3B qRTPCR

07 m02

676172 NANOG- 0.81338153 0.137254006 NANOG 10 Hep3B qRTPCR

07 m02

676153 NANOG- 1.1309655 0.262914375 NANOG 30 Hep3B qRTPCR

08 m02

676153 NANOG- 0.53720646 0.056639785 NANOG 10 Hep3B qRTPCR

08 m02

980954 NANOG- 1.13623808 0.311721656 NANOG 30 Hep3B qRTPCR

09 m02

980954 NANOG- 0.62598367 0.076901755 NANOG 10 Hep3B qRTPCR

09 m02 980955 NANOG- 1.37067156 0.291183385 NANOG 30 Hep3B q TPC 10 m02

980955 NANOG- 0.76710751 0.069499142 NANOG 10 Hep3B qRTPCR

10 m02

980956 NANOG- 1.0899083 0.143760688 NANOG 30 Hep3B qRTPCR

11 m02

980956 NANOG- 0.8524959 0.071439163 NANOG 10 Hep3B qRTPCR

11 m02

980957 NANOG- 1.0351184 0.285812629 NANOG 30 Hep3B qRTPCR

12 m02

980957 NANOG- 0.68035506 0.021921168 NANOG 10 Hep3B qRTPCR

12 m02

980958 NANOG- 1.39751126 0.211298623 NANOG 30 Hep3B qRTPCR

13 m02

980958 NANOG- 1.33954147 0.049756379 NANOG 10 Hep3B qRTPCR

13 m02

980959 NANOG- 0.85482688 0.072788648 NANOG 30 Hep3B qRTPCR

14 m02

980959 NANOG- 0.96752583 0.110576795 NANOG 10 Hep3B qRTPCR

14 m02

980960 NANOG- 1.29105542 0.143304441 NANOG 30 Hep3B qRTPCR

15 m02

980960 NANOG- 1.14475491 0.126395412 NANOG 10 Hep3B qRTPCR

15 m02

980961 NANOG- 1.16400137 0.105240448 NANOG 30 Hep3B qRTPCR

16 m02

980961 NANOG- 0.78375494 0.020758129 NANOG 10 Hep3B qRTPCR

16 m02

980962 NANOG- 0.82254246 0.092789171 NANOG 30 Hep3B qRTPCR

17 m02

980962 NANOG- 1.14092573 0.209640078 NANOG 10 Hep3B qRTPCR

17 m02

980963 NANOG- 0.94453194 0.171092921 NANOG 30 Hep3B qRTPCR

18 m02

980963 NANOG- 1.2475687 0.085635652 NANOG 10 Hep3B qRTPCR

18 m02

980964 NANOG- 1.45201023 0.303175478 NANOG 30 Hep3B qRTPCR

19 m02

980964 NANOG- 1.42005687 0.072650379 NANOG 10 Hep3B qRTPCR

19 m02

980965 NANOG- 1.47717139 0.087948106 NANOG 30 Hep3B qRTPCR

20 m02

980965 NANOG- 1.25411445 0.14110088 NANOG 10 Hep3B qRTPCR

20 m02

980966 NANOG- 0.99561981 0.071342207 NANOG 30 Hep3B qRTPCR

21 m02 980966 NANOG- 0.84845504 0.086337048 NANOG 10 Hep3B qRTPCR 21 m02

980967 NANOG- 1.03646996 0.024359611 NANOG 30 Hep3B qRTPCR

22 m02

980967 NANOG- 0.82917702 0.109955359 NANOG 10 Hep3B qRTPCR

22 m02

257592 NANOG- 1.14651886 0.052177639 NANOG 30 Hep3B qRTPCR

23 m02

257592 NANOG- 1.23896605 0.100186955 NANOG 10 Hep3B qRTPCR

23 m02

257616 NANOG- 1.04527848 0.07260045 NANOG 30 Hep3B qRTPCR

24 m02

257616 NANOG- 0.85159344 0.106460718 NANOG 10 Hep3B qRTPCR

24 m02

257636 NANOG- 0.99884904 0.206769455 NANOG 30 Hep3B qRTPCR

25 m02

257636 NANOG- 0.95192089 0.048327104 NANOG 10 Hep3B qRTPCR

25 m02

257645 NANOG- 1.58626852 0.637413979 NANOG 30 Hep3B qRTPCR

26 m02

257645 NANOG- 0.9729059 0.126526895 NANOG 10 Hep3B qRTPCR

26 m02

257669 NANOG- 1.83181357 0.712193422 NANOG 30 Hep3B qRTPCR

27 m02

257669 NANOG- 1.2914098 0.224177305 NANOG 10 Hep3B qRTPCR

27 m02

919649 NANOG- 1.36638333 0.428879204 NANOG 30 Hep3B qRTPCR

28 m02

919649 NANOG- 1.29782475 0.254824824 NANOG 10 Hep3B qRTPCR

28 m02

258607 NANOG- 1.17076146 0.541139039 NANOG 30 Hep3B qRTPCR

29 m02

258607 NANOG- 0.98683239 0.187021607 NANOG 10 Hep3B qRTPCR

29 m02

260711 NANOG- 0.89903751 0.250441055 NANOG 30 Hep3B qRTPCR

30 m02

260711 NANOG- 0.77639182 0.021376805 NANOG 10 Hep3B qRTPCR

30 m02

980968 Bl-01 1.01415747 0.018113463 RBI 100 Hep3B qRTPCR m03

980968 RBl-01 2.05747535 0.044986806 RBI 50 Hep3B qRTPCR m03

980969 RB1-02 1.21741131 0.053650288 RBI 100 Hep3B qRTPCR m03

980969 RB1-02 3.04069006 0.058878845 RBI 50 Hep3B qRTPCR m03 980970 B1-03 1.1285258 0.048338134 RBI 100 Hep3B qRTPCR m03

980970 RB1-03 3.26429625 0.08302377 RBI 50 Hep3B qRTPCR m03

980971 RB1-04 0.93918583 0.050181262 RBI 100 Hep3B qRTPCR m03

980971 RB1-04 1.38339374 0.00576832 RBI 50 Hep3B qRTPCR m03

980972 RB1-05 0.96530272 0.062937155 RBI 100 Hep3B qRTPCR m03

980972 RB1-05 1.94522208 0.103200969 RBI 50 Hep3B qRTPCR m03

980973 RB1-06 1.18973501 0.028471062 RBI 100 Hep3B qRTPCR m03

980973 RB1-06 4.16426903 0.316379789 RBI 50 Hep3B qRTPCR m03

980974 RB1-07 1.0221857 0.031910551 RBI 100 Hep3B qRTPCR m03

980974 RB1-07 1.57279287 0.055430164 RBI 50 Hep3B qRTPCR m03

980975 RB1-08 0.91567428 0.139663906 RBI 100 Hep3B qRTPCR m03

980975 RB1-08 1.48016406 0.049034353 RBI 50 Hep3B qRTPCR m03

980976 RB1-09 0.79869936 0.128610357 RBI 100 Hep3B qRTPCR m03

980976 RB1-09 1.5482107 0.026113225 RBI 50 Hep3B qRTPCR m03

980977 RBl-10 1.01798348 0.097762303 RBI 100 Hep3B qRTPCR m03

980977 RBl-10 1.03486083 0.030403217 RBI 50 Hep3B qRTPCR m03

980978 RBl-11 1.39780368 0.270760081 RBI 100 Hep3B qRTPCR m03

980978 RBl-11 3.93437134 0.100286198 RBI 50 Hep3B qRTPCR m03

980979 RB1-12 1.65146051 0.496276757 RBI 100 Hep3B qRTPCR m03

980979 RB1-12 3.9254789 0.195148471 RBI 50 Hep3B qRTPCR m03

980980 RB1-13 3.09122625 0.155432621 RBI 100 Hep3B qRTPCR m03

980980 RB1-13 4.13982018 0.168698471 RBI 50 Hep3B qRTPCR m03

980981 RB1-14 2.6612158 0.308586363 RBI 100 Hep3B qRTPCR m03 980981 B1-14 3.36076066 0.134120346 RBI 50 Hep3B qRTPCR m03

980982 B1-15 2.97842121 0.333096529 RBI 100 Hep3B qRTPCR m03

980982 RB1-15 3.75174301 0.352866871 RBI 50 Hep3B qRTPCR m03

980983 RB1-16 5.02222646 1.125451555 RBI 100 Hep3B qRTPCR m03

980983 RB1-16 4.99512098 0.307240728 RBI 50 Hep3B qRTPCR m03

980984 RB1-17 4.09824434 0.193241855 RBI 100 Hep3B qRTPCR m03

980984 RB1-17 4.91698834 0.124658286 RBI 50 Hep3B qRTPCR m03

319148 SERPINF1- 0.35037919 0.043150078 SERPINF1 30 RPTEC qRTPCR

01 m02

319148 SERPINF1- 0.85866303 0.212001425 SERPINF1 10 RPTEC qRTPCR

01 m02

711662 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

02 m02

711733 SERPINF1- 0.35859685 0.030905024 SERPINF1 30 RPTEC qRTPCR

03 m02

711733 SERPINF1- 0.54185821 0.103198417 SERPINF1 10 RPTEC qRTPCR

03 m02

711753 SERPINF1- 0.49708704 0.138011373 SERPINF1 30 RPTEC qRTPCR

04 m02

711753 SERPINF1- 0.65487941 0.104095674 SERPINF1 10 RPTEC qRTPCR

04 m02

320839 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

05 m02

320869 SERPINF1- 0.3878446 0.059597328 SERPINF1 30 RPTEC qRTPCR

06 m02

320869 SERPINF1- 0.54114896 0.059371237 SERPINF1 10 RPTEC qRTPCR

06 m02

320887 SERPINF1- 0.41144307 0.070022943 SERPINF1 30 RPTEC qRTPCR

07 m02

320887 SERPINF1- 2.11555698 0.945933772 SERPINF1 10 RPTEC qRTPCR

07 m02

980985 SERPINF1- 0.56586555 0.023303227 SERPINF1 30 RPTEC qRTPCR

08 m02

980985 SERPINF1- 1.35959162 0.281483272 SERPINF1 10 RPTEC qRTPCR

08 m02

980986 SERPINF1- 0.64449534 0.18522675 SERPINF1 30 RPTEC qRTPCR

09 m02

980986 SERPINF1- 0.9533543 0.007179 SERPINF1 10 RPTEC qRTPCR

09 m02 980987 SERPINF1- 0.82499291 0.146711632 SERPINF1 30 RPTEC qRTPCR 10 m02

980987 SERPINF1- 0.61424739 NA SERPINF1 10 RPTEC qRTPCR

10 m02

980988 SERPINF1- 0.40994662 0.069072959 SERPINF1 30 RPTEC qRTPCR

11 m02

980988 SERPINF1- 1.04772541 0.658532618 SERPINF1 10 RPTEC qRTPCR

11 m02

321295 SERPINF1- 0.47034132 0.185346709 SERPINF1 30 RPTEC qRTPCR

12 m02

321295 SERPINF1- 1.13454179 0.320171101 SERPINF1 10 RPTEC qRTPCR

12 m02

321322 SERPINF1- 0.88066317 0.090976028 SERPINF1 30 RPTEC qRTPCR

13 m02

321322 SERPINF1- 0.67838809 0.089750998 SERPINF1 10 RPTEC qRTPCR

13 m02

712560 SERPINF1- 0.62012299 0.17357326 SERPINF1 30 RPTEC qRTPCR

14 m02

712560 SERPINF1- 0.56860089 0.044192629 SERPINF1 10 RPTEC qRTPCR

14 m02

980989 SERPINF1- 0.60064517 0.014871947 SERPINF1 30 RPTEC qRTPCR

15 m02

980989 SERPINF1- 0.86654473 0.141966258 SERPINF1 10 RPTEC qRTPCR

15 m02

321360 SERPINF1- 0.3348382 0.047941093 SERPINF1 30 RPTEC qRTPCR

16 m02

321360 SERPINF1- 0.88012865 0.179232524 SERPINF1 10 RPTEC qRTPCR

16 m02

323831 SERPINF1- 0.80226894 0.226587961 SERPINF1 30 RPTEC qRTPCR

17 m02

323831 SERPINF1- 1.11738299 0.148912099 SERPINF1 10 RPTEC qRTPCR

17 m02

712608 SERPINF1- 0.28865992 0.011890682 SERPINF1 30 RPTEC qRTPCR

18 m02

712608 SERPINF1- 0.81425828 NA SERPINF1 10 RPTEC qRTPCR

18 m02

323876 SERPINF1- 0.16224041 0.022007503 SERPINF1 30 RPTEC qRTPCR

19 m02

323876 SERPINF1- 0.57595488 0.094579454 SERPINF1 10 RPTEC qRTPCR

19 m02

324530 SERPINF1- 0.36476019 0.018843907 SERPINF1 30 RPTEC qRTPCR

20 m02

324530 SERPINF1- 0.72518134 0.064490093 SERPINF1 10 RPTEC qRTPCR

20 m02

325195 SERPINF1- 0.21882334 0.020387581 SERPINF1 30 RPTEC qRTPCR

21 m02 325195 SERPINF1- 0.89612716 0.175145938 SERPINF1 10 RPTEC qRTPCR 21 m02

325220 SERPINF1- 0.4728922 0.045180406 SERPINF1 30 RPTEC qRTPCR

22 m02

325220 SERPINF1- 1.06290929 0.243856025 SERPINF1 10 RPTEC qRTPCR

22 m02

980990 SERPINF1- 0.70725381 0.099028835 SERPINF1 30 RPTEC qRTPCR

23 m02

980990 SERPINF1- 0.6709374 0.002790285 SERPINF1 10 RPTEC qRTPCR

23 m02

980991 SERPINF1- 0.47683893 0.100918855 SERPINF1 30 RPTEC qRTPCR

24 m02

980991 SERPINF1- 0.72345536 0.197232746 SERPINF1 10 RPTEC qRTPCR

24 m02

325718 SERPINF1- 0.50678878 0.061794062 SERPINF1 30 RPTEC qRTPCR

25 m02

325718 SERPINF1- 0.50869427 0.072065583 SERPINF1 10 RPTEC qRTPCR

25 m02

980992 SERPINF1- 0.6359499 0.205179639 SERPINF1 30 RPTEC qRTPCR

26 m02

980992 SERPINF1- 0.98104913 0.174406402 SERPINF1 10 RPTEC qRTPCR

26 m02

325892 SERPINF1- 0.25829413 0.037951455 SERPINF1 30 RPTEC qRTPCR

27 m02

325892 SERPINF1- 1.34713087 0.493260348 SERPINF1 10 RPTEC qRTPCR

27 m02

325817 SERPINF1- 0.32605364 0.045693913 SERPINF1 30 RPTEC qRTPCR

28 m02

325817 SERPINF1- 0.98557465 0.078068502 SERPINF1 10 RPTEC qRTPCR

28 m02

980993 SERPINF1- 0.51398623 0.037693895 SERPINF1 30 RPTEC qRTPCR

29 m02

980993 SERPINF1- 1.40853416 0.175762801 SERPINF1 10 RPTEC qRTPCR

29 m02

325952 SERPINF1- 0.48896641 0.25878185 SERPINF1 30 RPTEC qRTPCR

30 m02

325952 SERPINF1- 1.12050839 0.277079195 SERPINF1 10 RPTEC qRTPCR

30 m02

325929 SERPINF1- 1.01424328 0.195157461 SERPINF1 30 RPTEC qRTPCR

31 m02

325929 SERPINF1- 0.8942259 0.233599949 SERPINF1 10 RPTEC qRTPCR

31 m02

326045 SERPINF1- 0.87856488 0.296248451 SERPINF1 30 RPTEC qRTPCR

32 m02

326045 SERPINF1- 0.74590116 0.125458391 SERPINF1 10 RPTEC qRTPCR

32 m02 316159 SERPINF1- NA NA SERPINF1 0 NA qRTPCR 33 m02

980994 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

34 m02

315063 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

35 m02

980995 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

36 m02

314649 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

37 m02

314590 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

38 m02

980996 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

39 m02

980997 SERPINF1- NA NA SERPINF1 0 NA qRTPCR

40 m02

354004 SIRT6-01 NA NA SIRT6 0 NA qRTPCR m02

353990 SIRT6-02 1.54298794 0.285074313 SIRT6 30 Hep3B qRTPCR m02

353990 SIRT6-02 1.35553992 0.112119101 SIRT6 10 Hep3B qRTPCR m02

353975 SIRT6-03 0.89929025 0.004486534 SIRT6 30 Hep3B qRTPCR m02

353975 SIRT6-03 0.96782487 0.111337826 SIRT6 10 Hep3B qRTPCR m02

352095 SIRT6-04 0.56085503 0.010943833 SIRT6 30 Hep3B qRTPCR m02

352095 SIRT6-04 0.72493529 0.015655036 SIRT6 10 Hep3B qRTPCR m02

352083 SIRT6-05 0.82420833 0.016662848 SIRT6 30 Hep3B qRTPCR m02

352083 SIRT6-05 0.92149198 0.035019689 SIRT6 10 Hep3B qRTPCR m02

352072 SIRT6-06 0.6915929 0.029134955 SIRT6 30 Hep3B qRTPCR m02

352072 SIRT6-06 0.98599536 0.030581327 SIRT6 10 Hep3B qRTPCR m02

980998 SIRT6-07 1.1148062 0.088355387 SIRT6 30 Hep3B qRTPCR m02

980998 SIRT6-07 1.73035259 0.451369 SIRT6 10 Hep3B qRTPCR m02

980999 SIRT6-08 1.01846494 0.048974249 SIRT6 30 Hep3B qRTPCR m02

980999 SIRT6-08 1.08723908 0.043868313 SIRT6 10 Hep3B qRTPCR m02 981000 SI T6-09 0.84950471 0.059838223 SIRT6 30 Hep3B qRTPCR m02

981000 SI T6-09 0.98944794 0.066203433 SIRT6 10 Hep3B qRTPCR m02

981001 SIRT6-10 0.80222964 0.038524262 SIRT6 30 Hep3B qRTPCR m02

981001 SIRT6-10 0.8622621 0.116553439 SIRT6 10 Hep3B qRTPCR m02

981002 SIRT6-11 0.48245444 0.049603768 SIRT6 30 Hep3B qRTPCR m02

981002 SIRT6-11 0.8172485 0.070010956 SIRT6 10 Hep3B qRTPCR m02

981003 SIRT6-12 NA NA SIRT6 0 NA qRTPCR m02

981004 SIRT6-13 0.69661176 0.076398136 SIRT6 30 Hep3B qRTPCR m02

981004 SIRT6-13 0.66075574 0.056462502 SIRT6 10 Hep3B qRTPCR m02

981005 SIRT6-14 0.02272863 0.000630061 SIRT6 30 Hep3B qRTPCR m02

981005 SIRT6-14 0.05051788 0.014414898 SIRT6 10 Hep3B qRTPCR m02

#N/A SIRT6-15 NA NA SIRT6 0 NA qRTPCR mOO

981007 SIRT6-16 0.93936639 0.052754754 SIRT6 30 Hep3B qRTPCR m02

981007 SIRT6-16 1.0930298 0.114332558 SIRT6 10 Hep3B qRTPCR m02

981008 SIRT6-17 0.84946489 0.054842464 SIRT6 30 Hep3B qRTPCR m02

981008 SIRT6-17 0.88224472 0.076422571 SIRT6 10 Hep3B qRTPCR m02

981009 SIRT6-18 1.20375247 0.135463429 SIRT6 30 Hep3B qRTPCR m02

981009 SIRT6-18 0.95397587 0.089762001 SIRT6 10 Hep3B qRTPCR m02

981010 SIRT6-19 1.04886778 0.044532414 SIRT6 30 Hep3B qRTPCR m02

981010 SIRT6-19 1.06461555 0.206493298 SIRT6 10 Hep3B qRTPCR m02

981011 SIRT6-20 0.75405377 0.047328793 SIRT6 30 Hep3B qRTPCR m02

981011 SIRT6-20 0.87044637 0.111246336 SIRT6 10 Hep3B qRTPCR m02

981012 SIRT6-21 1.23496103 0.049080011 SIRT6 30 Hep3B qRTPCR m02 981012 SI T6-21 0.97850409 0.072276387 SIRT6 10 Hep3B qRTPCR m02

981013 SIRT6-22 0.99018678 0.033353127 SIRT6 30 Hep3B qRTPCR m02

981013 SIRT6-22 1.10084835 0.029126778 SIRT6 10 Hep3B qRTPCR m02

981014 SIRT6-23 1.18396951 0.119042905 SIRT6 30 Hep3B qRTPCR m02

981014 SIRT6-23 1.38826667 0.081526577 SIRT6 10 Hep3B qRTPCR m02

981015 SIRT6-24 1.08446648 0.136406702 SIRT6 30 Hep3B qRTPCR m02

981015 SIRT6-24 0.93150723 0.083708398 SIRT6 10 Hep3B qRTPCR m02

981016 SIRT6-25 0.86132645 0.045289199 SIRT6 30 Hep3B qRTPCR m02

981016 SIRT6-25 0.91068893 0.057241305 SIRT6 10 Hep3B qRTPCR m02

981017 SIRT6-26 NA NA SIRT6 0 NA qRTPCR m02

981018 SIRT6-27 0.64381003 0.027322953 SIRT6 30 Hep3B qRTPCR m02

981018 SIRT6-27 0.81259464 0.085991622 SIRT6 10 Hep3B qRTPCR m02

981019 SIRT6-28 0.95757443 0.042738721 SIRT6 30 Hep3B qRTPCR m02

981019 SIRT6-28 1.03069542 0.049168632 SIRT6 10 Hep3B qRTPCR m02

981020 SIRT6-29 0.90888037 0.221220787 SIRT6 30 Hep3B qRTPCR m02

981020 SIRT6-29 0.89370544 0.130584794 SIRT6 10 Hep3B qRTPCR m02

981029 ST7-01 1.15894107 0.037384873 ST7 100 RPTEC qRTPCR m03

981029 ST7-01 1.30157203 0.031004814 ST7 50 RPTEC qRTPCR m03

981030 ST7-02 1.23457542 0.046645195 ST7 100 RPTEC qRTPCR m03

981030 ST7-02 1.24348311 0.049597248 ST7 50 RPTEC qRTPCR m03

981031 ST7-03 1.37869128 0.076548843 ST7 100 RPTEC qRTPCR m03

981031 ST7-03 1.23995595 0.014089104 ST7 50 RPTEC qRTPCR m03

981032 ST7-04 1.23136772 0.025019858 ST7 100 RPTEC qRTPCR m03 981032 ST7-04 1.20028321 0.016532438 ST7 50 PTEC qRTPCR m03

981033 ST7-05 1.22826111 0.04853082 ST7 100 RPTEC qRTPCR m03

981033 ST7-05 1.28526328 0.018268018 ST7 50 RPTEC qRTPCR m03

981034 ST7-06 1.14806148 0.040982052 ST7 100 RPTEC qRTPCR m03

981034 ST7-06 1.16098959 0.023237379 ST7 50 RPTEC qRTPCR m03

981035 ST7-07 1.2554765 0.031070332 ST7 100 RPTEC qRTPCR m03

981035 ST7-07 1.29589246 0.014356093 ST7 50 RPTEC qRTPCR m03

981036 ST7-08 1.203351 0.007427892 ST7 100 RPTEC qRTPCR m03

981036 ST7-08 1.19406644 0.027607781 ST7 50 RPTEC qRTPCR m03

981037 ST7-09 1.13787985 0.063501389 ST7 100 RPTEC qRTPCR m03

981037 ST7-09 NA NA ST7 50 RPTEC qRTPCR m03

981038 ST7-10 1.28016943 0.043020861 ST7 100 RPTEC qRTPCR m03

981038 ST7-10 1.27328408 0.011524675 ST7 50 RPTEC qRTPCR m03

981039 ST7-11 1.22739645 0.062184944 ST7 100 RPTEC qRTPCR m03

981039 ST7-11 1.28422394 0.04080025 ST7 50 RPTEC qRTPCR m03

981040 ST7-12 1.24447605 0.03583797 ST7 100 RPTEC qRTPCR m03

981040 ST7-12 1.17017041 0.029950287 ST7 50 RPTEC qRTPCR m03

981041 ST7-13 1.26870157 0.004324418 ST7 100 RPTEC qRTPCR m03

981041 ST7-13 1.31597648 0.045603088 ST7 50 RPTEC qRTPCR m03

981042 ST7-14 1.18042605 0.035658882 ST7 100 RPTEC qRTPCR m03

981042 ST7-14 1.20876403 0.053576582 ST7 50 RPTEC qRTPCR m03

981043 ST7-15 1.29756634 0.046090768 ST7 100 RPTEC qRTPCR m03

981043 ST7-15 1.39243688 0.053478499 ST7 50 RPTEC qRTPCR m03 981044 ST7-16 1.24116232 0.027294171 ST7 100 PTEC qRTPCR m03

981044 ST7-16 1.28001562 0.00811923 ST7 50 RPTEC qRTPCR m03

981045 ST7-17 1.17000239 0.033114216 ST7 100 RPTEC qRTPCR m03

981045 ST7-17 1.32207883 0.052984756 ST7 50 RPTEC qRTPCR m03

981046 ST7-18 1.11329517 0.031683375 ST7 100 RPTEC qRTPCR m03

981046 ST7-18 1.09085494 0.004305551 ST7 50 RPTEC qRTPCR m03

981047 ST7-19 1.23622438 0.041320162 ST7 100 RPTEC qRTPCR m03

981047 ST7-19 1.19295472 0.027729196 ST7 50 RPTEC qRTPCR m03

981048 ST7-20 1.27087624 0.036133378 ST7 100 RPTEC qRTPCR m03

981048 ST7-20 1.17299465 0.026838418 ST7 50 RPTEC qRTPCR m03

981049 ST7-21 1.27610827 0.043881349 ST7 100 RPTEC qRTPCR m03

981049 ST7-21 1.23579388 0.032336152 ST7 50 RPTEC qRTPCR m03

981050 ST7-22 1.2391548 0.02685417 ST7 100 RPTEC qRTPCR m03

981050 ST7-22 1.27923425 0.024051238 ST7 50 RPTEC qRTPCR m03

981051 ST7-23 0.91152966 0.028188074 ST7 100 RPTEC qRTPCR m03

981051 ST7-23 1.13754746 0.068164787 ST7 50 RPTEC qRTPCR m03

981052 ST7-24 0.96346734 0.029104888 ST7 100 RPTEC qRTPCR m03

981052 ST7-24 0.93045924 0.079507424 ST7 50 RPTEC qRTPCR m03

981053 ST7-25 1.21966247 0.012291584 ST7 100 RPTEC qRTPCR m03

981053 ST7-25 1.22553285 0.017912483 ST7 50 RPTEC qRTPCR m03

981054 ST7-26 1.22177128 0.025715112 ST7 100 RPTEC qRTPCR m03

981054 ST7-26 1.32696644 0.050333551 ST7 50 RPTEC qRTPCR m03

981055 ST7-27 1.24786654 0.011738008 ST7 100 RPTEC qRTPCR m03 981055 ST7-27 1.28558175 0.019059018 ST7 50 PTEC qRTPCR m03

981056 ST7-28 1.31215354 0.051864431 ST7 100 RPTEC qRTPCR m03

981056 ST7-28 1.24703973 0.043426594 ST7 50 RPTEC qRTPCR m03

981057 ST7-29 1.28756567 0.038472461 ST7 100 RPTEC qRTPCR m03

981057 ST7-29 1.39545519 0.020039697 ST7 50 RPTEC qRTPCR m03

981058 ST7-30 1.20536071 0.065516956 ST7 100 RPTEC qRTPCR m03

981058 ST7-30 1.16269994 0.018650372 ST7 50 RPTEC qRTPCR m03

981059 STAT3-01 0.68081294 0.097984302 STAT3 10 Hep3B qRTPCR m02

981060 STAT3-02 0.71423947 0.073913445 STAT3 10 Hep3B qRTPCR m02

981061 STAT3-03 0.77081487 0.038454347 STAT3 10 Hep3B qRTPCR m02

981062 STAT3-04 0.99931236 0.096362877 STAT3 10 Hep3B qRTPCR m02

981063 STAT3-05 1.21304667 0.020800216 STAT3 10 Hep3B qRTPCR m02

981064 STAT3-06 0.7819596 0.061328415 STAT3 10 Hep3B qRTPCR m02

981065 STAT3-07 0.83641565 0.118732947 STAT3 10 Hep3B qRTPCR m02

981066 STAT3-08 1.07150323 0.297063254 STAT3 10 Hep3B qRTPCR m02

981067 STAT3-09 0.65005666 0.109654054 STAT3 10 Hep3B qRTPCR m02

981068 STAT3-10 0.7001003 0.116518178 STAT3 10 Hep3B qRTPCR m02

981069 STAT3-11 1.02118476 0.228814093 STAT3 10 Hep3B qRTPCR m02

981070 STAT3-12 0.95357478 0.15933069 STAT3 10 Hep3B qRTPCR m02

981071 STAT3-13 0.64706358 0.01196402 STAT3 10 Hep3B qRTPCR m02

981072 STAT3-14 0.63752956 0.139375642 STAT3 10 Hep3B qRTPCR m02

981073 STAT3-15 0.62804007 0.078787359 STAT3 10 Hep3B qRTPCR m02

981074 STAT3-16 0.6901822 0.135962199 STAT3 10 Hep3B qRTPCR m02 981075 STAT3-17 0.97643024 0.086652916 STAT3 10 Hep3B q TPC m02

981076 STAT3-18 0.96529563 0.042380286 STAT3 10 Hep3B qRTPCR m02

981078 STAT3-20 0.61060816 0.14714544 STAT3 10 Hep3B qRTPCR m02

981079 STAT3-21 0.6974985 0.148778379 STAT3 10 Hep3B qRTPCR m02

981080 STAT3-22 0.77887247 0.163861596 STAT3 10 Hep3B qRTPCR m02

981081 STAT3-23 0.55962497 0.207805656 STAT3 10 Hep3B qRTPCR m02

981082 STAT3-24 0.69355572 0.2018482 STAT3 10 Hep3B qRTPCR m02

981083 STAT3-25 0.59303203 0.221709077 STAT3 10 Hep3B qRTPCR m02

981086 STAT3-28 1.06881393 0.238573808 STAT3 10 Hep3B qRTPCR m02

981087 STAT3-29 0.75959176 0.094083798 STAT3 10 Hep3B qRTPCR m02

981088 STAT3-30 0.45709972 0.067948254 STAT3 10 Hep3B qRTPCR m02

981089 STAT3-31 0.91439092 0.037475132 STAT3 10 Hep3B qRTPCR m02

981089 STAT3-31 1.24866221 0.051931766 STAT3 30 Hep3B qRTPCR m02

981089 STAT3-31 0.59341428 0.001985656 STAT3 10 Hep3B qRTPCR m02

981090 STAT3-32 1.04480633 0.042088675 STAT3 10 Hep3B qRTPCR m02

981090 STAT3-32 1.51995051 0.01785135 STAT3 30 Hep3B qRTPCR m02

981090 STAT3-32 0.59471737 0.014008168 STAT3 10 Hep3B qRTPCR m02

981091 STAT3-33 0.96149677 0.068365068 STAT3 10 Hep3B qRTPCR m02

981091 STAT3-33 1.08181473 0.129506762 STAT3 30 Hep3B qRTPCR m02

981091 STAT3-33 0.70416358 0.078883938 STAT3 10 Hep3B qRTPCR m02

981092 STAT3-34 1.01511886 0.059376986 STAT3 10 Hep3B qRTPCR m02

981092 STAT3-34 0.87465826 0.10005428 STAT3 30 Hep3B qRTPCR m02

981092 STAT3-34 0.95844684 0.430932323 STAT3 30 Hep3B qRTPCR m02 981093 STAT3-35 0.86744037 0.053693293 STAT3 10 Hep3B qRTPCR m02

981093 STAT3-35 1.44467655 0.133642419 STAT3 30 Hep3B qRTPCR m02

981093 STAT3-35 0.42098621 0.078659856 STAT3 30 Hep3B qRTPCR m02

981094 STAT3-36 1.2072492 0.140491733 STAT3 10 Hep3B qRTPCR m02

981094 STAT3-36 1.93990313 0.128941801 STAT3 30 Hep3B qRTPCR m02

981094 STAT3-36 0.58815623 0.182692714 STAT3 30 Hep3B qRTPCR m02

981095 STAT3-37 0.81496524 0.050097957 STAT3 10 Hep3B qRTPCR m02

981095 STAT3-37 0.80914963 0.102123025 STAT3 30 Hep3B qRTPCR m02

981095 STAT3-37 0.33779008 0.031701817 STAT3 30 Hep3B qRTPCR m02

981096 CFT -01 0.79281285 0.184413463 CFTR 100 RPTEC qRTPCR m03

981096 CFTR-01 0.5758401 0.056001303 CFTR 50 RPTEC qRTPCR m03

981097 CFTR-02 1.19726828 0.466073658 CFTR 100 RPTEC qRTPCR m03

981097 CFTR-02 0.57110537 0.234612166 CFTR 50 RPTEC qRTPCR m03

981098 CFTR-03 1.68031042 0.221569397 CFTR 100 RPTEC qRTPCR m03

981098 CFTR-03 1.09356032 0.192228041 CFTR 50 RPTEC qRTPCR m03

981099 CFTR-04 0.30256318 0.06030635 CFTR 100 RPTEC qRTPCR m03

981099 CFTR-04 0.45202197 0.230631447 CFTR 50 RPTEC qRTPCR m03

981100 CFTR-05 0.78893458 0.258285973 CFTR 100 RPTEC qRTPCR m03

981100 CFTR-05 0.89687385 0.484520905 CFTR 50 RPTEC qRTPCR m03

981101 CFTR-06 0.67486527 0.078492631 CFTR 100 RPTEC qRTPCR m03

981101 CFTR-06 0.9106006 0.083284148 CFTR 50 RPTEC qRTPCR m03

981102 CFTR-07 1.15861342 0.0852313 CFTR 100 RPTEC qRTPCR m03

981102 CFTR-07 0.48889587 0.244635697 CFTR 50 RPTEC qRTPCR m03 981103 CFT -08 0.80641895 0.274712322 CFTR 100 RPTEC qRTPCR m03

981103 CFTR-08 0.57724641 0.186638729 CFTR 50 RPTEC qRTPCR m03

981104 CFTR-09 0.84180523 0.30810345 CFTR 100 RPTEC qRTPCR m03

981104 CFTR-09 2.29274676 0.249245367 CFTR 50 RPTEC qRTPCR m03

981105 CFTR-10 0.98257627 0.252414601 CFTR 100 RPTEC qRTPCR m03

981105 CFTR-10 0.79535469 0.312610938 CFTR 50 RPTEC qRTPCR m03

981106 CFTR-11 0.76420251 0.268108937 CFTR 100 RPTEC qRTPCR m03

981106 CFTR-11 0.29614519 0.093888846 CFTR 50 RPTEC qRTPCR m03

981107 CFTR-12 0.74645918 0.091852496 CFTR 100 RPTEC qRTPCR m03

981107 CFTR-12 0.60233476 0.210104005 CFTR 50 RPTEC qRTPCR m03

981108 CFTR-13 1.02755274 0.19955176 CFTR 100 RPTEC qRTPCR m03

981108 CFTR-13 0.56395557 0.235434045 CFTR 50 RPTEC qRTPCR m03

981109 CFTR-14 0.97624687 0.36826384 CFTR 100 RPTEC qRTPCR m03

981109 CFTR-14 0.41734906 0.045211303 CFTR 50 RPTEC qRTPCR m03

981110 CFTR-15 0.51045359 0.230213509 CFTR 100 RPTEC qRTPCR m03

981110 CFTR-15 0.53390918 0.176295141 CFTR 50 RPTEC qRTPCR m03

981111 CFTR-16 0.55372434 0.151068461 CFTR 100 RPTEC qRTPCR m03

981111 CFTR-16 0.4524799 0.104170584 CFTR 50 RPTEC qRTPCR m03

981112 CFTR-17 1.31767785 0.255890334 CFTR 100 RPTEC qRTPCR m03

981112 CFTR-17 0.6160011 0.189615377 CFTR 50 RPTEC qRTPCR m03

981113 CFTR-18 1.32319022 0.059735821 CFTR 100 RPTEC qRTPCR m03

981113 CFTR-18 1.35630703 0.308296212 CFTR 50 RPTEC qRTPCR m03

981114 CFTR-19 1.02158789 0.242829879 CFTR 100 RPTEC qRTPCR m03 981114 CFT -19 1.05232148 0.100649968 CFTR 50 RPTEC qRTPCR m03

981115 CFTR-20 0.93631117 0.232849017 CFTR 100 RPTEC qRTPCR m03

981115 CFTR-20 1.12591661 0.078383985 CFTR 50 RPTEC qRTPCR m03

981116 CFTR-21 0.55168062 0.421376798 CFTR 100 RPTEC qRTPCR m03

981116 CFTR-21 1.1514542 0.074529491 CFTR 50 RPTEC qRTPCR m03

981117 CFTR-22 1.12224588 0.025142805 CFTR 100 RPTEC qRTPCR m03

981117 CFTR-22 0.88637711 0.058032965 CFTR 50 RPTEC qRTPCR m03

981118 CFTR-23 0.59928327 0.077017402 CFTR 100 RPTEC qRTPCR m03

981118 CFTR-23 0.55996955 0.071853326 CFTR 50 RPTEC qRTPCR m03

981119 CFTR-24 0.51858709 0.139923956 CFTR 100 RPTEC qRTPCR m03

981119 CFTR-24 0.73286794 0.537382517 CFTR 50 RPTEC qRTPCR m03

981120 CFTR-25 0.8327123 0.177190013 CFTR 100 RPTEC qRTPCR m03

981120 CFTR-25 0.34596108 0.134271928 CFTR 50 RPTEC qRTPCR m03

981121 CFTR-26 1.05576915 0.049746733 CFTR 100 RPTEC qRTPCR m03

981121 CFTR-26 0.80966162 0.229310703 CFTR 50 RPTEC qRTPCR m03

981122 CFTR-27 0.75306615 0.124938866 CFTR 100 RPTEC qRTPCR m03

981122 CFTR-27 0.68763309 0.122547388 CFTR 50 RPTEC qRTPCR m03

981123 CFTR-28 0.88610265 0.169682384 CFTR 100 RPTEC qRTPCR m03

981123 CFTR-28 0.66075518 0.223035757 CFTR 50 RPTEC qRTPCR m03

981124 CFTR-29 0.91693169 0.16691104 CFTR 100 RPTEC qRTPCR m03

981124 CFTR-29 0.61850434 0.042956135 CFTR 50 RPTEC qRTPCR m03

981125 CFTR-30 0.56928413 0.078330035 CFTR 100 RPTEC qRTPCR m03

981125 CFTR-30 0.44192061 0.131245117 CFTR 50 RPTEC qRTPCR m03 981126 PAH-01 0.23981825 0.030122342 PAH 100 PTEC qRTPCR m03

981126 PAH-01 0.32710199 0.069694813 PAH 50 RPTEC qRTPCR m03

981127 PAH-02 0.26126019 0.021610081 PAH 100 RPTEC qRTPCR m03

981127 PAH-02 0.29981695 0.029605636 PAH 50 RPTEC qRTPCR m03

981128 PAH-03 0.24411626 0.013572871 PAH 100 RPTEC qRTPCR m03

981128 PAH-03 0.27926959 0.014674486 PAH 50 RPTEC qRTPCR m03

981129 PAH -04 0.14942997 0.017211093 PAH 100 RPTEC qRTPCR m03

981129 PAH -04 0.25898314 0.027819213 PAH 50 RPTEC qRTPCR m03

981130 PAH-05 0.22927688 0.030251173 PAH 100 RPTEC qRTPCR m03

981130 PAH-05 0.25098631 0.00283087 PAH 50 RPTEC qRTPCR m03

981131 PAH-06 0.35739505 0.021249213 PAH 100 RPTEC qRTPCR m03

981131 PAH-06 0.24892255 0.006310212 PAH 50 RPTEC qRTPCR m03

981132 PAH-07 0.50060787 0.251317665 PAH 100 RPTEC qRTPCR m03

981132 PAH-07 0.50725807 0.255402736 PAH 50 RPTEC qRTPCR m03

981133 PAH-08 0.37452517 0.133153658 PAH 100 RPTEC qRTPCR m03

981133 PAH-08 0.57247135 0.188265227 PAH 50 RPTEC qRTPCR m03

981134 PAH-09 0.37320102 0.085449629 PAH 100 RPTEC qRTPCR m03

981134 PAH-09 0.61877263 0.203298225 PAH 50 RPTEC qRTPCR m03

981135 PAH-10 0.71766851 0.098607144 PAH 100 RPTEC qRTPCR m03

981135 PAH-10 0.7463628 0.172977053 PAH 50 RPTEC qRTPCR m03

981136 PAH-11 0.49056734 0.180163371 PAH 100 RPTEC qRTPCR m03

981136 PAH-11 0.54541559 0.153684934 PAH 50 RPTEC qRTPCR m03

981137 PAH-12 0.55710203 0.052697026 PAH 100 RPTEC qRTPCR m03 981137 PAH-12 0.54052705 0.056164173 PAH 50 PTEC qRTPCR m03

981138 PAH-13 0.37809987 0.075724386 PAH 100 RPTEC qRTPCR m03

981138 PAH-13 0.32473399 0.08826494 PAH 50 RPTEC qRTPCR m03

981139 PAH-14 0.44671317 0.123586116 PAH 100 RPTEC qRTPCR m03

981139 PAH-14 0.42250052 0.118599637 PAH 50 RPTEC qRTPCR m03

981140 PAH-15 0.38355035 0.080709933 PAH 100 RPTEC qRTPCR m03

981140 PAH-15 0.7946908 0.422881663 PAH 50 RPTEC qRTPCR m03

981141 PAH-16 0.23910145 0.068869465 PAH 100 RPTEC qRTPCR m03

981141 PAH-16 0.38081621 0.130308426 PAH 50 RPTEC qRTPCR m03

981142 PAH-17 0.2290026 0.014716387 PAH 100 RPTEC qRTPCR m03

981142 PAH-17 0.35190507 0.032000898 PAH 50 RPTEC qRTPCR m03

981143 PAH-18 0.48222347 0.174202324 PAH 100 RPTEC qRTPCR m03

981143 PAH-18 0.28569492 0.020371259 PAH 50 RPTEC qRTPCR m03

981144 PAH-19 0.24661836 0.027061188 PAH 100 RPTEC qRTPCR m03

981144 PAH-19 0.26044948 0.06892563 PAH 50 RPTEC qRTPCR m03

981145 PAH-20 0.7505651 0.496952697 PAH 100 RPTEC qRTPCR m03

981145 PAH-20 0.24602928 0.023688277 PAH 50 RPTEC qRTPCR m03

981146 PAH-21 0.3791742 0.019175935 PAH 100 RPTEC qRTPCR m03

981146 PAH-21 0.41263689 0.031425679 PAH 50 RPTEC qRTPCR m03

981147 PAH-22 0.29467028 0.04347949 PAH 100 RPTEC qRTPCR m03

981147 PAH-22 0.27411715 0.024526794 PAH 50 RPTEC qRTPCR m03

981148 PAH-23 0.3434461 0.080358535 PAH 100 RPTEC qRTPCR m03

981148 PAH-23 0.320171 0.032700414 PAH 50 RPTEC qRTPCR m03 981149 PAH-24 0.33248658 0.026329709 PAH 100 PTEC qRTPCR m03

981149 PAH-24 0.32314297 0.017465814 PAH 50 RPTEC qRTPCR m03

981150 PAH-25 0.2773943 0.01464307 PAH 100 RPTEC qRTPCR m03

981150 PAH-25 0.28035 0.02196583 PAH 50 RPTEC qRTPCR m03

981151 PAH-26 0.28468169 0.025546105 PAH 100 RPTEC qRTPCR m03

981151 PAH-26 0.37430063 0.056736568 PAH 50 RPTEC qRTPCR m03

981152 PAH-27 0.25452333 0.015791081 PAH 100 RPTEC qRTPCR m03

981152 PAH-27 0.47014396 0.241487515 PAH 50 RPTEC qRTPCR m03

981153 PAH-28 0.23169397 0.013331663 PAH 100 RPTEC qRTPCR m03

981153 PAH-28 0.46003726 0.201788882 PAH 50 RPTEC qRTPCR m03

981154 PAH-29 0.28356567 0.028096983 PAH 100 RPTEC qRTPCR m03

981154 PAH-29 0.46889281 0.129349257 PAH 50 RPTEC qRTPCR m03

981155 PAH-30 0.33687387 0.012322177 PAH 100 RPTEC qRTPCR m03

981155 PAH-30 0.4323463 0.174257707 PAH 50 RPTEC qRTPCR m03

Table 6: Formatted oligonucleotide sequences made for testing in the lab showing nucleotide modifications.

Oligo Base Sequence Formatted Sequence SeqID Name

B CAl-01 ACTACTGACTGCAGC dAs;lnaCs;dTs;lnaAs;dCs;lnaTs;dGs;lnaAs;dCs; 980846 m02 lnaTs;dGs;lnaCs;dAs;lnaGs;dC-Sup

BRCAl-02 ACAGAGCCACAGGAC dAs;lnaCs;dAs;lnaGs;dAs;lnaGs;dCs;lnaCs;dAs 980847 m02 ;lnaCs;dAs;lnaGs;dGs;lnaAs;dC-Sup

BRCAl-03 TGGTGGTGTCTGGCC dTs;lnaGs;dGs;lnaTs;dGs;lnaGs;dTs;lnaGs;dTs; 980848 m02 lnaCs;dTs;lnaGs;dGs;lnaCs;dC-Sup

BRCAl-04 AC 1 1 1 I U G I GAAG I dAs;lnaCs;dTs;lnaTs;dTs;lnaTs;dCs;lnaTs;dGs;l 40033 m02 naTs;dGs;lnaAs;dAs;lnaGs;dT-Sup

BRCAl-05 AACAAGACATGAGTG dAs;lnaAs;dCs;lnaAs;dAs;lnaGs;dAs;lnaCs;dAs 39787 m02 ;lnaTs;dGs;lnaAs;dGs;lnaTs;dG-Sup

BRCAl-06 TGAAAGAAAAAACAG dTs;lnaGs;dAs;lnaAs;dAs;lnaGs;dAs;lnaAs;dAs 39765 m02 ;lnaAs;dAs;lnaAs;dCs;lnaAs;dG-Sup

BRCAl-07 TGATGTTATTGTGAT dTs;lnaGs;dAs;lnaTs;dGs;lnaTs;dTs;lnaAs;dTs;l 36210 m02 naTs;dGs;lnaTs;dGs;lnaAs;dT-Sup

BRCAl-08 I U 1 1 I AAAGU AGG dTs;lnaCs;dTs;lnaTs;dTs;lnaTs;dAs;lnaAs;dAs;l 36173 m02 naGs;dCs;lnaTs;dAs;lnaGs;dG-Sup

BRCAl-09 ATGATGAAGAAAGAG dAs;lnaTs;dGs;lnaAs;dTs;lnaGs;dAs;lnaAs;dGs 980849 m02 ;lnaAs;dAs;lnaAs;dGs;lnaAs;dG-Sup

BRCAl-10 TTTG G CTC AG G GTTA dTs;lnaTs;dTs;lnaGs;dGs;lnaCs;dTs;lnaCs;dAs;l 980850 m02 naGs;dGs;lnaGs;dTs;lnaTs;dA-Sup

BRCAl-11 A ATTG A ATG CT ATG C dAs;lnaAs;dTs;lnaTs;dGs;lnaAs;dAs;lnaTs;dGs; 980851 m02 lnaCs;dTs;lnaAs;dTs;lnaGs;dC-Sup

BRCAl-12 TTGAATGTTCCTCAA dTs;lnaTs;dGs;lnaAs;dAs;lnaTs;dGs;lnaTs;dTs;l 32373 m02 naCs;dCs;lnaTs;dCs;lnaAs;dA-Sup

BRCAl-13 ATTTCTCTTTC AG GT dAs;lnaTs;dTs;lnaTs;dCs;lnaTs;dCs;lnaTs;dTs;l 32392 m02 naTs;dCs;lnaAs;dGs;lnaGs;dT-Sup

BRCAl-14 1 I GA I 1 1 I L I I LU 1 dTs;lnaTs;dGs;lnaAs;dTs;lnaTs;dTs;lnaTs;dCs;l 32081 m02 naTs;dTs;lnaCs;dCs;lnaTs;dT-Sup

BRCAl-15 I GAL I 1 1 I GG I U 1 1 dTs;lnaGs;dAs;lnaCs;dTs;lnaTs;dTs;lnaTs;dGs;l 980852 m02 naGs;dTs;lnaCs;dTs;lnaTs;dT-Sup

BRCAl-16 AGTCGGGAAACAAGC dAs;lnaGs;dTs;lnaCs;dGs;lnaGs;dGs;lnaAs;dAs 980853 m02 ;lnaAs;dCs;lnaAs;dAs;lnaGs;dC-Sup

BRCAl-17 AGTCAGTGTGCAGCA dAs;lnaGs;dTs;lnaCs;dAs;lnaGs;dTs;lnaGs;dTs; 980854 m02 lnaGs;dCs;lnaAs;dGs;lnaCs;dA-Sup

BRCAl-18 GAATTTGTCAATCCT dGs;lnaAs;dAs;lnaTs;dTs;lnaTs;dGs;lnaTs;dCs;l 980855 m02 naAs;dAs;lnaTs;dCs;lnaCs;dT-Sup

BRCAl-19 AATCCTAGCCTTCCA dAs;lnaAs;dTs;lnaCs;dCs;lnaTs;dAs;lnaGs;dCs; 980856 m02 lnaCs;dTs;lnaTs;dCs;lnaCs;dA-Sup

BRCAl-20 AAGAACCTGCAACTG dAs;lnaAs;dGs;lnaAs;dAs;lnaCs;dCs;lnaTs;dGs; 521928 m02 lnaCs;dAs;lnaAs;dCs;lnaTs;dG-Sup B CAl-21 ACTGAATTGCAAATT dAs;lnaCs;dTs;lnaGs;dAs;lnaAs;dTs;lnaTs;dGs; 521823 m02 lnaCs;dAs;lnaAs;dAs;lnaTs;dT-Sup

BRCAl-22 AATATCCACAATTCA dAs;lnaAs;dTs;lnaAs;dTs;lnaCs;dCs;lnaAs;dCs;l 980857 m02 naAs;dAs;lnaTs;dTs;lnaCs;dA-Sup

BRCAl-23 ATTCTCATGACCACT dAs;lnaTs;dTs;lnaCs;dTs;lnaCs;dAs;lnaTs;dGs;l 31294 m02 naAs;dCs;lnaCs;dAs;lnaCs;dT-Sup

BRCAl-24 ATTAGTAATATTCAT dAs;lnaTs;dTs;lnaAs;dGs;lnaTs;dAs;lnaAs;dTs;l 31279 m02 naAs;dTs;lnaTs;dCs;lnaAs;dT-Sup

BRCAl-25 CTGAAAATCTAATTA dCs;lnaTs;dGs;lnaAs;dAs;lnaAs;dAs;lnaTs;dCs; 980858 m02 lnaTs;dAs;lnaAs;dTs;lnaTs;dA-Sup

BRCAl-26 TTTGTTACTGAGCCA dTs;lnaTs;dTs;lnaGs;dTs;lnaTs;dAs;lnaCs;dTs;l 980859 m02 naGs;dAs;lnaGs;dCs;lnaCs;dA-Sup

BRCAl-27 GTCCAACTCTCTAAC dGs;lnaTs;dCs;lnaCs;dAs;lnaAs;dCs;lnaTs;dCs;l 980860 m02 naTs;dCs;lnaTs;dAs;lnaAs;dC-Sup

BRCAl-28 AACTTGGAACTGTGA dAs;lnaAs;dCs;lnaTs;dTs;lnaGs;dGs;lnaAs;dAs; 980861 m02 lnaCs;dTs;lnaGs;dTs;lnaGs;dA-Sup

BRCAl-29 AG 1 1 A 1 1 1 1 ( 1 1 1 1 dAs;lnaGs;dTs;lnaTs;dAs;lnaTs;dTs;lnaTs;dTs;l 25727 m02 naCs;dCs;lnaTs;dTs;lnaTs;dT-Sup

BRCAl-30 TTTTGCAAAATTATA dTs;lnaTs;dTs;lnaTs;dGs;lnaCs;dAs;lnaAs;dAs;l 25714 m02 naAs;dTs;lnaTs;dAs;lnaTs;dA-Sup

F8-01 ACAGGTCTGATTGGA lnaAs;omeCs;lnaAs;omeGs;lnaGs;omeUs;lnaC 980862 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeUs;lnaGs;o

meGs;lnaA-Sup

F8-02 ATCAGTCTATTGGCA lnaAs;omeUs;lnaCs;omeAs;lnaGs;omeUs;lnaC 980863 mOl s;omeUs;lnaAs;omeUs;lnaTs;omeGs;lnaGs;o

meCs;lnaA-Sup

F8-03 CTCAATATTCCTCGA lnaCs;omeUs;lnaCs;omeAs;lnaAs;omeUs;lnaA 980864 mOl s;omeUs;lnaTs;omeCs;lnaCs;omeUs;lnaCs;om

eGs;lnaA-Sup

F8-04 CAATATTCCTCGAAG lnaCs;omeAs;lnaAs;omeUs;lnaAs;omeUs;lnaT 980865 mOl s;omeCs;lnaCs;omeUs;lnaCs;omeGs;lnaAs;om

eAs;lnaG-Sup

F8-05 AATATTCCTCGAAGG lnaAs;omeAs;lnaTs;omeAs;lnaTs;omeUs;lnaCs 980866 mOl ;omeCs;lnaTs;omeCs;lnaGs;omeAs;lnaAs;ome

Gs;lnaG-Sup

F8-06 ATATTCCTCGAAGGT lnaAs;omeUs;lnaAs;omeUs;lnaTs;omeCs;lnaC 980867 mOl s;omeUs;lnaCs;omeGs;lnaAs;omeAs;lnaGs;o

meGs;lnaT-Sup

F8-07 TATTCCTCGAAGGTC lnaTs;omeAs;lnaTs;omeUs;lnaCs;omeCs;lnaTs 980868 mOl ;omeCs;lnaGs;omeAs;lnaAs;omeGs;lnaGs;om

eUs;lnaC-Sup

F8-08 TCCTCGAAGGTCACA lnaTs;omeCs;lnaCs;omeUs;lnaCs;omeGs;lnaA 980869 mOl s;omeAs;lnaGs;omeGs;lnaTs;omeCs;lnaAs;om

eCs;lnaA-Sup

F8-09 CCTCGAAGGTCACAC lnaCs;omeCs;lnaTs;omeCs;lnaGs;omeAs;lnaAs 980870 mOl ;omeGs;lnaGs;omeUs;lnaCs;omeAs;lnaCs;om

eAs;lnaC-Sup F8-10 CTCGAAGGTCACACA lnaCs;omeUs;lnaCs;omeGs;lnaAs;omeAs;lnaG 980871 mOl s;omeGs;lnaTs;omeCs;lnaAs;omeCs;lnaAs;om

eCs;lnaA-Sup

F8-11 TCGCCAATAACTTTC lnaTs;omeCs;lnaGs;omeCs;lnaCs;omeAs;lnaAs 980872 mOl ;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaTs;om

eUs;lnaC-Sup

F8-12 CGCCAATAACTTTCC lnaCs;omeGs;lnaCs;omeCs;lnaAs;omeAs;lnaTs 980873 mOl ;omeAs;lnaAs;omeCs;lnaTs;omeUs;lnaTs;ome

Cs;lnaC-Sup

F8-13 CTCCGAAACTCATAT lnaCs;omeUs;lnaCs;omeCs;lnaGs;omeAs;lnaA 980874 mOl s;omeAs;lnaCs;omeUs;lnaCs;omeAs;lnaTs;om

eAs;lnaT-Sup

F8-14 CGTCCCTATTCCTTC lnaCs;omeGs;lnaTs;omeCs;lnaCs;omeCs;lnaTs 980875 mOl ;omeAs;lnaTs;omeUs;lnaCs;omeCs;lnaTs;ome

Us;lnaC-Sup

F8-15 ACTTTGTCAAGCCTA lnaAs;omeCs;lnaTs;omeUs;lnaTs;omeGs;lnaTs 980876 mOl ;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaCs;ome

Us;lnaA-Sup

F8-16 TTTGTCAAGCCTAAT lnaTs;omeUs;lnaTs;omeGs;lnaTs;omeCs;lnaAs 980877 mOl ;omeAs;lnaGs;omeCs;lnaCs;omeUs;lnaAs;om

eAs;lnaT-Sup

F8-17 AAGCCTAATGAAACC lnaAs;omeAs;lnaGs;omeCs;lnaCs;omeUs;lnaA 980878 mOl s;omeAs;lnaTs;omeGs;lnaAs;omeAs;lnaAs;om

eCs;lnaC-Sup

F8-18 CATATGGCACCCACT lnaCs;omeAs;lnaTs;omeAs;lnaTs;omeGs;lnaG 980879 mOl s;omeCs;lnaAs;omeCs;lnaCs;omeCs;lnaAs;om

eCs;lnaT-Sup

F8-19 CAGATGGAAGATCCC lnaCs;omeAs;lnaGs;omeAs;lnaTs;omeGs;lnaG 980880 mOl s;omeAs;lnaAs;omeGs;lnaAs;omeUs;lnaCs;om

eCs;lnaC-Sup

F8-20 AAAGAGAATTATCGC lnaAs;omeAs;lnaAs;omeGs;lnaAs;omeGs;lnaA 980881 mOl s;omeAs;lnaTs;omeUs;lnaAs;omeUs;lnaCs;om

eGs;lnaC-Sup

F8-21 AGAGAATTATCGCTT lnaAs;omeGs;lnaAs;omeGs;lnaAs;omeAs;lnaT 980882 mOl s;omeUs;lnaAs;omeUs;lnaCs;omeGs;lnaCs;o

meUs;lnaT-Sup

F8-22 GAGAATTATCGCTTC lnaGs;omeAs;lnaGs;omeAs;lnaAs;omeUs;lnaT 980883 mOl s;omeAs;lnaTs;omeCs;lnaGs;omeCs;lnaTs;om

eUs;lnaC-Sup

F8-23 AGAATTATCGCTTCC lnaAs;omeGs;lnaAs;omeAs;lnaTs;omeUs;lnaA 980884 mOl s;omeUs;lnaCs;omeGs;lnaCs;omeUs;lnaTs;om

eCs;lnaC-Sup

F8-24 AATTATCGCTTCCAT lnaAs;omeAs;lnaTs;omeUs;lnaAs;omeUs;lnaC 980885 mOl s;omeGs;lnaCs;omeUs;lnaTs;omeCs;lnaCs;om

eAs;lnaT-Sup

F8-25 TTATCGCTTCCATGG lnaTs;omeUs;lnaAs;omeUs;lnaCs;omeGs;lnaC 980886 mOl s;omeUs;lnaTs;omeCs;lnaCs;omeAs;lnaTs;om eGs;lnaG-Sup

F8-26 TATCGCTTCCATGGT lnaTs;omeAs;lnaTs;omeCs;lnaGs;omeCs;lnaTs 980887 mOl ;omeUs;lnaCs;omeCs;lnaAs;omeUs;lnaGs;om

eGs;lnaT-Sup

F8-27 TCGCTTCCATGGTAA lnaTs;omeCs;lnaGs;omeCs;lnaTs;omeUs;lnaCs 980888 mOl ;omeCs;lnaAs;omeUs;lnaGs;omeGs;lnaTs;om

eAs;lnaA-Sup

F8-28 CTCCAGCAATCAATG lnaCs;omeUs;lnaCs;omeCs;lnaAs;omeGs;lnaC 980889 mOl s;omeAs;lnaAs;omeUs;lnaCs;omeAs;lnaAs;om

eUs;lnaG-Sup

F8-29 GGATCAAAGGATTCG lnaGs;omeGs;lnaAs;omeUs;lnaCs;omeAs;lnaA 980890 mOl s;omeAs;lnaGs;omeGs;lnaAs;omeUs;lnaTs;o

meCs;lnaG-Sup

F8-30 GATCAAAGGATTCGA lnaGs;omeAs;lnaTs;omeCs;lnaAs;omeAs;lnaA 980891 mOl s;omeGs;lnaGs;omeAs;lnaTs;omeUs;lnaCs;om

eGs;lnaA-Sup

F8-31 ATCAAAGGATTCGAT lnaAs;omeUs;lnaCs;omeAs;lnaAs;omeAs;lnaG 980892 mOl s;omeGs;lnaAs;omeUs;lnaTs;omeCs;lnaGs;om

eAs;lnaT-Sup

F8-32 TCAAAGGATTCGATG lnaTs;omeCs;lnaAs;omeAs;lnaAs;omeGs;lnaG 980893 mOl s;omeAs;lnaTs;omeUs;lnaCs;omeGs;lnaAs;om

eUs;lnaG-Sup

F8-33 CAAAGGATTCGATGG lnaCs;omeAs;lnaAs;omeAs;lnaGs;omeGs;lnaA 980894 mOl s;omeUs;lnaTs;omeCs;lnaGs;omeAs;lnaTs;om

eGs;lnaG-Sup

F8-34 GGATTCGATGGTATC lnaGs;omeGs;lnaAs;omeUs;lnaTs;omeCs;lnaG 980895 mOl s;omeAs;lnaTs;omeGs;lnaGs;omeUs;lnaAs;o

meUs;lnaC-Sup

F8-35 GATTCGATGGTATCT lnaGs;omeAs;lnaTs;omeUs;lnaCs;omeGs;lnaA 980896 mOl s;omeUs;lnaGs;omeGs;lnaTs;omeAs;lnaTs;om

eCs;lnaT-Sup

F8-36 ATTCGATGGTATCTG lnaAs;omeUs;lnaTs;omeCs;lnaGs;omeAs;lnaT 980897 mOl s;omeGs;lnaGs;omeUs;lnaAs;omeUs;lnaCs;o

meUs;lnaG-Sup

F8-37 CTGTACGAAAAAAAG lnaCs;omeUs;lnaGs;omeUs;lnaAs;omeCs;lnaG 980898 mOl s;omeAs;lnaAs;omeAs;lnaAs;omeAs;lnaAs;om

eAs;lnaG-Sup

F8-38 TGTACGAAAAAAAGA lnaTs;omeGs;lnaTs;omeAs;lnaCs;omeGs;lnaA 980899 mOl s;omeAs;lnaAs;omeAs;lnaAs;omeAs;lnaAs;om

eGs;lnaA-Sup

F8-39 GTACGAAAAAAAGAG lnaGs;omeUs;lnaAs;omeCs;lnaGs;omeAs;lnaA 980900 mOl s;omeAs;lnaAs;omeAs;lnaAs;omeAs;lnaGs;om

eAs;lnaG-Sup

F8-40 GGAATGCCTTATTGG lnaGs;omeGs;lnaAs;omeAs;lnaTs;omeGs;lnaC 980901 mOl s;omeCs;lnaTs;omeUs;lnaAs;omeUs;lnaTs;om

eGs;lnaG-Sup F8-41 ATGCCTTATTGGCGA lnaAs;omeUs;lnaGs;omeCs;lnaCs;omeUs;lnaT 980902 mOl s;omeAs;lnaTs;omeUs;lnaGs;omeGs;lnaCs;om

eGs;lnaA-Sup

F8-42 TGCCTTATTGGCGAG lnaTs;omeGs;lnaCs;omeCs;lnaTs;omeUs;lnaAs 980903 mOl ;omeUs;lnaTs;omeGs;lnaGs;omeCs;lnaGs;om

eAs;lnaG-Sup

F8-43 GCCTTATTGGCGAGC lnaGs;omeCs;lnaCs;omeUs;lnaTs;omeAs;lnaTs 980904 mOl ;omeUs;lnaGs;omeGs;lnaCs;omeGs;lnaAs;om

eGs;lnaC-Sup

F8-44 CCTTATTGGCGAGCA lnaCs;omeCs;lnaTs;omeUs;lnaAs;omeUs;lnaTs 980905 mOl ;omeGs;lnaGs;omeCs;lnaGs;omeAs;lnaGs;om

eCs;lnaA-Sup

F8-45 CTTATTGGCGAGCAT lnaCs;omeUs;lnaTs;omeAs;lnaTs;omeUs;lnaG 980906 mOl s;omeGs;lnaCs;omeGs;lnaAs;omeGs;lnaCs;om

eAs;lnaT-Sup

F8-46 CAACAGATCCACCTA lnaCs;omeAs;lnaAs;omeCs;lnaAs;omeGs;lnaA 63756 mOl s;omeUs;lnaCs;omeCs;lnaAs;omeCs;lnaCs;om

eUs;lnaA-Sup

F8-47 TCTTGATGCCGTGAA lnaTs;omeCs;lnaTs;omeUs;lnaGs;omeAs;lnaTs 63784 mOl ;omeGs;lnaCs;omeCs;lnaGs;omeUs;lnaGs;om

eAs;lnaA-Sup

F8-48 CTGACGGGCACCCTG lnaCs;omeUs;lnaGs;omeAs;lnaCs;omeGs;lnaG 63801 mOl s;omeGs;lnaCs;omeAs;lnaCs;omeCs;lnaCs;om

eUs;lnaG-Sup

F8-49 TCTGACGGGCACCCT lnaTs;omeCs;lnaTs;omeGs;lnaAs;omeCs;lnaGs 63802 mOl ;omeGs;lnaGs;omeCs;lnaAs;omeCs;lnaCs;om

eCs;lnaT-Sup

F8-50 GAATTTCCTCGATAA lnaGs;omeAs;lnaAs;omeUs;lnaTs;omeUs;lnaC 63884 mOl s;omeCs;lnaTs;omeCs;lnaGs;omeAs;lnaTs;om

eAs;lnaA-Sup

F8-51 GGAATTTCCTCGATA lnaGs;omeGs;lnaAs;omeAs;lnaTs;omeUs;lnaT 63885 mOl s;omeCs;lnaCs;omeUs;lnaCs;omeGs;lnaAs;om

eUs;lnaA-Sup

F8-52 TGGAATTTCCTCGAT lnaTs;omeGs;lnaGs;omeAs;lnaAs;omeUs;lnaT 63886 mOl s;omeUs;lnaCs;omeCs;lnaTs;omeCs;lnaGs;om

eAs;lnaT-Sup

F8-53 CCATTAAGGTTCCAG lnaCs;omeCs;lnaAs;omeUs;lnaTs;omeAs;lnaA 63901 mOl s;omeGs;lnaGs;omeUs;lnaTs;omeCs;lnaCs;om

eAs;lnaG-Sup

F8-54 TACCATTAAGGTTCC lnaTs;omeAs;lnaCs;omeCs;lnaAs;omeUs;lnaTs 63903 mOl ;omeAs;lnaAs;omeGs;lnaGs;omeUs;lnaTs;om

eCs;lnaC-Sup

F8-55 ATACCATTAAGGTTC lnaAs;omeUs;lnaAs;omeCs;lnaCs;omeAs;lnaT 63904 mOl s;omeUs;lnaAs;omeAs;lnaGs;omeGs;lnaTs;o

meUs;lnaC-Sup

F8-56 C ATACC ATT AAG GTT lnaCs;omeAs;lnaTs;omeAs;lnaCs;omeCs;lnaAs 63905 mOl ;omeUs;lnaTs;omeAs;lnaAs;omeGs;lnaGs;om eUs;lnaT-Sup

FM l-01 GACGGCGAGCGCGGG lnaGs;omeAs;lnaCs;omeGs;lnaGs;omeCs;lnaG 570791 mOl s;omeAs;lnaGs;omeCs;lnaGs;omeCs;lnaGs;om

eGs;lnaG-Sup

FMR1-02 GGTGGTGGAAGTGCG lnaGs;omeGs;lnaTs;omeGs;lnaGs;omeUs;lnaG 570962 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeUs;lnaGs;o

meCs;lnaG-Sup

FMR1-03 TG G CG CTTTCT AC A A lnaTs;omeGs;lnaGs;omeCs;lnaGs;omeCs;lnaT 570986 mOl s;omeUs;lnaTs;omeCs;lnaTs;omeAs;lnaCs;om

eAs;lnaA-Sup

FMR1-04 GCATTAGCGATGCTG lnaGs;omeCs;lnaAs;omeUs;lnaTs;omeAs;lnaG 128433 mOl s;omeCs;lnaGs;omeAs;lnaTs;omeGs;lnaCs;om

eUs;lnaG-Sup

FMR1-05 GGCATTAGCGATGCT lnaGs;omeGs;lnaCs;omeAs;lnaTs;omeUs;lnaA 128434 mOl s;omeGs;lnaCs;omeGs;lnaAs;omeUs;lnaGs;o

meCs;lnaT-Sup

FMR1-06 C A AACG C AACTG GTC lnaCs;omeAs;lnaAs;omeAs;lnaCs;omeGs;lnaC 130960 mOl s;omeAs;lnaAs;omeCs;lnaTs;omeGs;lnaGs;om

eUs;lnaC-Sup

FMR1-07 CCAAACGCAACTGGT lnaCs;omeCs;lnaAs;omeAs;lnaAs;omeCs;lnaG 130961 mOl s;omeCs;lnaAs;omeAs;lnaCs;omeUs;lnaGs;om

eGs;lnaT-Sup

FMR1-08 TATCTGTACGATTTG lnaTs;omeAs;lnaTs;omeCs;lnaTs;omeGs;lnaTs 131033 mOl ;omeAs;lnaCs;omeGs;lnaAs;omeUs;lnaTs;om

eUs;lnaG-Sup

FMR1-09 CTCGACCCATTCCTT lnaCs;omeUs;lnaCs;omeGs;lnaAs;omeCs;lnaC 131078 mOl s;omeCs;lnaAs;omeUs;lnaTs;omeCs;lnaCs;om

eUs;lnaT-Sup

FMRl-10 TACCTCGACCCATTC lnaTs;omeAs;lnaCs;omeCs;lnaTs;omeCs;lnaGs 131081 mOl ;omeAs;lnaCs;omeCs;lnaCs;omeAs;lnaTs;ome

Us;lnaC-Sup

FMRl-11 ACTACCTCGACCCAT lnaAs;omeCs;lnaTs;omeAs;lnaCs;omeCs;lnaTs 131083 mOl ;omeCs;lnaGs;omeAs;lnaCs;omeCs;lnaCs;ome

As;lnaT-Sup

FMR1-12 TCTACTACCTCGACC lnaTs;omeCs;lnaTs;omeAs;lnaCs;omeUs;lnaAs 131086 mOl ;omeCs;lnaCs;omeUs;lnaCs;omeGs;lnaAs;om

eCs;lnaC-Sup

FMR1-13 GTCTACTACCTCGAC lnaGs;omeUs;lnaCs;omeUs;lnaAs;omeCs;lnaT 131087 mOl s;omeAs;lnaCs;omeCs;lnaTs;omeCs;lnaGs;om

eAs;lnaC-Sup

FMR1-14 CGTGCCCCCTATTTC lnaCs;omeGs;lnaTs;omeGs;lnaCs;omeCs;lnaCs 131108 mOl ;omeCs;lnaCs;omeUs;lnaAs;omeUs;lnaTs;ome

Us;lnaC-Sup

FMR1-15 GACCGCGTCTGCCGT lnaGs;omeAs;lnaCs;omeCs;lnaGs;omeCs;lnaG 131120 mOl s;omeUs;lnaCs;omeUs;lnaGs;omeCs;lnaCs;om

eGs;lnaT-Sup FM 1-16 ATCCAGGACCGCGTC lnaAs;omeUs;lnaCs;omeCs;lnaAs;omeGs;lnaG 131126 mOl s;omeAs;lnaCs;omeCs;lnaGs;omeCs;lnaGs;om

eUs;lnaC-Sup

FMR1-17 ATATCCAGGACCGCG lnaAs;omeUs;lnaAs;omeUs;lnaCs;omeCs;lnaA 131128 mOl s;omeGs;lnaGs;omeAs;lnaCs;omeCs;lnaGs;om

eCs;lnaG-Sup

FMR1-18 GTATATCCAGGACCG lnaGs;omeUs;lnaAs;omeUs;lnaAs;omeUs;lnaC 131130 mOl s;omeCs;lnaAs;omeGs;lnaGs;omeAs;lnaCs;om

eCs;lnaG-Sup

FMR1-19 CCTATCGAGAGTTAA lnaCs;omeCs;lnaTs;omeAs;lnaTs;omeCs;lnaGs 132179 mOl ;omeAs;lnaGs;omeAs;lnaGs;omeUs;lnaTs;om

eAs;lnaA-Sup

FMR1-20 ATTAGTTCCTATCGA lnaAs;omeUs;lnaTs;omeAs;lnaGs;omeUs;lnaT 132186 mOl s;omeCs;lnaCs;omeUs;lnaAs;omeUs;lnaCs;om

eGs;lnaA-Sup

FMR1-21 CGCCGTCCGTCTCCT lnaCs;omeGs;lnaCs;omeCs;lnaGs;omeUs;lnaC 132288 mOl s;omeCs;lnaGs;omeUs;lnaCs;omeUs;lnaCs;om

eCs;lnaT-Sup

FMR1-22 ACGCCGCCGTCCGTC lnaAs;omeCs;lnaGs;omeCs;lnaCs;omeGs;lnaC 132292 mOl s;omeCs;lnaGs;omeUs;lnaCs;omeCs;lnaGs;om

eUs;lnaC-Sup

FMR1-23 CGATTATCTGTTCGG lnaCs;omeGs;lnaAs;omeUs;lnaTs;omeAs;lnaT 132857 mOl s;omeCs;lnaTs;omeGs;lnaTs;omeUs;lnaCs;om

eGs;lnaG-Sup

FMR1-24 ACGATTATCTGTTCG lnaAs;omeCs;lnaGs;omeAs;lnaTs;omeUs;lnaA 132858 mOl s;omeUs;lnaCs;omeUs;lnaGs;omeUs;lnaTs;o

meCs;lnaG-Sup

FMR1-25 GGACGATTATCTGTT lnaGs;omeGs;lnaAs;omeCs;lnaGs;omeAs;lnaT 132860 mOl s;omeUs;lnaAs;omeUs;lnaCs;omeUs;lnaGs;o

meUs;lnaT-Sup

FMR1-26 TGGACGATTATCTGT lnaTs;omeGs;lnaGs;omeAs;lnaCs;omeGs;lnaA 132861 mOl s;omeUs;lnaTs;omeAs;lnaTs;omeCs;lnaTs;om

eGs;lnaT-Sup

FMR1-27 ACGTGGACGATTATC lnaAs;omeCs;lnaGs;omeUs;lnaGs;omeGs;lnaA 132864 mOl s;omeCs;lnaGs;omeAs;lnaTs;omeUs;lnaAs;om

eUs;lnaC-Sup

FMR1-28 TACGTGGACGATTAT lnaTs;omeAs;lnaCs;omeGs;lnaTs;omeGs;lnaG 132865 mOl s;omeAs;lnaCs;omeGs;lnaAs;omeUs;lnaTs;om

eAs;lnaT-Sup

FMR1-29 TTACGTGGACGATTA lnaTs;omeUs;lnaAs;omeCs;lnaGs;omeUs;lnaG 132866 mOl s;omeGs;lnaAs;omeCs;lnaGs;omeAs;lnaTs;om

eUs;lnaA-Sup

FMR1-30 ATTACGTGGACGATT lnaAs;omeUs;lnaTs;omeAs;lnaCs;omeGs;lnaT 132867 mOl s;omeGs;lnaGs;omeAs;lnaCs;omeGs;lnaAs;o

meUs;lnaT-Sup

FMR1-31 GATTACGTGGACGAT lnaGs;omeAs;lnaTs;omeUs;lnaAs;omeCs;lnaG 132868 mOl s;omeUs;lnaGs;omeGs;lnaAs;omeCs;lnaGs;o meAs;lnaT-Sup

FM 1-32 TGGATTACGTGGACG lnaTs;omeGs;lnaGs;omeAs;lnaTs;omeUs;lnaA 132870 mOl s;omeCs;lnaGs;omeUs;lnaGs;omeGs;lnaAs;o

meCs;lnaG-Sup

FMR1-33 TTACCCGTGCGCAGC lnaTs;omeUs;lnaAs;omeCs;lnaCs;omeCs;lnaG 135877 mOl s;omeUs;lnaGs;omeCs;lnaGs;omeCs;lnaAs;o

meGs;lnaC-Sup

FMR1-34 CTTTACCCGTGCGCA lnaCs;omeUs;lnaTs;omeUs;lnaAs;omeCs;lnaC 135879 mOl s;omeCs;lnaGs;omeUs;lnaGs;omeCs;lnaGs;o

meCs;lnaA-Sup

FMR1-35 TCTTTACCCGTGCGC lnaTs;omeCs;lnaTs;omeUs;lnaTs;omeAs;lnaCs 135880 mOl ;omeCs;lnaCs;omeGs;lnaTs;omeGs;lnaCs;ome

Gs;lnaC-Sup

FMR1-36 GATCTTTACCCGTGC lnaGs;omeAs;lnaTs;omeCs;lnaTs;omeUs;lnaTs 135882 mOl ;omeAs;lnaCs;omeCs;lnaCs;omeGs;lnaTs;ome

Gs;lnaC-Sup

FMR1-37 CGATCTTTACCCGTG lnaCs;omeGs;lnaAs;omeUs;lnaCs;omeUs;lnaT 135883 mOl s;omeUs;lnaAs;omeCs;lnaCs;omeCs;lnaGs;om

eUs;lnaG-Sup

FMR1-38 ACGATCTTTACCCGT lnaAs;omeCs;lnaGs;omeAs;lnaTs;omeCs;lnaTs 135884 mOl ;omeUs;lnaTs;omeAs;lnaCs;omeCs;lnaCs;ome

Gs;lnaT-Sup

FMR1-39 TACGATCTTTACCCG lnaTs;omeAs;lnaCs;omeGs;lnaAs;omeUs;lnaC 135885 mOl s;omeUs;lnaTs;omeUs;lnaAs;omeCs;lnaCs;om

eCs;lnaG-Sup

FMR1-40 GGTTACGATCTTTAC lnaGs;omeGs;lnaTs;omeUs;lnaAs;omeCs;lnaG 135888 mOl s;omeAs;lnaTs;omeCs;lnaTs;omeUs;lnaTs;om

eAs;lnaC-Sup

FMR1-41 CTGGTTACGATCTTT lnaCs;omeUs;lnaGs;omeGs;lnaTs;omeUs;lnaA 135890 mOl s;omeCs;lnaGs;omeAs;lnaTs;omeCs;lnaTs;om

eUs;lnaT-Sup

FMR1-42 ACTTTCGACCAGGAA lnaAs;omeCs;lnaTs;omeUs;lnaTs;omeCs;lnaGs 136836 mOl ;omeAs;lnaCs;omeCs;lnaAs;omeGs;lnaGs;om

eAs;lnaA-Sup

FMR1-43 AACTTTCGACCAGGA lnaAs;omeAs;lnaCs;omeUs;lnaTs;omeUs;lnaC 136837 mOl s;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaGs;om

eGs;lnaA-Sup

FMR1-44 TAACTTTCGACCAGG lnaTs;omeAs;lnaAs;omeCs;lnaTs;omeUs;lnaTs 136838 mOl ;omeCs;lnaGs;omeAs;lnaCs;omeCs;lnaAs;ome

Gs;lnaG-Sup

FMR1-45 CTAACTTTCGACCAG lnaCs;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaT 136839 mOl s;omeUs;lnaCs;omeGs;lnaAs;omeCs;lnaCs;om

eAs;lnaG-Sup

FMR1-46 ACTAACTTTCGACCA lnaAs;omeCs;lnaTs;omeAs;lnaAs;omeCs;lnaTs 136840 mOl ;omeUs;lnaTs;omeCs;lnaGs;omeAs;lnaCs;ome

Cs;lnaA-Sup FM 1-47 CCTACTAACTTTCGA lnaCs;omeCs;lnaTs;omeAs;lnaCs;omeUs;lnaAs 136843 mOl ;omeAs;lnaCs;omeUs;lnaTs;omeUs;lnaCs;ome

Gs;lnaA-Sup

FMR1-48 TCCTACTAACTTTCG lnaTs;omeCs;lnaCs;omeUs;lnaAs;omeCs;lnaTs 136844 mOl ;omeAs;lnaAs;omeCs;lnaTs;omeUs;lnaTs;ome

Cs;lnaG-Sup

FMR1-49 TGTCGCTAATATGTA lnaTs;omeGs;lnaTs;omeCs;lnaGs;omeCs;lnaTs 137645 mOl ;omeAs;lnaAs;omeUs;lnaAs;omeUs;lnaGs;om

eUs;lnaA-Sup

FMR1-50 AATCTGTTGTCG CT A lnaAs;omeAs;lnaTs;omeCs;lnaTs;omeGs;lnaTs 137652 mOl ;omeUs;lnaGs;omeUs;lnaCs;omeGs;lnaCs;om

eUs;lnaA-Sup

FMR1-51 CAATCTGTTGTCGCT lnaCs;omeAs;lnaAs;omeUs;lnaCs;omeUs;lnaG 137653 mOl s;omeUs;lnaTs;omeGs;lnaTs;omeCs;lnaGs;om

eCs;lnaT-Sup

FMR1-52 AGCGCCTTGCTGAAT lnaAs;omeGs;lnaCs;omeGs;lnaCs;omeCs;lnaT 137998 mOl s;omeUs;lnaGs;omeCs;lnaTs;omeGs;lnaAs;om

eAs;lnaT-Sup

FMR1-53 TAGCGCCTTGCTGAA lnaTs;omeAs;lnaGs;omeCs;lnaGs;omeCs;lnaC 137999 mOl s;omeUs;lnaTs;omeGs;lnaCs;omeUs;lnaGs;o

meAs;lnaA-Sup

FMR1-54 TTAGCGCCTTGCTGA lnaTs;omeUs;lnaAs;omeGs;lnaCs;omeGs;lnaC 138000 mOl s;omeCs;lnaTs;omeUs;lnaGs;omeCs;lnaTs;om

eGs;lnaA-Sup

FMR1-55 AAGTTAGCGCCTTGC lnaAs;omeAs;lnaGs;omeUs;lnaTs;omeAs;lnaG 138003 mOl s;omeCs;lnaGs;omeCs;lnaCs;omeUs;lnaTs;om

eGs;lnaC-Sup

FMR1-56 GCAAGTTAGCGCCTT lnaGs;omeCs;lnaAs;omeAs;lnaGs;omeUs;lnaT 138005 mOl s;omeAs;lnaGs;omeCs;lnaGs;omeCs;lnaCs;om

eUs;lnaT-Sup

FMR1-57 TAAGCAAGTTAGCGC lnaTs;omeAs;lnaAs;omeGs;lnaCs;omeAs;lnaA 138008 mOl s;omeGs;lnaTs;omeUs;lnaAs;omeGs;lnaCs;om

eGs;lnaC-Sup

GRN-01 GACACTGTGTGTGAC dGs;lnaAs;dCs;lnaAs;dCs;lnaTs;dGs;lnaTs;dGs; 980907 m02 lnaTs;dGs;lnaTs;dGs;lnaAs;dC-Sup

GRN-02 ACCTGATCCAGAGTA dAs;lnaCs;dCs;lnaTs;dGs;lnaAs;dTs;lnaCs;dCs;l 980908 m02 naAs;dGs;lnaAs;dGs;lnaTs;dA-Sup

GRN-03 TTTACGTGTGACACG dTs;lnaTs;dTs;lnaAs;dCs;lnaGs;dTs;lnaGs;dTs;l 980909 m02 naGs;dAs;lnaCs;dAs;lnaCs;dG-Sup

GRN-04 GGATGGAGAAGGCCC dGs;lnaGs;dAs;lnaTs;dGs;lnaGs;dAs;lnaGs;dAs 980910 m02 ;lnaAs;dGs;lnaGs;dCs;lnaCs;dC-Sup

GRN-05 AG CTC ACCTC AG CCT dAs;lnaGs;dCs;lnaTs;dCs;lnaAs;dCs;lnaCs;dTs;l 980911 m02 naCs;dAs;lnaGs;dCs;lnaCs;dT-Sup

GRN-06 CGTGTGTAGCTGAGG dCs;lnaGs;dTs;lnaGs;dTs;lnaGs;dTs;lnaAs;dGs; 980912 m02 lnaCs;dTs;lnaGs;dAs;lnaGs;dG-Sup

GRN-07 ACCCAGCCTTGAGAC dAs;lnaCs;dCs;lnaCs;dAs;lnaGs;dCs;lnaCs;dTs; 980913 m02 lnaTs;dGs;lnaAs;dGs;lnaAs;dC-Sup G N-08 CTAACCAAATTCTCC dCs;lnaTs;dAs;lnaAs;dCs;lnaCs;dAs;lnaAs;dAs; 980914 m02 lnaTs;dTs;lnaCs;dTs;lnaCs;dC-Sup

GRN-09 AATTCTCCCTGGACC dAs;lnaAs;dTs;lnaTs;dCs;lnaTs;dCs;lnaCs;dCs;l 980915 m02 naTs;dGs;lnaGs;dAs;lnaCs;dC-Sup

GRN-10 TTACCTACCAGATGC dTs;lnaTs;dAs;lnaCs;dCs;lnaTs;dAs;lnaCs;dCs;l 614647 m02 naAs;dGs;lnaAs;dTs;lnaGs;dC-Sup

GRN-11 TCCACCCTGAGTTGT dTs;lnaCs;dCs;lnaAs;dCs;lnaCs;dCs;lnaTs;dGs;l 614671 m02 naAs;dGs;lnaTs;dTs;lnaGs;dT-Sup

GRN-12 ATCTG GT AG GTA AG G dAs;lnaTs;dCs;lnaTs;dGs;lnaGs;dTs;lnaAs;dGs; 980916 m02 lnaGs;dTs;lnaAs;dAs;lnaGs;dG-Sup

GRN-13 AAACATCACACGACA dAs;lnaAs;dAs;lnaCs;dAs;lnaTs;dCs;lnaAs;dCs; 980917 m02 lnaAs;dCs;lnaGs;dAs;lnaCs;dA-Sup

GRN-14 TCCCATCTGGTTTCC dTs;lnaCs;dCs;lnaCs;dAs;lnaTs;dCs;lnaTs;dGs;l 615538 m02 naGs;dTs;lnaTs;dTs;lnaCs;dC-Sup

GRN-15 ACCTGCCAGTTAAAA dAs;lnaCs;dCs;lnaTs;dGs;lnaCs;dCs;lnaAs;dGs; 615581 m02 lnaTs;dTs;lnaAs;dAs;lnaAs;dA-Sup

GRN-16 TTCCCAGACTCAGCT dTs;lnaTs;dCs;lnaCs;dCs;lnaAs;dGs;lnaAs;dCs;l 615598 m02 naTs;dCs;lnaAs;dGs;lnaCs;dT-Sup

GRN-17 AAGATTTTAACTGGC dAs;lnaAs;dGs;lnaAs;dTs;lnaTs;dTs;lnaTs;dAs;l 980918 m02 naAs;dCs;lnaTs;dGs;lnaGs;dC-Sup

GRN-18 TC ATCTCTAG C A AAC dTs;lnaCs;dAs;lnaTs;dCs;lnaTs;dCs;lnaTs;dAs;l 616370 m02 naGs;dCs;lnaAs;dAs;lnaAs;dC-Sup

GRN-19 AGGCGCCTGCAGGAT dAs;lnaGs;dGs;lnaCs;dGs;lnaCs;dCs;lnaTs;dGs 616391 m02 ;lnaCs;dAs;lnaGs;dGs;lnaAs;dT-Sup

GRN-20 TTAAGGAAGGCGACG dTs;lnaTs;dAs;lnaAs;dGs;lnaGs;dAs;lnaAs;dGs 616409 m02 ;lnaGs;dCs;lnaGs;dAs;lnaCs;dG-Sup

GRN-21 TCCTTAACCCATCCT dTs;lnaCs;dCs;lnaTs;dTs;lnaAs;dAs;lnaCs;dCs;l 980919 m02 naCs;dAs;lnaTs;dCs;lnaCs;dT-Sup

GRN-22 GAGTTTGCTAGTGAT dGs;lnaAs;dGs;lnaTs;dTs;lnaTs;dGs;lnaCs;dTs; 980920 m02 lnaAs;dGs;lnaTs;dGs;lnaAs;dT-Sup

GRN-23 ATGTGAGCTTGAGGT dAs;lnaTs;dGs;lnaTs;dGs;lnaAs;dGs;lnaCs;dTs; 616771 m02 lnaTs;dGs;lnaAs;dGs;lnaGs;dT-Sup

GRN-24 AGCCGGAGACAACAG dAs;lnaGs;dCs;lnaCs;dGs;lnaGs;dAs;lnaGs;dAs 616800 m02 ;lnaCs;dAs;lnaAs;dCs;lnaAs;dG-Sup

GRN-25 TTACTGAAACTCCTT dTs;lnaTs;dAs;lnaCs;dTs;lnaGs;dAs;lnaAs;dAs; 616824 m02 lnaCs;dTs;lnaCs;dCs;lnaTs;dT-Sup

GRN-26 AAGGAGTTTCAGTAA dAs;lnaAs;dGs;lnaGs;dAs;lnaGs;dTs;lnaTs;dTs; 980921 m02 lnaCs;dAs;lnaGs;dTs;lnaAs;dA-Sup

GRN-27 AACCTCAAGCTCACA dAs;lnaAs;dCs;lnaCs;dTs;lnaCs;dAs;lnaAs;dGs; 980922 m02 lnaCs;dTs;lnaCs;dAs;lnaCs;dA-Sup

GRN-28 AATGCCCGGACTTCT dAs;lnaAs;dTs;lnaGs;dCs;lnaCs;dCs;lnaGs;dGs; 619515 m02 lnaAs;dCs;lnaTs;dTs;lnaCs;dT-Sup

GRN-29 ATAACACAGCACGTG dAs;lnaTs;dAs;lnaAs;dCs;lnaAs;dCs;lnaAs;dGs; 980923 m02 lnaCs;dAs;lnaCs;dGs;lnaTs;dG-Sup

GRN-30 ATTCGAACTGACTAT dAs;lnaTs;dTs;lnaCs;dGs;lnaAs;dAs;lnaCs;dTs;l 980924 m02 naGs;dAs;lnaCs;dTs;lnaAs;dT-Sup ILlO-01 AACCCTCCTCCTGCGC omeAs;omeAs;omeCs;omeCs;omeCs;omeUs; 980925 m03 CTCC omeCs;omeCs;omeUs;omeCs;omeCs;omeUs;

omeGs;omeCs;omeGs;omeCs;omeCs;omeUs;

omeCs;omeC-Sup

IL10-02 CCCTCCTCCTGCGCCTC omeCs;omeCs;omeCs;omeUs;omeCs;omeCs; 980926 m03 CAC omeUs;omeCs;omeCs;omeUs;omeGs;omeCs;

omeGs;omeCs;omeCs;omeUs;omeCs;omeCs;

omeAs;omeC-Sup

IL10-03 CCTGCGCCTCCACCTC omeCs;omeCs;omeUs;omeGs;omeCs;omeGs; 980927 m03 CATC omeCs;omeCs;omeUs;omeCs;omeCs;omeAs;

omeCs;omeCs;omeUs;omeCs;omeCs;omeAs;

omeUs;omeC-Sup

IL10-04 TGCGCCTCCACCTCCA omeUs;omeGs;omeCs;omeGs;omeCs;omeCs; 980928 m03 TCCC omeUs;omeCs;omeCs;omeAs;omeCs;omeCs;

omeUs;omeCs;omeCs;omeAs;omeUs;omeCs;

omeCs;omeC-Sup

IL10-05 GCGCCTCCACCTCCAT omeGs;omeCs;omeGs;omeCs;omeCs;omeUs; 980929 m03 CCCC omeCs;omeCs;omeAs;omeCs;omeCs;omeUs;

omeCs;omeCs;omeAs;omeUs;omeCs;omeCs;

omeCs;omeC-Sup

IL10-06 GCCTCCACCTCCATCC omeGs;omeCs;omeCs;omeUs;omeCs;omeCs; 980930 m03 CCAA omeAs;omeCs;omeCs;omeUs;omeCs;omeCs;

omeAs;omeUs;omeCs;omeCs;omeCs;omeCs;

omeAs;omeA-Sup

IL10-07 CAACACCTATTCCCCC omeCs;omeAs;omeAs;omeCs;omeAs;omeCs; 980931 m03 AAAC omeCs;omeUs;omeAs;omeUs;omeUs;omeCs;

omeCs;omeCs;omeCs;omeCs;omeAs;omeAs;

omeAs;omeC-Sup

IL10-08 CCAACACCTATTCCCC omeCs;omeCs;omeAs;omeAs;omeCs;omeAs; 980932 m03 CAAA omeCs;omeCs;omeUs;omeAs;omeUs;omeUs;

omeCs;omeCs;omeCs;omeCs;omeCs;omeAs;

omeAs;omeA-Sup

IL10-09 CCCAACACCTATTCCC omeCs;omeCs;omeCs;omeAs;omeAs;omeCs; 980933 m03 CCAA omeAs;omeCs;omeCs;omeUs;omeAs;omeUs;

omeUs;omeCs;omeCs;omeCs;omeCs;omeCs;

omeAs;omeA-Sup

ILlO-10 CCCCAACACCTATTCC omeCs;omeCs;omeCs;omeCs;omeAs;omeAs; 980934 m03 CCCA omeCs;omeAs;omeCs;omeCs;omeUs;omeAs;

omeUs;omeUs;omeCs;omeCs;omeCs;omeCs;

omeCs;omeA-Sup

ILlO-11 TCCCCAACACCTATTCC omeUs;omeCs;omeCs;omeCs;omeCs;omeAs; 980935 m03 CCC omeAs;omeCs;omeAs;omeCs;omeCs;omeUs;

omeAs;omeUs;omeUs;omeCs;omeCs;omeCs;

omeCs;omeC-Sup

IL10-12 ATCCCCAACACCTATT omeAs;omeUs;omeCs;omeCs;omeCs;omeCs; 980936 m03 CCCC omeAs;omeAs;omeCs;omeAs;omeCs;omeCs;

omeUs;omeAs;omeUs;omeUs;omeCs;omeCs; omeCs;omeC-Sup

IL10-13 CATCCCCAACACCTAT omeCs;omeAs;omeUs;omeCs;omeCs;omeCs; 980937 m03 TCCC omeCs;omeAs;omeAs;omeCs;omeAs;omeCs;

omeCs;omeUs;omeAs;omeUs;omeUs;omeCs;

omeCs;omeC-Sup

IL10-14 CCATCCCCAACACCTA omeCs;omeCs;omeAs;omeUs;omeCs;omeCs; 980938 m03 TTCC omeCs;omeCs;omeAs;omeAs;omeCs;omeAs;

omeCs;omeCs;omeUs;omeAs;omeUs;omeUs;

omeCs;omeC-Sup

IL10-15 TCCATCCCCAACACCT omeUs;omeCs;omeCs;omeAs;omeUs;omeCs; 980939 m03 ATTC omeCs;omeCs;omeCs;omeAs;omeAs;omeCs;

omeAs;omeCs;omeCs;omeUs;omeAs;omeUs;

omeUs;omeC-Sup

IL10-16 CTCCATCCCCAACACC omeCs;omeUs;omeCs;omeCs;omeAs;omeUs; 980940 m03 TATT omeCs;omeCs;omeCs;omeCs;omeAs;omeAs;

omeCs;omeAs;omeCs;omeCs;omeUs;omeAs;

omeUs;omeU-Sup

IL10-17 CCTCCATCCCCAACAC omeCs;omeCs;omeUs;omeCs;omeCs;omeAs; 980941 m03 CTAT omeUs;omeCs;omeCs;omeCs;omeCs;omeAs;

omeAs;omeCs;omeAs;omeCs;omeCs;omeUs;

omeAs;omeU-Sup

IL10-18 ACCTCCATCCCCAACA omeAs;omeCs;omeCs;omeUs;omeCs;omeCs; 980942 m03 CCTA omeAs;omeUs;omeCs;omeCs;omeCs;omeCs;

omeAs;omeAs;omeCs;omeAs;omeCs;omeCs;

omeUs;omeA-Sup

IL10-19 CACCTCCATCCCCAAC omeCs;omeAs;omeCs;omeCs;omeUs;omeCs; 980943 m03 ACCT omeCs;omeAs;omeUs;omeCs;omeCs;omeCs;

omeCs;omeAs;omeAs;omeCs;omeAs;omeCs;

omeCs;omeU-Sup

IL10-22 ACCTATTCCCCCAAAC omeAs;omeCs;omeCs;omeUs;omeAs;omeUs; 980944 m03 TTAA omeUs;omeCs;omeCs;omeCs;omeCs;omeCs;

omeAs;omeAs;omeAs;omeCs;omeUs;omeUs;

omeAs;omeA-Sup

IL10-23 CCTATTCCCCCAAACTT omeCs;omeCs;omeUs;omeAs;omeUs;omeUs; 980945 m03 AAA omeCs;omeCs;omeCs;omeCs;omeCs;omeAs;

omeAs;omeAs;omeCs;omeUs;omeUs;omeAs;

omeAs;omeA-Sup

IL10-24 CTATTCCCCCAAACTTA omeCs;omeUs;omeAs;omeUs;omeUs;omeCs; 980946 m03 AAT omeCs;omeCs;omeCs;omeCs;omeAs;omeAs;

omeAs;omeCs;omeUs;omeUs;omeAs;omeAs;

omeAs;omeU-Sup

IL10-25 TATTCCCCCAAACTTA omeUs;omeAs;omeUs;omeUs;omeCs;omeCs; 980947 m03 AATT omeCs;omeCs;omeCs;omeAs;omeAs;omeAs;

omeCs;omeUs;omeUs;omeAs;omeAs;omeAs;

omeUs;omeU-Sup

IL10-26 TCCCCCAAACTTAAAT omeUs;omeCs;omeCs;omeCs;omeCs;omeCs; 980948 m03 TCTT omeAs;omeAs;omeAs;omeCs;omeUs;omeUs; omeAs;omeAs;omeAs;omeUs;omeUs;omeCs;

omeUs;omeU-Sup

IL10-27 CCCCAAACTTAAATTC omeCs;omeCs;omeCs;omeCs;omeAs;omeAs; 980949 m03 TTAA omeAs;omeCs;omeUs;omeUs;omeAs;omeAs;

omeAs;omeUs;omeUs;omeCs;omeUs;omeUs;

omeAs;omeA-Sup

IL10-28 CCCAAACTTAAATTCTT omeCs;omeCs;omeCs;omeAs;omeAs;omeAs; 980950 m03 AAG omeCs;omeUs;omeUs;omeAs;omeAs;omeAs;

omeUs;omeUs;omeCs;omeUs;omeUs;omeAs;

omeAs;omeG-Sup

IL10-29 CCAAACTTAAATTCTT omeCs;omeCs;omeAs;omeAs;omeAs;omeCs; 980951 m03 AAGA omeUs;omeUs;omeAs;omeAs;omeAs;omeUs;

omeUs;omeCs;omeUs;omeUs;omeAs;omeAs;

omeGs;omeA-Sup

IL10-30 ACTTAAATTCTTAAGA omeAs;omeCs;omeUs;omeUs;omeAs;omeAs; 980952 m03 GAAT omeAs;omeUs;omeUs;omeCs;omeUs;omeUs;

omeAs;omeAs;omeGs;omeAs;omeGs;omeAs;

omeAs;omeU-Sup

NANOG- TTCTCATGTCTTTCA dTs;lnaTs;dCs;lnaTs;dCs;lnaAs;dTs;lnaGs;dTs;l 980953

01 m02 naCs;dTs;lnaTs;dTs;lnaCs;dA-Sup

NANOG- AGCTTCTTCCCAGGT dAs;lnaGs;dCs;lnaTs;dTs;lnaCs;dTs;lnaTs;dCs;l 256221

02 m02 naCs;dCs;lnaAs;dGs;lnaGs;dT-Sup

NANOG- TCGACTTCTGGCTTT dTs;lnaCs;dGs;lnaAs;dCs;lnaTs;dTs;lnaCs;dTs;l 256252

03 m02 naGs;dGs;lnaCs;dTs;lnaTs;dT-Sup

NANOG- G G CTCTTT AG CTTCT dGs;lnaGs;dCs;lnaTs;dCs;lnaTs;dTs;lnaTs;dAs;l 256229

04 m02 naGs;dCs;lnaTs;dTs;lnaCs;dT-Sup

NANOG- CCAAAGCTTGCCTTG dCs;lnaCs;dAs;lnaAs;dAs;lnaGs;dCs;lnaTs;dTs; 676139

05 m02 lnaGs;dCs;lnaCs;dTs;lnaTs;dG-Sup

NANOG- AACATGAGTGTGGAT dAs;lnaAs;dCs;lnaAs;dTs;lnaGs;dAs;lnaGs;dTs; 676113

06 m02 lnaGs;dTs;lnaGs;dGs;lnaAs;dT-Sup

NANOG- AAAACTATCCATC T dAs;lnaAs;dAs;lnaAs;dCs;lnaTs;dAs;lnaTs;dCs;l 676172

07 m02 naCs;dAs;lnaTs;dCs;lnaCs;dT-Sup

NANOG- GTGATTTGTGGGCCT dGs;lnaTs;dGs;lnaAs;dTs;lnaTs;dTs;lnaGs;dTs;l 676153

08 m02 naGs;dGs;lnaGs;dCs;lnaCs;dT-Sup

NANOG- TATAATGGAAAAAGG dTs;lnaAs;dTs;lnaAs;dAs;lnaTs;dGs;lnaGs;dAs; 980954

09 m02 lnaAs;dAs;lnaAs;dAs;lnaGs;dG-Sup

NANOG- AGGTGCCACCAAGTT dAs;lnaGs;dGs;lnaTs;dGs;lnaCs;dCs;lnaAs;dCs; 980955

10 m02 lnaCs;dAs;lnaAs;dGs;lnaTs;dT-Sup

NANOG- ACACTCCTGAGACCT dAs;lnaCs;dAs;lnaCs;dTs;lnaCs;dCs;lnaTs;dGs;l 980956

11 m02 naAs;dGs;lnaAs;dCs;lnaCs;dT-Sup

NANOG- TA ATTAG C A ATA AAT dTs;lnaAs;dAs;lnaTs;dTs;lnaAs;dGs;lnaCs;dAs; 980957

12 m02 lnaAs;dTs;lnaAs;dAs;lnaAs;dT-Sup

NANOG- TTAG GTCTTCTG G CT dTs;lnaTs;dAs;lnaGs;dGs;lnaTs;dCs;lnaTs;dTs;l 980958

13 m02 naCs;dTs;lnaGs;dGs;lnaCs;dT-Sup

NANOG- AAATCATGCTCATCC dAs;lnaAs;dAs;lnaTs;dCs;lnaAs;dTs;lnaGs;dCs; 980959

14 m02 lnaTs;dCs;lnaAs;dTs;lnaCs;dC-Sup NANOG- TTTGCCATGCCATTT dTs;lnaTs;dTs;lnaGs;dCs;lnaCs;dAs;lnaTs;dGs;l 980960

15 m02 naCs;dCs;lnaAs;dTs;lnaTs;dT-Sup

NANOG- TTGAAAACTACTGAA dTs;lnaTs;dGs;lnaAs;dAs;lnaAs;dAs;lnaCs;dTs; 980961

16 m02 lnaAs;dCs;lnaTs;dGs;lnaAs;dA-Sup

NANOG- ATTCTTG GTA AAGTT dAs;lnaTs;dTs;lnaCs;dTs;lnaTs;dGs;lnaGs;dTs;l 980962

17 m02 naAs;dAs;lnaAs;dGs;lnaTs;dT-Sup

NANOG- 1 1 1 I AAGU A I 1 1 I A dTs;lnaTs;dTs;lnaTs;dAs;lnaAs;dGs;lnaCs;dTs;l 980963

18 m02 naAs;dTs;lnaTs;dTs;lnaTs;dA-Sup

NANOG- ACTTGATCTCAGGGT dAs;lnaCs;dTs;lnaTs;dGs;lnaAs;dTs;lnaCs;dTs;l 980964

19 m02 naCs;dAs;lnaGs;dGs;lnaGs;dT-Sup

NANOG- AGTAGTTGGGAGGCT dAs;lnaGs;dTs;lnaAs;dGs;lnaTs;dTs;lnaGs;dGs; 980965

20 m02 lnaGs;dAs;lnaGs;dGs;lnaCs;dT-Sup

NANOG- GGGCATAGTGACACA dGs;lnaGs;dGs;lnaCs;dAs;lnaTs;dAs;lnaGs;dTs 980966

21 m02 ;lnaGs;dAs;lnaCs;dAs;lnaCs;dA-Sup

NANOG- I AA I 1 1 1 1 I AA I 1 AG dTs;lnaAs;dAs;lnaTs;dTs;lnaTs;dTs;lnaTs;dTs;l 980967

22 m02 naAs;dAs;lnaTs;dTs;lnaAs;dG-Sup

NANOG- AGCTGAGGTTCAGGA dAs;lnaGs;dCs;lnaTs;dGs;lnaAs;dGs;lnaGs;dTs 257592

23 m02 ;lnaTs;dCs;lnaAs;dGs;lnaGs;dA-Sup

NANOG- GACAAAACAAGCCTA dGs;lnaAs;dCs;lnaAs;dAs;lnaAs;dAs;lnaCs;dAs 257616

24 m02 ;lnaAs;dGs;lnaCs;dCs;lnaTs;dA-Sup

NANOG- TTTGTTCACCTTATT dTs;lnaTs;dTs;lnaGs;dTs;lnaTs;dCs;lnaAs;dCs;l 257636

25 m02 naCs;dTs;lnaTs;dAs;lnaTs;dT-Sup

NANOG- AG I LLAA I 1 1 1 I G I 1 dAs;lnaGs;dTs;lnaCs;dCs;lnaAs;dAs;lnaTs;dTs;l 257645

26 m02 naTs;dTs;lnaTs;dGs;lnaTs;dT-Sup

NANOG- ACAGAGGTCTTAGCC dAs;lnaCs;dAs;lnaGs;dAs;lnaGs;dGs;lnaTs;dCs 257669

27 m02 ;lnaTs;dTs;lnaAs;dGs;lnaCs;dC-Sup

NANOG- AAATACAAAAAATTA dAs;lnaAs;dAs;lnaTs;dAs;lnaCs;dAs;lnaAs;dAs; 919649

28 m02 lnaAs;dAs;lnaAs;dTs;lnaTs;dA-Sup

NANOG- AGGCTAGCCAACATG dAs;lnaGs;dGs;lnaCs;dTs;lnaAs;dGs;lnaCs;dCs; 258607

29 m02 lnaAs;dAs;lnaCs;dAs;lnaTs;dG-Sup

NANOG- AATTTACTTACATAT dAs;lnaAs;dTs;lnaTs;dTs;lnaAs;dCs;lnaTs;dTs;l 260711

30 m02 naAs;dCs;lnaAs;dTs;lnaAs;dT-Sup

Bl-01 GAAGCCGGAAAAGTC omeGs;omeAs;omeAs;omeGs;omeCs;omeCs; 980968 m03 GCAAT omeGs;omeGs;omeAs;omeAs;omeAs;omeAs;

omeGs;omeUs;omeCs;omeGs;omeCs;omeAs;

omeAs;omeU-Sup

RB1-02 AGAAGCCGGAAAAGT omeAs;omeGs;omeAs;omeAs;omeGs;omeCs; 980969 m03 CGCAA omeCs;omeGs;omeGs;omeAs;omeAs;omeAs;

omeAs;omeGs;omeUs;omeCs;omeGs;omeCs;

omeAs;omeA-Sup

RB1-03 GAGAAGCCGGAAAAG omeGs;omeAs;omeGs;omeAs;omeAs;omeGs; 980970 m03 TCGCA omeCs;omeCs;omeGs;omeGs;omeAs;omeAs;

omeAs;omeAs;omeGs;omeUs;omeCs;omeGs;

omeCs;omeA-Sup

RB1-04 GGAGAAGCCGGAAAA omeGs;omeGs;omeAs;omeGs;omeAs;omeAs; 980971 m03 GTCGC omeGs;omeCs;omeCs;omeGs;omeGs;omeAs;

omeAs;omeAs;omeAs;omeGs;omeUs;omeCs; omeGs;omeC-Sup

B1-05 AGGAGAAGCCGGAAA omeAs;omeGs;omeGs;omeAs;omeGs;omeAs; 980972 m03 AGTCG omeAs;omeGs;omeCs;omeCs;omeGs;omeGs;

omeAs;omeAs;omeAs;omeAs;omeGs;omeUs;

omeCs;omeG-Sup

RB1-06 GAGGAGAAGCCGGAA omeGs;omeAs;omeGs;omeGs;omeAs;omeGs; 980973 m03 AAGTC omeAs;omeAs;omeGs;omeCs;omeCs;omeGs;

omeGs;omeAs;omeAs;omeAs;omeAs;omeGs;

omeUs;omeC-Sup

RB1-07 AGAGGAGAAGCCGGA omeAs;omeGs;omeAs;omeGs;omeGs;omeAs; 980974 m03 AAAGT omeGs;omeAs;omeAs;omeGs;omeCs;omeCs;

omeGs;omeGs;omeAs;omeAs;omeAs;omeAs;

omeGs;omeU-Sup

RB1-08 GAGAGGAGAAGCCGG omeGs;omeAs;omeGs;omeAs;omeGs;omeGs; 980975 m03 AAAAG omeAs;omeGs;omeAs;omeAs;omeGs;omeCs;

omeCs;omeGs;omeGs;omeAs;omeAs;omeAs;

omeAs;omeG-Sup

RB1-09 GGAGAGGAGAAGCCG omeGs;omeGs;omeAs;omeGs;omeAs;omeGs; 980976 m03 GAAAA omeGs;omeAs;omeGs;omeAs;omeAs;omeGs;

omeCs;omeCs;omeGs;omeGs;omeAs;omeAs;

omeAs;omeA-Sup

RBl-10 GGAAATGGCTGATGG o me G s; o m eG s; o m e As; o m e As; o m e As; o me U s; 980977 m03 GAAGG omeGs;omeGs;omeCs;omeUs;omeGs;omeAs;

omeUs;omeGs;omeGs;omeGs;omeAs;omeAs;

omeGs;omeG-Sup

RBl-11 TTAAAAAAACAATGCG omeUs;omeUs;omeAs;omeAs;omeAs;omeAs; 980978 m03 GCGG omeAs;omeAs;omeAs;omeCs;omeAs;omeAs;

omeUs;omeGs;omeCs;omeGs;omeGs;omeCs;

omeGs;omeG-Sup

RB1-12 CTTAAAAAAACAATGC omeCs;omeUs;omeUs;omeAs;omeAs;omeAs; 980979 m03 GGCG omeAs;omeAs;omeAs;omeAs;omeCs;omeAs;

omeAs;omeUs;omeGs;omeCs;omeGs;omeGs;

omeCs;omeG-Sup

RB1-13 TCTTAAAAAAACAATG omeUs;omeCs;omeUs;omeUs;omeAs;omeAs; 980980 m03 CGGC omeAs;omeAs;omeAs;omeAs;omeAs;omeCs;

omeAs;omeAs;omeUs;omeGs;omeCs;omeGs;

omeGs;omeC-Sup

RB1-14 ATCTTAAAAAAACAAT omeAs;omeUs;omeCs;omeUs;omeUs;omeAs; 980981 m03 GCGG omeAs;omeAs;omeAs;omeAs;omeAs;omeAs;

omeCs;omeAs;omeAs;omeUs;omeGs;omeCs;

omeGs;omeG-Sup

RB1-15 AATCTTAAAAAAACAA omeAs;omeAs;omeUs;omeCs;omeUs;omeUs; 980982 m03 TGCG omeAs;omeAs;omeAs;omeAs;omeAs;omeAs;

omeAs;omeCs;omeAs;omeAs;omeUs;omeGs;

omeCs;omeG-Sup

RB1-16 AAATCTTAAAAAAACA omeAs;omeAs;omeAs;omeUs;omeCs;omeUs; 980983 m03 ATGC omeUs;omeAs;omeAs;omeAs;omeAs;omeAs; omeAs;omeAs;omeCs;omeAs;omeAs;omeUs;

omeGs;omeC-Sup

B1-17 GAAATCTTAAAAAAAC omeGs;omeAs;omeAs;omeAs;omeUs;omeCs; 980984 m03 AATG omeUs;omeUs;omeAs;omeAs;omeAs;omeAs;

omeAs;omeAs;omeAs;omeCs;omeAs;omeAs;

omeUs;omeG-Sup

SERPINF1- GTTCTGGCAGCTGCT dGs;lnaTs;dTs;lnaCs;dTs;lnaGs;dGs;lnaCs;dAs; 319148

01 m02 lnaGs;dCs;lnaTs;dGs;lnaCs;dT-Sup

SERPINF1- TCCTTTCTTCAAAGT dTs;lnaCs;dCs;lnaTs;dTs;lnaTs;dCs;lnaTs;dTs;l 711662

02 m02 naCs;dAs;lnaAs;dAs;lnaGs;dT-Sup

SERPINF1- TGCGATCCAGCACGA dTs;lnaGs;dCs;lnaGs;dAs;lnaTs;dCs;lnaCs;dAs; 711733

03 m02 lnaGs;dCs;lnaAs;dCs;lnaGs;dA-Sup

SERPINF1- ACGACCAACGTGCTC dAs;lnaCs;dGs;lnaAs;dCs;lnaCs;dAs;lnaAs;dCs; 711753

04 m02 lnaGs;dTs;lnaGs;dCs;lnaTs;dC-Sup

SERPINF1- TC A AGTC ATAGT AG A dTs;lnaCs;dAs;lnaAs;dGs;lnaTs;dCs;lnaAs;dTs;l 320839

05 m02 naAs;dGs;lnaTs;dAs;lnaGs;dA-Sup

SERPINF1- TATAGGTACCATGGA dTs;lnaAs;dTs;lnaAs;dGs;lnaGs;dTs;lnaAs;dCs; 320869

06 m02 lnaCs;dAs;lnaTs;dGs;lnaGs;dA-Sup

SERPINF1- CCGTGTCAAGGAGCT dCs;lnaCs;dGs;lnaTs;dGs;lnaTs;dCs;lnaAs;dAs; 320887

07 m02 lnaGs;dGs;lnaAs;dGs;lnaCs;dT-Sup

SERPINF1- AC ATCC ATG GTACCT dAs;lnaCs;dAs;lnaTs;dCs;lnaCs;dAs;lnaTs;dGs; 980985

08 m02 lnaGs;dTs;lnaAs;dCs;lnaCs;dT-Sup

SERPINF1- TACCTATAAGGAGCT dTs;lnaAs;dCs;lnaCs;dTs;lnaAs;dTs;lnaAs;dAs;l 980986

09 m02 naGs;dGs;lnaAs;dGs;lnaCs;dT-Sup

SERPINF1- AGCTCCTTGACACGG dAs;lnaGs;dCs;lnaTs;dCs;lnaCs;dTs;lnaTs;dGs;l 980987

10 m02 naAs;dCs;lnaAs;dCs;lnaGs;dG-Sup

SERPINF1- TTTCCAGAGGAGCCA dTs;lnaTs;dTs;lnaCs;dCs;lnaAs;dGs;lnaAs;dGs; 980988

11 m02 lnaGs;dAs;lnaGs;dCs;lnaCs;dA-Sup

SERPINF1- TGGTCCCATATGACT dTs;lnaGs;dGs;lnaTs;dCs;lnaCs;dCs;lnaAs;dTs;l 321295

12 m02 naAs;dTs;lnaGs;dAs;lnaCs;dT-Sup

SERPINF1- GAGGGTTGCCCGTCA dGs;lnaAs;dGs;lnaGs;dGs;lnaTs;dTs;lnaGs;dCs 321322

13 m02 ;lnaCs;dCs;lnaGs;dTs;lnaCs;dA-Sup

SERPINF1- AGAGATCAACAACTG dAs;lnaGs;dAs;lnaGs;dAs;lnaTs;dCs;lnaAs;dAs 712560

14 m02 ;lnaCs;dAs;lnaAs;dCs;lnaTs;dG-Sup

SERPINF1- AGGCCCAGAGTCCTG dAs;lnaGs;dGs;lnaCs;dCs;lnaCs;dAs;lnaGs;dAs 980989

15 m02 ;lnaGs;dTs;lnaCs;dCs;lnaTs;dG-Sup

SERPINF1- GAAGGAGAATGCTGA dGs;lnaAs;dAs;lnaGs;dGs;lnaAs;dGs;lnaAs;dAs 321360

16 m02 ;lnaTs;dGs;lnaCs;dTs;lnaGs;dA-Sup

SERPINF1- ATCCTCGAGGGAAGT dAs;lnaTs;dCs;lnaCs;dTs;lnaCs;dGs;lnaAs;dGs; 323831

17 m02 lnaGs;dGs;lnaAs;dAs;lnaGs;dT-Sup

SERPINF1- ATGAAGAGAGGACCG dAs;lnaTs;dGs;lnaAs;dAs;lnaGs;dAs;lnaGs;dAs 712608

18 m02 ;lnaGs;dGs;lnaAs;dCs;lnaCs;dG-Sup

SERPINF1- TGAATCCAAGCCATA dTs;lnaGs;dAs;lnaAs;dTs;lnaCs;dCs;lnaAs;dAs; 323876

19 m02 lnaGs;dCs;lnaCs;dAs;lnaTs;dA-Sup

SERPINF1- AGAGAGATCCGTGTG dAs;lnaGs;dAs;lnaGs;dAs;lnaGs;dAs;lnaTs;dCs 324530

20 m02 ;lnaCs;dGs;lnaTs;dGs;lnaTs;dG-Sup SERPINF1- ATTCTGGGTCACTTT dAs;lnaTs;dTs;lnaCs;dTs;lnaGs;dGs;lnaGs;dTs; 325195 21 m02 lnaCs;dAs;lnaCs;dTs;lnaTs;dT-Sup

SERPINF1- TGAGGCTCTCCTCTA dTs;lnaGs;dAs;lnaGs;dGs;lnaCs;dTs;lnaCs;dTs; 325220 22 m02 lnaCs;dCs;lnaTs;dCs;lnaTs;dA-Sup

SERPINF1- AAAGTGACCCAGAAT dAs;lnaAs;dAs;lnaGs;dTs;lnaGs;dAs;lnaCs;dCs; 980990 23 m02 lnaCs;dAs;lnaGs;dAs;lnaAs;dT-Sup

SERPINF1- AATTTGACCTTGATA dAs;lnaAs;dTs;lnaTs;dTs;lnaGs;dAs;lnaCs;dCs;l 980991 24 m02 naTs;dTs;lnaGs;dAs;lnaTs;dA-Sup

SERPINF1- CCAAGGGATCCCTTT dCs;lnaCs;dAs;lnaAs;dGs;lnaGs;dGs;lnaAs;dTs 325718 25 m02 ;lnaCs;dCs;lnaCs;dTs;lnaTs;dT-Sup

SERPINF1- GATCCCTTGGTTGGG dGs;lnaAs;dTs;lnaCs;dCs;lnaCs;dTs;lnaTs;dGs;l 980992 26 m02 naGs;dTs;lnaTs;dGs;lnaGs;dG-Sup

SERPINF1- TTAAGGTGATAGTCC dTs;lnaTs;dAs;lnaAs;dGs;lnaGs;dTs;lnaGs;dAs; 325892 27 m02 lnaTs;dAs;lnaGs;dTs;lnaCs;dC-Sup

SERPINF1- TCGTTCCACTCAAAG dTs;lnaCs;dGs;lnaTs;dTs;lnaCs;dCs;lnaAs;dCs;l 325817 28 m02 naTs;dCs;lnaAs;dAs;lnaAs;dG-Sup

SERPINF1- CC AG G G CTG C AG CCT dCs;lnaCs;dAs;lnaGs;dGs;lnaGs;dCs;lnaTs;dGs 980993 29 m02 ;lnaCs;dAs;lnaGs;dCs;lnaCs;dT-Sup

SERPINF1- TTGCCAATGAAGAGA dTs;lnaTs;dGs;lnaCs;dCs;lnaAs;dAs;lnaTs;dGs; 325952 30 m02 lnaAs;dAs;lnaGs;dAs;lnaGs;dA-Sup

SERPINF1- TGTGTCTGTGTCCCT dTs;lnaGs;dTs;lnaGs;dTs;lnaCs;dTs;lnaGs;dTs;l 325929 31 m02 naGs;dTs;lnaCs;dCs;lnaCs;dT-Sup

SERPINF1- TTCGTGTCCTGTGGA dTs;lnaTs;dCs;lnaGs;dTs;lnaGs;dTs;lnaCs;dCs;l 326045 32 m02 naTs;dGs;lnaTs;dGs;lnaGs;dA-Sup

SERPINF1- TGTCCACAGTGGTTG dTs;lnaGs;dTs;lnaCs;dCs;lnaAs;dCs;lnaAs;dGs; 316159 33 m02 lnaTs;dGs;lnaGs;dTs;lnaTs;dG-Sup

SERPINF1- TCACTCTCCCGTTAG dTs;lnaCs;dAs;lnaCs;dTs;lnaCs;dTs;lnaCs;dCs;l 980994 34 m02 naCs;dGs;lnaTs;dTs;lnaAs;dG-Sup

SERPINF1- AGACCCGACCCAGCA dAs;lnaGs;dAs;lnaCs;dCs;lnaCs;dGs;lnaAs;dCs; 315063 35 m02 lnaCs;dCs;lnaAs;dGs;lnaCs;dA-Sup

SERPINF1- TGAATGAAGTGAGTG dTs;lnaGs;dAs;lnaAs;dTs;lnaGs;dAs;lnaAs;dGs 980995 36 m02 ;lnaTs;dGs;lnaAs;dGs;lnaTs;dG-Sup

SERPINF1- ALAGAGU 1 1 1 1 1 I G dAs;lnaCs;dAs;lnaGs;dAs;lnaGs;dCs;lnaTs;dTs; 314649 37 m02 lnaTs;dTs;lnaTs;dTs;lnaTs;dG-Sup

SERPINF1- TCCTTTCTTAAAGCG dTs;lnaCs;dCs;lnaTs;dTs;lnaTs;dCs;lnaTs;dTs;l 314590 38 m02 naAs;dAs;lnaAs;dGs;lnaCs;dG-Sup

SERPINF1- AGAATCCAAATTTGA dAs;lnaGs;dAs;lnaAs;dTs;lnaCs;dCs;lnaAs;dAs; 980996 39 m02 lnaAs;dTs;lnaTs;dTs;lnaGs;dA-Sup

SERPINF1- TCGCTTTAAGAAAGG dTs;lnaCs;dGs;lnaCs;dTs;lnaTs;dTs;lnaAs;dAs;l 980997 40 m02 naGs;dAs;lnaAs;dAs;lnaGs;dG-Sup

SIRT6-01 ATCTGCAGCGATGTA dAs;lnaTs;dCs;lnaTs;dGs;lnaCs;dAs;lnaGs;dCs; 354004 m02 lnaGs;dAs;lnaTs;dGs;lnaTs;dA-Sup

SIRT6-02 ACCCAGCGTGATGGA dAs;lnaCs;dCs;lnaCs;dAs;lnaGs;dCs;lnaGs;dTs; 353990 m02 lnaGs;dAs;lnaTs;dGs;lnaGs;dA-Sup

SIRT6-03 CAGGTCGGCGTTCCT dCs;lnaAs;dGs;lnaGs;dTs;lnaCs;dGs;lnaGs;dCs 353975 m02 ;lnaGs;dTs;lnaTs;dCs;lnaCs;dT-Sup SI T6-04 ATTCTTCCACAAACA dAs;lnaTs;dTs;lnaCs;dTs;lnaTs;dCs;lnaCs;dAs;l 352095 m02 naCs;dAs;lnaAs;dAs;lnaCs;dA-Sup

SI T6-05 ACATGTTCCCGTGGA dAs;lnaCs;dAs;lnaTs;dGs;lnaTs;dTs;lnaCs;dCs;l 352083 m02 naCs;dGs;lnaTs;dGs;lnaGs;dA-Sup

SI T6-06 TGGAGCTCTGCCAGT dTs;lnaGs;dGs;lnaAs;dGs;lnaCs;dTs;lnaCs;dTs; 352072 m02 lnaGs;dCs;lnaCs;dAs;lnaGs;dT-Sup

SI T6-07 TGTCAGAAGGAAGCC dTs;lnaGs;dTs;lnaCs;dAs;lnaGs;dAs;lnaAs;dGs; 980998 m02 lnaGs;dAs;lnaAs;dGs;lnaCs;dC-Sup

SIRT6-08 TCTTTGCATGCAGGT dTs;lnaCs;dTs;lnaTs;dTs;lnaGs;dCs;lnaAs;dTs;l 980999 m02 naGs;dCs;lnaAs;dGs;lnaGs;dT-Sup

SIRT6-09 ATG C AG GTGTTTG CG dAs;lnaTs;dGs;lnaCs;dAs;lnaGs;dGs;lnaTs;dGs 981000 m02 ;lnaTs;dTs;lnaTs;dGs;lnaCs;dG-Sup

SIRT6-10 GGCGGCCGCCTACGT dGs;lnaGs;dCs;lnaGs;dGs;lnaCs;dCs;lnaGs;dCs 981001 m02 ;lnaCs;dTs;lnaAs;dCs;lnaGs;dT-Sup

SIRT6-11 ATGCTCGGGACCCTC dAs;lnaTs;dGs;lnaCs;dTs;lnaCs;dGs;lnaGs;dGs; 981002 m02 lnaAs;dCs;lnaCs;dCs;lnaTs;dC-Sup

SIRT6-12 ACCCTCAGACGCGCT dAs;lnaCs;dCs;lnaCs;dTs;lnaCs;dAs;lnaGs;dAs; 981003 m02 lnaCs;dGs;lnaCs;dGs;lnaCs;dT-Sup

SIRT6-13 TCACCTCCGGGAGGC dTs;lnaCs;dAs;lnaCs;dCs;lnaTs;dCs;lnaCs;dGs;l 981004 m02 naGs;dGs;lnaAs;dGs;lnaGs;dC-Sup

SIRT6-14 ACTTGCCCTTGTCCG dAs;lnaCs;dTs;lnaTs;dGs;lnaCs;dCs;lnaCs;dTs;l 981005 m02 naTs;dGs;lnaTs;dCs;lnaCs;dG-Sup

SIRT6-15 CCGCGTACGGCGGAC dCs;lnaCs;dGs;lnaCs;dGs;lnaTs;dAs;lnaCs;dGs; 981006 mlOOO A lnaGs;dCs;lnaGs;dGs;dAs;lnaCs;dA-Sup

SIRT6-16 ACTCCCCAGCCTGGC dAs;lnaCs;dTs;lnaCs;dCs;lnaCs;dCs;lnaAs;dGs; 981007 m02 lnaCs;dCs;lnaTs;dGs;lnaGs;dC-Sup

SIRT6-17 TCCTGGCCCGGCTCT dTs;lnaCs;dCs;lnaTs;dGs;lnaGs;dCs;lnaCs;dCs;l 981008 m02 naGs;dGs;lnaCs;dTs;lnaCs;dT-Sup

SIRT6-18 AACCTCCCAGGCCTA dAs;lnaAs;dCs;lnaCs;dTs;lnaCs;dCs;lnaCs;dAs;l 981009 m02 naGs;dGs;lnaCs;dCs;lnaTs;dA-Sup

SIRT6-19 CTCCAGGTGTGTTTA dCs;lnaTs;dCs;lnaCs;dAs;lnaGs;dGs;lnaTs;dGs; 981010 m02 lnaTs;dGs;lnaTs;dTs;lnaTs;dA-Sup

SIRT6-20 AGACCCAAAAGGGAA dAs;lnaGs;dAs;lnaCs;dCs;lnaCs;dAs;lnaAs;dAs; 981011 m02 lnaAs;dGs;lnaGs;dGs;lnaAs;dA-Sup

SIRT6-21 TGACTTCCCCAAAGT dTs;lnaGs;dAs;lnaCs;dTs;lnaTs;dCs;lnaCs;dCs;l 981012 m02 naCs;dAs;lnaAs;dAs;lnaGs;dT-Sup

SIRT6-22 AGCCGATCCCTCCAC dAs;lnaGs;dCs;lnaCs;dGs;lnaAs;dTs;lnaCs;dCs; 981013 m02 lnaCs;dTs;lnaCs;dCs;lnaAs;dC-Sup

SIRT6-23 AAAATGGATTGGAAA dAs;lnaAs;dAs;lnaAs;dTs;lnaGs;dGs;lnaAs;dTs; 981014 m02 lnaTs;dGs;lnaGs;dAs;lnaAs;dA-Sup

SIRT6-24 TTGTCCTCATGCCCC dTs;lnaTs;dGs;lnaTs;dCs;lnaCs;dTs;lnaCs;dAs;l 981015 m02 naTs;dGs;lnaCs;dCs;lnaCs;dC-Sup

SIRT6-25 CTCCTCTTCCTACAA dCs;lnaTs;dCs;lnaCs;dTs;lnaCs;dTs;lnaTs;dCs;l 981016 m02 naCs;dTs;lnaAs;dCs;lnaAs;dA-Sup

SIRT6-26 ACCTGCCTTGTCAAA dAs;lnaCs;dCs;lnaTs;dGs;lnaCs;dCs;lnaTs;dTs;l 981017 m02 naGs;dTs;lnaCs;dAs;lnaAs;dA-Sup SI T6-27 AAGCCCTGCCCTCCA dAs;lnaAs;dGs;lnaCs;dCs;lnaCs;dTs;lnaGs;dCs; 981018 m02 lnaCs;dCs;lnaTs;dCs;lnaCs;dA-Sup

SI T6-28 AAGCCCTTGATCTTG dAs;lnaAs;dGs;lnaCs;dCs;lnaCs;dTs;lnaTs;dGs; 981019 m02 lnaAs;dTs;lnaCs;dTs;lnaTs;dG-Sup

SI T6-29 AGGTGGACACAGATC dAs;lnaGs;dGs;lnaTs;dGs;lnaGs;dAs;lnaCs;dAs 981020 m02 ;lnaCs;dAs;lnaGs;dAs;lnaTs;dC-Sup

SI T6-30 ACAGATCCTCTGGCC dAs;lnaCs;dAs;lnaGs;dAs;lnaTs;dCs;lnaCs;dTs; 981021 m02 lnaCs;dTs;lnaGs;dGs;lnaCs;dC-Sup

SMAD7- TCAGCTCCAAAA TC dTs;lnaCs;dAs;lnaGs;dCs;lnaTs;dCs;lnaCs;dAs;l 981022 01 m02 naAs;dAs;lnaAs;dCs;lnaTs;dC-Sup

SMAD7- CCCTGCTTTTCCAAT dCs;lnaCs;dCs;lnaTs;dGs;lnaCs;dTs;lnaTs;dTs;l 981023 02 m02 naTs;dCs;lnaCs;dAs;lnaAs;dT-Sup

SMAD7- CCTCCGCCGCCGCCG dCs;lnaCs;dTs;lnaCs;dCs;lnaGs;dCs;lnaCs;dGs; 737807 03 m02 lnaCs;dCs;lnaGs;dCs;lnaCs;dG-Sup

SMAD7- CGCCGCGCCACCCTC dCs;lnaGs;dCs;lnaCs;dGs;lnaCs;dGs;lnaCs;dCs; 737817 04 m02 lnaAs;dCs;lnaCs;dCs;lnaTs;dC-Sup

SMAD7- GAAAGACCAGAGACT dGs;lnaAs;dAs;lnaAs;dGs;lnaAs;dCs;lnaCs;dAs 981024 05 m02 ;lnaGs;dAs;lnaGs;dAs;lnaCs;dT-Sup

SMAD7- TGTG C A AAGTGTTC A dTs;lnaGs;dTs;lnaGs;dCs;lnaAs;dAs;lnaAs;dGs; 738285 06 m02 lnaTs;dGs;lnaTs;dTs;lnaCs;dA-Sup

SMAD7- CCGGATCTCAGGCAT dCs;lnaCs;dGs;lnaGs;dAs;lnaTs;dCs;lnaTs;dCs; 738305 07 m02 lnaAs;dGs;lnaGs;dCs;lnaAs;dT-Sup

SMAD7- TTGGGCTAAAAGAAT dTs;lnaTs;dGs;lnaGs;dGs;lnaCs;dTs;lnaAs;dAs; 739678 08 m02 lnaAs;dAs;lnaGs;dAs;lnaAs;dT-Sup

SMAD7- AACCAACTGGTGAGT dAs;lnaAs;dCs;lnaCs;dAs;lnaAs;dCs;lnaTs;dGs; 739812 09 m02 lnaGs;dTs;lnaGs;dAs;lnaGs;dT-Sup

SMAD7- ACCCGATCCATTTTC dAs;lnaCs;dCs;lnaCs;dGs;lnaAs;dTs;lnaCs;dCs; 981025 10 m02 lnaAs;dTs;lnaTs;dTs;lnaTs;dC-Sup

SMAD7- ACTCACCCAAAACGT dAs;lnaCs;dTs;lnaCs;dAs;lnaCs;dCs;lnaCs;dAs;l 739976 11 m02 naAs;dAs;lnaAs;dCs;lnaGs;dT-Sup

SMAD7- AAAATAGAACAAAAA dAs;lnaAs;dAs;lnaAs;dTs;lnaAs;dGs;lnaAs;dAs 739998 12 m02 ;lnaCs;dAs;lnaAs;dAs;lnaAs;dA-Sup

SMAD7- TCAGTTTCTATGTCC dTs;lnaCs;dAs;lnaGs;dTs;lnaTs;dTs;lnaCs;dTs;l 740290 13 m02 naAs;dTs;lnaGs;dTs;lnaCs;dC-Sup

SMAD7- 1 I AGG I I GAA I 1 1 1 1 dTs;lnaTs;dAs;lnaGs;dGs;lnaTs;dTs;lnaGs;dAs; 740306 14 m02 lnaAs;dTs;lnaTs;dTs;lnaTs;dT-Sup

SMAD7- ATTG CTTTG GTGTGT dAs;lnaTs;dTs;lnaGs;dCs;lnaTs;dTs;lnaTs;dGs;l 740900 15 m02 naGs;dTs;lnaGs;dTs;lnaGs;dT-Sup

SMAD7- AGCTTCTAATGAGAA dAs;lnaGs;dCs;lnaTs;dTs;lnaCs;dTs;lnaAs;dAs;l 741357 16 m02 naTs;dGs;lnaAs;dGs;lnaAs;dA-Sup

SMAD7- TGCTTGAGATTCATA dTs;lnaGs;dCs;lnaTs;dTs;lnaGs;dAs;lnaGs;dAs; 741475 17 m02 lnaTs;dTs;lnaCs;dAs;lnaTs;dA-Sup

SMAD7- TATGTG G CT ACTAGT dTs;lnaAs;dTs;lnaGs;dTs;lnaGs;dGs;lnaCs;dTs; 741488 18 m02 lnaAs;dCs;lnaTs;dAs;lnaGs;dT-Sup

SMAD7- TTCTAATGACACAGG dTs;lnaTs;dCs;lnaTs;dAs;lnaAs;dTs;lnaGs;dAs;l 743259 19 m02 naCs;dAs;lnaCs;dAs;lnaGs;dG-Sup SMAD7- AGGGTGATGAATAGT dAs;lnaGs;dGs;lnaGs;dTs;lnaGs;dAs;lnaTs;dGs 744114

20 m02 ;lnaAs;dAs;lnaTs;dAs;lnaGs;dT-Sup

SMAD7- AATAGTAAGACAGAG dAs;lnaAs;dTs;lnaAs;dGs;lnaTs;dAs;lnaAs;dGs; 744123

21 m02 lnaAs;dCs;lnaAs;dGs;lnaAs;dG-Sup

SMAD7- CCCACCCAGCTTCCT dCs;lnaCs;dCs;lnaAs;dCs;lnaCs;dCs;lnaAs;dGs; 745905

22 m02 lnaCs;dTs;lnaTs;dCs;lnaCs;dT-Sup

SMAD7- TTTGTTGTCCCGAAT dTs;lnaTs;dTs;lnaGs;dTs;lnaTs;dGs;lnaTs;dCs;l 746188

23 m02 naCs;dCs;lnaGs;dAs;lnaAs;dT-Sup

SMAD7- AA AG CTTCTTGTGTT dAs;lnaAs;dAs;lnaGs;dCs;lnaTs;dTs;lnaCs;dTs;l 981026

24 m02 naTs;dGs;lnaTs;dGs;lnaTs;dT-Sup

SMAD7- TCAGAACACCCTCCT dTs;lnaCs;dAs;lnaGs;dAs;lnaAs;dCs;lnaAs;dCs; 981027

25 m02 lnaCs;dCs;lnaTs;dCs;lnaCs;dT-Sup

SMAD7- TCCTCCACACCAAAA dTs;lnaCs;dCs;lnaTs;dCs;lnaCs;dAs;lnaCs;dAs;l 981028

26 m02 naCs;dCs;lnaAs;dAs;lnaAs;dA-Sup

SMAD7- AAGAGGAGGAGCTGG dAs;lnaAs;dGs;lnaAs;dGs;lnaGs;dAs;lnaGs;dG 746304

27 m02 s;lnaAs;dGs;lnaCs;dTs;lnaGs;dG-Sup

SMAD7- CGTTCCTG C AGTCTG dCs;lnaGs;dTs;lnaTs;dCs;lnaCs;dTs;lnaGs;dCs;l 746450

28 m02 naAs;dGs;lnaTs;dCs;lnaTs;dG-Sup

SMAD7- TGTAG CGTCTTTCTT dTs;lnaGs;dTs;lnaAs;dGs;lnaCs;dGs;lnaTs;dCs; 747169

29 m02 lnaTs;dTs;lnaTs;dCs;lnaTs;dT-Sup

SMAD7- I L I 1 1 1 1 I GGLLA I L dTs;lnaCs;dTs;lnaTs;dTs;lnaTs;dTs;lnaTs;dGs;l 747180

30 m02 naGs;dCs;lnaCs;dAs;lnaTs;dC-Sup

ST7-01 GAAATGAGCATGAAA omeGs;omeAs;omeAs;omeAs;omeUs;omeGs; 981029 m03 CCAAA omeAs;omeGs;omeCs;omeAs;omeUs;omeGs;

omeAs;omeAs;omeAs;omeCs;omeCs;omeAs;

omeAs;omeA-Sup

ST7-02 GTATCCTAAGTCATAC omeGs;omeUs;omeAs;omeUs;omeCs;omeCs; 981030 m03 AGAC omeUs;omeAs;omeAs;omeGs;omeUs;omeCs;

omeAs;omeUs;omeAs;omeCs;omeAs;omeGs;

omeAs;omeC-Sup

ST7-03 CTA A AATAGTTG C ATA omeCs;omeUs;omeAs;omeAs;omeAs;omeAs; 981031 m03 ACAC omeUs;omeAs;omeGs;omeUs;omeUs;omeGs

;omeCs;omeAs;omeUs;omeAs;omeAs;omeCs;

omeAs;omeC-Sup

ST7-04 CCTCCAATACCATAGT omeCs;omeCs;omeUs;omeCs;omeCs;omeAs; 981032 m03 AATG omeAs;omeUs;omeAs;omeCs;omeCs;omeAs;

omeUs;omeAs;omeGs;omeUs;omeAs;omeAs;

omeUs;omeG-Sup

ST7-05 GTTATGTCACATCCCA omeGs;omeUs;omeUs;omeAs;omeUs;omeGs 981033 m03 ATTT ;omeUs;omeCs;omeAs;omeCs;omeAs;omeUs

;omeCs;omeCs;omeCs;omeAs;omeAs;omeUs;

omeUs;omeU-Sup

ST7-06 AAGTCAAAATGCCTTA omeAs;omeAs;omeGs;omeUs;omeCs;omeAs; 981034 m03 AGGT omeAs;omeAs;omeAs;omeUs;omeGs;omeCs;

omeCs;omeUs;omeUs;omeAs;omeAs;omeGs;

omeGs;omeU-Sup

ST7-07 AATCATACCTCAATTT omeAs;omeAs;omeUs;omeCs;omeAs;omeUs; 981035 m03 AAAA omeAs;omeCs;omeCs;omeUs;omeCs;omeAs;

omeAs;omeUs;omeUs;omeUs;omeAs;omeAs;

omeAs;omeA-Sup

ST7-08 CC ATT ATTG C AC A AAT omeCs;omeCs;omeAs;omeUs;omeUs;omeAs; 981036 m03 CACC omeUs;omeUs;omeGs;omeCs;omeAs;omeCs;

omeAs;omeAs;omeAs;omeUs;omeCs;omeAs;

omeCs;omeC-Sup

ST7-09 TCATATCCCCCCAACCT omeUs;omeCs;omeAs;omeUs;omeAs;omeUs; 981037 m03 GTC omeCs;omeCs;omeCs;omeCs;omeCs;omeCs;o

meAs;omeAs;omeCs;omeCs;omeUs;omeGs;o

meUs;omeC-Sup

ST7-10 AACCTCTATATTCAATT omeAs;omeAs;omeCs;omeCs;omeUs;omeCs; 981038 m03 TGC omeUs;omeAs;omeUs;omeAs;omeUs;omeUs;

omeCs;omeAs;omeAs;omeUs;omeUs;omeUs;

omeGs;omeC-Sup

ST7-11 TGTGAACTCCGGTTAA omeUs;omeGs;omeUs;omeGs;omeAs;omeAs; 981039 m03 ATCA omeCs;omeUs;omeCs;omeCs;omeGs;omeGs;

omeUs;omeUs;omeAs;omeAs;omeAs;omeUs;

omeCs;omeA-Sup

ST7-12 C A AAG CTTATCCTTCTT omeCs;omeAs;omeAs;omeAs;omeGs;omeCs; 981040 m03 TCC omeUs;omeUs;omeAs;omeUs;omeCs;omeCs;

omeUs;omeUs;omeCs;omeUs;omeUs;omeUs;

omeCs;omeC-Sup

ST7-13 TCCTTCTTTCCAAGCCC omeUs;omeCs;omeCs;omeUs;omeUs;omeCs; 981041 m03 AGA omeUs;omeUs;omeUs;omeCs;omeCs;omeAs;

omeAs;omeGs;omeCs;omeCs;omeCs;omeAs;

omeGs;omeA-Sup

ST7-14 CAACCTTCCAAATATC omeCs;omeAs;omeAs;omeCs;omeCs;omeUs; 981042 m03 CTTC omeUs;omeCs;omeCs;omeAs;omeAs;omeAs;

omeUs;omeAs;omeUs;omeCs;omeCs;omeUs;

omeUs;omeC-Sup

ST7-15 AAATGACCAATGAGA omeAs;omeAs;omeAs;omeUs;omeGs;omeAs; 981043 m03 AGTGC omeCs;omeCs;omeAs;omeAs;omeUs;omeGs;

omeAs;omeGs;omeAs;omeAs;omeGs;omeUs;

omeGs;omeC-Sup

ST7-16 CCTTTACTTCTAATCAT omeCs;omeCs;omeUs;omeUs;omeUs;omeAs; 981044 m03 TGT omeCs;omeUs;omeUs;omeCs;omeUs;omeAs;

omeAs;omeUs;omeCs;omeAs;omeUs;omeUs;

omeGs;omeU-Sup

ST7-17 GTATAATATGCAAACA omeGs;omeUs;omeAs;omeUs;omeAs;omeAs; 981045 m03 GCCT omeUs;omeAs;omeUs;omeGs;omeCs;omeAs;

omeAs;omeAs;omeCs;omeAs;omeGs;omeCs;

omeCs;omeU-Sup

ST7-18 CGAGTCACAAGTAAA omeCs;omeGs;omeAs;omeGs;omeUs;omeCs; 981046 m03 GAATG omeAs;omeCs;omeAs;omeAs;omeGs;omeUs;

omeAs;omeAs;omeAs;omeGs;omeAs;omeAs;

omeUs;omeG-Sup ST7-19 CATTCTTTACTTGTGAC omeCs;omeAs;omeUs;omeUs;omeCs;omeUs; 981047 m03 TCG omeUs;omeUs;omeAs;omeCs;omeUs;omeUs;

omeGs;omeUs;omeGs;omeAs;omeCs;omeUs;

omeCs;omeG-Sup

ST7-20 TACCAAAGTAAGTCAA omeUs;omeAs;omeCs;omeCs;omeAs;omeAs; 981048 m03 GAAC omeAs;omeGs;omeUs;omeAs;omeAs;omeGs;

omeUs;omeCs;omeAs;omeAs;omeGs;omeAs;

omeAs;omeC-Sup

ST7-21 CAAAGTAAGTCAAGA omeCs;omeAs;omeAs;omeAs;omeGs;omeUs; 981049 m03 ACCTG omeAs;omeAs;omeGs;omeUs;omeCs;omeAs;

omeAs;omeGs;omeAs;omeAs;omeCs;omeCs;

omeUs;omeG-Sup

ST7-22 TCAGCTCGATGGAAG omeUs;omeCs;omeAs;omeGs;omeCs;omeUs; 981050 m03 ATATA omeCs;omeGs;omeAs;omeUs;omeGs;omeGs;

omeAs;omeAs;omeGs;omeAs;omeUs;omeAs;

omeUs;omeA-Sup

ST7-23 CTGAGAGCGTCGGTA omeCs;omeUs;omeGs;omeAs;omeGs;omeAs; 981051 m03 ACAGC omeGs;omeCs;omeGs;omeUs;omeCs;omeGs;

omeGs;omeUs;omeAs;omeAs;omeCs;omeAs;

omeGs;omeC-Sup

ST7-24 C ATC ATTTTC ACTG CTT omeCs;omeAs;omeUs;omeCs;omeAs;omeUs; 981052 m03 CCC omeUs;omeUs;omeUs;omeCs;omeAs;omeCs;

omeUs;omeGs;omeCs;omeUs;omeUs;omeCs;

omeCs;omeC-Sup

ST7-25 CCCTGCCCCAAATTAC omeCs;omeCs;omeCs;omeUs;omeGs;omeCs; 981053 m03 TAAG omeCs;omeCs;omeCs;omeAs;omeAs;omeAs;

omeUs;omeUs;omeAs;omeCs;omeUs;omeAs;

omeAs;omeG-Sup

ST7-26 TTTGGACAATAGAGTC omeUs;omeUs;omeUs;omeGs;omeGs;omeAs 981054 m03 AT AC ;omeCs;omeAs;omeAs;omeUs;omeAs;omeGs

;omeAs;omeGs;omeUs;omeCs;omeAs;omeUs

;omeAs;omeC-Sup

ST7-27 CAGATGAAAGAGCAT omeCs;omeAs;omeGs;omeAs;omeUs;omeGs; 981055 m03 AGATG omeAs;omeAs;omeAs;omeGs;omeAs;omeGs;

omeCs;omeAs;omeUs;omeAs;omeGs;omeAs;

omeUs;omeG-Sup

ST7-28 CTTTTATGCCCTTGGCT omeCs;omeUs;omeUs;omeUs;omeUs;omeAs; 981056 m03 TTC omeUs;omeGs;omeCs;omeCs;omeCs;omeUs;

omeUs;omeGs;omeGs;omeCs;omeUs;omeUs;

omeUs;omeC-Sup

ST7-29 GCTTTGATTCCATTGA omeGs;omeCs;omeUs;omeUs;omeUs;omeGs; 981057 m03 CGAT omeAs;omeUs;omeUs;omeCs;omeCs;omeAs;

omeUs;omeUs;omeGs;omeAs;omeCs;omeGs;

omeAs;omeU-Sup

ST7-30 CCCTTAATGCTTTGATT omeCs;omeCs;omeCs;omeUs;omeUs;omeAs; 981058 m03 CCA omeAs;omeUs;omeGs;omeCs;omeUs;omeUs;

omeUs;omeGs;omeAs;omeUs;omeUs;omeCs; omeCs;omeA-Sup

STAT3-01 TACCTGCATTCTGCC dTs;lnaAs;dCs;lnaCs;dTs;lnaGs;dCs;lnaAs;dTs;l 981059 m02 naTs;dCs;lnaTs;dGs;lnaCs;dC-Sup

STAT3-02 GTTGACCTCGGAGTG dGs;lnaTs;dTs;lnaGs;dAs;lnaCs;dCs;lnaTs;dCs;l 981060 m02 naGs;dGs;lnaAs;dGs;lnaTs;dG-Sup

STAT3-03 ATGTGAGGAGCTGAG dAs;lnaTs;dGs;lnaTs;dGs;lnaAs;dGs;lnaGs;dAs 981061 m02 ;lnaGs;dCs;lnaTs;dGs;lnaAs;dG-Sup

STAT3-04 TATCCCTGGGAATGG dTs;lnaAs;dTs;lnaCs;dCs;lnaCs;dTs;lnaGs;dGs;l 981062 m02 naGs;dAs;lnaAs;dTs;lnaGs;dG-Sup

STAT3-05 TCCTTTCCTGCCCAG dTs;lnaCs;dCs;lnaTs;dTs;lnaTs;dCs;lnaCs;dTs;l 981063 m02 naGs;dCs;lnaCs;dCs;lnaAs;dG-Sup

STAT3-06 GTCAGCGTTTCCTCA dGs;lnaTs;dCs;lnaAs;dGs;lnaCs;dGs;lnaTs;dTs; 981064 m02 lnaTs;dCs;lnaCs;dTs;lnaCs;dA-Sup

STAT3-07 CC AG G C ACTC ATC AG dCs;lnaCs;dAs;lnaGs;dGs;lnaCs;dAs;lnaCs;dTs; 981065 m02 lnaCs;dAs;lnaTs;dCs;lnaAs;dG-Sup

STAT3-08 TGGGAGTATGGTTTA dTs;lnaGs;dGs;lnaGs;dAs;lnaGs;dTs;lnaAs;dTs; 981066 m02 lnaGs;dGs;lnaTs;dTs;lnaTs;dA-Sup

STAT3-09 TACACTAGAGTAGAA dTs;lnaAs;dCs;lnaAs;dCs;lnaTs;dAs;lnaGs;dAs; 981067 m02 lnaGs;dTs;lnaAs;dGs;lnaAs;dA-Sup

STAT3-10 AGGCATTCGGAAAGT dAs;lnaGs;dGs;lnaCs;dAs;lnaTs;dTs;lnaCs;dGs; 981068 m02 lnaGs;dAs;lnaAs;dAs;lnaGs;dT-Sup

STAT3-11 TTGGGTGGAGAAGGA dTs;lnaTs;dGs;lnaGs;dGs;lnaTs;dGs;lnaGs;dAs 981069 m02 ;lnaGs;dAs;lnaAs;dGs;lnaGs;dA-Sup

STAT3-12 AGAGGTAAGTTCTGC dAs;lnaGs;dAs;lnaGs;dGs;lnaTs;dAs;lnaAs;dGs 981070 m02 ;lnaTs;dTs;lnaCs;dTs;lnaGs;dC-Sup

STAT3-13 TGCAGCAGAATCGGA dTs;lnaGs;dCs;lnaAs;dGs;lnaCs;dAs;lnaGs;dAs 981071 m02 ;lnaAs;dTs;lnaCs;dGs;lnaGs;dA-Sup

STAT3-14 TCTGCAGAATTCAAA dTs;lnaCs;dTs;lnaGs;dCs;lnaAs;dGs;lnaAs;dAs; 981072 m02 lnaTs;dTs;lnaCs;dAs;lnaAs;dA-Sup

STAT3-15 ACACTTGGTATGTGG dAs;lnaCs;dAs;lnaCs;dTs;lnaTs;dGs;lnaGs;dTs; 981073 m02 lnaAs;dTs;lnaGs;dTs;lnaGs;dG-Sup

STAT3-16 CATTGACAAGTCCGT dCs;lnaAs;dTs;lnaTs;dGs;lnaAs;dCs;lnaAs;dAs; 981074 m02 lnaGs;dTs;lnaCs;dCs;lnaGs;dT-Sup

STAT3-17 TGTACAGCACCGGCC dTs;lnaGs;dTs;lnaAs;dCs;lnaAs;dGs;lnaCs;dAs; 981075 m02 lnaCs;dCs;lnaGs;dGs;lnaCs;dC-Sup

STAT3-18 AGAGGCGGCAACAGA dAs;lnaGs;dAs;lnaGs;dGs;lnaCs;dGs;lnaGs;dCs 981076 m02 ;lnaAs;dAs;lnaCs;dAs;lnaGs;dA-Sup

STAT3-19 AGGATGACTTTGATT dAs;lnaGs;dGs;lnaAs;dTs;lnaGs;dAs;lnaCs;dTs; 981077 m02 lnaTs;dTs;lnaGs;dAs;lnaTs;dT-Sup

STAT3-20 CTATAAAACCCTCAA dCs;lnaTs;dAs;lnaTs;dAs;lnaAs;dAs;lnaAs;dCs;l 981078 m02 naCs;dCs;lnaTs;dCs;lnaAs;dA-Sup

STAT3-21 GCAGCAGATGCTGGA dGs;lnaCs;dAs;lnaGs;dCs;lnaAs;dGs;lnaAs;dTs 981079 m02 ;lnaGs;dCs;lnaTs;dGs;lnaGs;dA-Sup

STAT3-22 TGGAGCTGCGGCAGT dTs;lnaGs;dGs;lnaAs;dGs;lnaCs;dTs;lnaGs;dCs; 981080 m02 lnaGs;dGs;lnaCs;dAs;lnaGs;dT-Sup

STAT3-23 TGACAGCTTCCCAAT dTs;lnaGs;dAs;lnaCs;dAs;lnaGs;dCs;lnaTs;dTs; 981081 m02 lnaCs;dCs;lnaCs;dAs;lnaAs;dT-Sup

STAT3-24 TTCCTTCTCTGTTGT dTs;lnaTs;dCs;lnaCs;dTs;lnaTs;dCs;lnaTs;dCs;l 981082 m02 naTs;dGs;lnaTs;dTs;lnaGs;dT-Sup

STAT3-25 TGTAGAATAACTATT dTs;lnaGs;dTs;lnaAs;dGs;lnaAs;dAs;lnaTs;dAs; 981083 m02 lnaAs;dCs;lnaTs;dAs;lnaTs;dT-Sup

STAT3-26 TAAAGTATTACCTAT dTs;lnaAs;dAs;lnaAs;dGs;lnaTs;dAs;lnaTs;dTs;l 981084 m02 naAs;dCs;lnaCs;dTs;lnaAs;dT-Sup

STAT3-27 ATGTGTGAGGGCCAG dAs;lnaTs;dGs;lnaTs;dGs;lnaTs;dGs;lnaAs;dGs; 981085 m02 lnaGs;dGs;lnaCs;dCs;lnaAs;dG-Sup

STAT3-28 AGGAGCCTGGTGTTT dAs;lnaGs;dGs;lnaAs;dGs;lnaCs;dCs;lnaTs;dGs 981086 m02 ;lnaGs;dTs;lnaGs;dTs;lnaTs;dT-Sup

STAT3-29 TTGTGTCTCAGGAAG dTs;lnaTs;dGs;lnaTs;dGs;lnaTs;dCs;lnaTs;dCs;l 981087 m02 naAs;dGs;lnaGs;dAs;lnaAs;dG-Sup

STAT3-30 AAGCCAACAGGAGGA dAs;lnaAs;dGs;lnaCs;dCs;lnaAs;dAs;lnaCs;dAs; 981088 m02 lnaGs;dGs;lnaAs;dGs;lnaGs;dA-Sup

STAT3-31 TTAATATGGTGGTTA dTs;lnaTs;dAs;lnaAs;dTs;lnaAs;dTs;lnaGs;dGs; 981089 m02 lnaTs;dGs;lnaGs;dTs;lnaTs;dA-Sup

STAT3-32 ATATACTCTTTGTTA dAs;lnaTs;dAs;lnaTs;dAs;lnaCs;dTs;lnaCs;dTs;l 981090 m02 naTs;dTs;lnaGs;dTs;lnaTs;dA-Sup

STAT3-33 AAGACGTAAGCGTAA dAs;lnaAs;dGs;lnaAs;dCs;lnaGs;dTs;lnaAs;dAs 981091 m02 ;lnaGs;dCs;lnaGs;dTs;lnaAs;dA-Sup

STAT3-34 AACTTCTG GTGTTCT dAs;lnaAs;dCs;lnaTs;dTs;lnaCs;dTs;lnaGs;dGs; 981092 m02 lnaTs;dGs;lnaTs;dTs;lnaCs;dT-Sup

STAT3-35 TCTTAGCTTATGGTT dTs;lnaCs;dTs;lnaTs;dAs;lnaGs;dCs;lnaTs;dTs;l 981093 m02 naAs;dTs;lnaGs;dGs;lnaTs;dT-Sup

STAT3-36 TTATGACTTGGTTCA dTs;lnaTs;dAs;lnaTs;dGs;lnaAs;dCs;lnaTs;dTs;l 981094 m02 naGs;dGs;lnaTs;dTs;lnaCs;dA-Sup

STAT3-37 GTTGTGATGGACGCT dGs;lnaTs;dTs;lnaGs;dTs;lnaGs;dAs;lnaTs;dGs; 981095 m02 lnaGs;dAs;lnaCs;dGs;lnaCs;dT-Sup

CFT -01 A ATG G ATGTCTG C AC A omeAs;omeAs;omeUs;omeGs;omeGs;omeAs; 981096 m03 AAAA omeUs;omeGs;omeUs;omeCs;omeUs;omeGs;

omeCs;omeAs;omeCs;omeAs;omeAs;omeAs;

omeAs;omeA-Sup

CFTR-02 AAAGGAAAATGGATG omeAs;omeAs;omeAs;omeGs;omeGs;omeAs; 981097 m03 TCTGC omeAs;omeAs;omeAs;omeUs;omeGs;omeGs;

omeAs;omeUs;omeGs;omeUs;omeCs;omeUs;

omeGs;omeC-Sup

CFTR-03 GAAAGGAAAATGGAT omeGs;omeAs;omeAs;omeAs;omeGs;omeGs; 981098 m03 GTCTG omeAs;omeAs;omeAs;omeAs;omeUs;omeGs;

omeGs;omeAs;omeUs;omeGs;omeUs;omeCs;

omeUs;omeG-Sup

CFTR-04 TTCAGTAGGCACCTGC omeUs;omeUs;omeCs;omeAs;omeGs;omeUs; 981099 m03 CCTG omeAs;omeGs;omeGs;omeCs;omeAs;omeCs;

omeCs;omeUs;omeGs;omeCs;omeCs;omeCs;

omeUs;omeG-Sup

CFTR-05 TATACTTCCTTG GTCT omeUs;omeAs;omeUs;omeAs;omeCs;omeUs; 981100 m03 GGAA omeUs;omeCs;omeCs;omeUs;omeUs;omeGs;

omeGs;omeUs;omeCs;omeUs;omeGs;omeGs;

omeAs;omeA-Sup

CFT -06 TTTATACTTCCTTGGTC omeUs;omeUs;omeUs;omeAs;omeUs;omeAs; 981101 m03 TGG omeCs;omeUs;omeUs;omeCs;omeCs;omeUs;

omeUs;omeGs;omeGs;omeUs;omeCs;omeUs;

omeGs;omeG-Sup

CFTR-07 G GTCCTTCTTT AT ACTT omeGs;omeGs;omeUs;omeCs;omeCs;omeUs; 981102 m03 CCT omeUs;omeCs;omeUs;omeUs;omeUs;omeAs;

omeUs;omeAs;omeCs;omeUs;omeUs;omeCs;

omeCs;omeU-Sup

CFTR-08 AU LAGA I 1 1 1 1 1 I G I A omeAs;omeCs;omeUs;omeCs;omeAs;omeGs; 981103 m03 ACA omeAs;omeUs;omeUs;omeUs;omeUs;omeUs

;omeUs;omeUs;omeGs;omeUs;omeAs;omeAs

;omeCs;omeA-Sup

CFTR-09 AAACAC 1 CAGA 1 1 1 1 1 omeAs;omeAs;omeAs;omeCs;omeAs;omeCs; 981104 m03 TTGT omeUs;omeCs;omeAs;omeGs;omeAs;omeUs;

omeUs;omeUs;omeUs;omeUs;omeUs;omeUs

;omeGs;omeU-Sup

CFTR-10 CTGTGTCCGCTAGAAA omeCs;omeUs;omeGs;omeUs;omeGs;omeUs; 981105 m03 CACT omeCs;omeCs;omeGs;omeCs;omeUs;omeAs;

omeGs;omeAs;omeAs;omeAs;omeCs;omeAs;

omeCs;omeU-Sup

CFTR-11 TATCTGTGTCCGCTAG omeUs;omeAs;omeUs;omeCs;omeUs;omeGs; 981106 m03 AAAC omeUs;omeGs;omeUs;omeCs;omeCs;omeGs;

omeCs;omeUs;omeAs;omeGs;omeAs;omeAs;

omeAs;omeC-Sup

CFTR-12 CAAATATCTGTGTCCG omeCs;omeAs;omeAs;omeAs;omeUs;omeAs; 981107 m03 CTAG omeUs;omeCs;omeUs;omeGs;omeUs;omeGs;

omeUs;omeCs;omeCs;omeGs;omeCs;omeUs;

omeAs;omeG-Sup

CFTR-13 AGACAAATATCTGTGT omeAs;omeGs;omeAs;omeCs;omeAs;omeAs; 981108 m03 CCGC omeAs;omeUs;omeAs;omeUs;omeCs;omeUs;

omeGs;omeUs;omeGs;omeUs;omeCs;omeCs;

omeGs;omeC-Sup

CFTR-14 CTAGACAAATATCTGT omeCs;omeUs;omeAs;omeGs;omeAs;omeCs; 981109 m03 GTCC omeAs;omeAs;omeAs;omeUs;omeAs;omeUs;

omeCs;omeUs;omeGs;omeUs;omeGs;omeUs;

omeCs;omeC-Sup

CFTR-15 CTCCTAGACAAATATC omeCs;omeUs;omeCs;omeCs;omeUs;omeAs; 981110 m03 TGTG omeGs;omeAs;omeCs;omeAs;omeAs;omeAs;

omeUs;omeAs;omeUs;omeCs;omeUs;omeGs;

omeUs;omeG-Sup

CFTR-16 CCCTCCTAGACAAATA omeCs;omeCs;omeCs;omeUs;omeCs;omeCs; 981111 m03 TCTG omeUs;omeAs;omeGs;omeAs;omeCs;omeAs;

omeAs;omeAs;omeUs;omeAs;omeUs;omeCs;

omeUs;omeG-Sup CFT -17 ATGTGAAATATGTTGT omeAs;omeUs;omeGs;omeUs;omeGs;omeAs; 981112 m03 GCAT omeAs;omeAs;omeUs;omeAs;omeUs;omeGs;

omeUs;omeUs;omeGs;omeUs;omeGs;omeCs;

omeAs;omeU-Sup

CFTR-18 CTATGTGAAATATGTT omeCs;omeUs;omeAs;omeUs;omeGs;omeUs; 981113 m03 GTGC omeGs;omeAs;omeAs;omeAs;omeUs;omeAs;

omeUs;omeGs;omeUs;omeUs;omeGs;omeUs

;omeGs;omeC-Sup

CFTR-19 AAAACTATGTGAAATA omeAs;omeAs;omeAs;omeAs;omeCs;omeUs; 981114 m03 TGTT omeAs;omeUs;omeGs;omeUs;omeGs;omeAs;

omeAs;omeAs;omeUs;omeAs;omeUs;omeGs;

omeUs;omeU-Sup

CFTR-20 AATCAGAAAACTATGT omeAs;omeAs;omeUs;omeCs;omeAs;omeGs; 981115 m03 GAAA omeAs;omeAs;omeAs;omeAs;omeCs;omeUs;

omeAs;omeUs;omeGs;omeUs;omeGs;omeAs;

omeAs;omeA-Sup

CFTR-21 CAAACTGAAATCAGAA omeCs;omeAs;omeAs;omeAs;omeCs;omeUs; 981116 m03 AACT omeGs;omeAs;omeAs;omeAs;omeUs;omeCs;

omeAs;omeGs;omeAs;omeAs;omeAs;omeAs;

omeCs;omeU-Sup

CFTR-22 TCTCC AC ATCCTC ATG C omeUs;omeCs;omeUs;omeCs;omeCs;omeAs; 981117 m03 CCC omeCs;omeAs;omeUs;omeCs;omeCs;omeUs;

omeCs;omeAs;omeUs;omeGs;omeCs;omeCs;

omeCs;omeC-Sup

CFTR-23 TGGAATACCCTCTCCA omeUs;omeGs;omeGs;omeAs;omeAs;omeUs; 981118 m03 CATC omeAs;omeCs;omeCs;omeCs;omeUs;omeCs;

omeUs;omeCs;omeCs;omeAs;omeCs;omeAs;

omeUs;omeC-Sup

CFTR-24 CTGGCATCCTGGAATA omeCs;omeUs;omeGs;omeGs;omeCs;omeAs; 981119 m03 CCCT omeUs;omeCs;omeCs;omeUs;omeGs;omeGs;

omeAs;omeAs;omeUs;omeAs;omeCs;omeCs;

omeCs;omeU-Sup

CFTR-25 TCCCTGTCTG G C ATCC omeUs;omeCs;omeCs;omeCs;omeUs;omeGs; 981120 m03 TGGA omeUs;omeCs;omeUs;omeGs;omeGs;omeCs;

omeAs;omeUs;omeCs;omeCs;omeUs;omeGs;

omeGs;omeA-Sup

CFTR-26 CATAATCTCCCTGTCT o me Cs; o m e As; o me U s; o m e As; o m e As; o me U s; 981121 m03 GGCA omeCs;omeUs;omeCs;omeCs;omeCs;omeUs;

omeGs;omeUs;omeCs;omeUs;omeGs;omeGs;

omeCs;omeA-Sup

CFTR-27 ATCCATAATCTCCCTGT omeAs;omeUs;omeCs;omeCs;omeAs;omeUs; 981122 m03 CTG omeAs;omeAs;omeUs;omeCs;omeUs;omeCs;

omeCs;omeCs;omeUs;omeGs;omeUs;omeCs;

omeUs;omeG-Sup

CFTR-28 AGAATTCTTCCAACTA omeAs;omeGs;omeAs;omeAs;omeUs;omeUs; 981123 m03 CTTT omeCs;omeUs;omeUs;omeCs;omeCs;omeAs;

omeAs;omeCs;omeUs;omeAs;omeCs;omeUs; omeUs;omeU-Sup

CFT -29 TAGAATTCTTCCAACT omeUs;omeAs;omeGs;omeAs;omeAs;omeUs; 981124 m03 ACTT omeUs;omeCs;omeUs;omeUs;omeCs;omeCs;

omeAs;omeAs;omeCs;omeUs;omeAs;omeCs;

omeUs;omeU-Sup

CFTR-30 CCCTAGAATTCTTCCA omeCs;omeCs;omeCs;omeUs;omeAs;omeGs; 981125 m03 ACTA omeAs;omeAs;omeUs;omeUs;omeCs;omeUs;

omeUs;omeCs;omeCs;omeAs;omeAs;omeCs;

omeUs;omeA-Sup

CFTR-31 TCCAATTTGCCATAT lnaTs;omeCs;lnaCs;omeAs;lnaAs;omeUs;lnaTs 817649 mOl ;omeUs;lnaGs;omeCs;lnaCs;omeAs;lnaTs;ome

As;lnaT-Sup

CFTR-32 TATTCCTTACTAAGA lnaTs;omeAs;lnaTs;omeUs;lnaCs;omeCs;lnaTs 821178 mOl ;omeUs;lnaAs;omeCs;lnaTs;omeAs;lnaAs;ome

Gs;lnaA-Sup

CFTR-33 CTGGTCCAGCTAAAA lnaCs;omeUs;lnaGs;omeGs;lnaTs;omeCs;lnaC 822550 mOl s;omeAs;lnaGs;omeCs;lnaTs;omeAs;lnaAs;om

eAs;lnaA-Sup

CFTR-34 TGGTATATGTCTGAC lnaTs;omeGs;lnaGs;omeUs;lnaAs;omeUs;lnaA 822604 mOl s;omeUs;lnaGs;omeUs;lnaCs;omeUs;lnaGs;o

meAs;lnaC-Sup

CFTR-35 GTG G C A ATA ACTT A A lnaGs;omeUs;lnaGs;omeGs;lnaCs;omeAs;lnaA 843983 mOl s;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaTs;om

eAs;lnaA-Sup

CFTR-36 GCCCTTCGGCGATGT lnaGs;omeCs;lnaCs;omeCs;lnaTs;omeUs;lnaCs 844765 mOl ;omeGs;lnaGs;omeCs;lnaGs;omeAs;lnaTs;om

eGs;lnaT-Sup

CFTR-37 CCCTTCGGCGATGTT lnaCs;omeCs;lnaCs;omeUs;lnaTs;omeCs;lnaGs 844766 mOl ;omeGs;lnaCs;omeGs;lnaAs;omeUs;lnaGs;om

eUs;lnaT-Sup

CFTR-38 CCTTCGGCGATGTTT lnaCs;omeCs;lnaTs;omeUs;lnaCs;omeGs;lnaG 844767 mOl s;omeCs;lnaGs;omeAs;lnaTs;omeGs;lnaTs;om

eUs;lnaT-Sup

CFTR-39 CTTCGGCGATGTTTT lnaCs;omeUs;lnaTs;omeCs;lnaGs;omeGs;lnaC 844768 mOl s;omeGs;lnaAs;omeUs;lnaGs;omeUs;lnaTs;o

meUs;lnaT-Sup

CFTR-40 CGGCGA I G I 1 1 1 1 I C lnaCs;omeGs;lnaGs;omeCs;lnaGs;omeAs;lnaT 844771 mOl s;omeGs;lnaTs;omeUs;lnaTs;omeUs;lnaTs;om

eUs;lnaC-Sup

CFTR-41 GGCGA I G I 1 1 1 1 I C I lnaGs;omeGs;lnaCs;omeGs;lnaAs;omeUs;lnaG 844772 mOl s;omeUs;lnaTs;omeUs;lnaTs;omeUs;lnaTs;om

eCs;lnaT-Sup

CFTR-42 GCGA I G I 1 1 1 1 I C I G lnaGs;omeCs;lnaGs;omeAs;lnaTs;omeGs;lnaT 844773 mOl s;omeUs;lnaTs;omeUs;lnaTs;omeUs;lnaCs;om

eUs;lnaG-Sup

CFTR-43 AGTTGGAATAGGTTT lnaAs;omeGs;lnaTs;omeUs;lnaGs;omeGs;lnaA 827700 mOl s;omeAs;lnaTs;omeAs;lnaGs;omeGs;lnaTs;om eUs;lnaT-Sup

CFT -44 ATAGTTGGAATAGGT lnaAs;omeUs;lnaAs;omeGs;lnaTs;omeUs;lnaG 827702 mOl s;omeGs;lnaAs;omeAs;lnaTs;omeAs;lnaGs;om

eGs;lnaT-Sup

CFTR-45 GTAGTGTGAAGGGTT lnaGs;omeUs;lnaAs;omeGs;lnaTs;omeGs;lnaT 828208 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeGs;lnaGs;o

meUs;lnaT-Sup

CFTR-46 CCCACAGTACTAAAT lnaCs;omeCs;lnaCs;omeAs;lnaCs;omeAs;lnaG 829603 mOl s;omeUs;lnaAs;omeCs;lnaTs;omeAs;lnaAs;om

eAs;lnaT-Sup

CFTR-47 CCTATGACACTGAGC lnaCs;omeCs;lnaTs;omeAs;lnaTs;omeGs;lnaAs 833275 mOl ;omeCs;lnaAs;omeCs;lnaTs;omeGs;lnaAs;ome

Gs;lnaC-Sup

CFTR-48 TCCTATGACACTGAG lnaTs;omeCs;lnaCs;omeUs;lnaAs;omeUs;lnaG 833276 mOl s;omeAs;lnaCs;omeAs;lnaCs;omeUs;lnaGs;om

eAs;lnaG-Sup

CFTR-49 GTTGTGCATGCTTTC lnaGs;omeUs;lnaTs;omeGs;lnaTs;omeGs;lnaC 833325 mOl s;omeAs;lnaTs;omeGs;lnaCs;omeUs;lnaTs;om

eUs;lnaC-Sup

CFTR-50 TGTAATGGCTGTCAT lnaTs;omeGs;lnaTs;omeAs;lnaAs;omeUs;lnaG 834171 mOl s;omeGs;lnaCs;omeUs;lnaGs;omeUs;lnaCs;o

meAs;lnaT-Sup

CFTR-51 CACTGAGTGGAGGTC lnaCs;omeAs;lnaCs;omeUs;lnaGs;omeAs;lnaG 847097 mOl s;omeUs;lnaGs;omeGs;lnaAs;omeGs;lnaGs;o

meUs;lnaC-Sup

CFTR-52 TGGATACCTAGATGT lnaTs;omeGs;lnaGs;omeAs;lnaTs;omeAs;lnaC 849696 mOl s;omeCs;lnaTs;omeAs;lnaGs;omeAs;lnaTs;om

eGs;lnaT-Sup

CFTR-53 GGATACCTAGATGTT lnaGs;omeGs;lnaAs;omeUs;lnaAs;omeCs;lnaC 849697 mOl s;omeUs;lnaAs;omeGs;lnaAs;omeUs;lnaGs;o

meUs;lnaT-Sup

CFTR-54 TACTTATA ATG CTC A lnaTs;omeAs;lnaCs;omeUs;lnaTs;omeAs;lnaTs 849757 mOl ;omeAs;lnaAs;omeUs;lnaGs;omeCs;lnaTs;om

eCs;lnaA-Sup

CFTR-55 T AT A ATG CTC ATG CT lnaTs;omeAs;lnaTs;omeAs;lnaAs;omeUs;lnaG 849761 mOl s;omeCs;lnaTs;omeCs;lnaAs;omeUs;lnaGs;om

eCs;lnaT-Sup

CFTR-56 AAATTGATGGTCAAC lnaAs;omeAs;lnaAs;omeUs;lnaTs;omeGs;lnaA 850784 mOl s;omeUs;lnaGs;omeGs;lnaTs;omeCs;lnaAs;om

eAs;lnaC-Sup

CFTR-57 TCAATCCTAACTGAG lnaTs;omeCs;lnaAs;omeAs;lnaTs;omeCs;lnaCs 851443 mOl ;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaGs;om

eAs;lnaG-Sup

CFTR-58 ATCCTAACTGAGACC lnaAs;omeUs;lnaCs;omeCs;lnaTs;omeAs;lnaA 851446 mOl s;omeCs;lnaTs;omeGs;lnaAs;omeGs;lnaAs;om

eCs;lnaC-Sup CFT -59 TCCTAACTGAGACCT lnaTs;omeCs;lnaCs;omeUs;lnaAs;omeAs;lnaCs 851447 mOl ;omeUs;lnaGs;omeAs;lnaGs;omeAs;lnaCs;om

eCs;lnaT-Sup

CFTR-60 CCTAACTGAGACCTT lnaCs;omeCs;lnaTs;omeAs;lnaAs;omeCs;lnaTs 851448 mOl ;omeGs;lnaAs;omeGs;lnaAs;omeCs;lnaCs;om

eUs;lnaT-Sup

CFTR-61 GAAGAAATTAACGAA lnaGs;omeAs;lnaAs;omeGs;lnaAs;omeAs;lnaA 851929 mOl s;omeUs;lnaTs;omeAs;lnaAs;omeCs;lnaGs;om

eAs;lnaA-Sup

CFTR-62 GAAATTAACGAAGAA lnaGs;omeAs;lnaAs;omeAs;lnaTs;omeUs;lnaA 851932 mOl s;omeAs;lnaCs;omeGs;lnaAs;omeAs;lnaGs;om

eAs;lnaA-Sup

CFTR-63 ATTAACGAAGAAGAC lnaAs;omeUs;lnaTs;omeAs;lnaAs;omeCs;lnaG 851935 mOl s;omeAs;lnaAs;omeGs;lnaAs;omeAs;lnaGs;o

meAs;lnaC-Sup

CFTR-64 TTAACGAAGAAGACT lnaTs;omeUs;lnaAs;omeAs;lnaCs;omeGs;lnaA 851936 mOl s;omeAs;lnaGs;omeAs;lnaAs;omeGs;lnaAs;o

meCs;lnaT-Sup

CFTR-65 TAACGAAGAAGACTT lnaTs;omeAs;lnaAs;omeCs;lnaGs;omeAs;lnaA 851937 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeAs;lnaCs;om

eUs;lnaT-Sup

CFTR-66 ACGAAGAAGACTTAA lnaAs;omeCs;lnaGs;omeAs;lnaAs;omeGs;lnaA 851939 mOl s;omeAs;lnaGs;omeAs;lnaCs;omeUs;lnaTs;om

eAs;lnaA-Sup

CFTR-67 GAATGGATTAGATCA lnaGs;omeAs;lnaAs;omeUs;lnaGs;omeGs;lnaA 856019 mOl s;omeUs;lnaTs;omeAs;lnaGs;omeAs;lnaTs;om

eCs;lnaA-Sup

CFTR-68 GGTGCATTGAAGTTA lnaGs;omeGs;lnaTs;omeGs;lnaCs;omeAs;lnaT 858972 mOl s;omeUs;lnaGs;omeAs;lnaAs;omeGs;lnaTs;o

meUs;lnaA-Sup

CFTR-69 TTTGCGGGAAGTACT lnaTs;omeUs;lnaTs;omeGs;lnaCs;omeGs;lnaG 859031 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeUs;lnaAs;o

meCs;lnaT-Sup

CFTR-70 TTGCGGGAAGTACTC lnaTs;omeUs;lnaGs;omeCs;lnaGs;omeGs;lnaG 859032 mOl s;omeAs;lnaAs;omeGs;lnaTs;omeAs;lnaCs;om

eUs;lnaC-Sup

CFTR-71 TGCGGGAAGTACTCT lnaTs;omeGs;lnaCs;omeGs;lnaGs;omeGs;lnaA 859033 mOl s;omeAs;lnaGs;omeUs;lnaAs;omeCs;lnaTs;om

eCs;lnaT-Sup

CFTR-72 TC ATT AGTA AAG GTC lnaTs;omeCs;lnaAs;omeUs;lnaTs;omeAs;lnaG 861044 mOl s;omeUs;lnaAs;omeAs;lnaAs;omeGs;lnaGs;o

meUs;lnaC-Sup

CFTR-73 1 I G I 1 1 I G I LGLA I lnaTs;omeUs;lnaGs;omeUs;lnaTs;omeUs;lnaT 836029 mOl s;omeGs;lnaGs;omeUs;lnaCs;omeGs;lnaCs;o

meAs;lnaT-Sup

CFTR-74 CTACAAGCTTTATGA lnaCs;omeUs;lnaAs;omeCs;lnaAs;omeAs;lnaG 837271 mOl s;omeCs;lnaTs;omeUs;lnaTs;omeAs;lnaTs;om eGs;lnaA-Sup

CFT -75 TCATCACTTCATAGC lnaTs;omeCs;lnaAs;omeUs;lnaCs;omeAs;lnaCs 837599 mOl ;omeUs;lnaTs;omeCs;lnaAs;omeUs;lnaAs;om

eGs;lnaC-Sup

CFTR-76 CATCCTCTTGGCGCT lnaCs;omeAs;lnaTs;omeCs;lnaCs;omeUs;lnaCs 838403 mOl ;omeUs;lnaTs;omeGs;lnaGs;omeCs;lnaGs;om

eCs;lnaT-Sup

CFTR-77 TAGATTAACCGTTTT lnaTs;omeAs;lnaGs;omeAs;lnaTs;omeUs;lnaA 863919 mOl s;omeAs;lnaCs;omeCs;lnaGs;omeUs;lnaTs;om

eUs;lnaT-Sup

CFTR-78 AGATTAACCGTTTTC lnaAs;omeGs;lnaAs;omeUs;lnaTs;omeAs;lnaA 863920 mOl s;omeCs;lnaCs;omeGs;lnaTs;omeUs;lnaTs;om

eUs;lnaC-Sup

CFTR-79 TCCTTATTACCCAAC lnaTs;omeCs;lnaCs;omeUs;lnaTs;omeAs;lnaTs 863947 mOl ;omeUs;lnaAs;omeCs;lnaCs;omeCs;lnaAs;ome

As;lnaC-Sup

CFTR-80 TCCTAAGCCATGGCC lnaTs;omeCs;lnaCs;omeUs;lnaAs;omeAs;lnaG 867045 mOl s;omeCs;lnaCs;omeAs;lnaTs;omeGs;lnaGs;om

eCs;lnaC-Sup

CFTR-81 TTCTCAGTAAGGCGA lnaTs;omeUs;lnaCs;omeUs;lnaCs;omeAs;lnaG 867090 mOl s;omeUs;lnaAs;omeAs;lnaGs;omeGs;lnaCs;o

meGs;lnaA-Sup

CFTR-82 CTTGATGAACCCAGT lnaCs;omeUs;lnaTs;omeGs;lnaAs;omeUs;lnaG 867116 mOl s;omeAs;lnaAs;omeCs;lnaCs;omeCs;lnaAs;om

eGs;lnaT-Sup

CFTR-83 TTGATGAACCCAGTG lnaTs;omeUs;lnaGs;omeAs;lnaTs;omeGs;lnaA 867117 mOl s;omeAs;lnaCs;omeCs;lnaCs;omeAs;lnaGs;om

eUs;lnaG-Sup

PAH-01 GAGATATGTGTACTTG omeGs;omeAs;omeGs;omeAs;omeUs;omeAs; 981126 m03 CAAT omeUs;omeGs;omeUs;omeGs;omeUs;omeAs

;omeCs;omeUs;omeUs;omeGs;omeCs;omeAs

;omeAs;omeU-Sup

PAH-02 AGATATGTGTACTTGC omeAs;omeGs;omeAs;omeUs;omeAs;omeUs; 981127 m03 AATT omeGs;omeUs;omeGs;omeUs;omeAs;omeCs;

omeUs;omeUs;omeGs;omeCs;omeAs;omeAs;

omeUs;omeU-Sup

PAH-03 TATGTGTACTTG CAAT omeUs;omeAs;omeUs;omeGs;omeUs;omeGs 981128 m03 TCCA ;omeUs;omeAs;omeCs;omeUs;omeUs;omeGs

;omeCs;omeAs;omeAs;omeUs;omeUs;omeCs

;omeCs;omeA-Sup

PAH-04 TGTACTTG C A ATTCC A omeUs;omeGs;omeUs;omeAs;omeCs;omeUs; 981129 m03 TTTC omeUs;omeGs;omeCs;omeAs;omeAs;omeUs;

omeUs;omeCs;omeCs;omeAs;omeUs;omeUs;

omeUs;omeC-Sup

PAH-05 TCCATTTCTATCTGTAA omeUs;omeCs;omeCs;omeAs;omeUs;omeUs; 981130 m03 AAC omeUs;omeCs;omeUs;omeAs;omeUs;omeCs;

omeUs;omeGs;omeUs;omeAs;omeAs;omeAs; omeAs;omeC-Sup

PAH-06 AATAACTGACAGTTCA omeAs;omeAs;omeUs;omeAs;omeAs;omeCs; 981131 m03 ATAT omeUs;omeGs;omeAs;omeCs;omeAs;omeGs;

omeUs;omeUs;omeCs;omeAs;omeAs;omeUs;

omeAs;omeU-Sup

PAH-07 TGACAGTTCAATATGT omeUs;omeGs;omeAs;omeCs;omeAs;omeGs; 981132 m03 CCTA omeUs;omeUs;omeCs;omeAs;omeAs;omeUs;

omeAs;omeUs;omeGs;omeUs;omeCs;omeCs;

omeUs;omeA-Sup

PAH-08 ATGTCCTAGAGAGTTG omeAs;omeUs;omeGs;omeUs;omeCs;omeCs; 981133 m03 GCCT omeUs;omeAs;omeGs;omeAs;omeGs;omeAs;

omeGs;omeUs;omeUs;omeGs;omeGs;omeCs;

omeCs;omeU-Sup

PAH-09 TCCTAGAGAGTTGGCC omeUs;omeCs;omeCs;omeUs;omeAs;omeGs; 981134 m03 TGAA omeAs;omeGs;omeAs;omeGs;omeUs;omeUs;

omeGs;omeGs;omeCs;omeCs;omeUs;omeGs;

omeAs;omeA-Sup

PAH-10 TTTAGAGTGAACCAAA omeUs;omeUs;omeUs;omeAs;omeGs;omeAs; 981135 m03 TTCA omeGs;omeUs;omeGs;omeAs;omeAs;omeCs;

omeCs;omeAs;omeAs;omeAs;omeUs;omeUs;

omeCs;omeA-Sup

PAH-11 TAGAGTGAACCAAATT omeUs;omeAs;omeGs;omeAs;omeGs;omeUs; 981136 m03 CAAA omeGs;omeAs;omeAs;omeCs;omeCs;omeAs;

omeAs;omeAs;omeUs;omeUs;omeCs;omeAs;

omeAs;omeA-Sup

PAH-12 GTGAACCAAATTCAAA omeGs;omeUs;omeGs;omeAs;omeAs;omeCs; 981137 m03 TTCT omeCs;omeAs;omeAs;omeAs;omeUs;omeUs;

omeCs;omeAs;omeAs;omeAs;omeUs;omeUs;

omeCs;omeU-Sup

PAH-13 AACCAAATTCAAATTC omeAs;omeAs;omeCs;omeCs;omeAs;omeAs; 981138 m03 TTAG omeAs;omeUs;omeUs;omeCs;omeAs;omeAs;

omeAs;omeUs;omeUs;omeCs;omeUs;omeUs;

omeAs;omeG-Sup

PAH-14 ACCAAATTCAAATTCT omeAs;omeCs;omeCs;omeAs;omeAs;omeAs; 981139 m03 TAGC omeUs;omeUs;omeCs;omeAs;omeAs;omeAs;

omeUs;omeUs;omeCs;omeUs;omeUs;omeAs;

omeGs;omeC-Sup

PAH-15 C A A ATTCTT AG C CTG G omeCs;omeAs;omeAs;omeAs;omeUs;omeUs; 981140 m03 ATCT omeCs;omeUs;omeUs;omeAs;omeGs;omeCs;

omeCs;omeUs;omeGs;omeGs;omeAs;omeUs;

omeCs;omeU-Sup

PAH-16 CCCCCTGCAGTTGGCA omeCs;omeCs;omeCs;omeCs;omeCs;omeUs; 981141 m03 GAGT omeGs;omeCs;omeAs;omeGs;omeUs;omeUs;

omeGs;omeGs;omeCs;omeAs;omeGs;omeAs;

omeGs;omeU-Sup

PAH-17 TGCAGTTGGCAGAGTT omeUs;omeGs;omeCs;omeAs;omeGs;omeUs; 981142 m03 GTTA omeUs;omeGs;omeGs;omeCs;omeAs;omeGs; omeAs;omeGs;omeUs;omeUs;omeGs;omeUs

;omeUs;omeA-Sup

PAH-18 CAGAGTTGTTAGTACA omeCs;omeAs;omeGs;omeAs;omeGs;omeUs; 981143 m03 GGTT omeUs;omeGs;omeUs;omeUs;omeAs;omeGs

;omeUs;omeAs;omeCs;omeAs;omeGs;omeGs

;omeUs;omeU-Sup

PAH-19 TGTTTACCAAGCACTT omeUs;omeGs;omeUs;omeUs;omeUs;omeAs 981144 m03 GACT ;omeCs;omeCs;omeAs;omeAs;omeGs;omeCs;

omeAs;omeCs;omeUs;omeUs;omeGs;omeAs;

omeCs;omeU-Sup

PAH-20 CCAAGCACTTGACTTA omeCs;omeCs;omeAs;omeAs;omeGs;omeCs; 981145 m03 AACC omeAs;omeCs;omeUs;omeUs;omeGs;omeAs;

omeCs;omeUs;omeUs;omeAs;omeAs;omeAs;

omeCs;omeC-Sup

PAH-21 CTTGACTTAAACCTCC omeCs;omeUs;omeUs;omeGs;omeAs;omeCs; 981146 m03 ATAG omeUs;omeUs;omeAs;omeAs;omeAs;omeCs;

omeCs;omeUs;omeCs;omeCs;omeAs;omeUs;

omeAs;omeG-Sup

PAH-22 GCAAAGCCAGTTAGA omeGs;omeCs;omeAs;omeAs;omeAs;omeGs; 981147 m03 AAGCC omeCs;omeCs;omeAs;omeGs;omeUs;omeUs;

omeAs;omeGs;omeAs;omeAs;omeAs;omeGs;

omeCs;omeC-Sup

PAH-23 CGTTGTTGAAGCAGA omeCs;omeGs;omeUs;omeUs;omeGs;omeUs; 981148 m03 GTGAA omeUs;omeGs;omeAs;omeAs;omeGs;omeCs;

omeAs;omeGs;omeAs;omeGs;omeUs;omeGs;

omeAs;omeA-Sup

PAH-24 AAGCAGAGTGAACAG omeAs;omeAs;omeGs;omeCs;omeAs;omeGs; 981149 m03 AGTCA omeAs;omeGs;omeUs;omeGs;omeAs;omeAs;

omeCs;omeAs;omeGs;omeAs;omeGs;omeUs;

omeCs;omeA-Sup

PAH-25 AGTGAACAGAGTCAG omeAs;omeGs;omeUs;omeGs;omeAs;omeAs; 981150 m03 ATAGT omeCs;omeAs;omeGs;omeAs;omeGs;omeUs;

omeCs;omeAs;omeGs;omeAs;omeUs;omeAs;

omeGs;omeU-Sup

PAH-26 AGCACCTAAAGGATTT omeAs;omeGs;omeCs;omeAs;omeCs;omeCs; 981151 m03 CAGA omeUs;omeAs;omeAs;omeAs;omeGs;omeGs;

omeAs;omeUs;omeUs;omeUs;omeCs;omeAs;

omeGs;omeA-Sup

PAH-27 A AG G C AAGTC AC AG C omeAs;omeAs;omeGs;omeGs;omeCs;omeAs; 981152 m03 CTCTG omeAs;omeGs;omeUs;omeCs;omeAs;omeCs;

omeAs;omeGs;omeCs;omeCs;omeUs;omeCs;

omeUs;omeG-Sup

PAH-28 CC AG G G CTA ACTCTTG omeCs;omeCs;omeAs;omeGs;omeGs;omeGs; 981153 m03 GTCA omeCs;omeUs;omeAs;omeAs;omeCs;omeUs;

omeCs;omeUs;omeUs;omeGs;omeGs;omeUs;

omeCs;omeA-Sup

PAH-29 I LA I 1 1 I LU U U GU omeUs;omeCs;omeAs;omeUs;omeUs;omeUs; 981154 m03 TAG omeUs;omeCs;omeCs;omeUs;omeCs;omeUs;

omeCs;omeUs;omeGs;omeCs;omeUs;omeUs;

omeAs;omeG-Sup

PAH-30 A l 1 1 I LU U U GU I A omeAs;omeUs;omeUs;omeUs;omeUs;omeCs; 981155 m03 GTT omeCs;omeUs;omeCs;omeUs;omeCs;omeUs;

omeGs;omeCs;omeUs;omeUs;omeAs;omeGs;

omeUs;omeU-Sup

CD274-01 ACTTAGATGCTGCAG lnaAs;omeCs;lnaTs;omeUs;lnaAs;omeGs;lnaA 968788 mOl s;omeUs;lnaGs;omeCs;lnaTs;omeGs;lnaCs;om

eAs;lnaGs-Sup

CD274-02 GACTTACTTAGATGC lnaGs;omeAs;lnaCs;omeUs;lnaTs;omeAs;lnaC 968793 mOl s;omeUs;lnaTs;omeAs;lnaGs;omeAs;lnaTs;om

eGs;lnaCs-Sup

CD274-03 GAAGAGACTTACTTA lnaGs;omeAs;lnaAs;omeGs;lnaAs;omeGs;lnaA 968798 mOl s;omeCs;lnaTs;omeUs;lnaAs;omeCs;lnaTs;om

eUs;lnaAs-Sup

CD274-04 GCGCAGGAAGAGACT lnaGs;omeCs;lnaGs;omeCs;lnaAs;omeGs;lnaG 968804 mOl s;omeAs;lnaAs;omeGs;lnaAs;omeGs;lnaAs;o

meCs;lnaTs-Sup

CD274-05 TAGCGCAGGAAGAGA lnaTs;omeAs;lnaGs;omeCs;lnaGs;omeCs;lnaA 968806 mOl s;omeGs;lnaGs;omeAs;lnaAs;omeGs;lnaAs;o

meGs;lnaAs-Sup

CD274-06 TTAGCGCAGGAAGAG lnaTs;omeUs;lnaAs;omeGs;lnaCs;omeGs;lnaC 968807 mOl s;omeAs;lnaGs;omeGs;lnaAs;omeAs;lnaGs;o

meAs;lnaGs-Sup

CD274-07 CTTAGCGCAGGAAGA lnaCs;omeUs;lnaTs;omeAs;lnaGs;omeCs;lnaG 968808 mOl s;omeCs;lnaAs;omeGs;lnaGs;omeAs;lnaAs;om

eGs;lnaAs-Sup

CD274-08 TAGGAGTAATAAAGG lnaTs;omeAs;lnaGs;omeGs;lnaAs;omeGs;lnaT 970534 mOl s;omeAs;lnaAs;omeUs;lnaAs;omeAs;lnaAs;om

eGs;lnaGs-Sup

CD274-09 CTGGTGGAGTTCTTG lnaCs;omeUs;lnaGs;omeGs;lnaTs;omeGs;lnaG 970576 mOl s;omeAs;lnaGs;omeUs;lnaTs;omeCs;lnaTs;om

eUs;lnaGs-Sup

CD274-10 ATG G CCT ACTCTG GT lnaAs;omeUs;lnaGs;omeGs;lnaCs;omeCs;lnaT 970586 mOl s;omeAs;lnaCs;omeUs;lnaCs;omeUs;lnaGs;o

meGs;lnaTs-Sup

CD274-11 TATG G CCT ACTCTG G lnaTs;omeAs;lnaTs;omeGs;lnaGs;omeCs;lnaCs 970587 mOl ;omeUs;lnaAs;omeCs;lnaTs;omeCs;lnaTs;ome

Gs;lnaGs-Sup

CD274-12 GTTTATGGCCTACTC lnaGs;omeUs;lnaTs;omeUs;lnaAs;omeUs;lnaG 970590 mOl s;omeGs;lnaCs;omeCs;lnaTs;omeAs;lnaCs;om

eUs;lnaCs-Sup

CD274-13 CC A ATGTTT ATG G CC lnaCs;omeCs;lnaAs;omeAs;lnaTs;omeGs;lnaTs 970595 mOl ;omeUs;lnaTs;omeAs;lnaTs;omeGs;lnaGs;om

eCs;lnaCs-Sup

CD274-14 AGCAAATATCCTCAT lnaAs;omeGs;lnaCs;omeAs;lnaAs;omeAs;lnaT 981164 mOl s;omeAs;lnaTs;omeCs;lnaCs;omeUs;lnaCs;om

eAs;lnaTs-Sup

CD274-15 TA ATTCG CTTGT AGT lnaTs;omeAs;lnaAs;omeUs;lnaTs;omeCs;lnaG 981166 mOl s;omeCs;lnaTs;omeUs;lnaGs;omeUs;lnaAs;om

eGs;lnaTs-Sup

CD274-16 CTTACCATTGACTTT lnaCs;omeUs;lnaTs;omeAs;lnaCs;omeCs;lnaAs 981168 mOl ;omeUs;lnaTs;omeGs;lnaAs;omeCs;lnaTs;ome

Us;lnaTs-Sup

CD274-17 CAGGAGTTCTACTTC lnaCs;omeAs;lnaGs;omeGs;lnaAs;omeGs;lnaT 981170 mOl s;omeUs;lnaCs;omeUs;lnaAs;omeCs;lnaTs;om

eUs;lnaCs-Sup

CD274-18 GGTATACTTCTCTAA lnaGs;omeGs;lnaTs;omeAs;lnaTs;omeAs;lnaC 974685 mOl s;omeUs;lnaTs;omeCs;lnaTs;omeCs;lnaTs;om

eAs;lnaAs-Sup

CD274-19 CTCTATACCATCACT lnaCs;omeUs;lnaCs;omeUs;lnaAs;omeUs;lnaA 974709 mOl s;omeCs;lnaCs;omeAs;lnaTs;omeCs;lnaAs;om

eCs;lnaTs-Sup

CD274-20 GAATCCCCTTCCATA lnaGs;omeAs;lnaAs;omeUs;lnaCs;omeCs;lnaC 974752 mOl s;omeCs;lnaTs;omeUs;lnaCs;omeCs;lnaAs;om

eUs;lnaAs-Sup

CD274-21 CGACTATTGGAATCC lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaTs 974761 mOl ;omeUs;lnaGs;omeGs;lnaAs;omeAs;lnaTs;om

eCs;lnaCs-Sup

CD274-22 ACGACTATTGGAATC lnaAs;omeCs;lnaGs;omeAs;lnaCs;omeUs;lnaA 974762 mOl s;omeUs;lnaTs;omeGs;lnaGs;omeAs;lnaAs;o

meUs;lnaCs-Sup

CD274-23 AACGACTATTGGAAT lnaAs;omeAs;lnaCs;omeGs;lnaAs;omeCs;lnaT 974763 mOl s;omeAs;lnaTs;omeUs;lnaGs;omeGs;lnaAs;o

meAs;lnaTs-Sup

CD274-24 CAACGACTATTGGAA lnaCs;omeAs;lnaAs;omeCs;lnaGs;omeAs;lnaC 974764 mOl s;omeUs;lnaAs;omeUs;lnaTs;omeGs;lnaGs;o

meAs;lnaAs-Sup

CD274-25 TCAACGACTATTGGA lnaTs;omeCs;lnaAs;omeAs;lnaCs;omeGs;lnaA 974765 mOl s;omeCs;lnaTs;omeAs;lnaTs;omeUs;lnaGs;om

eGs;lnaAs-Sup

CD274-26 TTTCAACGACTATTG lnaTs;omeUs;lnaTs;omeCs;lnaAs;omeAs;lnaCs 974767 mOl ;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaTs;ome

Us;lnaGs-Sup

CD274-27 A l l l l 1 LAALGAL 1 A lnaAs;omeUs;lnaTs;omeUs;lnaTs;omeUs;lnaC 974770 mOl s;omeAs;lnaAs;omeCs;lnaGs;omeAs;lnaCs;om

eUs;lnaAs-Sup

CD274-28 AA I 1 1 1 1 LAALGAL 1 lnaAs;omeAs;lnaTs;omeUs;lnaTs;omeUs;lnaTs 974771 mOl ;omeCs;lnaAs;omeAs;lnaCs;omeGs;lnaAs;ome

Cs;lnaTs-Sup

CD274-29 GGAATTTTTCAACGA lnaGs;omeGs;lnaAs;omeAs;lnaTs;omeUs;lnaT 974773 mOl s;omeUs;lnaTs;omeCs;lnaAs;omeAs;lnaCs;om

eGs;lnaAs-Sup CD274-30 GTATCTGGAGAGTGA lnaGs;omeUs;lnaAs;omeUs;lnaCs;omeUs;lna 976344 mOl Gs;omeGs;lnaAs;omeGs;lnaAs;omeGs;lnaTs;o

meGs;lnaAs-Sup

CD274-31 TGTATCTGGAGAGTG lnaTs;omeGs;lnaTs;omeAs;lnaTs;omeCs;lnaTs 976345 mOl ;omeGs;lnaGs;omeAs;lnaGs;omeAs;lnaGs;om

eUs;lnaGs-Sup

CD274-32 GTGTATCTGGAGAGT lnaGs;omeUs;lnaGs;omeUs;lnaAs;omeUs;lna 976346 mOl Cs;omeUs;lnaGs;omeGs;lnaAs;omeGs;lnaAs;o

meGs;lnaTs-Sup

CD274-33 TGAGGATATTTGCTG lnaTs;omeGs;lnaAs;omeGs;lnaGs;omeAs;lnaT 977593 mOl s;omeAs;lnaTs;omeUs;lnaTs;omeGs;lnaCs;om

eUs;lnaGs-Sup

CD274-34 GTGTACCGCTGCATG lnaGs;omeUs;lnaGs;omeUs;lnaAs;omeCs;lnaC 978835 mOl s;omeGs;lnaCs;omeUs;lnaGs;omeCs;lnaAs;o

meUs;lnaGs-Sup

CD274-35 TGTACCGCTGCATGA lnaTs;omeGs;lnaTs;omeAs;lnaCs;omeCs;lnaGs 978836 mOl ;omeCs;lnaTs;omeGs;lnaCs;omeAs;lnaTs;ome

Gs;lnaAs-Sup

CD274-36 CCGCTGCATGATCAG lnaCs;omeCs;lnaGs;omeCs;lnaTs;omeGs;lnaCs 978840 mOl ;omeAs;lnaTs;omeGs;lnaAs;omeUs;lnaCs;om

eAs;lnaGs-Sup

CD274-37 GGTGGTGCCGACTAC lnaGs;omeGs;lnaTs;omeGs;lnaGs;omeUs;lnaG 978859 mOl s;omeCs;lnaCs;omeGs;lnaAs;omeCs;lnaTs;om

eAs;lnaCs-Sup

CD274-38 GCCGACTACAAGCGA lnaGs;omeCs;lnaCs;omeGs;lnaAs;omeCs;lnaT 978865 mOl s;omeAs;lnaCs;omeAs;lnaAs;omeGs;lnaCs;om

eGs;lnaAs-Sup

CD274-39 CCGACTACAAGCGAA lnaCs;omeCs;lnaGs;omeAs;lnaCs;omeUs;lnaA 978866 mOl s;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaGs;om

eAs;lnaAs-Sup

CD274-40 CGACTACAAGCGAAT lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaCs 978867 mOl ;omeAs;lnaAs;omeGs;lnaCs;omeGs;lnaAs;om

eAs;lnaTs-Sup

CD274-41 GACTACAAGCGAATT lnaGs;omeAs;lnaCs;omeUs;lnaAs;omeCs;lnaA 978868 mOl s;omeAs;lnaGs;omeCs;lnaGs;omeAs;lnaAs;om

eUs;lnaTs-Sup

CD274-42 CTACAAGCGAATTAC lnaCs;omeUs;lnaAs;omeCs;lnaAs;omeAs;lnaG 978870 mOl s;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaTs;om

eAs;lnaCs-Sup

CD274-43 ACAAGCGAATTACTG lnaAs;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaG 978872 mOl s;omeAs;lnaAs;omeUs;lnaTs;omeAs;lnaCs;om

eUs;lnaGs-Sup

CD274-44 GCGAATTACTGTGAA lnaGs;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaT 978876 mOl s;omeAs;lnaCs;omeUs;lnaGs;omeUs;lnaGs;o

meAs;lnaAs-Sup

CD274-45 AAGTCAATGGTAAGA lnaAs;omeAs;lnaGs;omeUs;lnaCs;omeAs;lnaA 978890 mOl s;omeUs;lnaGs;omeGs;lnaTs;omeAs;lnaAs;o meGs;lnaAs-Sup

CD274-46 AGTCAATGGTAAGAA lnaAs;omeGs;lnaTs;omeCs;lnaAs;omeAs;lnaTs 978891 mOl ;omeGs;lnaGs;omeUs;lnaAs;omeAs;lnaGs;om

eAs;lnaAs-Sup

CD274-47 GTCAATGGTAAGAAT lnaGs;omeUs;lnaCs;omeAs;lnaAs;omeUs;lnaG 978892 mOl s;omeGs;lnaTs;omeAs;lnaAs;omeGs;lnaAs;om

eAs;lnaTs-Sup

CD274-48 GGAAGTAGAACTCCT lnaGs;omeGs;lnaAs;omeAs;lnaGs;omeUs;lnaA 981172 mOl s;omeGs;lnaAs;omeAs;lnaCs;omeUs;lnaCs;om

eCs;lnaTs-Sup

CD274-49 TCAATGTGACCAGCA lnaTs;omeCs;lnaAs;omeAs;lnaTs;omeGs;lnaTs 981174 mOl ;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaGs;om

eCs;lnaAs-Sup

CD274-50 ATCACTCTCCAGATA lnaAs;omeUs;lnaCs;omeAs;lnaCs;omeUs;lnaC 981176 mOl s;omeUs;lnaCs;omeCs;lnaAs;omeGs;lnaAs;om

eUs;lnaAs-Sup

CD274-01 ACTTAGATGCTGCAG lnaAs;omeCs;lnaTs;omeUs;lnaAs;omeGs;lnaA 968788 m04 s;omeUs;lnaGs;omeCs;lnaTs;omeGs;lnaCs;om

eAs;lnaGs

eAs;lnaG-Sup

CD274-02 GACTTACTTAGATGC lnaGs;omeAs;lnaCs;omeUs;lnaTs;omeAs;lnaC 968793 m04 s;omeUs;lnaTs;omeAs;lnaGs;omeAs;lnaTs;om

eGs;lnaCs

eGs;lnaC-Sup

CD274-03 GAAGAGACTTACTTA lnaGs;omeAs;lnaAs;omeGs;lnaAs;omeGs;lnaA 968798 m04 s;omeCs;lnaTs;omeUs;lnaAs;omeCs;lnaTs;om

eUs;lnaAs

eUs;lnaA-Sup

CD274-04 GCGCAGGAAGAGACT lnaGs;omeCs;lnaGs;omeCs;lnaAs;omeGs;lnaG 968804 m04 s;omeAs;lnaAs;omeGs;lnaAs;omeGs;lnaAs;o

meCs;lnaTs

meCs;lnaT-Sup

CD274-05 TAGCGCAGGAAGAGA lnaTs;omeAs;lnaGs;omeCs;lnaGs;omeCs;lnaA 968806 m04 s;omeGs;lnaGs;omeAs;lnaAs;omeGs;lnaAs;o

meGs;lnaAs

meGs;lnaA-Sup CD274-06 TTAGCGCAGGAAGAG lnaTs;omeUs;lnaAs;omeGs;lnaCs;omeGs;lnaC 968807 m04 s;omeAs;lnaGs;omeGs;lnaAs;omeAs;lnaGs;o

meAs;lnaGs

meAs;lnaG-Sup

CD274-07 CTTAGCGCAGGAAGA lnaCs;omeUs;lnaTs;omeAs;lnaGs;omeCs;lnaG 968808 m04 s;omeCs;lnaAs;omeGs;lnaGs;omeAs;lnaAs;om

eGs;lnaAs

eGs;lnaA-Sup

CD274-08 TAGGAGTAATAAAGG lnaTs;omeAs;lnaGs;omeGs;lnaAs;omeGs;lnaT 970534 m04 s;omeAs;lnaAs;omeUs;lnaAs;omeAs;lnaAs;om

eGs;lnaGs

eGs;lnaG-Sup

CD274-09 CTGGTGGAGTTCTTG lnaCs;omeUs;lnaGs;omeGs;lnaTs;omeGs;lnaG 970576 m04 s;omeAs;lnaGs;omeUs;lnaTs;omeCs;lnaTs;om

eUs;lnaGs

eUs;lnaG-Sup

CD274-10 ATG G CCT ACTCTG GT lnaAs;omeUs;lnaGs;omeGs;lnaCs;omeCs;lnaT 970586 m04 s;omeAs;lnaCs;omeUs;lnaCs;omeUs;lnaGs;o

meGs;lnaTs

meGs;lnaT-Sup

CD274-11 TATG G CCT ACTCTG G lnaTs;omeAs;lnaTs;omeGs;lnaGs;omeCs;lnaCs 970587 m04 ;omeUs;lnaAs;omeCs;lnaTs;omeCs;lnaTs;ome

Gs;lnaGs

Gs;lnaG-Sup

CD274-12 GTTTATGGCCTACTC lnaGs;omeUs;lnaTs;omeUs;lnaAs;omeUs;lnaG 970590 m04 s;omeGs;lnaCs;omeCs;lnaTs;omeAs;lnaCs;om

eUs;lnaCs

eUs;lnaC-Sup

CD274-13 CC A ATGTTT ATG G CC lnaCs;omeCs;lnaAs;omeAs;lnaTs;omeGs;lnaTs 970595 m04 ;omeUs;lnaTs;omeAs;lnaTs;omeGs;lnaGs;om

eCs;lnaCs

CD274-13 CC A ATGTTT ATG G CC lnaCs;omeCs;lnaAs;omeAs;lnaTs;omeGs;lnaTs 970595 mOl ;omeUs;lnaTs;omeAs;lnaTs;omeGs;lnaGs;om eCs;lnaC-Sup

CD274-14 AGCAAATATCCTCAT lnaAs;omeGs;lnaCs;omeAs;lnaAs;omeAs;lnaT 981164 m04 s;omeAs;lnaTs;omeCs;lnaCs;omeUs;lnaCs;om

eAs;lnaTs

eAs;lnaT-Sup

CD274-15 TA ATTCG CTTGT AGT lnaTs;omeAs;lnaAs;omeUs;lnaTs;omeCs;lnaG 981166 m04 s;omeCs;lnaTs;omeUs;lnaGs;omeUs;lnaAs;om

eGs;lnaTs

eGs;lnaT-Sup

CD274-16 CTTACCATTGACTTT lnaCs;omeUs;lnaTs;omeAs;lnaCs;omeCs;lnaAs 981168 m04 ;omeUs;lnaTs;omeGs;lnaAs;omeCs;lnaTs;ome

Us;lnaTs

Us;lnaT-Sup

CD274-17 CAGGAGTTCTACTTC lnaCs;omeAs;lnaGs;omeGs;lnaAs;omeGs;lnaT 981170 m04 s;omeUs;lnaCs;omeUs;lnaAs;omeCs;lnaTs;om

eUs;lnaCs

eUs;lnaC-Sup

CD274-18 GGTATACTTCTCTAA lnaGs;omeGs;lnaTs;omeAs;lnaTs;omeAs;lnaC 974685 m04 s;omeUs;lnaTs;omeCs;lnaTs;omeCs;lnaTs;om

eAs;lnaAs

eAs;lnaA-Sup

CD274-19 CTCTATACCATCACT lnaCs;omeUs;lnaCs;omeUs;lnaAs;omeUs;lnaA 974709 m04 s;omeCs;lnaCs;omeAs;lnaTs;omeCs;lnaAs;om

eCs;lnaTs

eCs;lnaT-Sup

CD274-20 GAATCCCCTTCCATA lnaGs;omeAs;lnaAs;omeUs;lnaCs;omeCs;lnaC 974752 m04 s;omeCs;lnaTs;omeUs;lnaCs;omeCs;lnaAs;om

eUs;lnaAs

eUs;lnaA-Sup

CD274-21 CGACTATTGGAATCC lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaTs 974761 m04 ;omeUs;lnaGs;omeGs;lnaAs;omeAs;lnaTs;om

eCs;lnaCs CD274-21 CGACTATTGGAATCC lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaTs 974761 mOl ;omeUs;lnaGs;omeGs;lnaAs;omeAs;lnaTs;om

eCs;lnaC-Sup

CD274-22 ACGACTATTGGAATC lnaAs;omeCs;lnaGs;omeAs;lnaCs;omeUs;lnaA 974762 m04 s;omeUs;lnaTs;omeGs;lnaGs;omeAs;lnaAs;o

meUs;lnaCs

meUs;lnaC-Sup

CD274-23 AACGACTATTGGAAT lnaAs;omeAs;lnaCs;omeGs;lnaAs;omeCs;lnaT 974763 m04 s;omeAs;lnaTs;omeUs;lnaGs;omeGs;lnaAs;o

meAs;lnaTs

meAs;lnaT-Sup

CD274-24 CAACGACTATTGGAA lnaCs;omeAs;lnaAs;omeCs;lnaGs;omeAs;lnaC 974764 m04 s;omeUs;lnaAs;omeUs;lnaTs;omeGs;lnaGs;o

meAs;lnaAs

meAs;lnaA-Sup

CD274-25 TCAACGACTATTGGA lnaTs;omeCs;lnaAs;omeAs;lnaCs;omeGs;lnaA 974765 m04 s;omeCs;lnaTs;omeAs;lnaTs;omeUs;lnaGs;om

eGs;lnaAs

eGs;lnaA-Sup

CD274-26 TTTCAACGACTATTG lnaTs;omeUs;lnaTs;omeCs;lnaAs;omeAs;lnaCs 974767 m04 ;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaTs;ome

Us;lnaGs

Us;lnaG-Sup

CD274-27 A l l l l 1 LAALGAL 1 A lnaAs;omeUs;lnaTs;omeUs;lnaTs;omeUs;lnaC 974770 m04 s;omeAs;lnaAs;omeCs;lnaGs;omeAs;lnaCs;om

eUs;lnaAs

eUs;lnaA-Sup

CD274-28 AA I 1 1 1 1 LAALGAL 1 lnaAs;omeAs;lnaTs;omeUs;lnaTs;omeUs;lnaTs 974771 m04 ;omeCs;lnaAs;omeAs;lnaCs;omeGs;lnaAs;ome

Cs;lnaTs

Cs;lnaT-Sup

CD274-29 GGAATTTTTCAACGA lnaGs;omeGs;lnaAs;omeAs;lnaTs;omeUs;lnaT 974773 m04 s;omeUs;lnaTs;omeCs;lnaAs;omeAs;lnaCs;om eGs;lnaAs

eGs;lnaA-Sup

CD274-30 GTATCTGGAGAGTGA lnaGs;omeUs;lnaAs;omeUs;lnaCs;omeUs;lna 976344 m04 Gs;omeGs;lnaAs;omeGs;lnaAs;omeGs;lnaTs;o

meGs;lnaAs

CD274-30 GTATCTGGAGAGTGA lnaGs;omeUs;lnaAs;omeUs;lnaCs;omeUs;lna 976344 mOl Gs;omeGs;lnaAs;omeGs;lnaAs;omeGs;lnaTs;o

meGs;lnaA-Sup

CD274-31 TGTATCTGGAGAGTG lnaTs;omeGs;lnaTs;omeAs;lnaTs;omeCs;lnaTs 976345 m04 ;omeGs;lnaGs;omeAs;lnaGs;omeAs;lnaGs;om

eUs;lnaGs

eUs;lnaG-Sup

CD274-32 GTGTATCTGGAGAGT lnaGs;omeUs;lnaGs;omeUs;lnaAs;omeUs;lna 976346 m04 Cs;omeUs;lnaGs;omeGs;lnaAs;omeGs;lnaAs;o

meGs;lnaTs

meGs;lnaT-Sup

CD274-33 TGAGGATATTTGCTG lnaTs;omeGs;lnaAs;omeGs;lnaGs;omeAs;lnaT 977593 m04 s;omeAs;lnaTs;omeUs;lnaTs;omeGs;lnaCs;om

eUs;lnaGs

eUs;lnaG-Sup

CD274-34 GTGTACCGCTGCATG lnaGs;omeUs;lnaGs;omeUs;lnaAs;omeCs;lnaC 978835 m04 s;omeGs;lnaCs;omeUs;lnaGs;omeCs;lnaAs;o

meUs;lnaGs

meUs;lnaG-Sup

CD274-35 TGTACCGCTGCATGA lnaTs;omeGs;lnaTs;omeAs;lnaCs;omeCs;lnaGs 978836 m04 ;omeCs;lnaTs;omeGs;lnaCs;omeAs;lnaTs;ome

Gs;lnaAs

Gs;lnaA-Sup

CD274-36 CCGCTGCATGATCAG lnaCs;omeCs;lnaGs;omeCs;lnaTs;omeGs;lnaCs 978840 m04 ;omeAs;lnaTs;omeGs;lnaAs;omeUs;lnaCs;om

eAs;lnaGs

eAs;lnaG-Sup CD274-37 GGTGGTGCCGACTAC lnaGs;omeGs;lnaTs;omeGs;lnaGs;omeUs;lnaG 978859 m04 s;omeCs;lnaCs;omeGs;lnaAs;omeCs;lnaTs;om

eAs;lnaCs

eAs;lnaC-Sup

CD274-38 GCCGACTACAAGCGA lnaGs;omeCs;lnaCs;omeGs;lnaAs;omeCs;lnaT 978865 m04 s;omeAs;lnaCs;omeAs;lnaAs;omeGs;lnaCs;om

eGs;lnaAs

eGs;lnaA-Sup

CD274-39 CCGACTACAAGCGAA lnaCs;omeCs;lnaGs;omeAs;lnaCs;omeUs;lnaA 978866 m04 s;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaGs;om

eAs;lnaAs

eAs;lnaA-Sup

CD274-40 CGACTACAAGCGAAT lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaCs 978867 m04 ;omeAs;lnaAs;omeGs;lnaCs;omeGs;lnaAs;om

eAs;lnaTs

eAs;lnaT-Sup

CD274-41 GACTACAAGCGAATT lnaGs;omeAs;lnaCs;omeUs;lnaAs;omeCs;lnaA 978868 m04 s;omeAs;lnaGs;omeCs;lnaGs;omeAs;lnaAs;om

eUs;lnaTs

eUs;lnaT-Sup

CD274-42 CTACAAGCGAATTAC lnaCs;omeUs;lnaAs;omeCs;lnaAs;omeAs;lnaG 978870 m04 s;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaTs;om

eAs;lnaCs

eAs;lnaC-Sup

CD274-43 ACAAGCGAATTACTG lnaAs;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaG 978872 m04 s;omeAs;lnaAs;omeUs;lnaTs;omeAs;lnaCs;om

eUs;lnaGs

eUs;lnaG-Sup

CD274-44 GCGAATTACTGTGAA lnaGs;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaT 978876 m04 s;omeAs;lnaCs;omeUs;lnaGs;omeUs;lnaGs;o

meAs;lnaAs

CD274-44 GCGAATTACTGTGAA lnaGs;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaT 978876 mOl s;omeAs;lnaCs;omeUs;lnaGs;omeUs;lnaGs;o meAs;lnaA-Sup

CD274-45 AAGTCAATGGTAAGA lnaAs;omeAs;lnaGs;omeUs;lnaCs;omeAs;lnaA 978890 m04 s;omeUs;lnaGs;omeGs;lnaTs;omeAs;lnaAs;o

meGs;lnaAs

CD274-45 AAGTCAATGGTAAGA lnaAs;omeAs;lnaGs;omeUs;lnaCs;omeAs;lnaA 978890 mOl s;omeUs;lnaGs;omeGs;lnaTs;omeAs;lnaAs;o

meGs;lnaA-Sup

CD274-46 AGTCAATGGTAAGAA lnaAs;omeGs;lnaTs;omeCs;lnaAs;omeAs;lnaTs 978891 m04 ;omeGs;lnaGs;omeUs;lnaAs;omeAs;lnaGs;om

eAs;lnaAs

eAs;lnaA-Sup

CD274-47 GTCAATGGTAAGAAT lnaGs;omeUs;lnaCs;omeAs;lnaAs;omeUs;lnaG 978892 m04 s;omeGs;lnaTs;omeAs;lnaAs;omeGs;lnaAs;om

eAs;lnaTs

eAs;lnaT-Sup

CD274-48 GGAAGTAGAACTCCT lnaGs;omeGs;lnaAs;omeAs;lnaGs;omeUs;lnaA 981172 m04 s;omeGs;lnaAs;omeAs;lnaCs;omeUs;lnaCs;om

eCs;lnaTs

eCs;lnaT-Sup

CD274-49 TCAATGTGACCAGCA lnaTs;omeCs;lnaAs;omeAs;lnaTs;omeGs;lnaTs 981174 m04 ;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaGs;om

eCs;lnaAs

eCs;lnaA-Sup

CD274-50 ATCACTCTCCAGATA lnaAs;omeUs;lnaCs;omeAs;lnaCs;omeUs;lnaC 981176 m04 s;omeUs;lnaCs;omeCs;lnaAs;omeGs;lnaAs;om

eUs;lnaAs

CD274-50 ATCACTCTCCAGATA lnaAs;omeUs;lnaCs;omeAs;lnaCs;omeUs;lnaC 981176 m05 s;omeUs;lnaCs;omeCs;lnaAs;omeGs;lnaAs;om

+bios eUs;lnaA-Sup

CEP290- GGCGGTTCCGCCAGG lnaGs;omeGs;lnaCs;omeGs;lnaGs;omeUs;lnaT 954316

01 mOl s;omeCs;lnaCs;omeGs;lnaCs;omeCs;lnaAs;om

eGs;lnaG-Sup

CEP290- GCTGCTAGGCGACAC lnaGs;omeCs;lnaTs;omeGs;lnaCs;omeUs;lnaA 902370

02 mOl s;omeGs;lnaGs;omeCs;lnaGs;omeAs;lnaCs;om

eAs;lnaC-Sup

CEP290- GGCTGCTAGGCGACA lnaGs;omeGs;lnaCs;omeUs;lnaGs;omeCs;lnaT 902371

03 mOl s;omeAs;lnaGs;omeGs;lnaCs;omeGs;lnaAs;o

meCs;lnaA-Sup CEP290- GCGGCTGCTAGGCGA lnaGs;omeCs;lnaGs;omeGs;lnaCs;omeUs;lnaG 902373

04 mOl s;omeCs;lnaTs;omeAs;lnaGs;omeGs;lnaCs;om

eGs;lnaA-Sup

CEP290- CGTAAAAACCGAGTA lnaCs;omeGs;lnaTs;omeAs;lnaAs;omeAs;lnaA 907318

05 mOl s;omeAs;lnaCs;omeCs;lnaGs;omeAs;lnaGs;om

eUs;lnaA-Sup

CEP290- ACGTAAAAACCGAGT lnaAs;omeCs;lnaGs;omeUs;lnaAs;omeAs;lnaA 907319

06 mOl s;omeAs;lnaAs;omeCs;lnaCs;omeGs;lnaAs;om

eGs;lnaT-Sup

CEP290- TACGTAAAAACCGAG lnaTs;omeAs;lnaCs;omeGs;lnaTs;omeAs;lnaAs 907320

07 mOl ;omeAs;lnaAs;omeAs;lnaCs;omeCs;lnaGs;ome

As;lnaG-Sup

CEP290- TTACGTAAAAACCGA lnaTs;omeUs;lnaAs;omeCs;lnaGs;omeUs;lnaA 907321

08 mOl s;omeAs;lnaAs;omeAs;lnaAs;omeCs;lnaCs;om

eGs;lnaA-Sup

CEP290- TACTTGATACCAATC lnaTs;omeAs;lnaCs;omeUs;lnaTs;omeGs;lnaA 907712

09 mOl s;omeUs;lnaAs;omeCs;lnaCs;omeAs;lnaAs;om

eUs;lnaC-Sup

CEP290- TCGAAGAGCCAACTA lnaTs;omeCs;lnaGs;omeAs;lnaAs;omeGs;lnaA 910029

10 mOl s;omeGs;lnaCs;omeCs;lnaAs;omeAs;lnaCs;om

eUs;lnaA-Sup

CEP290- ATTTCGAAGAGCCAA lnaAs;omeUs;lnaTs;omeUs;lnaCs;omeGs;lnaA 910032

11 mOl s;omeAs;lnaGs;omeAs;lnaGs;omeCs;lnaCs;om

eAs;lnaA-Sup

CEP290- CCTCATTTCGAAGAG lnaCs;omeCs;lnaTs;omeCs;lnaAs;omeUs;lnaTs 910036

12 mOl ;omeUs;lnaCs;omeGs;lnaAs;omeAs;lnaGs;om

eAs;lnaG-Sup

CEP290- TCCTCATTTCGAAGA lnaTs;omeCs;lnaCs;omeUs;lnaCs;omeAs;lnaTs 910037

13 mOl ;omeUs;lnaTs;omeCs;lnaGs;omeAs;lnaAs;om

eGs;lnaA-Sup

CEP290- CTCCTCATTTCGAAG lnaCs;omeUs;lnaCs;omeCs;lnaTs;omeCs;lnaAs 910038

14 mOl ;omeUs;lnaTs;omeUs;lnaCs;omeGs;lnaAs;om

eAs;lnaG-Sup

CEP290- CCTCCTCATTTCGAA lnaCs;omeCs;lnaTs;omeCs;lnaCs;omeUs;lnaCs 910039

15 mOl ;omeAs;lnaTs;omeUs;lnaTs;omeCs;lnaGs;ome

As;lnaA-Sup

CEP290- TGCCTCCTCATTTCG lnaTs;omeGs;lnaCs;omeCs;lnaTs;omeCs;lnaCs 910041

16 mOl ;omeUs;lnaCs;omeAs;lnaTs;omeUs;lnaTs;ome

Cs;lnaG-Sup

CEP290- AGACGTTTGTTCTAC lnaAs;omeGs;lnaAs;omeCs;lnaGs;omeUs;lnaT 910681

17 mOl s;omeUs;lnaGs;omeUs;lnaTs;omeCs;lnaTs;om

eAs;lnaC-Sup

CEP290- TTTAGACGTTTGTTC lnaTs;omeUs;lnaTs;omeAs;lnaGs;omeAs;lnaC 910684

18 mOl s;omeGs;lnaTs;omeUs;lnaTs;omeGs;lnaTs;om

eUs;lnaC-Sup

CEP290- CG GTAGTC ACTGTCT lnaCs;omeGs;lnaGs;omeUs;lnaAs;omeGs;lnaT 910913

19 mOl s;omeCs;lnaAs;omeCs;lnaTs;omeGs;lnaTs;om eCs;lnaT-Sup

CEP290- TCG GT AGTC ACTGTC lnaTs;omeCs;lnaGs;omeGs;lnaTs;omeAs;lnaG 910914

20 mOl s;omeUs;lnaCs;omeAs;lnaCs;omeUs;lnaGs;o

meUs;lnaC-Sup

CEP290- GATCGGTAGTCACTG lnaGs;omeAs;lnaTs;omeCs;lnaGs;omeGs;lnaT 910916

21 mOl s;omeAs;lnaGs;omeUs;lnaCs;omeAs;lnaCs;om

eUs;lnaG-Sup

CEP290- TGATCGGTAGTCACT lnaTs;omeGs;lnaAs;omeUs;lnaCs;omeGs;lnaG 910917

22 mOl s;omeUs;lnaAs;omeGs;lnaTs;omeCs;lnaAs;om

eCs;lnaT-Sup

CEP290- GTGATCGGTAGTCAC lnaGs;omeUs;lnaGs;omeAs;lnaTs;omeCs;lnaG 910918

23 mOl s;omeGs;lnaTs;omeAs;lnaGs;omeUs;lnaCs;om

eAs;lnaC-Sup

CEP290- TGTGATCGGTAGTCA lnaTs;omeGs;lnaTs;omeGs;lnaAs;omeUs;lnaC 910919

24 mOl s;omeGs;lnaGs;omeUs;lnaAs;omeGs;lnaTs;o

meCs;lnaA-Sup

CEP290- CTGTGATCGGTAGTC lnaCs;omeUs;lnaGs;omeUs;lnaGs;omeAs;lnaT 910920

25 mOl s;omeCs;lnaGs;omeGs;lnaTs;omeAs;lnaGs;om

eUs;lnaC-Sup

CEP290- CAACTGTGATCGGTA lnaCs;omeAs;lnaAs;omeCs;lnaTs;omeGs;lnaTs 910923

26 mOl ;omeGs;lnaAs;omeUs;lnaCs;omeGs;lnaGs;om

eUs;lnaA-Sup

CEP290- AC A ACTGTG ATCG GT lnaAs;omeCs;lnaAs;omeAs;lnaCs;omeUs;lnaG 910924

27 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeCs;lnaGs;om

eGs;lnaT-Sup

CEP290- GACAACTGTGATCGG lnaGs;omeAs;lnaCs;omeAs;lnaAs;omeCs;lnaT 910925

28 mOl s;omeGs;lnaTs;omeGs;lnaAs;omeUs;lnaCs;om

eGs;lnaG-Sup

CEP290- GCCATTTGACGAATT lnaGs;omeCs;lnaCs;omeAs;lnaTs;omeUs;lnaTs 917988

29 mOl ;omeGs;lnaAs;omeCs;lnaGs;omeAs;lnaAs;om

eUs;lnaT-Sup

CEP290- AGCCATTTGACGAAT lnaAs;omeGs;lnaCs;omeCs;lnaAs;omeUs;lnaT 917989

30 mOl s;omeUs;lnaGs;omeAs;lnaCs;omeGs;lnaAs;o

meAs;lnaT-Sup

CEP290- TGAGCCATTTGACGA lnaTs;omeGs;lnaAs;omeGs;lnaCs;omeCs;lnaA 917991

31 mOl s;omeUs;lnaTs;omeUs;lnaGs;omeAs;lnaCs;om

eGs;lnaA-Sup

CEP290- TTGAGCCATTTGACG lnaTs;omeUs;lnaGs;omeAs;lnaGs;omeCs;lnaC 917992

32 mOl s;omeAs;lnaTs;omeUs;lnaTs;omeGs;lnaAs;om

eCs;lnaG-Sup

CEP290- CGAATCCATCTGAAG lnaCs;omeGs;lnaAs;omeAs;lnaTs;omeCs;lnaCs 921640

33 mOl ;omeAs;lnaTs;omeCs;lnaTs;omeGs;lnaAs;ome

As;lnaG-Sup

CEP290- CCGAATCCATCTGAA lnaCs;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaC 921641

34 mOl s;omeCs;lnaAs;omeUs;lnaCs;omeUs;lnaGs;o

meAs;lnaA-Sup CEP290- TCCGAATCCATCTGA lnaTs;omeCs;lnaCs;omeGs;lnaAs;omeAs;lnaTs 921642

35 mOl ;omeCs;lnaCs;omeAs;lnaTs;omeCs;lnaTs;ome

Gs;lnaA-Sup

CEP290- GTAACTTGGAACACC lnaGs;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaT 956697

36 mOl s;omeGs;lnaGs;omeAs;lnaAs;omeCs;lnaAs;om

eCs;lnaC-Sup

CEP290- CCAGTTGATTACCTA lnaCs;omeCs;lnaAs;omeGs;lnaTs;omeUs;lnaG 924441

37 mOl s;omeAs;lnaTs;omeUs;lnaAs;omeCs;lnaCs;om

eUs;lnaA-Sup

CEP290- ACGAAGTTCTTCTAT lnaAs;omeCs;lnaGs;omeAs;lnaAs;omeGs;lnaT 924465

38 mOl s;omeUs;lnaCs;omeUs;lnaTs;omeCs;lnaTs;om

eAs;lnaT-Sup

CEP290- GACGAAGTTCTTCTA lnaGs;omeAs;lnaCs;omeGs;lnaAs;omeAs;lnaG 924466

39 mOl s;omeUs;lnaTs;omeCs;lnaTs;omeUs;lnaCs;om

eUs;lnaA-Sup

CEP290- I ALL I 1 1 I G I GLLGL lnaTs;omeAs;lnaCs;omeCs;lnaTs;omeUs;lnaTs 925830

40 mOl ;omeUs;lnaGs;omeUs;lnaGs;omeCs;lnaCs;om

eGs;lnaC-Sup

CEP290- ATCGAAGCCTCAGTT lnaAs;omeUs;lnaCs;omeGs;lnaAs;omeAs;lnaG 927453

41 mOl s;omeCs;lnaCs;omeUs;lnaCs;omeAs;lnaGs;om

eUs;lnaT-Sup

CEP290- AATCGAAGCCTCAGT lnaAs;omeAs;lnaTs;omeCs;lnaGs;omeAs;lnaA 927454

42 mOl s;omeGs;lnaCs;omeCs;lnaTs;omeCs;lnaAs;om

eGs;lnaT-Sup

CEP290- CAATCGAAGCCTCAG lnaCs;omeAs;lnaAs;omeUs;lnaCs;omeGs;lnaA 927455

43 mOl s;omeAs;lnaGs;omeCs;lnaCs;omeUs;lnaCs;om

eAs;lnaG-Sup

CEP290- GCAATCGAAGCCTCA lnaGs;omeCs;lnaAs;omeAs;lnaTs;omeCs;lnaG 927456

44 mOl s;omeAs;lnaAs;omeGs;lnaCs;omeCs;lnaTs;om

eCs;lnaA-Sup

CEP290- GTGGCAGGCAATCGA lnaGs;omeUs;lnaGs;omeGs;lnaCs;omeAs;lnaG 927463

45 mOl s;omeGs;lnaCs;omeAs;lnaAs;omeUs;lnaCs;om

eGs;lnaA-Sup

CEP290- CCAGACGAATAAAAT lnaCs;omeCs;lnaAs;omeGs;lnaAs;omeCs;lnaG 929045

46 mOl s;omeAs;lnaAs;omeUs;lnaAs;omeAs;lnaAs;om

eAs;lnaT-Sup

CEP290- GCCAGACGAATAAAA lnaGs;omeCs;lnaCs;omeAs;lnaGs;omeAs;lnaC 929046

47 mOl s;omeGs;lnaAs;omeAs;lnaTs;omeAs;lnaAs;om

eAs;lnaA-Sup

CEP290- TCTCAGCCAGACGAA lnaTs;omeCs;lnaTs;omeCs;lnaAs;omeGs;lnaCs 929051

48 mOl ;omeCs;lnaAs;omeGs;lnaAs;omeCs;lnaGs;om

eAs;lnaA-Sup

CEP290- TTGGCTCTTTAGCCG lnaTs;omeUs;lnaGs;omeGs;lnaCs;omeUs;lnaC 931917

49 mOl s;omeUs;lnaTs;omeUs;lnaAs;omeGs;lnaCs;om

eCs;lnaG-Sup

CEP290- CGACTAAGTGCCTAA lnaCs;omeGs;lnaAs;omeCs;lnaTs;omeAs;lnaA 932905

50 mOl s;omeGs;lnaTs;omeGs;lnaCs;omeCs;lnaTs;om eAs;lnaA-Sup

CEP290- CCGACTAAGTGCCTA lnaCs;omeCs;lnaGs;omeAs;lnaCs;omeUs;lnaA 932906

51 mOl s;omeAs;lnaGs;omeUs;lnaGs;omeCs;lnaCs;o

meUs;lnaA-Sup

CEP290- CCCGACTAAGTGCCT lnaCs;omeCs;lnaCs;omeGs;lnaAs;omeCs;lnaTs 932907

52 mOl ;omeAs;lnaAs;omeGs;lnaTs;omeGs;lnaCs;om

eCs;lnaT-Sup

CEP290- GCCCGACTAAGTGCC lnaGs;omeCs;lnaCs;omeCs;lnaGs;omeAs;lnaC 932908

53 mOl s;omeUs;lnaAs;omeAs;lnaGs;omeUs;lnaGs;o

meCs;lnaC-Sup

CEP290- TAG CTCTCT AGT ATG lnaTs;omeAs;lnaGs;omeCs;lnaTs;omeCs;lnaTs 933029

54 mOl ;omeCs;lnaTs;omeAs;lnaGs;omeUs;lnaAs;om

eUs;lnaG-Sup

CEP290- TCTTTATCGGCTCTG lnaTs;omeCs;lnaTs;omeUs;lnaTs;omeAs;lnaTs 936226

55 mOl ;omeCs;lnaGs;omeGs;lnaCs;omeUs;lnaCs;om

eUs;lnaG-Sup

CEP290- GTTTCTCTTT ATCG G lnaGs;omeUs;lnaTs;omeUs;lnaCs;omeUs;lnaC 936231

56 mOl s;omeUs;lnaTs;omeUs;lnaAs;omeUs;lnaCs;om

eGs;lnaG-Sup

CEP290- TTCTGTTTCG CTC AT lnaTs;omeUs;lnaCs;omeUs;lnaGs;omeUs;lnaT 959197

57 mOl s;omeUs;lnaCs;omeGs;lnaCs;omeUs;lnaCs;om

eAs;lnaT-Sup

CEP290- TCGAGATTCTGTTGT lnaTs;omeCs;lnaGs;omeAs;lnaGs;omeAs;lnaT 960537

58 mOl s;omeUs;lnaCs;omeUs;lnaGs;omeUs;lnaTs;o

meGs;lnaT-Sup

PAH-31 GAGATATGTGTACTT lnaGs;omeAs;lnaGs;omeAs;lnaTs;omeAs;lnaT 887554 mOl s;omeGs;lnaTs;omeGs;lnaTs;omeAs;lnaCs;om

eUs;lnaT-Sup

PAH-32 AGATATGTGTACTTG lnaAs;omeGs;lnaAs;omeUs;lnaAs;omeUs;lnaG 887553 mOl s;omeUs;lnaGs;omeUs;lnaAs;omeCs;lnaTs;om

eUs;lnaG-Sup

PAH-33 TATGTGTACTTG C A A lnaTs;omeAs;lnaTs;omeGs;lnaTs;omeGs;lnaTs 887550 mOl ;omeAs;lnaCs;omeUs;lnaTs;omeGs;lnaCs;ome

As;lnaA-Sup

PAH-34 TGTACTTGCAATTCC lnaTs;omeGs;lnaTs;omeAs;lnaCs;omeUs;lnaTs 887546 mOl ;omeGs;lnaCs;omeAs;lnaAs;omeUs;lnaTs;om

eCs;lnaC-Sup

PAH-35 TCCATTTCTATCTGT lnaTs;omeCs;lnaCs;omeAs;lnaTs;omeUs;lnaTs 887534 mOl ;omeCs;lnaTs;omeAs;lnaTs;omeCs;lnaTs;ome

Gs;lnaT-Sup

PAH-36 AATAACTGACAGTTC lnaAs;omeAs;lnaTs;omeAs;lnaAs;omeCs;lnaTs 886159 mOl ;omeGs;lnaAs;omeCs;lnaAs;omeGs;lnaTs;om

eUs;lnaC-Sup

PAH-37 TGACAGTTCAATATG lnaTs;omeGs;lnaAs;omeCs;lnaAs;omeGs;lnaT 886153 mOl s;omeUs;lnaCs;omeAs;lnaAs;omeUs;lnaAs;o

meUs;lnaG-Sup PAH-38 ATGTCCTAGAGAGTT lnaAs;omeUs;lnaGs;omeUs;lnaCs;omeCs;lnaT 886141 mOl s;omeAs;lnaGs;omeAs;lnaGs;omeAs;lnaGs;o

meUs;lnaT-Sup

PAH-39 TCCTAGAGAGTTGGC lnaTs;omeCs;lnaCs;omeUs;lnaAs;omeGs;lnaA 886138 mOl s;omeGs;lnaAs;omeGs;lnaTs;omeUs;lnaGs;o

meGs;lnaC-Sup

PAH-40 TTTAGAGTGAACCAA lnaTs;omeUs;lnaTs;omeAs;lnaGs;omeAs;lnaG 882457 mOl s;omeUs;lnaGs;omeAs;lnaAs;omeCs;lnaCs;om

eAs;lnaA-Sup

PAH-41 TAGAGTGAACCAAAT lnaTs;omeAs;lnaGs;omeAs;lnaGs;omeUs;lnaG 882455 mOl s;omeAs;lnaAs;omeCs;lnaCs;omeAs;lnaAs;om

eAs;lnaT-Sup

PAH-42 GTGAACCAAATTCAA lnaGs;omeUs;lnaGs;omeAs;lnaAs;omeCs;lnaC 882451 mOl s;omeAs;lnaAs;omeAs;lnaTs;omeUs;lnaCs;om

eAs;lnaA-Sup

PAH-43 AACCAAATTCAAATT lnaAs;omeAs;lnaCs;omeCs;lnaAs;omeAs;lnaA 882448 mOl s;omeUs;lnaTs;omeCs;lnaAs;omeAs;lnaAs;om

eUs;lnaT-Sup

PAH-44 ACCAAATTCAAATTC lnaAs;omeCs;lnaCs;omeAs;lnaAs;omeAs;lnaTs 882447 mOl ;omeUs;lnaCs;omeAs;lnaAs;omeAs;lnaTs;ome

Us;lnaC-Sup

PAH-45 C A AATTCTT AG CCTG lnaCs;omeAs;lnaAs;omeAs;lnaTs;omeUs;lnaC 882439 mOl s;omeUs;lnaTs;omeAs;lnaGs;omeCs;lnaCs;om

eUs;lnaG-Sup

PAH-46 CCCCCTGCAGTTGGC lnaCs;omeCs;lnaCs;omeCs;lnaCs;omeUs;lnaG 879091 mOl s;omeCs;lnaAs;omeGs;lnaTs;omeUs;lnaGs;om

eGs;lnaC-Sup

PAH-47 TGCAGTTGGCAGAGT lnaTs;omeGs;lnaCs;omeAs;lnaGs;omeUs;lnaT 879086 mOl s;omeGs;lnaGs;omeCs;lnaAs;omeGs;lnaAs;o

meGs;lnaT-Sup

PAH-48 CAGAGTTGTTAGTAC lnaCs;omeAs;lnaGs;omeAs;lnaGs;omeUs;lnaT 879077 mOl s;omeGs;lnaTs;omeUs;lnaAs;omeGs;lnaTs;om

eAs;lnaC-Sup

PAH-49 TGTTTACCAAGCACT lnaTs;omeGs;lnaTs;omeUs;lnaTs;omeAs;lnaCs 879055 mOl ;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaAs;ome

Cs;lnaT-Sup

PAH-50 CCAAGCACTTGACTT lnaCs;omeCs;lnaAs;omeAs;lnaGs;omeCs;lnaA 879049 mOl s;omeCs;lnaTs;omeUs;lnaGs;omeAs;lnaCs;om

eUs;lnaT-Sup

PAH-51 CTTGACTTAAACCTC lnaCs;omeUs;lnaTs;omeGs;lnaAs;omeCs;lnaTs 879042 mOl ;omeUs;lnaAs;omeAs;lnaAs;omeCs;lnaCs;om

eUs;lnaC-Sup

PAH-52 GCAAAGCCAGTTAGA lnaGs;omeCs;lnaAs;omeAs;lnaAs;omeGs;lnaC 877935 mOl s;omeCs;lnaAs;omeGs;lnaTs;omeUs;lnaAs;om

eGs;lnaA-Sup

PAH-53 CGTTGTTGAAGCAGA lnaCs;omeGs;lnaTs;omeUs;lnaGs;omeUs;lnaT 877916 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeCs;lnaAs;om eGs;lnaA-Sup

PAH-54 AAGCAGAGTGAACAG lnaAs;omeAs;lnaGs;omeCs;lnaAs;omeGs;lnaA 877908 mOl s;omeGs;lnaTs;omeGs;lnaAs;omeAs;lnaCs;om

eAs;lnaG-Sup

PAH-55 AGTGAACAGAGTCAG lnaAs;omeGs;lnaTs;omeGs;lnaAs;omeAs;lnaC 877902 mOl s;omeAs;lnaGs;omeAs;lnaGs;omeUs;lnaCs;o

meAs;lnaG-Sup

PAH-56 AGCACCTAAAGGATT lnaAs;omeGs;lnaCs;omeAs;lnaCs;omeCs;lnaTs 877861 mOl ;omeAs;lnaAs;omeAs;lnaGs;omeGs;lnaAs;om

eUs;lnaT-Sup

PAH-57 A AG G C AAGTC AC AG C lnaAs;omeAs;lnaGs;omeGs;lnaCs;omeAs;lnaA 874660 mOl s;omeGs;lnaTs;omeCs;lnaAs;omeCs;lnaAs;om

eGs;lnaC-Sup

PAH-58 CC AG G G CT AACTCTT lnaCs;omeCs;lnaAs;omeGs;lnaGs;omeGs;lnaC 870661 mOl s;omeUs;lnaAs;omeAs;lnaCs;omeUs;lnaCs;om

eUs;lnaT-Sup

PAH-59 I LA I 1 1 I LU U U G lnaTs;omeCs;lnaAs;omeUs;lnaTs;omeUs;lnaTs 870644 mOl ;omeCs;lnaCs;omeUs;lnaCs;omeUs;lnaCs;ome

Us;lnaG-Sup

PAH-60 A l 1 1 I LU U U GU lnaAs;omeUs;lnaTs;omeUs;lnaTs;omeCs;lnaCs 870642 mOl ;omeUs;lnaCs;omeUs;lnaCs;omeUs;lnaGs;om

eCs;lnaT-Sup

PTGS2-01 GATGCAACCTACTCC lnaGs;omeAs;lnaTs;omeGs;lnaCs;omeAs;lnaA 678259 mOl s;omeCs;lnaCs;omeUs;lnaAs;omeCs;lnaTs;om

eCs;lnaC-Sup

PTGS2-02 ACAAATTGAGGTACC lnaAs;omeCs;lnaAs;omeAs;lnaAs;omeUs;lnaT 678548 mOl s;omeGs;lnaAs;omeGs;lnaGs;omeUs;lnaAs;o

meCs;lnaC-Sup

PTGS2-03 LA I AL I 1 1 I GALA lnaCs;omeAs;lnaTs;omeAs;lnaCs;omeGs;lnaTs 679060 mOl ;omeUs;lnaTs;omeUs;lnaGs;omeGs;lnaAs;om

eCs;lnaA-Sup

PTGS2-04 CGTCCCTGCAAATTC lnaCs;omeGs;lnaTs;omeCs;lnaCs;omeCs;lnaTs 679080 mOl ;omeGs;lnaCs;omeAs;lnaAs;omeAs;lnaTs;ome

Us;lnaC-Sup

PTGS2-05 GTGCTGCATATAGAG lnaGs;omeUs;lnaGs;omeCs;lnaTs;omeGs;lnaC 679382 mOl s;omeAs;lnaTs;omeAs;lnaTs;omeAs;lnaGs;om

eAs;lnaG-Sup

PTGS2-06 CTTAACCTTACTCGC lnaCs;omeUs;lnaTs;omeAs;lnaAs;omeCs;lnaCs 679451 mOl ;omeUs;lnaTs;omeAs;lnaCs;omeUs;lnaCs;ome

Gs;lnaC-Sup

PTGS2-07 CGACGTGACTTCCTC lnaCs;omeGs;lnaAs;omeCs;lnaGs;omeUs;lnaG 679478 mOl s;omeAs;lnaCs;omeUs;lnaTs;omeCs;lnaCs;om

eUs;lnaC-Sup

PTGS2-08 CTAAAGACGTACAGA lnaCs;omeUs;lnaAs;omeAs;lnaAs;omeGs;lnaA 679499 mOl s;omeCs;lnaGs;omeUs;lnaAs;omeCs;lnaAs;om

eGs;lnaA-Sup PTGS2-08 CTAAAGACGTACAGA lnaCs;lnaTs;lnaAs;dAs;dAs;dGs;dAs;dCs;dGs;d 679499 m08 Ts;dAs;dCs;lnaAs;lnaGs;lnaA-Sup

PTGS2-08 CGGCACGAAAATTAA lnaCs;lnaGs;lnaGs;dCs;dAs;dCs;dGs;dAs;dAs;d 981177 scrOl As;dAs;dTs;lnaTs;lnaAs;lnaA-Sup

mOl

PTGS2-08 ACTA A AC AACG G GT A lnaAs;lnaCs;lnaTs;dAs;dAs;dAs;dCs;dAs;dAs;d 981178 scrl3 Cs;dGs;dGs;lnaGs;lnaTs;lnaA-Sup

mOl

PTGS2-08 CAAACTGACGAATAG lnaCs;lnaAs;lnaAs;dAs;dCs;dTs;dGs;dAs;dCs;d 981179 scr25 Gs;dAs;dAs;lnaTs;lnaAs;lnaG-Sup

mOl

PTGS2-09 GC I I ACGCAA I 1 1 1 1 lnaGs;omeCs;lnaTs;omeUs;lnaAs;omeCs;lnaG 679854 mOl s;omeCs;lnaAs;omeAs;lnaTs;omeUs;lnaTs;om

eUs;lnaT-Sup

PTGS2-10 GACCAATTGTCATAC lnaGs;omeAs;lnaCs;omeCs;lnaAs;omeAs;lnaT 679985 mOl s;omeUs;lnaGs;omeUs;lnaCs;omeAs;lnaTs;om

eAs;lnaC-Sup

PTGS2-11 CACGTCCAGGAACTC lnaCs;omeAs;lnaCs;omeGs;lnaTs;omeCs;lnaCs 680022 mOl ;omeAs;lnaGs;omeGs;lnaAs;omeAs;lnaCs;om

eUs;lnaC-Sup

PTGS2-12 CCTGGCGCTCAGCCA lnaCs;omeCs;lnaTs;omeGs;lnaGs;omeCs;lnaG 680154 mOl s;omeCs;lnaTs;omeCs;lnaAs;omeGs;lnaCs;om

eCs;lnaA-Sup

PTGS2-13 GTTTCCGCTCTGACC lnaGs;omeUs;lnaTs;omeUs;lnaCs;omeCs;lnaG 680227 mOl s;omeCs;lnaTs;omeCs;lnaTs;omeGs;lnaAs;om

eCs;lnaC-Sup

PTGS2-14 CTATCCCAGTACTCC lnaCs;omeUs;lnaAs;omeUs;lnaCs;omeCs;lnaC 680250 mOl s;omeAs;lnaGs;omeUs;lnaAs;omeCs;lnaTs;om

eCs;lnaC-Sup

PTGS2-15 CTCCGAATAGAGAAG lnaCs;omeUs;lnaCs;omeCs;lnaGs;omeAs;lnaA 680272 mOl s;omeUs;lnaAs;omeGs;lnaAs;omeGs;lnaAs;o

meAs;lnaG-Sup

PTGS2-16 CGAAAGAACTCCGTG lnaCs;omeGs;lnaAs;omeAs;lnaAs;omeGs;lnaA 680324 mOl s;omeAs;lnaCs;omeUs;lnaCs;omeCs;lnaGs;om

eUs;lnaG-Sup

PTGS2-17 GTTACTTAACCGATC lnaGs;omeUs;lnaTs;omeAs;lnaCs;omeUs;lnaT 680380 mOl s;omeAs;lnaAs;omeCs;lnaCs;omeGs;lnaAs;om

eUs;lnaC-Sup

PTGS2-18 GCAGGTTGTCATTAT lnaGs;omeCs;lnaAs;omeGs;lnaGs;omeUs;lnaT 680439 mOl s;omeGs;lnaTs;omeCs;lnaAs;omeUs;lnaTs;om

eAs;lnaT-Sup

PTGS2-19 GTTGTCATTATGATA lnaGs;omeUs;lnaTs;omeGs;lnaTs;omeCs;lnaA 680443 mOl s;omeUs;lnaTs;omeAs;lnaTs;omeGs;lnaAs;om

eUs;lnaA-Sup

PTGS2-20 GTCATTATGATAAGA lnaGs;omeUs;lnaCs;omeAs;lnaTs;omeUs;lnaA 680446 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeAs;lnaAs;om

eGs;lnaA-Sup PTGS2-21 AAAGCCCGGATTATG lnaAs;omeAs;lnaAs;omeGs;lnaCs;omeCs;lnaC 680563 mOl s;omeGs;lnaGs;omeAs;lnaTs;omeUs;lnaAs;o

meUs;lnaG-Sup

PTGS2-22 GTGTACTAGATCCAT lnaGs;omeUs;lnaGs;omeUs;lnaAs;omeCs;lnaT 680646 mOl s;omeAs;lnaGs;omeAs;lnaTs;omeCs;lnaCs;om

eAs;lnaT-Sup

PTGS2-23 U ALG I 1 1 1 A 1 CCA 1 lnaCs;omeUs;lnaAs;omeCs;lnaGs;omeUs;lnaT 680809 mOl s;omeUs;lnaTs;omeAs;lnaTs;omeCs;lnaCs;om

eAs;lnaT-Sup

PTGS2-24 CCATGTCAAAACCGA lnaCs;omeCs;lnaAs;omeUs;lnaGs;omeUs;lnaC 680994 mOl s;omeAs;lnaAs;omeAs;lnaAs;omeCs;lnaCs;om

eGs;lnaA-Sup

PTGS2-25 CATGTCAAAACCGAG lnaCs;omeAs;lnaTs;omeGs;lnaTs;omeCs;lnaAs 680995 mOl ;omeAs;lnaAs;omeAs;lnaCs;omeCs;lnaGs;ome

As;lnaG-Sup

PTGS2-26 ATGTCAAAACCGAGG lnaAs;omeUs;lnaGs;omeUs;lnaCs;omeAs;lnaA 680996 mOl s;omeAs;lnaAs;omeCs;lnaCs;omeGs;lnaAs;om

eGs;lnaG-Sup

PTGS2-27 GATTTGACCAGTATA lnaGs;omeAs;lnaTs;omeUs;lnaTs;omeGs;lnaA 681028 mOl s;omeCs;lnaCs;omeAs;lnaGs;omeUs;lnaAs;om

eUs;lnaA-Sup

PTGS2-28 TTGACCAGTATAAGT lnaTs;omeUs;lnaGs;omeAs;lnaCs;omeCs;lnaA 681031 mOl s;omeGs;lnaTs;omeAs;lnaTs;omeAs;lnaAs;om

eGs;lnaT-Sup

PTGS2-29 TGACCAGTATAAGTG lnaTs;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaG 681032 mOl s;omeUs;lnaAs;omeUs;lnaAs;omeAs;lnaGs;o

meUs;lnaG-Sup

PTGS2-30 GACCAGTATAAGTGC lnaGs;omeAs;lnaCs;omeCs;lnaAs;omeGs;lnaT 681033 mOl s;omeAs;lnaTs;omeAs;lnaAs;omeGs;lnaTs;om

eGs;lnaC-Sup

PTGS2-31 CAGTATAAGTGCGAT lnaCs;omeAs;lnaGs;omeUs;lnaAs;omeUs;lnaA 681036 mOl s;omeAs;lnaGs;omeUs;lnaGs;omeCs;lnaGs;o

meAs;lnaT-Sup

PTGS2-32 TGTACCCGGACAGGA lnaTs;omeGs;lnaTs;omeAs;lnaCs;omeCs;lnaCs 681051 mOl ;omeGs;lnaGs;omeAs;lnaCs;omeAs;lnaGs;om

eGs;lnaA-Sup

PTGS2-33 GTACCCGGACAGGAT lnaGs;omeUs;lnaAs;omeCs;lnaCs;omeCs;lnaG 681052 mOl s;omeGs;lnaAs;omeCs;lnaAs;omeGs;lnaGs;o

meAs;lnaT-Sup

PTGS2-34 ACCCGGACAGGATTC lnaAs;omeCs;lnaCs;omeCs;lnaGs;omeGs;lnaA 681054 mOl s;omeCs;lnaAs;omeGs;lnaGs;omeAs;lnaTs;om

eUs;lnaC-Sup

PTGS2-35 CCGGACAGGATTCTA lnaCs;omeCs;lnaGs;omeGs;lnaAs;omeCs;lnaA 681056 mOl s;omeGs;lnaGs;omeAs;lnaTs;omeUs;lnaCs;om

eUs;lnaA-Sup

PTGS2-36 CGGACAGGATTCTAT lnaCs;omeGs;lnaGs;omeAs;lnaCs;omeAs;lnaG 681057 mOl s;omeGs;lnaAs;omeUs;lnaTs;omeCs;lnaTs;om eAs;lnaT-Sup

PTGS2-37 GGACAGGATTCTATG lnaGs;omeGs;lnaAs;omeCs;lnaAs;omeGs;lnaG 681058 mOl s;omeAs;lnaTs;omeUs;lnaCs;omeUs;lnaAs;om

eUs;lnaG-Sup

PTGS2-38 AAATTCCGCTGCAAG lnaAs;omeAs;lnaAs;omeUs;lnaTs;omeCs;lnaC 261246 mOl s;omeGs;lnaCs;omeUs;lnaGs;omeCs;lnaAs;o

meAs;lnaG-Sup

PTGS2-39 GTTATTCACAACGTT lnaGs;omeUs;lnaTs;omeAs;lnaTs;omeUs;lnaC 261339 mOl s;omeAs;lnaCs;omeAs;lnaAs;omeCs;lnaGs;om

eUs;lnaT-Sup

PTGS2-40 CATTATACCAAGACG lnaCs;omeAs;lnaTs;omeUs;lnaAs;omeUs;lnaA 262380 mOl s;omeCs;lnaCs;omeAs;lnaAs;omeGs;lnaAs;om

eCs;lnaG-Sup

PTGS2-41 AACTGATGCGTGAAG lnaAs;omeAs;lnaCs;omeUs;lnaGs;omeAs;lnaT 262736 mOl s;omeGs;lnaCs;omeGs;lnaTs;omeGs;lnaAs;om

eAs;lnaG-Sup

PTGS2-42 GCCCGTTGGTGAAAG lnaGs;omeCs;lnaCs;omeCs;lnaGs;omeUs;lnaT 262780 mOl s;omeGs;lnaGs;omeUs;lnaGs;omeAs;lnaAs;o

meAs;lnaG-Sup

PTGS2-43 ATTCTTACGAATAAC lnaAs;omeUs;lnaTs;omeCs;lnaTs;omeUs;lnaA 263215 mOl s;omeCs;lnaGs;omeAs;lnaAs;omeUs;lnaAs;om

eAs;lnaC-Sup

PTGS2-44 GCCAGAGTTTCACCG lnaGs;omeCs;lnaCs;omeAs;lnaGs;omeAs;lnaG 263558 mOl s;omeUs;lnaTs;omeUs;lnaCs;omeAs;lnaCs;om

eCs;lnaG-Sup

PTGS2-45 ATAAGCGGTAATAAC lnaAs;omeUs;lnaAs;omeAs;lnaGs;omeCs;lnaG 263650 mOl s;omeGs;lnaTs;omeAs;lnaAs;omeUs;lnaAs;om

eAs;lnaC-Sup

PTGS2-46 CAGTCAAAGATACTC lnaCs;omeAs;lnaGs;omeUs;lnaCs;omeAs;lnaA 681149 mOl s;omeAs;lnaGs;omeAs;lnaTs;omeAs;lnaCs;om

eUs;lnaC-Sup

PTGS2-47 GAGATGATCTACCCT lnaGs;omeAs;lnaGs;omeAs;lnaTs;omeGs;lnaA 681169 mOl s;omeUs;lnaCs;omeUs;lnaAs;omeCs;lnaCs;om

eCs;lnaT-Sup

PTGS2-48 ATCTACCCTCCTCAA lnaAs;omeUs;lnaCs;omeUs;lnaAs;omeCs;lnaC 681175 mOl s;omeCs;lnaTs;omeCs;lnaCs;omeUs;lnaCs;om

eAs;lnaA-Sup

PTGS2-49 GGTCTGATGATGTAT lnaGs;omeGs;lnaTs;omeCs;lnaTs;omeGs;lnaA 681244 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeGs;lnaTs;om

eAs;lnaT-Sup

PTGS2-50 CAACAGAGTATGCGA lnaCs;omeAs;lnaAs;omeCs;lnaAs;omeGs;lnaA 681282 mOl s;omeGs;lnaTs;omeAs;lnaTs;omeGs;lnaCs;om

eGs;lnaA-Sup

PTGS2-51 GCGATGTGCTTAAAC lnaGs;omeCs;lnaGs;omeAs;lnaTs;omeGs;lnaT 681293 mOl s;omeGs;lnaCs;omeUs;lnaTs;omeAs;lnaAs;om

eAs;lnaC-Sup PTGS2-52 A I ALGA I 1 1 I G I AL lnaAs;omeUs;lnaAs;omeCs;lnaGs;omeAs;lnaT 264014 mOl s;omeUs;lnaTs;omeUs;lnaGs;omeGs;lnaTs;om

eAs;lnaC-Sup

PTGS2-53 GTTGAATCATTCACC lnaGs;omeUs;lnaTs;omeGs;lnaAs;omeAs;lnaT 681552 mOl s;omeCs;lnaAs;omeUs;lnaTs;omeCs;lnaAs;om

eCs;lnaC-Sup

PTGS2-54 GCCACGGAAATTATT lnaGs;omeCs;lnaCs;omeAs;lnaCs;omeGs;lnaG 681642 mOl s;omeAs;lnaAs;omeAs;lnaTs;omeUs;lnaAs;om

eUs;lnaT-Sup

PTGS2-55 CGAACGTTCTTTTAG lnaCs;omeGs;lnaAs;omeAs;lnaCs;omeGs;lnaT 265321 mOl s;omeUs;lnaCs;omeUs;lnaTs;omeUs;lnaTs;om

eAs;lnaG-Sup

PTGS2-56 AAGACGTCAAAACTC lnaAs;omeAs;lnaGs;omeAs;lnaCs;omeGs;lnaT 265586 mOl s;omeCs;lnaAs;omeAs;lnaAs;omeAs;lnaCs;om

eUs;lnaC-Sup

PTGS2-57 GAAACATCGACAGTG lnaGs;omeAs;lnaAs;omeAs;lnaCs;omeAs;lnaT 265696 mOl s;omeCs;lnaGs;omeAs;lnaCs;omeAs;lnaGs;om

eUs;lnaG-Sup

PTGS2-58 AATTAACGAAGCATC lnaAs;omeAs;lnaTs;omeUs;lnaAs;omeAs;lnaC 267428 mOl s;omeGs;lnaAs;omeAs;lnaGs;omeCs;lnaAs;om

eUs;lnaC-Sup

PTGS2-59 CAGCGTTTGATTTAA lnaCs;omeAs;lnaGs;omeCs;lnaGs;omeUs;lnaT 267503 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeUs;lnaTs;om

eAs;lnaA-Sup

PTGS2-60 GAAACATTCGCATAC lnaGs;omeAs;lnaAs;omeAs;lnaCs;omeAs;lnaT 267768 mOl s;omeUs;lnaCs;omeGs;lnaCs;omeAs;lnaTs;om

eAs;lnaC-Sup

PTGS2-61 GTCGCAGTGAATAAG lnaGs;omeUs;lnaCs;omeGs;lnaCs;omeAs;lnaG 268068 mOl s;omeUs;lnaGs;omeAs;lnaAs;omeUs;lnaAs;o

meAs;lnaG-Sup

PTGS2-62 GACAATTAGACGTTG lnaGs;omeAs;lnaCs;omeAs;lnaAs;omeUs;lnaT 269032 mOl s;omeAs;lnaGs;omeAs;lnaCs;omeGs;lnaTs;om

eUs;lnaG-Sup

PTGS2-63 ACCCTCTAAAGACGT lnaAs;omeCs;lnaCs;omeCs;lnaTs;omeCs;lnaTs 679494 mOl ;omeAs;lnaAs;omeAs;lnaGs;omeAs;lnaCs;om

eGs;lnaT-Sup

PTGS2-64 CCCTCTAAAGACGTA lnaCs;omeCs;lnaCs;omeUs;lnaCs;omeUs;lnaA 679495 mOl s;omeAs;lnaAs;omeGs;lnaAs;omeCs;lnaGs;om

eUs;lnaA-Sup

PTGS2-65 CCTCTAAAGACGTAC lnaCs;omeCs;lnaTs;omeCs;lnaTs;omeAs;lnaAs 679496 mOl ;omeAs;lnaGs;omeAs;lnaCs;omeGs;lnaTs;om

eAs;lnaC-Sup

PTGS2-66 CTCTAAAGACGTACA lnaCs;omeUs;lnaCs;omeUs;lnaAs;omeAs;lnaA 679497 mOl s;omeGs;lnaAs;omeCs;lnaGs;omeUs;lnaAs;o

meCs;lnaA-Sup

PTGS2-67 TCTAAAGACGTACAG lnaTs;omeCs;lnaTs;omeAs;lnaAs;omeAs;lnaGs 679498 mOl ;omeAs;lnaCs;omeGs;lnaTs;omeAs;lnaCs;ome As;lnaG-Sup

PTGS2-68 TAAAGACGTACAGAC lnaTs;omeAs;lnaAs;omeAs;lnaGs;omeAs;lnaC 679500 mOl s;omeGs;lnaTs;omeAs;lnaCs;omeAs;lnaGs;om

eAs;lnaC-Sup

PTGS2-69 AAAGACGTACAGACC lnaAs;omeAs;lnaAs;omeGs;lnaAs;omeCs;lnaG 679501 mOl s;omeUs;lnaAs;omeCs;lnaAs;omeGs;lnaAs;om

eCs;lnaC-Sup

PTGS2-70 AAGACGTACAGACCA lnaAs;omeAs;lnaGs;omeAs;lnaCs;omeGs;lnaT 679502 mOl s;omeAs;lnaCs;omeAs;lnaGs;omeAs;lnaCs;om

eCs;lnaA-Sup

PTGS2-71 AGACGTACAGACCAG lnaAs;omeGs;lnaAs;omeCs;lnaGs;omeUs;lnaA 679503 mOl s;omeCs;lnaAs;omeGs;lnaAs;omeCs;lnaCs;om

eAs;lnaG-Sup

PTGS2-72 GACGTACAGACCAGA lnaGs;omeAs;lnaCs;omeGs;lnaTs;omeAs;lnaC 679504 mOl s;omeAs;lnaGs;omeAs;lnaCs;omeCs;lnaAs;om

eGs;lnaA-Sup

PTGS2-73 ATTGGTCGCTAACCG lnaAs;omeUs;lnaTs;omeGs;lnaGs;omeUs;lnaC 981180 mOl s;omeGs;lnaCs;omeUs;lnaAs;omeAs;lnaCs;om

eCs;lnaG-Sup

PTGS2-74 AATTG GTCG CT AACC lnaAs;omeAs;lnaTs;omeUs;lnaGs;omeGs;lnaT 981181 mOl s;omeCs;lnaGs;omeCs;lnaTs;omeAs;lnaAs;om

eCs;lnaC-Sup

PTGS2-75 C A ATTG GTCG CTA AC lnaCs;omeAs;lnaAs;omeUs;lnaTs;omeGs;lnaG 981182 mOl s;omeUs;lnaCs;omeGs;lnaCs;omeUs;lnaAs;o

meAs;lnaC-Sup

PTGS2-76 AC AATTG GTCG CT AA lnaAs;omeCs;lnaAs;omeAs;lnaTs;omeUs;lnaG 981183 mOl s;omeGs;lnaTs;omeCs;lnaGs;omeCs;lnaTs;om

eAs;lnaA-Sup

PTGS2-77 GACAATTGGTCGCTA lnaGs;omeAs;lnaCs;omeAs;lnaAs;omeUs;lnaT 981184 mOl s;omeGs;lnaGs;omeUs;lnaCs;omeGs;lnaCs;o

meUs;lnaA-Sup

unc-232 CTACGCGTCGACGGT lnaCs;dTs;lnaAs;dCs;lnaGs;dCs;lnaGs;dTs;lnaC 981185 ml2 s;dGs;lnaAs;dCs;lnaGs;dGs;lnaT-Sup

unc-232 CTACGCGTCGACGGT lnaCs;omeUs;lnaAs;omeCs;lnaGs;omeCs;lnaG 981185 mOl s;omeUs;lnaCs;omeGs;lnaAs;omeCs;lnaGs;o

meGs;lnaT-Sup

unc-293 CCGATTCGCGCGTAA lnaCs;dCs;lnaGs;dAs;lnaTs;dTs;lnaCs;dGs;lnaC 981186 ml2 s;dGs;lnaCs;dGs;lnaTs;dAs;lnaA-Sup

unc-293 CCGATTCGCGCGTAA lnaCs;omeCs;lnaGs;omeAs;lnaTs;omeUs;lnaC 981186 mOl s;omeGs;lnaCs;omeGs;lnaCs;omeGs;lnaTs;om

eAs;lnaA-Sup

ADIPOQ- CTCC ACTA AT AG GTG C omeCs;omeUs;omeCs;omeCs;omeAs;omeCs; 989617

01 m03 GATC omeUs;omeAs;omeAs;omeUs;omeAs;omeGs;

omeGs;omeUs;omeGs;omeCs;omeGs;omeAs;

omeUs;omeC-Sup

ADIPOQ- TTTCTCCACTAATAGG omeUs;omeUs;omeUs;omeCs;omeUs;omeCs; 989618

02 m03 TGCG omeCs;omeAs;omeCs;omeUs;omeAs;omeAs; omeUs;omeAs;omeGs;omeGs;omeUs;omeGs;

omeCs;omeG-Sup

ADIPOQ- ATTTCTCCACTAATAG omeAs;omeUs;omeUs;omeUs;omeCs;omeUs; 989619

03 m03 GTGC omeCs;omeCs;omeAs;omeCs;omeUs;omeAs;

omeAs;omeUs;omeAs;omeGs;omeGs;omeUs;

omeGs;omeC-Sup

ADIPOQ- CAGATTTCTCCACTAA omeCs;omeAs;omeGs;omeAs;omeUs;omeUs; 989620

04 m03 TAGG omeUs;omeCs;omeUs;omeCs;omeCs;omeAs;

o me Cs; o m e U s; o m e As; o m e As; o m e U s; o m e As;

omeGs;omeG-Sup

ADIPOQ- ACAGATTTCTCCACTA omeAs;omeCs;omeAs;omeGs;omeAs;omeUs; 989621

05 m03 ATAG omeUs;omeUs;omeCs;omeUs;omeCs;omeCs;

omeAs;omeCs;omeUs;omeAs;omeAs;omeUs;

omeAs;omeG-Sup

ADIPOQ- GACAGATTTCTCCACT omeGs;omeAs;omeCs;omeAs;omeGs;omeAs; 989622

06 m03 AATA omeUs;omeUs;omeUs;omeCs;omeUs;omeCs;

omeCs;omeAs;omeCs;omeUs;omeAs;omeAs;

omeUs;omeA-Sup

ADIPOQ- TATGGACAGATTTCTC omeUs;omeAs;omeUs;omeGs;omeGs;omeAs; 989623

07 m03 CACT omeCs;omeAs;omeGs;omeAs;omeUs;omeUs;

omeUs;omeCs;omeUs;omeCs;omeCs;omeAs;

omeCs;omeU-Sup

ADIPOQ- TATTATGGACAGATTT omeUs;omeAs;omeUs;omeUs;omeAs;omeUs; 989624

08 m03 CTCC omeGs;omeGs;omeAs;omeCs;omeAs;omeGs;

omeAs;omeUs;omeUs;omeUs;omeCs;omeUs;

omeCs;omeC-Sup

ADIPOQ- TCAGTATTATGGACAG omeUs;omeCs;omeAs;omeGs;omeUs;omeAs; 989625

09 m03 ATTT omeUs;omeUs;omeAs;omeUs;omeGs;omeGs

;omeAs;omeCs;omeAs;omeGs;omeAs;omeUs

;omeUs;omeU-Sup

ADIPOQ- TTCAGTATTATGGACA omeUs;omeUs;omeCs;omeAs;omeGs;omeUs; 989626

10 m03 GATT omeAs;omeUs;omeUs;omeAs;omeUs;omeGs;

omeGs;omeAs;omeCs;omeAs;omeGs;omeAs;

omeUs;omeU-Sup

ADIPOQ- ACTTCAGTATTATGGA omeAs;omeCs;omeUs;omeUs;omeCs;omeAs; 989627

11 m03 CAGA omeGs;omeUs;omeAs;omeUs;omeUs;omeAs;

omeUs;omeGs;omeGs;omeAs;omeCs;omeAs;

omeGs;omeA-Sup

ADIPOQ- A ACTTC AGT ATT ATG G omeAs;omeAs;omeCs;omeUs;omeUs;omeCs; 989628

12 m03 ACAG omeAs;omeGs;omeUs;omeAs;omeUs;omeUs;

omeAs;omeUs;omeGs;omeGs;omeAs;omeCs;

omeAs;omeG-Sup

ADIPOQ- TCCTCCTCTATTCTGCC omeUs;omeCs;omeCs;omeUs;omeCs;omeCs; 989629

13 m03 TAC omeUs;omeCs;omeUs;omeAs;omeUs;omeUs;

omeCs;omeUs;omeGs;omeCs;omeCs;omeUs;

omeAs;omeC-Sup

ADIPOQ- CTCCTCCTCTATTCTGC omeCs;omeUs;omeCs;omeCs;omeUs;omeCs; 989630 14 m03 CTA omeCs;omeUs;omeCs;omeUs;omeAs;omeUs;

omeUs;omeCs;omeUs;omeGs;omeCs;omeCs;

omeUs;omeA-Sup

ADIPOQ- TCTCCTCCTCTATTCTG omeUs;omeCs;omeUs;omeCs;omeCs;omeUs; 989631 15 m03 CCT omeCs;omeCs;omeUs;omeCs;omeUs;omeAs;

omeUs;omeUs;omeCs;omeUs;omeGs;omeCs;

omeCs;omeU-Sup

ADIPOQ- CTCTCCTCCTCTATTCT omeCs;omeUs;omeCs;omeUs;omeCs;omeCs; 989632 16 m03 GCC omeUs;omeCs;omeCs;omeUs;omeCs;omeUs;

omeAs;omeUs;omeUs;omeCs;omeUs;omeGs;

omeCs;omeC-Sup

ADIPOQ- GTCTCTCCTCCTCTATT omeGs;omeUs;omeCs;omeUs;omeCs;omeUs; 989633 17 m03 CTG omeCs;omeCs;omeUs;omeCs;omeCs;omeUs;

omeCs;omeUs;omeAs;omeUs;omeUs;omeCs;

omeUs;omeG-Sup

ADIPOQ- GGATGTCTCTCCTCCT omeGs;omeGs;omeAs;omeUs;omeGs;omeUs; 989634 18 m03 CTAT omeCs;omeUs;omeCs;omeUs;omeCs;omeCs;

omeUs;omeCs;omeCs;omeUs;omeCs;omeUs;

omeAs;omeU-Sup

ADIPOQ- ATCTAGGATGTCTCTC omeAs;omeUs;omeCs;omeUs;omeAs;omeGs; 989635 19 m03 CTCC omeGs;omeAs;omeUs;omeGs;omeUs;omeCs;

omeUs;omeCs;omeUs;omeCs;omeCs;omeUs;

omeCs;omeC-Sup

ADIPOQ- CATCTAGGATGTCTCT omeCs;omeAs;omeUs;omeCs;omeUs;omeAs; 989636 20 m03 CCTC omeGs;omeGs;omeAs;omeUs;omeGs;omeUs;

omeCs;omeUs;omeCs;omeUs;omeCs;omeCs;

omeUs;omeC-Sup

ADIPOQ- CTCCATCTAGGATGTC omeCs;omeUs;omeCs;omeCs;omeAs;omeUs; 989637 21 m03 TCTC omeCs;omeUs;omeAs;omeGs;omeGs;omeAs;

omeUs;omeGs;omeUs;omeCs;omeUs;omeCs;

omeUs;omeC-Sup

ADIPOQ- CCTCCATCTAGGATGT omeCs;omeCs;omeUs;omeCs;omeCs;omeAs; 989638 22 m03 CTCT omeUs;omeCs;omeUs;omeAs;omeGs;omeGs;

omeAs;omeUs;omeGs;omeUs;omeCs;omeUs;

omeCs;omeU-Sup

ADIPOQ- CCCTCCATCTAGGATG omeCs;omeCs;omeCs;omeUs;omeCs;omeCs; 989639 23 m03 TCTC omeAs;omeUs;omeCs;omeUs;omeAs;omeGs;

omeGs;omeAs;omeUs;omeGs;omeUs;omeCs;

omeUs;omeC-Sup

ADIPOQ- CCCCTCCATCTAGGAT omeCs;omeCs;omeCs;omeCs;omeUs;omeCs; 989640 24 m03 GTCT omeCs;omeAs;omeUs;omeCs;omeUs;omeAs;

omeGs;omeGs;omeAs;omeUs;omeGs;omeUs;

omeCs;omeU-Sup

ADIPOQ- ATCTTCTACAATCAGC omeAs;omeUs;omeCs;omeUs;omeUs;omeCs; 989641 25 m03 AAAA omeUs;omeAs;omeCs;omeAs;omeAs;omeUs;

omeCs;omeAs;omeGs;omeCs;omeAs;omeAs;

omeAs;omeA-Sup ADIPOQ- CTTCT AC AATC AG C A A omeCs;omeUs;omeUs;omeCs;omeUs;omeAs; 989642

26 m03 AACC omeCs;omeAs;omeAs;omeUs;omeCs;omeAs;

omeGs;omeCs;omeAs;omeAs;omeAs;omeAs;

omeCs;omeC-Sup

ADIPOQ- TCT AC AATC AG C AA A A omeUs;omeCs;omeUs;omeAs;omeCs;omeAs; 989643

27 m03 CCAC omeAs;omeUs;omeCs;omeAs;omeGs;omeCs;

omeAs;omeAs;omeAs;omeAs;omeCs;omeCs;

omeAs;omeC-Sup

ADIPOQ- CTAC A ATC AG C A A AAC omeCs;omeUs;omeAs;omeCs;omeAs;omeAs; 989644

28 m03 CACT omeUs;omeCs;omeAs;omeGs;omeCs;omeAs;

omeAs;omeAs;omeAs;omeCs;omeCs;omeAs;

omeCs;omeU-Sup

ADIPOQ- ACAATCAGCAAAACCA omeAs;omeCs;omeAs;omeAs;omeUs;omeCs; 989645

29 m03 CTAT omeAs;omeGs;omeCs;omeAs;omeAs;omeAs;

omeAs;omeCs;omeCs;omeAs;omeCs;omeUs;

omeAs;omeU-Sup

ADIPOQ- CAATCAGCAAAACCAC omeCs;omeAs;omeAs;omeUs;omeCs;omeAs; 989646

30 m03 TATG omeGs;omeCs;omeAs;omeAs;omeAs;omeAs;

omeCs;omeCs;omeAs;omeCs;omeUs;omeAs;

omeUs;omeG-Sup

ADIPOQ- ACGTGGCACATCCAA lnaAs;omeCs;lnaGs;omeUs;lnaGs;omeGs;lnaC 985031

31 mOl s;omeAs;lnaCs;omeAs;lnaTs;omeCs;lnaCs;om

eAs;lnaA-Sup

ADIPOQ- ACGTGGCACATCCAA lnaAs;lnaCs;lnaGs;dTs;dGs;dGs;dCs;dAs;dCs;d 985031

31 m08 As;dTs;dCs;lnaCs;lnaAs;lnaA-Sup

ADIPOQ- TC ACGTG G C AC ATCC lnaTs;omeCs;lnaAs;omeCs;lnaGs;omeUs;lnaG 985033

32 mOl s;omeGs;lnaCs;omeAs;lnaCs;omeAs;lnaTs;om

eCs;lnaC-Sup

ADIPOQ- TC ACGTG G C AC ATCC lnaTs;lnaCs;lnaAs;dCs;dGs;dTs;dGs;dGs;dCs;d 985033

32 m08 As;dCs;dAs;lnaTs;lnaCs;lnaC-Sup

ADIPOQ- CAGGTTGGATGGCGG lnaCs;omeAs;lnaGs;omeGs;lnaTs;omeUs;lnaG 989647

33 mOl s;omeGs;lnaAs;omeUs;lnaGs;omeGs;lnaCs;o

meGs;lnaG-Sup

ADIPOQ- CAGGTTGGATGGCGG lnaCs;lnaAs;lnaGs;dGs;dTs;dTs;dGs;dGs;dAs;d 989647

33 m08 Ts;dGs;dGs;lnaCs;lnaGs;lnaG-Sup

ADIPOQ- CCGCCATCCAACCTG lnaCs;omeCs;lnaGs;omeCs;lnaCs;omeAs;lnaTs 986431

34 mOl ;omeCs;lnaCs;omeAs;lnaAs;omeCs;lnaCs;ome

Us;lnaG-Sup

ADIPOQ- CCGCCATCCAACCTG lnaCs;lnaCs;lnaGs;dCs;dCs;dAs;dTs;dCs;dCs;d 986431

34 m08 As;dAs;dCs;lnaCs;lnaTs;lnaG-Sup

ADIPOQ- CCCGCCATCCAACCT lnaCs;omeCs;lnaCs;omeGs;lnaCs;omeCs;lnaAs 986432

35 mOl ;omeUs;lnaCs;omeCs;lnaAs;omeAs;lnaCs;ome

Cs;lnaT-Sup

ADIPOQ- CCCGCCATCCAACCT lnaCs;lnaCs;lnaCs;dGs;dCs;dCs;dAs;dTs;dCs;d 986432

35 m08 Cs;dAs;dAs;lnaCs;lnaCs;lnaT-Sup

ADIPOQ- ATGCCCGCCATCCAA lnaAs;omeUs;lnaGs;omeCs;lnaCs;omeCs;lnaG 986435

36 mOl s;omeCs;lnaCs;omeAs;lnaTs;omeCs;lnaCs;om eAs;lnaA-Sup

ADIPOQ- ATGCCCGCCATCCAA lnaAs;lnaTs;lnaGs;dCs;dCs;dCs;dGs;dCs;dCs;d 986435

36 m08 As;dTs;dCs;lnaCs;lnaAs;lnaA-Sup

ADIPOQ- GATGCCCGCCATCCA lnaGs;omeAs;lnaTs;omeGs;lnaCs;omeCs;lnaC 986436

37 mOl s;omeGs;lnaCs;omeCs;lnaAs;omeUs;lnaCs;om

eCs;lnaA-Sup

ADIPOQ- GATGCCCGCCATCCA lnaGs;lnaAs;lnaTs;dGs;dCs;dCs;dCs;dGs;dCs;d 986436

37 m08 Cs;dAs;dTs;lnaCs;lnaCs;lnaA-Sup

ADIPOQ- GGATGCCCGCCATCC lnaGs;omeGs;lnaAs;omeUs;lnaGs;omeCs;lnaC 986437

38 mOl s;omeCs;lnaGs;omeCs;lnaCs;omeAs;lnaTs;om

eCs;lnaC-Sup

ADIPOQ- GGATGCCCGCCATCC lnaGs;lnaGs;lnaAs;dTs;dGs;dCs;dCs;dCs;dGs;d 986437

38 m08 Cs;dCs;dAs;lnaTs;lnaCs;lnaC-Sup

ADIPOQ- GCCATCACGGCCTGG lnaGs;omeCs;lnaCs;omeAs;lnaTs;omeCs;lnaAs 986478

39 mOl ;omeCs;lnaGs;omeGs;lnaCs;omeCs;lnaTs;ome

Gs;lnaG-Sup

ADIPOQ- GCCATCACGGCCTGG lnaGs;lnaCs;lnaCs;dAs;dTs;dCs;dAs;dCs;dGs;d 986478

39 m08 Gs;dCs;dCs;lnaTs;lnaGs;lnaG-Sup

ADIPOQ- CAGGCCGTGATGGCA lnaCs;omeAs;lnaGs;omeGs;lnaCs;omeCs;lnaG 989648

40 mOl s;omeUs;lnaGs;omeAs;lnaTs;omeGs;lnaGs;o

meCs;lnaA-Sup

ADIPOQ- CAGGCCGTGATGGCA lnaCs;lnaAs;lnaGs;dGs;dCs;dCs;dGs;dTs;dGs;d 989648

40 m08 As;dTs;dGs;lnaGs;lnaCs;lnaA-Sup

ADIPOQ- TGCCATCACGGCCTG lnaTs;omeGs;lnaCs;omeCs;lnaAs;omeUs;lnaC 986479

41 mOl s;omeAs;lnaCs;omeGs;lnaGs;omeCs;lnaCs;om

eUs;lnaG-Sup

ADIPOQ- TGCCATCACGGCCTG lnaTs;lnaGs;lnaCs;dCs;dAs;dTs;dCs;dAs;dCs;d 986479

41 m08 Gs;dGs;dCs;lnaCs;lnaTs;lnaG-Sup

ADIPOQ- GGCCGTGATGGCAGA lnaGs;omeGs;lnaCs;omeCs;lnaGs;omeUs;lnaG 989649

42 mOl s;omeAs;lnaTs;omeGs;lnaGs;omeCs;lnaAs;om

eGs;lnaA-Sup

ADIPOQ- GGCCGTGATGGCAGA lnaGs;lnaGs;lnaCs;dCs;dGs;dTs;dGs;dAs;dTs;d 989649

42 m08 Gs;dGs;dCs;lnaAs;lnaGs;lnaA-Sup

ADIPOQ- TCTGCCATCACGGCC lnaTs;omeCs;lnaTs;omeGs;lnaCs;omeCs;lnaAs 986481

43 mOl ;omeUs;lnaCs;omeAs;lnaCs;omeGs;lnaGs;om

eCs;lnaC-Sup

ADIPOQ- TCTGCCATCACGGCC lnaTs;lnaCs;lnaTs;dGs;dCs;dCs;dAs;dTs;dCs;d 986481

43 m08 As;dCs;dGs;lnaGs;lnaCs;lnaC-Sup

ADIPOQ- TAG GTCTT ATTG GTC lnaTs;omeAs;lnaGs;omeGs;lnaTs;omeCs;lnaTs 987444

44 mOl ;omeUs;lnaAs;omeUs;lnaTs;omeGs;lnaGs;om

eUs;lnaC-Sup

ADIPOQ- TAG GTCTT ATTG GTC lnaTs;lnaAs;lnaGs;dGs;dTs;dCs;dTs;dTs;dAs;d 987444

44 m08 Ts;dTs;dGs;lnaGs;lnaTs;lnaC-Sup

ADIPOQ- GACCAATAAGACCTA lnaGs;omeAs;lnaCs;omeCs;lnaAs;omeAs;lnaT 989650

45 mOl s;omeAs;lnaAs;omeGs;lnaAs;omeCs;lnaCs;om

eUs;lnaA-Sup ADIPOQ- GACCAATAAGACCTA lnaGs;lnaAs;lnaCs;dCs;dAs;dAs;dTs;dAs;dAs;d 989650

45 m08 Gs;dAs;dCs;lnaCs;lnaTs;lnaA-Sup

ADIPOQ- AG GTCTT ATTG GTCC lnaAs;omeGs;lnaGs;omeUs;lnaCs;omeUs;lnaT 987445

46 mOl s;omeAs;lnaTs;omeUs;lnaGs;omeGs;lnaTs;om

eCs;lnaC-Sup

ADIPOQ- AG GTCTT ATTG GTCC lnaAs;lnaGs;lnaGs;dTs;dCs;dTs;dTs;dAs;dTs;d 987445

46 m08 Ts;dGs;dGs;lnaTs;lnaCs;lnaC-Sup

ADIPOQ- GGACCAATAAGACCT lnaGs;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaA 989651

47 mOl s;omeUs;lnaAs;omeAs;lnaGs;omeAs;lnaCs;om

eCs;lnaT-Sup

ADIPOQ- GGACCAATAAGACCT lnaGs;lnaGs;lnaAs;dCs;dCs;dAs;dAs;dTs;dAs;d 989651

47 m08 As;dGs;dAs;lnaCs;lnaCs;lnaT-Sup

ADIPOQ- CCCTTAGGACCAATA lnaCs;omeCs;lnaCs;omeUs;lnaTs;omeAs;lnaG 989652

48 mOl s;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaAs;om

eUs;lnaA-Sup

ADIPOQ- CCCTTAGGACCAATA lnaCs;lnaCs;lnaCs;dTs;dTs;dAs;dGs;dGs;dAs;d 989652

48 m08 Cs;dCs;dAs;lnaAs;lnaTs;lnaA-Sup

ADIPOQ- CG CTC AG C ATTC AGT lnaCs;omeGs;lnaCs;omeUs;lnaCs;omeAs;lnaG 987566

49 mOl s;omeCs;lnaAs;omeUs;lnaTs;omeCs;lnaAs;om

eGs;lnaT-Sup

ADIPOQ- CG CTC AG C ATTC AGT lnaCs;lnaGs;lnaCs;dTs;dCs;dAs;dGs;dCs;dAs;d 987566

49 m08 Ts;dTs;dCs;lnaAs;lnaGs;lnaT-Sup

ADIPOQ- ACTGAATGCTGAGCG lnaAs;omeCs;lnaTs;omeGs;lnaAs;omeAs;lnaTs 989653

50 mOl ;omeGs;lnaCs;omeUs;lnaGs;omeAs;lnaGs;om

eCs;lnaG-Sup

ADIPOQ- ACTGAATGCTGAGCG lnaAs;lnaCs;lnaTs;dGs;dAs;dAs;dTs;dGs;dCs;d 989653

50 m08 Ts;dGs;dAs;lnaGs;lnaCs;lnaG-Sup

ADIPOQ- TGCCCATTCGCTTTA lnaTs;omeGs;lnaCs;omeCs;lnaCs;omeAs;lnaTs 987615

51 mOl ;omeUs;lnaCs;omeGs;lnaCs;omeUs;lnaTs;om

eUs;lnaA-Sup

ADIPOQ- TGCCCATTCGCTTTA lnaTs;lnaGs;lnaCs;dCs;dCs;dAs;dTs;dTs;dCs;d 987615

51 m08 Gs;dCs;dTs;lnaTs;lnaTs;lnaA-Sup

ADIPOQ- GCCCATTCGCTTTAC lnaGs;omeCs;lnaCs;omeCs;lnaAs;omeUs;lnaT 987616

52 mOl s;omeCs;lnaGs;omeCs;lnaTs;omeUs;lnaTs;om

eAs;lnaC-Sup

ADIPOQ- GCCCATTCGCTTTAC lnaGs;lnaCs;lnaCs;dCs;dAs;dTs;dTs;dCs;dGs;d 987616

52 m08 Cs;dTs;dTs;lnaTs;lnaAs;lnaC-Sup

ADIPOQ- CCCATTCGCTTTACC lnaCs;omeCs;lnaCs;omeAs;lnaTs;omeUs;lnaCs 987617

53 mOl ;omeGs;lnaCs;omeUs;lnaTs;omeUs;lnaAs;om

eCs;lnaC-Sup

ADIPOQ- CCCATTCGCTTTACC lnaCs;lnaCs;lnaCs;dAs;dTs;dTs;dCs;dGs;dCs;dT 987617

53 m08 s;dTs;dTs;lnaAs;lnaCs;lnaC-Sup

ADIPOQ- CCATTCGCTTTACCA lnaCs;omeCs;lnaAs;omeUs;lnaTs;omeCs;lnaG 987618

54 mOl s;omeCs;lnaTs;omeUs;lnaTs;omeAs;lnaCs;om

eCs;lnaA-Sup

ADIPOQ- CCATTCGCTTTACCA lnaCs;lnaCs;lnaAs;dTs;dTs;dCs;dGs;dCs;dTs;dT 987618

54 m08 s;dTs;dAs;lnaCs;lnaCs;lnaA-Sup ADIPOQ- TGGTAAAGCGAATGG lnaTs;omeGs;lnaGs;omeUs;lnaAs;omeAs;lnaA 989654

55 mOl s;omeGs;lnaCs;omeGs;lnaAs;omeAs;lnaTs;om

eGs;lnaG-Sup

ADIPOQ- TGGTAAAGCGAATGG lnaTs;lnaGs;lnaGs;dTs;dAs;dAs;dAs;dGs;dCs;d 989654

55 m08 Gs;dAs;dAs;lnaTs;lnaGs;lnaG-Sup

ADIPOQ- CATTCGCTTTACCAA lnaCs;omeAs;lnaTs;omeUs;lnaCs;omeGs;lnaC 987619

56 mOl s;omeUs;lnaTs;omeUs;lnaAs;omeCs;lnaCs;om

eAs;lnaA-Sup

ADIPOQ- CATTCGCTTTACCAA lnaCs;lnaAs;lnaTs;dTs;dCs;dGs;dCs;dTs;dTs;dT 987619

56 m08 s;dAs;dCs;lnaCs;lnaAs;lnaA-Sup

ADIPOQ- TTGGTAAAGCGAATG lnaTs;omeUs;lnaGs;omeGs;lnaTs;omeAs;lnaA 989655

57 mOl s;omeAs;lnaGs;omeCs;lnaGs;omeAs;lnaAs;om

eUs;lnaG-Sup

ADIPOQ- TTGGTAAAGCGAATG lnaTs;lnaTs;lnaGs;dGs;dTs;dAs;dAs;dAs;dGs;d 989655

57 m08 Cs;dGs;dAs;lnaAs;lnaTs;lnaG-Sup

ADIPOQ- ATTCGCTTTACCAAG lnaAs;omeUs;lnaTs;omeCs;lnaGs;omeCs;lnaTs 987620

58 mOl ;omeUs;lnaTs;omeAs;lnaCs;omeCs;lnaAs;ome

As;lnaG-Sup

ADIPOQ- ATTCGCTTTACCAAG lnaAs;lnaTs;lnaTs;dCs;dGs;dCs;dTs;dTs;dTs;dA 987620

58 m08 s;dCs;dCs;lnaAs;lnaAs;lnaG-Sup

ADIPOQ- CTTGGTAAAGCGAAT lnaCs;omeUs;lnaTs;omeGs;lnaGs;omeUs;lnaA 989656

59 mOl s;omeAs;lnaAs;omeGs;lnaCs;omeGs;lnaAs;om

eAs;lnaT-Sup

ADIPOQ- CTTGGTAAAGCGAAT lnaCs;lnaTs;lnaTs;dGs;dGs;dTs;dAs;dAs;dAs;d 989656

59 m08 Gs;dCs;dGs;lnaAs;lnaAs;lnaT-Sup

ADIPOQ- TTCGCTTTACCAAGA lnaTs;omeUs;lnaCs;omeGs;lnaCs;omeUs;lnaT 987621

60 mOl s;omeUs;lnaAs;omeCs;lnaCs;omeAs;lnaAs;om

eGs;lnaA-Sup

ADIPOQ- TTCGCTTTACCAAGA lnaTs;lnaTs;lnaCs;dGs;dCs;dTs;dTs;dTs;dAs;dC 987621

60 m08 s;dCs;dAs;lnaAs;lnaGs;lnaA-Sup

ADIPOQ- TCTTGGTAAAGCGAA lnaTs;omeCs;lnaTs;omeUs;lnaGs;omeGs;lnaTs 989657

61 mOl ;omeAs;lnaAs;omeAs;lnaGs;omeCs;lnaGs;om

eAs;lnaA-Sup

ADIPOQ- TCTTGGTAAAGCGAA lnaTs;lnaCs;lnaTs;dTs;dGs;dGs;dTs;dAs;dAs;d 989657

61 m08 As;dGs;dCs;lnaGs;lnaAs;lnaA-Sup

ADIPOQ- TCGCTTTACCAAGAT lnaTs;omeCs;lnaGs;omeCs;lnaTs;omeUs;lnaTs 987622

62 mOl ;omeAs;lnaCs;omeCs;lnaAs;omeAs;lnaGs;ome

As;lnaT-Sup

ADIPOQ- TCGCTTTACCAAGAT lnaTs;lnaCs;lnaGs;dCs;dTs;dTs;dTs;dAs;dCs;dC 987622

62 m08 s;dAs;dAs;lnaGs;lnaAs;lnaT-Sup

ADIPOQ- ATCTTGGTAAAGCGA lnaAs;omeUs;lnaCs;omeUs;lnaTs;omeGs;lnaG 989658

63 mOl s;omeUs;lnaAs;omeAs;lnaAs;omeGs;lnaCs;om

eGs;lnaA-Sup

ADIPOQ- ATCTTGGTAAAGCGA lnaAs;lnaTs;lnaCs;dTs;dTs;dGs;dGs;dTs;dAs;d 989658

63 m08 As;dAs;dGs;lnaCs;lnaGs;lnaA-Sup

ADIPOQ- CGCTTTACCAAGATC lnaCs;omeGs;lnaCs;omeUs;lnaTs;omeUs;lnaA 987623

64 mOl s;omeCs;lnaCs;omeAs;lnaAs;omeGs;lnaAs;om eUs;lnaC-Sup

ADIPOQ- CGCTTTACCAAGATC lnaCs;lnaGs;lnaCs;dTs;dTs;dTs;dAs;dCs;dCs;d 987623

64 m08 As;dAs;dGs;lnaAs;lnaTs;lnaC-Sup

ADIPOQ- GATCTTGGTAAAGCG lnaGs;omeAs;lnaTs;omeCs;lnaTs;omeUs;lnaG 989659

65 mOl s;omeGs;lnaTs;omeAs;lnaAs;omeAs;lnaGs;om

eCs;lnaG-Sup

ADIPOQ- GATCTTGGTAAAGCG lnaGs;lnaAs;lnaTs;dCs;dTs;dTs;dGs;dGs;dTs;d 989659

65 m08 As;dAs;dAs;lnaGs;lnaCs;lnaG-Sup

ADIPOQ- TTTACCAAGATCTTC lnaTs;omeUs;lnaTs;omeAs;lnaCs;omeCs;lnaAs 987626

66 mOl ;omeAs;lnaGs;omeAs;lnaTs;omeCs;lnaTs;ome

Us;lnaC-Sup

ADIPOQ- TTTACCAAGATCTTC lnaTs;lnaTs;lnaTs;dAs;dCs;dCs;dAs;dAs;dGs;d 987626

66 m08 As;dTs;dCs;lnaTs;lnaTs;lnaC-Sup

ADIPOQ- GAAGATCTTGGTAAA lnaGs;omeAs;lnaAs;omeGs;lnaAs;omeUs;lnaC 989660

67 mOl s;omeUs;lnaTs;omeGs;lnaGs;omeUs;lnaAs;o

meAs;lnaA-Sup

ADIPOQ- GAAGATCTTGGTAAA lnaGs;lnaAs;lnaAs;dGs;dAs;dTs;dCs;dTs;dTs;d 989660

67 m08 Gs;dGs;dTs;lnaAs;lnaAs;lnaA-Sup

ADIPOQ- TAATGTGGACCAGGC lnaTs;omeAs;lnaAs;omeUs;lnaGs;omeUs;lnaG 987808

68 mOl s;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaGs;om

eGs;lnaC-Sup

ADIPOQ- TAATGTGGACCAGGC lnaTs;lnaAs;lnaAs;dTs;dGs;dTs;dGs;dGs;dAs;d 987808

68 m08 Cs;dCs;dAs;lnaGs;lnaGs;lnaC-Sup

ADIPOQ- GCCTGGTCCACATTA lnaGs;omeCs;lnaCs;omeUs;lnaGs;omeGs;lnaT 989661

69 mOl s;omeCs;lnaCs;omeAs;lnaCs;omeAs;lnaTs;om

eUs;lnaA-Sup

ADIPOQ- GCCTGGTCCACATTA lnaGs;lnaCs;lnaCs;dTs;dGs;dGs;dTs;dCs;dCs;d 989661

69 m08 As;dCs;dAs;lnaTs;lnaTs;lnaA-Sup

ADIPOQ- AATGTGGACCAGGCC lnaAs;omeAs;lnaTs;omeGs;lnaTs;omeGs;lnaG 987809

70 mOl s;omeAs;lnaCs;omeCs;lnaAs;omeGs;lnaGs;om

eCs;lnaC-Sup

ADIPOQ- AATGTGGACCAGGCC lnaAs;lnaAs;lnaTs;dGs;dTs;dGs;dGs;dAs;dCs;d 987809

70 m08 Cs;dAs;dGs;lnaGs;lnaCs;lnaC-Sup

ADIPOQ- GGCCTGGTCCACATT lnaGs;omeGs;lnaCs;omeCs;lnaTs;omeGs;lnaG 989662

71 mOl s;omeUs;lnaCs;omeCs;lnaAs;omeCs;lnaAs;om

eUs;lnaT-Sup

ADIPOQ- GGCCTGGTCCACATT lnaGs;lnaGs;lnaCs;dCs;dTs;dGs;dGs;dTs;dCs;d 989662

71 m08 Cs;dAs;dCs;lnaAs;lnaTs;lnaT-Sup

ADIPOQ- TCCGGCTCTGTGCTC lnaTs;omeCs;lnaCs;omeGs;lnaGs;omeCs;lnaTs 987824

72 mOl ;omeCs;lnaTs;omeGs;lnaTs;omeGs;lnaCs;ome

Us;lnaC-Sup

ADIPOQ- TCCGGCTCTGTGCTC lnaTs;lnaCs;lnaCs;dGs;dGs;dCs;dTs;dCs;dTs;d 987824

72 m08 Gs;dTs;dGs;lnaCs;lnaTs;lnaC-Sup

ADIPOQ- GAGCACAGAGCCGGA lnaGs;omeAs;lnaGs;omeCs;lnaAs;omeCs;lnaA 989663

73 mOl s;omeGs;lnaAs;omeGs;lnaCs;omeCs;lnaGs;om

eGs;lnaA-Sup ADIPOQ- GAGCACAGAGCCGGA lnaGs;lnaAs;lnaGs;dCs;dAs;dCs;dAs;dGs;dAs;d 989663

73 m08 Gs;dCs;dCs;lnaGs;lnaGs;lnaA-Sup

ADIPOQ- TTGGTCGCCCACCTC lnaTs;omeUs;lnaGs;omeGs;lnaTs;omeCs;lnaG 989664

74 mOl s;omeCs;lnaCs;omeCs;lnaAs;omeCs;lnaCs;om

eUs;lnaC-Sup

ADIPOQ- TTGGTCGCCCACCTC lnaTs;lnaTs;lnaGs;dGs;dTs;dCs;dGs;dCs;dCs;d 989664

74 m08 Cs;dAs;dCs;lnaCs;lnaTs;lnaC-Sup

ADIPOQ- CTTGGTCGCCCACCT lnaCs;omeUs;lnaTs;omeGs;lnaGs;omeUs;lnaC 989665

75 mOl s;omeGs;lnaCs;omeCs;lnaCs;omeAs;lnaCs;om

eCs;lnaT-Sup

ADIPOQ- CTTGGTCGCCCACCT lnaCs;lnaTs;lnaTs;dGs;dGs;dTs;dCs;dGs;dCs;d 989665

75 m08 Cs;dCs;dAs;lnaCs;lnaCs;lnaT-Sup

ADIPOQ- ACTTGGTCGCCCACC lnaAs;omeCs;lnaTs;omeUs;lnaGs;omeGs;lnaT 989666

76 mOl s;omeCs;lnaGs;omeCs;lnaCs;omeCs;lnaAs;om

eCs;lnaC-Sup

ADIPOQ- ACTTGGTCGCCCACC lnaAs;lnaCs;lnaTs;dTs;dGs;dGs;dTs;dCs;dGs;d 989666

76 m08 Cs;dCs;dCs;lnaAs;lnaCs;lnaC-Sup

ADIPOQ- GACTTGGTCGCCCAC lnaGs;omeAs;lnaCs;omeUs;lnaTs;omeGs;lnaG 989667

77 mOl s;omeUs;lnaCs;omeGs;lnaCs;omeCs;lnaCs;om

eAs;lnaC-Sup

ADIPOQ- GACTTGGTCGCCCAC lnaGs;lnaAs;lnaCs;dTs;dTs;dGs;dGs;dTs;dCs;d 989667

77 m08 Gs;dCs;dCs;lnaCs;lnaAs;lnaC-Sup

ADIPOQ- AGACTTGGTCGCCCA lnaAs;omeGs;lnaAs;omeCs;lnaTs;omeUs;lnaG 989668

78 mOl s;omeGs;lnaTs;omeCs;lnaGs;omeCs;lnaCs;om

eCs;lnaA-Sup

ADIPOQ- AGACTTGGTCGCCCA lnaAs;lnaGs;lnaAs;dCs;dTs;dTs;dGs;dGs;dTs;d 989668

78 m08 Cs;dGs;dCs;lnaCs;lnaCs;lnaA-Sup

ADIPOQ- CAGACTTGGTCGCCC lnaCs;omeAs;lnaGs;omeAs;lnaCs;omeUs;lnaT 989669

79 mOl s;omeGs;lnaGs;omeUs;lnaCs;omeGs;lnaCs;o

meCs;lnaC-Sup

ADIPOQ- CAGACTTGGTCGCCC lnaCs;lnaAs;lnaGs;dAs;dCs;dTs;dTs;dGs;dGs;d 989669

79 m08 Ts;dCs;dGs;lnaCs;lnaCs;lnaC-Sup

ADIPOQ- GGCGACCAAGTCTGG lnaGs;omeGs;lnaCs;omeGs;lnaAs;omeCs;lnaC 987854

80 mOl s;omeAs;lnaAs;omeGs;lnaTs;omeCs;lnaTs;om

eGs;lnaG-Sup

ADIPOQ- GGCGACCAAGTCTGG lnaGs;lnaGs;lnaCs;dGs;dAs;dCs;dCs;dAs;dAs;d 987854

80 m08 Gs;dTs;dCs;lnaTs;lnaGs;lnaG-Sup

ADIPOQ- CCAGACTTGGTCGCC lnaCs;omeCs;lnaAs;omeGs;lnaAs;omeCs;lnaTs 989670

81 mOl ;omeUs;lnaGs;omeGs;lnaTs;omeCs;lnaGs;om

eCs;lnaC-Sup

ADIPOQ- CCAGACTTGGTCGCC lnaCs;lnaCs;lnaAs;dGs;dAs;dCs;dTs;dTs;dGs;d 989670

81 m08 Gs;dTs;dCs;lnaGs;lnaCs;lnaC-Sup

ADIPOQ- GCGACCAAGTCTGGC lnaGs;omeCs;lnaGs;omeAs;lnaCs;omeCs;lnaA 987855

82 mOl s;omeAs;lnaGs;omeUs;lnaCs;omeUs;lnaGs;o

meGs;lnaC-Sup

ADIPOQ- GCGACCAAGTCTGGC lnaGs;lnaCs;lnaGs;dAs;dCs;dCs;dAs;dAs;dGs;d 987855

82 m08 Ts;dCs;dTs;lnaGs;lnaGs;lnaC-Sup ADIPOQ- GCCAGACTTGGTCGC lnaGs;omeCs;lnaCs;omeAs;lnaGs;omeAs;lnaC 989671

83 mOl s;omeUs;lnaTs;omeGs;lnaGs;omeUs;lnaCs;o

meGs;lnaC-Sup

ADIPOQ- GCCAGACTTGGTCGC lnaGs;lnaCs;lnaCs;dAs;dGs;dAs;dCs;dTs;dTs;d 989671

83 m08 Gs;dGs;dTs;lnaCs;lnaGs;lnaC-Sup

ADIPOQ- CGACCAAGTCTGGCT lnaCs;omeGs;lnaAs;omeCs;lnaCs;omeAs;lnaA 987856

84 mOl s;omeGs;lnaTs;omeCs;lnaTs;omeGs;lnaGs;om

eCs;lnaT-Sup

ADIPOQ- CGACCAAGTCTGGCT lnaCs;lnaGs;lnaAs;dCs;dCs;dAs;dAs;dGs;dTs;d 987856

84 m08 Cs;dTs;dGs;lnaGs;lnaCs;lnaT-Sup

ADIPOQ- AGCCAGACTTGGTCG lnaAs;omeGs;lnaCs;omeCs;lnaAs;omeGs;lnaA 989672

85 mOl s;omeCs;lnaTs;omeUs;lnaGs;omeGs;lnaTs;om

eCs;lnaG-Sup

ADIPOQ- AGCCAGACTTGGTCG lnaAs;lnaGs;lnaCs;dCs;dAs;dGs;dAs;dCs;dTs;d 989672

85 m08 Ts;dGs;dGs;lnaTs;lnaCs;lnaG-Sup

ADIPOQ- CATACACCTGGAGCC lnaCs;omeAs;lnaTs;omeAs;lnaCs;omeAs;lnaCs 989673

86 mOl ;omeCs;lnaTs;omeGs;lnaGs;omeAs;lnaGs;om

eCs;lnaC-Sup

ADIPOQ- CATACACCTGGAGCC lnaCs;lnaAs;lnaTs;dAs;dCs;dAs;dCs;dCs;dTs;d 989673

86 m08 Gs;dGs;dAs;lnaGs;lnaCs;lnaC-Sup

ADIPOQ- GCTCCAGGTGTATGG lnaGs;omeCs;lnaTs;omeCs;lnaCs;omeAs;lnaG 987868

87 mOl s;omeGs;lnaTs;omeGs;lnaTs;omeAs;lnaTs;om

eGs;lnaG-Sup

ADIPOQ- GCTCCAGGTGTATGG lnaGs;lnaCs;lnaTs;dCs;dCs;dAs;dGs;dGs;dTs;d 987868

87 m08 Gs;dTs;dAs;lnaTs;lnaGs;lnaG-Sup

ADIPOQ- CCATACACCTGGAGC lnaCs;omeCs;lnaAs;omeUs;lnaAs;omeCs;lnaA 989674

88 mOl s;omeCs;lnaCs;omeUs;lnaGs;omeGs;lnaAs;o

meGs;lnaC-Sup

ADIPOQ- CCATACACCTGGAGC lnaCs;lnaCs;lnaAs;dTs;dAs;dCs;dAs;dCs;dCs;d 989674

88 m08 Ts;dGs;dGs;lnaAs;lnaGs;lnaC-Sup

ADIPOQ- GACTCTATGCTGATA lnaGs;omeAs;lnaCs;omeUs;lnaCs;omeUs;lnaA 987900

89 mOl s;omeUs;lnaGs;omeCs;lnaTs;omeGs;lnaAs;om

eUs;lnaA-Sup

ADIPOQ- GACTCTATGCTGATA lnaGs;lnaAs;lnaCs;dTs;dCs;dTs;dAs;dTs;dGs;d 987900

89 m08 Cs;dTs;dGs;lnaAs;lnaTs;lnaA-Sup

ADIPOQ- TATCAGCATAGAGTC lnaTs;omeAs;lnaTs;omeCs;lnaAs;omeGs;lnaCs 989675

90 mOl ;omeAs;lnaTs;omeAs;lnaGs;omeAs;lnaGs;om

eUs;lnaC-Sup

ADIPOQ- TATCAGCATAGAGTC lnaTs;lnaAs;lnaTs;dCs;dAs;dGs;dCs;dAs;dTs;d 989675

90 m08 As;dGs;dAs;lnaGs;lnaTs;lnaC-Sup

BRIEF DESCRIPTION OF THE SEQUENCE LISTING SEQ ID Chrom Gene Chr. Start Chr. End Strand

1 chr2 BCL2L11 111866490 111938022 +

2 chr2 BCL2L11 111866490 111938022 -

3 chr2 Bcl2lll 127939773 128000283 +

4 chr2 Bcl2lll 127939773 128000283 -

5 chrl7 BRCA1 41184311 41289340 -

6 chrl7 BRCA1 41184311 41289340 +

7 chrll Brcal 101338077 101425269 -

8 chrll Brcal 101338077 101425269 +

9 chrX F8 154052063 154126577 -

10 chrX F8 154052063 154126577 +

11 chrX F8 72406055 72637380 -

12 chrX F8 72406055 72637380 +

13 chrll FLU 128551812 128695162 +

14 chrll FLU 128551812 128695162 -

15 chr9 Flil 32217792 32360953 -

16 chr9 Flil 32217792 32360953 +

17 chrX FMR1 146981468 147044647 +

18 chrX FMR1 146981468 147044647 -

19 chrX Fmrl 65919729 65983136 +

20 chrX Fmrl 65919729 65983136 -

21 chrl FNDC5 33315868 33348414 -

22 chrl FNDC5 33315868 33348414 +

23 chr4 Fndc5 128802303 128833837 +

24 chr4 Fndc5 128802303 128833837 -

25 chr7 GCK 44171869 44210887 -

26 chr7 GCK 44171869 44210887 +

27 chrll Gck 5788825 5861602 -

28 chrll Gck 5788825 5861602 +

29 chr6 GLP1R 39004556 39067520 +

30 chr6 GLP1R 39004556 39067520 -

31 chrl7 Glplr 31026811 31085455 +

32 chrl7 Glplr 31026811 31085455 -

33 chrl7 GRN 42410490 42442470 +

34 chrl7 GRN 42410490 42442470 -

35 chrll Grn 102279635 102310123 +

36 chrll Grn 102279635 102310123 -

37 chrl9 HAMP 35761409 35788045 +

38 chrl9 HAMP 35761409 35788045 - SEQ ID Chrom Gene Chr. Start Chr. End Strand

39 chr7 Hamp 31715387 31741036 -

40 chr7 Hamp 31715387 31741036 +

41 chrX Hprt 50329254 50386837 +

42 chrX Hprt 50329254 50386837 -

43 chrX HPRT1 133582174 133646698 +

44 chrX HPRT1 133582174 133646698 -

45 chr8 ID01 39759327 39798309 +

46 chr8 ID01 39759327 39798309 -

47 chr8 Idol 25682612 25719481 -

48 chr8 Idol 25682612 25719481 +

49 chrl2 IGF1 102799453 102886378 -

50 chrl2 IGF1 102799453 102886378 +

51 chrlO Igfl 87311855 87390515 +

52 chrlO Igfl 87311855 87390515 -

53 chrl IL10 206928947 206957839 -

54 chrl IL10 206928947 206957839 +

55 chrl 1110 132904421 132933547 +

56 chrl 1110 132904421 132933547 -

57 chrl9 LDLR 11188037 11256505 +

58 chrl9 LDLR 11188037 11256505 -

59 chr9 Ldlr 21516037 21566362 +

60 chr9 Ldlr 21516037 21566362 -

61 chrl2 NANOG 7929994 7960655 +

62 chrl2 NANOG 7929994 7960655 -

63 chr6 Nanog 122645585 122675796 +

64 chr6 Nanog 122645585 122675796 -

65 chrl PTGS2 186628943 186661559 -

66 chrl PTGS2 186628943 186661559 +

67 chrl Ptgs2 151935253 151967142 +

68 chrl Ptgs2 151935253 151967142 -

69 chrl3 RBI 48865882 49068026 +

70 chrl3 RBI 48865882 49068026 -

71 chrl4 Rbl 73583308 73737598 -

72 chrl4 Rbl 73583308 73737598 +

73 chrl7 SERPINF1 1653258 1692859 +

74 chrl7 SERPINF1 1653258 1692859 -

75 chrll Serpinfl 75211530 75248125 -

76 chrll Serpinfl 75211530 75248125 + SEQ ID Chrom Gene Chr. Start Chr. End Strand

77 chrlO SIRT1 69632426 69690147 +

78 chrlO SIRT1 69632426 69690147 -

79 chrlO Sirtl 62769752 62813780 -

80 chrlO Sirtl 62769752 62813780 +

81 chrl9 SIRT6 4162105 4194596 -

82 chrl9 SIRT6 4162105 4194596 +

83 chrlO Sirt6 81072530 81102353 -

84 chrlO Sirt6 81072530 81102353 +

85 chrl8 SMAD7 46434222 46489081 -

86 chrl8 SMAD7 46434222 46489081 +

87 chrl8 Smad7 75515018 75567588 +

88 chrl8 Smad7 75515018 75567588 -

89 chr7 ST7 116581380 116875961 +

90 chr7 ST7 116581380 116875961 -

91 chr6 St7 17687215 17905022 +

92 chr6 St7 17687215 17905022 -

93 chrl7 STAT3 40453342 40552405 -

94 chrl7 STAT3 40453342 40552405 +

95 chrll Stat3 100736123 100812825 -

96 chrll Stat3 100736123 100812825 +

815175 chr7 CFTR 117108016 117320718 +

815176 chr7 CFTR 117108016 117320718 -

815177 chr6 Cftr 18108686 18284769 +

815178 chr6 Cftr 18108686 18284769 -

868590 chrl2 PAH 103220103 103323381 -

868591 chrl2 PAH 103220103 103323381 +

868592 chrlO Pah 86972539 87058882 +

868593 chrlO Pah 86972539 87058882 -

899865 chrl2 CEP290 88430789 88547993 -

899866 chrl2 CEP290 88430789 88547993 +

899867 chrlO Cep290 99938922 100048289 +

899868 chrlO Cep290 99938922 100048289 -

962801 chr9 CD274 5438502 5482567 +

962802 chr9 CD274 5438502 5482567 -

962803 chrl9 Cd274 29429927 29474584 +

962804 chrl9 Cd274 29429927 29474584 -

981187 ADIPOQ chr3 186548463 186588252 +

981188 ADIPOQ chr3 186548463 186588252 - SEQ ID Chrom Gene Chr. Start Chr. End Strand

981189 Adipoq chrl6 23134609 23170041 +

981190 Adipoq chrl6 23134609 23170041 -

PRC2 Associated Regions and Target Genes

Target Gene (same strand Target Gene (opposite strand

SeqID Chrom Chr. Start Chr. End match) match)

97 chrl 33321540 33321585 FNDC5(252995)[-6283] S100PBP(64766)[45]

98 chrl 33327956 33328002 FNDC5(252995)[46] S100PBP(64766)[-3480]

99 chrl 33333728 33333780 FNDC5(252995)[52] S100PBP(64766)[-9252]

100 chrl 33336337 33336421 FNDC5(252995)[84]

101 chrl 186641043 186641090 PTGS2(5743)[47]

102 chrl 186641447 186641494 PTGS2(5743)[47]

103 chrl 186641571 186641616 PTGS2(5743)[45]

104 chrl 186641730 186641783 PTGS2(5743)[53]

105 chrl 186641798 186641842 PTGS2(5743)[44]

106 chrl 186642310 186642358 PTGS2(5743)[48]

107 chrl 186642568 186642614 PTGS2(5743)[46]

108 chrl 186643025 186643073 PTGS2(5743)[48]

109 chrl 186643197 186643247 PTGS2(5743)[50]

110 chrl 186643588 186643635 PTGS2(5743)[47]

111 chrl 186643651 186643697 PTGS2(5743)[46]

112 chrl 186643756 186643844 PTGS2(5743)[88]

113 chrl 186644457 186644492 PTGS2(5743)[35]

114 chrl 186645239 186645287 PTGS2(5743)[48]

115 chrl 186645959 186646004 PTGS2(5743)[45]

116 chrl 186646852 186646898 PTGS2(5743)[46]

117 chrl 186646902 186646950 PTGS2(5743)[48]

118 chrl 186647483 186647534 PTGS2(5743)[51]

119 chrl 206945495 206945527 IL10(3586)[32]

SI Tl(23411)[-592],

120 chrlO 69643788 69643834 RPL12P8(645161)[-9139]

SIRT1(23411)[44],

121 chrlO 69644430 69644474 RPL12P8(645161)[-9781]

122 chrlO 69645138 69645179 SIRT1(23411)[41]

123 chrlO 69648720 69648798 SIRT1(23411)[78]

124 chrlO 69651156 69651201 SIRT1(23411)[45]

125 chrlO 69651247 69651292 SIRT1(23411)[45]

126 chrlO 69666351 69666408 SIRT1(23411)[57] 127 chrlO 69666574 69666606 SI T1(23411)[32]

128 chrlO 69672728 69672777 SIRT1(23411)[49] HERC4(26091)[-8878]

129 chrlO 69677033 69677081 SIRT1(23411)[48] HERC4(26091)[-4574]

LOC100507392(100507392)[-

130 chrll 128554928 128554974 FLIl(2313)[-8836] 6592]

LOC100507392(100507392)[-

131 chrll 128557815 128557845 FLIl(2313)[-5965] 3721]

132 chrll 128562433 128562475 FLI1(2313)[-1335] LOC100507392(100507392)[42]

133 chrll 128563529 128563575 FLIl(2313)[-235] LOC100507392(100507392)[46]

134 chrll 128563795 128563845 FLI1(2313)[35] LOC100507392(100507392)[50]

135 chrll 128564848 128564903 FLI1(2313)[55] LOC100507392(100507392)[55]

136 chrll 128586909 128586943 FLI1(2313)[34]

137 chrll 128590789 128590827 FLI1(2313)[38]

138 chrll 128614877 128614917 FLI1(2313)[40]

139 chrll 128617946 128617991 FLI1(2313)[45]

140 chrll 128653829 128653891 FLI1(2313)[62]

141 chrll 128670605 128670650 FLI1(2313)[45]

142 chrll 128681526 128681572 FLI1(2313)[46]

143 chrl2 7942097 7942135 NANOG(79923)[38]

144 chrl2 7942251 7942298 NANOG(79923)[47]

145 chrl2 7947518 7947563 NANOG(79923)[45]

146 chrl2 102807122 102807162 IGF1(3479)[40]

147 chrl2 102833633 102833675 IGF1(3479)[42]

148 chrl2 102833864 102833896 IGF1(3479)[32]

149 chrl2 102877198 102877238 IGFl(3479)[-2820]

150 chrl3 48878529 48878560 RB1(5925)[31]

151 chrl3 48884097 48884143 RB1(5925)[46] PPP1R26P1(100418740)[-6851]

PCNPP5(100507361)[22],

152 chrl3 48902095 48902117 RB1(5925)[22] PPPlR26Pl(100418740)[-7485]

PCNPP5(100507361)[39],

153 chrl3 48902671 48902710 RB1(5925)[39] PPP1R26P1(100418740)[-8061]

154 chrl3 48914793 48914835 RB1(5925)[42]

155 chrl3 48933249 48933270 RB1(5925)[21]

156 chrl3 48933319 48933350 RB1(5925)[31]

157 chrl3 48933383 48933428 RB1(5925)[45]

158 chrl3 48933786 48933829 RB1(5925)[43]

159 chrl3 48942430 48942480 RB1(5925)[50]

160 chrl3 48945786 48945886 RB1(5925)[100]

161 chrl3 48945901 48946294 RB1(5925)[393]

162 chrl3 48966237 48966563 RB1(5925)[326]

163 chrl3 48966646 48966696 RB1(5925)[50]

164 chrl3 48967853 48967895 RB1(5925)[42] 165 chrl3 48975772 48975818 RB1(5925)[46] LPAR6(10161)[-9363]

166 chrl3 48976287 48976339 RB1(5925)[52] LPAR6(10161)[-8842]

167 chrl3 48977888 48977941 RB1(5925)[53] LPAR6(10161)[-7240]

168 chrl3 49010203 49010249 RB1(5925)[46] LPAR6(10161)[46]

169 chrl3 49030430 49030476 RB1(5925)[46]

170 chrl3 49055892 49055939 RB1(5925)[47] RCBTB2(1102)[-7159]

SERPINF1(5176)[39],

171 chrl7 1666284 1666323 SERPINF2(5345)[-7725]

172 chrl7 1670235 1670277 SERPINF1(5176)[42]

173 chrl7 1674355 1674437 SERPINF1(5176)[82] SMYD4(114826)[-8391]

174 chrl7 1675185 1675255 SERPINF1(5176)[70] SMYD4(114826)[-7573]

175 chrl7 1675312 1675358 SERPINF1(5176)[46] SMYD4(114826)[-7470]

176 chrl7 1678374 1678420 SERPINF1(5176)[46] SMYD4(114826)[-4408]

177 chrl7 1678449 1678495 SERPINF1(5176)[46] SMYD4(114826)[-4333]

178 chrl7 1679184 1679241 SERPINF1(5176)[57] SMYD4(114826)[-3587]

179 chrl7 1679860 1679952 SERPINF1(5176)[92] SMYD4(114826)[-2876]

180 chrl7 1680411 1680447 SERPINF1(5176)[36] SMYD4(114826)[-2381]

181 chrl7 1680537 1680660 SERPINF1(5176)[123] SMYD4(114826)[-2168]

182 chrl7 1680674 1680717 SERPINF1(5176)[43] SMYD4(114826)[-2111]

183 chrl7 1680770 1680832 SERPINF1(5176)[62] SMYD4(114826)[-1996]

184 chrl7 1686489 1686539 SERPINFl(5176)[-5630] SMYD4(114826)[50]

185 chrl7 1690784 1690829 SERPINFl(5176)[-9925] SMYD4(114826)[45]

186 chrl7 40458254 40458299 STAT3(6774)[-7043] STAT5A(6776)[45]

187 chrl7 40458587 40458634 STAT3(6774)[-6708] STAT5A(6776)[47]

188 chrl7 40462644 40462690 STAT3(6774)[-2652] STAT5A(6776)[46]

189 chrl7 40467685 40467729 STAT3(6774)[44] STAT5A(6776)[-3725]

190 chrl7 40467751 40467796 STAT3(6774)[45] STAT5A(6776)[-3791]

191 chrl7 40469121 40469156 STAT3(6774)[35] STAT5A(6776)[-5161]

192 chrl7 40471938 40472007 STAT3(6774)[69] STAT5A(6776)[-7978]

193 chrl7 40473573 40473627 STAT3(6774)[54] STAT5A(6776)[-9613]

194 chrl7 40474301 40474392 STAT3(6774)[91]

195 chrl7 40475018 40475062 STAT3(6774)[44]

196 chrl7 40478110 40478142 STAT3(6774)[32]

197 chrl7 40481557 40481595 STAT3(6774)[38]

198 chrl7 40483477 40483503 STAT3(6774)[26]

199 chrl7 40485939 40485980 STAT3(6774)[41]

200 chrl7 40489494 40489536 STAT3(6774)[42]

201 chrl7 40490756 40490801 STAT3(6774)[45]

202 chrl7 40491345 40491391 STAT3(6774)[46]

203 chrl7 40500426 40500468 STAT3(6774)[42]

204 chrl7 40501605 40501650 STAT3(6774)[45] 205 chrl7 40506887 40506937 STAT3(6774)[50]

206 chrl7 40514881 40514946 STAT3(6774)[65]

207 chrl7 40531595 40531657 STAT3(6774)[62]

208 chrl7 40535596 40535704 STAT3(6774)[108]

209 chrl7 40535736 40535778 STAT3(6774)[42]

210 chrl7 40537565 40537603 STAT3(6774)[38]

211 chrl7 40539000 40539044 STAT3(6774)[44]

212 chrl7 40540181 40540233 STAT3(6774)[52]

213 chrl7 41196483 41196519 BRCA1(672)[36]

214 chrl7 41197661 41197730 BRCA1(672)[69]

215 chrl7 41197911 41198817 BRCA1(672)[906]

216 chrl7 41202966 41203009 BRCA1(672)[43]

217 chrl7 41211738 41211793 BRCA1(672)[55]

218 chrl7 41213401 41213478 BRCA1(672)[77]

219 chrl7 41214577 41215228 BRCA1(672)[651]

220 chrl7 41217147 41217193 BRCA1(672)[46]

221 chrl7 41218773 41219139 BRCA1(672)[366]

222 chrl7 41221904 41222301 BRCA1(672)[397] RPL21P4(140660)[-8976]

223 chrl7 41222949 41222991 BRCA1(672)[42] RPL21P4(140660)[-8286]

224 chrl7 41228584 41228629 BRCA1(672)[45] RPL21P4(140660)[-2648]

225 chrl7 41229105 41229149 BRCA1(672)[44] RPL21P4(140660)[-2128]

226 chrl7 41234824 41234884 BRCA1(672)[60] RPL21P4(140660)[-2991]

227 chrl7 41243483 41243524 BRCA1(672)[41]

228 chrl7 41243934 41243963 BRCA1(672)[29]

229 chrl7 41244287 41244331 BRCA1(672)[44]

230 chrl7 41244494 41244540 BRCA1(672)[46]

231 chrl7 41244814 41244865 BRCA1(672)[51]

232 chrl7 41245007 41245056 BRCA1(672)[49]

233 chrl7 41245122 41245168 BRCA1(672)[46]

234 chrl7 41245261 41245289 BRCA1(672)[28]

235 chrl7 41245362 41245408 BRCA1(672)[46]

236 chrl7 41245484 41245549 BRCA1(672)[65]

237 chrl7 41245606 41245652 BRCA1(672)[46]

238 chrl7 41245726 41245768 BRCA1(672)[42]

239 chrl7 41245883 41245913 BRCA1(672)[30]

240 chrl7 41246073 41246124 BRCA1(672)[51]

241 chrl7 41251844 41251892 BRCA1(672)[48]

242 chrl7 41256224 41256269 BRCA1(672)[45]

243 chrl7 42428434 42428480 GRN(2896)[46] FAM171A2(284069)[-2620]

244 chrl7 42428931 42428977 GRN(2896)[46] FAM171A2(284069)[-2123]

245 chrl7 42429010 42429056 GRN(2896)[46] FAM171A2(284069)[-2044] 246 chrl7 42429408 42429453 GRN(2896)[45] FAM171A2(284069)[-1647]

247 chrl7 42430115 42430161 GRN(2896)[46] FAM171A2(284069)[-939]

248 chrl7 42430242 42430293 GRN(2896)[51] FAM171A2(284069)[-807]

249 chrl7 42431151 42431193 GRN(2896)[-681] FAM171A2(284069)[42]

FAM171A2(284069)[31],

250 chrl7 42435098 42435129 GRN(2896)[-4628] RPL7LlP5(390800)[-7255]

251 chrl8 46446327 46446370 SMAD7(4092)[43]

252 chrl8 46446538 46446584 SMAD7(4092)[46]

253 chrl8 46447045 46447088 SMAD7(4092)[43]

254 chrl8 46448077 46448141 SMAD7(4092)[64]

255 chrl8 46448226 46448271 SMAD7(4092)[45]

256 chrl8 46448491 46448539 SMAD7(4092)[48]

257 chrl8 46448944 46448981 SMAD7(4092)[37]

258 chrl8 46449786 46449831 SMAD7(4092)[45]

259 chrl8 46450423 46450538 SMAD7(4092)[115]

260 chrl8 46450886 46450923 SMAD7(4092)[37]

261 chrl8 46451155 46451213 SMAD7(4092)[58]

262 chrl8 46451355 46451402 SMAD7(4092)[47]

263 chrl8 46455352 46455392 SMAD7(4092)[40]

264 chrl8 46455564 46455605 SMAD7(4092)[41]

265 chrl8 46455678 46455723 SMAD7(4092)[45]

266 chrl8 46455988 46456026 SMAD7(4092)[38]

267 chrl8 46456321 46456365 SMAD7(4092)[44]

268 chrl8 46456495 46456544 SMAD7(4092)[49]

269 chrl8 46458464 46458511 SMAD7(4092)[47]

270 chrl8 46458614 46458638 SMAD7(4092)[24]

271 chrl8 46458872 46458926 SMAD7(4092)[54]

272 chrl8 46459269 46459310 SMAD7(4092)[41]

273 chrl8 46461123 46461227 SMAD7(4092)[104]

274 chrl8 46461237 46461307 SMAD7(4092)[70]

275 chrl8 46461371 46461429 SMAD7(4092)[58]

276 chrl8 46461518 46461557 SMAD7(4092)[39]

277 chrl8 46461579 46461693 SMAD7(4092)[114]

278 chrl8 46464744 46464809 SMAD7(4092)[65]

279 chrl8 46465648 46465694 SMAD7(4092)[46]

280 chrl8 46466370 46466424 SMAD7(4092)[54]

281 chrl8 46466536 46466582 SMAD7(4092)[46]

282 chrl8 46467360 46467384 SMAD7(4092)[24]

283 chrl8 46467488 46467525 SMAD7(4092)[37]

284 chrl8 46468211 46468285 SMAD7(4092)[74]

285 chrl8 46469650 46469693 SMAD7(4092)[43] 286 chrl8 46469752 46469801 SMAD7(4092)[49]

287 chrl8 46469838 46469883 SMAD7(4092)[45]

288 chrl8 46469956 46470022 SMAD7(4092)[66]

289 chrl8 46470181 46470229 SMAD7(4092)[48]

290 chrl8 46470289 46470370 SMAD7(4092)[81]

291 chrl8 46470511 46470573 SMAD7(4092)[62]

292 chrl8 46470595 46470667 SMAD7(4092)[72]

293 chrl8 46471007 46471074 SMAD7(4092)[67]

294 chrl8 46471422 46471919 SMAD7(4092)[497]

295 chrl8 46471976 46472031 SMAD7(4092)[55]

296 chrl8 46472475 46472519 SMAD7(4092)[44]

297 chrl8 46472920 46472966 SMAD7(4092)[46]

298 chrl8 46473058 46473103 SMAD7(4092)[45]

299 chrl8 46473468 46473512 SMAD7(4092)[44]

300 chrl8 46473917 46473968 SMAD7(4092)[51]

301 chrl8 46474400 46474446 SMAD7(4092)[46]

302 chrl8 46476824 46476866 SMAD7(4092)[42]

303 chrl8 46477311 46477380 SMAD7(4092)[-230]

304 chrl8 46477380 46477448 SMAD7(4092)[-299]

305 chrl8 46477565 46477612 SMAD7(4092)[-484]

306 chrl8 46477641 46477689 SMAD7(4092)[-560]

307 chrl8 46477743 46477810 SMAD7(4092)[-662]

308 chrl8 46478765 46478861 SMAD7(4092)[-1684]

309 chrl9 4171996 4172038 SIRT6(51548)[-2067] CREB3L3(84699)[42]

CREB3L3(84699)[-2058],

310 chrl9 4175106 4175148 SIRT6(51548)[42] ANKRD24(170961)[-8202]

CREB3L3(84699)[-4033],

311 chrl9 4177081 4177127 SIRT6(51548)[46] ANKRD24(170961)[-6223]

312 chrl9 11200245 11200291 LDLR(3949)[46]

313 chrl9 11200383 11200486 LDLR(3949)[103]

314 chrl9 11203622 11203668 LDLR(3949)[46]

315 chrl9 11210902 11210935 LDLR(3949)[33]

316 chrl9 11210970 11211012 LDLR(3949)[42]

317 chrl9 11218034 11218089 LDLR(3949)[55]

318 chrl9 11221381 11221426 LDLR(3949)[45]

319 chrl9 11224284 11224326 LDLR(3949)[42]

320 chrl9 11230020 11230046 LDLR(3949)[26]

321 chrl9 11231073 11231115 LDLR(3949)[42]

322 chrl9 11231140 11231182 LDLR(3949)[42]

323 chrl9 11242210 11242295 LDLR(3949)[85]

324 chrl9 11242349 11242411 LDLR(3949)[62] 325 chrl9 11243907 11243955 LDLR(3949)[48]

326 chrl9 11244132 11244210 LDLR(3949)[78]

327 chrl9 11244409 11244455 LDLR(3949)[46]

USF2(7392)[56], LSR(51599)[-

328 chrl9 35763523 35763579 4656], HAMP(57817)[-9830]

USF2(7392)[143], LSR(51599)[-

329 chrl9 35763599 35763742 4732], HAMP(57817)[-9667]

USF2(7392)[35], LSR(51599)[-

330 chrl9 35763775 35763810 4908], HAMP(57817)[-9599]

USF2(7392)[67], LSR(51599)[-

331 chrl9 35764216 35764283 5349], HAMP(57817)[-9126]

USF2(7392)[67],

332 chrl9 35769783 35769850 HAMP(57817)[-3559]

USF2(7392)[50],

333 chrl9 35770630 35770680 HAMP(57817)[-2729]

MAG(4099)[-2548],

HAMP(57817)[-4363],

334 chrl9 35780408 35780440 USF2(7392)[-9690]

ACOXL(55289)[59],

335 chr2 111874741 111874800 BCL2Lll(10018)[-3690] FLJ44006(400997)[-2979]

ACOXL(55289)[42],

336 chr2 111875484 111875526 BCL2Lll(10018)[-2964] FLJ44006(400997)[-3722]

ACOXL(55289)[-771],

337 chr2 111876570 111876609 BCL2L11(10018)[-1881] FLJ44006(400997)[-4808]

BCL2L11(10018)[54],

338 chr2 111884760 111884814 ACOXL(55289)[-8961]

339 chr2 111900874 111900919 BCL2L11(10018)[45]

340 chr2 111901576 111901618 BCL2L11(10018)[42]

341 chr2 111909725 111909767 BCL2L11(10018)[42]

342 chr2 111912202 111912286 BCL2L11(10018)[84]

343 chr2 111913452 111913475 BCL2L11(10018)[23]

344 chr2 111913810 111913867 BCL2L11(10018)[57]

345 chr2 111918896 111918926 BCL2L11(10018)[30]

346 chr2 111919307 111919329 BCL2L11(10018)[22]

347 chr2 111921357 111921435 BCL2L11(10018)[78]

348 chr2 111921782 111921828 BCL2L11(10018)[46]

349 chr2 111921983 111922029 BCL2L11(10018)[46]

350 chr2 111922061 111922112 BCL2L11(10018)[51]

351 chr2 111923184 111923229 BCL2L11(10018)[45]

352 chr2 111923480 111923533 BCL2L11(10018)[53]

353 chr2 111924148 111924178 BCL2L11(10018)[30]

354 chr6 39019719 39019758 GLP1R(2740)[39]

355 chr6 39026997 39027047 GLP1R(2740)[50]

356 chr6 39027295 39027329 GLP1R(2740)[34] 357 chr6 39028068 39028124 GLP1 (2740)[56]

358 chr6 39028771 39028817 GLP1R(2740)[46]

359 chr6 39047993 39048028 GLP1R(2740)[35]

360 chr6 39054054 39054101 GLP1R(2740)[47]

361 chr6 39056381 39056477 GLP1R(2740)[-861]

MYL7(58498)[-348],

362 chr7 44178060 44178114 GCK(2645)[-5755]

MYL7(58498)[42], GCK(2645)[-

363 chr7 44179962 44180004 3865]

MYL7(58498)[46], GCK(2645)[-

364 chr7 44180335 44180381 3488]

GCK(2645)[-269],

365 chr7 44183576 44183600 MYL7(58498)[-2660]

GCK(2645)[42], MYL7(58498)[-

366 chr7 44190023 44190065 9107]

367 chr7 44191933 44191978 GCK(2645)[45]

368 chr7 44196261 44196302 GCK(2645)[41]

369 chr7 44228529 44228580 GCK(2645)[51]

ST7(7982)[38], ST7-

370 chr7 116595999 116596037 OT4(338069)[38] ST7-AS1(93653)[-1611]

371 chr7 116624638 116624690 ST7(7982)[52]

372 chr7 116625757 116625802 ST7(7982)[45]

373 chr7 116650635 116650688 ST7(7982)[53]

374 chr7 116660757 116660806 ST7(7982)[49]

375 chr7 116662866 116662927 ST7(7982)[61]

376 chr7 116676974 116677010 ST7(7982)[36]

377 chr7 116686722 116686769 ST7(7982)[47]

378 chr7 116707400 116707483 ST7(7982)[83]

379 chr7 116720624 116720666 ST7(7982)[42]

380 chr7 116724345 116724391 ST7(7982)[46]

381 chr7 116725722 116725775 ST7(7982)[53]

382 chr7 116726550 116726589 ST7(7982)[39]

383 chr7 116726815 116726855 ST7(7982)[40]

384 chr7 116756048 116756092 ST7(7982)[44] ST7-AS2(93654)[44]

385 chr7 116764078 116764126 ST7(7982)[48] ST7-AS2(93654)[48]

386 chr7 116769409 116769434 ST7(7982)[25] ST7-AS2(93654)[25]

387 chr7 116770594 116770635 ST7(7982)[41] ST7-AS2(93654)[41]

388 chr7 116774356 116774402 ST7(7982)[46] ST7-AS2(93654)[46]

389 chr7 116774449 116774493 ST7(7982)[44] ST7-AS2(93654)[44]

390 chr7 116774569 116774629 ST7(7982)[60] ST7-AS2(93654)[60]

391 chr7 116774725 116774770 ST7(7982)[45] ST7-AS2(93654)[45]

392 chr7 116775116 116775168 ST7(7982)[52] ST7-AS2(93654)[52] 393 chr7 116776217 116776269 ST7(7982)[52] ST7-AS2(93654)[52]

394 chr7 116778263 116778308 ST7(7982)[45] ST7-AS2(93654)[45]

395 chr7 116778487 116778584 ST7(7982)[97] ST7-AS2(93654)[97]

ST7(7982)[44], ST7-

396 chr7 116813917 116813961 OT3(93655)[-8773]

ST7(7982)[51], ST7-

397 chr7 116818961 116819012 OT3(93655)[-3722]

ST7(7982)[61], ST7-

398 chr7 116820336 116820397 OT3(93655)[-2337]

ST7(7982)[40], ST7-

399 chr7 116821346 116821386 OT3(93655)[-1348]

ST7(7982)[46], ST7-

400 chr7 116830139 116830185 OT3(93655)[46]

ST7(7982)[42], ST7-

401 chr7 116847544 116847586 OT3(93655)[42]

402 chr7 116862145 116862183 ST7(7982)[38]

403 chr7 116862240 116862284 ST7(7982)[44]

404 chr7 116865552 116865593 ST7(7982)[41]

405 chr8 39778542 39778579 IDOl(3620)[37]

406 chrX 133597598 133597645 HPRT1(3251)[47]

407 chrX 133609331 133609378 HPRT1(3251)[47]

408 chrX 133621494 133621542 HPRT1(3251)[48]

409 chrX 133621803 133621843 HPRT1(3251)[40]

410 chrX 133624277 133624349 HPRT1(3251)[72]

411 chrX 133627514 133627603 HPRT1(3251)[89]

412 chrX 133628177 133628202 HPRT1(3251)[25]

413 chrX 133628358 133628403 HPRT1(3251)[45]

414 chrX 133634063 133634112 HPRT1(3251)[49]

415 chrX 133634219 133634273 HPRT1(3251)[54]

416 chrX 133634349 133634419 HPRT1(3251)[70]

417 chrX 146994273 146994317 FMR1(2332)[44] FMR1-AS1(100126270)[44]

418 chrX 146994340 146994407 FMR1(2332)[67] FMR1-AS1(100126270)[67]

419 chrX 146994536 146994651 FMR1(2332)[115] FMR1-AS1(100126270)[115]

420 chrX 146994704 146994754 FMR1(2332)[50] FMR1-AS1(100126270)[50]

421 chrX 146994910 146994962 FMR1(2332)[52] FMR1-AS1(100126270)[52]

422 chrX 146995057 146995114 FMR1(2332)[57] FMR1-AS1(100126270)[57]

423 chrX 146995153 146995247 FMR1(2332)[94] FMR1-AS1(100126270)[94]

424 chrX 146995834 146995880 FMR1(2332)[46] FMR1-AS1(100126270)[46]

425 chrX 146997285 146997332 FMR1(2332)[47] FMR1-AS1(100126270)[47]

426 chrX 146999318 146999381 FMR1(2332)[63] FMR1-AS1(100126270)[63]

427 chrX 146999780 146999822 FMR1(2332)[42] FMR1-AS1(100126270)[42]

428 chrX 147003704 147003762 FMR1(2332)[58] FMRl-ASl(100126270)[-28] 429 chrX 147006583 147006630 FMR1(2332)[47] FMRl-ASl(100126270)[-2907]

430 chrX 147007061 147007111 FMR1(2332)[50] FMRl-ASl(100126270)[-3385]

431 chrX 147009255 147009307 FMR1(2332)[52] FMRl-ASl(100126270)[-5579]

432 chrX 147009866 147009911 FMR1(2332)[45] FMR1-AS1(100126270)[-6190]

433 chrX 147014001 147014047 FMR1(2332)[46]

434 chrX 147016764 147016808 FMR1(2332)[44]

435 chrX 147018028 147018101 FMR1(2332)[73]

436 chrX 147020266 147020312 FMR1(2332)[46]

437 chrX 147020375 147020450 FMR1(2332)[75]

438 chrX 147022776 147022871 FMR1(2332)[95]

439 chrX 147023821 147023867 FMR1(2332)[46]

440 chrX 147024122 147024162 FMR1(2332)[40]

441 chrX 147024653 147024741 FMR1(2332)[88]

442 chrX 147024859 147024904 FMR1(2332)[45]

443 chrX 147025738 147025821 FMR1(2332)[83]

444 chrX 147025910 147025956 FMR1(2332)[46]

445 chrX 147026054 147026120 FMR1(2332)[66]

446 chrX 147026148 147026223 FMR1(2332)[75]

447 chrX 147026308 147026380 FMR1(2332)[72]

448 chrX 147026455 147026506 FMR1(2332)[51]

449 chrX 147030397 147030443 FMR1(2332)[46]

450 chrX 147030600 147030644 FMR1(2332)[44]

451 chrX 147030762 147030809 FMR1(2332)[47]

452 chrX 147030873 147030925 FMR1(2332)[52]

453 chrX 147031114 147031160 FMR1(2332)[46]

454 chrX 147032022 147032068 FMR1(2332)[46]

455 chrX 147032538 147032587 FMR1(2332)[49]

456 chrX 154124781 154124812 F8(2157)[31]

457 chrX 154197368 154197405 F8(2157)[37]

458 chrX 154255514 154255559 F8(2157)[-4516] FUNDC2(65991)[45]

459 chrX 154255647 154255679 F8(2157)[-4649] FUNDC2(65991)[32]

460 chrl 33319540 33323585 FNDC5(252995)[-6283] S100PBP(64766)[45]

461 chrl 33325956 33330002 FNDC5(252995)[46] S100PBP(64766)[-3480]

462 chrl 33331728 33335780 FNDC5(252995)[52] S100PBP(64766)[-9252]

463 chrl 33334337 33338421 FNDC5(252995)[84]

464 chrl 186639043 186643090 PTGS2(5743)[47]

465 chrl 186639447 186643494 PTGS2(5743)[47]

466 chrl 186639571 186643616 PTGS2(5743)[45]

467 chrl 186639730 186643783 PTGS2(5743)[53]

468 chrl 186639798 186643842 PTGS2(5743)[44]

469 chrl 186640310 186644358 PTGS2(5743)[48] 470 chrl 186640568 186644614 PTGS2(5743)[46]

471 chrl 186641025 186645073 PTGS2(5743)[48]

472 chrl 186641197 186645247 PTGS2(5743)[50]

473 chrl 186641588 186645635 PTGS2(5743)[47]

474 chrl 186641651 186645697 PTGS2(5743)[46]

475 chrl 186641756 186645844 PTGS2(5743)[88]

476 chrl 186642457 186646492 PTGS2(5743)[35]

Ml chrl 186643239 186647287 PTGS2(5743)[48]

478 chrl 186643959 186648004 PTGS2(5743)[45]

479 chrl 186644852 186648898 PTGS2(5743)[46]

480 chrl 186644902 186648950 PTGS2(5743)[48]

481 chrl 186645483 186649534 PTGS2(5743)[51]

482 chrl 206943495 206947527 IL10(3586)[32]

SI Tl(23411)[-592],

483 chrlO 69641788 69645834 RPL12P8(645161)[-9139]

SIRT1(23411)[44],

484 chrlO 69642430 69646474 RPL12P8(645161)[-9781]

485 chrlO 69643138 69647179 SIRT1(23411)[41]

486 chrlO 69646720 69650798 SIRT1(23411)[78]

487 chrlO 69649156 69653201 SIRT1(23411)[45]

488 chrlO 69649247 69653292 SIRT1(23411)[45]

489 chrlO 69664351 69668408 SIRT1(23411)[57]

490 chrlO 69664574 69668606 SIRT1(23411)[32]

491 chrlO 69670728 69674777 SIRT1(23411)[49] HERC4(26091)[-8878]

492 chrlO 69675033 69679081 SIRT1(23411)[48] HERC4(26091)[-4574]

LOC100507392(100507392)[-

493 chrll 128552928 128556974 FLIl(2313)[-8836] 6592]

LOC100507392(100507392)[-

494 chrll 128555815 128559845 FLIl(2313)[-5965] 3721]

495 chrll 128560433 128564475 FLI1(2313)[-1335] LOC100507392(100507392)[42]

496 chrll 128561529 128565575 FLIl(2313)[-235] LOC100507392(100507392)[46]

497 chrll 128561795 128565845 FLI1(2313)[35] LOC100507392(100507392)[50]

498 chrll 128562848 128566903 FLI1(2313)[55] LOC100507392(100507392)[55]

499 chrll 128584909 128588943 FLI1(2313)[34]

500 chrll 128588789 128592827 FLI1(2313)[38]

501 chrll 128612877 128616917 FLI1(2313)[40]

502 chrll 128615946 128619991 FLI1(2313)[45]

503 chrll 128651829 128655891 FLI1(2313)[62]

504 chrll 128668605 128672650 FLI1(2313)[45]

505 chrll 128679526 128683572 FLI1(2313)[46]

506 chrl2 7940097 7944135 NANOG(79923)[38]

507 chrl2 7940251 7944298 NANOG(79923)[47] 508 chrl2 7945518 7949563 NANOG(79923)[45]

509 chrl2 102805122 102809162 IGF1(3479)[40]

510 chrl2 102831633 102835675 IGF1(3479)[42]

511 chrl2 102831864 102835896 IGF1(3479)[32]

512 chrl2 102875198 102879238 IGFl(3479)[-2820]

513 chrl3 48876529 48880560 RB1(5925)[31]

514 chrl3 48882097 48886143 RB1(5925)[46] PPP1R26P1(100418740)[-6851]

PCNPP5(100507361)[22],

515 chrl3 48900095 48904117 RB1(5925)[22] PPPlR26Pl(100418740)[-7485]

PCNPP5(100507361)[39],

516 chrl3 48900671 48904710 RB1(5925)[39] PPP1R26P1(100418740)[-8061]

517 chrl3 48912793 48916835 RB1(5925)[42]

518 chrl3 48931249 48935270 RB1(5925)[21]

519 chrl3 48931319 48935350 RB1(5925)[31]

520 chrl3 48931383 48935428 RB1(5925)[45]

521 chrl3 48931786 48935829 RB1(5925)[43]

522 chrl3 48940430 48944480 RB1(5925)[50]

523 chrl3 48943786 48947886 RB1(5925)[100]

524 chrl3 48943901 48948294 RB1(5925)[393]

525 chrl3 48964237 48968563 RB1(5925)[326]

526 chrl3 48964646 48968696 RB1(5925)[50]

527 chrl3 48965853 48969895 RB1(5925)[42]

528 chrl3 48973772 48977818 RB1(5925)[46] LPAR6(10161)[-9363]

529 chrl3 48974287 48978339 RB1(5925)[52] LPAR6(10161)[-8842]

530 chrl3 48975888 48979941 RB1(5925)[53] LPAR6(10161)[-7240]

531 chrl3 49008203 49012249 RB1(5925)[46] LPAR6(10161)[46]

532 chrl3 49028430 49032476 RB1(5925)[46]

533 chrl3 49053892 49057939 RB1(5925)[47] RCBTB2(1102)[-7159]

SERPINF1(5176)[39],

534 chrl7 1664284 1668323 SERPINF2(5345)[-7725]

535 chrl7 1668235 1672277 SERPINF1(5176)[42]

536 chrl7 1672355 1676437 SERPINF1(5176)[82] SMYD4(114826)[-8391]

537 chrl7 1673185 1677255 SERPINF1(5176)[70] SMYD4(114826)[-7573]

538 chrl7 1673312 1677358 SERPINF1(5176)[46] SMYD4(114826)[-7470]

539 chrl7 1676374 1680420 SERPINF1(5176)[46] SMYD4(114826)[-4408]

540 chrl7 1676449 1680495 SERPINF1(5176)[46] SMYD4(114826)[-4333]

541 chrl7 1677184 1681241 SERPINF1(5176)[57] SMYD4(114826)[-3587]

542 chrl7 1677860 1681952 SERPINF1(5176)[92] SMYD4(114826)[-2876]

543 chrl7 1678411 1682447 SERPINF1(5176)[36] SMYD4(114826)[-2381]

544 chrl7 1678537 1682660 SERPINF1(5176)[123] SMYD4(114826)[-2168]

545 chrl7 1678674 1682717 SERPINF1(5176)[43] SMYD4(114826)[-2111]

546 chrl7 1678770 1682832 SERPINF1(5176)[62] SMYD4(114826)[-1996] 547 chrl7 1684489 1688539 SERPINFl(5176)[-5630] SMYD4(114826)[50]

548 chrl7 1688784 1692829 SERPINFl(5176)[-9925] SMYD4(114826)[45]

549 chrl7 40456254 40460299 STAT3(6774)[-7043] STAT5A(6776)[45]

550 chrl7 40456587 40460634 STAT3(6774)[-6708] STAT5A(6776)[47]

551 chrl7 40460644 40464690 STAT3(6774)[-2652] STAT5A(6776)[46]

552 chrl7 40465685 40469729 STAT3(6774)[44] STAT5A(6776)[-3725]

553 chrl7 40465751 40469796 STAT3(6774)[45] STAT5A(6776)[-3791]

554 chrl7 40467121 40471156 STAT3(6774)[35] STAT5A(6776)[-5161]

555 chrl7 40469938 40474007 STAT3(6774)[69] STAT5A(6776)[-7978]

556 chrl7 40471573 40475627 STAT3(6774)[54] STAT5A(6776)[-9613]

557 chrl7 40472301 40476392 STAT3(6774)[91]

558 chrl7 40473018 40477062 STAT3(6774)[44]

559 chrl7 40476110 40480142 STAT3(6774)[32]

560 chrl7 40479557 40483595 STAT3(6774)[38]

561 chrl7 40481477 40485503 STAT3(6774)[26]

562 chrl7 40483939 40487980 STAT3(6774)[41]

563 chrl7 40487494 40491536 STAT3(6774)[42]

564 chrl7 40488756 40492801 STAT3(6774)[45]

565 chrl7 40489345 40493391 STAT3(6774)[46]

566 chrl7 40498426 40502468 STAT3(6774)[42]

567 chrl7 40499605 40503650 STAT3(6774)[45]

568 chrl7 40504887 40508937 STAT3(6774)[50]

569 chrl7 40512881 40516946 STAT3(6774)[65]

570 chrl7 40529595 40533657 STAT3(6774)[62]

571 chrl7 40533596 40537704 STAT3(6774)[108]

572 chrl7 40533736 40537778 STAT3(6774)[42]

573 chrl7 40535565 40539603 STAT3(6774)[38]

574 chrl7 40537000 40541044 STAT3(6774)[44]

575 chrl7 40538181 40542233 STAT3(6774)[52]

576 chrl7 41194483 41198519 BRCA1(672)[36]

577 chrl7 41195661 41199730 BRCA1(672)[69]

578 chrl7 41195911 41200817 BRCA1(672)[906]

579 chrl7 41200966 41205009 BRCA1(672)[43]

580 chrl7 41209738 41213793 BRCA1(672)[55]

581 chrl7 41211401 41215478 BRCA1(672)[77]

582 chrl7 41212577 41217228 BRCA1(672)[651]

583 chrl7 41215147 41219193 BRCA1(672)[46]

584 chrl7 41216773 41221139 BRCA1(672)[366]

585 chrl7 41219904 41224301 BRCA1(672)[397] RPL21P4(140660)[-8976]

586 chrl7 41220949 41224991 BRCA1(672)[42] RPL21P4(140660)[-8286]

587 chrl7 41226584 41230629 BRCA1(672)[45] RPL21P4(140660)[-2648] 588 chrl7 41227105 41231149 B CA1(672)[44] RPL21P4(140660)[-2128]

589 chrl7 41232824 41236884 BRCA1(672)[60] RPL21P4(140660)[-2991]

590 chrl7 41241483 41245524 BRCA1(672)[41]

591 chrl7 41241934 41245963 BRCA1(672)[29]

592 chrl7 41242287 41246331 BRCA1(672)[44]

593 chrl7 41242494 41246540 BRCA1(672)[46]

594 chrl7 41242814 41246865 BRCA1(672)[51]

595 chrl7 41243007 41247056 BRCA1(672)[49]

596 chrl7 41243122 41247168 BRCA1(672)[46]

597 chrl7 41243261 41247289 BRCA1(672)[28]

598 chrl7 41243362 41247408 BRCA1(672)[46]

599 chrl7 41243484 41247549 BRCA1(672)[65]

600 chrl7 41243606 41247652 BRCA1(672)[46]

601 chrl7 41243726 41247768 BRCA1(672)[42]

602 chrl7 41243883 41247913 BRCA1(672)[30]

603 chrl7 41244073 41248124 BRCA1(672)[51]

604 chrl7 41249844 41253892 BRCA1(672)[48]

605 chrl7 41254224 41258269 BRCA1(672)[45]

606 chrl7 42426434 42430480 GRN(2896)[46] FAM171A2(284069)[-2620]

607 chrl7 42426931 42430977 GRN(2896)[46] FAM171A2(284069)[-2123]

608 chrl7 42427010 42431056 GRN(2896)[46] FAM171A2(284069)[-2044]

609 chrl7 42427408 42431453 GRN(2896)[45] FAM171A2(284069)[-1647]

610 chrl7 42428115 42432161 GRN(2896)[46] FAM171A2(284069)[-939]

611 chrl7 42428242 42432293 GRN(2896)[51] FAM171A2(284069)[-807]

612 chrl7 42429151 42433193 GRN(2896)[-681] FAM171A2(284069)[42]

FAM171A2(284069)[31],

613 chrl7 42433098 42437129 GRN(2896)[-4628] RPL7LlP5(390800)[-7255]

614 chrl8 46444327 46448370 SMAD7(4092)[43]

615 chrl8 46444538 46448584 SMAD7(4092)[46]

616 chrl8 46445045 46449088 SMAD7(4092)[43]

617 chrl8 46446077 46450141 SMAD7(4092)[64]

618 chrl8 46446226 46450271 SMAD7(4092)[45]

619 chrl8 46446491 46450539 SMAD7(4092)[48]

620 chrl8 46446944 46450981 SMAD7(4092)[37]

621 chrl8 46447786 46451831 SMAD7(4092)[45]

622 chrl8 46448423 46452538 SMAD7(4092)[115]

623 chrl8 46448886 46452923 SMAD7(4092)[37]

624 chrl8 46449155 46453213 SMAD7(4092)[58]

625 chrl8 46449355 46453402 SMAD7(4092)[47]

626 chrl8 46453352 46457392 SMAD7(4092)[40]

627 chrl8 46453564 46457605 SMAD7(4092)[41] 628 chrl8 46453678 46457723 SMAD7(4092)[45]

629 chrl8 46453988 46458026 SMAD7(4092)[38]

630 chrl8 46454321 46458365 SMAD7(4092)[44]

631 chrl8 46454495 46458544 SMAD7(4092)[49]

632 chrl8 46456464 46460511 SMAD7(4092)[47]

633 chrl8 46456614 46460638 SMAD7(4092)[24]

634 chrl8 46456872 46460926 SMAD7(4092)[54]

635 chrl8 46457269 46461310 SMAD7(4092)[41]

636 chrl8 46459123 46463227 SMAD7(4092)[104]

637 chrl8 46459237 46463307 SMAD7(4092)[70]

638 chrl8 46459371 46463429 SMAD7(4092)[58]

639 chrl8 46459518 46463557 SMAD7(4092)[39]

640 chrl8 46459579 46463693 SMAD7(4092)[114]

641 chrl8 46462744 46466809 SMAD7(4092)[65]

642 chrl8 46463648 46467694 SMAD7(4092)[46]

643 chrl8 46464370 46468424 SMAD7(4092)[54]

644 chrl8 46464536 46468582 SMAD7(4092)[46]

645 chrl8 46465360 46469384 SMAD7(4092)[24]

646 chrl8 46465488 46469525 SMAD7(4092)[37]

647 chrl8 46466211 46470285 SMAD7(4092)[74]

648 chrl8 46467650 46471693 SMAD7(4092)[43]

649 chrl8 46467752 46471801 SMAD7(4092)[49]

650 chrl8 46467838 46471883 SMAD7(4092)[45]

651 chrl8 46467956 46472022 SMAD7(4092)[66]

652 chrl8 46468181 46472229 SMAD7(4092)[48]

653 chrl8 46468289 46472370 SMAD7(4092)[81]

654 chrl8 46468511 46472573 SMAD7(4092)[62]

655 chrl8 46468595 46472667 SMAD7(4092)[72]

656 chrl8 46469007 46473074 SMAD7(4092)[67]

657 chrl8 46469422 46473919 SMAD7(4092)[497]

658 chrl8 46469976 46474031 SMAD7(4092)[55]

659 chrl8 46470475 46474519 SMAD7(4092)[44]

660 chrl8 46470920 46474966 SMAD7(4092)[46]

661 chrl8 46471058 46475103 SMAD7(4092)[45]

662 chrl8 46471468 46475512 SMAD7(4092)[44]

663 chrl8 46471917 46475968 SMAD7(4092)[51]

664 chrl8 46472400 46476446 SMAD7(4092)[46]

665 chrl8 46474824 46478866 SMAD7(4092)[42]

666 chrl8 46475311 46479380 SMAD7(4092)[-230]

667 chrl8 46475380 46479448 SMAD7(4092)[-299]

668 chrl8 46475565 46479612 SMAD7(4092)[-484] 669 chrl8 46475641 46479689 SMAD7(4092)[-560]

670 chrl8 46475743 46479810 SMAD7(4092)[-662]

671 chrl8 46476765 46480861 SMAD7(4092)[-1684]

672 chrl9 4169996 4174038 SIRT6(51548)[-2067] CREB3L3(84699)[42]

CREB3L3(84699)[-2058],

673 chrl9 4173106 4177148 SIRT6(51548)[42] ANKRD24(170961)[-8202]

CREB3L3(84699)[-4033],

674 chrl9 4175081 4179127 SIRT6(51548)[46] ANKRD24(170961)[-6223]

675 chrl9 11198245 11202291 LDLR(3949)[46]

676 chrl9 11198383 11202486 LDLR(3949)[103]

677 chrl9 11201622 11205668 LDLR(3949)[46]

678 chrl9 11208902 11212935 LDLR(3949)[33]

679 chrl9 11208970 11213012 LDLR(3949)[42]

680 chrl9 11216034 11220089 LDLR(3949)[55]

681 chrl9 11219381 11223426 LDLR(3949)[45]

682 chrl9 11222284 11226326 LDLR(3949)[42]

683 chrl9 11228020 11232046 LDLR(3949)[26]

684 chrl9 11229073 11233115 LDLR(3949)[42]

685 chrl9 11229140 11233182 LDLR(3949)[42]

686 chrl9 11240210 11244295 LDLR(3949)[85]

687 chrl9 11240349 11244411 LDLR(3949)[62]

688 chrl9 11241907 11245955 LDLR(3949)[48]

689 chrl9 11242132 11246210 LDLR(3949)[78]

690 chrl9 11242409 11246455 LDLR(3949)[46]

USF2(7392)[56], LSR(51599)[-

691 chrl9 35761523 35765579 4656], HAMP(57817)[-9830]

USF2(7392)[143], LSR(51599)[-

692 chrl9 35761599 35765742 4732], HAMP(57817)[-9667]

USF2(7392)[35], LSR(51599)[-

693 chrl9 35761775 35765810 4908], HAMP(57817)[-9599]

USF2(7392)[67], LSR(51599)[-

694 chrl9 35762216 35766283 5349], HAMP(57817)[-9126]

USF2(7392)[67],

695 chrl9 35767783 35771850 HAMP(57817)[-3559]

USF2(7392)[50],

696 chrl9 35768630 35772680 HAMP(57817)[-2729]

MAG(4099)[-2548],

HAMP(57817)[-4363],

697 chrl9 35778408 35782440 USF2(7392)[-9690]

ACOXL(55289)[59],

698 chr2 111872741 111876800 BCL2Lll(10018)[-3690] FLJ44006(400997)[-2979]

ACOXL(55289)[42],

699 chr2 111873484 111877526 BCL2Lll(10018)[-2964] FLJ44006(400997)[-3722]

700 chr2 111874570 111878609 ACOXL(55289)[-771], FU44006(400997)[-4808] BCL2L11(10018)[-1881]

BCL2L11(10018)[54],

701 chr2 111882760 111886814 ACOXL(55289)[-8961]

702 chr2 111898874 111902919 BCL2L11(10018)[45]

703 chr2 111899576 111903618 BCL2L11(10018)[42]

704 chr2 111907725 111911767 BCL2L11(10018)[42]

705 chr2 111910202 111914286 BCL2L11(10018)[84]

706 chr2 111911452 111915475 BCL2L11(10018)[23]

707 chr2 111911810 111915867 BCL2L11(10018)[57]

708 chr2 111916896 111920926 BCL2L11(10018)[30]

709 chr2 111917307 111921329 BCL2L11(10018)[22]

710 chr2 111919357 111923435 BCL2L11(10018)[78]

711 chr2 111919782 111923828 BCL2L11(10018)[46]

712 chr2 111919983 111924029 BCL2L11(10018)[46]

713 chr2 111920061 111924112 BCL2L11(10018)[51]

714 chr2 111921184 111925229 BCL2L11(10018)[45]

715 chr2 111921480 111925533 BCL2L11(10018)[53]

716 chr2 111922148 111926178 BCL2L11(10018)[30]

717 chr6 39017719 39021758 GLP1 (2740)[39]

718 chr6 39024997 39029047 GLP1R(2740)[50]

719 chr6 39025295 39029329 GLP1R(2740)[34]

720 chr6 39026068 39030124 GLP1R(2740)[56]

721 chr6 39026771 39030817 GLP1R(2740)[46]

722 chr6 39045993 39050028 GLP1R(2740)[35]

723 chr6 39052054 39056101 GLP1R(2740)[47]

724 chr6 39054381 39058477 GLP1R(2740)[-861]

MYL7(58498)[-348],

725 chr7 44176060 44180114 GCK(2645)[-5755]

MYL7(58498)[42], GCK(2645)[-

726 chr7 44177962 44182004 3865]

MYL7(58498)[46], GCK(2645)[-

727 chr7 44178335 44182381 3488]

GCK(2645)[-269],

728 chr7 44181576 44185600 MYL7(58498)[-2660]

GCK(2645)[42], MYL7(58498)[-

729 chr7 44188023 44192065 9107]

730 chr7 44189933 44193978 GCK(2645)[45]

731 chr7 44194261 44198302 GCK(2645)[41]

732 chr7 44226529 44230580 GCK(2645)[51]

ST7(7982)[38], ST7-

733 chr7 116593999 116598037 OT4(338069)[38] ST7-AS1(93653)[-1611]

734 chr7 116622638 116626690 ST7(7982)[52]

735 chr7 116623757 116627802 ST7(7982)[45] 736 chr7 116648635 116652688 ST7(7982)[53]

737 chr7 116658757 116662806 ST7(7982)[49]

738 chr7 116660866 116664927 ST7(7982)[61]

739 chr7 116674974 116679010 ST7(7982)[36]

740 chr7 116684722 116688769 ST7(7982)[47]

741 chr7 116705400 116709483 ST7(7982)[83]

742 chr7 116718624 116722666 ST7(7982)[42]

743 chr7 116722345 116726391 ST7(7982)[46]

744 chr7 116723722 116727775 ST7(7982)[53]

745 chr7 116724550 116728589 ST7(7982)[39]

746 chr7 116724815 116728855 ST7(7982)[40]

747 chr7 116754048 116758092 ST7(7982)[44] ST7-AS2(93654)[44]

748 chr7 116762078 116766126 ST7(7982)[48] ST7-AS2(93654)[48]

749 chr7 116767409 116771434 ST7(7982)[25] ST7-AS2(93654)[25]

750 chr7 116768594 116772635 ST7(7982)[41] ST7-AS2(93654)[41]

751 chr7 116772356 116776402 ST7(7982)[46] ST7-AS2(93654)[46]

752 chr7 116772449 116776493 ST7(7982)[44] ST7-AS2(93654)[44]

753 chr7 116772569 116776629 ST7(7982)[60] ST7-AS2(93654)[60]

754 chr7 116772725 116776770 ST7(7982)[45] ST7-AS2(93654)[45]

755 chr7 116773116 116777168 ST7(7982)[52] ST7-AS2(93654)[52]

756 chr7 116774217 116778269 ST7(7982)[52] ST7-AS2(93654)[52]

757 chr7 116776263 116780308 ST7(7982)[45] ST7-AS2(93654)[45]

758 chr7 116776487 116780584 ST7(7982)[97] ST7-AS2(93654)[97]

ST7(7982)[44], ST7-

759 chr7 116811917 116815961 OT3(93655)[-8773]

ST7(7982)[51], ST7-

760 chr7 116816961 116821012 OT3(93655)[-3722]

ST7(7982)[61], ST7-

761 chr7 116818336 116822397 OT3(93655)[-2337]

ST7(7982)[40], ST7-

762 chr7 116819346 116823386 OT3(93655)[-1348]

ST7(7982)[46], ST7-

763 chr7 116828139 116832185 OT3(93655)[46]

ST7(7982)[42], ST7-

764 chr7 116845544 116849586 OT3(93655)[42]

765 chr7 116860145 116864183 ST7(7982)[38]

766 chr7 116860240 116864284 ST7(7982)[44]

767 chr7 116863552 116867593 ST7(7982)[41]

768 chr8 39776542 39780579 IDOl(3620)[37]

769 chrX 133595598 133599645 HP T1(3251)[47]

770 chrX 133607331 133611378 HPRT1(3251)[47]

771 chrX 133619494 133623542 HPRT1(3251)[48] 772 chrX 133619803 133623843 HPRT1(3251)[40]

773 chrX 133622277 133626349 HPRT1(3251)[72]

774 chrX 133625514 133629603 HPRT1(3251)[89]

775 chrX 133626177 133630202 HPRT1(3251)[25]

776 chrX 133626358 133630403 HPRT1(3251)[45]

777 chrX 133632063 133636112 HPRT1(3251)[49]

778 chrX 133632219 133636273 HPRT1(3251)[54]

779 chrX 133632349 133636419 HPRT1(3251)[70]

780 chrX 146992273 146996317 FMR1(2332)[44] FMR1-AS1(100126270)[44]

781 chrX 146992340 146996407 FMR1(2332)[67] FMR1-AS1(100126270)[67]

782 chrX 146992536 146996651 FMR1(2332)[115] FMR1-AS1(100126270)[115]

783 chrX 146992704 146996754 FMR1(2332)[50] FMR1-AS1(100126270)[50]

784 chrX 146992910 146996962 FMR1(2332)[52] FMR1-AS1(100126270)[52]

785 chrX 146993057 146997114 FMR1(2332)[57] FMR1-AS1(100126270)[57]

786 chrX 146993153 146997247 FMR1(2332)[94] FMR1-AS1(100126270)[94]

787 chrX 146993834 146997880 FMR1(2332)[46] FMR1-AS1(100126270)[46]

788 chrX 146995285 146999332 FMR1(2332)[47] FMR1-AS1(100126270)[47]

789 chrX 146997318 147001381 FMR1(2332)[63] FMR1-AS1(100126270)[63]

790 chrX 146997780 147001822 FMR1(2332)[42] FMR1-AS1(100126270)[42]

791 chrX 147001704 147005762 FMR1(2332)[58] FMRl-ASl(100126270)[-28]

792 chrX 147004583 147008630 FMR1(2332)[47] FMRl-ASl(100126270)[-2907]

793 chrX 147005061 147009111 FMR1(2332)[50] FMRl-ASl(100126270)[-3385]

794 chrX 147007255 147011307 FMR1(2332)[52] FMRl-ASl(100126270)[-5579]

795 chrX 147007866 147011911 FMR1(2332)[45] FMR1-AS1(100126270)[-6190]

796 chrX 147012001 147016047 FMR1(2332)[46]

797 chrX 147014764 147018808 FMR1(2332)[44]

798 chrX 147016028 147020101 FMR1(2332)[73]

799 chrX 147018266 147022312 FMR1(2332)[46]

800 chrX 147018375 147022450 FMR1(2332)[75]

801 chrX 147020776 147024871 FMR1(2332)[95]

802 chrX 147021821 147025867 FMR1(2332)[46]

803 chrX 147022122 147026162 FMR1(2332)[40]

804 chrX 147022653 147026741 FMR1(2332)[88]

805 chrX 147022859 147026904 FMR1(2332)[45]

806 chrX 147023738 147027821 FMR1(2332)[83]

807 chrX 147023910 147027956 FMR1(2332)[46]

808 chrX 147024054 147028120 FMR1(2332)[66]

809 chrX 147024148 147028223 FMR1(2332)[75]

810 chrX 147024308 147028380 FMR1(2332)[72]

811 chrX 147024455 147028506 FMR1(2332)[51]

812 chrX 147028397 147032443 FMR1(2332)[46] 813 chrX 147028600 147032644 FM 1(2332)[44]

814 chrX 147028762 147032809 FMR1(2332)[47]

815 chrX 147028873 147032925 FMR1(2332)[52]

816 chrX 147029114 147033160 FMR1(2332)[46]

817 chrX 147030022 147034068 FMR1(2332)[46]

818 chrX 147030538 147034587 FMR1(2332)[49]

819 chrX 154122781 154126812 F8(2157)[31]

820 chrX 154195368 154199405 F8(2157)[37]

821 chrX 154253514 154257559 F8(2157)[-4516] FUNDC2(65991)[45]

822 chrX 154253647 154257679 F8(2157)[-4649] FUNDC2(65991)[32]

823 chrl 33318693 33318738 S100PBP(64766)[45] FNDC5(252995)[-9130]

824 chrl 33323628 33323672 S100PBP(64766)[44] FNDC5(252995)[-4196]

825 chrl 33323707 33323769 S100PBP(64766)[62] FNDC5(252995)[-4099]

826 chrl 33324429 33324474 S100PBP(64766)[45] FNDC5(252995)[-3394]

827 chrl 33332884 33332938 S100PBP(64766)[-8408] FNDC5(252995)[54]

828 chrl 33334220 33334256 S100PBP(64766)[-9744] FNDC5(252995)[36]

829 chrl 33334327 33334373 S100PBP(64766)[-9851] FNDC5(252995)[46]

830 chrl 33335299 33335363 FNDC5(252995)[64]

831 chrl 186645046 186645088 PTGS2(5743)[42]

832 chrl 186645744 186645790 PTGS2(5743)[46]

833 chrl 186649369 186649411 PTGS2(5743)[42]

834 chrl 206945490 206945522 IL10(3586)[32]

SIRT1(23411)[-119],

835 chrlO 69644282 69644307 RPL12P8(645161)[-9633]

836 chrlO 69648683 69648729 SIRT1(23411)[46]

837 chrlO 69651264 69651310 SIRT1(23411)[46]

838 chrlO 69682246 69682296 HERC4(26091)[50] SIRTl(23411)[-4099]

839 chrlO 69682882 69682924 HERC4(26091)[42] SIRTl(23411)[-4735]

840 chrlO 69684915 69684965 HERC4(26091)[50] SIRTl(23411)[-6768]

LOC100507392(100507392)[-

841 chrll 128554012 128554084 7482] FLIl(2313)[-9726]

LOC100507392(100507392)[-

842 chrll 128556087 128556155 5411] FLIl(2313)[-7655]

843 chrll 128563904 128563948 LOC100507392(100507392)[44] FLI1(2313)[44]

LOC100507392(100507392)[-

844 chrll 128566093 128566115 175] FLI1(2313)[22]

LOC100507392(100507392)[-

845 chrll 128572440 128572475 6522] FLI1(2313)[35]

846 chrll 128598811 128598859 FLI1(2313)[48]

847 chrll 128604941 128604972 FLI1(2313)[31]

848 chrll 128606828 128606880 FLI1(2313)[52]

849 chrll 128609407 128609452 FLI1(2313)[45] 850 chrll 128631220 128631270 FLI1(2313)[50]

851 chrll 128631552 128631594 FLI1(2313)[42]

852 chrll 128636236 128636278 FLI1(2313)[42]

853 chrll 128636411 128636456 FLI1(2313)[45]

854 chrll 128640108 128640151 FLI1(2313)[43]

855 chrll 128675064 128675122 FLI1(2313)[58]

856 chrl2 7942203 7942249 NANOG(79923)[46]

857 chrl2 7942281 7942325 NANOG(79923)[44]

858 chrl2 102792744 102792775 IGF1(3479)[31]

859 chrl2 102801497 102801542 IGF1(3479)[45]

860 chrl2 102823235 102823296 IGF1(3479)[61]

861 chrl2 102836469 102836510 IGF1(3479)[41]

862 chrl2 102863096 102863141 IGF1(3479)[45]

863 chrl2 102866947 102866982 IGF1(3479)[35]

864 chrl2 102869486 102869532 IGF1(3479)[46]

865 chrl3 48878033 48878099 RB1(5925)[66]

PCNPP5(100507361)[49],

866 chrl3 48900554 48900603 PPPlR26Pl(100418740)[-5944] RB1(5925)[49]

PCNPP5(100507361)[58],

867 chrl3 48900896 48900954 PPPlR26Pl(100418740)[-6286] RB1(5925)[58]

PCNPP5(100507361)[47],

868 chrl3 48902138 48902185 PPPlR26Pl(100418740)[-7528] RB1(5925)[47]

PCNPP5(100507361)[80],

869 chrl3 48902350 48902430 PPPlR26Pl(100418740)[-7740] RB1(5925)[80]

PCNPP5(100507361)[48],

870 chrl3 48902510 48902558 PPPlR26Pl(100418740)[-7900] RB1(5925)[48]

871 chrl3 48942380 48942424 RB1(5925)[44]

872 chrl3 48948325 48948373 RB1(5925)[48]

873 chrl3 48954982 48955017 RB1(5925)[35]

874 chrl3 48985855 48985901 LPAR6(10161)[46] RB1(5925)[46]

875 chrl3 49030437 49030479 RB1(5925)[42]

876 chrl3 49063768 49063818 RCBTB2(1102)[50] RBl(5925)[-7742]

SERPINF2(5345)[41],

877 chrl7 1657585 1657626 SERPINFl(5176)[-7632]

878 chrl7 1673187 1673228 SMYD4(114826)[-9600] SERPINF1(5176)[41]

879 chrl7 1673256 1673304 SMYD4(114826)[-9524] SERPINF1(5176)[48]

880 chrl7 1674373 1674450 SMYD4(114826)[-8378] SERPINF1(5176)[77]

881 chrl7 1675218 1675313 SMYD4(114826)[-7515] SERPINF1(5176)[95]

882 chrl7 1678400 1678450 SMYD4(114826)[-4378] SERPINF1(5176)[50]

883 chrl7 1679867 1679914 SMYD4(114826)[-2914] SERPINF1(5176)[47]

884 chrl7 1680412 1680453 SMYD4(114826)[-2375] SERPINF1(5176)[41]

885 chrl7 1680584 1680627 SMYD4(114826)[-2201] SERPINF1(5176)[43] 886 chrl7 1683417 1683469 SMYD4(114826)[52] SERPINFl(5176)[-2558]

887 chrl7 1684672 1684718 SMYD4(114826)[46] SERPINF1(5176)[-3813]

888 chrl7 1686655 1686697 SMYD4(114826)[42] SERPINFl(5176)[-5796]

889 chrl7 40458377 40458423 STAT5A(6776)[46] STAT3(6774)[-6919]

890 chrl7 40465708 40465750 STAT5A(6776)[-1748] STAT3(6774)[42]

891 chrl7 40467567 40467609 STAT5A(6776)[-3607] STAT3(6774)[42]

892 chrl7 40481315 40481352 STAT3(6774)[37]

893 chrl7 40489818 40489864 STAT3(6774)[46]

894 chrl7 40498715 40498756 STAT3(6774)[41]

895 chrl7 40537800 40537845 STAT3(6774)[45]

896 chrl7 41203104 41203130 BRCA1(672)[26]

897 chrl7 41229006 41229051 RPL21P4(140660)[-2226] BRCA1(672)[45]

898 chrl7 41238265 41238288 RPL21P4(140660)[-6432] BRCA1(672)[23]

899 chrl7 41243836 41243881 BRCA1(672)[45]

900 chrl7 41243981 41244027 BRCA1(672)[46]

901 chrl7 41245476 41245569 BRCA1(672)[93]

902 chrl7 41245602 41245647 BRCA1(672)[45]

903 chrl7 41245791 41245835 BRCA1(672)[44]

904 chrl7 41245920 41245965 BRCA1(672)[45]

905 chrl7 41251151 41251187 BRCA1(672)[36]

906 chrl7 41257619 41257668 BRCA1(672)[49]

907 chrl7 41267754 41267815 NBR2(10230)[-9784] BRCA1(672)[61]

908 chrl7 42421658 42421736 FAM171A2(284069)[-9364] GRN(2896)[-754]

909 chrl7 42427887 42427933 FAM171A2(284069)[-3167] GRN(2896)[46]

910 chrl7 42428632 42428717 FAM171A2(284069)[-2383] GRN(2896)[85]

911 chrl7 42430812 42430878 FAM171A2(284069)[-222] GRN(2896)[-342]

912 chrl7 42430878 42430946 FAM171A2(284069)[-154] GRN(2896)[-408]

FAM171A2(284069)[55],

RPL7L1P5(390800)[-2194],

913 chrl7 42440135 42440190 ITGA2B(3674)[-9359] GRN(2896)[-9665]

914 chrl8 46446996 46447042 SMAD7(4092)[46]

915 chrl8 46448944 46448981 SMAD7(4092)[37]

916 chrl8 46449426 46449468 SMAD7(4092)[42]

917 chrl8 46449560 46449613 SMAD7(4092)[53]

918 chrl8 46450467 46450550 SMAD7(4092)[83]

919 chrl8 46450662 46450699 SMAD7(4092)[37]

920 chrl8 46450805 46450847 SMAD7(4092)[42]

921 chrl8 46454854 46454888 SMAD7(4092)[34]

922 chrl8 46455617 46455650 SMAD7(4092)[33]

923 chrl8 46460409 46460453 SMAD7(4092)[44]

924 chrl8 46464660 46464708 SMAD7(4092)[48] 925 chrl8 46467632 46467678 SMAD7(4092)[46]

926 chrl8 46468584 46468626 SMAD7(4092)[42]

927 chrl8 46472616 46472679 SMAD7(4092)[63]

928 chrl8 46472920 46472965 SMAD7(4092)[45]

929 chrl8 46474744 46474790 SMAD7(4092)[46]

930 chrl8 46474873 46474918 SMAD7(4092)[45]

931 chrl8 46476280 46476325 SMAD7(4092)[45]

932 chrl8 46477514 46477557 SMAD7(4092)[-433]

933 chrl8 46477784 46477833 SMAD7(4092)[-703]

934 chrl8 46477897 46477979 SMAD7(4092)[-816]

935 chrl8 46480695 46480765 SMAD7(4092)[-3614]

936 chrl8 46484413 46484458 SMAD7(4092)[-7332]

937 chrl9 4168341 4168384 CREB3L3(84699)[43] SIRT6(51548)[-5721]

938 chrl9 11231035 11231121 LDLR(3949)[86]

939 chrl9 11231140 11231182 LDLR(3949)[42]

940 chrl9 11240206 11240249 LDLR(3949)[43]

941 chrl9 11242367 11242432 LDLR(3949)[65]

USF2(7392)[48], LSR(51599)[-

942 chrl9 35764119 35764167 5252], HAMP(57817)[-9242]

HAMP(57817)[-37],

USF2(7392)[-2618],

943 chrl9 35773336 35773372 MAG(4099)[-9616]

ACOXL(55289)[22],

944 chr2 111875557 111875579 FU44006(400997)[-3795] BCL2L11(10018)[-2911]

BCL2L11(10018)[42],

945 chr2 111878709 111878751 FU44006(400997)[-6947] ACOXL(55289)[-2910]

BCL2L11(10018)[50],

946 chr2 111881774 111881824 ACOXL(55289)[-5975]

BCL2L11(10018)[37],

947 chr2 111884848 111884885 ACOXL(55289)[-9049]

948 chr2 111902031 111902076 BCL2L11(10018)[45]

949 chr2 111907647 111907691 BCL2L11(10018)[44]

950 chr2 111925311 111925378 BCL2L11(10018)[67]

LOC100128655(100128655)[-

951 chr6 39017036 39017117 9275] GLP1R(2740)[81]

LOC100128655(100128655)[-

952 chr6 39017532 39017577 9771] GLP1R(2740)[45]

953 chr6 39017904 39017955 GLP1R(2740)[51]

954 chr6 39021794 39021856 GLP1R(2740)[62]

955 chr6 39022326 39022379 GLP1R(2740)[53]

956 chr6 39027543 39027589 GLP1R(2740)[46]

957 chr6 39032288 39032322 GLP1R(2740)[34]

958 chr6 39041838 39041884 GLP1R(2740)[46] 959 chr6 39048467 39048509 GLP1 (2740)[42]

960 chr6 39048707 39048753 GLP1R(2740)[46]

961 chr6 39055249 39055292 GLP1R(2740)[43]

962 chr6 39055855 39055923 GLPlR(2740)[-335]

963 chr6 39056119 39056160 GLPlR(2740)[-599]

MYL7(58498)[30], GCK(2645)[-

964 chr7 44179539 44179569 4300]

MYL7(58498)[30], GCK(2645)[-

965 chr7 44180455 44180485 3384]

MYL7(58498)[45], GCK(2645)[-

966 chr7 44180553 44180598 3271]

GCK(2645)[47], MYL7(58498)[-

967 chr7 44184152 44184199 3236]

GCK(2645)[55], MYL7(58498)[-

968 chr7 44184364 44184419 3448]

GCK(2645)[43], MYL7(58498)[-

969 chr7 44185300 44185343 4384]

GCK(2645)[35], MYL7(58498)[-

970 chr7 44187650 44187685 6734]

971 chr7 44199272 44199309 GCK(2645)[37]

ST7(7982)[45], ST7-

972 chr7 116593600 116593645 ST7-AS1(93653)[45] OT4(338069)[-307]

973 chr7 116618378 116618420 TPM3Pl(252956)[-5344] ST7(7982)[42]

974 chr7 116623689 116623719 ST7(7982)[30]

975 chr7 116641826 116641873 ST7(7982)[47]

976 chr7 116656497 116656538 ST7(7982)[41]

977 chr7 116661796 116661843 ST7(7982)[47]

978 chr7 116700499 116700546 ST7(7982)[47]

979 chr7 116704561 116704604 ST7(7982)[43]

980 chr7 116726694 116726732 ST7(7982)[38]

981 chr7 116728168 116728220 ST7(7982)[52]

982 chr7 116753703 116753744 ST7-AS2(93654)[41] ST7(7982)[41]

983 chr7 116755913 116755980 ST7-AS2(93654)[67] ST7(7982)[67]

984 chr7 116763993 116764028 ST7-AS2(93654)[35] ST7(7982)[35]

985 chr7 116765305 116765356 ST7-AS2(93654)[51] ST7(7982)[51]

986 chr7 116765540 116765571 ST7-AS2(93654)[31] ST7(7982)[31]

987 chr7 116770595 116770641 ST7-AS2(93654)[46] ST7(7982)[46]

988 chr7 116772915 116772959 ST7-AS2(93654)[44] ST7(7982)[44]

989 chr7 116774221 116774266 ST7-AS2(93654)[45] ST7(7982)[45]

990 chr7 116805886 116805932 ST7(7982)[46]

ST7(7982)[24], ST7-

991 chr7 116815347 116815371 OT3(93655)[-7363]

992 chr7 116817687 116817732 ST7(7982)[45], ST7- OT3(93655)[-5002]

ST7(7982)[44], ST7-

993 chr7 116828642 116828686 OT3(93655)[44]

ST7(7982)[43], ST7-

994 chr7 116829989 116830032 OT3(93655)[43]

ST7(7982)[25], ST7-

995 chr7 116844555 116844580 OT3(93655)[25]

996 chr7 116861351 116861398 ST7(7982)[47]

997 chr7 116866075 116866109 ST7(7982)[34]

998 chr8 39771698 39771735 IDOl(3620)[37]

999 chr8 39776381 39776422 IDOl(3620)[41]

1000 chr8 39780978 39781001 IDOl(3620)[23]

1001 chrX 133594301 133594346 HPRT1(3251)[45]

1002 chrX 133596974 133597024 HPRT1(3251)[50]

1003 chrX 133597154 133597198 HPRT1(3251)[44]

1004 chrX 133607384 133607413 HPRT1(3251)[29]

1005 chrX 133621697 133621732 HPRT1(3251)[35]

1006 chrX 133621814 133621856 HPRT1(3251)[42]

1007 chrX 133634191 133634233 HPRT1(3251)[42]

1008 chrX 146992226 146992269 FMR1-AS1(100126270)[43] FMR1(2332)[-1199]

1009 chrX 146992317 146992340 FMR1-AS1(100126270)[23] FMR1(2332)[-1128]

1010 chrX 146993666 146993715 FMR1-AS1(100126270)[49] FMR1(2332)[49]

1011 chrX 146994919 146994964 FMR1-AS1(100126270)[45] FMR1(2332)[45]

1012 chrX 147009767 147009816 FMR1-AS1(100126270)[-6091] FMR1(2332)[49]

1013 chrX 147025640 147025686 FMR1(2332)[46]

1014 chrX 147026121 147026181 FMR1(2332)[60]

F8(2157)[44],

1015 chrX 154131833 154131877 EEF1A1P31(553820)[-5221]

1016 chrX 154197605 154197651 F8(2157)[46]

1017 chrl 33316693 33320738 S100PBP(64766)[45] FNDC5(252995)[-9130]

1018 chrl 33321628 33325672 S100PBP(64766)[44] FNDC5(252995)[-4196]

1019 chrl 33321707 33325769 S100PBP(64766)[62] FNDC5(252995)[-4099]

1020 chrl 33322429 33326474 S100PBP(64766)[45] FNDC5(252995)[-3394]

1021 chrl 33330884 33334938 S100PBP(64766)[-8408] FNDC5(252995)[54]

1022 chrl 33332220 33336256 S100PBP(64766)[-9744] FNDC5(252995)[36]

1023 chrl 33332327 33336373 S100PBP(64766)[-9851] FNDC5(252995)[46]

1024 chrl 33333299 33337363 FNDC5(252995)[64]

1025 chrl 186643046 186647088 PTGS2(5743)[42]

1026 chrl 186643744 186647790 PTGS2(5743)[46]

1027 chrl 186647369 186651411 PTGS2(5743)[42]

1028 chrl 206943490 206947522 IL10(3586)[32]

1029 chrlO 69642282 69646307 SIRT1(23411)[-119], RPL12P8(645161)[-9633]

1030 chrlO 69646683 69650729 SIRT1(23411)[46]

1031 chrlO 69649264 69653310 SIRT1(23411)[46]

1032 chrlO 69680246 69684296 HERC4(26091)[50] SIRTl(23411)[-4099]

1033 chrlO 69680882 69684924 HERC4(26091)[42] SIRTl(23411)[-4735]

1034 chrlO 69682915 69686965 HERC4(26091)[50] SIRTl(23411)[-6768]

LOC100507392(100507392)[-

1035 chrll 128552012 128556084 7482] FLIl(2313)[-9726]

LOC100507392(100507392)[-

1036 chrll 128554087 128558155 5411] FLIl(2313)[-7655]

1037 chrll 128561904 128565948 LOC100507392(100507392)[44] FLI1(2313)[44]

LOC100507392(100507392)[-

1038 chrll 128564093 128568115 175] FLI1(2313)[22]

LOC100507392(100507392)[-

1039 chrll 128570440 128574475 6522] FLI1(2313)[35]

1040 chrll 128596811 128600859 FLI1(2313)[48]

1041 chrll 128602941 128606972 FLI1(2313)[31]

1042 chrll 128604828 128608880 FLI1(2313)[52]

1043 chrll 128607407 128611452 FLI1(2313)[45]

1044 chrll 128629220 128633270 FLI1(2313)[50]

1045 chrll 128629552 128633594 FLI1(2313)[42]

1046 chrll 128634236 128638278 FLI1(2313)[42]

1047 chrll 128634411 128638456 FLI1(2313)[45]

1048 chrll 128638108 128642151 FLI1(2313)[43]

1049 chrll 128673064 128677122 FLI1(2313)[58]

1050 chrl2 7940203 7944249 NANOG(79923)[46]

1051 chrl2 7940281 7944325 NANOG(79923)[44]

1052 chrl2 102790744 102794775 IGF1(3479)[31]

1053 chrl2 102799497 102803542 IGF1(3479)[45]

1054 chrl2 102821235 102825296 IGF1(3479)[61]

1055 chrl2 102834469 102838510 IGF1(3479)[41]

1056 chrl2 102861096 102865141 IGF1(3479)[45]

1057 chrl2 102864947 102868982 IGF1(3479)[35]

1058 chrl2 102867486 102871532 IGF1(3479)[46]

1059 chrl3 48876033 48880099 RB1(5925)[66]

PCNPP5(100507361)[49],

1060 chrl3 48898554 48902603 PPPlR26Pl(100418740)[-5944] RB1(5925)[49]

PCNPP5(100507361)[58],

1061 chrl3 48898896 48902954 PPPlR26Pl(100418740)[-6286] RB1(5925)[58]

PCNPP5(100507361)[47],

1062 chrl3 48900138 48904185 PPPlR26Pl(100418740)[-7528] RB1(5925)[47]

PCNPP5(100507361)[80],

1063 chrl3 48900350 48904430 PPPlR26Pl(100418740)[-7740] RB1(5925)[80] PCNPP5(100507361)[48],

1064 chrl3 48900510 48904558 PPPlR26Pl(100418740)[-7900] RB1(5925)[48]

1065 chrl3 48940380 48944424 RB1(5925)[44]

1066 chrl3 48946325 48950373 RB1(5925)[48]

1067 chrl3 48952982 48957017 RB1(5925)[35]

1068 chrl3 48983855 48987901 LPAR6(10161)[46] RB1(5925)[46]

1069 chrl3 49028437 49032479 RB1(5925)[42]

1070 chrl3 49061768 49065818 RCBTB2(1102)[50] RBl(5925)[-7742]

SERPINF2(5345)[41],

1071 chrl7 1655585 1659626 SERPINFl(5176)[-7632]

1072 chrl7 1671187 1675228 SMYD4(114826)[-9600] SERPINF1(5176)[41]

1073 chrl7 1671256 1675304 SMYD4(114826)[-9524] SERPINF1(5176)[48]

1074 chrl7 1672373 1676450 SMYD4(114826)[-8378] SERPINF1(5176)[77]

1075 chrl7 1673218 1677313 SMYD4(114826)[-7515] SERPINF1(5176)[95]

1076 chrl7 1676400 1680450 SMYD4(114826)[-4378] SERPINF1(5176)[50]

1077 chrl7 1677867 1681914 SMYD4(114826)[-2914] SERPINF1(5176)[47]

1078 chrl7 1678412 1682453 SMYD4(114826)[-2375] SERPINF1(5176)[41]

1079 chrl7 1678584 1682627 SMYD4(114826)[-2201] SERPINF1(5176)[43]

1080 chrl7 1681417 1685469 SMYD4(114826)[52] SERPINFl(5176)[-2558]

1081 chrl7 1682672 1686718 SMYD4(114826)[46] SERPINF1(5176)[-3813]

1082 chrl7 1684655 1688697 SMYD4(114826)[42] SERPINFl(5176)[-5796]

1083 chrl7 40456377 40460423 STAT5A(6776)[46] STAT3(6774)[-6919]

1084 chrl7 40463708 40467750 STAT5A(6776)[-1748] STAT3(6774)[42]

1085 chrl7 40465567 40469609 STAT5A(6776)[-3607] STAT3(6774)[42]

1086 chrl7 40479315 40483352 STAT3(6774)[37]

1087 chrl7 40487818 40491864 STAT3(6774)[46]

1088 chrl7 40496715 40500756 STAT3(6774)[41]

1089 chrl7 40535800 40539845 STAT3(6774)[45]

1090 chrl7 41201104 41205130 BRCA1(672)[26]

1091 chrl7 41227006 41231051 RPL21P4(140660)[-2226] BRCA1(672)[45]

1092 chrl7 41236265 41240288 RPL21P4(140660)[-6432] BRCA1(672)[23]

1093 chrl7 41241836 41245881 BRCA1(672)[45]

1094 chrl7 41241981 41246027 BRCA1(672)[46]

1095 chrl7 41243476 41247569 BRCA1(672)[93]

1096 chrl7 41243602 41247647 BRCA1(672)[45]

1097 chrl7 41243791 41247835 BRCA1(672)[44]

1098 chrl7 41243920 41247965 BRCA1(672)[45]

1099 chrl7 41249151 41253187 BRCA1(672)[36]

1100 chrl7 41255619 41259668 BRCA1(672)[49]

1101 chrl7 41265754 41269815 NBR2(10230)[-9784] BRCA1(672)[61]

1102 chrl7 42419658 42423736 FAM171A2(284069)[-9364] GRN(2896)[-754] 1103 chrl7 42425887 42429933 FAM171A2(284069)[-3167] GRN(2896)[46]

1104 chrl7 42426632 42430717 FAM171A2(284069)[-2383] GRN(2896)[85]

1105 chrl7 42428812 42432878 FAM171A2(284069)[-222] GRN(2896)[-342]

1106 chrl7 42428878 42432946 FAM171A2(284069)[-154] GRN(2896)[-408]

FAM171A2(284069)[55],

RPL7L1P5(390800)[-2194],

1107 chrl7 42438135 42442190 ITGA2B(3674)[-9359] GRN(2896)[-9665]

1108 chrl8 46444996 46449042 SMAD7(4092)[46]

1109 chrl8 46446944 46450981 SMAD7(4092)[37]

1110 chrl8 46447426 46451468 SMAD7(4092)[42]

1111 chrl8 46447560 46451613 SMAD7(4092)[53]

1112 chrl8 46448467 46452550 SMAD7(4092)[83]

1113 chrl8 46448662 46452699 SMAD7(4092)[37]

1114 chrl8 46448805 46452847 SMAD7(4092)[42]

1115 chrl8 46452854 46456888 SMAD7(4092)[34]

1116 chrl8 46453617 46457650 SMAD7(4092)[33]

1117 chrl8 46458409 46462453 SMAD7(4092)[44]

1118 chrl8 46462660 46466708 SMAD7(4092)[48]

1119 chrl8 46465632 46469678 SMAD7(4092)[46]

1120 chrl8 46466584 46470626 SMAD7(4092)[42]

1121 chrl8 46470616 46474679 SMAD7(4092)[63]

1122 chrl8 46470920 46474965 SMAD7(4092)[45]

1123 chrl8 46472744 46476790 SMAD7(4092)[46]

1124 chrl8 46472873 46476918 SMAD7(4092)[45]

1125 chrl8 46474280 46478325 SMAD7(4092)[45]

1126 chrl8 46475514 46479557 SMAD7(4092)[-433]

1127 chrl8 46475784 46479833 SMAD7(4092)[-703]

1128 chrl8 46475897 46479979 SMAD7(4092)[-816]

1129 chrl8 46478695 46482765 SMAD7(4092)[-3614]

1130 chrl8 46482413 46486458 SMAD7(4092)[-7332]

1131 chrl9 4166341 4170384 CREB3L3(84699)[43] SIRT6(51548)[-5721]

1132 chrl9 11229035 11233121 LDLR(3949)[86]

1133 chrl9 11229140 11233182 LDLR(3949)[42]

1134 chrl9 11238206 11242249 LDLR(3949)[43]

1135 chrl9 11240367 11244432 LDLR(3949)[65]

USF2(7392)[48], LSR(51599)[-

1136 chrl9 35762119 35766167 5252], HAMP(57817)[-9242]

HAMP(57817)[-37],

USF2(7392)[-2618],

1137 chrl9 35771336 35775372 MAG(4099)[-9616]

ACOXL(55289)[22],

1138 chr2 111873557 111877579 FU44006(400997)[-3795] BCL2L11(10018)[-2911] BCL2L11(10018)[42],

1139 chr2 111876709 111880751 FU44006(400997)[-6947] ACOXL(55289)[-2910]

BCL2L11(10018)[50],

1140 chr2 111879774 111883824 ACOXL(55289)[-5975]

BCL2L11(10018)[37],

1141 chr2 111882848 111886885 ACOXL(55289)[-9049]

1142 chr2 111900031 111904076 BCL2L11(10018)[45]

1143 chr2 111905647 111909691 BCL2L11(10018)[44]

1144 chr2 111923311 111927378 BCL2L11(10018)[67]

LOC100128655(100128655)[-

1145 chr6 39015036 39019117 9275] GLP1 (2740)[81]

LOC100128655(100128655)[-

1146 chr6 39015532 39019577 9771] GLP1R(2740)[45]

1147 chr6 39015904 39019955 GLP1R(2740)[51]

1148 chr6 39019794 39023856 GLP1R(2740)[62]

1149 chr6 39020326 39024379 GLP1R(2740)[53]

1150 chr6 39025543 39029589 GLP1R(2740)[46]

1151 chr6 39030288 39034322 GLP1R(2740)[34]

1152 chr6 39039838 39043884 GLP1R(2740)[46]

1153 chr6 39046467 39050509 GLP1R(2740)[42]

1154 chr6 39046707 39050753 GLP1R(2740)[46]

1155 chr6 39053249 39057292 GLP1R(2740)[43]

1156 chr6 39053855 39057923 GLPlR(2740)[-335]

1157 chr6 39054119 39058160 GLPlR(2740)[-599]

MYL7(58498)[30], GCK(2645)[-

1158 chr7 44177539 44181569 4300]

MYL7(58498)[30], GCK(2645)[-

1159 chr7 44178455 44182485 3384]

MYL7(58498)[45], GCK(2645)[-

1160 chr7 44178553 44182598 3271]

GCK(2645)[47], MYL7(58498)[-

1161 chr7 44182152 44186199 3236]

GCK(2645)[55], MYL7(58498)[-

1162 chr7 44182364 44186419 3448]

GCK(2645)[43], MYL7(58498)[-

1163 chr7 44183300 44187343 4384]

GCK(2645)[35], MYL7(58498)[-

1164 chr7 44185650 44189685 6734]

1165 chr7 44197272 44201309 GCK(2645)[37]

ST7(7982)[45], ST7-

1166 chr7 116591600 116595645 ST7-AS1(93653)[45] OT4(338069)[-307]

1167 chr7 116616378 116620420 TPM3Pl(252956)[-5344] ST7(7982)[42]

1168 chr7 116621689 116625719 ST7(7982)[30]

1169 chr7 116639826 116643873 ST7(7982)[47] 1170 chr7 116654497 116658538 ST7(7982)[41]

1171 chr7 116659796 116663843 ST7(7982)[47]

1172 chr7 116698499 116702546 ST7(7982)[47]

1173 chr7 116702561 116706604 ST7(7982)[43]

1174 chr7 116724694 116728732 ST7(7982)[38]

1175 chr7 116726168 116730220 ST7(7982)[52]

1176 chr7 116751703 116755744 ST7-AS2(93654)[41] ST7(7982)[41]

1177 chr7 116753913 116757980 ST7-AS2(93654)[67] ST7(7982)[67]

1178 chr7 116761993 116766028 ST7-AS2(93654)[35] ST7(7982)[35]

1179 chr7 116763305 116767356 ST7-AS2(93654)[51] ST7(7982)[51]

1180 chr7 116763540 116767571 ST7-AS2(93654)[31] ST7(7982)[31]

1181 chr7 116768595 116772641 ST7-AS2(93654)[46] ST7(7982)[46]

1182 chr7 116770915 116774959 ST7-AS2(93654)[44] ST7(7982)[44]

1183 chr7 116772221 116776266 ST7-AS2(93654)[45] ST7(7982)[45]

1184 chr7 116803886 116807932 ST7(7982)[46]

ST7(7982)[24], ST7-

1185 chr7 116813347 116817371 OT3(93655)[-7363]

ST7(7982)[45], ST7-

1186 chr7 116815687 116819732 OT3(93655)[-5002]

ST7(7982)[44], ST7-

1187 chr7 116826642 116830686 OT3(93655)[44]

ST7(7982)[43], ST7-

1188 chr7 116827989 116832032 OT3(93655)[43]

ST7(7982)[25], ST7-

1189 chr7 116842555 116846580 OT3(93655)[25]

1190 chr7 116859351 116863398 ST7(7982)[47]

1191 chr7 116864075 116868109 ST7(7982)[34]

1192 chr8 39769698 39773735 IDOl(3620)[37]

1193 chr8 39774381 39778422 IDOl(3620)[41]

1194 chr8 39778978 39783001 IDOl(3620)[23]

1195 chrX 133592301 133596346 HPRT1(3251)[45]

1196 chrX 133594974 133599024 HPRT1(3251)[50]

1197 chrX 133595154 133599198 HPRT1(3251)[44]

1198 chrX 133605384 133609413 HPRT1(3251)[29]

1199 chrX 133619697 133623732 HPRT1(3251)[35]

1200 chrX 133619814 133623856 HPRT1(3251)[42]

1201 chrX 133632191 133636233 HPRT1(3251)[42]

1202 chrX 146990226 146994269 FMR1-AS1(100126270)[43] FMR1(2332)[-1199]

1203 chrX 146990317 146994340 FMR1-AS1(100126270)[23] FMR1(2332)[-1128]

1204 chrX 146991666 146995715 FMR1-AS1(100126270)[49] FMR1(2332)[49]

1205 chrX 146992919 146996964 FMR1-AS1(100126270)[45] FMR1(2332)[45]

1206 chrX 147007767 147011816 FMR1-AS1(100126270)[-6091] FMR1(2332)[49] 1207 chrX 147023640 147027686 FM 1(2332)[46]

1208 chrX 147024121 147028181 FM R1(2332)[60]

F8(2157)[44],

1209 chrX 154129833 154133877 EEF1A1P31(553820)[-5221]

1210 chrX 154195605 154199651 F8(2157)[46]

Further PRC2 Associated Regions and Target Genes

SeqID Gene Chrom Chr. Start Chr. End Strand

815179 CFTR chr7 117136700 117136746 +

815180 CFTR chr7 117143005 117143077 +

815181 CFTR chr7 117181291 117181338 +

815182 CFTR chr7 117200864 117200924 +

815183 CFTR chr7 117204870 117204916 +

815184 CFTR chr7 117286463 117286531 +

815185 CFTR chr7 117302831 117302873 +

815186 CFTR chr7 117134700 117138746 +

815187 CFTR chr7 117141005 117145077 +

815188 CFTR chr7 117179291 117183338 +

815189 CFTR chr7 117198864 117202924 +

815190 CFTR chr7 117202870 117206916 +

815191 CFTR chr7 117284463 117288531 +

815192 CFTR chr7 117300831 117304873 +

815193 CFTR chr7 117148302 117148326 -

815194 CFTR chr7 117228715 117228750 -

815195 CFTR chr7 117229731 117229779 -

815196 CFTR chr7 117232568 117232614 -

815197 CFTR chr7 117260532 117260584 -

815198 CFTR chr7 117280931 117280967 -

815199 CFTR chr7 117296900 117296925 -

815200 CFTR chr7 117304311 117304363 -

815201 CFTR chr7 117146302 117150326 -

815202 CFTR chr7 117226715 117230750 -

815203 CFTR chr7 117227731 117231779 -

815204 CFTR chr7 117230568 117234614 -

815205 CFTR chr7 117258532 117262584 -

815206 CFTR chr7 117278931 117282967 -

815207 CFTR chr7 117294900 117298925 -

815208 CFTR chr7 117302311 117306363 - 868594 PAH chrl2 103237900 103237947 -

868595 PAH chrl2 103239302 103239344 -

868596 PAH chrl2 103243417 103243456 -

868597 PAH chrl2 103270854 103270932 -

868598 PAH chrl2 103272048 103272151 -

868599 PAH chrl2 103285132 103285154 -

868600 PAH chrl2 103310283 103310328 -

868601 PAH chrl2 103235900 103239947 -

868602 PAH chrl2 103237302 103241344 -

868603 PAH chrl2 103241417 103245456 -

868604 PAH chrl2 103268854 103272932 -

868605 PAH chrl2 103270048 103274151 -

868606 PAH chrl2 103283132 103287154 -

868607 PAH chrl2 103308283 103312328 -

868608 PAH chrl2 103237237 103237282 +

868609 PAH chrl2 103246085 103246108 +

868610 PAH chrl2 103247903 103247930 +

868611 PAH chrl2 103281391 103281435 +

868612 PAH chrl2 103282675 103282692 +

868613 PAH chrl2 103235237 103239282 +

868614 PAH chrl2 103244085 103248108 +

868615 PAH chrl2 103245903 103249930 +

868616 PAH chrl2 103279391 103283435 +

868617 PAH chrl2 103280675 103284692 +

899869 CEP290 chrl2 88442999 88443045 -

899870 CEP290 chrl2 88449482 88449523 -

899871 CEP290 chrl2 88456477 88456522 -

899872 CEP290 chrl2 88465619 88465664 -

899873 CEP290 chrl2 88474127 88474168 -

899874 CEP290 chrl2 88476609 88476667 -

899875 CEP290 chrl2 88477171 88477208 -

899876 CEP290 chrl2 88480171 88480217 -

899877 CEP290 chrl2 88499877 88499936 -

899878 CEP290 chrl2 88500553 88500598 -

899879 CEP290 chrl2 88512420 88512456 -

899880 CEP290 chrl2 88513987 88514032 -

899881 CEP290 chrl2 88522734 88522780 -

899882 CEP290 chrl2 88523504 88523548 -

899883 CEP290 chrl2 88523600 88523646 - 899884 CEP290 chrl2 88530462 88530514 -

899885 CEP290 chrl2 88532498 88532641 -

899886 CEP290 chrl2 88532655 88532701 -

899887 CEP290 chrl2 88533289 88533320 -

899888 CEP290 chrl2 88534203 88534270 -

899889 CEP290 chrl2 88534751 88534796 -

899890 CEP290 chrl2 88534984 88535049 -

899891 CEP290 chrl2 88535711 88535752 -

899892 CEP290 chrl2 88537115 88537171 -

899893 CEP290 chrl2 88440999 88445045 -

899894 CEP290 chrl2 88447482 88451523 -

899895 CEP290 chrl2 88454477 88458522 -

899896 CEP290 chrl2 88463619 88467664 -

899897 CEP290 chrl2 88472127 88476168 -

899898 CEP290 chrl2 88474609 88478667 -

899899 CEP290 chrl2 88475171 88479208 -

899900 CEP290 chrl2 88478171 88482217 -

899901 CEP290 chrl2 88497877 88501936 -

899902 CEP290 chrl2 88498553 88502598 -

899903 CEP290 chrl2 88510420 88514456 -

899904 CEP290 chrl2 88511987 88516032 -

899905 CEP290 chrl2 88520734 88524780 -

899906 CEP290 chrl2 88521504 88525548 -

899907 CEP290 chrl2 88521600 88525646 -

899908 CEP290 chrl2 88528462 88532514 -

899909 CEP290 chrl2 88530498 88534641 -

899910 CEP290 chrl2 88530655 88534701 -

899911 CEP290 chrl2 88531289 88535320 -

899912 CEP290 chrl2 88532203 88536270 -

899913 CEP290 chrl2 88532751 88536796 -

899914 CEP290 chrl2 88532984 88537049 -

899915 CEP290 chrl2 88533711 88537752 -

899916 CEP290 chrl2 88535115 88539171 -

899917 CEP290 chrl2 88462087 88462133 +

899918 CEP290 chrl2 88496147 88496188 +

899919 CEP290 chrl2 88499934 88499980 +

899920 CEP290 chrl2 88535092 88535133 +

899921 CEP290 chrl2 88536167 88536208 +

899922 CEP290 chrl2 88536495 88536523 + 899923 CEP290 chrl2 88536556 88536624 +

899924 CEP290 chrl2 88542150 88542215 +

899925 CEP290 chrl2 88460087 88464133 +

899926 CEP290 chrl2 88494147 88498188 +

899927 CEP290 chrl2 88497934 88501980 +

899928 CEP290 chrl2 88533092 88537133 +

899929 CEP290 chrl2 88534167 88538208 +

899930 CEP290 chrl2 88534495 88538523 +

899931 CEP290 chrl2 88534556 88538624 +

899932 CEP290 chrl2 88540150 88544215 +

962805 CD274 chr9 5443108 5443164 +

962806 CD274 chr9 5450978 5451029 +

962807 CD274 chr9 5452788 5452833 +

962808 CD274 chr9 5466094 5466139 +

962809 CD274 chr9 5466227 5466273 +

962810 CD274 chr9 5441108 5445164 +

962811 CD274 chr9 5448978 5453029 +

962812 CD274 chr9 5450788 5454833 +

962813 CD274 chr9 5464094 5468139 +

962814 CD274 chr9 5464227 5468273 +

962815 CD274 chr9 5457325 5457367 -

962816 CD274 chr9 5455325 5459367 -

981191 ADIPOQ chr3 186566782 186566827 +

981192 ADIPOQ chr3 186571631 186571674 +

981193 ADIPOQ chr3 186564782 186568827 +

981194 ADIPOQ chr3 186569631 186573674 +

981195 ADIPOQ chr3 186572161 186572189 -

981196 ADIPOQ chr3 186570161 186574189 -

Single Strand Oligonucleotides (Antisense Strand of Target Gene):

SEQ ID NOS: 1211 to 497442, 815209 to 842011, 868618 to 887872, 899933 to 949635, 962817 to 976788, 981197 to 987384, 989617 to 989640, 989650 to 989675, 989676 to 1412676

Single Strand Oligonucleotides (Sense Strand of Target Gene):

SEQ ID NOS: 497443 to 815174, 842012 to 868589, 887873 to 899864, 949636 to 962800, 976789 to 980845, 987385 to 989598, 989641 to 989649, 1412677-1914950 This application contains a sequence listing, the entirety of which is incorporated herein by reference. File Name: R069370014WO00 Sequence Listing.txt. Created May 16, 2013. Size: 315,306,652 bytes.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

Claims

CLAIMS What is claimed is:

1. A single stranded oligonucleotide having a sequence 5'-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 1-23 nucleotides in length, wherein the single stranded oligonucleotide is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a target gene listed in Table 4.

2. The single stranded oligonucleotide of claim 1, wherein the oligonucleotide does not comprise three or more consecutive guanosine nucleotides.

3. The single stranded oligonucleotide of claim 1 or claim 2, wherein the oligonucleotide does not comprise four or more consecutive guanosine nucleotides.

4. The single stranded oligonucleotide of any one of claims 1 to 3, wherein the oligonucleotide is 8 to 30 nucleotides in length.

5. The single stranded oligonucleotide of any one of claims 1 to 3, wherein the oligonucleotide is 8 to 10 nucleotides in length and all but 1, 2, or 3 of the nucleotides of the complementary sequence of the PRC2-associated region are cytosine or guanosine nucleotides.

6. The single stranded oligonucleotide of any one of claims 1 to 5, wherein at least one nucleotide of the oligonucleotide is a nucleotide analogue.

7. The single stranded oligonucleotide of claim 6, wherein the at least one nucleotide analogue results in an increase in Tm of the oligonucleotide in a range of 1 to 5 °C compared with an oligonucleotide that does not have the at least one nucleotide analogue.

8. The single stranded oligonucleotide of any one of claims 1 to 7, wherein at least one nucleotide of the oligonucleotide comprises a 2' O-methyl.

9. The single stranded oligonucleotide of any one of claims 1 to 8, wherein each nucleotide of the oligonucleotide comprises a 2' O-methyl.

10. The single stranded oligonucleotide of any one of claims 1 to 8, wherein the oligonucleotide comprises at least one ribonucleotide, at least one deoxyribonucleotide, or at least one bridged nucleotide.

11. The single strand oligonucleotide of claim 10, wherein the bridged nucleotide is a LNA nucleotide, a cEt nucleotide or a ENA modified nucleotide.

12. The single stranded oligonucleotide of any one of claims 1 to 6, wherein each nucleotide of the oligonucleotide is a LNA nucleotide.

13. The single stranded oligonucleotide of any one of claims 1 to 6, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2'-fluoro- deoxyribonucleotides.

14. The single stranded oligonucleotide of any one of claims 1 to 6, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and 2'-0- methyl nucleotides.

15. The single stranded oligonucleotide of any one of claims 1 to 6, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and ENA nucleotide analogues.

16. The single stranded oligonucleotide of any one of claims 1 to 6, wherein the nucleotides of the oligonucleotide comprise alternating deoxyribonucleotides and LNA nucleotides.

17. The single stranded oligonucleotide of any one of claims 13 to 16, wherein the 5' nucleotide of the oligonucleotide is a deoxyribonucleotide.

18. The single stranded oligonucleotide of any one of claims 1 to 6, wherein the nucleotides of the oligonucleotide comprise alternating LNA nucleotides and 2' -O-methyl nucleotides.

19. The single stranded oligonucleotide of claim 18, wherein the 5' nucleotide of the oligonucleotide is a LNA nucleotide.

20. The single stranded oligonucleotide of any one of claims 1 to 8, wherein the nucleotides of the oligonucleotide comprise deoxyribonucleotides flanked by at least one LNA nucleotide on each of the 5' and 3' ends of the deoxyribonucleotides.

21. The single stranded oligonucleotide of any one of claims 1 to 20, further comprising phosphorothioate internucleotide linkages between at least two nucleotides.

22. The single stranded oligonucleotide of claim 21, further comprising phosphorothioate internucleotide linkages between all nucleotides.

23. The single stranded oligonucleotide of any one of claims 1 to 22, wherein the nucleotide at the 3' position of the oligonucleotide has a 3' hydroxyl group.

24. The single stranded oligonucleotide of any one of claims 1 to 22, wherein the nucleotide at the 3' position of the oligonucleotide has a 3' thiophosphate.

25. The single stranded oligonucleotide of any one of claims 1 to 24, further comprising a biotin moiety conjugated to the 5' nucleotide.

26. A single stranded oligonucleotide comprising a region of complementarity that is complementary with at least 8 consecutive nucleotides of a PRC2-associated region of a target gene listed in Table 4, wherein the oligonucleotide has at least one of: a) a sequence that is 5'X-Y-Z, wherein X is any nucleotide and wherein X is anchored at the 5' end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 1 to 23 nucleotides in length; b) a sequence that does not comprise three or more consecutive guanosine

nucleotides; c) a sequence that has less than a threshold level of sequence identity with every sequence of nucleotides, of equivalent length to the second nucleotide sequence, that are between 50 kilobases upstream of a 5 '-end of an off-target gene and 50 kilobases downstream of a 3 '-end of the off-target gene; d) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and/or e) a sequence that has greater than 60% G-C content.

27. The single stranded oligonucleotide of claim 26, wherein the oligonucleotide has the sequence 5 'X-Y-Z and wherein the oligonucleotide is 8-50 nucleotides in length.

28. A composition comprising a single stranded oligonucleotide of any one of claims 1 to 27 and a carrier.

29. A composition comprising a single stranded oligonucleotide of any one of claims 1 to 27 in a buffered solution.

30. A composition of claim 28, wherein the oligonucleotide is conjugated to the carrier.

31. The composition of claim 30, wherein the carrier is a peptide.

32. The composition of claim 30, wherein the carrier is a steroid.

33. A pharmaceutical composition comprising a composition of any one of claims 28 to 32 and a pharmaceutically acceptable carrier.

34. A kit comprising a container housing the composition of any one of claims 28 to 33.

35. A method of increasing expression of a target gene in a cell, the method comprising delivering the single stranded oligonucleotide of any one of claims 1 to 27 into the cell.

36. The method of claim 35, wherein delivery of the single stranded

oligonucleotide into the cell results in a level of expression of a target gene that is at least 50% greater than a level of expression of the target gene in a control cell that does not comprise the single stranded oligonucleotide.

37. A method increasing levels of a target gene in a subject, the method comprising administering the single stranded oligonucleotide of any one of claims 1 to 27 to the subject.

38. A method of treating a condition associated with decreased levels of a target gene in a subject, the method comprising administering the single stranded oligonucleotide of any one of claims 1 to 27 to the subject.

39. The method of claim 38, wherein the target gene is listed in Table 4.

40. The method of claim 39, wherein the condition is listed in Table 4 or otherwise disclosed herein.